text
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella specific antibodies detected after vaccination/ natural infection: March 2013
Choices:
A. IgM
B. IgG
C. IgA
D. IgE
Answer: [/INST] IgG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother has uncontrolled PKU during pregnancy, though this is rare in the patient’s own presentation.  
3. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history: severe neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** is atypical for classic PKU (which usually causes *low* tyrosine due to PAH deficiency) but may suggest a rare PAH variant or secondary metabolic disruption.  
5. **Upper airway/chronic pulmonary obstruction** could stem from comorbid infections or neuromuscular dysfunction from chronic metabolic damage.  
6. **Neonatal death** is uncommon with modern screening but plausible in undiagnosed/severe cases.  

Note: While hypertyrosinemia and respiratory symptoms are unusual, PKU is strongly supported by hyperphenylalaninemia and the fatal progression described. Tyrosinemia or combined metabolic disorders should be ruled out clinically. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis-
Choices:
A. Angio-invasion
B. Lymph invasion
C. Septate hyphae
D. All
Answer: [/INST] Angio-invasion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Xeroderma Pigmentosum, defect is in?
Choices:
A. Base pair defect
B. Nucleotide Excision Repair
C. Mismatch repair defect
D. Protein folding
Answer: [/INST] Nucleotide Excision Repair </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia includes the following except:
Choices:
A. Night blindness
B. Severe pain in the eye
C. Xerosis of the cornea
D. Perforation of cornea
Answer: [/INST] Severe pain in the eye </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteopetrosis is also known as:
Choices:
A. Albers Schonberg disease
B. Marble bone disease
C. Fragilis generalisata
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Following are true regarding Typhoid ulcer EXCEPT
Choices:
A. Bleeding common
B. Commonly in ileum
C. Perforation occurs
D. Stricture occurs
Answer: [/INST] Stricture occurs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Characteristic Auto antibodies of Autoimmune Hepatitis include all of the following, Except:
Choices:
A. Antinuclear Antibodies (ANA)
B. Anti SLA
C. Anti LKMI
D. ANCA
Answer: [/INST] ANCA </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Glioblastoma multiforme may occur in the following except:
Choices:
A. Cerebrum of adult
B. Brain stem of child
C. Spinal cord of adult
D. Adrenal medulla of child
Answer: [/INST] Adrenal medulla of child </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is the type of Galactosemia cataract?
Choices:
A. Snowflake
B. Oil drop
C. Blue dot
D. Polychromaticlustre
Answer: [/INST] Oil drop </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: X ray appearance of Osteosarcoma are all except
Choices:
A. Perosteal reaction
B. Codmnans triangle
C. Soap bubble
D. Sun ray appearance
Answer: [/INST] Soap bubble </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Glioma of optic nerve is associated with ?
Choices:
A. Neurofibromatosis type I
B. Neurofibromatosis type II
C. Both the above
D. None of the above
Answer: [/INST] Neurofibromatosis type I </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Short chin', 'Abnormal pinna morphology', 'Blepharitis', 'Exotropia', 'Upslanted palpebral fissure', 'Pectus excavatum', 'Global developmental delay', 'Craniosynostosis', 'Hip dysplasia', 'Failure to thrive', 'Eosinophilia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Coxa vara', 'Lumbar hyperlordosis', 'Thoracic scoliosis', 'Spinal canal stenosis', 'Severe combined immunodeficiency', 'Severe platyspondyly', 'Pear-shaped vertebrae', 'Severe T-cell immunodeficiency', 'Wide intermamillary distance', 'Cervical spinal canal stenosis', 'Infantile muscular hypotonia', 'Limb undergrowth', 'Chalazion', 'Hip subluxation', 'Increased intervertebral space']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID) and severe T-cell immunodeficiency are hallmark features of ISDNA, linked to defects in EXTL3, which disrupts glycosaminoglycan synthesis critical for immune cell function.  
2. **Skeletal Abnormalities**: Severe platyspondyly, pear-shaped vertebrae, coxa vara, pectus excavatum, and spinal canal stenosis align with ISDNA’s characteristic skeletal dysplasia due to aberrant bone development.  
3. **Neurodevelopmental Delays**: Global developmental delay and infantile hypotonia reflect the neurodevelopmental component of ISDNA, caused by EXTL3’s role in neural development.  
4. **Supportive Features**: Limb undergrowth, failure to thrive, and facial dysmorphisms (short chin, wide intermamillary distance) further support a multisystem disorder. Eosinophilia and hypertriglyceridemia may stem from metabolic dysregulation secondary to immunodeficiency.  
5. **Exclusion of Alternatives**: Absence of nephropathy (unlike Schimke immuno-osseous dysplasia) or retinal defects (unlike Roifman syndrome) strengthens ISDNA as the diagnosis.  

This triad of skeletal, immune, and neurodevelopmental abnormalities, alongside genetic and biochemical mechanisms, confirms ISDNA. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: For preventing Retinopathy of Prematurity, concentration of oxygen should be: March 2007
Choices:
A. 20-30%
B. 30-40%
C. 50-60%
D. 60-70%
Answer: [/INST] 50-60% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Agammaglobulinemia can present with?
Choices:
A. Rhinitis
B. Bronchiectasis
C. Giardia infections
D. All above
Answer: [/INST] All above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Screening of immigrants from infectious diseases such as Tuberculosis and Syphilis to protect the home population is an example of:
Choices:
A. High-risk screening
B. Prospective screening
C. Prescriptive screeing
D. Periodic health examinations
Answer: [/INST] Prospective screening </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: WHO Malaria Mass Drug Administration ?
Choices:
A. API >5
B. > 2
C. 15
D. 25
Answer: [/INST] > 2 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the kidney', 'Hypertelorism', 'Abnormal location of ears', 'Hearing impairment', 'Small earlobe', 'Prominent antihelix', 'Progressive sensorineural hearing impairment', 'Wide nasal bridge', 'Choanal atresia', 'Chorioretinal coloboma', 'Coloboma', 'Iris coloboma', 'Atypical behavior', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Flexion contracture', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Tachycardia', 'Respiratory distress', 'Difficulty walking', 'Developmental regression', 'Scoliosis', 'Thoracolumbar scoliosis', 'Difficulty standing', 'Short stature', 'Type I truncus arteriosus', 'Bilateral choanal atresia', 'Supraventricular tachycardia', 'Abnormal bone ossification', 'Flat face', 'Anisometropia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental Features**: Intellectual disability, global developmental delay, absent speech, seizures, hypotonia, developmental regression, and atypical behavior align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Ocular Anomalies**: Chorioretinal coloboma, iris coloboma, and anisometropia indicate structural eye defects, a hallmark of NEDBEH.  
3. **Cardiac Defects**: Type I truncus arteriosus and supraventricular tachycardia correlate with the ""heart anomalies"" component of the disorder.  
4. **Craniofacial Dysmorphism**: Hypertelorism, wide nasal bridge, flat face, abnormal ear location, small earlobes, and prominent antihelix match the facial gestalt seen in NEDBEH.  
5. **Systemic Involvement**: Bilateral choanal atresia, respiratory distress, growth delay, skeletal anomalies (abnormal bone ossification, hip dysplasia, scoliosis), and renal abnormalities support multi-organ involvement typical of NEDBEH.  
6. **Progressive Features**: Sensorineural hearing impairment and developmental regression suggest a degenerative trajectory, consistent with reported BRD4-related NEDBEH cases.  
7. **Exclusion of Overlap Syndromes**: While CHARGE syndrome (coloboma, choanal atresia) was considered, the presence of truncus arteriosus, hypotonia, and regression favors NEDBEH, which encompasses broader neurodevelopmental and systemic anomalies.  

This constellation of symptoms, particularly the triad of neurodevelopmental regression, structural eye/heart defects, and multi-system involvement, strongly supports a diagnosis of NEDBEH, likely linked to BRD4 mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are features of Hemophagocytic Lymphohistiocytosis (HLH), except:
Choices:
A. Fever
B. Splenomegaly
C. Hyperferritinemia
D. Hyperfibrinogenemia
Answer: [/INST] Hyperfibrinogenemia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 30 year old patient developed high fever of sudden onset. Peripheral blood smear showed crescent shaped gametocytes. Malaria pigment was dark brown in colour. Which of the following malarial parasites is the causative agent?
Choices:
A. Plasmodium vivax
B. Plasmodium malariae
C. Plasmodium falciparum
D. Plasmodium ovale
Answer: [/INST] Plasmodium falciparum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis can mimic which tumor?
Choices:
A. Osteoclastoma
B. Ewing sarcoma
C. Chondroma
D. None of above
Answer: [/INST] Ewing sarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Macrophage, granuloma, erythrophagocytosis are found ina)  Ulcerative colitisb) Necrotising enterocolitisc)  Regional ileitisd)  Typhoid
Choices:
A. ab
B. bc
C. cd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Brucellosis can be transmitted by all EXCEPT
Choices:
A. Contect with infected placenta
B. Ingestion of raw vegetables from infected farms
C. Person to person transmission
D. Inhalation of infected dust or aerosol
Answer: [/INST] Person to person transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient was diagnosed to have single skin lesion of Leprosy without any AFB positive bacteria from the scrapings. What should be the treatment of this patient according to latests guidelines?
Choices:
A. (Rifampicin + Dapsone + Clofazamine) for 12 months
B. (Rifampicin + Dapsone + Clofazamine) for 6 months
C. (Rifampicin + Dapsone) for 12 months
D. (Rifampicin + Dapsone) for 6 months
Answer: [/INST] (Rifampicin + Dapsone + Clofazamine) for 6 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true in relation to Osteosarcoma?
Choices:
A. Paget's disease & prior irradiation are factors
B. Rb gene mutation is associated with hereditary variant
C. c-myc gene implicated in the genesis
D. Codman's triangle is the characteristic x-ray finding
Answer: [/INST] c-myc gene implicated in the genesis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are components/features of Tetralogy of Fallot, EXCEPT
Choices:
A. RV outlet obstruction
B. Left ventricular hypertrophy
C. Aorta over riding VSD
D. Malaligned VSD
Answer: [/INST] Left ventricular hypertrophy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Congo red staining of abdominal fat has confirmed a diagnosis of Amyloidosis in a 28-year-old man. Which is the most common cause of death in primary AL Amylodosis?
Choices:
A. Respiratory failure
B. Cardiac failure
C. Renal failure
D. Septicemia
Answer: [/INST] Cardiac failure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy is considered a public health problem if the prevalence of leprosy is more than
Choices:
A. 2 per 10,000
B. 1 per 10,000
C. 5 per 10,000
D. 10 per 10,000
Answer: [/INST] 1 per 10,000 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements regarding Craniopharyngiomas are true, except :
Choices:
A. Arise from Rathke's pouch
B. Can cause visual disturbances
C. Presents with hypopituitarism in adults
D. Usually Infrasellar in location
Answer: [/INST] Usually Infrasellar in location </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tetralogy of Fallot's present with one of the following:
Choices:
A. Cenral cyanosis with clubbing
B. Cardiomegaly
C. Left ventricular hypertrophy
D. Normal ECG and Chest x-ray
Answer: [/INST] Cenral cyanosis with clubbing </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is seen in which of the following infections -
Choices:
A. Chicken pox
B. Mumps
C. Diarrhoea
D. All
Answer: [/INST] Diarrhoea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Osteoporosis', 'Generalized hypotonia', 'Obesity', 'Abnormal foot morphology', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Clumsiness', 'Poor coordination', 'Hyperalaninemia', 'Severe short stature', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: PA disrupts propionyl-CoA carboxylase, impairing amino acid catabolism (isoleucine, valine), leading to toxic metabolite accumulation that inhibits the urea cycle (causing hyperammonemia) and secondary glycine elevation.  
2. **Abnormal Amino Acid Concentrations (Hyperleucinemia, Hyperalaninemia)**: Branched-chain amino acid metabolism defects result in elevated leucine and alanine due to blocked degradation pathways.  
3. **Abnormal Carnitine Levels**: Propionyl-CoA conjugates with carnitine for excretion, depleting free carnitine and causing deficiency.  
4. **Leukopenia**: Toxic metabolites (e.g., propionic acid) suppress bone marrow function, reducing white blood cell production.  
5. **Gastrointestinal Inflammation & Failure to Thrive**: Chronic metabolic acidosis and toxin buildup lead to feeding intolerance, vomiting, and malnutrition, contributing to severe short stature.  
6. **Neurological Symptoms (Hypotonia, Clumsiness, Hearing Loss)**: Metabolic crises damage the basal ganglia and nervous system, causing hypotonia, poor coordination, and sensorineural hearing impairment.  
7. **Osteoporosis**: Chronic acidosis leaches calcium from bones, weakening skeletal structure.  
8. **Early Mortality (Childhood/Adolescence/Adulthood)**: Severe metabolic decompensation episodes, cardiomyopathy, or infections result in progressive organ failure and reduced lifespan.  
9. **Abnormal Porphyrins & Aspartate Family Amino Acids**: Secondary disruption of heme synthesis and aspartate metabolism due to enzyme dysfunction and mitochondrial toxicity.  

PA’s hallmark triad of metabolic acidosis, hyperammonemia, and multisystem involvement aligns with the patient’s symptoms, confirming the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Hepatic failure', 'Growth delay', 'Death in infancy', 'Congestive heart failure', 'Pancreatitis', 'Exocrine pancreatic insufficiency', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Acute kidney injury', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Cerebral edema', 'Sparse scalp hair', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating cysteine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, increased serum lactate, and acute kidney injury suggest a metabolic disorder disrupting amino acid catabolism.  
2. **Amino Acid Abnormalities**: Elevated isoleucine, valine, and abnormal aspartate/glutamine align with PA’s defect in propionyl-CoA carboxylase, impairing breakdown of these amino acids.  
3. **Secondary Glycine Dysregulation**: Hyperglycinemia/hyperglycinuria occur due to propionate inhibition of glycine cleavage enzyme.  
4. **Hematologic Involvement**: Thrombocytopenia, leukopenia, and anemia stem from bone marrow suppression by toxic metabolites (e.g., propionyl-CoA).  
5. **Pancreatic/Kidney Dysfunction**: Exocrine pancreatic insufficiency and chronic kidney disease result from chronic acidosis and metabolic stress.  
6. **Neurological Features**: Seizures, cerebral edema, and developmental delays reflect neurotoxicity from hyperammonemia and organic acid accumulation.  
7. **Hepatic/Cardiac Manifestations**: Hepatomegaly, hepatic failure, and congestive heart failure arise from mitochondrial energy deficiency and toxic metabolite deposition.  
8. **Urinary Biomarkers**: Hyperglycinuria and elevated urinary carboxylic acids (e.g., methylcitrate, 3-hydroxypropionate) are pathognomonic for PA.  
9. **Early Mortality**: Death in infancy/childhood is consistent with severe PA phenotypes, often triggered by infections or metabolic decompensation.  
10. **Carnitine Dysregulation**: Abnormal carnitine levels occur due to sequestration by propionyl-CoA, exacerbating metabolic dysfunction.  

The constellation of metabolic derangements, multi-organ involvement, and characteristic biochemical markers confirm propionic acidemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Multiple Sclerosis is
Choices:
A. Toxic disorder
B. Infectious disorder
C. Degenerative disorder
D. Demylinating disorder
Answer: [/INST] Demylinating disorder </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastomas arising in the context of germ-line mutations not only may be bilateral, but also may be associated with______ (so called ""trilateral"" retinoblastoma)
Choices:
A. Medulloblastoma
B. Pinealoblastoma
C. Neuroblastoma
D. Hemangioblastoma
Answer: [/INST] Pinealoblastoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Acute kidney injury', 'Vomiting', 'Respiratory insufficiency', 'Increased serum lactate', 'Hyperkalemia', 'Hematemesis', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Excessive salivation', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Hypoxemia', 'Chronic kidney disease', 'Increased circulating lactate dehydrogenase concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Aciduria Patterns**: The presence of **dicarboxylic aciduria** and **3-methylglutaconic aciduria** strongly suggests a defect in leucine catabolism or ketogenesis, both central to HMG-CoA lyase deficiency.  
2. **Energy Crisis Manifestations**: **Increased serum lactate**, **hypoxemia**, and **respiratory insufficiency** align with impaired ketogenesis, leading to energy depletion in critical tissues (e.g., brain, heart).  
3. **Hyperkalemia & Kidney Dysfunction**: **Acute/chronic kidney injury** and **hyperkalemia** result from metabolic acidosis (due to accumulated organic acids) and direct tubular toxicity from toxic metabolites.  
4. **Neurological Symptoms**: **Seizures** and **neonatal death** reflect acute metabolic decompensation with encephalopathy, exacerbated by hypoglycemia (common in HMG-CoA lyase deficiency).  
5. **Enzyme-Specific Biomarkers**: **Elevated urinary carboxylic acids** (e.g., 3-hydroxy-3-methylglutaric acid) and **abnormal aspartate-family amino acids** directly link to HMG-CoA lyase’s role in ketone body synthesis and leucine metabolism.  
6. **Early Lethality**: **Death in infancy/neonatal death** is typical in severe presentations due to rapid metabolic crises triggered by catabolic stressors (e.g., fasting, infection).  
7. **Secondary Organ Effects**: **Hematemesis** and **excessive salivation** may stem from autonomic dysfunction or acid-induced mucosal injury, while **bradycardia** reflects electrolyte imbalances or cardiac energy failure.  
8. **Diagnostic Confirmation**: **Increased lactate dehydrogenase** supports cellular necrosis from metabolic stress, consistent with this disorder.  

The constellation of metabolic acidosis, characteristic organic aciduria, and multisystem collapse in infancy confirms HMG-CoA lyase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Irritability', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric aciduria and elevated circulating glutaric acid concentration are pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Neurological Symptoms**: Dystonia, dyskinesia, and generalized hypotonia align with basal ganglia damage, a hallmark of GA-I due to neurotoxic metabolite accumulation.  
3. **Macrocephaly**: Often presents pre-symptomatically in infancy, reflecting abnormal brain development or subdural effusions.  
4. **Metabolic Decompensation Episodes**: Vomiting, diarrhea, dehydration, fever, and lethargy during catabolic stress (e.g., infections) trigger acute crises, leading to irreversible neurological injury.  
5. **Carnitine Deficiency**: Decreased plasma free carnitine results from secondary carnitine depletion, as carnitine binds to glutaric acid for excretion.  
6. **Poor Prognosis Indicators**: Death in infancy/childhood and neonatal death (in severe cases) reflect untreated metabolic instability or encephalopathic crises.  
7. **Supportive Symptoms**: Irritability, drowsiness, hyperhidrosis, and feeding difficulties are consistent with chronic metabolic dysregulation and acute energy deficits.  
8. **Exclusion of Mimics**: Symptoms overlap with other organic acidemias, but glutaric acid elevation and specific neurological progression confirm GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Q fever is caused by?
Choices:
A. Rickettsia typhi
B. Rochalimea Quintana
C. Coxiella burnetii
D. Rickettsia ricketssi
Answer: [/INST] Coxiella burnetii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal saccadic eye movements', 'Cyanosis', 'Seizure', 'Death in infancy', 'Vomiting', 'Abnormal cerebral morphology', 'Dyspnea', 'Glutaric aciduria', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation, pathognomonic for GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Abnormal cerebral morphology**: Macrocephaly and striatal degeneration (e.g., basal ganglia atrophy) are hallmark neuroimaging findings in GA-I.  
3. **Seizures & abnormal saccadic eye movements**: Result from acute or chronic neurotoxicity caused by glutaric acid and 3-hydroxyglutaric acid, damaging neurons and disrupting neurotransmission.  
4. **Feeding difficulties & vomiting**: Common early signs of metabolic decompensation triggered by catabolic stress (e.g., infections, fasting).  
5. **Dyspnea & cyanosis**: May arise during metabolic crises due to acidosis or secondary respiratory complications from encephalopathy.  
6. **Death in infancy**: Untreated GA-I often leads to severe neurological injury or fatal metabolic crises in early life, consistent with the natural history of the disease.  
The combination of **neurodevelopmental regression**, **organic aciduria**, and **characteristic neuroimaging** strongly confirms GA-I. Early diagnosis is critical to prevent irreversible damage via dietary management (lysine/tryptophan restriction) and emergency protocols during metabolic stress. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Myocarditis can be caused by -
Choices:
A. Schistosomia
B. Ankylostoma duodenale
C. Trichuris trichura
D. Trichinella spiralis
Answer: [/INST] Trichinella spiralis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 23-year-old woman, gravida 2, para 1, at 20 weeks of gestation comes to the physician for a routine prenatal exam. Her last pregnancy was unremarkable and she gave birth to a healthy rhesus (RhD) positive girl. Her past medical history is notable for a blood transfusion after a car accident with a complex femur fracture about 3 years ago. Her temperature is 37.2°C (99°F), pulse is 92/min, and blood pressure is 138/82 mm Hg. Examination shows that the uterus is at the umbilicus. Ultrasound examination reveals normal fetal heart rate, movement, and anatomy. Routine prenatal labs show the following:
Blood type A Rh-
Leukocyte count 11,000/mm3
Hemoglobin 12.5 g/dL
Platelet count 345,000/mm3
Serum
Anti-D antibody screen Negative
Rubella IgM Negative
Rubella IgG Negative
Varicella IgM Negative
Varicella IgG Positive
STD panel Negative
Urine
Protein Trace
Culture No growth
Cervical cytology Normal
Which of the following is the best next step in management of this patient?""
Choices:
A. Administer anti-D immunoglobulin now and repeat antibody screening shortly before delivery..
B. Repeat antibody screening at 28 weeks. Administer anti-D immunoglobulin at 28 weeks and after delivery if the newborn is Rh(D) positive..
C. Repeat antibody screening at 28 weeks and administer anti-D immunoglobulin at 28 weeks. No further management is needed..
D. No further screening is needed. Administer anti-D immunoglobulin shortly after delivery.
Answer: [/INST] Repeat antibody screening at 28 weeks. Administer anti-D immunoglobulin at 28 weeks and after delivery if the newborn is Rh(D) positive.. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Post exposure active immunization can be done fora)  Rabiesb)  Measlesc)  Cholerad)  Yellow fever
Choices:
A. da
B. ab
C. da
D. ac
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis of kidney may be seen in the following except-
Choices:
A. Enteric fever
B. Ulcerative colitis
C. Suppurative lung disease
D. Hansen's disease
Answer: [/INST] Enteric fever </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following tumors are seen in metaphysis -a) Osteomyelitisb) Osteosarcomac) Chondrosarcomad) Osteoclastomae)  Ewing's sarcoma
Choices:
A. a
B. c
C. bc
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal vagina morphology', 'Oral ulcer', 'Xerostomia', 'Keratoconjunctivitis sicca', 'Abnormal finger morphology', 'Diarrhea', 'Abdominal pain', 'Hepatomegaly', 'Headache', 'Abnormality of the lower limb', 'Arthralgia', 'Neoplasm of the liver', 'Hypercholesterolemia', 'Low alkaline phosphatase', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Cachexia', 'Gastritis', 'Focal white matter lesions', 'Uterine neoplasm', 'Abnormal circulating protein concentration', 'Lower limb pain', 'Dysesthesia', 'Autoimmune antibody positivity', 'Oral cavity bleeding', 'Night sweats', 'obsolete Abnormal fecal test result', 'Esophagitis', 'Abnormality of nail color']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning:  
1. **Key diagnostic criteria**: Keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth) are hallmark features of Sjögren syndrome, reflecting exocrine gland dysfunction.  
2. **Autoimmune evidence**: Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports an autoimmune etiology, a core component of Sjögren syndrome.  
3. **Systemic involvement**:  
   - **Mucocutaneous**: Oral ulcers and oral cavity bleeding may arise from mucosal dryness and inflammation.  
   - **Gastrointestinal**: Gastritis, esophagitis, and abdominal pain align with dysmotility or autoimmune-mediated mucosal injury.  
   - **Neurological**: Somatic sensory dysfunction, dysesthesia, and focal white matter lesions suggest peripheral/CNS involvement, recognized in Sjögren-related neuropathy or vasculitis.  
   - **Musculoskeletal**: Arthralgia and lower limb pain reflect common inflammatory joint manifestations.  
4. **Lymphoproliferative risk**: Neoplasm of the liver (possibly lymphoma) and uterine neoplasm, alongside night sweats and cachexia, raise suspicion for Sjögren-associated B-cell lymphoma, a known severe complication.  
5. **Laboratory anomalies**: Abnormal circulating protein concentration (e.g., hypergammaglobulinemia) and low alkaline phosphatase (potential cholestatic liver involvement) fit with chronic autoimmune activity.  
6. **Exclusion of overlap syndromes**: While symptoms like abnormal nail color or hepatomegaly could suggest other conditions (e.g., scleroderma or autoimmune hepatitis), the constellation of sicca symptoms, autoantibodies, and systemic features prioritizes Primary Sjögren syndrome as the unifying diagnosis.  

Note: Further evaluation (e.g., salivary gland biopsy, lymphoma workup) is critical to confirm and assess disease severity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treacher Collins Syndrome is
Choices:
A. Maxiaofacial Dysostosis
B. MandibuLofacial Dysostosis
C. Maxillomandibutofacial Dysostosis
D. Condylar Dysostosis
Answer: [/INST] MandibuLofacial Dysostosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia & Abnormality of galactoside metabolism**: Directly indicate impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties & Spasticity**: Common in infants with galactosemia due to toxin accumulation (e.g., galactitol) affecting the liver, brain, and kidneys.  
3. **Hyperammonemia & Abnormal amino acid concentrations**: Caused by liver dysfunction from toxic metabolite buildup (galactose-1-phosphate), disrupting urea cycle and amino acid metabolism.  
4. **Prolonged PTT**: Results from coagulopathy secondary to liver damage.  
5. **Neonatal/Infancy/Childhood death**: Untreated classic galactosemia leads to sepsis, liver failure, or neurological complications, often fatal early in life.  
6. **Prenatal developmental abnormality**: May reflect intrauterine toxicity from maternal galactose exposure in severe cases.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning:  
- Overlaps with classic galactosemia but emphasizes the broader category. Key symptoms (hypergalactosemia, liver dysfunction, metabolic abnormalities) align with galactosemia subtypes. Early mortality and hyperammonemia reinforce the diagnosis.  
- Differentiation: Classic galactosemia (GALT deficiency) is the most severe form, explaining the fatal trajectory, while ""galactosemia"" may encompass other enzymatic defects (e.g., GALK1, GALE), though the symptom severity here points to GALT deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Microcephaly', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and 4-hydroxyphenylacetic aciduria directly indicate a defect in tyrosine metabolism. These metabolites accumulate due to fumarylacetoacetate hydrolase (FAH) deficiency, a hallmark of HT-1.  
2. **Liver dysfunction**: Elevated alpha-fetoprotein (AFP) reflects hepatic damage, consistent with HT-1’s hepatotoxic effects, leading to neonatal liver failure and risk of early death (neonatal/infancy/childhood).  
3. **Neurological and developmental features**: Motor delay, hypotonia, and microcephaly may arise from toxic metabolite-induced neurotoxicity or prenatal metabolic disruption.  
4. **Prenatal/structural anomalies**: Hypospadias and prenatal developmental abnormalities could stem from intrauterine metabolic stress, though these are less typical and may suggest severe early-onset disease.  
5. **Mortality**: Early death aligns with untreated HT-1 progression, involving liver failure, renal disease, or neurological crises.  
6. **Hyperphenylalaninemia**: Likely secondary due to downstream tyrosine pathway disruption, though phenylalanine levels are less prominently elevated in HT-1 compared to phenylketonuria.  

Key confirmatory factors: Tyrosine metabolite elevation + AFP + clinical progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Death in childhood', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADHD causes accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine due to impaired GABA metabolism.  
2. **Neurological symptoms (Seizure, Ataxia, Hypotonia)**: GHB toxicity disrupts neurotransmission, leading to seizures, cerebellar dysfunction (ataxia), and reduced muscle tone.  
3. **Developmental delays (Speech, Motor)**: Chronic GABA imbalance impairs neurodevelopment, affecting speech and motor milestones.  
4. **Hyperactivity**: Paradoxical excitatory effects of excess GHB contribute to hyperactive behavior.  
5. **Early mortality (Infancy/Childhood)**: Severe metabolic dysfunction or refractory seizures in acute crises may lead to premature death.  
SSADHD is confirmed via genetic testing and elevated GHB in urine/blood, aligning with the symptom profile. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Yellow Fever vaccination stas protection after how many days of injection -
Choices:
A. 5 days
B. 10 days
C. 15 days
D. 20 days
Answer: [/INST] 10 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cysticercosis cellulosae causes infection with
Choices:
A. Taenia saginata
B. Echinococcus granulosus
C. Taenia solium
D. Diphyllobothrium latum
Answer: [/INST] Taenia solium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Incubation period of Rabies depends on:
Choices:
A. Severity of bite
B. Number of bite
C. Site of bite
D. All of the above.
Answer: [/INST] All of the above. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Elevated urinary carboxylic acid', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal circulating leucine concentration**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of branched-chain amino acids (BCAAs: leucine, isoleucine, valine). Elevated leucine is neurotoxic and a hallmark of MSUD.  
2. **Elevated urinary carboxylic acid**: Excess BCAAs are metabolized into ketoacids, which are excreted in urine as carboxylic acids (e.g., α-ketoisocaproic acid), detectable via urine organic acid analysis.  
3. **Body odor**: The presence of sotolon, a metabolite of isoleucine, produces a distinctive maple syrup or burnt sugar odor in bodily fluids.  
4. **Neurological symptoms (Lethargy, Hypotonia, Tremor, Opisthotonus, Drowsiness)**: Leucine toxicity disrupts neurotransmitter synthesis and cerebral energy metabolism, causing encephalopathy, hypotonia, and hypertonic posturing (opisthotonus).  
5. **Sleep disturbance, Neonatal/Infant death**: Untreated classic MSUD rapidly progresses to cerebral edema, seizures, coma, and death within weeks to months of birth due to metabolic crisis.  
6. **Early mortality**: Classic MSUD manifests neonatally; without dietary BCAA restriction and metabolic support, fatal outcomes are inevitable.  

The combination of metabolic derangements (leucine elevation, urinary ketoacids), neurotoxicity, and pathognomonic odor confirms MSUD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are true of Craniopharyngioma except -
Choices:
A. Derived from Rathke's pouch
B. Contains epithelial cells
C. Present in sella or infrasellar location
D. Causes visual disturbances
Answer: [/INST] Present in sella or infrasellar location </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated severe PKU can lead to toxic accumulation of phenylalanine, causing irreversible neurological damage, seizures, and failure to thrive, which may result in early mortality if undiagnosed and unmanaged.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated hyperphenylalaninemia during pregnancy) can cause fetal developmental abnormalities (e.g., microcephaly, congenital heart defects). However, if the infant itself has PKU, metabolic disruption post-birth may contribute to developmental issues.  
4. **Exclusion of BH4 deficiencies**: While hyperphenylalaninemia can also occur in tetrahydrobiopterin (BH4) deficiencies, the listed symptoms align more with classic PKU when neonatal screening/treatment is unavailable or delayed.  

Conclusion: The combination of hyperphenylalaninemia and early lethality strongly supports PKU, particularly in settings lacking newborn screening or dietary intervention. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following signs are seen in Dermatomyositis except
Choices:
A. Heliotrope sign
B. Gottron sign
C. Dimple sign
D. Shawl sign
Answer: [/INST] Dimple sign </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Opisthotonus', 'Cerebral edema', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia and Oroticaciduria**: Core features of urea cycle disorders (UCDs). Elevated ammonia results from impaired urea synthesis, while oroticaciduria arises due to mitochondrial carbamoyl phosphate ""shunting"" into cytoplasmic pyrimidine synthesis.  
2. **Neonatal/Infantile Presentation**: Death in infancy/neonatal death, feeding difficulties, and apathy align with severe UCDs presenting shortly after birth.  
3. **Neurological Symptoms**: Seizures, cerebral edema, and opisthotonus reflect acute hyperammonemic crises causing neurotoxicity and intracranial hypertension.  
4. **Citrullinemia Type I vs. Type II**:  
   - Type I (ASS1 deficiency) is neonatal-onset with marked citrulline elevation in plasma and urine.  
   - Type II (SLC25A13 mutation) typically presents later (adult-onset) and lacks oroticaciduria.  
   - The presence of **oroticaciduria** and **neonatal lethality** specifically points to Type I.  
5. **Cyanosis**: Likely secondary to metabolic acidosis or respiratory compromise during crisis.  

Conclusion: Classic citrullinemia (Type I) is confirmed by hyperammonemia, oroticaciduria, neonatal severity, and citrulline accumulation due to argininosuccinate synthetase (ASS1) deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera vaccination is indicated ?
Choices:
A. To control epidemics
B. For travellers
C. In endemic areas
D. In Neonates
Answer: [/INST] In endemic areas </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Subependymal Gaint Cell Astrocytoma is commonly associated with which of the following condition?
Choices:
A. Neurofibroma
B. Schwannoma
C. Ependymoma
D. Tuberous sclerosis
Answer: [/INST] Tuberous sclerosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal saccadic eye movements', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Lipodystrophy', 'Abnormal skeletal morphology', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation affecting cerebellar development.  
2. **Generalized hypotonia**: Common in glycosylation disorders due to neuromuscular involvement.  
3. **Lipodystrophy**: Altered fat distribution linked to metabolic dysregulation from glycosylation defects.  
4. **Thromboembolism**: Coagulation factor deficiencies (e.g., antithrombin III) are frequent in PMM2-CDG.  
5. **Abnormal saccadic eye movements**: Reflects cerebellar/brainstem dysfunction.  
6. **Neonatal death/Death in infancy**: Severe forms of PMM2-CDG often lead to early mortality.  
7. **Abnormal skeletal morphology**: Dysostosis and growth retardation are recognized features.  
**Confirmatory evidence**: PMM2-CDG is the most prevalent CDG subtype, and this symptom cluster aligns with its multisystemic presentation (neurodevelopmental, hepatic, and coagulation abnormalities). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Intellectual disability, mild', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability (mild), global developmental delay, ADHD/hyperactivity, and atypical behavior align with the core neurocognitive deficits in NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum, cerebellar vermis, and pons morphology, cerebral hypomyelination, ventriculomegaly, and delayed myelination match the ""brain"" phenotype in NEDBEH.  
3. **Ocular anomalies**: Coloboma, microphthalmia, blepharophimosis, Peters anomaly, optic atrophy, and iris/eyebrow abnormalities satisfy the ""eye"" criterion.  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return correspond to the ""heart"" component.  
5. **Supportive systemic features**: Cleft lip, renal cysts, gastrointestinal anomalies (pyloric stenosis, duodenal atresia), and skeletal findings (syndactyly, scoliosis) are reported in NEDBEH.  
6. **Overlapping dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, and narrow mouth are consistent with facial gestalt seen in NEDBEH.  
7. **Hypotonia/spasticity**: Generalized hypotonia and spastic tetraparesis reflect the CNS involvement typical of the disorder.  

The constellation of neurodevelopmental delays, structural brain/eye/heart anomalies, and multisystem involvement strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Rubinstein-Taybi) due to the absence of pathognomonic features for other entities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Commonest location for Craniopharyngioma is
Choices:
A. Intrasellar
B. Suprasellar
C. Intraventricular
D. Intracerebral
Answer: [/INST] Suprasellar </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 59-year-old male came with Hb 18.0 gm/dl on three occasions. The resident doctor wants to exclude Polycythemia Vera. Which of the following is the most relevant investigation :
Choices:
A. Hematocrit
B. Total leukocyte count
C. Red cell mass
D. Reticulocyte count
Answer: [/INST] Red cell mass </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), leading to the accumulation of phenylalanine in the blood. This directly explains the elevated phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: In PKU, phenylalanine is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and developmental failure, often leading to early mortality if dietary phenylalanine restriction is not implemented.  
4. **Hypertyrosinemia discrepancy**: Classic PKU typically causes *low* tyrosine due to blocked PAH activity. Hypertyrosinemia here may reflect a lab error, concurrent tyrosine supplementation, or an atypical presentation (e.g., transient tyrosinemia from liver dysfunction).  
5. **Recurrent viral infections**: Unrelated to PKU pathophysiology but could arise from secondary complications (e.g., malnutrition, immunosuppression due to systemic metabolic stress).  

Conclusion: Core symptoms (hyperphenylalaninemia, urinary phenylketones) align with PKU. Atypical features (hypertyrosinemia, infections) require further investigation but do not override the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Ataxia', 'Dysarthria', 'Anemia', 'Gait ataxia', 'Bone marrow hypocellularity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Ataxia-pancytopenia syndrome: The patient exhibits **nystagmus**, **ataxia**, **dysarthria**, and **gait ataxia**, indicating cerebellar dysfunction. Concurrent **anemia** and **bone marrow hypocellularity** suggest pancytopenia due to impaired hematopoiesis. Ataxia-pancytopenia syndrome (APS) is a rare genetic disorder characterized by cerebellar degeneration and bone marrow failure, aligning with this symptom constellation. The triad of neurological deficits, cytopenias, and hypocellular marrow distinguishes APS from isolated cerebellar ataxias or acquired hematologic disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nephrocalcinosis', 'Cutis laxa', 'Abnormal heart morphology', 'Abnormal facial shape']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cutis laxa, autosomal recessive, type IIC (ARCL2C)  
Reasoning:  
1. **Cutis laxa**: A primary feature of ARCL2C, caused by mutations in the PYCR1 gene, which disrupts mitochondrial function and collagen/proline metabolism, leading to loose, inelastic skin.  
2. **Nephrocalcinosis**: Linked to metabolic dysfunction in ARCL2C, where impaired mitochondrial energy production may cause renal tubular acidosis or calcium deposition in the kidneys.  
3. **Abnormal heart morphology**: PYCR1 mutations are associated with cardiac anomalies such as pulmonary artery stenosis or septal defects, contributing to structural heart abnormalities.  
4. **Abnormal facial shape**: ARCL2C presents with distinct facial dysmorphism (triangular face, prominent eyes, large fontanelles, and a prematurely aged appearance), aligning with the patient’s symptoms.  
5. **Consistency with ARCL2C**: The combination of connective tissue, renal, cardiac, and craniofacial anomalies strongly supports this diagnosis, as other cutis laxa subtypes (e.g., ARCL2A/B) typically involve different organ systems or lack nephrocalcinosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common Morphological difference between Ulcerative Colitis and Crohn's disease:
Choices:
A. Crypt abscess
B. Diffuse polyps
C. Mucosal edema
D. Lymphoid aggregates
Answer: [/INST] Crypt abscess </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tetralogy of Fallot classically consists of the combination of ail except -
Choices:
A. Obstruction to right ventricular outflow (pulmonary' stenosis)
B. Ventricular septal defect (VSD)
C. Dextroposition of the aorta with septal over-ride
D. Left ventricular hypertrophy
Answer: [/INST] Left ventricular hypertrophy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which soft tissue sarcoma commonly gives to bone secondarya) Fibrosarcomab) Liposarcomac) Osteosarcomad) Neurofibromae) Synovial sarcoma
Choices:
A. ab
B. ad
C. be
D. ce
Answer: [/INST] be </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following agents is the drug of choice for Central Diabetes Insipidus -
Choices:
A. Desmopressin
B. Demeclocycline
C. Thiazide Diuretics
D. Lithium
Answer: [/INST] Desmopressin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination compagin between 9-14 years age for elimination is -
Choices:
A. Keep up
B. Follow up
C. Mop up
D. Catch up
Answer: [/INST] Catch up </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chemotherapy agents used for Retinoblastoma includes
Choices:
A. Vincristine, Etoposide, Carboplatin
B. Vincristine, Doxorubicin, Carboplatin
C. Doxorubicin, Etoposide, Carboplatin
D. Actinomycin, Doxorubicin, Carboplatin
Answer: [/INST] Vincristine, Etoposide, Carboplatin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal penis morphology', 'Oral ulcer', 'Epistaxis', 'Uveitis', 'Visual loss', 'Hematuria', 'Hypertension', 'Arthritis', 'Ankle swelling', 'Abdominal pain', 'Fasciculations', 'Arthralgia', 'Elevated hepatic transaminase', 'Increased CSF protein concentration', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Myalgia', 'Muscle spasm', 'Spinal canal stenosis', 'Back pain', 'Somatic sensory dysfunction', 'Focal white matter lesions', 'Foot dorsiflexor weakness', 'Stomatitis', 'Abnormal metacarpophalangeal joint morphology', 'Fatigue', 'Dysesthesia', 'Increased circulating lactate dehydrogenase concentration', 'Elevated gamma-glutamyltransferase level', 'Unusual infection', 'Aphthous ulcer', 'Dysuria', 'Epigastric pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: The patient presents with oral ulcers (aphthous ulcer, stomatitis) and genital ulcers (implied by ""abnormal penis morphology""), fulfilling the International Criteria for Behçet’s Disease (ICBD) major criteria.  
2. **Ocular Manifestations**: Uveitis and visual loss are classic features of Behçet’s, often leading to severe complications if untreated.  
3. **Neurological Involvement**: Increased CSF protein, focal white matter lesions, and somatic sensory dysfunction suggest neuro-Behçet’s, a serious subtype affecting the central nervous system.  
4. **Vasculitic Features**: Epistaxis, hematuria, and hypertension may reflect systemic vasculitis, a hallmark of Behçet’s that can involve small and large vessels.  
5. **Musculoskeletal Symptoms**: Arthritis, arthralgia, and ankle swelling align with inflammatory joint involvement common in Behçet’s.  
6. **Gastrointestinal Involvement**: Abdominal/epigastric pain could indicate intestinal ulcers, part of the ""intestinal Behçet’s"" phenotype.  
7. **Elevated Inflammatory Markers**: Elevated creatine kinase, LDH, and hepatic transaminases suggest systemic inflammation, consistent with Behçet’s multisystemic nature.  
8. **Exclusion of Mimics**: Symptoms like recurrent infections are atypical but may reflect immunosuppressive therapy rather than an infectious etiology. The absence of more specific markers for diseases like lupus or sarcoidosis strengthens the Behçet’s diagnosis.  

**Conclusion**: The combination of recurrent oral/genital ulcers, uveitis, vasculitis, and multisystem inflammation strongly supports Behçet’s syndrome, aligning with ICBD diagnostic criteria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leiomyosarcoma most common age group is -
Choices:
A. 20 - 40 years
B. 30 - 50 years
C. 40 - 60 years
D. 50 - 70 years
Answer: [/INST] 40 - 60 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Anemia', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Feeding difficulties', 'Hypergalactosemia', 'Decreased circulating ferritin concentration', 'Decreased serum iron']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** and **abnormality of galactoside metabolism** directly indicate impaired galactose processing, a hallmark of galactosemia.  
2. **Feeding difficulties**, **generalized hypotonia**, **motor delay**, and **intellectual disability** align with metabolic dysfunction and neurological sequelae caused by toxic galactose metabolite accumulation.  
3. **Elevated alkaline phosphatase** and **anemia** suggest liver damage and hematopoietic disruption, common in untreated galactosemia due to galactitol toxicity.  
4. **Decreased serum iron/ferritin** may reflect secondary iron deficiency from malabsorption or chronic illness.  
5. **Abnormal porphyrin levels** could arise from hepatic dysfunction impairing heme synthesis.  
6. **Prenatal abnormalities**, **microcephaly**, and early mortality (**neonatal/infant/childhood death**) correlate with severe metabolic crises in classic galactosemia when galactose exposure begins in utero or postnatally.  
7. **Obesity** is atypical but reported in survivors with long-term metabolic complications.  

Disease: Galactosemia/GAL  
Reasoning:  
- This broader diagnosis encompasses the same pathophysiology as classic galactosemia, with overlapping symptoms (e.g., **hypergalactosemia**, **feeding difficulties**, **hepatic/neurologic involvement**) but allows for phenotypic variability.  
- The specificity of **abnormality of galactoside metabolism** and exclusion of other metabolic disorders (e.g., tyrosinemia) confirm galactosemia as the unifying diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Age group affected by Osteosarcoma
Choices:
A. Up-to 10 yrs
B. 10 -20 yrs
C. 30-40 yrs
D. Older than 45 yrs
Answer: [/INST] 10 -20 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are features of Pertussis except –
Choices:
A. Encephalopathy
B. Cerebellar Ataxia
C. Subconjunctival hemorrhage
D. Bronchiectasis
Answer: [/INST] Cerebellar Ataxia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Neurological complications following Rabies vaccine is common with ?
Choices:
A. HDCS Vaccine
B. Chick embryo Vaccine
C. Semple Vaccine
D. Duck Egg Vaccine
Answer: [/INST] Semple Vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on chromosome ?
Choices:
A. 6
B. 9
C. 13
D. 21
Answer: [/INST] 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Confirmatory test for the diagnosis of Amyloidosis is :
Choices:
A. Diagnostic peritoneal lavage
B. Tongue biopsy
C. Rectal biopsy
D. Whole body CT scan
Answer: [/INST] Rectal biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological and developmental features**: Intellectual disability, motor delay, ataxia, and generalized hypotonia align with PMM2-CDG’s hallmark cerebellar dysfunction.  
2. **Cerebellar abnormalities**: Cerebellar atrophy and agenesis are consistent with structural brain defects seen in severe PMM2-CDG cases.  
3. **Ocular signs**: Strabismus and nystagmus are common due to cerebellar and brainstem involvement.  
4. **Systemic involvement**: Growth delay, microcephaly, and infantile death reflect multisystem pathology from impaired glycosylation.  
5. **Hyporeflexia and encephalopathy**: Indicate widespread neurological dysfunction, typical of PMM2-CDG’s metabolic derangements.  
6. **Diagnostic confirmation**: While genetic testing for *PMM2* mutations is definitive, the clinical triad of cerebellar hypoplasia, developmental delay, and multisystem involvement strongly supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis verrucosa cutis is a form of –
Choices:
A. Tuberculid
B. Primary tuberculosis
C. Postprimary tuberculosis with good resistance
D. Post primary tuberculosis with poor resistance
Answer: [/INST] Postprimary tuberculosis with good resistance </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Type of DCIS Which of the following true regarding Hemophilia A?
Choices:
A. Serum levels of factor VIII are decreased
B. Deficiency of factor IX
C. PT increased
D. PPT decreased
Answer: [/INST] Serum levels of factor VIII are decreased </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypothyroidism', 'Splenomegaly', 'Lymphopenia', 'Microcytic anemia', 'Fever', 'Nausea', 'Dyspnea', 'Pleuritis', 'Pleural effusion', 'Hypocalcemia', 'Poor appetite', 'Abnormal blood sodium concentration', 'Elevated circulating C-reactive protein concentration', 'Sinus tachycardia', 'Fatigue', 'Chills', 'Increased circulating lactate dehydrogenase concentration', 'Cervicitis', 'Chest pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Familial Mediterranean fever, AR  
Reasoning:  
1. **Recurrent fever, chills, and systemic inflammation**: Elevated CRP and lactate dehydrogenase (LDH) align with FMF’s hallmark episodic inflammatory attacks.  
2. **Serositis manifestations**: Pleuritis, pleural effusion, and chest pain reflect pleural inflammation, a classic FMF feature. Dyspnea may arise from pleural effusion.  
3. **Splenomegaly and lymphopenia**: Common during acute FMF flares due to immune activation and cytokine release.  
4. **Microcytic anemia**: Likely secondary to chronic inflammation (anemia of chronic disease) rather than iron deficiency.  
5. **Hypocalcemia and abnormal sodium**: Electrolyte imbalances may occur due to transient renal dysfunction or inflammatory stress.  
6. **Absence of infectious etiology**: Fever, nausea, and fatigue are nonspecific but recurrent without clear infection (e.g., cervicitis could be coincidental).  
7. **Autosomal recessive (AR) inheritance**: FMF is predominantly AR (MEFV gene mutations); the AD form is exceedingly rare and less consistent with this presentation.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. **Overlap in inflammatory symptoms**: Fever, CRP elevation, and pleuritis are shared with AR-FMF.  
2. **Atypical features**: Cervicitis and hypothyroidism are not typical for FMF but might suggest comorbid autoimmune processes, which are less commonly associated with AD-FMF.  
3. **Limited evidence**: AD-FMF is poorly characterized compared to AR-FMF; this diagnosis is less likely unless family history strongly supports autosomal dominant transmission.  

**Final Diagnosis**: Familial Mediterranean fever, AR is the most probable diagnosis given the recurrent serositis, inflammatory markers, and population prevalence of AR inheritance. AD-FMF remains a differential but requires genetic confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Pseudohypoparathyroidism are true, except:
Choices:
A. Low Serum PTH
B. Low Serum calcium
C. High Serum Phosphate
D. Albreight's Hereditary osteodystrophy
Answer: [/INST] Low Serum PTH </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is a disease of -
Choices:
A. Neural transmission caused by the toxin of the bacterium Clostridium botulinum
B. Muscular transmission caused by the toxin of the bacterium Clostridium botulinum
C. Neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum
D. Non neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum
Answer: [/INST] Neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Polydipsia', 'Elevated hepatic transaminase', 'Decreased circulating ceruloplasmin concentration', 'Death in adolescence', 'Decreased circulating copper concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin and copper concentrations**: Wilson disease is caused by ATP7B gene mutations, impairing copper transport and incorporation into ceruloplasmin, leading to low serum ceruloplasmin and copper levels.  
2. **Elevated hepatic transaminases**: Copper accumulation in the liver causes hepatocellular injury, manifesting as elevated liver enzymes.  
3. **Polydipsia**: Neurological involvement (e.g., hypothalamic dysfunction) or renal tubular acidosis (secondary to copper toxicity) may cause excessive thirst.  
4. **Death in adolescence**: Untreated Wilson disease progresses to liver failure, hemolytic crises, or neuropsychiatric complications, often fatal in adolescence/early adulthood without timely intervention.  
5. **Exclusion of mimics**: Symptoms align with Wilson disease’s triad (hepatic, neurologic, psychiatric) and biochemical profile, distinguishing it from other copper disorders (e.g., Menkes disease) or isolated liver pathologies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Babesiosis -a) Caused by Babesia microtib) Resides in RBCc) Resides in WBCd) Chloroquine is the treament of choicee) It is filarial parasite
Choices:
A. ab
B. a
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles belongs to,
Choices:
A. Togavirus
B. Paramyxovirus
C. Arbovirus
D. none of the above
Answer: [/INST] Paramyxovirus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma associated Turcot syndrome is characterized by mutation in :
Choices:
A. KRAS
B. P53
C. APL
D. PTEN
Answer: [/INST] APL </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Teduglutide is a recently introduced drug for Short Bowel Syndrome- What is it?
Choices:
A. GLP- 2 analogue
B. GLP anta agonist
C. Somatostatin analogue
D. H1 blocker
Answer: [/INST] GLP- 2 analogue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['High palate', 'Microcephaly', 'Epicanthus', 'Micrognathia', 'Ptosis', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Ventriculomegaly', 'Increased serum lactate', 'EEG abnormality', 'Abnormal midbrain morphology', 'Scoliosis', 'Short nose', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Alveolar ridge overgrowth', 'Peripheral neuropathy', 'Underdeveloped supraorbital ridges', 'Small hand']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A hallmark feature of CDDG1, directly listed in the patient’s symptoms.  
2. **Liver dysfunction**: Suggested by elevated alpha-fetoprotein (marker for hepatic issues) and prolonged neonatal jaundice.  
3. **Neurological involvement**: Global developmental delay, seizures, hypotonia, EEG abnormalities, and ventriculomegaly align with CDDG1’s neurodevelopmental deficits.  
4. **Craniofacial/skeletal anomalies**: Microcephaly, micrognathia, epicanthus, short nose, underdeveloped supraorbital ridges, small hands, short feet, and scoliosis reflect multisystem dysmorphism typical of glycosylation disorders.  
5. **Peripheral neuropathy**: Reduced tendon reflexes and peripheral neuropathy suggest nerve involvement, consistent with deglycosylation defects.  
6. **Metabolic markers**: Elevated serum lactate and abnormal midbrain morphology support mitochondrial or metabolic dysfunction seen in CDG disorders.  
7. **Supportive features**: Intrauterine growth retardation, constipation, and alveolar ridge overgrowth further correlate with systemic manifestations of CDDG1.  
8. **Exclusion of mimics**: While other CDG types (e.g., PMM2-CDG) share overlapping symptoms, the presence of alacrima and elevated AFP specifically points to CDDG1/NGLY1 deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acromegaly is due to excess of:
Choices:
A. Somatomedin
B. Growth hormone
C. Somatostation
D. Insulin
Answer: [/INST] Growth hormone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Spatulate thumbs', 'Congenital hip dislocation', 'Talipes equinovarus', 'Vertebral fusion', 'Elbow dislocation', 'Tapered humerus', 'Short stature', 'Congenital knee dislocation', 'Vertebral arch anomaly', 'Midface retrusion', 'Abnormal bone ossification']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Larsen syndrome  
Reasoning:  
1. **Congenital joint dislocations** (hip, knee, elbow) are hallmark features of Larsen syndrome, caused by connective tissue abnormalities.  
2. **Cleft palate** and **midface retrusion** align with craniofacial manifestations commonly seen in the syndrome.  
3. **Spatulate thumbs** and **talipes equinovarus** are characteristic limb anomalies associated with Larsen syndrome.  
4. **Vertebral fusion** and **vertebral arch anomaly** reflect spinal malformations, a key diagnostic criterion.  
5. **Tapered humerus** and **abnormal bone ossification** correlate with skeletal dysplasia observed in the disorder.  
6. **Short stature** is consistent with systemic skeletal involvement.  
The combination of craniofacial, spinal, joint, and limb anomalies strongly supports the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid oral vaccine is given ?
Choices:
A. 1, 3, 5 days
B. 1, 2, 3 days
C. 1, 2, 4 days
D. 1, 7, 14 days
Answer: [/INST] 1, 3, 5 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Deeply set eye', 'Developmental cataract', 'Dry skin', 'Cutaneous photosensitivity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cockayne syndrome, type B  
Reasoning:  
1. **Microcephaly** and **developmental delays** align with Cockayne syndrome’s hallmark neurological and growth abnormalities.  
2. **Deeply set eyes** (enophthalmos) is a common craniofacial feature in Cockayne syndrome due to facial fat loss and skeletal dysplasia.  
3. **Developmental cataracts** are characteristic of Cockayne syndrome type B, arising from DNA repair defects affecting lens transparency.  
4. **Dry skin** and **cutaneous photosensitivity** reflect defective nucleotide excision repair (NER), leading to UV-induced damage and premature aging of skin.  
5. The combination of photosensitivity, neurodegeneration, and ocular abnormalities strongly differentiates Cockayne syndrome from other DNA repair disorders (e.g., xeroderma pigmentosum).  
6. Type B is distinguished by earlier onset and severe progression, consistent with the listed symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cataract', 'Delayed speech and language development', 'Cholelithiasis', 'Intellectual disability', 'Spasticity', 'Failure to thrive', 'Death in infancy', 'Abnormal foot morphology', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Feeding difficulties', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and abnormal galactoside metabolism, hallmark biochemical features of galactosemia. Symptoms like cataracts (galactitol accumulation), hepatomegaly, elevated hepatic transaminases, and cholelithiasis align with liver dysfunction caused by toxic galactose metabolites. Failure to thrive, vomiting, and feeding difficulties are common neonatal presentations. Intellectual disability, delayed speech, and spasticity reflect neurological damage from chronic toxicity. Elevated alkaline phosphatase and abnormal amino acid concentrations (aspartate/alanine) suggest secondary liver impairment. Early mortality (infancy/childhood/adolescence) underscores untreated disease severity, consistent with classic galactosemia caused by GALT deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Miliary Tuberculosis are true Except:
Choices:
A. May occur following primary infection
B. May occur following secondary reactivation
C. Sputum microscopy is usually negative
D. Montoux is always positive
Answer: [/INST] Montoux is always positive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mainstay of treatment of Nephrogenic Diabetes Insipidus is:
Choices:
A. Desmopressin
B. Thiazide / Amiloride diuretics and salt restriction
C. Desmopressin and salt restriction
D. Vasopressin and salt restriction
Answer: [/INST] Thiazide / Amiloride diuretics and salt restriction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is most commonly seen in DM -
Choices:
A. Maturity onset DM
B. Type I DM
C. Type II DM
D. Hypertension
Answer: [/INST] Type II DM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Hepatic failure', 'Death in infancy', 'Premature birth', 'Diarrhea', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with hypergalactosemia and an abnormality in galactoside metabolism, hallmark features of galactosemia. Neonatal symptoms like hepatic failure, prolonged partial thromboplastin time (indicating coagulopathy), diarrhea, and increased bilirubin align with acute metabolic decompensation due to galactose toxicity. Premature birth and early mortality (neonatal/infant/childhood death) reflect severe disease progression. Intellectual disability and motor delays suggest chronic neurological damage from toxic metabolite accumulation (e.g., galactitol). Abnormal aspartate and alanine concentrations point to secondary liver dysfunction disrupting amino acid metabolism. Classic galactosemia (GALT deficiency) is confirmed by this triad: failure to thrive, liver injury, and hypergalactosemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Narrow mouth', 'Microcephaly', 'Posteriorly rotated ears', 'Prominent nose', 'Strabismus', 'Downslanted palpebral fissures', 'Long eyelashes', 'Thick eyebrow', 'Coloboma', 'Dental crowding', 'Dental malocclusion', 'Autistic behavior', 'Anxiety', 'Delayed speech and language development', 'Hirsutism', 'Global developmental delay', 'Intellectual disability, moderate', 'Highly arched eyebrow', 'Scoliosis', 'Delayed skeletal maturation', 'Feeding difficulties in infancy', 'Low hanging columella', 'Broad hallux', 'Keloids', 'Talon cusp', 'Broad thumb']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency/Rubinstein-Taybi syndrome 2  
Reasoning:  
1. **Craniofacial features**: Narrow mouth, microcephaly, posteriorly rotated ears, prominent nose, downslanted palpebral fissures, long eyelashes, thick/highly arched eyebrows, and low-hanging columella align with the characteristic facial dysmorphism of Rubinstein-Taybi syndrome (RSTS).  
2. **Limb anomalies**: Broad hallux and broad thumb are hallmark signs of RSTS.  
3. **Dental abnormalities**: Dental crowding, malocclusion, and talon cusp are commonly reported in RSTS due to craniofacial and dental developmental defects.  
4. **Ocular findings**: Strabismus and coloboma (though less frequent) are consistent with ocular manifestations of RSTS.  
5. **Developmental delays**: Global developmental delay, moderate intellectual disability, delayed speech, and autistic behavior match the neurocognitive profile of RSTS.  
6. **Skeletal features**: Scoliosis and delayed skeletal maturation are recognized skeletal anomalies in RSTS.  
7. **Additional supportive signs**: Feeding difficulties in infancy, hirsutism, and keloids (less common but reported) further support the diagnosis.  
8. **Genetic correlation**: EP300 haploinsufficiency (RSTS type 2) explains the phenotype, as EP300 mutations cause overlapping features with CREBBP-associated RSTS (type 1), including distinct facial traits, broad digits, and neurodevelopmental delays. Talon cusp and keloids may be more prevalent in EP300-related cases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid vaccine efficacy is -
Choices:
A. 85%
B. 50%
C. 95%
D. 100%
Answer: [/INST] 85% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achalasia cardia
Choices:
A. Absence of nerves
B. Absence of muscles
C. Hyperophy of nerves
D. Hyperophy of muscles
Answer: [/INST] Absence of nerves </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Triangular face', 'Cupped ear', 'Protruding ear', 'Myopia', 'Exotropia', 'Autistic behavior', 'Intellectual disability', 'Global developmental delay', 'Clinodactyly of the 5th finger', 'Clinodactyly of the 2nd toe', 'Bilateral sensorineural hearing impairment', 'Prominent ear helix', 'Cerebral palsy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Craniofacial features**: Triangular face, cupped/protruding ears, and prominent ear helix are consistent with dysmorphic facial features observed in NEDBEH.  
2. **Neurodevelopmental symptoms**: Autistic behavior, intellectual disability, and global developmental delay align with the disorder’s core neurocognitive phenotype.  
3. **Ocular anomalies**: Myopia and exotropia (eye misalignment) correlate with the ""eye anomalies"" component of NEDBEH.  
4. **Skeletal findings**: Clinodactyly (5th finger and 2nd toe) supports subtle skeletal involvement, a recognized feature.  
5. **Neurological overlap**: Cerebral palsy-like motor dysfunction may reflect underlying brain anomalies (e.g., structural malformations or white matter changes).  
6. **Hearing impairment**: Bilateral sensorineural hearing loss, while not universally present in NEDBEH, can occur due to genetic or neurodevelopmental disruptions.  
7. **Exclusion of mimics**: The constellation rules out syndromes like Fragile X (no hyperextensible joints/macrocephaly) or chromosomal disorders (clinodactyly alone is nonspecific).  
8. **Genetic basis**: PHF21A variants are implicated in NEDBEH, which disrupt neurodevelopment and craniofacial patterning, explaining multisystem involvement. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coarse facial features', 'Strabismus', 'Pectus excavatum', 'Deformed rib cage', 'Hypotonia', 'Motor delay', 'Hepatic cysts', 'Omphalocele', 'Redundant skin', 'Mitral regurgitation', 'Abnormal facial shape', 'Spinal cord compression', 'Spondyloepimetaphyseal dysplasia', 'Coxa valga', 'Kyphoscoliosis', 'Radial head subluxation', 'Hypoplasia of the capital femoral epiphysis', 'Neonatal hyperbilirubinemia', 'Abnormality of the cervical spine', 'Short stature', 'Severe platyspondyly', 'Cervical instability', 'Abnormal pelvis bone morphology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: The patient exhibits *spondyloepimetaphyseal dysplasia*, *severe platyspondyly*, *coxa valga*, and *abnormal pelvis bone morphology*, which are hallmark features of ISDNA. These align with the ""immunoskeletal"" component of the disease, reflecting dysostosis multiplex-like skeletal dysplasia.  
2. **Neurodevelopmental Delays**: *Hypotonia* and *motor delay* correlate with ISDNA-associated neurodevelopmental impairments, often linked to cerebellar hypoplasia or white matter changes.  
3. **Cervical Instability/Spinal Involvement**: *Cervical instability*, *spinal cord compression*, and *abnormality of the cervical spine* are critical findings in ISDNA due to defective bone maturation and ligamentous laxity.  
4. **Hepatic and Neonatal Features**: *Hepatic cysts* and *neonatal hyperbilirubinemia* suggest systemic involvement, consistent with ISDNA’s multisystemic nature. *Omphalocele* may reflect connective tissue dysfunction.  
5. **Dysmorphic Features**: *Coarse facial features*, *abnormal facial shape*, and *redundant skin* are seen in ISDNA, likely due to glycosylation defects or extracellular matrix disruption.  
6. **Cardiac and Ocular Manifestations**: *Mitral regurgitation* and *strabismus* align with connective tissue/craniofacial anomalies reported in ISDNA.  
7. **Genetic Link**: While not explicitly stated, ISDNA is caused by biallelic *EXOC6B* mutations, which disrupt exocytosis and glycosylation, explaining the skeletal, hepatic, and neurodevelopmental phenotypes.  

The constellation of severe skeletal dysplasia, neurodevelopmental delays, systemic involvement (hepatic/cardiac), and dysmorphism strongly supports ISDNA over other skeletal dysplasias (e.g., Morquio syndrome lacks neurodevelopmental features; COMP-associated disorders lack hepatic cysts). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Otitis media', 'Cyanosis', 'Pericardial effusion', 'Abnormal toe morphology', 'Pleural effusion', 'Arthralgia', 'Peripheral neuropathy', 'Abnormal cardiovascular system physiology', 'Gangrene']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Granulomatosis with polyangiitis (GPA):  
1. **Otitis media**: GPA frequently involves upper respiratory tract inflammation, leading to chronic otitis media or sinusitis.  
2. **Cyanosis & Pleural/Pericardial effusions**: Systemic vasculitis in GPA can cause lung parenchymal disease (nodules, hemorrhage) and serositis, reducing oxygenation (cyanosis) and triggering fluid accumulation in pleural/pericardial spaces.  
3. **Arthralgia & Peripheral neuropathy**: Immune-mediated vascular inflammation damages joints and vasa nervorum, causing joint pain and neuropathic symptoms.  
4. **Abnormal cardiovascular physiology**: Vasculitis-induced endothelial injury disrupts blood flow dynamics, while pericardial effusion exacerbates cardiac dysfunction.  
5. **Gangrene & Abnormal toe morphology**: Necrotizing vasculitis compromises distal blood supply, leading to ischemic tissue damage (gangrene) and structural toe changes (e.g., digital clubbing or necrosis).  
6. **Multi-organ involvement**: The combination of ENT, pulmonary, cardiovascular, musculoskeletal, and peripheral vascular symptoms aligns with GPA’s systemic nature. ANCA-associated pathology (e.g., PR3-ANCA) further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to elevated phenylalanine levels in the blood.  
2. **Abnormality of prenatal development or birth** may occur if maternal PKU is untreated during pregnancy, resulting in fetal exposure to high phenylalanine levels, causing microcephaly, congenital heart defects, or developmental delays.  
3. **Death in infancy/Neonatal death** is rare in classic PKU due to newborn screening and dietary management. However, untreated severe cases can lead to irreversible neurological damage, seizures, and failure to thrive, potentially progressing to fatal outcomes in early life.  
4. The combination of hyperphenylalaninemia with severe early-life complications aligns with PKU when undiagnosed/unmanaged, particularly in regions lacking newborn screening programs. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid in first week of illness is best diagnosed by:-
Choices:
A. Serum widal test
B. Stool culture
C. Urine test
D. Blood culture
Answer: [/INST] Blood culture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Low-set ears', 'Nystagmus', 'Spasticity', 'Death in infancy', 'Dyspnea', 'Fair hair', 'High, narrow palate', 'Increased total bilirubin', 'Neonatal death', 'Stridor', 'White hair', 'Feeding difficulties', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Increased total bilirubin**: Caused by hemolytic anemia, a hallmark of glutathione synthetase deficiency due to impaired antioxidant defense in red blood cells.  
2. **Neonatal death/Death in infancy**: Matches the severe, early-onset form of the disorder, often fatal without intervention.  
3. **Dyspnea/Stridor**: Results from metabolic acidosis-induced compensatory hyperventilation or respiratory muscle spasticity.  
4. **Spasticity/Nystagmus**: Reflects neurological damage from oxidative stress and 5-oxoprolinuria, secondary to glutathione deficiency.  
5. **Feeding difficulties/Fatigue**: Linked to metabolic instability, acidosis, and anemia impairing energy metabolism.  
6. **Fair/White hair**: Pigment dilution due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **High, narrow palate/Low-set ears**: Congenital anomalies occasionally associated with inborn errors of metabolism.  
8. **Supporting exclusion**: Symptoms align with glutathione synthetase deficiency rather than similar disorders (e.g., Menkes syndrome lacks hemolysis, Crigler-Najjar lacks acidosis). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achalasia cardia due to:
Choices:
A. Degeneration of myenteric plexus due to toxin
B. Degeneration and absence of ganglion cells in auerbach' Plexus
C. Excess of Ganglion cells in auerbach Plexus
D. Degeneration of meissner's Plexus
Answer: [/INST] Degeneration and absence of ganglion cells in auerbach' Plexus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about primary Tuberculosis are true, Except:
Choices:
A. Cavitatory lesion
B. Pleural effusion
C. Fibrocasseous lesion
D. Phlyctenular conjunctivitis
Answer: [/INST] Cavitatory lesion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mumps is caused by:
Choices:
A. Orthomyxo virus
B. Paramyxo virus
C. Rheno virus
D. EB virus
Answer: [/INST] Paramyxo virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Tall stature', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Hypertrophic cardiomyopathy', 'Abnormal facial shape', 'Bilateral tonic-clonic seizure', 'Ventriculomegaly', 'Kyphoscoliosis', 'Aortic aneurysm']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning: The patient's symptoms align with ARCL2D caused by PYCR1 mutations. Key indicators include cutis laxa (characteristic loose skin), generalized hypotonia, flexion contractures, hip dysplasia, and kyphoscoliosis (musculoskeletal involvement). Neurological features (bilateral tonic-clonic seizures, ventriculomegaly) and cardiovascular abnormalities (hypertrophic cardiomyopathy, aortic aneurysm) support systemic connective tissue dysfunction. Entropion and abnormal facial shape correlate with craniofacial manifestations of PYCR1 deficiency. Disproportionate tall stature, though atypical in some cutis laxa subtypes, is compatible with ARCL2D's variable phenotypic spectrum. The combination of skin, skeletal, neurological, and cardiac findings distinguishes this from other ARCL subtypes or Marfan-like syndromes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not seen in Hereditary Spherocytosis
Choices:
A. Direct Coomb's Positive
B. Increased Osmotic Fragility
C. Splenomegaly
D. Gall stones
Answer: [/INST] Direct Coomb's Positive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chemoprophylaxis of Malaria can be done by all except
Choices:
A. Chloroquine
B. Mefloquine
C. Primaquine
D. Proguanil
Answer: [/INST] Primaquine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia A has increased:
Choices:
A. PT
B. PTT
C. PT & PTT
D. None
Answer: [/INST] PTT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Keratoconus, all are seen except:
Choices:
A. Munson's sign
B. Thinning of cornea in center
C. Distoion of corneal reflex at center
D. Hypermetropic refractive error fond
Answer: [/INST] Hypermetropic refractive error fond </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient's symptoms of neonatal death, death in infancy/childhood, and abnormal circulating carnitine align with MCADD, a fatty acid oxidation disorder. MCADD impairs breakdown of medium-chain fatty acids, leading to hypoglycemia and metabolic crises during fasting. Neonatal and childhood fatalities are hallmark features due to delayed diagnosis. Abnormal carnitine levels occur secondary to disrupted fatty acid metabolism. The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase"" is likely a misstatement; MCADD specifically involves deficient *medium-chain acyl-CoA dehydrogenase*, critical for beta-oxidation. Obesity may reflect metabolic dysregulation or compensatory feeding patterns. Prenatal abnormalities, though less common, could arise from fetal metabolic stress. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella cataract is seen as -
Choices:
A. Posterior polar cataract
B. Nuclear cataract
C. Blue dot cataract in young
D. Cuneiform cataract
Answer: [/INST] Nuclear cataract </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug resistance in Tuberculosis is due to-
Choices:
A. Transformation
B. Transduction
C. conjugation
D. Mutation
Answer: [/INST] Mutation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis in children true is?
Choices:
A. Commonly sputum negative
B. Incidence < 5% of all TB casesv
C. Clinically child does not show sign of florid TB.
D. All of above
Answer: [/INST] All of above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Nervous tissue Rabies vaccines are usually manufactured from
Choices:
A. Duck embryos
B. Human diploid cell
C. Sheep
D. Chick embryos
Answer: [/INST] Sheep </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is associated with -
Choices:
A. 21P
B. 22P
C. Y chromosome
D. 17 Q
Answer: [/INST] 21P </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ameloblastoma most frequently occurs in
Choices:
A. Mandibular molar region
B. Maxillary molar region
C. Mandibular premolar region
D. Maxillary premolar region
Answer: [/INST] Mandibular molar region </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While biotinidase deficiency (BTDD) typically manifests postnatally, severe untreated cases may indirectly contribute to developmental anomalies due to progressive metabolic dysfunction. Prenatal reliance on maternal biotin usually prevents in utero symptoms, but postnatal failure to recycle biotin disrupts carboxylase enzymes, potentially leading to congenital-like metabolic instability.  
2. **Death in infancy/Neonatal death**: Untreated BTDD causes profound metabolic crises (e.g., lactic acidosis, hyperammonemia, organic acidemia) due to impaired carboxylase activity. These crises rapidly progress to neurological decline (seizures, coma) and multisystem failure, often fatal within weeks to months without biotin supplementation. Neonatal death may occur if symptoms onset early and diagnosis/treatment are delayed.  
3. **Late-onset vs. timing**: Despite being termed ""late-onset"" (compared to holocarboxylase synthetase deficiency), BTDD can present acutely in infancy. The absence of newborn screening or delayed intervention explains the fatal trajectory in this case. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia A due to deficiency of
Choices:
A. Factor VIII
B. Factor IX
C. Factor X
D. Factr XI
Answer: [/INST] Factor VIII </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Surgery is indicated in Ulcerative Colitis in all except?
Choices:
A. Toxic megacolon
B. Colonic polyp
C. Colonic obstruction
D. Refractory fistula
Answer: [/INST] Colonic polyp </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Period of isolation for Measles is from
Choices:
A. Onset of catarrhal symptoms to 3 days after
B. Onset of catarrhal symptoms to 7 days after
C. Onset of catarrhal symptoms to 6 days after
D. Onset of catarrhal symptoms to 8 days after
Answer: [/INST] Onset of catarrhal symptoms to 3 days after </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is most commonly seen in-
Choices:
A. Maturity onset DM
B. Type I DM
C. Type II DM
D. HTN
Answer: [/INST] Type II DM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: End stage Lung disease seen in -a) Sarcoidosisb) Interstitial lung diseasec) Langerhans cell histiocytosisd) Aspergillosise) Asbestosis
Choices:
A. bcde
B. abce
C. acde
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which among the following drug is not used in the
treatment of Tetralogy of Fallot?
Choices:
A. β blocker
B. α agonists
C. Calcium channel blockers
D. Morphine
Answer: [/INST] Calcium channel blockers </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria relapse common with which type plasmodium species?
Choices:
A. Plasmodium malariae and vivax
B. Plasmodium falciparum and vivax
C. Plasmodium vivax and ovale
D. Plasmodium ovale and malariae
Answer: [/INST] Plasmodium vivax and ovale </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Smallpox vaccine was introduced by
Choices:
A. Paul Ehrlich
B. Robe Koch
C. Louis Pasteur
D. Edward Jenner
Answer: [/INST] Edward Jenner </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statement about Q fever is false-
Choices:
A. Highly infectious zoonotic disease
B. The mode of transmission is by inhalation
C. Ahropods are involved in its transmission to man
D. There is no rash or local lesion
Answer: [/INST] Ahropods are involved in its transmission to man </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Symptoms of Neuroleptic Malignant Syndrome (NMS) are all of the following except?
Choices:
A. Confusion
B. Hypothermia
C. Diaphoresis
D. Hypertension
Answer: [/INST] Hypothermia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which receptors are blocked in Myasthenia Gravis.
Choices:
A. Ach receptors
B. Calcium receptors
C. Sodium receptors
D. Opioid receptors
Answer: [/INST] Ach receptors </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient develops red eye , 2 two days after an episode of Malaria Probable cause is -
Choices:
A. Conjunctivitis
B. Anterior uveitis
C. Viral keratitis
D. End ophthalmitis
Answer: [/INST] Viral keratitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Abnormality of male external genitalia', 'Shawl scrotum', 'Micropenis', 'Abnormality of the face', 'Hypertelorism', 'Facial asymmetry', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Low-set ears', 'Prominent nose', 'Abnormality of the eye', 'Atypical behavior', 'Autistic behavior', 'Cutis marmorata', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Impaired smooth pursuit', 'Pineal cyst', 'Lymphangioma']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Genetic Basis**: Caused by heterozygous pathogenic variants in *PHIP*, aligning with multi-system congenital anomalies.  
2. **Facial Dysmorphism**: Hypertelorism, facial asymmetry, prominent nose, and ear anomalies (posteriorly rotated, low-set) match reported craniofacial features.  
3. **Genital Abnormalities**: Cryptorchidism, micropenis, and shawl scrotum correlate with urogenital malformations documented in the syndrome.  
4. **Neurological Features**: Intellectual disability, seizures, hypotonia, and impaired smooth pursuit are hallmark neurodevelopmental traits.  
5. **Behavioral Phenotype**: Autistic behavior aligns with developmental delay and social communication deficits.  
6. **Cutaneous Findings**: Cutis marmorata may reflect vascular dysregulation, occasionally observed in genetic syndromes.  
7. **Ancillary Features**: Pineal cyst and lymphangioma, while less specific, fit within the spectrum of variable congenital anomalies.  
8. **Exclusion**: Overlap with Noonan or Smith-Lemli-Opitz syndromes is unlikely due to absence of key features (e.g., cardiac defects, cholesterol deficiency signs).  

Conclusion: The constellation of symptoms strongly supports Stankiewicz-Isidor syndrome, driven by *PHIP* dysfunction. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria control means
Choices:
A. To reduce Malaria moality to Zero
B. To prevent local transmission for 3 years
C. To reduce Malaria disease so that its no longer a Public Health Problem
D. To reduce Incidence to Zero
Answer: [/INST] To reduce Malaria disease so that its no longer a Public Health Problem </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Rabies virus, except?
Choices:
A. Single Stranded RNA virus
B. Linear
C. Negative sense
D. Space vehicle shaped
Answer: [/INST] Space vehicle shaped </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine. This aligns with the patient’s lab findings.  
2. **Abnormality of prenatal development/birth** and **neonatal death** may reflect *maternal PKU syndrome* (if the mother had untreated PKU during pregnancy), causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
3. **Death in infancy/childhood/adolescence** correlates with untreated PKU progression: severe neurological damage, seizures, and organ failure due to phenylalanine toxicity. Without early dietary intervention, fatal outcomes are likely.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low). This may suggest a co-occurring condition (e.g., tyrosinemia type II) or transient neonatal tyrosinemia, but PKU remains primary due to hyperphenylalaninemia.  
5. The absence of tyrosine hydroxylase cofactors (e.g., BH4 deficiency) could exacerbate metabolic dysregulation, though this is a PKU subtype.  

**Conclusion**: PKU is confirmed by hyperphenylalaninemia and clinical progression. Early mortality and prenatal abnormalities reflect untreated/severe disease. Hypertyrosinemia warrants further investigation but does not override the PKU diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The hea lesion not found in Congenital Rubella infection is:
Choices:
A. ASD
B. VSD
C. PDA
D. PS
Answer: [/INST] ASD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the genitourinary system', 'Hydrocephalus', 'Intellectual disability, mild', 'Cerebellar hypoplasia', 'Pancytopenia', 'Asthma', 'Unsteady gait', 'Abnormal cerebral white matter morphology', 'Coxa valga', 'Decreased circulating IgG level', 'Short telomere length', 'Arachnoid cyst']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Core diagnostic criteria**:  
   - **Pancytopenia** (key feature of ATXPC) and **unsteady gait** (ataxia) are hallmark symptoms.  
   - **Cerebellar hypoplasia** directly explains ataxia and is a defining neurological feature of the syndrome.  
   - **Short telomere length** aligns with bone marrow dysfunction, a recognized mechanism in ATXPC.  

2. **Supportive neurological findings**:  
   - **Abnormal cerebral white matter morphology** and **hydrocephalus** may reflect structural brain anomalies linked to SAMD9L mutations.  
   - **Arachnoid cyst** and **mild intellectual disability** could arise from disrupted neurodevelopment.  

3. **Systemic manifestations**:  
   - **Decreased circulating IgG level** suggests immune dysfunction secondary to bone marrow failure.  
   - **Coxa valga** and **genitourinary abnormalities** fit the multisystemic nature of SAMD9L-related disorders.  

4. **Exclusion of mimics**:  
   - Asthma is likely incidental or secondary to immune deficiency.  
   - Telomere shortening distinguishes ATXPC from isolated cerebellar hypoplasia or other bone marrow failure syndromes (e.g., Dyskeratosis congenita lacks cerebellar features).  

Conclusion: The constellation of neurological, hematological, and systemic features strongly supports ATXPC, driven by SAMD9L mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder affecting fatty acid oxidation, which can lead to intrauterine stress and developmental issues due to energy deficiency.  
2. **Neonatal/Infancy/Childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, often fatal in early life without prompt diagnosis and management.  
3. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to accumulation of toxic medium-chain acylcarnitines, which bind free carnitine, reducing its availability for fatty acid transport.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misinterpretation or mislabelling of enzyme testing. MCADD directly involves *medium-chain acyl-CoA dehydrogenase (MCAD)* deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This discrepancy may stem from overlapping terminology or assay cross-reactivity in biochemical profiling.  

The constellation of early mortality, metabolic instability, and carnitine abnormalities strongly aligns with MCADD, a common fatty acid oxidation defect. Confirmatory testing would include genetic analysis of *ACADM* gene mutations and acylcarnitine profile showing elevated C6-C10 species. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which one of the following is NOT true of Ameloblastoma -
Choices:
A. Most common odontogenic tumour
B. Generally benign
C. Common in 3rd to 5th decade
D. Arises from mesenchymal tissue
Answer: [/INST] Arises from mesenchymal tissue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Kernicterus is associated with:
Choices:
A. Choreoathetoid cerebral palsy
B. Hearing abnormalities
C. Upward gaze palsy
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Nystagmus', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
**Step 1:** The symptoms **cerebellar atrophy** and **cerebellar agenesis** indicate severe structural brain abnormalities, a hallmark of PMM2-CDG due to disrupted glycosylation during neurodevelopment.  
**Step 2:** **Ataxia**, **motor delay**, and **generalized hypotonia** align with cerebellar dysfunction, a core feature of PMM2-CDG.  
**Step 3:** **Strabismus** and **nystagmus** are linked to brainstem/cerebellar defects affecting ocular motor control.  
**Step 4:** **Encephalopathy** and **hyporeflexia** reflect global neurological impairment from abnormal glycosylation of neuronal proteins.  
**Step 5:** **Growth delay** and **death in infancy** are systemic consequences of glycosylation failure, impacting metabolism and organ function.  
**Step 6:** PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns, which correlate with the severity of cerebellar and multisystemic symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Werner Syndrome, most common site of Gastrinoma is?
Choices:
A. Pancreas
B. Stomach
C. Colon
D. Small Intestione
Answer: [/INST] Small Intestione </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A lady had Meningioma with inflammatory edematous lesion. She was planned for surgery. Junior resident's mistake in writing pre-op notes is:
Choices:
A. Stop Steroids
B. Wash head with shampoo
C. Antibiotic Sensitivity
D. Continue antiepileptics
Answer: [/INST] Stop Steroids </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies in not found in
Choices:
A. Lakshadweep Islands
B. Rajasthan
C. Meghalaya
D. Orrisa
Answer: [/INST] Lakshadweep Islands </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin acts by which mechanism?
Choices:
A. Overactivates adenylate cyclase (cAMP) by permanently activating Gs
B. Mimics the adenylate cyclase enzyme (cAMP)
C. Overactivates guanylate cyclase (cGMP)
D. Inactivate elongation factor (EF-2)
Answer: [/INST] Overactivates adenylate cyclase (cAMP) by permanently activating Gs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the causative agent of Yaws?
Choices:
A. Treponema peenue
B. Treponema carateum
C. Treponema pallidum
D. Treponema endemicum
Answer: [/INST] Treponema peenue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal foot morphology', 'Fever', 'Tachypnea', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of MCADD, as carnitine conjugates with unmetabolized medium-chain acyl-CoA derivatives, reducing free carnitine levels.  
2. **Metabolic instability in infancy/childhood**: Neonatal death, death in infancy, and childhood death align with MCADD's risk of fatal hypoglycemia and metabolic crisis during fasting or illness.  
3. **Acute symptoms (Fever, Tachypnea)**: Reflect metabolic decompensation, with tachypnea potentially secondary to metabolic acidosis.  
4. **Fatty acid oxidation defect**: MCADD impairs medium-chain fatty acid breakdown, leading to energy deficiency and toxic metabolite accumulation, especially under metabolic stress.  
5. **Prenatal/developmental abnormalities**: While less typical, prolonged intrauterine metabolic disturbances may contribute to developmental anomalies.  
6. **Exclusion of other disorders**: Symptoms prioritize MCADD over other fatty acid oxidation defects (e.g., VLCADD, LCHADD) due to medium-chain specificity and absence of cardiomyopathy/retinopathy.  
**Conclusion**: MCADD is the primary diagnosis, driven by carnitine deficiency, life-threatening metabolic crises, and hypoglycemia risk. Early recognition and fasting avoidance are critical to prevent mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chronic fibrosing mediastinitis is seen ina) Tuberculosisb) Histoplasmosisc) Plagued) Sarcoidosis
Choices:
A. acd
B. bcd
C. abc
D. abd
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Hypothyroidism', 'Dysarthria', 'Spastic diplegia', 'Encephalopathy', 'Hyperreflexia', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Ethylmalonic aciduria** and **cytochrome C oxidase-negative muscle fibers** are hallmark biochemical and histopathological findings in mitochondrial complex IV (cytochrome c oxidase) deficiency, directly implicating impaired oxidative phosphorylation.  
2. **Encephalopathy**, **hyperreflexia**, **spastic tetraplegia/diplegia**, and **dysarthria** reflect severe neurological dysfunction due to energy failure in neurons and corticospinal tract damage.  
3. **Delayed speech/language development** aligns with global neurodevelopmental delays caused by chronic cerebral energy deficits.  
4. **Hypothyroidism** and **recurrent viral infections** suggest multisystem involvement, as mitochondrial dysfunction affects thyroid metabolism and immune cell energetics.  
5. **Abnormal circulating glycine concentration** may arise from disrupted mitochondrial metabolism of amino acids.  
6. **Death in adolescence/early adulthood** is consistent with progressive neurodegeneration and multisystem failure in severe mitochondrial disorders.  
7. Nuclear type 1 (OMIM 220110) specifically involves mutations in *SURF1*, a gene critical for complex IV assembly, explaining the COX-negative fibers and systemic phenotype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria caused by deficiency of
Choices:
A. Tyrosine transaminase
B. Tyrosine hydroxylase
C. Phenylalanine hydroxylase
D. Phenylketonuria hydroxylase
Answer: [/INST] Phenylalanine hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: National Leprosy Eradication Programme was started in –
Choices:
A. 1949
B. 1955
C. 1973
D. 1983
Answer: [/INST] 1983 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Components of Tetralogy of Fallot is/are ?
Choices:
A. VSD
B. Lt. Ventricular hyperophy
C. Lt. Axis detion
D. All
Answer: [/INST] VSD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tetralogy of Fallot's present with one of the following –
Choices:
A. Cenral cyanosis with clubbing
B. Cardiomegaly
C. Left ventricular hypertrophy
D. Normal ECG and Chest x-ray
Answer: [/INST] Cenral cyanosis with clubbing </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common clinical manifestation of Multiple Sclerosis is
Choices:
A. Intemuclear Ophthalmoplegia
B. Ataxia
C. Optic Neuritis
D. Diplopia
Answer: [/INST] Optic Neuritis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common manifestation of Multiple Sclerosis is
Choices:
A. Weakness
B. Ataxia
C. Optic neuritis
D. Inter neuclear ophthalmoplegia
Answer: [/INST] Optic neuritis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cotton wool spot is /are seen in – a) DRb) Hypertensive retinopathyc) AIDSd) Retinoblastomae) Toxaemia of pregnancy
Choices:
A. abce
B. abcd
C. acde
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 35-year-old female presented to the medicine OPD with paresthesias and weakness of B/L lower limbs with a band like sensation of tightness around the torso along with painful loss of vision in both eyes along with diplopia and periorbital pain. There is a history of similar attacks in the past with period of normalcy in between O/E, Ataxia- present Papillitis (on fundus examination) Facial myokymia Bladder incontinence and constipation CSF studies revealed mononuclear cell pleocytosis along with increased IgG. Which of the following are the oral drugs approved for the above condition: - 1. Fingolimod 2. Natalizumab 3. Teriflunomide 4. Glatiramer acetate
Choices:
A. Only 1
B. Both 1 and 3
C. 1,2 and 3
D. All of the above
Answer: [/INST] Both 1 and 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are used in the treatment of Leishmaniasis except:
Choices:
A. Hydoroxychloroquine
B. Miltefosine
C. Paromomycin
D. Rifabutin
Answer: [/INST] Rifabutin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The highest incidence of Gestational Trophoblastic Disease is in :
Choices:
A. Australia
B. Asia
C. Noh America
D. Western Europe
Answer: [/INST] Asia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Fever', 'Hyperammonemia', 'Abnormality of urine homeostasis', 'Neonatal death', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), directly implicating defects in ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset metabolic crisis, consistent with UCDs like CPS1 deficiency, which often presents within days of life.  
3. **Feeding difficulties** and **generalized hypotonia** align with neurological dysfunction caused by ammonia toxicity.  
4. **Tachycardia** and **fever** may reflect systemic stress from hyperammonemic encephalopathy or secondary infections triggered by metabolic instability.  
5. **Abnormality of urine homeostasis** could indicate disrupted nitrogen excretion pathways, though CPS1 deficiency typically shows low/neutral urine orotic acid (unlike other UCDs), narrowing the diagnosis.  
6. Exclusion of other UCDs (e.g., OTC deficiency, which elevates urine orotic acid) and organic acidemias (which cause metabolic acidosis) strengthens the likelihood of CPS1 deficiency, an autosomal recessive disorder affecting the first urea cycle enzyme.  
7. The absence of treatment (e.g., nitrogen scavengers) explains rapid progression to neonatal demise. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is NOT an indicator for Malaria surveillance in a population?
Choices:
A. Annual parasite index
B. Annual parasite incidence
C. Annual falciparum incidence
D. Slide falciparum rate
Answer: [/INST] Annual parasite index </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: WHO Malaria Mass Drug Administration –
Choices:
A. API >5
B. > 2
C. 15
D. 25
Answer: [/INST] > 2 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achalasia cardia presents with all EXCEPT:
Choices:
A. Increased lower esophalgus sphincter tone
B. Normal peristalsis
C. Dilatation proximally
D. Malignancy
Answer: [/INST] Normal peristalsis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A six year old child managed by complete surgical removal of Craniopharyngioma developed multiple endocrinopathies. Which of following hormones should be replaced first?
Choices:
A. Hydrocoisone
B. Growth hormone
C. Thyroxine
D. Prolactin
Answer: [/INST] Hydrocoisone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Polyarteritis Nodosa (PAN) typically involves which of the following?
Choices:
A. Large elastic arteries
B. Small- or medium-sized muscular arteries
C. Arterioles
D. Capillaries
Answer: [/INST] Small- or medium-sized muscular arteries </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ptosis', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal foot morphology', 'High, narrow palate', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Elevated 7-dehydrocholesterol and 8-dehydrocholesterol**: Pathognomonic biochemical markers of Smith-Lemli-Opitz syndrome (SLOS), caused by a deficiency in 7-dehydrocholesterol reductase, which disrupts cholesterol synthesis.  
2. **Syndactyly and abnormal foot morphology**: Classic physical features of SLOS, particularly 2-3 toe syndactyly and/or clubfoot.  
3. **Developmental delays (speech, motor, intellectual) and hypotonia**: Neurological manifestations due to impaired cholesterol-dependent myelination and synaptic function.  
4. **High, narrow palate and ptosis**: Common craniofacial dysmorphisms in SLOS.  
5. **Early mortality (infancy/childhood/adolescence)**: Severe forms of SLOS are associated with life-threatening malformations (e.g., cardiac, pulmonary) or metabolic instability.  
6. **Generalized hypotonia**: Reflects both neurological dysfunction and potential structural abnormalities (e.g., poor muscle development).  
The combination of sterol abnormalities, syndactyly, neurodevelopmental deficits, and dysmorphic features confirms SLOS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which type of Amyloidosis is caused by the mutation of a transthyretin protein?
Choices:
A. Dialysis associated amyloidosis
B. Familial Mediterranean fever
C. Familial amyloidotic polyneuropathy
D. Prion protein associated amyloidosis
Answer: [/INST] Familial amyloidotic polyneuropathy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is commonly associated with:
Choices:
A. Chronic osteomyelitis
B. Periostitis
C. Acute osteomyelitis
D. Multiple myeloma
Answer: [/INST] Multiple myeloma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia causes:
Choices:
A. Increased amplitude of action potential
B. Hyperpolarisation
C. Resting membrane potential becomes less negative
D. Tetany
Answer: [/INST] Hyperpolarisation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hydrocephalus', 'Macrocephaly', 'Hyperhidrosis', 'Seizure', 'Lethargy', 'Dystonia', 'Hyperreflexia', 'Death in infancy', 'Anemia', 'Fever', 'Vomiting', 'Cerebral atrophy', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Upper airway obstruction', 'Increased CSF protein concentration', 'Glutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Chronic pulmonary obstruction', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Core biochemical marker**: The explicit mention of ""Glutaric aciduria"" directly aligns with GA-I, a disorder caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological features**:  
   - **Macrocephaly** at birth is a hallmark of GA-I, often preceding metabolic crises.  
   - **Dystonia**, **opisthotonus**, **seizures**, and **cerebral atrophy** reflect striatal injury and basal ganglia degeneration, typical of GA-I encephalopathic crises.  
   - **Hyperreflexia** and **fasciculations** suggest upper motor neuron involvement due to neurotoxicity.  
3. **Acute metabolic decompensation**:  
   - Symptoms like **lethargy**, **vomiting**, **fever**, and **drowsiness** are triggered by catabolic stressors (e.g., infections, fasting), common in GA-I crises.  
   - **Increased CSF protein concentration** may occur during acute neurological deterioration.  
4. **Prognostic indicators**:  
   - **Death in infancy/childhood/adolescence** correlates with untreated GA-I’s natural history. Early mortality arises from metabolic crises or secondary complications (e.g., **upper airway obstruction** due to dystonia).  
   - **Chronic pulmonary obstruction** and **recurrent viral infections** may stem from dysautonomia or impaired immune-metabolic interplay.  
5. **Supporting clues**:  
   - **Sleep disturbances** and **anemia** are nonspecific but consistent with chronic metabolic disease.  
   - **Hydrocephalus** (often ""communicating"") in GA-I is linked to macrocephaly and CSF dynamics alterations, not structural defects.  

GA-I explains the full clinical spectrum, from biochemical derangements to fatal neurological progression, distinguishing it from mimics (e.g., mitochondrial disorders, other organic acidemias). Early diagnosis is critical for dietary/ metabolic interventions to mitigate outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a causative agent of Visceral Leishmaniasis?
Choices:
A. Leishmania braziliensis
B. Leishmania panamensis
C. Leishmania donovani
D. Leishmania major
Answer: [/INST] Leishmania donovani </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common site of Tuberculosis of spine is in
Choices:
A. Dorsal region
B. Dorsolumbar region
C. Lumbar region
D. Lumbosacral region
Answer: [/INST] Dorsolumbar region </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, along with **metabolic acidosis** caused by toxic accumulation of methylmalonic acid. **Seizures** and **generalized hypotonia** align with neurological complications of MMA. **Neonatal death** and **death in infancy** reflect the severe, early-onset nature of the disease due to metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of response to vitamin B12 (implied by the absence of hematologic abnormalities and rapid progression) points to a **mutase deficiency subtype**. This subtype is caused by mutations in the *MUT* gene, leading to dysfunctional methylmalonyl-CoA mutase. The severity of symptoms (e.g., **neonatal death**) and metabolic instability are characteristic of this variant, which typically does not improve with B12 supplementation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The eponymus Trisomy 18 is
Choices:
A. Cri du chat syndrome
B. Patau's syndrome
C. Down's syndrome
D. Edward's syndrome
Answer: [/INST] Edward's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is approved oral therapy for Leishmaniasis?
Choices:
A. Sodium Stibogluconate
B. Miltefosine
C. Pentomedine
D. Amphoterium B
Answer: [/INST] Miltefosine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for EGFR T790M mutation of Non-Small Cell Lung Cancer is
Choices:
A. Lapatinib
B. Crizotinib
C. Alemtuzumzb
D. Osimeinib
Answer: [/INST] Osimeinib </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hematuria', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Increased serum lactate', 'Increased CSF lactate', 'Feeding difficulties', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** directly indicates a defect in methylmalonyl-CoA metabolism. Combined with **metabolic acidosis**, **increased serum/CSF lactate**, and **feeding difficulties**, this aligns with MMA's hallmark metabolic decompensation. **Generalized hypotonia** and **death in infancy** reflect severe neurological and systemic involvement, while **diarrhea** and **hematuria** may stem from renal tubular dysfunction and metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The lack of vitamin B12 responsiveness points to a **mutase deficiency** (mut⁰ or mut⁻ subtypes). Elevated lactate in serum and CSF suggests impaired mitochondrial energy production due to dysfunctional methylmalonyl-CoA mutase. **Death in infancy** and severe acidosis are typical in B12-unresponsive forms, as residual enzyme activity is minimal. Genetic confirmation would identify mutations in the *MUT* gene, solidifying this subtype diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dose of Chloroquine when used for Chemoprohylaxis of Malaria is
Choices:
A. 300 mg twice/week
B. 600 mg once/week
C. 300 mg Once/week
D. 600 mg/week
Answer: [/INST] 300 mg Once/week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Psychosis', 'Osteoporosis', 'Intellectual disability', 'Anemia', 'Hyperammonemia', 'Cerebral atrophy', 'Hyperglycinemia', 'Kyphoscoliosis', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Severe hearing impairment', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA, a disorder of propionyl-CoA carboxylase deficiency. This causes accumulation of propionic acid derivatives (e.g., methylcitrate, 3-hydroxypropionate), disrupting amino acid metabolism and urea cycle function.  
2. **Neurological involvement**: Psychosis, intellectual disability, and cerebral atrophy result from neurotoxic effects of ammonia and organic acids, compounded by energy deficits in the brain.  
3. **Hematological/renal signs**: Anemia arises from bone marrow suppression by toxic metabolites. Elevated blood urea nitrogen (BUN) and creatinine reflect renal stress due to chronic metabolic acidosis.  
4. **Skeletal/growth issues**: Severe short stature, osteoporosis, and kyphoscoliosis stem from chronic protein catabolism, malnutrition, and metabolic bone disease.  
5. **Odor/abnormal metabolites**: Body odor (sweaty feet) and abnormal carnitine/porphyrin levels reflect disrupted fatty acid oxidation and heme synthesis secondary to propionyl-CoA accumulation.  
6. **Early mortality**: Death in adolescence/early adulthood is typical in severe PA due to metabolic crises, cardiac complications, or neurodegeneration.  
7. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme, leading to secondary glycine elevation.  
8. **Hearing impairment**: Sensorineural deafness may occur due to mitochondrial dysfunction in cochlear cells.  

PA explains all symptoms via defective propionate metabolism, mitochondrial toxicity, and multi-organ sequelae. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the inheritance of Incontinentia Pigmenti?
Choices:
A. AD
B. AR
C. X-linked dominant
D. X-linked recessive
Answer: [/INST] X-linked dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common site of bony metastases in Retinoblastoma-
Choices:
A. Skull bones
B. Hip bones
C. Ribs
D. Veebrae
Answer: [/INST] Skull bones </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly is best diagnosed using :
Choices:
A. Maternal serum alpha-fetoprotein
B. Amniotic fluid alpha-fetoprotein
C. USG
D. X-ray
Answer: [/INST] USG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Gastroschisis and omphalocele which of the following statement is false?
Choices:
A. Intestinal obstruction is common in Gastroschisis
B. Liver is content of Omphalocele
C. Gastroschisis is associated with multiple anomalies
D. Umbilical cord is attached in normal position in Omphalocele
Answer: [/INST] Gastroschisis is associated with multiple anomalies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Ataxia', 'Dysarthria', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Abnormal foot morphology', 'Diarrhea', 'Abnormal basal ganglia morphology', 'Increased serum lactate', 'Spastic tetraplegia', 'Ethylmalonic aciduria', 'Increased serum pyruvate', 'Cytochrome C oxidase-negative muscle fibers', 'Death in childhood', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Neurological and motor deficits**: Symptoms like spastic tetraplegia/diplegia, hyperreflexia, ataxia, dysarthria, and motor delays suggest upper motor neuron involvement and cerebellar dysfunction, consistent with mitochondrial encephalopathies.  
2. **Metabolic abnormalities**: Increased serum lactate and pyruvate, ethylmalonic aciduria, and cytochrome C oxidase (COX)-negative muscle fibers directly indicate a defect in mitochondrial energy metabolism, specifically complex IV (COX) deficiency.  
3. **Systemic manifestations**: Growth delay, diarrhea, and generalized hypotonia reflect multi-organ energy failure. Abnormal basal ganglia morphology aligns with mitochondrial dysfunction in brain regions sensitive to oxidative phosphorylation defects.  
4. **Fatal early course**: Death in infancy/childhood/adolescence is typical in severe mitochondrial disorders due to progressive metabolic crises and neurological decline.  
5. **Nuclear genetic origin**: The ""nuclear type 1"" designation implicates pathogenic variants in nuclear genes (e.g., *SURF1*) critical for COX assembly, distinguishing it from mitochondrial DNA-related complex IV defects.  

The combination of COX-negative fibers, ethylmalonic aciduria, and spasticity with early lethality is pathognomonic for this disorder. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about pituitary adenomaa) Accounts for 10% of brain tumorsb) Erodes the sellar and extends into surrounding areac) Prolactinoma is least commond) It is differentiated by reticulin stain
Choices:
A. acd
B. abd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In unconjugated hyperbilirubinemia, which of the drug increase the chance for Kernicterus?
Choices:
A. Ceftriaxone
B. Phenobarbitone
C. Ampicillin
D. Sulphonamide
Answer: [/INST] Sulphonamide </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Fetal Hydantoin Syndrome is caused by:
Choices:
A. Phenytoin
B. Alcohol
C. Tetracycline
D. Sodium valproate
Answer: [/INST] Phenytoin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Metabolic acidosis & elevated lactate**: Impaired activity of biotin-dependent carboxylases (pyruvate carboxylase, propionyl-CoA carboxylase) disrupts gluconeogenesis and the citric acid cycle, causing lactic acidosis.  
2. **Hyperammonemia**: Secondary urea cycle dysfunction due to metabolic stress or propionate accumulation from propionyl-CoA carboxylase deficiency.  
3. **Propionyl-CoA carboxylase deficiency & decreased pyruvate carboxylase activity**: HLCS is required to activate these enzymes via biotinylation; deficiency leads to functional defects in multiple carboxylases.  
4. **Abnormal urinary carboxylic acids & aminoaciduria**: Accumulation of toxic metabolites (e.g., propionate, 3-hydroxypropionate) due to blocked carboxylase pathways, causing renal tubular damage and organic aciduria.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion from binding/excretion of acyl-CoA metabolites.  
6. **Abnormal circulating glycine**: Glycine metabolism disruption via the glycine cleavage system (biotin-dependent) or competition with organic acids for renal transport.  
7. **Generalized hypotonia & apathy**: Neurological effects of metabolic acidosis, hyperammonemia, and energy deficiency.  
8. **Tachypnea**: Respiratory compensation for metabolic acidosis.  
9. **Death in infancy**: Untreated HLCS deficiency causes severe metabolic crises, typically fatal without biotin supplementation.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic acidosis, hyperammonemia, and characteristic biochemical markers confirms HLCS deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera vaccine effectiveness is -
Choices:
A. 20% for 12 months
B. 50% for 12 months
C. 20% for 36 months
D. 50% for 36 months
Answer: [/INST] 50% for 12 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cataract', 'Hip dysplasia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Anemia', 'Hyperammonemia', 'Elevated circulating creatinine concentration', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The presence of **methylmalonic aciduria** is pathognomonic for methylmalonic acidemia (MMA), a rare inborn error of metabolism. Key symptoms like **hyperammonemia**, **elevated creatinine** (indicative of renal dysfunction), **anemia**, and **abnormal carnitine levels** align with MMA’s metabolic disruptions. Neonatal or early childhood **death** and **premature birth** are consistent with severe forms of MMA, where toxic metabolite accumulation leads to multiorgan failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnosis) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, causing **methylmalonic aciduria**, **hyperammonemia**, and metabolic acidosis. Symptoms like **small for gestational age** and **death in infancy/childhood** reflect the disease’s severe, early-onset phenotype. **Hip dysplasia** and **cataracts** may arise secondary to chronic metabolic stress or mitochondrial dysfunction. Elevated creatinine and neonatal death underscore renal and systemic toxicity from methylmalonic acid and propionate accumulation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma associated with which variety of asbestos ?
Choices:
A. Serpentine
B. Amphibole
C. Both the above
D. None of the above
Answer: [/INST] Amphibole </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achondroplasia shows which of the following type of inheritance
Choices:
A. Autosomal Dominant
B. Autosomal Recessive
C. X-Linked Dominant
D. X-Linked Recessive
Answer: [/INST] Autosomal Dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal insufficiency', 'Abnormality of the nose', 'Abnormal pinna morphology', 'Visual loss', 'Osteopenia', 'Facial erythema', 'Abnormal finger morphology', 'Wrist swelling', 'Abnormal toe morphology', 'Eosinophilia', 'Microcytic anemia', 'Exercise intolerance', 'Upper limb amyotrophy', 'Pedal edema', 'Abnormal metacarpophalangeal joint morphology', 'Foot pain', 'Shoulder pain', 'Episcleritis', 'Gangrene']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Relapsing polychondritis  
Reasoning:  
1. **Cartilage involvement**:  
   - **Abnormality of the nose** (saddle nose deformity from nasal cartilage collapse) and **abnormal pinna morphology** (ear cartilage inflammation) are hallmark features of relapsing polychondritis (RP).  
   - **Wrist swelling**, **abnormal metacarpophalangeal joint morphology**, and **abnormal finger/toe morphology** suggest inflammatory arthritis secondary to cartilage damage.  

2. **Ocular manifestations**:  
   - **Episcleritis** and **visual loss** align with RP-associated ocular inflammation.  

3. **Systemic inflammation**:  
   - **Facial erythema** and **eosinophilia** reflect systemic autoimmune activity.  
   - **Renal insufficiency** may stem from vasculitis or secondary amyloidosis, both linked to advanced RP.  

4. **Musculoskeletal complications**:  
   - **Osteopenia** and **upper limb amyotrophy** correlate with chronic inflammation and immobility due to joint pain (**shoulder pain**, **foot pain**).  

5. **Vascular involvement**:  
   - **Gangrene** and **pedal edema** suggest vasculitis-induced ischemia, a rare but severe RP complication.  

6. **Hematologic abnormalities**:  
   - **Microcytic anemia** and **exercise intolerance** are consistent with chronic disease and renal dysfunction.  

The constellation of cartilage destruction, multisystem inflammation, and vasculitic features strongly supports RP. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Serological diagnosis is made in -a) Actinomycosis b) T.B.c) Syphilisd) Gonorrhoeae) Q fever
Choices:
A. abd
B. acd
C. cde
D. ade
Answer: [/INST] cde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of skin is called as
Choices:
A. Lupus profundis
B. Scrofuloderma
C. Lupus vulgaris
D. Lupus pernio
Answer: [/INST] Lupus vulgaris </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Neonatal death**, **death in infancy/childhood/adolescence** align with untreated PKU, where toxic phenylalanine accumulation leads to severe neurological damage, organ failure, and early mortality without dietary intervention.  
3. **Vomiting** and **gastrointestinal inflammation** may reflect metabolic crises or protein intolerance due to impaired phenylalanine metabolism.  
4. **Obesity** could stem from restrictive dietary management (high-carbohydrate, low-protein diets) often used in PKU, predisposing to weight gain.  
5. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine levels). This may indicate a concurrent condition (e.g., tyrosinemia Type II), a PAH deficiency variant affecting tyrosine regulation, or a reporting error.  
6. **Fever** is non-specific but could arise from secondary infections or metabolic instability in severe cases.  
**Conclusion**: Hyperphenylalaninemia is pathognomonic for PKU. Early lethality and systemic symptoms reflect untreated disease progression, though hypertyrosinemia warrants further investigation for comorbidities or diagnostic inaccuracies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Fatty acid oxidation disorder**: MCADD impairs breakdown of medium-chain fatty acids into acetyl-CoA, causing energy deficiency during fasting.  
2. **Neonatal/infant/childhood mortality**: Unrecognized MCADD leads to hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy during metabolic stress (e.g., infections or fasting), explaining death in early life stages.  
3. **Gastrointestinal inflammation**: Acute crises trigger vomiting/diarrhea due to metabolic decompensation. Chronic carnitine deficiency may exacerbate mucosal damage.  
4. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine conjugates with accumulating toxic metabolites (e.g., octanoylcarnitine) for urinary excretion.  
5. **Prenatal abnormalities**: While less common, intrauterine metabolic stress from placental insufficiency or maternal fasting could theoretically contribute to developmental perturbations in severe cases.  

Key biochemical clues: Hypoketotic hypoglycemia + elevated C6-C10 acylcarnitines (especially C8) on tandem mass spectrometry would confirm MCADD. Early diagnosis via newborn screening prevents mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which drug is used for Achalasia cardia-
Choices:
A. Nifedipine
B. Propranolal
C. Atenolol
D. Bethnecol
Answer: [/INST] Nifedipine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Brucellosis can be transmitted by all of the following modes, except-
Choices:
A. Contact with infected placenta
B. Ingestion of raw vegetables from infected forms
C. Person to person transmission
D. Inhalation of infected dust or aerosol
Answer: [/INST] Person to person transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of male external genitalia', 'Hypospadias', 'Abnormality of the kidney', 'Horseshoe kidney', 'Ectopic kidney', 'Abnormal mandible morphology', 'Microretrognathia', 'Abnormality of the outer ear', 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set ears', 'Abnormality of the eye', 'Strabismus', 'Nystagmus', 'Horizontal nystagmus', 'Atypical behavior', 'Delayed speech and language development', 'Intellectual disability', 'Hypotonia', 'Motor delay', 'Generalized hypotonia', 'Absent speech', 'Abnormality of the cardiovascular system', 'Ventricular septal defect', 'Atrial septal defect', 'Patent ductus arteriosus', 'Truncus arteriosus', 'Pneumonia', 'Abnormality of the upper limb', 'Crossed fused renal ectopia', 'Recurrent pneumonia', 'Aplasia/Hypoplasia of the thumb', 'Feeding difficulties', 'Hypoplastic aortic arch']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Urogenital and Renal Abnormalities**: Hypospadias, horseshoe kidney, ectopic kidney, and crossed fused renal ectopia align with the renal and genital anomalies commonly seen in Stankiewicz-Isidor syndrome (STISS), caused by mutations in *PSMD12*.  
2. **Craniofacial Features**: Microretrognathia, posteriorly rotated ears, low-set ears, and strabismus/nystagmus match the craniofacial dysmorphism and ocular abnormalities reported in STISS.  
3. **Developmental and Neurological Issues**: Intellectual disability, absent speech, motor delay, and generalized hypotonia are hallmark features of STISS, reflecting its neurodevelopmental impact.  
4. **Cardiovascular Defects**: Ventricular/atrial septal defects, patent ductus arteriosus, truncus arteriosus, and hypoplastic aortic arch are consistent with congenital heart defects observed in STISS.  
5. **Limb Anomalies**: Thumb hypoplasia/aplasia correlates with the upper limb malformations associated with STISS.  
6. **Systemic Complications**: Recurrent pneumonia and feeding difficulties likely stem from hypotonia, dysphagia, and aspiration risks, further supporting the diagnosis.  
7. **Exclusion of Overlapping Syndromes**: The constellation of symptoms (renal, cardiac, craniofacial, limb) differentiates STISS from similar syndromes (e.g., CHARGE, 22q11 deletion), which lack this specific combination.  

The diagnosis is strongly supported by the convergence of neurodevelopmental, cardiovascular, renal, craniofacial, and limb anomalies, characteristic of *PSMD12*-related Stankiewicz-Isidor syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Filariasis is cuased due to lymphatic obstruction by -
Choices:
A. R vivax
B. V. bancrofti
C. C. sinerses
D. S. hemetabium
Answer: [/INST] V. bancrofti </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Mastoiditis', 'Hearing impairment', 'Horizontal nystagmus', 'Irregular menstruation', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Palpitations', 'Vertigo', 'Decreased circulating complement C3 concentration', 'Facial palsy', 'Autoimmune antibody positivity', 'Decreased circulating complement C4 concentration', 'Oral mucosal blisters']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient’s **facial palsy**, **hearing impairment**, and **horizontal nystagmus** suggest neurosarcoidosis, which often involves cranial nerves (e.g., VII and VIII). **Mastoiditis** may reflect granulomatous inflammation in the mastoid bone. **Autoimmune antibody positivity** and **decreased C3/C4 complement levels** align with sarcoidosis-associated immune dysregulation. **Oral mucosal blisters** and **weight loss** are consistent with systemic granulomatous disease. **Tachycardia** and **palpitations** could indicate cardiac sarcoidosis, while **ankle swelling** may reflect renal or cardiac involvement.  

Sarcoidosis, susceptibility to, 2:  
Genetic susceptibility loci (e.g., HLA-DRB1 variants) may predispose to multisystem granulomatous inflammation. The combination of **neurological**, **otologic**, **cardiac**, and **mucocutaneous symptoms** supports a systemic presentation. **Irregular menstruation** might stem from hypothalamic-pituitary axis involvement (rare but documented). Hypocomplementemia (**low C3/C4**) and autoantibodies further suggest immune-mediated pathology, characteristic of sarcoidosis subtypes linked to genetic susceptibility. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Apathy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Cerebral atrophy', 'Glutaric aciduria', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase.  
2. **Macrocephaly** and **cerebral atrophy** align with frontotemporal atrophy, a hallmark of GA-I due to toxic metabolite accumulation.  
3. **Generalized hypotonia** and **feeding difficulties** reflect early neurological dysfunction from striatal injury.  
4. **Vomiting** and **diarrhea** suggest metabolic decompensation triggered by catabolic stress (e.g., infections/fasting).  
5. **Apathy** correlates with encephalopathic crises during metabolic derangement.  
6. **Death in infancy** occurs in untreated cases due to acute striatal necrosis or severe metabolic crises.  
7. All symptoms collectively match GA-I’s triad: macrocephaly, movement disorders, and metabolic instability. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about communicability of Malaria,except -
Choices:
A. The number of gametocytes in blood increases with time
B. Gametocytes appear in blood 4-5 days after the appearance of the asexual parasite, in vivax infection.
C. Gametocytes appear in blood 10-12 days after the appearance of asexual parasite, in falciparum infection
D. In the early stage of infection, their density may exceed 1000 per cmm of blood.
Answer: [/INST] The number of gametocytes in blood increases with time </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial pigment is formed by:
Choices:
A. Parasite
B. Bilirubin
C. Hemoglobin
D. Any of the above
Answer: [/INST] Hemoglobin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Intellectual disability**: A core feature of PMM2-CDG due to impaired glycosylation affecting neuronal development and function.  
2. **Ataxia and cerebellar atrophy/agenesis**: PMM2-CDG disrupts cerebellar development, leading to structural abnormalities (agenesis/atrophy) and motor incoordination.  
3. **Thromboembolism**: Glycosylation defects alter clotting factors (e.g., antithrombin III deficiency), increasing thrombotic risk.  
4. **Early mortality (infancy/childhood)**: Severe multisystem involvement (hepatic, cardiac, neurological) often leads to fatal complications.  
5. **Exclusion of other CDG subtypes**: PMM2-CDG (type Ia) is the most common CDG and aligns with this phenotype, whereas other subtypes (e.g., ALG6-CDG) lack thromboembolism or cerebellar agenesis.  
6. **Biochemical confirmation**: Hypothetical elevated carbohydrate-deficient transferrin (CDT) and PMM2 enzyme deficiency would confirm diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Ataxia', 'Lethargy', 'Dysarthria', 'Gait disturbance', 'Muscle weakness', 'Tachycardia', 'Acidosis', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Myopathic facies', 'Dyspnea', 'Increased serum lactate', 'Drooling', 'Elevated hepatic transaminase', 'Myoglobinuria', 'Ketonuria', 'Lactic acidosis', 'Myopathy', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Limb muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Premature ventricular contraction', 'Lateral ventricle dilatation', 'Lower limb muscle weakness', 'Elevated circulating aldolase concentration', 'Elevated circulating acylcarnitine concentration', 'Lateral ventricular asymmetry']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Acidosis (metabolic/lactic), hypoglycemia, hyperammonemia, ketonuria, and elevated lactate/acylcarnitine suggest impaired mitochondrial energy metabolism and fatty acid oxidation.  
2. **Neuromuscular Involvement**: Myopathy, rhabdomyolysis, limb muscle weakness, elevated CK/aldolase, and myoglobinuria indicate recurrent muscle breakdown, consistent with metabolic crises.  
3. **Cardiac Arrhythmias**: Ventricular tachycardia, prolonged QTc, and premature contractions align with cardiac ion channel dysfunction or metabolic toxicity from rhabdomyolysis.  
4. **Neurodegeneration/Encephalopathy**: Intellectual disability, seizures, ataxia, lethargy, dysarthria, and ventricular dilatation/asymmetry point to chronic/progressive CNS injury from metabolic insults.  
5. **Systemic Features**: Elevated hepatic transaminases, dyspnea, and drooling reflect multi-organ dysfunction during crises.  
6. **Pattern Recognition**: The combination of recurrent metabolic decompensation, muscle breakdown, arrhythmias, and neurodegeneration matches this specific syndrome’s phenotype, distinct from isolated mitochondrial disorders or fatty acid oxidation defects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Hyporeflexia', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Cerebral atrophy', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Cerebral atrophy**: A hallmark of Canavan disease due to spongy degeneration of white matter caused by aspartoacylase deficiency.  
2. **Abnormal circulating aspartate family amino acid concentration**: Directly linked to elevated N-acetylaspartic acid (NAA) levels, a diagnostic biomarker for Canavan disease.  
3. **Generalized hypotonia and hyporeflexia**: Result from progressive neurological deterioration and impaired myelination.  
4. **Strabismus**: Associated with disrupted motor neuron function and cerebral damage.  
5. **Death in infancy**: Consistent with the severe infantile form of the disease, which leads to rapid neurological decline.  
6. **Fever**: Likely secondary to complications (e.g., aspiration pneumonia) due to dysphagia or immobility.  
7. **Obesity**: Atypical for Canavan disease; may indicate comorbid factors or misreporting, but does not exclude the diagnosis given other pathognomonic features.  

Exclusion of other leukodystrophies is supported by the specific biochemical profile (NAA accumulation) and clinical progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Brugada Syndrome is associated with:
Choices:
A. Left Bundle Branch Block
B. Left Anterior Fascicular block
C. Left Posterior Fascicular block
D. Right Bundle Branch Block
Answer: [/INST] Right Bundle Branch Block </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true regarding Tetralogy of Fallot except -
Choices:
A. Ejection systolic murmur in second intercostal space
B. Single second hea sound
C. Predominantly left to right shunt
D. Normal jugular venous pressure
Answer: [/INST] Predominantly left to right shunt </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella vaccine is given in which age ?
Choices:
A. 1-14 yrs
B. < 5 yrs
C. > 50 yrs
D. None
Answer: [/INST] 1-14 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Hepatic steatosis', 'Death in infancy', 'Cardiomegaly', 'Pericardial effusion', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Paroxysmal tachycardia', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic derangements**: Hypoglycemia, hyperammonemia, and metabolic acidosis align with impaired fatty acid β-oxidation, a hallmark of VLCADD. Fatty acids are critical for energy during fasting; their defective metabolism leads to hypoglycemia and compensatory protein catabolism (causing hyperammonemia).  
2. **Hepatic involvement**: Hepatic steatosis, hepatomegaly, and abnormal liver enzymes (elevated lactate dehydrogenase) reflect liver dysfunction due to toxic accumulation of unmetabolized long-chain fatty acids.  
3. **Cardiac manifestations**: Cardiomegaly, pericardial effusion, and paroxysmal tachycardia correlate with long-chain fatty acid deposition in cardiac tissue, leading to cardiomyopathy and arrhythmias.  
4. **Muscular symptoms**: Generalized hypotonia and lethargy result from energy deficiency in muscles, as long-chain fatty acids cannot fuel muscle metabolism.  
5. **Lab abnormalities**: Decreased plasma free carnitine (due to secondary carnitine deficiency from acyl-CoA trapping) and abnormal aspartate/alanine concentrations (indicative of mitochondrial dysfunction) strongly support a fatty acid oxidation disorder.  
6. **Respiratory and systemic signs**: Tachypnea and dyspnea may stem from metabolic acidosis, while vomiting/diarrhea reflect multisystem metabolic stress.  
7. **Severe prognosis**: Death in infancy is consistent with acute metabolic crises in untreated VLCADD, triggered by catabolic states (e.g., fasting, infection).  

VLCADD is distinguished from other fatty acid oxidation defects by its predilection for cardiac/hepatic involvement and characteristic laboratory markers (e.g., elevated C14:1 acylcarnitine). Early-onset symptoms with multisystemic dysfunction confirm this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on -
Choices:
A. Chromosome 5
B. Chromosome 8
C. Chromosome 13
D. Chromosome 16
Answer: [/INST] Chromosome 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Carrier stage seen in -a)  Poliob)  Cholerac)  Pertusis d) Plague e)  Tetanus
Choices:
A. da
B. abc
C. dea
D. ac
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Duchenne Muscular Dystrophy is a disease of:
Choices:
A. Neuromuscular junction
B. Sarcolemmal proteins
C. Muscle contractile proteins
D. Disuse atrophy due to muscle weakness
Answer: [/INST] Sarcolemmal proteins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG is characterized by neurodevelopmental defects, including cerebellar hypoplasia/atrophy, leading to ataxia.  
2. **Neurological symptoms**: Intellectual disability, generalized hypotonia, and abnormal calvaria morphology align with multisystem neurological involvement in PMM2-CDG.  
3. **Dysmorphic features**: Abnormal facial shape and strabismus are common due to craniofacial and connective tissue glycosylation defects.  
4. **Severe infantile course**: Death in infancy correlates with severe PMM2-CDG subtypes, often from organ failure or infections.  
5. **Systemic involvement**: Glycosylation defects disrupt multiple organs, explaining the combination of CNS, skeletal, and dysmorphic features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements are about Non Typhoid Salmonella (NTS) are true, EXCEPT:
Choices:
A. Humans are the only reservoir
B. Transmission is most commonly associated with eggs, poultry and undercooked meat
C. Common in Immunocompromised individuals
D. Resistance to fluroquinolones has emerged
Answer: [/INST] Humans are the only reservoir </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucocutaneous Leishmaniasis is caused by
Choices:
A. L. Brasiliensis
B. L. tropica
C. L. donovani
D. L. Chagasi
Answer: [/INST] L. Brasiliensis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a feature of Tuberculosis of the spine:
Choices:
A. Back pain earliest symptom
B. Stiffness of back
C. Exaggerated lumbar lordosis
D. Cold abscess
Answer: [/INST] Exaggerated lumbar lordosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant woman with PKU causes congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus.  
3. **Hypertyrosinemia** may occur secondarily due to disrupted phenylalanine-tyrosine metabolism or overlap with tyrosinemia type II (rare), but PKU remains primary given the clinical context.  
4. **Early mortality (infancy, childhood, adolescence)** reflects untreated PKU complications: severe neurotoxicity (seizures, developmental delay), metabolic instability, and susceptibility to infections.  
5. Neonatal screening typically detects PKU, but lack of dietary intervention (low-phenylalanine diet) leads to progressive neurological deterioration and premature death.  

Note: Hypertyrosinemia is atypical in classic PKU but may arise in variant forms or coexisting metabolic disturbances. Maternal PKU explains prenatal abnormalities, while untreated PKU in the child drives hyperphenylalaninemia and fatal outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Nystagmus', 'Hyperactivity', 'Cyanosis', 'Edema', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Diarrhea', 'Pneumonia', 'Dyspnea', 'Hyperkalemia', 'Opisthotonus', 'Hepatomegaly', 'Fair hair', 'Spastic tetraplegia', 'Hypocalcemia', 'Neonatal death', 'Stridor', 'White hair', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutathione synthetase deficiency  
Reasoning:  
1. **Metabolic acidosis**: A hallmark of glutathione synthetase deficiency (GSSD), caused by accumulation of 5-oxoproline due to impaired glutathione synthesis.  
2. **Neurological symptoms (seizures, intellectual disability, spastic tetraplegia/diplegia, motor delay, hypotonia, opisthotonus)**: Result from oxidative stress and neuronal damage due to glutathione deficiency, critical for antioxidant defense.  
3. **Recurrent infections (pneumonia) and dyspnea**: Glutathione is essential for immune function; deficiency increases susceptibility to infections and oxidative lung injury.  
4. **Hepatomegaly and edema**: Hepatic dysfunction from oxidative damage and metabolic stress.  
5. **Electrolyte imbalances (hyperkalemia, hypocalcemia)**: Secondary to renal tubular acidosis, a known complication of GSSD.  
6. **Fair/white hair**: Reduced melanin synthesis due to disrupted cysteine metabolism (cysteine is a glutathione precursor).  
7. **Early mortality (neonatal death, death in infancy)**: Severe metabolic instability and infections in untreated cases.  
8. **Diarrhea and stridor**: Gastrointestinal and respiratory manifestations of systemic metabolic dysfunction.  
9. **Cyanosis and severe hearing impairment**: Hypoxia from respiratory compromise and oxidative damage to cochlear cells, respectively.  

The combination of metabolic acidosis, neurological deficits, immune dysfunction, and pigmentary changes strongly aligns with glutathione synthetase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about HIV, Osteomyelitis is all except -
Choices:
A. Necrosis absent
B. Often bilateral
C. Periosteal new bone formation
D. Most common cause is staph. aureus
Answer: [/INST] Necrosis absent </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Sun ray appearance is seen in – a) Osteosarcomab) Ewing sarcomac) Osteoclastomad) Multiple myeloma
Choices:
A. ac
B. ab
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Acne', 'Tachycardia', 'Left ventricular hypertrophy', 'Palpitations', 'Arthralgia', 'Abnormal EKG', 'Abnormality of galactoside metabolism', 'Edema of the dorsum of hands', 'Upper limb pain', 'Finger swelling', 'Finger pain', 'Knee pain', 'Ankle pain', 'Papule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Fabry disease  
Reasoning:  
1. **Cardiac Manifestations**: Tachycardia, palpitations, left ventricular hypertrophy (LVH), and abnormal EKG align with Fabry disease's progressive cardiac involvement due to globotriaosylceramide (Gb3) accumulation in myocardial tissue, leading to arrhythmias and structural changes.  
2. **Neuropathic Pain**: Arthralgia, upper limb pain, finger/knee/ankle pain correlate with Fabry-associated acroparesthesias, characterized by episodic burning or tingling in extremities.  
3. **Metabolic Abnormality**: The explicit mention of ""abnormality of galactoside metabolism"" directly implicates alpha-galactosidase A deficiency, the enzymatic defect in Fabry disease.  
4. **Dermatologic Features**: Papules may represent angiokeratomas, a pathognomonic skin lesion of Fabry disease.  
5. **Edema and Swelling**: Edema of the hands and finger swelling may reflect vascular dysfunction or secondary renal impairment, though less typical, they reinforce multisystem involvement.  
6. **Exclusion of Alternatives**: Symptoms collectively point to a lysosomal storage disorder, with the metabolic clue excluding rheumatologic or isolated cardiac conditions. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Ataxia', 'Lethargy', 'Hyperreflexia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Oroticaciduria', 'Death in childhood', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as OTC is a urea cycle enzyme. Deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate enters pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (seizures, ataxia, lethargy, drowsiness, hyperreflexia, fasciculations): Result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Metabolic acidosis**: Secondary to organic acid accumulation from alternative ammonia detoxification pathways.  
5. **Gastrointestinal symptoms** (diarrhea): Common in urea cycle disorders due to metabolic stress.  
6. **Early mortality**: Untreated OTCD causes recurrent hyperammonemic crises, leading to death in childhood/adolescence without intervention.  
7. **Fever**: May trigger metabolic decompensation (e.g., infection-induced catabolism exacerbating ammonia accumulation).  
8. **Sleep disturbance**: Linked to encephalopathy from chronic hyperammonemia.  
*Exclusion of other urea cycle disorders*: Oroticaciduria distinguishes OTCD from CPS1 or NAGS deficiencies, which share hyperammonemia but lack this feature. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are complication of Typhoid ulcer EXCEPT -
Choices:
A. Perforation
B. Stricture
C. Haemorrhage
D. Endocarditis
Answer: [/INST] Stricture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Intellectual disability & motor delay**: PMM2-CDG disrupts N-glycosylation, impairing neuronal development and cerebellar function, leading to neurodevelopmental deficits.  
2. **Cerebellar atrophy/agenesis**: Glycosylation defects cause structural brain abnormalities, particularly cerebellar hypoplasia/agenesis, a hallmark of PMM2-CDG.  
3. **Hypoproteinemia & hypocholesterolemia**: Impaired hepatic synthesis of glycosylated transport proteins (e.g., albumin, lipoproteins) reduces serum protein and cholesterol.  
4. **Lipodystrophy**: Abnormal fat distribution due to glycosylation-dependent adipocyte signaling and lipid metabolism dysfunction.  
5. **Acute/chronic hepatitis**: Liver involvement (elevated transaminases, steatosis) is common, progressing to fibrosis in severe cases.  
6. **Death in infancy**: Severe multisystemic disease (neurological, hepatic, and coagulopathic complications) often leads to early mortality in classical PMM2-CDG.  

The triad of **neurological impairment**, **protein-losing enteropathy/hypoalbuminemia**, and **hepatopathy** strongly supports PMM2-CDG. Confirmatory testing (phosphomannomutase 2 enzyme activity, genetic analysis for _PMM2_ variants) is required. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vasculitis not commonly seen in adults-
Choices:
A. Kawasaki disease
B. Henoch schonlein purpura
C. Temporal arteritis
D. PAN
Answer: [/INST] Kawasaki disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine is prepared from:
Choices:
A. Liver virus
B. Street virus
C. Fixed virus
D. None of the above.
Answer: [/INST] Fixed virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Typhoid EXCEPT:
Choices:
A. Incubation period 10 to 14 days
B. Most common among males
C. Carrier are treated by Ampicillin
D. Highest incidence occurs in 30-40 years age group
Answer: [/INST] Highest incidence occurs in 30-40 years age group </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Long philtrum', 'Macrotia', 'Bulbous nose', 'Tachycardia', 'Bilateral tonic-clonic seizure', 'Apnea', 'Abnormal cortical gyration', 'Recurrent infections', 'Breathing dysregulation', 'Respiratory acidosis', 'Diffuse white matter abnormalities', 'EEG with frontal sharp waves', 'Low APGAR score', 'Postaxial polydactyly']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like abnormal cortical gyration, diffuse white matter abnormalities, and EEG with frontal sharp waves align with structural and functional brain abnormalities characteristic of PLAA-NDD.  
2. **Seizures and Autonomic Dysregulation**: Bilateral tonic-clonic seizures, apnea, breathing dysregulation, and respiratory acidosis suggest central nervous system involvement, particularly brainstem dysfunction, which is consistent with this disorder.  
3. **Craniofacial Features**: Long philtrum, macrotia, and bulbous nose match reported dysmorphic traits in PLAA-NDD.  
4. **Postaxial Polydactyly**: While uncommon, polydactyly has been observed in some cases, possibly linked to broader developmental disruptions.  
5. **Early Neonatal Compromise**: Low APGAR score reflects perinatal distress, often seen in congenital neurodevelopmental disorders.  
6. **Recurrent Infections**: May result from respiratory compromise (e.g., aspiration due to dysphagia or breathing irregularities) rather than primary immunodeficiency.  
7. **Progressive Microcephaly**: Though not explicitly listed, abnormal cortical gyration and white matter changes imply evolving brain pathology, fitting the ""progressive"" nature of the disorder.  

The constellation of neurological, dysmorphic, and systemic features strongly supports PLAA-NDD, driven by PLAA gene mutations impacting neurodevelopment and autonomic regulation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is a disease of: -
Choices:
A. Neural transmission caused by the toxin of the bacterium Clostridium botulinum
B. Muscular transmission caused by the toxin of the bacterium Clostridium botulinum
C. Neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum
D. Non neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum
Answer: [/INST] Neuromuscular transmission caused by the toxin of the bacterium Clostridium botulinum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about communicability of Malaria, except -
Choices:
A. The number of gametocytes in blood increases with time
B. Gametocytes appear in blood 4-5 days after the appearance of the asexual parasite, in vivax infection.
C. Gametocytes appear in blood 10-12 days after the appearance of asexual parasite, in falciparum infection
D. In the early stage of infection, their density may exceed 1000 per cmm of blood.
Answer: [/INST] The number of gametocytes in blood increases with time </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Retinoblastoma –a) Leukocoria is most common presentationb) Always unilateralc) May have family historyd) Enucleation is the only treatmente) Most common age group affected is 1–2 year
Choices:
A. acd
B. bde
C. ace
D. ade
Answer: [/INST] ace </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where uncontrolled maternal phenylalanine levels during pregnancy cause congenital anomalies.  
3. **Neonatal death/Death in infancy/Death in adolescence** reflects untreated PKU complications: severe neurotoxicity, seizures, and organ damage without dietary intervention.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low) but may indicate a concurrent condition, lab error, or severe metabolic dysregulation in terminal stages.  
5. The symptom constellation prioritizes PKU due to hyperphenylalaninemia, with early mortality explained by lack of treatment (e.g., phenylalanine-restricted diet).  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia, BH4 deficiency), but PKU remains the primary diagnosis based on hyperphenylalaninemia and clinical context. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Normal pressure Hydrocephalus is characterized by all except:
Choices:
A. Aphasia
B. Dementia
C. Ataxia
D. Urinary incontinence
Answer: [/INST] Aphasia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Aspergillosis can present with all except
Choices:
A. Lung cavity
B. Ear infection
C. Normal component in sputum
D. Rhinocerebral involvement
Answer: [/INST] Rhinocerebral involvement </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anthrax bacilli differs from anthracoid bacilli by being
Choices:
A. Non-capsulated
B. Strict aerobe
C. Non-motile
D. Haemolytic colonies on blood agar
Answer: [/INST] Non-motile </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma most commonly metastasize to
Choices:
A. Lung
B. CSF
C. Liver
D. Bone
Answer: [/INST] CSF </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Miliary Tuberculosis are true Except -
Choices:
A. May occur following primar in fection
B. May occur follwoing secondary reactivation
C. Sputum microscopy is usually negative
D. Montoux is always positive
Answer: [/INST] Montoux is always positive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis is caused by
Choices:
A. Sporothrix
B. Mucor
C. Rhizopus
D. Cryptococcus neoformans
Answer: [/INST] Cryptococcus neoformans </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia**: Common in organic acidemias due to secondary inhibition of the urea cycle.  
2. **Abnormal carnitine**: IVA causes carnitine depletion via conjugation with isovaleric acid (isovalerylcarnitine excretion).  
3. **Abnormal glycine**: Excess isovaleric acid is detoxified via glycine conjugation (elevated isovalerylglycine in urine).  
4. **Neonatal/Infancy death**: Untreated IVA leads to metabolic crises, encephalopathy, and early mortality.  
5. **Prenatal abnormalities**: Severe metabolic stress may indirectly affect fetal development, though IVA typically manifests postnatally.  
6. **Exclusion of mimics**: Differentiated from other organic acidemias (e.g., propionic/methylmalonic acidemia) by specific biomarkers (isovalerylglycine, C5 acylcarnitine). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: NOT a feature of Holt Oram Syndrome is
Choices:
A. Absent Radius
B. Atrial septal defect
C. Thrombocytopenia
D. Autosomal dominant inheritance
Answer: [/INST] Thrombocytopenia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera vaccination is indicated -
Choices:
A. To control epidemics
B. For travellers
C. In endemic areas
D. In Neonates
Answer: [/INST] In endemic areas </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Blastomycosis is characterized by all except
Choices:
A. Yeast like fungus
B. Commonly involves lung and skin
C. Dimorphic fungus
D. Common in South America
Answer: [/INST] Common in South America </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Trophic ulcers are caused by -a) Leprosyb) Buerger's diseasec) Syringomyeliad) DVTe) Varicose veins
Choices:
A. ac
B. bc
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma is associated with -
Choices:
A. Chlonorchis sinensis
B. Schistosoma
C. Plasmodium
D. None
Answer: [/INST] Chlonorchis sinensis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing impairment', 'Neonatal hypotonia', 'Decreased liver function', 'Failure to thrive in infancy', 'Left ventricular hypertrophy', 'Acidosis', 'Poor suck', 'Respiratory distress', 'Polymicrogyria', 'Increased serum lactate', 'Increased CSF lactate', 'Elevated hepatic transaminase', 'Lactic acidosis', 'Feeding difficulties in infancy', 'Nasogastric tube feeding']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Combined oxidative phosphorylation deficiency 30 (COXPD30)  
Reasoning:  
1. **Lactic acidosis** (elevated serum and CSF lactate) indicates impaired mitochondrial energy metabolism, a hallmark of oxidative phosphorylation defects.  
2. **Neurological involvement**: Polymicrogyria (abnormal brain development), neonatal hypotonia, and hearing impairment align with mitochondrial encephalopathies caused by defective mitochondrial translation (e.g., MTFMT gene mutations in COXPD30).  
3. **Multi-organ dysfunction**:  
   - **Hepatic**: Elevated transaminases and decreased liver function suggest mitochondrial hepatopathy.  
   - **Cardiac**: Left ventricular hypertrophy reflects energy-deficient cardiac tissue stress.  
   - **Failure to thrive** and feeding difficulties (poor suck, nasogastric dependence) stem from systemic metabolic insufficiency.  
4. **Respiratory distress** may arise from combined metabolic acidosis and neuromuscular weakness.  
5. **MTFMT mutations** disrupt mitochondrial protein synthesis, causing combined respiratory chain deficiencies, consistent with the patient’s multi-systemic presentation.  

Disease: Combined oxidative phosphorylation defect type 30  
Reasoning:  
- This is a synonym for COXPD30, reaffirmed by the same genetic basis (MTFMT) and phenotypic overlap:  
  - **Biochemical markers**: Persistent lactic acidosis and elevated hepatic transaminases.  
  - **Clinical triad**: Encephalopathy (polymicrogyria, hypotonia), cardiomyopathy, and hepatopathy.  
  - **Infantile onset**: Symptoms like respiratory distress, feeding difficulties, and failure to thrive manifest early, typical of severe mitochondrial disorders.  
- The dual elevation of lactate in serum and CSF excludes isolated organ defects, supporting a systemic oxidative phosphorylation defect. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Giant cells seen in Measles are called?
Choices:
A. Hp bodies
B. Inclusion containing polykaryon
C. Koplik cells
D. Wahin-Finkeldey cells
Answer: [/INST] Wahin-Finkeldey cells </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Anemia', 'Vomiting', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Hypocalcemia', 'Neonatal death', 'Abnormality of acid-base homeostasis', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic acidosis**: ""Abnormality of acid-base homeostasis"" and ""hypocalcemia"" align with PA-induced metabolic acidosis due to propionate accumulation.  
2. **Neurological symptoms**: ""Lethargy,"" ""coma,"" ""drowsiness,"" and ""sleep disturbance"" result from neurotoxicity of propionic acid and ammonia.  
3. **Hematologic abnormalities**: ""Thrombocytopenia"" and ""anemia"" stem from bone marrow suppression caused by toxic metabolites.  
4. **Neonatal fatality**: ""Death in infancy"" and ""neonatal death"" reflect PA’s severe, early-onset metabolic crises if untreated.  
5. **Gastrointestinal issues**: ""Vomiting"" and ""feeding difficulties"" arise from protein intolerance and metabolic decompensation.  
6. **Muscular involvement**: ""Generalized hypotonia"" links to energy deficiency in muscle cells due to disrupted mitochondrial function.  
7. **Biomarkers**: ""Elevated urinary carboxylic acids"" (e.g., 3-hydroxypropionate, methylcitrate) and ""abnormal glycine concentrations"" are hallmark biochemical features of PA.  
8. **Respiratory distress**: ""Dyspnea"" may reflect compensatory hyperventilation to counteract acidosis.  
9. **Porphyrin disruption**: ""Abnormal circulating porphyrins"" occur due to secondary inhibition of heme synthesis pathways by propionyl-CoA.  

PA is confirmed by enzyme assays (propionyl-CoA carboxylase deficiency) and genetic testing. Early intervention with dietary protein restriction and metabolic support is critical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hydrocephalus is best detected antenately by:
Choices:
A. X-ray abdomen
B. Amniocentesis
C. Clinical examination
D. Ultrasonography
Answer: [/INST] Ultrasonography </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Intermittent dysphagia is caused by -a) Strictureb) Reflux esophagitisc) Achalasia cardiad) Pharyngeal diverticulme) Diffuse esophageal spasm
Choices:
A. ab
B. bc
C. cd
D. de
Answer: [/INST] de </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly causes all except :
Choices:
A. Prematurity
B. Face presentation
C. Hydramnios
D. None
Answer: [/INST] None </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hydroureter', 'Splenomegaly', 'Elevated circulating creatinine concentration', 'Aortic aneurysm', 'Retroperitoneal fibrosis', 'Ureterovesical stenosis', 'Elevated circulating C-reactive protein concentration', 'Plasmacytosis', 'Splenic cyst', 'Increased circulating IgG4 level', 'Dilatation of renal calices']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] IgG4-related retroperitoneal fibrosis:  
1. **Retroperitoneal fibrosis** is a hallmark of IgG4-related disease (IgG4-RD), characterized by fibroinflammatory tissue that often entraps ureters, leading to **hydroureter** and **ureterovesical stenosis**.  
2. **Elevated circulating IgG4 level** and **plasmacytosis** are diagnostic biomarkers of IgG4-RD, reflecting systemic plasmacytic infiltration.  
3. **Splenomegaly** and **splenic cyst** align with IgG4-RD’s multisystemic nature, which can involve the spleen.  
4. **Aortic aneurysm** is a known vascular manifestation of IgG4-RD due to inflammatory aortitis.  
5. **Dilatation of renal calices** and **elevated creatinine** indicate obstructive uropathy secondary to retroperitoneal fibrosis.  
6. **Elevated C-reactive protein** underscores the inflammatory activity, consistent with IgG4-RD’s pathophysiology.  
7. The convergence of fibrosis, elevated IgG4, and multi-organ involvement excludes mimics like malignancy or idiopathic fibrosis, confirming IgG4-related retroperitoneal fibrosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Motor delay', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Death in childhood', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Metabolic Pathway Disruption**: The symptoms ""abnormal circulating monocarboxylic acid concentration"" and ""elevated urinary carboxylic acid"" align with the accumulation of γ-hydroxybutyric acid (GHB) and succinic semialdehyde (SSA) due to SSADH enzyme deficiency, disrupting GABA degradation.  
2. **Neurological Manifestations**: ""Intellectual disability"" and ""motor delay"" are hallmark features of SSADHD, stemming from GABA and GHB neurotoxicity, leading to developmental delays and hypotonia.  
3. **Urinary Biomarkers**: Elevated urinary GHB (a carboxylic acid) is pathognomonic for SSADHD, explaining the ""elevated urinary carboxylic acid"" finding.  
4. **Severe Prognosis**: While death in childhood is rare, severe cases may involve intractable seizures, metabolic crises, or respiratory failure, consistent with the listed symptom.  
5. **Dysmorphic Features**: ""Abnormal facial shape"" and ""abnormal calvaria morphology"" are atypical but reported in some SSADHD cases, potentially linked to chronic metabolic stress or co-occurring genetic factors.  
6. **Exclusion of Alternatives**: Other organic acidurias (e.g., glutaric aciduria) were considered but ruled out due to the specificity of GHB elevation and lack of characteristic crises (e.g., ketoacidosis). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Ketonuria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: β-Ketothiolase Deficiency (Beta-ketothiolase deficiency)  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, and increased serum lactate**: Indicate a defect in mitochondrial energy metabolism, specifically in ketone body utilization and isoleucine catabolism, which are impaired in β-ketothiolase deficiency (BKD).  
2. **Ketonuria and elevated urinary carboxylic acids**: Result from the accumulation of ketones (acetoacetate, 3-hydroxybutyrate) and toxic metabolites like α-methylacetoacetate due to deficient mitochondrial acetoacetyl-CoA thiolase activity.  
3. **Abnormal circulating glycine and carnitine concentrations**: Secondary to metabolic decompensation; carnitine depletion occurs as it conjugates with toxic acyl-CoA intermediates for excretion.  
4. **Vomiting, diarrhea, and fever**: Common triggers of metabolic crises in BKD, often precipitated by infections or fasting, leading to catabolism and acute intoxication.  
5. **Coma and early mortality (infancy/childhood)**: Reflect severe metabolic derangements during crises, including hyperammonemia, cerebral edema, or energy failure.  
6. **Pustules**: May arise from secondary infections during catabolic stress or metabolic toxicity affecting immune responses.  
7. **Genetic confirmation**: Definitive diagnosis requires identification of *ACAT1* gene mutations or enzyme assay showing reduced thiolase activity.  

The constellation of episodic ketoacidosis, ketonuria, and characteristic organic aciduria aligns pathognomonically with BKD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Whole body radiation is indicated in –  a) Advanced head & neck tumours  b) BM transplantation  c) Medulloblastoma  d) Mycosis fungoides  e) Histiocytosis-x
Choices:
A. ab
B. bd
C. ac
D. dc
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Hyperthreoninuria', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating tyrosine concentration', 'Galactosuria', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with key metabolic abnormalities indicative of galactose processing dysfunction, including hypergalactosemia, galactosuria, and abnormal galactoside metabolism. Classic galactosemia (GALT deficiency) disrupts the Leloir pathway, causing toxic accumulation of galactose-1-phosphate. This explains neonatal/childhood mortality due to fulminant liver failure, sepsis, or CNS complications. Abnormal amino acid concentrations (aspartate, alanine, tyrosine) reflect secondary hepatic dysfunction, while hyperthreoninuria may arise from proximal renal tubular damage from metabolite toxicity. Intellectual disability and speech delays align with long-term neurotoxic effects of untreated galactose metabolites. The constellation of life-threatening metabolic crises in infancy and specific biochemical markers strongly supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spastic paraplegia', 'Dysarthria', 'Gait ataxia', 'Limb ataxia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spastic paraplegia** indicates upper motor neuron dysfunction, a hallmark of hereditary spastic paraplegias (HSPs).  
2. **Gait and limb ataxia** suggest cerebellar involvement, distinguishing SPG76 from ""pure"" HSP subtypes.  
3. **Dysarthria** further supports cerebellar or bulbar pathology, aligning with SPG76’s association with combined pyramidal and cerebellar features.  
4. SPG76, caused by biallelic *CAPN1* mutations, is characterized by progressive spasticity, ataxia, and dysarthria, consistent with the symptom profile.  
5. Exclusion of mimics (e.g., SPG7, SPG11) relies on genetic testing, but the clinical triad strongly supports SPG76. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of these doesn't present with granulomatous Vasculitis?
Choices:
A. Polyarteritis nodosa
B. Wegeners
C. Churg strauss syndrome
D. Microscopic polyangitis
Answer: [/INST] Microscopic polyangitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Blastomycosis is characterized by all except ?
Choices:
A. Yeast like fungus
B. Commonly involves lung and skin
C. Dimorphic fungus
D. Common in South America
Answer: [/INST] Common in South America </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spastic paraplegia', 'Dysarthria', 'Spastic gait', 'Difficulty walking', 'Distal muscle weakness', 'Hyporeflexia of lower limbs', 'Distal peripheral sensory neuropathy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, and difficulty walking align with hereditary spastic paraplegia (HSP), a hallmark of SPG76.  
2. **Neuropathy Overlap**: Distal peripheral sensory neuropathy and hyporeflexia suggest peripheral nerve involvement, consistent with SPG76’s association with axonal neuropathy.  
3. **Upper vs. Lower Motor Neuron Signs**: Hyporeflexia (lower motor neuron) contrasts with spasticity (upper motor neuron), indicating a ""complicated"" HSP subtype, which SPG76 exemplifies.  
4. **Dysarthria**: Though rare in pure HSP, dysarthria is reported in SPG76 due to overlapping cerebellar or bulbar dysfunction.  
5. **Genetic Confirmation**: SPG76 is linked to CAPN1 mutations, which cause progressive spasticity and neuropathy, matching the symptom profile.  
6. **Exclusion of Alternatives**: Features lack cognitive decline or structural brain anomalies seen in other HSP subtypes (e.g., SPG11/SPG15), narrowing the diagnosis to SPG76. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are true of Tuberculosis except -a) For sputum to be positive,bacilli should be > 104/ mlb) Niacin test differentiates M. tuberculosis and M. bovisc) Pathogenicity to rabbits differentiates M. tuberculosis and M. bovisd) Culture techniques have low sensitivity
Choices:
A. ab
B. bc
C. cd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Negri bodies, which are pathognomonic of Rabies, are commonly found in which of the following cells?
Choices:
A. Anterior horn motor neurons of the spinal cord
B. Purkinje cells of the cerebellum
C. Microglial cells
D. Ependymal lining cells
Answer: [/INST] Purkinje cells of the cerebellum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with Hypeension presents with Hypokalemia. Aldosterone levels and Renin levels are both elevated. The most likely diagnosis is:
Choices:
A. Renal AeryStenosis
B. Primary Hyperaldosteronism (Conn's Syndrome)
C. Addison's Disease
D. Cushing's Syndrome
Answer: [/INST] Renal AeryStenosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Inheritance of ""Familial Hypercholesterolemia"" is:
Choices:
A. AD
B. AR
C. X Linked dominant
D. X linked recessive
Answer: [/INST] AD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nocturia', 'Renal cyst', 'Ovarian cyst', 'Hyperhidrosis', 'Facial erythema', 'Joint swelling', 'Hepatic steatosis', 'Ascites', 'Tachycardia', 'Acute pancreatitis', 'Abnormal toe morphology', 'Vomiting', 'Diarrhea', 'Nausea', 'Cerebral atrophy', 'Dyspnea', 'Pleuritis', 'Hyperuricemia', 'Hypertriglyceridemia', 'Pleural effusion', 'Hepatomegaly', 'Arthralgia', 'Neoplasm of the liver', 'Rheumatoid factor positive', 'Hypercholesterolemia', 'Hyperuricosuria', 'Increased circulating ferritin concentration', 'Myalgia', 'Back pain', 'Increased circulating IgM level', 'Exercise intolerance', 'Increased total bilirubin', 'Generalized morning stiffness', 'Abnormality of complement system', 'Enlarged metacarpophalangeal joints', 'Renal neoplasm', 'Peripheral neuropathy', 'Elevated circulating C-reactive protein concentration', 'obsolete Increased urinary urate', 'Increased circulating beta-2-microglobulin level', 'Neck pain', 'Shoulder pain', 'Finger pain', 'Elevated gamma-glutamyltransferase level', 'Perinephric fluid collection', 'Groin pain', 'Increased circulating IgG4 level', 'Low levels of vitamin D', 'Abnormality of nail color', 'Insomnia', 'Increased hepatitis A virus antibody level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Antisynthetase syndrome  
Reasoning:  
1. **Key Triad Features**:  
   - **Myositis**: Suggested by *myalgia* and *exercise intolerance* (common in muscle inflammation).  
   - **Interstitial Lung Disease (ILD)**: Supported by *dyspnea*, *pleural effusion*, and *pleuritis*.  
   - **Inflammatory Arthritis**: Evidenced by *joint swelling*, *arthralgia*, *enlarged metacarpophalangeal joints*, and *morning stiffness*.  

2. **Autoimmune Markers**:  
   - *Rheumatoid factor positive* and *elevated CRP* align with systemic inflammation.  
   - *Abnormality of complement system* and *increased IgG4/IgM* suggest immune dysregulation, though anti-synthetase antibodies (e.g., anti-Jo-1) are pathognomonic (not explicitly listed but inferred).  

3. **Overlapping Systemic Involvement**:  
   - *Hepatomegaly* and *hepatic steatosis* may reflect secondary metabolic dysfunction or inflammation.  
   - *Hyperuricemia* and *hypertriglyceridemia* could arise from systemic inflammation or comorbid metabolic syndrome.  

4. **Exclusions/Comorbidities**:  
   - *Renal cysts*, *neoplasms*, and *cerebral atrophy* are atypical for antisynthetase syndrome, suggesting comorbidities or alternative diagnoses (e.g., genetic disorders like HNF1B or VHL).  
   - *Acute pancreatitis* and *vitamin D deficiency* likely stem from metabolic disturbances rather than primary autoimmune pathology.  

5. **Supportive Findings**:  
   - *Facial erythema* and *abnormal nail color* may reflect vasculopathy or Raynaud’s phenomenon (common in overlap syndromes).  
   - *Peripheral neuropathy* and *fatigue* are nonspecific but compatible with chronic inflammatory states.  

Conclusion: The constellation of myositis, ILD, and inflammatory arthritis, alongside autoimmune markers, strongly supports antisynthetase syndrome. Further confirmation requires anti-synthetase antibody testing (e.g., anti-Jo-1) and imaging (e.g., HRCT for ILD). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Bifid scrotum', 'Micropenis', 'Ambiguous genitalia', 'Low-set ears', 'Atopic dermatitis', 'Hypocholesterolemia', 'Short nose', 'Elevated 8-dehydrocholesterol', '2-3 toe syndactyly', 'Decreased testicular size', 'Elevated 7-dehydrocholesterol', 'Abnormal circulating testosterone concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol Synthesis Defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol confirm a block in cholesterol biosynthesis due to DHCR7 enzyme deficiency, a hallmark of SLOS.  
2. **Genital Abnormalities**: Hypospadias, bifid scrotum, micropenis, ambiguous genitalia, and decreased testicular size align with SLOS-associated urogenital malformations and impaired steroidogenesis.  
3. **Craniofacial Features**: Short nose and low-set ears are classic dysmorphic traits in SLOS.  
4. **Limb Anomalies**: 2-3 toe syndactyly is a pathognomonic feature of SLOS.  
5. **Biochemical Markers**: Hypocholesterolemia and abnormal testosterone levels reflect disrupted cholesterol-dependent processes (e.g., hormone synthesis).  
6. **Dermatologic Manifestation**: Atopic dermatitis correlates with skin barrier dysfunction due to cholesterol deficiency.  
The constellation of biochemical, structural, and clinical findings is diagnostic for Smith-Lemli-Opitz syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertelorism', 'Anteverted nares', 'Self-mutilation', 'Delayed speech and language development', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Abnormal foot morphology', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Hypocholesterolemia and elevated 7-/8-dehydrocholesterol are pathognomonic for SLOS, caused by *DHCR7* mutations impairing cholesterol biosynthesis.  
2. **Craniofacial features**: Hypertelorism and anteverted nares align with SLOS-associated dysmorphism.  
3. **Limb/skeletal anomalies**: Syndactyly and abnormal foot morphology are classic SLOS findings (e.g., 2-3 toe syndactyly).  
4. **Neurodevelopmental issues**: Intellectual disability, speech/motor delays, seizures, and hyperactivity reflect SLOS’s neurological impact.  
5. **Sensory deficits**: Severe hearing impairment is a recognized but variable feature.  
6. **Self-injurious behavior**: Rarely reported in SLOS, potentially linked to neurodevelopmental severity.  
7. **Mortality**: Neonatal/childhood death correlates with severe SLOS phenotypes, often due to organ malformations or metabolic complications.  
*Conclusion*: Combined biochemical, dysmorphic, and developmental features confirm SLOS. Cholesterol precursor testing is diagnostic. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Death in infancy/childhood/adolescence**: Untreated PKU leads to severe neurological damage, seizures, and failure to thrive, often resulting in early mortality without dietary intervention.  
3. **Elevated urinary carboxylic acids**: Phenylalanine derivatives like phenylpyruvate and phenyllactate (classic phenylketones) may be detected as urinary carboxylic acids.  

**Inconsistencies/Additional Considerations**:  
- **Hypertyrosinemia**: Not typical in PKU (tyrosine levels are usually low/normal). Suggests possible comorbid tyrosinemia or BH4 deficiency (a PKU variant).  
- **Recurrent viral infections**: Unrelated to classic PKU; may indicate immune dysfunction from malnutrition or a secondary disorder.  
- **Abnormal porphyrins/decreased ferritin**: Could reflect hepatic dysfunction or nutritional deficiencies due to restricted diets in PKU management.  

While PKU explains hyperphenylalaninemia and early mortality, hypertyrosinemia and immune issues warrant investigation for overlapping metabolic disorders (e.g., BH4 deficiency) or comorbidities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about Tetralogy of Fallot?
Choices:
A. Cyanosis is often present in the first few days of life
B. There is a right sided aoic arch in about 50% of cases
C. The murmur becomes so er during a cyano c spell as flow through the pulmonary valve is increased
D. There is an association with DiGeorge syndrome
Answer: [/INST] There is an association with DiGeorge syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following tests is abnormal in patients with ALS (Amyotrophic Lateral Sclerosis)?
Choices:
A. V.E.P
B. MRI whole spine
C. CT whole Spine
D. Electromyography
Answer: [/INST] Electromyography </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Age group most prone to Rubella is?
Choices:
A. Infants
B. Adolescent girls
C. Pregnant females
D. Women of child bearing age
Answer: [/INST] Women of child bearing age </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Rabies, true is -
Choices:
A. Incubation period depends on the site of bite
B. Diagnosis is by eosinophilic intranuclear inclusion
C. It is a RNA virus
D. Caused only by dogs
Answer: [/INST] Incubation period depends on the site of bite </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratoconus is defined as: March 2013 (h)
Choices:
A. Degeneration of conjunctiva
B. Cornea undergoes necrosis due to vitamin A deficiency
C. Cornea thins near the centre & bulges forwards
D. Recurrent corneal ulcerations of cornea
Answer: [/INST] Cornea thins near the centre & bulges forwards </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles stored at PHC at what temperature?
Choices:
A. 0degC
B. 2-8degC
C. 20degC
D. Room temperature
Answer: [/INST] 2-8degC </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Normal pressure Hydrocephalus is characterized by all except -
Choices:
A. Aphasia
B. Dementia
C. Ataxia
D. Urinary incontinence
Answer: [/INST] Aphasia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy treatment includes following drugs except :
Choices:
A. Dapsone
B. Rifampicin
C. Penicillin
D. Clofazimine
Answer: [/INST] Penicillin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seborrheic dermatitis', 'Seizure', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Aminoaciduria & Elevated Urinary Carboxylic Acids**: Biotinidase deficiency impairs biotin recycling, disrupting carboxylase enzymes (propionyl-CoA, pyruvate, 3-methylcrotonyl-CoA), leading to organic acidemia and abnormal metabolite excretion.  
2. **Seborrheic Dermatitis**: Biotin deficiency causes skin manifestations due to impaired fatty acid metabolism and keratinocyte dysfunction.  
3. **Seizures & Hypotonia/Hyporeflexia**: Accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and disrupted energy metabolism in the central nervous system.  
4. **Abnormal Circulating Glycine**: Secondary inhibition of glycine cleavage system by organic acids, elevating glycine levels (non-ketotic hyperglycinemia-like presentation).  
5. **Body Odor**: Excretion of volatile organic acids (e.g., 3-hydroxyisovalerate) through sweat and urine.  
6. **Death in Infancy**: Untreated BTDD causes progressive metabolic crises, respiratory failure, or neurological damage.  
**Diagnostic Confirmation**: Low serum biotinidase activity (<10% normal) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Incubation period of Rabies depends on: September 2010
Choices:
A. Number of bites
B. Site of bite
C. Animal species
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Motor delay', 'Cerebellar atrophy', 'Tremor', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development and function.  
2. **Motor delay and tremor**: Result from cerebellar dysfunction, disrupting coordination and motor control.  
3. **Intellectual disability**: Linked to global neurodevelopmental deficits due to abnormal glycosylation of brain proteins.  
4. **Strabismus**: Associated with neurological and muscular involvement from glycosylation defects.  
5. **Death in childhood**: Reflects severe multisystemic complications (e.g., liver failure, cardiomyopathy) common in classical PMM2-CDG.  
6. **Consistent with PMM2-CDG type Ia**: These features align with the phenotype of phosphomannomutase 2 deficiency, the most prevalent and well-characterized CDG subtype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly is associated with the following factor :
Choices:
A. Hydramnios
B. Postmaturity
C. Prematurity
D. All of these
Answer: [/INST] All of these </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following age group is most severely affected by Rubella infection -
Choices:
A. Females aged 25 -- 35 Year
B. Young girls
C. Adolescent girls
D. Unborn child
Answer: [/INST] Unborn child </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Ataxia', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical Marker**: The presence of L-2-hydroxyglutaric aciduria in urine is pathognomonic for this disorder, confirming a defect in the L2HGDH gene, which disrupts lysine and tryptophan metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, ataxia, and tremor align with progressive neurodegeneration caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: Early-onset symptoms (e.g., developmental delay) progressing to severe neurological deterioration and death in childhood reflect the aggressive nature of the disorder.  
4. **Exclusion of Mimics**: Specific biochemical findings rule out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or mitochondrial disorders with overlapping symptoms.  
5. **Genetic Confirmation**: While not explicitly stated here, the biochemical evidence (urinary acid elevation) is sufficient for clinical diagnosis, with genetic testing as confirmatory. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma associated with which variety of asbestos -
Choices:
A. Serpentine
B. Amphibole
C. Both the above
D. None of the above
Answer: [/INST] Amphibole </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: National Tuberculosis Institute is located at
Choices:
A. Bangalore
B. Chingelput
C. New Delhi
D. Chennai
Answer: [/INST] Bangalore </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Ataxia', 'Reduced tendon reflexes', 'Increased serum lactate', 'Increased CSF lactate', 'Glutaric aciduria', 'Increased serum pyruvate', 'Decreased plasma free carnitine', 'Abnormal immunoglobulin level', 'Hyperalbuminemia', 'Occipital neuralgia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by glutaryl-CoA dehydrogenase deficiency, leading to accumulation of glutaric acid.  
2. **Neurological symptoms (Nystagmus, Ataxia)**: GA-I damages the basal ganglia and white matter, causing dystonia, movement disorders, and cerebellar dysfunction.  
3. **Reduced tendon reflexes**: Suggests peripheral neuropathy, a known complication of metabolic toxicity in GA-I.  
4. **Elevated serum/CSF lactate & pyruvate**: Mitochondrial dysfunction from metabolic stress disrupts the tricarboxylic acid cycle, increasing anaerobic metabolism.  
5. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to toxic metabolites (e.g., glutaric acid) for excretion.  
6. **Death in early adulthood**: Untreated GA-I causes progressive neurodegeneration and metabolic crises, often leading to early mortality.  
7. **Hyperalbuminemia/Abnormal immunoglobulins**: Less specific but may reflect chronic metabolic stress or incidental findings; not core diagnostic criteria.  
8. **Occipital neuralgia**: Likely a secondary consequence of chronic neurological damage or unrelated comorbidity.  

Key exclusion: Other organic acidemias (e.g., MMA/PA) lack glutaric aciduria and typically present with severe ketoacidosis, which is less prominent in GA-I. The triad of glutaric aciduria, striatal injury, and characteristic biochemical profile confirms GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about communicability of Malaria, except-
Choices:
A. The number of gametocytes in blood increases with time
B. Gametocytes appear in blood 4-5 days after the appearance of the asexual parasite, in vivax infection.
C. Gametocytes appear in blood 10-12 days after the appearance of asexual parasite, in falciparum infection
D. In the early stage of infection, their density may exceed 1000 per cmm of blood.
Answer: [/INST] The number of gametocytes in blood increases with time </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Rod-cone dystrophy', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Absent speech', 'Craniosynostosis', 'Pes planus', 'Hallux valgus', 'Delayed gross motor development', 'Short stature', 'Multiple cafe-au-lait spots']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Rod-cone dystrophy**: Indicates retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
2. **Brachydactyly and short stature**: Directly aligns with the skeletal anomalies component (brachydactyly) and growth deficiency (short stature) in the syndrome.  
3. **Craniosynostosis**: Supports skeletal involvement, as craniofacial abnormalities can co-occur with syndromic RP variants.  
4. **Delayed speech/absent speech and motor delays**: Reflects potential neurodevelopmental impacts, consistent with multisystem genetic syndromes.  
5. **Pes planus and hallux valgus**: Further skeletal manifestations, reinforcing the ""skeletal anomalies"" classification.  
6. **Cafe-au-lait spots**: Less typical but occasionally reported in syndromic RP variants; may indicate phenotypic variability or overlap with other disorders (e.g., NF1), though the core triad (RP, brachydactyly, short stature) dominates the diagnosis.  

The combination of retinal degeneration, skeletal defects, and growth delays strongly prioritizes this syndrome over isolated RP or other café-au-lait-associated disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: 23 years old female comes to OG, because she thinks pregnant. She missed her last two cycles and she feels different. Urine pregnancy test was positive. On USG, the pregnancy was confirmed to be 12 weeks. She is very concerned because she received Measles Mumps Rubella (MMR) vaccine 4 months ago and she was told to wait for 3 months to conceive. The pregnancy is desired. The most appropriate step is
Choices:
A. Vaccine risk is minimal, not itself a reason to terminate the pregnancy
B. Vaccine risk is nil, termination is completely inappropriate
C. Vaccine risk is high, termination should be strongly considered
D. Vaccine risk is high, termination is mandated.
Answer: [/INST] Vaccine risk is minimal, not itself a reason to terminate the pregnancy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Enzyme deficient in Alkaptonuria?
Choices:
A. Phenylalanine hydroxylase
B. Cystathionine synthase
C. Homogentisic acid oxidase
D. Tyrosinase
Answer: [/INST] Homogentisic acid oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
- **Elevated urinary carboxylic acids**: Reflects alternative phenylalanine metabolism (e.g., phenylpyruvate, phenyllactate), excreted as urinary metabolites.  
- **Abnormality of prenatal development**: Likely due to maternal PKU during pregnancy, exposing the fetus to toxic phenylalanine levels.  
- **Neonatal death/Death in infancy**: Severe untreated PKU can lead to metabolic crises, neurological damage, and failure to thrive without early dietary intervention.  
- **Death in early adulthood**: Untreated PKU causes chronic complications (e.g., intellectual disability, seizures, organ damage) reducing life expectancy.  
- **Hypertyrosinemia anomaly**: Unusual for PKU (typically low tyrosine), possibly a lab error, co-existing condition, or secondary tyrosine dysregulation in severe metabolic disruption.  

Note: Hypertyrosinemia may warrant investigation for co-occurring disorders (e.g., BH4 deficiency) but does not override PKU diagnosis given hallmark symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Seizures**: A hallmark of Canavan disease due to progressive leukodystrophy and severe neurological degeneration.  
2. **Motor delay**: Caused by impaired myelination and spongiform degeneration of white matter in the brain.  
3. **Death in infancy**: Severe forms of Canavan disease often lead to early mortality due to rapid neurological decline.  
4. **Abnormal circulating aspartate family amino acid concentration**: Specifically, elevated *N-acetylaspartic acid (NAA)* in urine/blood, resulting from *aspartoacylase enzyme deficiency*, a pathognomonic feature of Canavan disease.  
5. **Confirmatory evidence**: Genetic testing for *ASPA gene mutations* would validate the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Candidates (s) for global eradication by WHO
a. Malariab. Dracunculosis c. Polio d. Measles e. Chicken pox
Choices:
A. ab
B. abd
C. abc
D. bcd
Answer: [/INST] bcd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Recommended Larvicides for control of Malaria includes all of the following except -
Choices:
A. Abate
B. Pyrethrium
C. Fenthian
D. Copper Acetoarsenite
Answer: [/INST] Pyrethrium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis is caused by
Choices:
A. Rhizopus arrhizus
B. Rhizopus oryzae
C. Absidia corymbifera
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hyperglycinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: IVA disrupts the urea cycle via toxic metabolite accumulation (isovaleric acid), leading to secondary hyperammonemia. Hyperglycinemia may arise from glycine conjugation to isovaleric acid, forming isovalerylglycine, a diagnostic urinary marker.  
2. **Increased Serum Lactate**: Metabolic crises in IVA cause acidosis, impairing mitochondrial function and promoting lactic acidosis.  
3. **Abnormal Carnitine Levels**: Isovaleric acid conjugates with carnitine (forming isovalerylcarnitine), depleting free carnitine and altering circulating levels—a hallmark of IVA.  
4. **Gastrointestinal Symptoms (Vomiting, Feeding Difficulties, Inflammation)**: Acute metabolic decompensation triggers vomiting and gut inflammation, exacerbating feeding challenges.  
5. **Early Mortality & Growth Failure**: Untreated IVA causes rapid neonatal/childhood deterioration due to metabolic instability, leading to death. Chronic toxicity results in severe short stature and intellectual disability from neurodevelopmental damage.  
6. **Exclusion of Mimics**: Symptoms align with IVA over urea cycle defects (hyperlactatemia uncommon) or propionic acidemia (hyperglycinemia overlaps, but carnitine profile and isovalerylglycine specificity confirm IVA). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Polyneuropathy is seen in -a) Vitamin deficiencyb) Osteoporosisc) DMd) Myxoedemae) Amyloidosis
Choices:
A. bce
B. acde
C. abcd
D. abde
Answer: [/INST] acde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: THEME AND FOCUS: METABOLISM OF NUCLEOTIDES Case Study: A 17- month- old girl suffered from recurring respiratory infections. Injection of Diphtheria-Peussis-Tetanus (DPT) and Typhoid vaccine produced only a minimal response. The lysate of girl's erythrocytes were found to lack detectable adenosine deaminase activity. Her mother and father both showed approximately 50% of the normal red cell adenosine deaminase activity. Lead Question: Diagnose the disease.
Choices:
A. SCID
B. Crushing Muscular Trauma
C. Lesch -Nyhan Syndrome
D. Hypokalemia
Answer: [/INST] SCID </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Botulism are true except -
Choices:
A. Botulism is caused by endotoxin
B. Honey ingestion causes infant botulism
C. Constipation is seen
D. Detection of antitoxin in the serum can aid in diagnosis
Answer: [/INST] Botulism is caused by endotoxin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leptospirosis is transmitted by:
Choices:
A. Fecal oral route
B. Aerosol route
C. Infected rats urine
D. Milk
Answer: [/INST] Infected rats urine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Visual impairment', 'Osteoporosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Hyperreflexia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Fasciculations', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Severe muscular hypotonia', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Abnormality of muscle size']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
- **Characteristic facial features**: Narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, exaggerated cupid’s bow, and highly arched eyebrows align with the dysmorphic facies typical of TBCK syndrome.  
- **Neuromuscular abnormalities**: Severe muscular hypotonia, areflexia/hyperreflexia (mixed reflexes due to peripheral neuropathy and central nervous system involvement), fasciculations, and peripheral axonal neuropathy reflect the syndrome’s impact on both central and peripheral nervous systems.  
- **Neurodevelopmental deficits**: Profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia correlate with psychomotor retardation and cerebellar dysfunction.  
- **Structural brain anomalies**: Hypoplasia of the corpus callosum, ventriculomegaly, and small basal ganglia are consistent with neuroimaging findings in TBCK-related disorders.  
- **Seizures/EEG abnormalities**: Epileptiform activity and seizures are common due to cortical and subcortical malformations.  
- **Systemic involvement**: Osteoporosis (secondary to immobility from hypotonia), respiratory insufficiency (muscle weakness), and feeding difficulties (bulbar dysfunction) support multisystemic disease progression.  
- **Genetic basis**: TBCK gene mutations disrupt mTOR signaling and autophagy, explaining the combination of neurodevelopmental, muscular, and degenerative features.  

The constellation of facial dysmorphism, hypotonia, neurodevelopmental regression, brain malformations, and mixed neurological signs strongly supports the diagnosis of TBCK-related intellectual disability syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Disease having autosomal recessive inheritance -a) Cystic fibrosisb)  Hydrocephalusc)  Duchene muscular dystrophyd) Albinisme)  Vitamin D resistant ricket
Choices:
A. b
B. ad
C. ac
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The gold standard Lab test for diagnosis of PNH (Paroxysmal Nocturnal Hemoglobinuria) is?
Choices:
A. Ham test
B. Haptoglobin
C. Flow cytometry
D. Sucrose Lysis test
Answer: [/INST] Flow cytometry </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is associated with
Choices:
A. Measles
B. Mumps
C. Chicken pox
D. Rubella
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Under the DOTS strategy of Revised National Tuberculosis Programme, the recommended line of management is category I patients, if the sputum is positive after 2 months of intensive phase treatment with 4 drugs, is to -
Choices:
A. Sta the continuation phase of treatment with INH and rifampicin
B. Continue the intensive phase of treatment with 4 drugs for 1 more month only, regardless of sputum positivity after that
C. Continue the intensive phase of treatment with 4 drugs until the sputum becomes negative
D. Add one more drug, that is, to use 5 drugs until the sputum becomes negative
Answer: [/INST] Continue the intensive phase of treatment with 4 drugs for 1 more month only, regardless of sputum positivity after that </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia.may be a feature of all following diseases, except -
Choices:
A. Addison's disease
B. Cushing's syndrome
C. Baer's syndrome
D. Guelman's syndrome
Answer: [/INST] Addison's disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are true of Craniopharyngioma except
Choices:
A. Derived from Rathke's pouch
B. Contains epithelial cells
C. Present in sella or infra-sellar location
D. Causes visual disturbances
Answer: [/INST] Present in sella or infra-sellar location </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Rod-cone dystrophy', 'Pigmentary retinopathy', 'Nyctalopia', 'Visual field defect', 'Reduced visual acuity', 'Attenuation of retinal blood vessels', 'Diffuse optic disc pallor', 'Hypoautofluorescent retinal lesion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Retinitis pigmentosa 78  
Reasoning:  
1. **Rod-cone dystrophy**: A hallmark of retinitis pigmentosa (RP), where rod photoreceptor degeneration precedes cone loss, aligning with progressive nyctalopia and visual field constriction.  
2. **Pigmentary retinopathy**: Characteristic bone-spicule pigment deposits in RP, caused by retinal pigment epithelium migration into the retina.  
3. **Nyctalopia**: Early symptom due to rod dysfunction, typical in RP.  
4. **Visual field defect**: Progressive peripheral vision loss (""tunnel vision"") from peripheral retinal degeneration.  
5. **Reduced visual acuity**: Occurs later as cones become affected.  
6. **Attenuation of retinal blood vessels & diffuse optic disc pallor**: Reflects chronic retinal atrophy and optic nerve degeneration in advanced RP.  
7. **Hypoautofluorescent retinal lesions**: Indicates areas of photoreceptor/RPE atrophy, consistent with RP progression.  
**RP78** specifically involves mutations in the **RP1L1** gene, which disrupts photoreceptor structure. The clinical triad of nyctalopia, pigmentary retinopathy, and vascular attenuation strongly supports this diagnosis. Genetic testing for RP1L1 variants would confirm RP78. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Yellow Fever except
Choices:
A. Incubation period is 3-6 days
B. Validity of Int’l certificate of Vaccination lasts up to 10 years
C. Urban form is controlled by 17 D vaccine
D. Aedes aegypti index should not be more than 10% to ensure freedom from yellow Fever
Answer: [/INST] Aedes aegypti index should not be more than 10% to ensure freedom from yellow Fever </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability**: Untreated PKU results in neurotoxicity from elevated phenylalanine, impairing brain development.  
3. **Strabismus**: Neurological damage from phenylalanine toxicity can affect cranial nerve function, including ocular motor control.  
4. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) causes fetal developmental anomalies; alternatively, severe neonatal hyperphenylalaninemia may disrupt early development.  
5. **Early mortality (infancy, adolescence, adulthood)**: Untreated PKU leads to progressive neurological decline, seizures, and organ damage, potentially causing premature death.  
6. **Hypertyrosinemia**: Uncommon in classic PKU but may arise secondary to metabolic dysregulation or overlapping enzyme deficiencies (e.g., tetrahydrobiopterin (BH4) defects).  
7. **Obesity**: Linked to dietary management challenges (high-carbohydrate, low-protein diets) or metabolic disturbances in later stages.  

Note: Neonatal death and hypertyrosinemia are atypical for classical PKU and may suggest a comorbid condition (e.g., BH4 deficiency) or severe phenotypic variants. However, hyperphenylalaninemia remains the primary diagnostic anchor. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma exclusively occurs in the:
Choices:
A. Medulla
B. Cerebellum
C. Cerebral hemispheres
D. Spinal cord
Answer: [/INST] Cerebellum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis verrucosa cutis is a form of:
Choices:
A. Tuberculid
B. Primary tuberculosis
C. Postprimary tuberculosis with good resistance
D. Post primary tuberculosis with poor resistance
Answer: [/INST] Postprimary tuberculosis with good resistance </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Classic Galactosemia is due to deficiency of:
Choices:
A. Hexosaminidase
B. Glucocerebroside
C. Sphingomyelinase
D. Galactose-1-Phosphate-Uridyl-Transferase
Answer: [/INST] Galactose-1-Phosphate-Uridyl-Transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypoparathyroidism following thyroid surgery occurs within
Choices:
A. 24 hours
B. 2-5 days
C. 7-14 days
D. 2-3 weeks
Answer: [/INST] 2-5 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Urban Malaria Scheme, following is not true
Choices:
A. Utilization of anti-larva measures
B. Slide positivity rate more than 10%
C. It is done in town/city with minimum 50,000 population
D. Introduction of active surveillance
Answer: [/INST] Slide positivity rate more than 10% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with severe untreated PKU variants (e.g., classic or malignant forms), where rapid neurological deterioration, seizures, and organ failure occur without early dietary intervention.  
3. **Abnormality of prenatal development** may reflect maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy), causing fetal microcephaly, congenital heart defects, or growth restriction. However, if the infant itself has PKU, prenatal abnormalities could stem from metabolic stress in utero or comorbid genetic factors.  
4. PKU is typically asymptomatic at birth but manifests post-feeding. Neonatal death suggests an extreme presentation or delayed diagnosis, emphasizing the critical need for newborn screening and immediate phenylalanine-restricted diets. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Carious teeth', 'Intellectual disability', 'Death in childhood', 'Hyperphenylalaninemia', 'Ichthyosis', 'Abnormal circulating tyrosine concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis.  
3. **Abnormal circulating tyrosine concentration**: Low tyrosine levels occur due to blocked conversion from phenylalanine, aligning with PKU biochemistry.  
4. **Carious teeth**: High-phenylalanine diets (used historically) or sugary substitutes in managed diets increase caries risk.  
5. **Early mortality (childhood/adolescence)**: Severe untreated PKU causes progressive neurological damage, seizures, and organ failure, leading to premature death.  
6. **Ichthyosis**: Atypical for classic PKU but may reflect comorbid conditions, misdiagnosed eczema (common in PKU), or rare PKU variants with secondary metabolic disruptions affecting skin integrity.  

Note: While ichthyosis is not a core PKU feature, the remaining symptoms strongly support this diagnosis. Further testing (e.g., genetic analysis for PAH mutations, tetrahydrobiopterin deficiency exclusion) would refine the evaluation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglycinuria', 'Hyperalaninemia', 'Death in childhood', 'Ichthyosis', 'Abnormal circulating glutamine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia  
Reasoning:  
- **Hyperammonemia**: Due to inhibition of urea cycle enzymes by accumulated propionyl-CoA metabolites.  
- **Hyperglycinemia/Hyperglycinuria**: Propionyl-CoA inhibits glycine cleavage enzyme, impairing glycine metabolism.  
- **Elevated urinary carboxylic acids**: Propionate derivatives (e.g., 3-hydroxypropionate, methylcitrate) are excreted in urine.  
- **Abnormal carnitine concentration**: Secondary carnitine deficiency from conjugation with propionate (propionylcarnitine).  
- **Vomiting, Death in infancy/childhood**: Metabolic decompensation episodes cause acute crises, leading to fatal outcomes.  
- **Hyperalaninemia**: Secondary disruption of amino acid metabolism due to mitochondrial dysfunction.  
- **Ichthyosis**: Rarely reported, possibly linked to metabolic stress or lipid metabolism abnormalities.  

The combination of organic acidemia markers (elevated urinary carboxylic acids, hyperammonemia) with glycine metabolism abnormalities and carnitine depletion is pathognomonic for propionic acidemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following denotes the MANAGEMENT of Acute Osteomyelitis?
Choices:
A. Surgical excision of infected bone
B. Antibiotic treatment soon after taking blood sample
C. Sequestrectomy
D. Amputation
Answer: [/INST] Antibiotic treatment soon after taking blood sample </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Investigation not useful in Multiple Myeloma
Choices:
A. CT SCAN
B. MRI
C. BONE SCAN
D. PET
Answer: [/INST] BONE SCAN </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achondroplasia shows which of the following type of inheritance?
Choices:
A. Autosomal dominant
B. Autosomal recessive
C. X linked dominant
D. X linked recessive
Answer: [/INST] Autosomal dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Alopecia', 'Death in childhood', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, reducing activity of biotin-dependent carboxylases (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts fatty acid synthesis, gluconeogenesis, and amino acid catabolism, leading to urinary excretion of abnormal organic acids.  
2. **Seizures**: Biotin is critical for neuronal metabolism. Deficiency causes accumulation of neurotoxic metabolites (e.g., lactate, ammonia) and impaired energy production in the brain, triggering seizures.  
3. **Alopecia**: Biotin deficiency disrupts keratinocyte function and hair follicle integrity, resulting in hair loss.  
4. **Death in infancy/childhood**: Untreated BTDD causes progressive metabolic acidosis, hyperammonemia, and irreversible neurological damage (e.g., respiratory failure, coma). Neonatal-onset forms are often fatal within months without biotin supplementation.  

The term ""late-onset multiple carboxylase deficiency"" refers specifically to BTDD, distinguishing it from holocarboxylase synthetase deficiency (early-onset). Prompt biotin therapy reverses symptoms, emphasizing the urgency of early diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The multidrug regimen under the National Leprosy Eradication Programme for the treatment of all multibacillary leprosy would include -
Choices:
A. Clofazimine, thiacetazone and dapsone
B. Clofazimine, rifampicin and dapsone
C. Ethionamide, rifampicin and dapsone
D. Propionamide, rifampicin and dapsone
Answer: [/INST] Clofazimine, rifampicin and dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acromegaly is associated with
Choices:
A. Class. I malocclusion
B. Class. I cross bite
C. Class. II malocclusion
D. Class. III malocclusion
Answer: [/INST] Class. III malocclusion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is due to an abnormality in -
Choices:
A. Hypothalamus
B. Neocortex
C. Cerebellum
D. Medulla oblongata
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Earliest X-Ray finding in Osteomyelitis:
Choices:
A. Involucrum
B. Sequestrum
C. Cloacae
D. Periosteal reaction
Answer: [/INST] Periosteal reaction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal saccadic eye movements', 'Abnormality of visual evoked potentials', 'Seizure', 'Spasticity', 'Death in infancy', 'Hypoglycemia', 'Fever', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine', 'Paraplegia/paraparesis', 'Elevated circulating acylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key biochemical markers**: Elevated glutaric acid (urine/blood) and glutarylcarnitine (acylcarnitine profile) directly result from glutaryl-CoA dehydrogenase deficiency, impairing lysine and tryptophan metabolism.  
2. **Carnitine abnormalities**: Decreased free carnitine and elevated acylcarnitine occur as carnitine conjugates with toxic metabolites (e.g., glutaric acid), leading to secondary deficiency.  
3. **Neurological manifestations**:  
   - **Abnormal cerebral morphology** (macrocephaly, frontotemporal atrophy) and **spasticity/paraparesis** stem from striatal degeneration and white matter damage.  
   - **Seizures** and **abnormal saccadic eye movements** reflect basal ganglia and cortical dysfunction.  
   - **Abnormal visual evoked potentials** suggest optic pathway involvement.  
4. **Metabolic crises**: Triggered by fever/infections, causing **hypoglycemia**, **hyperammonemia**, and encephalopathy due to energy depletion and metabolite accumulation.  
5. **Early lethality**: Untreated crises result in irreversible neurological damage or **death in infancy**.  
6. **Confirmatory findings**: **Glutaric aciduria** and genetic confirmation of GCDH mutations solidify the diagnosis.  

GA-I is distinguished from other organic acidemias by its specific metabolite profile (glutaric acid/glutarylcarnitine) and characteristic neuroimaging findings (striatal injury, frontotemporal atrophy). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Fever', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Elevated circulating alkaline phosphatase concentration', 'Oroticaciduria', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Hyperleucinemia', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Feeding difficulties', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Hyperammonemia** indicates a urea cycle disorder, as ammonia is not effectively converted to urea.  
2. **Elevated plasma citrulline** and **oroticaciduria** localize the defect to argininosuccinate lyase (ASL) deficiency, as citrulline accumulates due to the enzymatic block, and excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid.  
3. **Aminoaciduria** and **abnormal amino acid concentrations** (arginine, aspartate family, proline, glycine, alanine) reflect metabolic dysregulation from urea cycle failure, protein catabolism, and secondary mitochondrial dysfunction.  
4. **Hyperleucinemia** and **elevated lactate** suggest metabolic decompensation and energy crisis due to hyperammonemia.  
5. **Neonatal/childhood death**, **feeding difficulties**, and **hypotonia** align with severe urea cycle disorder presentations, where toxic ammonia levels cause neurological damage and multisystem failure.  
6. **Premature birth** and **small for gestational age** may result from in utero metabolic stress.  
7. **Elevated alkaline phosphatase** and **abnormal carnitine** levels are nonspecific markers of metabolic dysfunction.  

This constellation of findings—especially hyperammonemia, citrullinemia, and oroticaciduria—confirms **argininosuccinic aciduria** due to ASL deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is seen in Angelman Syndrome
Choices:
A. Uniparental disomy of maternal Chromosome
B. Obesity
C. Defective genomic imprinting of maternal chromosome
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is -
Choices:
A. AD
B. AR
C. X linked dominant
D. X linked recessive
Answer: [/INST] AR </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is transmitted by all EXCEPT?
Choices:
A. X. Cheopsis
B. X. Astia
C. Pulexirritans
D. Culex
Answer: [/INST] Culex </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Lennox-Gastaut Syndrome is characterized by:
Choices:
A. Single seizure type
B. Good prognosis and adequate controlled epilepsy
C. Affects mainly adolescents
D. Multiple seizure types that are difficult to control
Answer: [/INST] Multiple seizure types that are difficult to control </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment for Filariasis is,
Choices:
A. Chloroquin
B. Diethyl Carbamazine
C. Tetracycline
D. Praziquantel
Answer: [/INST] Diethyl Carbamazine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Organic aciduria', 'Drowsiness', 'Sleep disturbance']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Organic aciduria** is a hallmark of biotinidase deficiency due to impaired activity of carboxylase enzymes (propionyl-CoA, pyruvate, and 3-methylcrotonyl-CoA carboxylases), leading to accumulation of organic acids.  
2. **Neurological symptoms (lethargy, drowsiness, spasticity)** arise from metabolic acidosis, hyperammonemia, and disrupted neurotransmitter function secondary to biotin-dependent enzyme dysfunction.  
3. **Generalized hypotonia** correlates with mitochondrial energy deficiency in muscles caused by defective pyruvate carboxylase.  
4. **Anemia** may result from bone marrow suppression due to metabolic toxicity or secondary mitochondrial dysfunction.  
5. **Sleep disturbances** and **death in infancy** reflect progressive neurological deterioration and metabolic crises if untreated. Early-onset presentations align with classic biotinidase deficiency, where symptoms manifest after biotin stores deplete postnatally. Confirmation requires serum biotinidase enzyme assay or genetic testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Seizure', 'Generalized hypotonia', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning: The combination of irritability, seizures, generalized hypotonia, hyperreflexia, and opisthotonus points to severe neurological dysfunction. Death in infancy and feeding difficulties align with progressive infantile neurodegenerative disorders. Abnormal circulating aspartate family amino acids (specifically elevated N-acetylaspartic acid due to aspartoacylase deficiency) is pathognomonic for Canavan disease. The triad of hypotonia, hyperreflexia, and macrocephaly (implied by rapid neurodegeneration and intracranial pressure causing opisthotonus) further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma commonly affects: September 2005
Choices:
A. Metaphysis
B. Diaphysis
C. Epiphysis
D. None of the above
Answer: [/INST] Metaphysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis:
Choices:
A. Never occurs in infants
B. In acute cases fracture mandible is very common
C. Of mandible can show symptoms of lip Paresthesia
D. Produces no tymphadenopathy
Answer: [/INST] Of mandible can show symptoms of lip Paresthesia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A clinical specimen was obtained from the wound of a patient diagnosed as Nocardiosis. For the selective isolation of Nocardia sp. Which one of the following would be the best method -
Choices:
A. Paraffin bait technique
B. Castaneda's culture method
C. Craige's tube method
D. Hair bait technique
Answer: [/INST] Paraffin bait technique </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine.  
3. **Abnormality of prenatal development/birth** may align with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing fetal complications.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe untreated PKU, where neurotoxicity from phenylalanine causes seizures, intellectual disability, and fatal complications.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to dietary management (e.g., tyrosine supplementation) or overlapping metabolic disturbances.  
6. **Neonatal death** is rare in PKU but could occur in extreme cases with rapid metabolic decompensation or comorbid conditions.  

While hypertyrosinemia and elevated urinary carboxylic acids might suggest tyrosinemia, the dominant hyperphenylalaninemia and structured clinical context prioritize PKU as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Spasticity', 'Death in infancy', 'Hyperammonemia', 'Increased serum lactate', 'Tachypnea', 'Oroticaciduria', 'Neonatal death', 'Elevated circulating acylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Core feature of urea cycle disorders like OTCD, caused by impaired ammonia detoxification due to deficient OTC enzyme.  
2. **Oroticaciduria**: Pathognomonic for OTCD; accumulation of carbamoyl phosphate shunts into pyrimidine synthesis, increasing orotic acid excretion.  
3. **Elevated serum lactate**: Secondary to mitochondrial dysfunction from hyperammonemia or respiratory chain inhibition.  
4. **Tachypnea**: Compensatory response to metabolic acidosis induced by hyperammonemia and lactic acidosis.  
5. **Seizures/Spasticity**: Neurotoxicity from ammonia crossing the blood-brain barrier, causing cerebral edema and neuronal excitation.  
6. **Elevated acylcarnitines**: May reflect secondary carnitine depletion or metabolic stress disrupting fatty acid oxidation.  
7. **Neonatal death/Death in infancy**: Severe OTCD typically presents catastrophically in males (X-linked) shortly after birth due to hyperammonemic crisis if untreated.  

The constellation of hyperammonemia, oroticaciduria, and neonatal demise strongly prioritizes OTCD over other urea cycle disorders or metabolic diseases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Thin upper lip vermilion', 'Microcephaly', 'Low anterior hairline', 'Long philtrum', 'Synophrys', 'Delayed speech and language development', 'Intellectual disability, moderate', 'Depressed nasal bridge', 'Curly eyelashes', 'Postnatal growth retardation']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cornelia de Lange syndrome/Cornelia de Lange syndrome 1  
Reasoning:  
1. **Facial Features**: Thin upper lip vermilion, long philtrum, depressed nasal bridge, and synophrys (unibrow) are hallmark craniofacial features of Cornelia de Lange syndrome (CdLS).  
2. **Microcephaly and Growth Retardation**: Microcephaly and postnatal growth retardation align with CdLS-associated developmental abnormalities.  
3. **Neurodevelopmental Delays**: Moderate intellectual disability and delayed speech/language development are consistent with the syndrome’s cognitive profile.  
4. **Ancillary Features**: Low anterior hairline and curly eyelashes are supportive phenotypic clues frequently observed in CdLS.  
5. **Exclusion of Alternatives**: The constellation of symptoms (especially synophrys, distinct facial gestalt, and growth/neurodevelopmental patterns) is pathognomonic for CdLS, differentiating it from other syndromes with overlapping features (e.g., Rubinstein-Taybi, fetal alcohol spectrum disorders). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The MOST common site of Tuberculosis in female genital tract is?
Choices:
A. Cervix
B. Endometrium
C. Ovaries
D. Fallopian tubes
Answer: [/INST] Fallopian tubes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria affects all the following organs except ?
Choices:
A. Brain
B. Hea
C. Liver
D. Spleen
Answer: [/INST] Hea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 4-year-old child comes to you with a history of dog bite from a street dog. This child had already received Rabies vaccine last year (full course). What will be your next course of action with regard to immunization:
Choices:
A. Repeat the entire schedule of Rabies vaccine
B. No further dosages of Rabies vaccines required
C. Two booster doses at day 0 and day 3
D. Two booster dosages at day 0 and day 14
Answer: [/INST] Two booster doses at day 0 and day 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in childhood', 'Death in adolescence', 'Impaired glucose tolerance', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: MODY (Maturity-onset diabetes of the young, type 1)  
Reasoning:  
1. **Impaired glucose tolerance** aligns with MODY, a monogenic diabetes caused by mutations in genes like *HNF4A* (type 1). MODY typically manifests as early-onset, non-ketotic hyperglycemia, often misdiagnosed as type 1 or 2 diabetes.  
2. **Early mortality** (childhood/adolescence/early adulthood) suggests severe complications from undiagnosed or mismanaged hyperglycemia. For example:  
   - Acute crises (e.g., diabetic ketoacidosis or severe hypoglycemia) due to delayed diagnosis.  
   - Chronic vascular/nephropathy from prolonged poor glycemic control.  
3. MODY type 1 (*HNF4A* mutations) is associated with progressive beta-cell dysfunction and sensitivity to sulfonylureas. Without timely genetic diagnosis and tailored therapy, insulin deficiency worsens, accelerating complications.  
4. Familial autosomal dominant inheritance (common in MODY) could explain multi-generational early deaths if undiagnosed in relatives.  

Disease: Maturity-onset diabetes of the young, type 1  
Reasoning:  
1. **Genetic basis**: *HNF4A* mutations disrupt pancreatic beta-cell function and insulin secretion, causing glucose intolerance.  
2. **Clinical course**: Symptoms often emerge in adolescence/early adulthood but may manifest earlier. Neonatal hypoglycemia (linked to *HNF4A*) could predispose to lethal hypoglycemic events in infancy/childhood if unrecognized.  
3. **Mortality drivers**:  
   - Lack of targeted treatment (e.g., sulfonylureas) leads to reliance on insulin, increasing hypoglycemia risk.  
   - Rapid progression to insulin dependence in some cases, exacerbating metabolic instability.  
4. **Diagnostic delay**: Misclassification as type 1 diabetes may result in suboptimal care, hastening complications (e.g., renal failure, cardiovascular events) and early death.  

Both diagnoses hinge on genetic testing to confirm *HNF4A* variants, enabling precision therapy to mitigate mortality risks. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A child is diagnosed with Osteosarcoma based on Sunray appearance seen on x-ray. This is because of
Choices:
A. Calcification along the periosteum
B. Calcification along the blood vessels
C. Perosteal reaction
D. Soft tissue invasion
Answer: [/INST] Perosteal reaction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is transmitted in urban areas by -
Choices:
A. Anopheles stephensi
B. Anopheles culicifacies
C. Culex
D. Phlebotomus
Answer: [/INST] Anopheles stephensi </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a feature of Phenylketonuria?
Choices:
A. Severe mental retardation
B. Reduced tendon reflexes
C. Hypopigmentation in skin
D. Hair loss
Answer: [/INST] Reduced tendon reflexes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of the spine commonly affects all of the following parts of the vertebra except -
Choices:
A. Body
B. Lamina
C. Spinous process
D. Pedicle
Answer: [/INST] Spinous process </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The features of Achondroplasia inlcude all,except -a) Defective headb) Mental retardationc)  Autosomal recessived) Familial
Choices:
A. bc
B. c
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Membranoproliferative glomerulonephritis', 'Leukocytosis', 'Recurrent respiratory infections', 'Vasculitis', 'Increased circulating IgM level', 'Cryoglobulinemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
1. **Cryoglobulinemia** is directly noted, a hallmark of the disease, where cryoglobulins precipitate in cold conditions, causing vascular inflammation.  
2. **Vasculitis** aligns with cryoglobulin-induced vascular damage, a core feature of cryoglobulinemic vasculitis.  
3. **Membranoproliferative glomerulonephritis (MPGN)** is a common renal manifestation of cryoglobulinemia due to immune complex deposition in glomeruli.  
4. **Increased circulating IgM** suggests type II cryoglobulinemia (mixed), where IgM acts as a rheumatoid factor, forming immune complexes.  
5. **Recurrent respiratory infections** may stem from immune dysfunction secondary to chronic immune complex deposition or complement consumption.  
6. **Leukocytosis** reflects systemic inflammation driven by vasculitis and recurrent infections.  
The familial form indicates a genetic predisposition, differentiating it from secondary causes (e.g., hepatitis C). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The gene responsible for Ataxia Telangiectasia is located on:
Choices:
A. Chromosome 1
B. Chromosome 5
C. Chromosome 11
D. Chromosome 12
Answer: [/INST] Chromosome 11 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are seen in Keratoconus EXCEPT:
Choices:
A. Progressive vision loss due to increasing myopia and irregular astigmatism
B. Keyser Fleischer Ring
C. Scissoring reflex in retinoscopy
D. Munson sign Positive
Answer: [/INST] Keyser Fleischer Ring </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is due to the abnormality in
Choices:
A. Hypothalamus
B. Neocoex
C. Cerebellum
D. Medulla oblongata
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: False about Brucellosis
Choices:
A. Also known as undulant  fever
B. B. melitensis is most virulent
C. Incubation period is 1-3 weeks
D. Antibiotic of choice is Ampicillin
Answer: [/INST] Antibiotic of choice is Ampicillin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Leptospirosis-
Choices:
A. Penicillin
B. Tetracycline
C. Suplhonamide
D. Erythromycin
Answer: [/INST] Penicillin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Conjunctivitis', 'Urticaria', 'Papilledema', 'Headache', 'Increased intracranial pressure', 'Vasculitis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Muckle-Wells syndrome  
Reasoning:  
1. **Urticaria & Conjunctivitis**: Hallmark features of cryopyrin-associated periodic syndromes (CAPS), including Muckle-Wells syndrome (MWS), caused by NLRP3 gene mutations.  
2. **Systemic Inflammation**: Elevated ESR, CRP, and neutrophilia align with chronic autoinflammatory dysregulation in MWS.  
3. **Neurological Involvement**: Headache, papilledema, and increased intracranial pressure suggest meningeal inflammation, a rare but documented CNS manifestation of CAPS.  
4. **Vasculitis**: Likely secondary to systemic inflammation from IL-1β overproduction, a key cytokine driver in MWS.  
5. **Exclusion of Alternatives**: Symptoms lack specificity for other autoinflammatory diseases (e.g., FMF, TRAPS) due to the absence of serositis or prolonged fever, while urticaria and neurological signs favor MWS. Early-stage MWS may not yet exhibit amyloidosis or deafness.  

This constellation of mucocutaneous, inflammatory, and neurological symptoms strongly supports Muckle-Wells syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya is transmitted by
Choices:
A. Aedes
B. Culex
C. Mansonoides
D. Anopheles
Answer: [/INST] Aedes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is associated with which thyroid carcinoma?
Choices:
A. Papillary
B. Follicular
C. Anaplastic
D. Medullary
Answer: [/INST] Medullary </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Premature birth', 'Hypertriglyceridemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Premature birth** and early mortality (**neonatal death, death in infancy/childhood**) align with MCADD, a fatty acid oxidation disorder causing metabolic crises triggered by fasting, often fatal if undiagnosed.  
2. **Hypertriglyceridemia** arises due to impaired mitochondrial β-oxidation of medium-chain fatty acids, leading to alternative lipid metabolism pathways and triglyceride accumulation.  
3. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as excess unmetabolized medium-chain acyl-CoA intermediates bind carnitine, promoting its urinary excretion.  
4. MCADD typically presents with hypoglycemia, lethargy, and vomiting during metabolic stress (e.g., fasting), progressing to seizures, coma, or death—consistent with the fatal outcomes described.  
5. Ruled out long-chain fatty acid oxidation disorders (e.g., VLCADD) due to absence of cardiomyopathy/muscle weakness, which are less prominent in MCADD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Ameloblastoma: (PGI Dec 2006)
Choices:
A. Cystic lesion
B. Rapidly growing
C. Malignant disease
D. MC site is Tibia
Answer: [/INST] Cystic lesion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Dehydration', 'Fever', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The patient exhibits key features of MCADD, including hypoglycemia due to impaired fatty acid oxidation during fasting, decreased plasma free carnitine (secondary to conjugation with unmetabolized medium-chain fatty acids), and gastrointestinal symptoms (vomiting, diarrhea, inflammation) triggered by metabolic stress. Neonatal/childhood death and dehydration align with acute metabolic crises, while fatigue reflects energy deficiency. Though MCADD does not directly cause prenatal abnormalities, early mortality and failure to thrive in infancy/childhood are hallmarks of untreated cases. The absence of ketosis during hypoglycemia (not explicitly listed but inferred) further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Hernia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may suggest **BH4 (tetrahydrobiopterin) deficiency**, a rare PKU variant. BH4 is a cofactor for PAH and tyrosine/tryptophan hydroxylases; its deficiency disrupts both phenylalanine and tyrosine metabolism.  
3. **Severe short stature** aligns with chronic metabolic disruption and malnutrition if untreated.  
4. **Premature birth**, **neonatal death**, and **death in infancy** correlate with severe metabolic crises in untreated PKU/BH4 deficiency, leading to neurological deterioration and organ failure.  
5. **Hypospadias** and **hernia** are not typical PKU features but may represent coincidental congenital anomalies or part of a broader syndromic form (e.g., chromosomal or epigenetic interactions).  

Note: While classic PKU does not explain hypertyrosinemia, BH4 deficiency (a PKU subtype) accounts for both hyperphenylalaninemia and hypertyrosinemia, supporting the diagnosis. Other symptoms may reflect complications of metabolic instability or unrelated congenital factors. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Receptor on neural membrane that induces development of Glioma-
Choices:
A. CD133
B. CD33
C. CD48
D. CD44
Answer: [/INST] CD133 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis in sickle cell anemia is due to DELETE
Choices:
A. Salmonella
B. Streptococcus
C. Hemophilus
D. Neisseria
Answer: [/INST] Salmonella </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency/Biotinidase deficiency/multiple carboxylase deficiency, late-onset  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Biotinidase deficiency impairs biotin recycling, reducing activity of carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). This disrupts organic acid metabolism, leading to urinary accumulation of carboxylic acids (e.g., 3-hydroxyisovaleric acid, lactic acid).  
2. **Seizures**: Biotin-dependent carboxylases are critical for fatty acid synthesis, gluconeogenesis, and neurotransmitter regulation. Deficiency causes metabolic acidosis and energy deficits, triggering neuroexcitability and seizures.  
3. **Generalized hypotonia**: Metabolic acidosis and disrupted mitochondrial energy production impair muscle function, manifesting as hypotonia.  
4. **Death in infancy**: Untreated biotinidase deficiency progresses to severe metabolic crises, respiratory failure, and neurological damage, often fatal within the first year without biotin supplementation.  
**Diagnostic confirmation**: Low serum biotinidase enzyme activity (<10% normal activity) and genetic testing for *BTD* gene mutations. Early biotin supplementation reverses symptoms, emphasizing urgency in diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperammonemia', 'Vomiting', 'Hyperglutaminemia', 'Oroticaciduria', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Indicates impaired urea cycle function, as OTC is a key enzyme in converting ammonia to urea.  
2. **Vomiting**: A nonspecific but common symptom of acute hyperammonemic crises in urea cycle disorders.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine via glutamine synthetase, a compensatory mechanism in urea cycle defects.  
4. **Oroticaciduria**: Caused by carbamoyl phosphate accumulation (due to OTC deficiency), which shunts into pyrimidine synthesis, overproducing orotic acid.  
5. **Death in childhood**: Severe OTCD (often in males with neonatal-onset forms) leads to fatal hyperammonemia without prompt treatment.  
The combination of urea cycle dysfunction (hyperammonemia, hyperglutaminemia) with oroticaciduria is pathognomonic for OTCD, distinguishing it from other urea cycle defects or isolated pyrimidine disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Post exposure immunization is done for-a) Measlesb) Polio c) Rabiesd) Chicken pox
Choices:
A. a
B. bc
C. ad
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not a feature of Ocular Mucous Membrane Pemphigoid
Choices:
A. Loss of fornices
B. Lid: Trichaiasis& Entropion
C. Involvement of mucosa of mouth
D. Type 1 hypersensitivity
Answer: [/INST] Type 1 hypersensitivity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Severe, untreated PKU can lead to rapid neurological deterioration and metabolic crisis, particularly in rare cases with near-complete PAH deficiency.  
3. **Premature birth**: Maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) may cause fetal complications like prematurity, though the infant’s own PKU diagnosis explains hyperphenylalaninemia.  
4. **Hypertyrosinemia**: Atypical for classic PKU (where tyrosine is typically low). May reflect secondary liver dysfunction, transient neonatal tyrosinemia, or a coexisting metabolic disturbance, but does not exclude PKU as the primary diagnosis.  

Key evidence prioritizes hyperphenylalaninemia and clinical severity, aligning with PKU despite atypical tyrosine elevation. Early demise underscores untreated metabolic dysfunction. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Gingival overgrowth', 'Microcephaly', 'Progressive microcephaly', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Carious teeth', 'Abnormality of the skeletal system', 'Sacral dimple', 'Hemangioma', 'Brachydactyly', 'Hypotonia', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Muscle weakness', 'Hepatic cysts', 'Failure to thrive', 'Overgrowth', 'Polyhydramnios', 'Frontal bossing', 'Rigidity', 'Pneumonia', 'Spinal cord compression', 'Hepatomegaly', 'Kyphosis', 'Decreased circulating total IgM', 'Abnormal ilium morphology', 'Hyperbilirubinemia', 'Lumbar hyperlordosis', 'Metaphyseal widening', 'Short nose', 'Neonatal hyperbilirubinemia', 'Hyperlordosis', 'Spinal canal stenosis', 'Limb muscle weakness', 'Trident hand', 'Decreased circulating IgG level', 'Severe platyspondyly', 'Restricted large joint movement', 'Depressed nasal bridge', 'Capillary hemangioma', 'Thoracolumbar kyphosis', 'Recurrent pneumonia', 'Lower limb muscle weakness', 'Axial hypotonia', 'Limb undergrowth', 'Cognitive impairment', 'Enlarged thorax', 'Broad ischia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly (progressive), brachydactyly, kyphosis, severe platyspondyly, metaphyseal widening, and spinal canal stenosis align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Immunodeficiency**: Recurrent pneumonia, decreased IgG/IgM levels, and failure to thrive suggest humoral immune dysfunction, consistent with ISDNA’s B-cell defects.  
3. **Neurodevelopmental Delays**: Cognitive impairment, motor delay, axial/limb hypotonia, and muscle weakness reflect the neurodevelopmental axis of ISDNA, linked to EXTL3 mutations affecting heparan sulfate synthesis.  
4. **Hepatic Involvement**: Hepatic cysts and hepatomegaly are reported in ISDNA due to disrupted glycosaminoglycan metabolism.  
5. **Dysmorphic Features**: Anteverted nares, depressed nasal bridge, frontal bossing, and trident hand correlate with craniofacial and skeletal anomalies in ISDNA.  
6. **Overlap with Known Cases**: ISDNA’s triad of skeletal dysplasia, immune deficiency, and neurodevelopmental deficits matches the patient’s multisystem presentation, excluding mimics like mucopolysaccharidoses (no coarse features) or isolated skeletal dysplasias (no immune/neuro involvement). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cerebellar atrophy', 'Encephalopathy', 'Death in infancy', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Neonatal death', 'Death in adolescence', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis and encephalopathy are hallmark features of PMM2-CDG, reflecting severe central nervous system dysfunction due to impaired glycosylation.  
2. **Dysmorphic features**: Abnormal facial shape (e.g., inverted nipples, large ears, strabismus) and calvaria abnormalities (e.g., occipital prominence) are common phenotypic traits.  
3. **Early lethality**: Neonatal death, death in infancy, or adolescence align with the severe multisystemic nature of PMM2-CDG, often involving liver failure, coagulopathy, or infections.  
4. **Hepatic dysfunction**: Acute/chronic hepatitis correlates with the liver involvement seen in PMM2-CDG, including steatosis, fibrosis, and elevated transaminases.  
5. **Systemic manifestations**: The combination of neurological, hepatic, and dysmorphic symptoms strongly supports a glycosylation disorder, with PMM2-CDG (type Ia) being the most prevalent form. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Tuberculosis HIV patients -
Choices:
A. Sputum positivity
B. INH prophyaxis prevent development ofT.B
C. Lack characteristics feature of T.B
D. Highly positive PPD reaction
Answer: [/INST] Lack characteristics feature of T.B </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Glutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of glutaric acid accumulation in urine, confirming impaired glutaryl-CoA dehydrogenase activity.  
2. **Generalized hypotonia & reduced tendon reflexes**: Neurotoxic effects of glutaric acid and 3-hydroxyglutaric acid damage basal ganglia and white matter, causing motor deficits.  
3. **Fever, vomiting, diarrhea**: Metabolic decompensation triggered by catabolic stressors (e.g., infections), exacerbating toxic metabolite accumulation.  
4. **Death in infancy**: Untreated GA-I leads to acute encephalopathic crises with striatal necrosis, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. **Consistency with GA-I pathophysiology**: Autosomal recessive GCDH gene mutations disrupt lysine/hydroxylysine metabolism, producing neurotoxic dicarboxylic acids. Early-onset neurological and systemic features align with classic GA-I presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Incubation period of Mumps -
Choices:
A. 4-5 days
B. 7-15 days
C. 12-24 days
D. 50 days
Answer: [/INST] 12-24 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following disease causes Achalasia
Choices:
A. Kala azar
B. Chaga's disease
C. KFD
D. Schistosomiasis
Answer: [/INST] Chaga's disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Carious teeth', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylpyruvate, phenyllactate, and phenylacetate, excreted in urine, aligning with PKU’s biochemical profile.  
3. **Neurological symptoms (Microcephaly, Delayed speech)**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and function.  
4. **Hypertyrosinemia**: Secondary tyrosine deficiency due to PAH dysfunction may alter tyrosine metabolism, though this is atypical and could indicate a comorbid metabolic disturbance or variant PKU.  
5. **Prenatal abnormalities/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and early mortality. Maternal PKU during pregnancy can also induce congenital anomalies (e.g., microcephaly) in offspring.  
6. **Carious teeth**: Chronic metabolic imbalance or high-carbohydrate/low-protein diets (used to manage PKU) may predispose to dental decay.  
**Conclusion**: The constellation of hyperphenylalaninemia, urinary carboxylic acids, and neurodevelopmental deficits strongly supports PKU. Early mortality and prenatal issues reflect untreated or late-diagnosed cases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Case finding tool which has been stopped as a general measure of case finding in Tuberculosis is:
Choices:
A. Sputum microscopy
B. Sputum culture
C. Mass Miniature radiography
D. Tuberculin Testing
Answer: [/INST] Mass Miniature radiography </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Odynophagia occurs ina) Achalasiab) Herpes esophagitisc) Monilial esophagitisd) Barret's oesophagus
Choices:
A. a
B. c
C. ac
D. bc
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Ataxia', 'Obesity', 'Death in infancy', 'Apnea', 'Hypertyrosinemia', 'Paresthesia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU can lead to congenital anomalies due to phenylalanine toxicity during pregnancy.  
3. **Neurological symptoms (Ataxia, Paresthesia)**: Accumulated phenylalanine disrupts myelination and neurotransmitter synthesis, causing progressive neurological damage.  
4. **Obesity**: Managed PKU patients often consume low-protein, high-carbohydrate diets, which may contribute to weight gain.  
5. **Early mortality (Death in infancy/Neonatal death/Death in early adulthood)**: Untreated PKU results in severe intellectual disability, seizures, and systemic complications, leading to premature death without dietary intervention.  
6. **Apnea**: Rarely observed in severe neonatal cases due to metabolic instability or neurological dysfunction.  
7. **Hypertyrosinemia discrepancy**: Likely a typographical error; PKU typically causes *hypo*tyrosinemia (due to blocked phenylalanine conversion). If accurate, this could suggest a concurrent metabolic disorder (e.g., tyrosinemia) or a BH4-deficient PKU variant, though the primary diagnosis remains PKU.  

The constellation of hyperphenylalaninemia, neurodevelopmental deficits, and dietary management complications strongly aligns with PKU, despite atypical features like hypertyrosinemia requiring further investigation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Profile**: The presence of cystinuria, argininuria, hyperlysinuria, and ornithinuria is pathognomonic for cystinuria. These amino acids share a common renal tubular transport system (SLC3A1/SLC7A9 genes), and their urinary excretion indicates a defect in this system.  
2. **Dermatological Symptoms**: Eczematoid dermatitis and skin rash are atypical for classic cystinuria. These may arise secondary to malnutrition or infections due to chronic illness, but they are not direct features of the disease.  
3. **Death in Infancy**: Severe complications (e.g., obstructive uropathy, renal failure) from recurrent cystine stones or metabolic disturbances could theoretically lead to early mortality, though this is rare. Alternatively, coexisting conditions or misreported clinical history may contribute.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) or urea cycle disorders were considered but ruled out due to the absence of hyperammonemia, hepatosplenomegaly, or neutral aminoaciduria. Cystinosis was excluded as it causes generalized Fanconi syndrome, not isolated dibasic aminoaciduria.  

Final diagnosis aligns with cystinuria based on the definitive aminoaciduria pattern, while secondary factors or comorbidities may explain the atypical symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Choanal atresia', 'Webbed neck', 'Cystic hygroma', 'Multiple pterygia', 'Atrial septal defect', 'Scoliosis', 'Abnormal rib ossification']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate & Pierre-Robin sequence**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis, and airway obstruction, often accompanied by cleft palate.  
2. **Abnormal rib ossification & scoliosis**: Hallmark skeletal defects in CCMS, including rib gaps, malformation, and scoliosis secondary to thoracic abnormalities.  
3. **Choanal atresia**: Observed in some CCMS cases due to craniofacial maldevelopment.  
4. **Atrial septal defect**: Congenital heart defects, though less common, are reported in CCMS.  
5. **Webbed neck, cystic hygroma, multiple pterygia**: These may overlap with lymphatic or connective tissue anomalies, potentially linked to broader developmental disruptions in CCMS. While not classic features, they could reflect phenotypic variability or secondary effects of skeletal and craniofacial defects.  

The diagnosis prioritizes the triad of micrognathia (Pierre-Robin), cleft palate, and rib malformations, with other symptoms contextualized within the syndrome’s spectrum. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Gastroesophageal reflux', 'Increased serum lactate', 'Hematemesis', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Abnormality of prenatal development or birth** and **neonatal death** may occur in severe, untreated cases due to toxic phenylalanine accumulation affecting neurodevelopment.  
3. **Death in infancy/childhood** aligns with untreated PKU, where elevated phenylalanine leads to irreversible neurological damage, seizures, and systemic complications.  
4. **Hypertyrosinemia** is atypical in classical PKU but could arise from secondary metabolic disturbances or overlapping enzyme deficiencies (e.g., transient tyrosine elevation due to liver immaturity or stress).  
5. **Increased serum lactate** and **hematemesis** may reflect metabolic decompensation, organ failure (e.g., liver dysfunction), or catabolic states triggered by prolonged metabolic imbalance.  
6. **Gastroesophageal reflux** is a nonspecific symptom but could result from neurological dysfunction or feeding difficulties common in severely affected infants.  

Note: Hypertyrosinemia is unusual in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap, but PKU remains primary due to hyperphenylalaninemia dominating the clinical picture. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Purpura is a feature of-  a) Disseminated Intravascular Coagulation  b) Henoch Schonlein Purpura  c) Meningococcemia  d) Schamberg's disease
Choices:
A. abc
B. abd
C. acd
D. ac
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pertussis vaccine side effect -
Choices:
A. Local pain
B. Excessive cry
C. Fever
D. All of above
Answer: [/INST] All of above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is transmitted through:-
Choices:
A. Tick
B. Mite
C. Flea
D. Mosquito
Answer: [/INST] Flea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common pa of larynx involved in Tuberculosis is
Choices:
A. Anterior
B. Posterior
C. Middle
D. Anywhere
Answer: [/INST] Posterior </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Abnormal cerebral morphology', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability & abnormal cerebral morphology**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting myelination and neurotransmitter synthesis, causing brain damage.  
3. **Hypertyrosinemia**: Secondary tyrosine elevation may occur due to metabolic dysregulation in PKU or overlapping enzyme deficiencies (e.g., transient tyrosinemia in neonates).  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) are excreted as urinary carboxylic acids.  
5. **Neonatal/infant death or death in adolescence**: Severe untreated PKU causes progressive neurodegeneration, seizures, and multisystem failure; early mortality reflects delayed diagnosis or poor dietary compliance.  
6. **Obesity**: A complication of PKU management due to high-carbohydrate/low-protein diets required to restrict phenylalanine intake.  
7. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) causes fetal developmental defects, though this overlaps less with neonatal PKU presentation.  

PKU is the unifying diagnosis, with most symptoms explained by phenylalanine toxicity or dietary management challenges. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common complications of Mumps is
Choices:
A. Orchitis and Oophoritis
B. Encephalitis
C. Pneumonia
D. Myocarditis
Answer: [/INST] Orchitis and Oophoritis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency leads to phenylalanine accumulation, explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia discrepancy**: Classical PKU typically results in *low* tyrosine levels due to impaired conversion. However, this symptom could arise from concurrent factors (e.g., tyrosine supplementation in treated PKU, liver dysfunction, or an overlapping metabolic disorder).  
3. **Death in early adulthood**: Untreated PKU causes severe neurological damage, seizures, and organ failure. Without lifelong dietary management (low-phenylalanine diet), complications progress, leading to early mortality.  
4. **Exclusion of BH4 deficiency**: While BH4 cofactor defects also cause hyperphenylalaninemia, they typically involve neurotransmitter deficiencies and distinct symptoms (e.g., hypotonia, developmental delays), which are not listed here. PKU remains the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for secondary causes or diagnostic errors, but the core diagnosis aligns with hyperphenylalaninemia and clinical severity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella cataract is seen as-
Choices:
A. Posterior polar cataract
B. Nuclear cataract
C. Blue dot cataract in young
D. Cuneiform cataract
Answer: [/INST] Nuclear cataract </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Leprosy which of the following is not seen:
Choices:
A. Abnormal EMG
B. Voluntary muscle wasting
C. Decreased Proprioception
D. Decreased response to tactile sensation
Answer: [/INST] Decreased Proprioception </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Multidrug Resistance Tuberculosis (MDR-TB) should be considered in patients with:
Choices:
A. Contact with a known case of MDR TB
B. Clinical Deterioration
C. Sputum smear positive at 5 months of treatment
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Premature birth', 'Glutaric aciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hypoxemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** and **hyperalaninemia** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** often develops due to abnormal brain metabolism and fluid accumulation (e.g., subdural effusions), a classic early sign of GA-I.  
3. **Delayed speech/language development** reflects neurological damage from metabolic crises, typically triggered by catabolic stressors (e.g., infections), causing striatal injury.  
4. **Abnormal circulating lysine concentration** and **elevated plasma citrulline** align with disrupted lysine and tryptophan metabolism, while **abnormal carnitine levels** result from secondary carnitine depletion from detoxification of toxic metabolites.  
5. **Neonatal death**, **death in infancy/childhood**, and **hypoxemia** correlate with acute metabolic decompensation (e.g., encephalopathic crises, rhabdomyolysis, or cardiac complications) if untreated.  
6. **Hypervalinemia** and **obesity** may reflect secondary metabolic disturbances or comorbidities, though they are less specific to GA-I.  
7. **Premature birth** is not directly linked to GA-I but could contribute to symptom severity due to metabolic immaturity.  

The constellation of neurodevelopmental, biochemical, and acute metabolic features strongly supports GA-I as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid carriers harbor bacteria in
Choices:
A. Gallbladder
B. Urinary bladder
C. Pancreas
D. Spleen
Answer: [/INST] Gallbladder </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seborrheic dermatitis', 'Death in infancy', 'Increased serum lactate', 'Fair hair', 'Brittle hair', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'White hair', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic abnormalities**: Increased serum lactate and hyperalaninemia indicate mitochondrial dysfunction and impaired amino acid metabolism, consistent with biotin-dependent carboxylase deficiencies (e.g., pyruvate carboxylase, propionyl-CoA carboxylase).  
2. **Dermatological features**: Seborrheic dermatitis and hair abnormalities (brittle, fair/white hair) result from biotin’s critical role in keratin synthesis and epidermal integrity.  
3. **Early mortality**: Neonatal/childhood death aligns with untreated BTDD’s progressive metabolic crises (acidosis, hyperammonemia) and neurologic deterioration.  
4. **Diagnostic confirmation**: BTDD specifically disrupts biotin recycling, causing secondary multiple carboxylase deficiency. Symptoms resolve with biotin supplementation, underscoring the enzyme deficiency as the root cause. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The enzyme deficient in Galactosemia is:
Choices:
A. Hexoseaminidase B
B. Hexosaminidase A
C. Galactose 1 phosphate uridyltransferase
D. Glucocerebrosidase
Answer: [/INST] Galactose 1 phosphate uridyltransferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Hypercholesterolemia', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning: Hyperphenylalaninemia is pathognomonic for PKU, caused by phenylalanine hydroxylase (PAH) deficiency. Classic PKU typically results in **low tyrosine** due to impaired phenylalanine-to-tyrosine conversion. However, the reported hypertyrosinemia could suggest an atypical variant (e.g., partial PAH activity with compensatory dietary tyrosine intake) or secondary metabolic dysregulation. Obesity and hypercholesterolemia may stem from carbohydrate-rich diets used to restrict phenylalanine. Early adulthood mortality aligns with untreated or poorly managed PKU, leading to severe neurological decline, cardiovascular complications, or metabolic instability. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypoparathyroidism after thyroidectomy commonly manifests in
Choices:
A. 1 day
B. 2-5 days
C. After a week
D. After a month
Answer: [/INST] 2-5 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: ""Cholera"" is caused by:
Choices:
A. Vibriocholera .01
B. Vibriocholera .001
C. Vibrio parahemolyticus
D. Vibriocholera .0001
Answer: [/INST] Vibriocholera .01 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria parasites -
Choices:
A. Has man as its intermediate host
B. Has a life cycle that alternates between man and tse-tse fly
C. Has 4 impoant species in man
D. Can be easily cultured in the laboratory
Answer: [/INST] Has man as its intermediate host </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis causes which type of cardiomyopathy?
Choices:
A. Constrictive
B. Restrictive
C. Hypertrophic
D. Any of the above
Answer: [/INST] Restrictive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinemia', 'Opisthotonus', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Abnormality of vitamin D metabolism', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased methylmalonyl-CoA mutase activity**, which are pathognomonic for this disorder. Methylmalonyl-CoA mutase deficiency directly impairs propionate metabolism, leading to toxic metabolite accumulation.  
2. **Metabolic derangements**: **Hyperammonemia**, **metabolic acidosis**, and **hyperglycinemia** arise due to disrupted urea cycle function and secondary inhibition of glycine cleavage systems by accumulated methylmalonic acid.  
3. **Neurological features**: **Opisthotonus**, **motor delay**, and **intellectual disability** reflect neurotoxicity from elevated methylmalonic acid, ammonia, and glycine. **Irritability** and **feeding difficulties** are early signs of metabolic decompensation.  
4. **Systemic complications**: **Abnormal carnitine/creatinine levels** and **hypervalinemia** occur due to secondary mitochondrial dysfunction and amino acid metabolism disturbances. **Abnormal vitamin D metabolism** may stem from chronic renal tubular damage.  
5. **Clinical trajectory**: **Neonatal death**, **death in infancy**, and **death in early adulthood** align with severe, treatment-resistant forms of mutase-deficient MMA. B12-unresponsiveness is confirmed by persistent enzyme deficiency despite B12 cofactor availability.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Diagnostic confirmation**: The presence of **methylmalonic acidemia** and **methylmalonic aciduria** in symptomology meets the biochemical criteria for MMA.  
2. **Subtype differentiation**: While overlapping with the mutase-deficient form, this broader diagnosis encompasses all MMA subtypes (e.g., cblA, cblB). However, **decreased methylmalonyl-CoA mutase activity** specifically localizes the defect to the mutase enzyme itself.  
3. **Symptom constellation**: **Hyperammonemia**, **acidosis**, **hyperglycinemia**, and **opisthotonus** collectively form the classic MMA phenotype, distinct from other organic acidemias.  
4. **Prognostic markers**: Early lethality (**neonatal/infant death**) and multisystem involvement (**abnormal carnitine**, **vitamin D metabolism**) reflect disease severity typical of MMA. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following statement is TRUE for Pityriasis Rosea:
Choices:
A. Self limiting
B. Chronic relapsing
C. Life threatening infection
D. Caused by dermatophytes
Answer: [/INST] Self limiting </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Following causes distension of abdomen-a) Hirschsprungsb) Hypokalemiac) Hyperkalemiad) Hypomagnesmia
Choices:
A. acd
B. bcd
C. abc
D. abd
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia A has following except -
Choices:
A. ↓ VIII factor
B. ↑PTT
C. ↑PT
D. Normal BT
Answer: [/INST] ↑PT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of the spine commonly affects all of the following pas of the veebra, EXCEPT:
Choices:
A. Body
B. Lamina
C. Pedicle
D. Spinous process
Answer: [/INST] Spinous process </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Narcolepsy
Choices:
A. Modafinil
B. Sildenafil
C. Disulfiram
D. Dexemedotimidine
Answer: [/INST] Modafinil </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline and hyperammonemia strongly suggest a urea cycle disorder. Citrullinemia is characterized by impaired conversion of citrulline to argininosuccinate due to argininosuccinate synthetase (ASS1) deficiency. This results in citrulline accumulation and toxic ammonia buildup. Neonatal death and infant mortality align with the severe, early-onset form of the disease.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""classic"" citrullinemia (type I) directly correlates with ASS1 deficiency. Premature birth may reflect intrauterine metabolic stress, while hyperammonemia and neonatal death are hallmarks of acute neonatal-onset cases. Elevated citrulline levels (>1,000 µmol/L) are pathognomonic for this subtype, distinguishing it from other urea cycle disorders or citrullinemia type II (citrin deficiency). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Low-set ears', 'Strabismus', 'Ptosis', 'Hypermetropia', 'Eczematoid dermatitis', 'Skin rash', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Vomiting', 'Constipation', 'Drowsiness', 'Sleep disturbance', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Hypoxemia', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) with hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, impairing 7-DHC reductase activity.  
2. **Congenital anomalies**: Syndactyly (especially 2nd–3rd toe), cryptorchidism, hypospadias, microcephaly, and low-set ears align with SLOS-associated malformations.  
3. **Neurodevelopmental features**: Intellectual disability, motor delay, generalized hypotonia, dystonia, and lethargy reflect disrupted cholesterol-dependent myelination and neuronal development.  
4. **Ocular findings**: Ptosis, strabismus, and hypermetropia are common in SLOS due to craniofacial dysmorphism and connective tissue abnormalities.  
5. **Gastrointestinal/dysautonomia symptoms**: Feeding difficulties, vomiting, constipation, and sleep disturbances correlate with autonomic dysfunction and gastrointestinal dysmotility.  
6. **Cutaneous manifestations**: Eczematoid dermatitis and skin rash result from defective epidermal barrier function due to cholesterol deficiency.  
7. **Severe outcomes**: Neonatal/childhood death, hypoxemia, and recurrent infections reflect multisystem failure and immune dysfunction from cholesterol insufficiency.  
8. **Supporting biochemical markers**: Elevated 7-DHC/8-DHC on sterol analysis confirms the diagnosis.  

This constellation of structural, metabolic, and developmental abnormalities is diagnostic of Smith-Lemli-Opitz syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Under the National Leprosy Elimination Programme, mass survey for leprosy is done if prevalence of leprosy is more than:
Choices:
A. 1/1000
B. 5/1000
C. 10/1000
D. 20/1000
Answer: [/INST] 10/1000 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: DOC for lithium induced Nephrogenic Diabetes Insipidus
Choices:
A. Spiranolactone
B. Furosemide
C. Amiloride
D. None of the above
Answer: [/INST] Amiloride </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is ,located on chromosome:
Choices:
A. 13
B. 14
C. 17
D. 22
Answer: [/INST] 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Death in infancy', 'Hepatomegaly', 'Hypoproteinemia', 'Hypocholesterolemia', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Cerebellar atrophy/agenesis, motor delay, seizures, and intellectual disability are hallmark features of PMM2-CDG, reflecting disrupted glycosylation critical for brain development and function.  
2. **Hepatic manifestations**: Hepatomegaly, acute/chronic hepatitis, hypoproteinemia, and hypocholesterolemia align with PMM2-CDG’s multisystemic impact, including liver dysfunction due to impaired glycoprotein synthesis.  
3. **Metabolic abnormalities**: Hypocholesterolemia and hypoproteinemia stem from defective glycosylation of apolipoproteins and transport proteins, while lipodystrophy reflects adipose tissue dysregulation.  
4. **Severe infantile course**: Death in infancy is consistent with the life-threatening complications (e.g., organ failure, severe infections) seen in classical PMM2-CDG type Ia.  
5. **Exclusion of mimics**: The combination of cerebellar defects, liver disease, and metabolic derangements distinguishes PMM2-CDG from other metabolic disorders (e.g., Niemann-Pick, peroxisomal disorders) that lack glycosylation-specific biomarkers (e.g., abnormal transferrin isoforms). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Abnormal foot morphology', 'Hyperammonemia', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Hyperammonemia**: A hallmark of BTDD due to impaired urea cycle function from deficient carboxylases (e.g., propionyl-CoA carboxylase), leading to metabolic acidosis and ammonia accumulation.  
2. **Abnormal foot morphology**: Neuromuscular abnormalities (e.g., hypotonia, spasticity) in untreated BTDD may cause skeletal deformities, including foot malalignment or pes equinovarus.  
3. **Obesity**: Uncommon but plausible in chronic metabolic dysregulation; biotin-dependent enzymes regulate lipid metabolism, and dysfunction may alter energy homeostasis.  
4. **Death in childhood**: Untreated BTDD causes progressive neurological decline, respiratory failure, or metabolic crises, often fatal in early life without biotin supplementation.  
**Key Link**: The combination of hyperammonemia, neurological/skeletal defects, and early mortality aligns with BTDD’s multisystemic presentation. Obesity may reflect secondary metabolic disturbances rather than a primary feature. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following agents is recommended for treatment of Gastrointestinal Stromal Tumors (GIST) -
Choices:
A. Sorafenib
B. Imatinib
C. Gefitinib
D. Erlotinib
Answer: [/INST] Imatinib </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Inguinal hernia', 'Cryptorchidism', 'Tall stature', 'Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Seizure', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Death in infancy', 'Abnormal heart morphology', 'Congestive heart failure', 'Abnormal cardiac septum morphology', 'Abnormal facial shape', 'Kyphoscoliosis', 'Aortic aneurysm', 'Abnormal subcutaneous fat tissue distribution']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cutis laxa, autosomal recessive, type IID  
Reasoning:  
1. **Cutis laxa** is a hallmark feature, involving loose, sagging skin, directly aligning with the diagnosis.  
2. **Abnormal cardiac septum morphology**, **aortic aneurysm**, and **congestive heart failure** indicate severe cardiovascular involvement, characteristic of type IID due to connective tissue defects.  
3. **Hip dysplasia**, **kyphoscoliosis**, and **flexion contractures** reflect skeletal abnormalities linked to systemic connective tissue dysfunction.  
4. **Abnormality of the genitourinary system** (e.g., cryptorchidism, inguinal hernia) and **abnormal facial shape** (entropion) are common in autosomal recessive cutis laxa subtypes.  
5. **Generalized hypotonia** and **seizures** suggest potential neurological compromise, reported in severe cases of type IID.  
6. **Disproportionate tall stature** and **abnormal subcutaneous fat distribution** further support a systemic connective tissue disorder.  
7. **Death in infancy** correlates with the severe prognosis of this subtype, driven by cardiovascular complications.  
The combination of cutaneous, cardiovascular, skeletal, and genitourinary anomalies with autosomal recessive inheritance confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypoglycemia', 'Glycosuria', 'Abnormal circulating porphyrin concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: MODY (Maturity-Onset Diabetes of the Young)  
Reasoning: Hypoglycemia and glycosuria suggest a defect in glucose regulation. MODY is a monogenic form of diabetes characterized by beta-cell dysfunction, often presenting with atypical diabetes features. The coexistence of hypoglycemia (indicative of insulin dysregulation) and glycosuria (glucose excretion despite normal or low blood glucose levels) points to a renal threshold alteration or fluctuating glucose levels, common in MODY subtypes.  

Disease: MODY type 1 (HNF4A mutation)  
Reasoning:  
1. **Hypoglycemia**: Neonatal or childhood hypoglycemia is a hallmark of HNF4A-MODY due to transient hyperinsulinism in early life.  
2. **Glycosuria**: Progressive beta-cell dysfunction leads to hyperglycemia in adolescence/adulthood, causing glycosuria. Reduced renal glucose reabsorption (via SGLT2 downregulation) may also contribute.  
3. **Abnormal porphyrins**: HNF4A regulates hepatic genes involved in metabolism, potentially affecting heme synthesis pathways indirectly. This could explain abnormal porphyrin levels, though this association is less defined and may require further investigation.  

This combination aligns with MODY type 1, where hypoglycemia precedes diabetes onset, and metabolic dysregulation impacts multiple pathways. Genetic testing for HNF4A mutations is critical for confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Acromegaly All of the following are seen EXCEPT
Choices:
A. Visceromegaly
B. Decreased sweating
C. Hypertension
D. Soft tissue and bone enlargement
Answer: [/INST] Decreased sweating </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following are included in Malaria Vector Indices in pre-eradication era ? a)Spleen ratio b)Human blood index c) Slide positivity rate d)Parasite density index
Choices:
A. 1,3
B. 1,4
C. 1, 2, 3
D. 4,3,1
Answer: [/INST] 1,4 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common cause of Acute Aseptic Meningitis in children is
Choices:
A. Arbovirus
B. Respiratory syncytial virus
C. Enterovirus
D. Herpes family
Answer: [/INST] Enterovirus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Epistaxis', 'Hemoptysis', 'Pulmonary infiltrates', 'Arthralgia', 'Microscopic hematuria', 'Elevated circulating C-reactive protein concentration', 'Decreased glomerular filtration rate', 'Cytoplasmic antineutrophil antibody positivity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Respiratory involvement**: Epistaxis (nasal inflammation) and hemoptysis (alveolar hemorrhage) with pulmonary infiltrates suggest granulomatous inflammation and vasculitis in the upper/lower respiratory tract.  
2. **Renal involvement**: Microscopic hematuria and decreased glomerular filtration rate indicate pauci-immune glomerulonephritis, a hallmark of systemic vasculitis.  
3. **Systemic inflammation**: Elevated C-reactive protein and arthralgia reflect systemic inflammation.  
4. **Immunological markers**: Cytoplasmic antineutrophil antibody (c-ANCA) positivity, typically targeting PR3, strongly supports GPA.  
5. **Triad alignment**: Combined respiratory, renal, and systemic features with c-ANCA positivity fulfill diagnostic criteria for GPA, distinguishing it from other ANCA-associated vasculitides (e.g., microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The population of a community on the 1st of June was recorded as 1,65,000. Total no. of new cases of Tuberculosis, recorded from 1st January to 31st June were 22. Total Registered cases of tuberculosis in the community were recorded as 220. What is the incidence of TB in this community per 10 lakh population?
Choices:
A. 133
B. 220
C. 13.3
D. 22
Answer: [/INST] 133 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Measles rash appearance:
Choices:
A. Along with Koplik spots
B. 1-2 days before Koplik spots
C. 1-2 days after Koplik spots
D. Post measles stage
Answer: [/INST] 1-2 days after Koplik spots </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal dysplasia', 'Microcephaly', 'Hypothyroidism', 'Cyanosis', 'Eczematoid dermatitis', 'Myoclonus', 'Abnormal facial shape', 'Apnea', 'Immunodeficiency', 'Respiratory failure', 'Elevated circulating thyroid-stimulating hormone concentration', 'Limb joint contracture', 'Severe T-cell immunodeficiency', 'Secondary microcephaly', 'Respiratory arrest', 'Axial hypotonia', 'Abnormality of the umbilical cord', 'Inflammatory abnormality of the skin', 'Abnormal renal physiology', 'Oligoclonal T cell expansion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe T-cell immunodeficiency and oligoclonal T cell expansion indicate a profound defect in T-cell development, a hallmark of ISDNA caused by *EXTL3* mutations.  
2. **Skeletal/Renal Involvement**: Limb joint contractures and renal dysplasia align with the ""immunoskeletal"" aspect of ISDNA, which disrupts glycosaminoglycan synthesis critical for skeletal and renal development.  
3. **Neurodevelopmental Abnormalities**: Microcephaly (primary and secondary), axial hypotonia, and myoclonus reflect neurodevelopmental deficits due to impaired EXTL3-dependent neural and cerebellar development.  
4. **Cutaneous and Endocrine Features**: Inflammatory skin abnormalities (eczematoid dermatitis) and hypothyroidism (elevated TSH) may stem from dysregulated immune responses and multisystemic dysfunction.  
5. **Respiratory Complications**: Apnea and respiratory failure/arrest likely result from hypotonia, immunodeficiency-related infections, or central nervous system dysregulation.  
6. **Congenital Anomalies**: Abnormal facial shape and umbilical cord abnormalities further support a syndromic congenital disorder like ISDNA.  

The convergence of severe T-cell defects, skeletal/renal malformations, neurodevelopmental delays, and multisystem involvement strongly points to ISDNA as the unifying diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur secondary to metabolic dysregulation or dietary mismanagement (e.g., unbalanced tyrosine intake).  
3. **Neonatal death/Death in infancy/adolescence**: Untreated PKU can cause severe neurological damage, seizures, and organ failure, potentially leading to early mortality without strict dietary intervention.  
4. **Obesity**: May arise from excessive calorie intake in low-phenylalanine diets or metabolic imbalances from prolonged poor disease control.  
5. **Exclusion of alternatives**: Tyrosinemia or other aminoacidurias were considered but ruled out due to the prominence of hyperphenylalaninemia and alignment with PKU pathophysiology.  

Note: Hypertyrosinemia and early death suggest atypical severity or comorbidities, but PKU remains the primary diagnosis based on hyperphenylalaninemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma spreads to CNS through:
Choices:
A. Direct
B. Lymphatic
C. Arterial
D. Vitreous
Answer: [/INST] Direct </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vasculitis not commonly seen in adults
Choices:
A. Kawasaki disease
B. Henoch schonlein purpura
C. Temporal aeritis
D. PAN
Answer: [/INST] Kawasaki disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: If a claw hand develops in a patient with Leprosy, the deformity is –
Choices:
A. Grade 0
B. Grade I
C. Grade II
D. Grade III
Answer: [/INST] Grade II </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Babesiosis is transmitted by ?
Choices:
A. Tick
B. Mites
C. Flea
D. Mosquito
Answer: [/INST] Tick </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Commonest route of spread of Tuberculosis to genital tract is:
Choices:
A. Lymphatic spread
B. Hematogenous spread
C. Direct spread
D. Sexually transmitted
Answer: [/INST] Hematogenous spread </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not true about Narcolepsy is
Choices:
A. Cataplexy
B. Sleep architecture normal
C. Loss of muscle tone
D. Hallucination
Answer: [/INST] Sleep architecture normal </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Metabolic acidosis', 'Vomiting', 'Death in childhood', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis, vomiting, and methylmalonic aciduria—hallmark features of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder caused by defects in methylmalonyl-CoA metabolism, leading to toxic accumulation of methylmalonic acid. The symptom ""death in childhood"" aligns with severe forms of MMA, which can result in early mortality due to metabolic crises or organ failure if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of ""vitamin B12-unresponsive"" points to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme deficiency prevents the conversion of methylmalonyl-CoA to succinyl-CoA, independent of vitamin B12 (cobalamin) metabolism. The lack of response to B12 supplementation distinguishes this subtype from other MMA forms (e.g., cblA/cblB types). Early lethality underscores the severe biochemical disruption caused by complete mutase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common cardiac defect seen in Rubella syndrome
Choices:
A. Pulmonary stenosis
B. VSD
C. ASD
D. Mitral regurgitation
Answer: [/INST] Pulmonary stenosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, caused by deficient activity of galactose-1-phosphate uridylyltransferase (GALT). Neonatal death and infant mortality align with severe metabolic derangements (e.g., liver failure, sepsis) if untreated.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (Type I) specifically involves GALT enzyme deficiency. Untreated infants develop life-threatening complications (e.g., jaundice, vomiting, E. coli sepsis) within days of galactose exposure (breast milk/formula), explaining neonatal death. Hypergalactosemia confirms impaired galactose metabolism. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia with hypertension is associated with following except
Choices:
A. Liddle's syndrome
B. Conn's syndrome
C. Bartter's syndrome
D. Cushing's syndrome
Answer: [/INST] Bartter's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Delayed speech/language development** and **generalized hypotonia** align with untreated PKU, where toxic phenylalanine accumulation damages the developing nervous system.  
3. **Neonatal death**, **death in infancy/childhood** may occur in severe, undiagnosed cases due to metabolic crisis or progressive neurological decline.  
4. **Abnormality of prenatal development** could reflect maternal PKU syndrome (if the mother has PKU), though this is less common in the patient’s presentation.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise from secondary metabolic disruptions or overlap with other tyrosine metabolism disorders (e.g., transient tyrosinemia of the newborn), suggesting possible comorbidities or diagnostic complexity. However, hyperphenylalaninemia remains the primary indicator.  
6. Early dietary management (phenylalanine restriction) is critical to prevent symptoms, underscoring the importance of newborn screening for PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Prominent forehead', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **decreased plasma free carnitine** are hallmark biochemical findings in GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and secondary carnitine depletion.  
2. **Abnormal cerebral morphology** (e.g., frontotemporal atrophy, widened Sylvian fissures) and **prominent forehead** (macrocephaly) are classic neuroimaging and clinical features of GA-I due to striatal injury and impaired brain development.  
3. **Generalized hypotonia** and **feeding difficulties** reflect acute or chronic neurologic dysfunction, common in infancy during metabolic decompensation.  
4. **Fever** often triggers catabolic crises, exacerbating metabolic derangements and neurodegeneration.  
5. **Death in infancy** aligns with untreated GA-I, as acute encephalopathic crises or progressive neurologic damage can be fatal without dietary management (protein restriction, carnitine supplementation) and emergency care during metabolic stress.  
6. The constellation of metabolic, neurologic, and dysmorphic features excludes other organic acidemias or mitochondrial disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 65 yr old man is presenting with chronic cigarette cough which has recently changed its character. Tuberculosis and other infectious causes have been ruled out. What should be the next investigation:
Choices:
A. Sputum cytology
B. Bronchoscopy and biopsy
C. CT guided FNAC
D. Barium X-Ray
Answer: [/INST] Bronchoscopy and biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug resistance in Tuberculosis is due to -
Choices:
A. Transformation
B. Transduction
C. Conjugation
D. Mutation
Answer: [/INST] Mutation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Dicarboxylic aciduria', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hepatic dysfunction** (elevated transaminases, hepatomegaly, acute/chronic hepatitis) indicate a urea cycle disorder (UCD).  
2. **Oroticaciduria** and **uraciluria** are pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Elevated plasma citrulline** may initially seem contradictory (classic OTCD features low citrulline), but partial enzyme activity or alternative metabolic stress (e.g., liver damage) can paradoxically elevate citrulline.  
4. **Hyperglutaminemia** and **hyperalaninemia** reflect nitrogen accumulation via alternative pathways, consistent with UCDs.  
5. **Metabolic acidosis**, **dicarboxylic aciduria**, and **elevated lactate dehydrogenase** suggest secondary mitochondrial dysfunction during metabolic crises.  
6. **Recurrent infections** and **prolonged PTT** align with hepatic synthetic failure (reduced clotting factors/immune proteins).  
7. **Early lethality** (infancy/childhood/adolescence) matches severe OTCD phenotypes, exacerbated by triggers like infection (pneumonia) or catabolism.  

Key differentiators from other UCDs (e.g., citrullinemia): Distinct **oroticaciduria** and **pyrimidine abnormalities** (uraciluria, abnormal circulating pyrimidines) are hallmark features of OTCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is transmitted by the bite of
Choices:
A. Rat flea
B. Culex mosquito
C. Body louse
D. Tse-Tse fly
Answer: [/INST] Rat flea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Diabetes mellitus', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Abnormal cerebral white matter morphology', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability & microcephaly**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, impairing brain development.  
3. **Seizures & abnormal cerebral white matter**: Chronic phenylalanine toxicity disrupts myelination and neuronal function, consistent with MRI findings.  
4. **Body odor**: Phenylacetate, a metabolite of phenylalanine, excreted in sweat, produces a musty odor.  
5. **Hypertyrosinemia**: Atypical in classic PKU but may occur in rare variants (e.g., BH4 cofactor deficiency) or secondary metabolic disturbances.  
6. **Early mortality**: Severe untreated PKU can lead to fatal neurological complications; survival into early adulthood suggests partial management.  
7. **Diabetes mellitus**: Unrelated to PKU but possibly a comorbid condition, as PKU does not directly affect glucose metabolism.  

Note: Hypertyrosinemia warrants investigation for BH4 deficiency (e.g., genetic testing) to exclude atypical PKU forms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria I is due to deficiency of -
Choices:
A. Phenylalanine hydroxylase
B. Homogentisate oxidase
C. Tyrosinase
D. None
Answer: [/INST] Phenylalanine hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Lung granuloma with necrosis are seen in -a)  PANb)  TBc)  Histoplasmosisd) Cryptococcosise)  Wegener's granulomatosis
Choices:
A. bce
B. bc
C. acd
D. ace
Answer: [/INST] bce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: WHO Malaria Mass Drug Administration -
Choices:
A. API >5
B. > 2
C. 15
D. 25
Answer: [/INST] > 2 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ptosis', 'Ectopia lentis', 'Large hands', 'Intellectual disability', 'Motor delay', 'Long foot', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in childhood', 'Death in adolescence', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia** and **hypermethioninemia**, biochemical hallmarks of homocystinuria. Symptoms like **ectopia lentis** (lens dislocation) and **ptosis** are classic ocular manifestations. **Intellectual disability** and **motor delay** align with neurological complications from toxic homocysteine accumulation. **Long foot** and **large hands** suggest Marfanoid habitus, a skeletal feature of this disorder. Early mortality (**death in childhood/adolescence**) reflects severe untreated metabolic dysfunction.  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: This subtype is confirmed by **hypermethioninemia**, as cystathionine beta-synthase (CBS) deficiency impairs homocysteine-to-cystathionine conversion, causing methionine buildup. **Ectopia lentis** and skeletal abnormalities are pathognomonic for CBS-deficient homocystinuria. **Fatigue** may stem from metabolic stress, while early death underscores disease severity without intervention (e.g., pyridoxine responsiveness or dietary methionine restriction). The absence of cystathionine beta-synthase activity directly links to this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteonecrosis is not seen in -
Choices:
A. Olliers disease
B. Kienboch
C. Kohlers disease
D. Perthes disease
Answer: [/INST] Olliers disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is -
Choices:
A. Occurs due to Vit-A deficiency
B. Relatively benign condition
C. First feature of Vit- A deficiency
D. Also seen in retinitis pigmentosa
Answer: [/INST] Occurs due to Vit-A deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Hypotonia', 'Spasticity', 'Profound global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Nystagmus** suggests brainstem/cerebellar dysfunction, common in hypomyelinating leukodystrophies due to disrupted white matter integrity.  
2. **Hypotonia** in infancy aligns with early-onset myelin defects, as myelination is critical for proper neuronal signaling and muscle tone regulation.  
3. **Spasticity** emerges later as corticospinal tract involvement progresses, reflecting upper motor neuron damage from impaired myelination.  
4. **Profound global developmental delay** correlates with severe, diffuse hypomyelination disrupting neurodevelopment and synaptic connectivity.  
5. **NKX6-2 mutations** directly impair oligodendrocyte maturation and myelination, explaining the phenotype. Autosomal recessive inheritance matches the rarity and familial recurrence pattern.  
6. Differentiation from other leukodystrophies (e.g., Pelizaeus-Merzbacher) is based on genetic testing and absence of peripheral neuropathy. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Differential diagnosis of Botulism are all except -
Choices:
A. GB syndrome
B. Myasthenia gravis
C. Lambe Eaton syndrome
D. Clostridial myonecrosis
Answer: [/INST] Clostridial myonecrosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Death in infancy/childhood**: MCADD disrupts fatty acid β-oxidation, causing hypoglycemia and metabolic crises during fasting. Infants/children are vulnerable due to limited glycogen stores, leading to life-threatening events if undiagnosed.  
2. **Recurrent viral infections**: Metabolic stress during infections (e.g., vomiting, reduced intake) exacerbates energy deficits, increasing risk of decompensation.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency arises from conjugation of accumulated medium-chain acyl-CoA species, depleting free carnitine.  
4. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects a misstated lab finding; MCADD directly involves MCAD enzyme deficiency, not 3-hydroxyacyl-CoA dehydrogenase. This may indicate overlapping testing artifacts or pathway crosstalk.  

Key confirmation would include genetic testing for *ACADM* mutations and elevated C6-C10 acylcarnitines on tandem mass spectrometry. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cystinuria is characterised by –
Choices:
A. Generalised aminoaciduria
B. Systemic acidosis
C. Deposition of cystine crystals in Renal tubular cells
D. Recurrent urinary caliculi
Answer: [/INST] Recurrent urinary caliculi </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Barret's esophagus can lead to -a) Strictureb) Reflux esophagitisc) Peptic ulcerd) Achalasia
Choices:
A. ac
B. bc
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid is treated by all except ?
Choices:
A. Erythromycin
B. Ceftriaxone
C. Amikacin
D. Ciprofloxacin
Answer: [/INST] Erythromycin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma histologically resembles ?
Choices:
A. Sq. cell type
B. Schirrhous type
C. Columnar cell type
D. All
Answer: [/INST] Schirrhous type </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common cause of paraplegia of early onset of Tuberculosis of spine is:
Choices:
A. Spinal artery thrombosis
B. Sudden collapse of vertebra
C. Sequestrum pressing on cord
D. Cold abscess pressing on the cord
Answer: [/INST] Cold abscess pressing on the cord </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are major criteria in the diagnosis of Acute Rheumatic Fever, Except:
Choices:
A. Migratory Polyahralgia
B. Subcutaneous Nodules
C. Chorea
D. Carditis
Answer: [/INST] Migratory Polyahralgia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, which impairs the conversion of phenylalanine to tyrosine. Elevated phenylalanine levels are diagnostic.  
2. **Hypertyrosinemia**: While atypical in classic PKU (where tyrosine is typically low/normal), this could result from **dietary management**. PKU treatment includes tyrosine supplementation to compensate for reduced endogenous synthesis. Excess supplementation or impaired tyrosine metabolism (e.g., secondary liver dysfunction from untreated PKU) might explain elevated tyrosine.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early death aligns with historical cases before newborn screening and dietary interventions.  

Note: The coexistence of hyperphenylalaninemia and hypertyrosinemia is unusual in PKU. Consider ruling out **BH4 deficiency** (a PKU mimic) or **tyrosinemia type I/II** (primary tyrosine disorders) if confirmatory testing (e.g., enzyme assays, genetic analysis) is available. However, the provided diagnosis prioritizes PKU as the primary condition. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria carriers contain -
Choices:
A. Trophozoite
B. Gametocytes
C. Merozoites
D. Trophozoites
Answer: [/INST] Gametocytes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are characteristic of Turner Syndrome EXCEPT-
Choices:
A. Webbing of Neck
B. Cubitus valgus
C. Umbilical Hernia
D. Coarctation of Aoa
Answer: [/INST] Umbilical Hernia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella vaccine is given in which age -
Choices:
A. 1-14 yrs
B. < 5 yrs
C. > 50 yrs
D. None
Answer: [/INST] 1-14 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Hip dysplasia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently due to secondary metabolic disruptions or overlapping enzyme deficiencies (e.g., tyrosine metabolism defects).  
3. **Generalized hypotonia** and **motor delay** align with untreated PKU, where toxic phenylalanine accumulation disrupts neurotransmitter synthesis and myelination.  
4. **Abnormality of prenatal development or birth** and **hip dysplasia** are uncommon in PKU but may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy.  
5. **Death in infancy/neonatal death** is rare in isolated PKU but could indicate severe metabolic crises (e.g., rapid phenylalanine accumulation) or comorbid conditions.  

Note: Hypertyrosinemia and neonatal lethality suggest atypical presentations (e.g., BH4-deficient PKU or dual metabolic disorders), warranting genetic testing for PAH/BH4 pathway mutations and tyrosine metabolism enzymes (e.g., TAT, HPD). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Fever', 'Vomiting', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis and hypoglycemia**: Central features of HMGCLD due to impaired leucine catabolism and ketogenesis, leading to accumulation of toxic metabolites (e.g., 3-hydroxy-3-methylglutaric acid) and energy deficiency.  
2. **Glutaric aciduria and 3-methylglutaric aciduria**: Direct biochemical markers of HMG-CoA lyase deficiency, as the enzyme deficiency disrupts the breakdown of leucine and ketone body synthesis.  
3. **Seizures, lethargy, and progressive neurologic deterioration**: Result from neurotoxic effects of accumulated organic acids and recurrent metabolic crises.  
4. **Recurrent viral infections**: Metabolic decompensation often triggered by catabolic stressors like infections, which exacerbate energy deficits.  
5. **Abnormal glycine concentrations**: Secondary hyperglycinemia may occur as glycine conjugates with toxic metabolites to facilitate excretion.  
6. **Death in infancy/childhood**: Characteristic of untreated cases due to acute metabolic crises or irreversible neurological damage.  
7. **Elevated urinary carboxylic acids**: Reflects systemic spillage of incompletely metabolized intermediates (e.g., 3-hydroxy-3-methylglutarate, glutarate).  
8. **Hypoglycemia without ketosis**: Pathognomonic in HMGCLD, as the enzyme defect prevents ketogenesis during fasting. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Abetalipoproteinemia is due to deficiency of -
Choices:
A. Lecithin Cholesterol Acyl Transferase
B. ATP Binding Cassette Transporter-1
C. Mitochondrial Triglyceride Transfer Protein
D. ApoCII
Answer: [/INST] Mitochondrial Triglyceride Transfer Protein </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Direct zoonose is -a)  Rabiesb)  Brucellosisc)  Taeniasisd)  Hydatid disease
Choices:
A. ac
B. a
C. ad
D. ab
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a 'Small Vessel Vasculitis':
Choices:
A. Polyaeritis Nodosa (PAN)
B. Microscopic polyangitis
C. Giant cell vasculitis
D. Takayasu's Disease
Answer: [/INST] Microscopic polyangitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Biphasic histopathology is seen in -a)  Rhabdomyomab)  Mesotheliomac)  Neurofibromatosisd)  Synovial sarcoma
Choices:
A. bd
B. d
C. ab
D. ac
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pierre-Robin sequence', 'High palate', 'Abnormal thorax morphology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cerebrocostomandibular syndrome (CCMS)  
Reasoning:  
1. **Pierre-Robin sequence (PRS)** is a hallmark of CCMS, presenting with micrognathia (small jaw), glossoptosis (tongue displacement), and airway obstruction.  
2. **High palate** is a secondary feature of PRS due to restricted oral cavity space during fetal development.  
3. **Abnormal thorax morphology** (e.g., rib gaps, hypoplastic ribs, or ""coat-hanger"" rib defects) is a critical diagnostic criterion for CCMS, distinguishing it from isolated PRS.  
4. CCMS is a rare autosomal recessive disorder caused by variants in the *SNRPB* gene, linking craniofacial and thoracic anomalies.  
5. The triad of PRS, high palate, and thoracic defects aligns with CCMS, excluding other syndromes (e.g., Stickler or Treacher Collins syndromes) that lack rib abnormalities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Spasticity', 'Death in infancy', 'Fever', 'Glutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Elevated glutaric acid in urine is a hallmark of GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Ataxia & Spasticity**: GA-I damages the basal ganglia and white matter, leading to dystonia, spasticity, and impaired coordination.  
3. **Fever-triggered crises**: Metabolic decompensation during infections/fever exacerbates symptoms due to increased catabolism and toxin accumulation.  
4. **Death in infancy**: Untreated GA-I often causes severe neurological damage, metabolic strokes, or respiratory failure in early childhood.  
5. **Consistency with presentation**: The triad of neurodevelopmental regression, organic aciduria, and acute crises aligns with GA-I’s clinical profile. Early diagnosis via newborn screening (elevated C5DC) and treatment (lysine-restricted diet, carnitine) can improve outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Third nerve palsy with pupillary sparing is seen in-a) Hypertensionb) Aneurysm of posterior communicating arteryc) Diabetes mellitusd) Craniopharyngioma
Choices:
A. a
B. bc
C. ad
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Hyperthreoninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hypervalinemia', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties', 'Decreased serum creatinine', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic crises (hyperammonemia, vomiting, feeding difficulties). Elevated branched-chain amino acid derivatives (hypervalinemia, abnormal isoleucine) align with impaired propionate metabolism due to defective methylmalonyl-CoA mutase or vitamin B12 metabolism. Neonatal/childhood death and hypotonia reflect severe enzymatic dysfunction, while hypoproteinemia and abnormal carnitine levels suggest secondary metabolic stress.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: **Recurrent viral infections** and **death in infancy** indicate a severe, B12-unresponsive subtype. Mutase deficiency prevents methylmalonyl-CoA conversion to succinyl-CoA, causing toxic metabolite accumulation (hyperammonemia, methylmalonic aciduria). **Decreased serum creatinine** and **increased blood urea nitrogen** point to renal dysfunction from metabolic acidosis. Neurological symptoms (intellectual disability, motor delay) and neonatal mortality are consistent with irreversible cellular damage from chronic toxicity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Where was the last case of Smallpox occured?
Choices:
A. Somalia
B. Libya
C. Sudan
D. Uganda
Answer: [/INST] Somalia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ogilvie syndrome is?
Choices:
A. Small bowel obstruction
B. Large bowel obstruction
C. Colonic pseudo-obstruction
D. Bowel ischemia
Answer: [/INST] Colonic pseudo-obstruction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A drug not effective in Multiple Myeloma is?
Choices:
A. Boezomib
B. Hydroxyurea
C. Melphalan
D. Cylcophosphamide
Answer: [/INST] Hydroxyurea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is caused by –
Choices:
A. Asbestosis
B. Silicosis
C. Baggasois
D. Anthracosis
Answer: [/INST] Asbestosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Delinking Malaria activity from Family planning was under the recommendation of
Choices:
A. Mudaliar committee
B. Chadah committee
C. Mukerji committee
D. Kaar Singh committee
Answer: [/INST] Chadah committee </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Delayed speech and language development', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The explicit mention of ""L-2-hydroxyglutaric aciduria"" indicates elevated L-2-hydroxyglutaric acid in urine or blood, a hallmark of this autosomal recessive neurometabolic disorder.  
2. **Neurological Symptoms**: Strabismus and delayed speech/language development align with the disease’s typical neurological manifestations, including cerebellar dysfunction, intellectual disability, and motor deficits caused by toxic metabolite accumulation.  
3. **Prognosis**: ""Death in childhood"" reflects the severe progression of untreated cases, often due to neurodegeneration, seizures, or complications like respiratory infections.  
4. **Exclusion of Mimics**: Symptoms are consistent with L-2-hydroxyglutaric aciduria and not other organic acidurias (e.g., D-2-hydroxyglutaric aciduria), as the specific biochemical marker and clinical course differentiate it.  
5. **Confirmatory Testing**: Genetic testing for mutations in *L2HGDH* or MRI findings (e.g., leukoencephalopathy, basal ganglia changes) would solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is transmitted by
Choices:
A. Female anopheles mosquito
B. Male anopheles mosquito
C. Culex mosquito
D. Aedes mosquito
Answer: [/INST] Female anopheles mosquito </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis of heart presents with -a) Arrhythmiab) AV blockc) ↑ed mass/voltage d) Hypertrophic cardiomyopathy
Choices:
A. ab
B. abc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are seen in Keratoconus EXCEPT
Choices:
A. Keyser Fleischer Ring
B. Progressive vision loss due to increasing myopia and irregular astigmatism
C. Scissoring reflex in retinoscopy
D. Munson sign Positive
Answer: [/INST] Keyser Fleischer Ring </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic acidemia', 'Neonatal death', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic acidemia** and **methylmalonic aciduria**, which are hallmark biochemical markers of MMA. Symptoms like **metabolic acidosis**, **hyperammonemia**, **vomiting**, and **seizures** align with metabolic decompensation caused by MMA. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression due to toxic metabolite accumulation. **Generalized hypotonia** and **neonatal death/death in infancy** reflect the severe, early-onset nature of this disorder.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the absence of B12 deficiency symptoms) and the inclusion of **neonatal death** strongly suggest a **mutase deficiency subtype**. This subtype is caused by defects in the *MUT* gene, leading to impaired methylmalonyl-CoA mutase activity. The severe clinical course (death in infancy) and biochemical features (persistent methylmalonic aciduria despite B12 levels) confirm this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 15 year old boy presents was brought to OPD with a history of pain and swelling in the right thigh. Biopsy of the mass demonstrates Osteosarcoma. His mother was diagnosed with breast cancer 1 year ago and his maternal grandmother died of the breast cancer 10 years ago. The child has 3 younger siblings. Siblings are at an increased risk of developing which of the following cancer ?
Choices:
A. Wilms
B. Neuroblastoma
C. Hepatoblastoma
D. Glioma
Answer: [/INST] Glioma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Deficiency of growth hormone leads to –a) Delayed fusion of epiphysisb) Proportionate dwarfismc) Acromegaly d)  Mental retardation
Choices:
A. ac
B. a
C. ab
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with Hypeension presents with Hypokalemia. Aldosterone levels and Renin levels are both elevated. The most likely diagnosis is
Choices:
A. Renal Aery stenosis
B. Primary Hyperaldosteronism {Conn's syndrome}
C. Addison's disease
D. Cushing's syndrome
Answer: [/INST] Renal Aery stenosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis caused by Cryptococcus neoformans is most often acquired by
Choices:
A. Head trauma
B. Primary gastrointestinal infection
C. Hematogenous spread of fungus from the lung
D. Ohopedic surgery
Answer: [/INST] Hematogenous spread of fungus from the lung </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Incubation period of Measles
Choices:
A. 14 days
B. 1 month
C. 3 month
D. 5 month
Answer: [/INST] 14 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common site for Osteomyelitis:
Choices:
A. Epiphysis
B. Metaphysis
C. Diaphysis
D. Sub-chondral growth plate
Answer: [/INST] Metaphysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statement are true regarding Q fever except:
Choices:
A. It is a zoonotic disease
B. Human disease is characterized by an interstitial pneumonia
C. No rash is seen
D. Weil Felix reactions is very useful for diagnosis
Answer: [/INST] Weil Felix reactions is very useful for diagnosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Q fever is caused by which Rickettsial Agent
Choices:
A. R. prowazekii
B. R. tsutsugamushi
C. C. burnetii
D. Rochalimaea quintana
Answer: [/INST] C. burnetii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common cause of pulmonary abscesses in Cystic Fibrosis is?
Choices:
A. Pseudomonas aeruginosa
B. Staphylococcus aureus
C. Burkholderia cenocepacia
D. Nontuberculous mycobacteria
Answer: [/INST] Pseudomonas aeruginosa </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cystinuria', 'Argininuria', 'Abnormal circulating arginine concentration', 'Abnormal circulating citrulline concentration', 'Uraciluria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Argininuria and elevated circulating arginine**: Arginase deficiency disrupts the urea cycle, preventing the conversion of arginine to ornithine and urea. This results in arginine accumulation in the blood (abnormal circulating arginine) and its excretion in urine (argininuria).  
2. **Abnormal citrulline**: While citrulline levels are typically normal or mildly elevated in arginase deficiency, secondary metabolic disruptions or partial upstream urea cycle inhibition may explain the abnormal citrulline concentration.  
3. **Cystinuria**: High plasma arginine may competitively inhibit renal reabsorption of cystine (a dibasic amino acid), leading to its urinary excretion. This is a secondary effect of hyperargininemia.  
4. **Uraciluria**: Excess arginine can drive pyrimidine synthesis via alternative pathways, increasing orotic acid and uracil production, which is excreted in urine. This links to observed uraciluria despite it being more classically associated with other urea cycle disorders (e.g., OTC deficiency).  

The constellation of amino acid transport disturbances (cystinuria, argininuria) and metabolic byproducts (uraciluria) aligns with the primary pathology of arginase deficiency, where hyperargininemia drives multisystemic biochemical cascades. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy affects all the following except :
Choices:
A. Testes
B. Ovaries
C. Eyes
D. Nerves
Answer: [/INST] Ovaries </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which carcinoma metastases to heart?a)  Ca breastb) Ca stomach c)  Ca lungd)  Ca urinary bladder  e) Osteosarcoma
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucopolysaccharidoses are caused by
Choices:
A. An increased rate of synthesis of proteoglycans
B. Defects in the degradation of proteoglycans
C. The synthesis of polysaccharides with an altered structure
D. An insufficient amount of proteolytic enzymes
Answer: [/INST] Defects in the degradation of proteoglycans </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Streptococcal Toxic Shock Syndrome is due to
Choices:
A. Erythrogenic toxin
B. Enterotoxin F
C. Enteoxin C
D. None
Answer: [/INST] Erythrogenic toxin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is caused by -
Choices:
A. Asbestosis
B. Silicosis
C. Baggasosis
D. Anthracosis
Answer: [/INST] Asbestosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Ataxia', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Pancreatitis', 'Thrombocytopenia', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Dehydration', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Kyphoscoliosis', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Severe hearing impairment', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: The patient exhibits *methylmalonic acidemia* and *methylmalonic aciduria*, hallmarks of methylmalonyl-CoA mutase deficiency. Elevated methylmalonic acid disrupts the propionate pathway, leading to metabolic crises.  
2. **Metabolic derangements**: Symptoms like *metabolic acidosis*, *hyperammonemia*, *increased serum lactate*, and *hyperglycinemia* align with impaired mitochondrial energy metabolism and toxic metabolite accumulation.  
3. **Organ system involvement**:  
   - **Neurological**: *Intellectual disability*, *ataxia*, *motor delay*, and *hypotonia* result from chronic neurotoxicity due to methylmalonic acid and ammonia.  
   - **Hematological**: *Thrombocytopenia*, *leukopenia*, and *abnormal erythrocyte morphology* stem from bone marrow suppression caused by metabolic stress.  
   - **Renal**: *Elevated creatinine*, *increased blood urea nitrogen*, and *hyperuricemia* indicate renal tubular dysfunction and acute kidney injury.  
4. **Systemic complications**: *Feeding difficulties*, *dehydration*, *gastrointestinal inflammation*, and *recurrent infections* (e.g., pneumonia, sepsis) reflect global metabolic instability and immune dysfunction.  
5. **Early mortality**: *Neonatal death*, *death in infancy/childhood/adolescence* are consistent with severe, B12-unresponsive MMA variants, where metabolic decompensation is irreversible without liver transplantation.  
6. **Carnitine/porphyrin abnormalities**: Secondary *abnormal carnitine* and *porphyrin levels* arise due to mitochondrial dysfunction and disrupted heme synthesis.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria (General Diagnosis)  
Reasoning:  
- **Clinical confirmation**: The presence of *methylmalonic acidemia* and *aciduria* in symptomology directly supports this overarching diagnosis.  
- **Phenotypic spectrum**: Symptoms like *obesity*, *kyphoscoliosis*, and *severe short stature* suggest chronic multisystemic disease progression, while *hyperalaninemia* and *hypoproteinemia* point to amino acid metabolism dysregulation.  
- **Diagnostic exclusion**: Lack of responsiveness to B12 supplementation (implied by the severity and early mortality) differentiates this from B12-responsive subtypes.  

The patient’s presentation is pathognomonic for **severe, mutase-deficient MMA**, characterized by enzymatic defects in methylmalonyl-CoA mutase, leading to catastrophic metabolic failure and early mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following does not include the clinical features of Chronic Osteomyelitis?
Choices:
A. Excruciating pain and tenderness
B. Non healing bony and overlying soft tissue wounds with indurated soft tissue
C. Wooden character of bone
D. Draining sinuses
Answer: [/INST] Excruciating pain and tenderness </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true regarding Tetralogy of Fallot except –
Choices:
A. Ejection systolic murmur in second intercostal space
B. Single second heart sound
C. Predominantly left to right shunt
D. Normal jugular venous pressure
Answer: [/INST] Predominantly left to right shunt </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Chorioretinal atrophy', 'Nystagmus', 'Oculomotor apraxia', 'Delayed speech and language development', 'Abnormally large globe', 'Motor delay', 'Generalized hypotonia', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia', 'High myopia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The patient exhibits *cerebellar dysplasia* and *inferior cerebellar vermis hypoplasia*, key neuroimaging features of Poretti-Boltshauser syndrome (PBS). These structural defects disrupt cerebellar function, contributing to *motor delay*, *generalized hypotonia*, and ataxia (implied by cerebellar signs).  
2. **Oculomotor Deficits**: *Oculomotor apraxia* and *nystagmus* are hallmark ocular motor impairments in PBS, linked to cerebellar malformations. *Strabismus* and *abnormally large globe* may arise from disrupted coordination of eye movements and structural ocular abnormalities.  
3. **Retinal Involvement**: *Chorioretinal atrophy* and *high myopia* align with PBS-associated retinal dystrophy caused by pathogenic variants in *LAMA1*, a gene critical for retinal and cerebellar basement membrane integrity.  
4. **Developmental Delays**: *Delayed speech and language development* and *motor delay* reflect global developmental delays secondary to cerebellar dysfunction and potential intellectual disability (a core feature of PBS).  
5. **Exclusion of Mimics**: The constellation of cerebellar cysts/hypoplasia, retinal changes, and oculomotor apraxia distinguishes PBS from similar disorders (e.g., Joubert syndrome, which typically presents with a ""molar tooth sign"" on imaging and lacks chorioretinal atrophy).  

This pattern strongly supports a diagnosis of Poretti-Boltshauser syndrome, confirmed genetically via *LAMA1* testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Features of Typhoid Ulcers include all of the following Except:
Choices:
A. Bleeding
B. Perforation
C. Stricture and obstruction
D. Longitudinal orientation
Answer: [/INST] Stricture and obstruction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Small intestinal biopsy is specific for-a)  Tropical sprueb)  Celiac spruec)  Whipple's diseased)  Amyloidosis
Choices:
A. cd
B. bc
C. bd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following Vasculitis causes necrotizing inflammation
Choices:
A. Polyarteritis nodosa
B. Wegener's granulomatosis
C. Kawasaki disease
D. Microscopic polyangitis
Answer: [/INST] Kawasaki disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Bloom Syndrome -
Choices:
A. Decreased IgG
B. Decreased IgM
C. IgA absent
D. Increased IgE
Answer: [/INST] Decreased IgM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Demyelination is the major feature of Multiple Sclerosis. Which of the following cells forms myelin in the central nervous system?
Choices:
A. Astrocytes
B. Ependymal cells
C. Microglia
D. OIigodendrocytes
Answer: [/INST] OIigodendrocytes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The presence of **hyperammonemia** and **elevated plasma citrulline** strongly indicates a urea cycle disorder. Citrullinemia type I (argininosuccinate synthetase deficiency) is characterized by severe neonatal hyperammonemia due to impaired citrulline-to-argininosuccinate conversion. This leads to rapid accumulation of ammonia and citrulline, causing neurological decline, **neonatal death**, or **death in infancy** if untreated. The absence of cholestasis or liver-specific symptoms aligns with classic urea cycle dysfunction rather than hepatic pathology.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: **Elevated citrulline** and **hyperammonemia** can also occur in citrin deficiency (type II citrullinemia). Neonatal intrahepatic cholestasis (NICCD) manifests with transient liver dysfunction and cholestasis (implied in the disease name), which may compound metabolic stress. While citrulline levels are typically lower than in type I, severe cases can lead to **death in infancy/childhood** due to liver failure or metabolic decompensation. **Abnormality of prenatal development** may reflect intrauterine growth restriction from mitochondrial energy deficits caused by citrin deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true about Glioblastoma..
Choices:
A. Also known as Butterfly tumor
B. Frontal lobe of the brain is common location
C. It belongs to WHO grade 3 Astrocytoma
D. Serpentine necrosis and glomeruloid bodies
Answer: [/INST] It belongs to WHO grade 3 Astrocytoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis verrucosa cutis is a form of:-
Choices:
A. Tuberculid
B. Primary tuberculosis
C. Post primary tuberculosis with good resistance
D. Post primary tuberculosis with poor resistance
Answer: [/INST] Post primary tuberculosis with good resistance </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia
Choices:
A. Occurs due to Vitamin A deficiency
B. Relative Benign condition
C. First feature of Vitamin A deficiency
D. Also seen in retinitis pigmentosa
Answer: [/INST] Occurs due to Vitamin A deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella vaccine is given in which age-
Choices:
A. 1-14 yrs
B. <5 yrs
C. >50 yrs
D. None
Answer: [/INST] 1-14 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following cardiac lesion is least likely to occur in Congenital Rubella syndrome?
Choices:
A. ASD
B. VSD
C. PDA
D. Pulmonary Stenosis
Answer: [/INST] ASD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurotoxicity, seizures, and organ failure without dietary intervention.  
4. **Hypertyrosinemia** may seem atypical (PAH deficiency typically reduces tyrosine), but secondary tyrosine elevation can occur due to metabolic stress or overlapping enzyme disruptions in severe cases.  
5. **Abnormality of prenatal development** could reflect maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy), causing fetal complications like microcephaly, though this is distinct from the infant’s own PKU diagnosis.  

Key confirmation: Hyperphenylalaninemia + phenylketonuria (via urinary carboxylic acids) are diagnostic for PKU. Early mortality underscores untreated disease severity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most potential route for transmission of Meningitis from CNS to Inner ear is -
Choices:
A. Cochlear Aqueduct
B. Endolymphatic sac
C. Vestibular Aqueduct
D. Hyrtle fissure
Answer: [/INST] Cochlear Aqueduct </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypothyroidism', 'Pruritus', 'Cholelithiasis', 'obsolete Mood changes', 'Dilated cardiomyopathy', 'Bradycardia', 'Acute pancreatitis', 'Weight loss', 'Macrocytic anemia', 'Leukocytosis', 'Nausea', 'Loss of speech', 'Incomprehensible speech', 'Vasculitis', 'Obstructive sleep apnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Abnormal EKG', 'Elevated circulating parathyroid hormone level', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Atrioventricular dissociation', 'Elevated gamma-glutamyltransferase level', 'Unhappy demeanor', 'Decreased circulating free T3', 'Perinuclear antineutrophil antibody positivity', 'Increased circulating IgG4 level', 'Carotid artery stenosis', 'Thyroiditis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: IgG4 related disease; IgG4-RD  
**Reasoning**:  
1. **Elevated IgG4 level** (Increased circulating IgG4 level) is a hallmark diagnostic criterion for IgG4-RD.  
2. **Multi-organ involvement**:  
   - **Thyroid**: Hypothyroidism, thyroiditis, elevated TSH, and low free T3 align with IgG4-related thyroid disease (e.g., Riedel’s thyroiditis).  
   - **Pancreas/biliary**: Acute pancreatitis, cholelithiasis, and elevated gamma-glutamyltransferase suggest IgG4-related autoimmune pancreatitis/sclerosing cholangitis.  
   - **Vascular**: Vasculitis, carotid stenosis, and antinuclear/ANCA positivity reflect systemic fibroinflammatory vasculopathy.  
3. **Inflammatory markers**: Elevated ESR, CRP, leukocytosis, and antinuclear antibody positivity support systemic inflammation.  
4. **Fibrosis**: Dilated cardiomyopathy (cardiac fibrosis), obstructive sleep apnea (airway fibrosis), and retroperitoneal fibrosis (linked to IgG4-RD spectrum).  
5. **Exclusion of mimics**: Macrocytic anemia and mood changes may arise from chronic inflammation, while antineutrophil antibodies and parathyroid hormone elevation are atypical but not contradictory in systemic autoimmune disorders.  

Disease: IgG4-related retroperitoneal fibrosis  
**Reasoning**:  
- A subset of IgG4-RD, retroperitoneal fibrosis explains **weight loss**, **nausea**, and potential ureteral obstruction (not explicitly listed but commonly associated).  
- Linked to elevated IgG4 levels and perivascular fibrosis (carotid stenosis, vasculitis).  

Disease: Multifocal fibrosclerosis  
**Reasoning**:  
- Historical term for IgG4-RD manifestations, encompassing fibrosis in **thyroid**, **pancreas**, **retroperitoneum**, and **vascular system** (carotid stenosis, AV dissociation from cardiac fibrosis).  
- Explains **dilated cardiomyopathy** (myocardial fibrosis) and **pruritus** (bile duct fibrosis/cholestasis).  

**Conclusion**: The patient’s multi-organ fibrosis, autoimmune features, and elevated IgG4 confirm **IgG4-RD** with retroperitoneal fibrosis and multifocal fibrosclerosis as overlapping phenotypes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Liver biopsy in Malaria will have:
Choices:
A. Microabscesses
B. Kupffer cell hyperplasia
C. Piecemeal necrosis
D. Non caseating granuloma
Answer: [/INST] Kupffer cell hyperplasia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common translocation associated with poor prognosis in patients with Multiple Myeloma is
Choices:
A. t(11;14)
B. t(4;14)
C. t(14;16)
D. t(14;20)
Answer: [/INST] t(4;14) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Short foot', 'Constipation', 'Gliosis', 'EEG abnormality', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Peripheral neuropathy', 'Chalazion', 'Dilation of Virchow-Robin spaces', 'Small hand']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima** (absent tear production) is a cardinal feature of this disorder and directly reflects the ""alacrimia"" in the syndrome's name.  
2. **Hepatic fibrosis**, **elevated hepatic transaminases**, and **prolonged neonatal jaundice** align with the liver dysfunction component, a hallmark of the disease.  
3. **Seizures**, **hypotonia**, **global developmental delay**, **EEG abnormality**, and **gliosis** indicate severe neurological involvement, consistent with the ""choreoathetosis"" and neurodegenerative features of the disorder.  
4. **Peripheral neuropathy** and **reduced tendon reflexes** reflect peripheral nervous system pathology, a known manifestation of congenital disorders of deglycosylation.  
5. **Elevated alpha-fetoprotein** is a biomarker frequently associated with glycosylation defects, supporting the molecular diagnosis.  
6. **Recurrent corneal erosions** and **chalazion** correlate with ocular surface abnormalities secondary to alacrima and systemic inflammation.  
7. **Dilation of Virchow-Robin spaces** and **small hand/short foot** suggest congenital structural anomalies linked to abnormal glycosylation during development.  
8. **Constipation** may stem from autonomic neuropathy or gastrointestinal dysmotility, common in systemic metabolic disorders.  
This constellation of ocular, hepatic, neurological, and developmental abnormalities, combined with biomarker findings, strongly implicates a congenital disorder of deglycosylation (NGLY1 deficiency or related subtype). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Obesity', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or comorbid metabolic disruptions.  
3. **Generalized hypotonia** and **recurrent viral infections** align with untreated PKU’s neurodevelopmental and immune dysregulation effects due to toxic phenylalanine accumulation.  
4. **Obesity** may reflect dietary challenges from lifelong phenylalanine-restricted diets, often rich in carbohydrates.  
5. **Ventricular septal defect** is likely an incidental congenital anomaly, as PKU does not directly cause cardiac defects.  
6. **Death in infancy/childhood** and **neonatal death** suggest severe, untreated PKU with metabolic crises or complications (e.g., seizures, cerebral edema), though modern neonatal screening mitigates this outcome.  

Note: Hypertyrosinemia and cardiac defects are atypical for PKU and warrant investigation for coexisting disorders (e.g., tyrosinemia, BH4 deficiency) or misdiagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine in an untreated pregnant mother disrupts fetal development.  
3. **Neonatal death/Death in infancy** may occur in severe untreated PKU due to metabolic crises, neurological damage, or secondary complications (e.g., infections).  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise transiently from liver immaturity or secondary metabolic disturbances in critically ill infants.  
5. **Gastrointestinal inflammation** could result from protein-rich feedings exacerbating metabolic stress or comorbid conditions in a metabolically unstable infant.  
6. While PKU typically causes low tyrosine, confounding factors (e.g., transient neonatal tyrosinemia, assay interference) may explain the lab result. The dominant hyperphenylalaninemia strongly prioritizes PKU over tyrosinemia disorders.  

Note: Confirmatory testing (PAH gene variants, phenylalanine/tyrosine ratios, tetrahydrobiopterin status) would solidify the diagnosis and exclude BH4 deficiencies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin –
Choices:
A. increase the levels of intracellular cyclic GMP
B. Act through opiate receptor
C. causes continued activation of adenyl cyclase
D. inhibit the enzyme phosphodiesterase
Answer: [/INST] causes continued activation of adenyl cyclase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia ;s associated with:
Choices:
A. Measles
B. Mumps
C. Rubella
D. Chicken pox
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: HCV is associated with -a) Anti LKM-1 antibody b) Sclerodermac) Cryoglobulinemiad) Polyarteritis nodosa
Choices:
A. a
B. ac
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinopathy of Prematurity (ROP) screening is done in the following babies
Choices:
A. Preterm < 34 weeks of gestation
B. Preterm of 33 weeks of gestation who required mechanical ventilation
C. Babies with birth weight < 1.8 kg
D. Babies with birth weight < 2 kg
Answer: [/INST] Preterm of 33 weeks of gestation who required mechanical ventilation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dose of Rubella immunoglobulin is:
Choices:
A. 5 ml
B. 10 ml
C. 20 ml
D. 40 ml
Answer: [/INST] 20 ml </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about inheritance of Myotonic Dystrophy are true, except:
Choices:
A. Type 1 is caused by mutation in DMPK gene
B. Type 2 is caused by mutation in CNBP gene
C. Type 2 gene is located on Chromosome 19
D. Type 1 is caused by a CTG trinucleotide repeat expansion
Answer: [/INST] Type 2 gene is located on Chromosome 19 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Negative sense nucleic acid genome is found in -a) Poliovirusb) Rabiesc) Measlesd) Picornaviruse) Influenzae
Choices:
A. ab
B. bc
C. acd
D. bce
Answer: [/INST] bce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia indicators**: Symptoms like seizures, lethargy, vomiting, drowsiness, and neonatal death align with hyperammonemia, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: Elevated urinary orotic acid occurs in OTCD due to carbamoyl phosphate accumulation, which is diverted to pyrimidine synthesis. This distinguishes OTCD from other urea cycle defects.  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via glutamine synthetase, increasing glutamine levels.  
4. **Neonatal/Infantile lethality**: Severe OTCD often presents catastrophically in males (X-linked) shortly after birth, consistent with ""death in infancy.""  
5. **Exclusion of alternatives**: Oroticaciduria differentiates OTCD from CPS1 deficiency (no orotic acid elevation). Symptoms also exclude organic acidemias or mitochondrial disorders, which lack urea cycle-specific markers.  

The triad of **hyperammonemia, oroticaciduria, and hyperglutaminemia** confirms OTCD as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Motor delay', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Motor delay** aligns with Canavan disease, a leukodystrophy causing progressive neurological deterioration due to defective myelination.  
2. **Death in infancy** is consistent with severe, early-onset forms of Canavan disease, which can lead to rapid neurological decline and fatal outcomes.  
3. **Abnormal circulating aspartate family amino acids** (specifically elevated *N-acetylaspartic acid [NAA]*) directly results from aspartoacylase deficiency, the enzyme defect in Canavan disease. This biochemical marker confirms the diagnosis.  
4. The triad of neurological regression, fatal infantile course, and NAA accumulation is pathognomonic for Canavan disease, ruling out other leukodystrophies or metabolic disorders with overlapping symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: ECG change seen in Hypokalemia
Choices:
A. Tall 'T' wave
B. U wave
C. Sine wave configration
D. Shoening of QT interval
Answer: [/INST] U wave </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Ameloblastoma -a) Cystic lesionb) Rapidly growingc) Malignant diseased) MC site is Tibiae) Presented in children
Choices:
A. ae
B. b
C. ab
D. ad
Answer: [/INST] ae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion. Untreated PKU results in toxic phenylalanine accumulation, leading to severe neurological damage, seizures, and **early death** (childhood/adolescence). While **hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are typically low), it may indicate a comorbid condition (e.g., tyrosinemia type II) or a rare PKU variant involving tetrahydrobiopterin (BH4) deficiency. BH4 defects disrupt both phenylalanine metabolism and tyrosine breakdown, potentially elevating both metabolites. Despite this inconsistency, hyperphenylalaninemia and early mortality strongly prioritize PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following Px is true for Typhoid carriers?
Choices:
A. Ciprofloxacin + azithromycin
B. Cotrimoxazole
C. Amoxicillin + probenecid
D. None
Answer: [/INST] Amoxicillin + probenecid </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid perforation occurs during
Choices:
A. Ist week
B. 2nd week
C. 3rd week
D. 4th week
Answer: [/INST] 3rd week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is used for culturing M.Tuberculosis?
Choices:
A. L.J medium
B. Sabouraud's medium
C. Pick's medium
D. NIH medium
Answer: [/INST] L.J medium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Trigger finger occurs in -a) Rheumatoid athritisb) Traumac) Osteosarcomad) Osteoarthritis
Choices:
A. ac
B. ab
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Hepatic steatosis', 'Death in infancy', 'Vomiting', 'Cerebral edema', 'Abnormal circulating acetylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating acetylcarnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to elevated medium-chain acylcarnitines (C8-C10), a hallmark diagnostic biomarker.  
2. **Hepatic steatosis**: Impaired fatty acid metabolism causes lipid accumulation in the liver.  
3. **Vomiting and cerebral edema**: During metabolic stress (e.g., fasting), unmetabolized fatty acids and toxic metabolites (e.g., octanoic acid) induce encephalopathy, cerebral edema, and gastrointestinal symptoms.  
4. **Coma and death in infancy**: Prolonged hypoglycemia and energy deficiency in crises result in neurological deterioration; untreated MCADD has high mortality in early life due to rapid metabolic decompensation.  
5. **Consistency with MCADD phenotype**: The triad of hypoketotic hypoglycemia, hepatic dysfunction, and acute neurological crises aligns with MCADD pathophysiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Obesity', 'Anemia', 'Hyperammonemia', 'Progressive neurologic deterioration', 'Difficulty walking', 'Spastic tetraplegia', 'Oroticaciduria', 'Aminoaciduria', 'Difficulty climbing stairs', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Hyperornithinemia', 'Uraciluria', 'Increased circulating lactate dehydrogenase concentration', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Arginase deficiency/Argininemia  
Reasoning:  
1. **Hyperammonemia**: Central to urea cycle disorders like arginase deficiency, as impaired arginase prevents conversion of arginine to urea and ornithine.  
2. **Oroticaciduria/Uraciluria**: Blocked urea cycle diverts carbamoyl phosphate to pyrimidine synthesis, increasing orotic acid and uracil excretion.  
3. **Aminoaciduria/Abnormal amino acid concentrations**: Elevated plasma arginine (argininemia) and secondary disturbances in aspartate-family amino acids, proline, and alanine due to metabolic dysregulation.  
4. **Neurological symptoms**: Progressive spastic tetraplegia/diplegia, motor delays, seizures, and intellectual disability stem from arginine/ammonia neurotoxicity and cerebral degeneration.  
5. **Liver involvement**: Acute/chronic hepatitis and prolonged PTT reflect hepatic dysfunction, common in urea cycle disorders due to ammonia overload and metabolic stress.  
6. **Hyperornithinemia**: Likely compensatory or secondary to arginine accumulation disrupting ornithine metabolism.  
7. **Early mortality**: Death in childhood/adolescence aligns with severe, untreated arginase deficiency causing neurological decline and metabolic crises.  
8. **LDH elevation**: Indicates tissue damage, potentially from liver injury or muscle breakdown due to spasticity.  
9. **Obesity/Anemia**: May arise from dietary management (protein restriction) or metabolic comorbidities, though less specific to the diagnosis.  

Key biochemical hallmarks (argininemia, hyperammonemia, oroticaciduria) and progressive neurologic deterioration solidify the diagnosis of arginase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Glioma of the optic nerve is usually –
Choices:
A. Gemistocytic
B. Pilocytic
C. Fibrillary
D. Lamellar
Answer: [/INST] Pilocytic </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine. This results in toxic accumulation of phenylalanine in the blood, consistent with hyperphenylalaninemia.  
2. **Abnormal circulating tyrosine concentration**: Reduced PAH activity decreases tyrosine synthesis, explaining low tyrosine levels (""abnormal"" in this context).  
3. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (low-phenylalanine diet), metabolic derangements and complications may lead to early mortality.  
4. **Abnormality of prenatal development or birth**: While PKU itself does not directly affect prenatal development, maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus. If the patient’s mother had uncontrolled PKU, this could explain prenatal abnormalities.  
5. **Consistency with PKU**: The combination of metabolic findings (elevated phenylalanine, low tyrosine) and clinical outcomes aligns with severe, untreated PKU. Neonatal screening typically identifies PKU, but delayed diagnosis or lack of treatment could result in the described fatal course. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Keratitis', 'Conjunctivitis', 'Photophobia', 'Hyperkeratosis', 'Intellectual disability', 'Seizure', 'Hypertyrosinemia', 'Death in childhood', 'Epiphora']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 2/Tyrosine transaminase deficiency  
Reasoning:  
1. **Hypertyrosinemia** is a hallmark biochemical feature of tyrosinemia type 2, caused by deficient tyrosine transaminase activity.  
2. **Ocular symptoms** (keratitis, conjunctivitis, photophobia, epiphora) arise from tyrosine crystal deposition in corneal epithelial cells, leading to inflammation and damage.  
3. **Hyperkeratosis** (palmar/plantar) occurs due to tyrosine accumulation in the skin, causing painful lesions.  
4. **Neurological involvement** (intellectual disability, seizures) may result from chronic tyrosine neurotoxicity or secondary metabolic disturbances.  
5. **Death in childhood** reflects severe untreated cases with complications like metabolic decompensation, infections, or neurological deterioration.  
6. **Consistency with phenotype**: The triad of dermatological, ocular, and neurological manifestations aligns with Richner-Hanhart syndrome (tyrosinemia type 2), distinguishing it from hepatic/renal-predominant tyrosinemia type 1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: Reflects alternative metabolism of phenylalanine into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine.  
3. **Early mortality (infancy to adulthood)**: Untreated PKU causes severe neurological damage, seizures, and organ failure, often resulting in premature death without dietary intervention.  
4. **Obesity**: May arise from metabolic dysregulation or compensatory high-calorie diets low in phenylalanine.  
5. **Hypertyrosinemia**: Uncommon in classic PKU but could indicate a co-occurring tyrosinemia or secondary metabolic disruption from chronic phenylalanine toxicity.  
6. **Prenatal abnormalities**: Likely reflects maternal PKU syndrome (uncontrolled phenylalanine in a pregnant mother affecting fetal development), though not typical in the affected individual themselves.  

Note: While some symptoms (e.g., hypertyrosinemia) are atypical for isolated PKU, they may suggest complex metabolic interactions or comorbid conditions. The core diagnosis remains PKU due to hyperphenylalaninemia and urinary phenylketone derivatives. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Craniopharyngioma except?
Choices:
A. Solid-cystic lesion
B. Commonly calcifies in adults
C. Admantinomatous type is common in children
D. Machine oily protein rich content
Answer: [/INST] Commonly calcifies in adults </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Blindness', 'Anemia', 'Hyperammonemia', 'Malabsorption', 'Hyperglycinemia', 'Headache', 'Severe short stature', 'Death in childhood', 'Hypoargininemia', 'Death in adolescence', 'Feeding difficulties', 'Hyperornithinemia', 'Abnormal circulating serine concentration', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Gyrate atrophy of choroid and retina with ornithinemia  
Reasoning:  
1. **Hyperornithinemia**: Central to the diagnosis, caused by deficiency of ornithine aminotransferase (OAT), leading to ornithine accumulation.  
2. **Hypoargininemia**: OAT deficiency disrupts the proline synthesis pathway, indirectly affecting arginine metabolism and urea cycle function.  
3. **Hyperammonemia**: Impaired urea cycle due to low arginine levels results in toxic ammonia buildup.  
4. **Blindness**: Progressive chorioretinal degeneration, a hallmark of gyrate atrophy, leads to vision loss.  
5. **Severe short stature/Feeding difficulties/Malabsorption**: Chronic metabolic stress, malnutrition, and systemic amino acid imbalances contribute to growth failure and GI dysfunction.  
6. **Hyperglycinemia/Abnormal serine**: Secondary metabolic disruptions from urea cycle dysfunction and mitochondrial amino acid pathway interference.  
7. **Neurological symptoms (headache)**: Linked to hyperammonemia and metabolic encephalopathy.  
8. **Early mortality**: Reflects severe systemic complications, including metabolic decompensation and organ damage.  

The combination of ocular degeneration, hyperornithinemia, and urea cycle-related metabolic abnormalities confirms gyrate atrophy with ornithinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Coma', 'Fever', 'Vomiting', 'Tachypnea', 'Death in childhood', 'Hypervalinemia', 'Hyperisoleucinemia', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Abnormalities**: Hypervalinemia and hyperisoleucinemia indicate elevated branched-chain amino acids (BCAAs: valine, isoleucine, leucine), a hallmark of MSUD due to defective BCKD enzyme complex.  
2. **Neurological Symptoms**: Seizures, coma, and rapid neurological decline align with acute metabolic decompensation from toxic BCAA accumulation.  
3. **Systemic Manifestations**: Fever, vomiting, and tachypnea suggest metabolic acidosis and encephalopathy, common during crises.  
4. **Early Mortality**: Death in childhood is typical in untreated classical MSUD due to irreversible metabolic crises.  
5. **Feeding Difficulties**: Infants with MSUD struggle to tolerate protein intake, worsening BCAA accumulation.  
6. **Absence of Maple Syrup Odor Note**: While classic, this symptom may not always be reported or recognized, but biochemical findings confirm diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Lymph node metastasis is common in   a) Osteosarcoma  b) Fibrous histiocytoma  c) Angiosarcoma  d) Rhabdomyosarcoma
Choices:
A. abc
B. acd
C. cd
D. bd
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Neonatal death', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with methylmalonic aciduria, metabolic acidosis, and life-threatening neonatal/infantile symptoms (seizures, neonatal death). These are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder caused by impaired metabolism of methylmalonyl-CoA. Accumulation of methylmalonic acid leads to metabolic acidosis and neurological toxicity, explaining seizures. Neonatal lethality reflects severe metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The presence of methylmalonic aciduria unresponsive to vitamin B12 therapy (implied by ""death in infancy"" despite likely standard care) points specifically to mutations in the *MUT* gene, which encodes methylmalonyl-CoA mutase. This enzyme defect prevents isomerization of methylmalonyl-CoA to succinyl-CoA, causing irreversible accumulation of methylmalonic acid. B12-unresponsive forms are typically severe, manifesting in the neonatal period with rapid metabolic deterioration, consistent with the patient’s clinical course. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera transmission by -
Choices:
A. Food transmits
B. Vaccination gives 90% efficiency
C. Healthy carrier
D. Chlorination is nor effective
Answer: [/INST] Food transmits </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Pericardial effusion', 'Pleural effusion', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Feeding difficulties**: Common in untreated infants due to poor metabolic regulation and neurological dysfunction.  
3. **Microcephaly/Severe short stature**: Untreated PKU leads to neurotoxicity from phenylalanine accumulation, disrupting brain development and growth.  
4. **Abnormality of prenatal development/Small for gestational age**: Maternal PKU (if the mother has uncontrolled phenylalanine levels during pregnancy) can cause intrauterine growth restriction and congenital anomalies.  
5. **Death in infancy/childhood/Neonatal death**: Historically, severe untreated PKU results in progressive neurological decline, seizures, and early mortality. Modern newborn screening and dietary management prevent this outcome.  
6. **Hypertyrosinemia**: Atypical for classic PKU (which typically causes low tyrosine). This may suggest a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic disruption from liver dysfunction in severe cases.  
7. **Pericardial/Pleural effusions**: Not typical for PKU. These could indicate an overlapping condition (e.g., metabolic crises, cardiac dysfunction) or complications from prolonged systemic metabolic instability.  

**Note**: While PKU explains hyperphenylalaninemia and neurodevelopmental symptoms, hypertyrosinemia and effusions suggest additional complexities, warranting further investigation for comorbid disorders or atypical presentations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **elevated plasma citrulline**: Core indicators of urea cycle dysfunction. While OTCD classically presents with *low citrulline*, partial enzyme activity or compensatory mechanisms (e.g., arginine supplementation) may explain citrulline elevation in some cases.  
2. **Oroticaciduria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid.  
3. **Hyperglutaminemia** and **hyperalaninemia**: Glutamine acts as an ammonia buffer, while alanine transports nitrogen to the liver, both elevated due to ammonia toxicity.  
4. **Neonatal/childhood death, feeding difficulties, lethargy, drowsiness**: Reflect acute hyperammonemic crises, common in severe OTCD.  
5. **Recurrent viral infections**: Metabolic stress from hyperammonemia may impair immune function.  
6. **Abnormal arginine/aspartate family amino acids**: Disrupted urea cycle alters arginine synthesis and aspartate utilization.  
7. **Obesity and sleep disturbances**: Chronic metabolic derangements may contribute to these phenotypes.  

Note: Elevated citrulline is atypical for OTCD but does not exclude the diagnosis, as atypical presentations or confounding factors (e.g., treatment, coexisting conditions) may occur. The triad of hyperammonemia, oroticaciduria, and clinical progression aligns strongly with OTCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Death in infancy', 'Vomiting', 'Clumsiness', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Increased urinary glycerol']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol**: A hallmark symptom of glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its excretion in urine.  
2. **Vomiting**: Common during metabolic crises due to glycerol accumulation and potential ketotic hypoglycemia.  
3. **Delayed speech, clumsiness, poor coordination**: Neurological manifestations may arise from episodic metabolic decompensation affecting brain function during critical developmental stages.  
4. **Death in infancy/childhood/neonatal death**: While rare in *isolated* GKD, severe metabolic instability or misdiagnosis (e.g., overlapping with contiguous Xp21 deletion syndrome) could contribute to early mortality.  
5. Exclusion of other disorders: Symptoms align with GKD rather than broader mitochondrial or fatty acid oxidation disorders, given the specificity of glyceroluria.  
Note: Isolated GKD typically has mild-to-moderate presentations; severe outcomes may suggest comorbid conditions or diagnostic overlap. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Roll Back Malaria program, which of the following is not a component?
Choices:
A. Training for health care worker
B. Using Insecticide-treated bednets
C. Developing newer insecticides
D. Strengthening health system
Answer: [/INST] Developing newer insecticides </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Mumps, EXCEPT
Choices:
A. Incubation period 18-21 days
B. Extensive tissue damage
C. Multiplies in respiratory epithelium
D. Spreads through Stenson's duct to Parotid gland
Answer: [/INST] Spreads through Stenson's duct to Parotid gland </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is false about Takotsubo Cardiomyopathy
Choices:
A. Due to major catecholamine discharge
B. Lv Contractile dysfunction
C. Presents with acute chest pain
D. Echo never reverts back to normal
Answer: [/INST] Echo never reverts back to normal </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Angioid streaks is seen in -a) Pseudoxanthoma Elasticumb) Acromegalyc) Paget's diseased) All of above
Choices:
A. a
B. ac
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 2 year old un immunised child from a hilly tribal area developed Keratomalacia after a viral infection. Which of the following could have lead to the development of Keratomalacia?
Choices:
A. Rubella
B. Rubeola
C. Mumps
D. Varicella
Answer: [/INST] Rubeola </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute Osteomyelitis is most commonly caused by -
Choices:
A. Staphylococcus aureus
B. Actinomyces bovis
C. Nocardia asteroids
D. Borrelia vincentii
Answer: [/INST] Staphylococcus aureus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true for Craniopharyngioma except?
Choices:
A. Derived from Rathke's pouch
B. Can lead to central DI
C. Present in sellar or infrasellar location
D. Causes visual disturbances
Answer: [/INST] Present in sellar or infrasellar location </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about TB meningitis-a) Exudates are formed on the convexities of brainb) CSF stored at 4°C in the time of transportationc) Hydrocephalus is common sequalaed) Meningoencephalitis is common manifestation
Choices:
A. abc
B. bcd
C. ac
D. bd
Answer: [/INST] bcd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Esotropia', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Absent speech', 'Hyperreflexia', 'Poor head control', 'Respiratory failure', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Self-injurious behavior']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Brachycephaly, sloping forehead, long philtrum, deeply set eyes, shallow orbits, tented upper lip vermilion, and open mouth align with the craniofacial dysmorphisms reported in TBCK syndrome.  
2. **Neuromuscular deficits**: Severe muscular hypotonia (a hallmark of TBCK) explains poor head control, respiratory failure (due to weakness), and motor delay. Hyperreflexia may reflect mixed upper/lower motor neuron dysfunction.  
3. **Developmental delays**: Absent speech and reduced eye contact correlate with profound intellectual disability and psychomotor retardation.  
4. **Neurobehavioral features**: Self-injurious behavior is consistent with behavioral phenotypes observed in genetic neurodevelopmental disorders like TBCK.  
5. **Ocular findings**: Esotropia and shallow orbits are recurrently associated with TBCK-related syndromes.  
6. **Systemic involvement**: Respiratory failure secondary to hypotonia further supports the diagnosis, as respiratory complications are common in severe infantile-onset TBCK cases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Death Rate due to Tuberculosis in 2109
Choices:
A. 1 Person per 1 Minute
B. 1 Person per 4 Minutes
C. 1 person per 10 Minutes
D. 1 person per 1 Hour
Answer: [/INST] 1 Person per 4 Minutes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Phenylketonuria the main aim of first line therapy is:
Choices:
A. Replacement of the defective enzyme
B. Replacement of the deficient product
C. Limiting the substrate for deficient enzyme
D. Giving the missing amino acid by diet
Answer: [/INST] Limiting the substrate for deficient enzyme </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits metabolic acidosis, hyperammonemia, vomiting, and methylmalonic aciduria—hallmark features of MMA. This autosomal recessive disorder disrupts methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. Death in infancy aligns with severe, untreated cases. Methylmalonic aciduria directly confirms impaired propionate pathway function.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specificity of vitamin B12-unresponsive MMA stems from mutations in the *MUT* gene, encoding methylmalonyl-CoA mutase. B12-unresponsiveness indicates defective enzyme activity (not cofactor deficiency). Hyperammonemia arises secondary to metabolic decompensation, disrupting the urea cycle. Early lethality underscores the severity of mutase deficiency, which lacks therapeutic response to B12. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true about Cystinosis?
Choices:
A. Cysteine stones in urine common
B. Corneal crystals
C. Fanconi syndrome
D. White blond hair and photophobia
Answer: [/INST] Cysteine stones in urine common </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: An adolescent child complains of night pain in the knee. It could be due to –a) Juvenile rheumatoid arthritisb) Idiopathic growth painc) Osteosarcomad) Paget's diseasee) Osteomyelitis
Choices:
A. a
B. ac
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Falciparum Malaria is:-
Choices:
A. Chloroquine
B. Mefloquine
C. ACT
D. Proguanil
Answer: [/INST] ACT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Filariasis involves
Choices:
A. Only superficial lymphatics
B. Only deep lymphatics
C. Both superficial and deep lymphatics
D. Only skin
Answer: [/INST] Only superficial lymphatics </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cysticercosis is caused by larva of:
Choices:
A. Taenia solium
B. T. saginata
C. Echinococcus
D. Ascaris
Answer: [/INST] Taenia solium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: If a claw hand develops in a patient with Leprosy, the deformity is -
Choices:
A. Grade 0
B. Grade I
C. Grade II
D. Grade III
Answer: [/INST] Grade II </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Intramuscular Rabies vaccine Post exposure prophylaxis schedule is
Choices:
A. 1-1-0-1-1
B. 1-1-1-1-1
C. 2-2-2-0-2
D. 8-0-4-0-0-4
Answer: [/INST] 1-1-1-1-1 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 45 years old male patient comes to OPD with cough and diarrhea since last 3 weeks. On diagnosis he is found to be HIV positive with Tuberculosis, Next line of management should be:-
Choices:
A. Sta ATT followed by A
B. Sta A followed by ATT
C. Sta ATT
D. Sta A then sta ATT after 6-8 weeks
Answer: [/INST] Sta ATT followed by A </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress from maternal-fetal interactions or placental insufficiency during fasting could contribute to subtle developmental anomalies.  
2. **Death in infancy/childhood and neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness. Undiagnosed cases lead to sudden mortality due to energy deficiency, hepatic dysfunction, or cardiac complications.  
3. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and acidosis, triggering secondary gastrointestinal inflammation from toxic metabolite accumulation (e.g., medium-chain acylcarnitines).  
4. **Decreased plasma free carnitine**: MCADD traps carnitine as medium-chain acylcarnitines (e.g., octanoylcarnitine), reducing free carnitine levels. This reflects the body’s attempt to detoxify accumulating fatty acid intermediates.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase (HADH) level**: Likely a misinterpretation or indirect effect. MCADD specifically involves medium-chain acyl-CoA dehydrogenase (ACADM) deficiency. HADH activity may appear reduced in assays due to overlapping substrate specificity or secondary mitochondrial dysfunction in severe crises.  

**Conclusion**: The constellation of early mortality, hypoketotic hypoglycemia risk, and biochemical findings align with MCADD, a fatty acid oxidation disorder requiring urgent dietary management to prevent catabolic crises. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following drug is NOT used to treat Leishmaniasis
Choices:
A. Cyclosporine
B. Ketoconazole
C. Pentamidine
D. Amphotericin B
Answer: [/INST] Cyclosporine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Hyperreflexia', 'Death in infancy', 'Difficulty walking', 'Abnormal cerebral white matter morphology', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Neurological and developmental symptoms**: Delayed speech/language development and intellectual disability align with the progressive neurocognitive decline seen in L-2-hydroxyglutaric aciduria (L-2-HGA).  
2. **Motor dysfunction**: Difficulty walking, climbing stairs, and running correlate with cerebellar ataxia and pyramidal involvement (hyperreflexia), common in this disorder.  
3. **Neuroimaging findings**: Abnormal cerebral white matter morphology is characteristic of L-2-HGA, often showing leukoencephalopathy on MRI.  
4. **Early mortality**: Death in infancy/childhood occurs in severe cases due to metabolic crises or progressive neurological deterioration.  
5. **Metabolic hallmark**: Excess L-2-hydroxyglutaric acid in urine/CSF confirms the diagnosis, though clinical and imaging features strongly support it here.  
6. **Exclusion of mimics**: Symptoms differentiate it from other leukodystrophies (e.g., Canavan disease) due to specific motor and imaging patterns. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following diseases have incubation period < 10 days -a)  Cholerab)  Influenzac)  Plagued)  Measlese) Rubella
Choices:
A. ab
B. bc
C. abc
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Maternal Rubella, in newborn causes all Except
Choices:
A. Neural tube defects
B. CVS defects
C. Cataract
D. Deafness
Answer: [/INST] Neural tube defects </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Abdominal pain', 'Hypothermia', 'Pneumonia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormality of bone marrow cell morphology', 'Hypervalinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Fatigue', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, hyperalaninemia, hypervalinemia, and hyperisoleucinemia suggest a defect in branched-chain amino acid (BCAA) metabolism. IVA specifically disrupts isovaleric acid breakdown due to isovaleryl-CoA dehydrogenase deficiency.  
2. **Acute Decompensation Symptoms**: Lethargy, hypoglycemia, dehydration, fever, hypothermia, and drowsiness align with metabolic crises caused by toxic isovaleric acid accumulation, triggering acidosis and energy depletion.  
3. **Hematological Dysfunction**: Thrombocytopenia, leukopenia, and abnormal bone marrow morphology result from bone marrow suppression by toxic metabolites.  
4. **Characteristic Odor**: ""Sweaty feet"" body odor is pathognomonic for IVA, caused by excess isovaleric acid excretion.  
5. **Early Mortality**: Neonatal death, infant/childhood/adolescent fatality reflects severe, untreated IVA progression to metabolic coma, infections (e.g., pneumonia), or organ failure.  
6. **Secondary Carnitine Dysregulation**: Abnormal carnitine levels occur as the body attempts to conjugate isovaleric acid for excretion.  
7. **Feeding Difficulties/Fatigue**: Common in neonates with metabolic stress due to poor feeding tolerance and energy deficits.  
8. **Recurrent Infections**: Immune dysfunction from metabolic instability increases susceptibility to infections like pneumonia.  

IVA is distinguished from other organic acidemias (e.g., propionic acidemia) by its unique biochemical profile (elevated isovalerylcarnitine) and odor. Confirmation requires urine organic acid analysis (elevated isovalerylglycine) and genetic testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hypoglycemia', 'Leukocytosis', 'Hyperammonemia', 'Hypertriglyceridemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs medium-chain fatty acid oxidation, critical during fasting, leading to glucose depletion.  
2. **Hypertriglyceridemia**: Inefficient fatty acid metabolism results in triglyceride accumulation.  
3. **Hyperammonemia**: Secondary urea cycle inhibition due to metabolic stress or accumulated toxic intermediates.  
4. **Abnormal carnitine levels**: Carnitine depletion occurs from excessive acylcarnitine formation (e.g., C8, C10 species) and urinary loss.  
5. **Seizures & hypotonia**: Energy deficiency in brain/muscle from impaired ketogenesis and ATP production.  
6. **Apathy**: Neurological dysfunction due to hypoglycemia and metabolic derangements.  
7. **Premature birth & severe short stature**: Intrauterine metabolic stress affecting growth; postnatal malnutrition exacerbates this.  
8. **Neonatal/childhood death**: Untreated MCADD causes lethal metabolic crises triggered by fasting or infection.  
9. **Recurrent infections**: Metabolic decompensation weakens stress responses, increasing infection susceptibility.  
10. **Amino acid abnormalities**: Disrupted gluconeogenesis (elevated alanine) and liver dysfunction alter aspartate metabolism.  
11. **Leukocytosis**: Stress response during acute metabolic decompensation.  

Key biochemical hallmarks (hypoglycemia, hyperammonemia, hypertriglyceridemia, acylcarnitine abnormalities) align with MCADD pathophysiology. Early fatality without intervention confirms severity typical of untreated cases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Anemia', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration', 'Pregnancy exposure', 'Decreased serum iron', 'Abnormality of vitamin D metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Pregnancy exposure**: Maternal PKU syndrome, where untreated maternal hyperphenylalaninemia during pregnancy results in congenital anomalies (e.g., premature birth, developmental issues) and neonatal complications (e.g., neonatal death).  
3. **Decreased serum iron/ferritin & anemia**: Likely secondary to restrictive dietary management of PKU, which may limit iron-rich protein sources.  
4. **Vitamin D metabolism abnormality**: Due to dietary restrictions (low-phenylalanine diets often lack fortified foods or natural sources of vitamin D).  
5. **Hypertyrosinemia**: Uncommon in classic PKU but may occur transiently due to metabolic stress or concurrent hepatic dysfunction (e.g., tyrosine catabolism disruption).  
6. **Early mortality (infancy/childhood)**: Untreated PKU causes severe neurological damage; maternal PKU syndrome exacerbates risks (cardiac/developmental defects).  
**Key exclusion**: Tyrosinemia or BH4 deficiencies were considered but ruled out as the diagnosis explicitly aligns with PKU. Hypertyrosinemia here is atypical but explained contextually. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cystinuria presents with excess of
Choices:
A. Cysteine
B. Tyrosine
C. Glutamine
D. Valine
Answer: [/INST] Cysteine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is seen in which type of diabetes mellitus?
Choices:
A. Maturity onset DM
B. Type I DM
C. Type II DM
D. all of the above
Answer: [/INST] Type II DM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which investigation is not required in diagnosis of Achalasia?
Choices:
A. Esophageal manometry
B. Barium swallow
C. Anti-neuronal antibodies
D. Enterocylsis
Answer: [/INST] Enterocylsis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Global developmental delay', 'Generalized hypotonia', 'Failure to thrive', 'Metabolic acidosis', 'Hypoglycemia', 'Ketosis', 'Hyperammonemia', 'Vomiting', 'Respiratory distress', 'Increased serum lactate', 'Rhabdomyolysis', 'Lacticaciduria', 'Arrhythmia', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, ketosis, hyperammonemia, elevated lactate, and dicarboxylic acidemia** indicate a severe mitochondrial or fatty acid oxidation disorder. These findings suggest impaired energy metabolism, leading to toxic metabolite accumulation.  
2. **Rhabdomyolysis, arrhythmia, and lacticaciduria** point to muscle and cardiac involvement, aligning with the syndrome's hallmark features of recurrent rhabdomyolysis and cardiac complications.  
3. **Elevated acylcarnitine levels** reflect disrupted fatty acid β-oxidation, a key feature of this disorder.  
4. **Intellectual disability, seizures, and global developmental delay** correlate with neurodegeneration and encephalopathic crises caused by metabolic decompensation.  
5. **Vomiting, respiratory distress, and failure to thrive** are secondary to acute metabolic crises and chronic energy deficiency.  
6. The combination of **neurodegeneration, metabolic crises, and multi-organ involvement** (muscle, heart, CNS) uniquely matches this rare syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis bacteria are normally present in?
Choices:
A. Nasopharynx
B. Skin
C. Genitals
D. Lower G.I.T
Answer: [/INST] Nasopharynx </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin binds to which receptors in intestine:
Choices:
A. Sphingosine through A subunit
B. Sphingosine through B subunit
C. GM1 gangliosides through A subunit
D. GM1 gangliosides through B subunit
Answer: [/INST] GM1 gangliosides through B subunit </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chromosome involved in Myotonic Dystrophy is
Choices:
A. Chromosome 19
B. Chromosome 20
C. Chromosome 21
D. Chromosome 22
Answer: [/INST] Chromosome 19 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Intermittent dysphagia is caused by -a) Strictureb) Reflux esophagitisc) Achalasia cardiad) Pharyngeal diverticululame) Diffuse esophageal spasm
Choices:
A. ab
B. bc
C. de
D. bd
Answer: [/INST] de </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Recurrent urinary tract infections', 'Nephritis', 'Hematuria', 'Death in infancy', 'Cystinuria', 'Argininuria', 'Hyperlysinuria', 'Ornithinuria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cystinuria  
Reasoning:  
1. **Cystinuria, argininuria, hyperlysinuria, and ornithinuria** indicate a defect in renal tubular reabsorption of dibasic amino acids (cystine, ornithine, lysine, arginine), a hallmark of cystinuria.  
2. **Recurrent urinary tract infections (UTIs), nephritis, and hematuria** arise from cystine stone formation in the urinary tract, causing obstruction, inflammation, and secondary infections.  
3. **Death in infancy** suggests a severe phenotype, potentially due to early-onset renal failure or complications from recurrent UTIs and nephritis in untreated cases.  
4. The combined aminoacidurias align with cystinuria’s pathophysiology (defect in SLC3A1/SLC7A9 genes), differentiating it from isolated amino acid transport disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with known mutation in the 'Rb gene' is 'disease free' from Retinoblastoma. This patient is at highest risk of developing which of the following malignancies?
Choices:
A. Osteosarcoma
B. Pinealoblastoma
C. Chondrosarcoma
D. Renal cell carcinoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy and agenesis**: PMM2-CDG is associated with structural cerebellar abnormalities, including hypoplasia (often misinterpreted as agenesis on imaging) and progressive atrophy due to impaired glycosylation, critical for cerebellar development and maintenance.  
2. **Death in childhood**: Severe PMM2-CDG cases involve multi-organ failure (hepatic, cardiac), recurrent infections, and coagulopathies, leading to early mortality.  
3. **Neurological hallmark**: The cerebellum is highly sensitive to glycosylation defects, explaining both developmental (agenesis-like hypoplasia) and degenerative (atrophy) features.  
4. **Exclusion of mimics**: Pontocerebellar hypoplasia or spinocerebellar ataxias lack the systemic manifestations (e.g., endocrine dysfunction, inverted nipples) typical of PMM2-CDG.  
5. **Diagnostic confirmation**: Elevated serum transferrin isoforms (via isoelectric focusing) and *PMM2* gene sequencing would validate the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', '4-Hydroxyphenylpyruvic aciduria', 'Elevated urinary delta-aminolevulinic acid', 'Hypertyrosinemia', 'Death in childhood', 'Abnormal circulating phenylalanine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia I; hepatorenal tyrosinemia; HT-1/Tyrosinemia type 1/Tyrosinemia, type I  
Reasoning:  
1. **Hypertyrosinemia** directly indicates impaired tyrosine metabolism, a hallmark of tyrosinemia.  
2. **4-Hydroxyphenylpyruvic aciduria** arises from a block in tyrosine catabolism at fumarylacetoacetate hydrolase (FAH), causing upstream accumulation of toxic intermediates like 4-hydroxyphenylpyruvate (4-HPP).  
3. **Elevated urinary delta-aminolevulinic acid (ALA)** is due to inhibition of ALA dehydratase by succinylacetone, a toxic metabolite unique to Tyrosinemia I.  
4. **Abnormal circulating phenylalanine** may reflect secondary disruption of phenylalanine metabolism or assay interference from tyrosine metabolites.  
5. **Delayed speech/language development** aligns with neurotoxicity from succinylacetone and chronic liver/kidney dysfunction.  
6. **Death in childhood** correlates with untreated HT-1 progression to liver failure, renal Fanconi syndrome, or porphyria-like crises.  
The combination of hepatic, renal, and neurological involvement with specific biochemical markers confirms Tyrosinemia type I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common organism cultured from Acute Osteomyelitis is:
Choices:
A. Gonococcus.
B. Staphylococcus aureus.
C. Staphylococcus albicans.
D. Streptococci.
Answer: [/INST] Staphylococcus aureus. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Intellectual disability** aligns with untreated PKU, as elevated phenylalanine levels are neurotoxic, impairing brain development.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is not a direct symptom of the patient’s own PKU.  
4. **Early mortality** (infancy, childhood, adolescence) is atypical in modern managed PKU but reflects historical untreated cases, where toxic metabolite accumulation caused severe neurological decline, seizures, and organ failure.  
5. The absence of dietary management (low-phenylalanine diet) explains progression to lethal outcomes, emphasizing the critical role of newborn screening and early intervention in PKU.  

Note: The listed symptoms collectively describe a severe, untreated PKU presentation, historically common before widespread neonatal screening and dietary therapy. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Scar carcinoma of lung is seen most commonly following -a)  Tuberculosisb)  Irradiationc)  Infarctd)  Lung abscess
Choices:
A. abc
B. bc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the hand', 'Weight loss', 'Elevated hepatic transaminase', 'Rheumatoid factor positive', 'Increased circulating ferritin concentration', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Increased alpha-globulin', 'Limited wrist movement', 'Elevated circulating C-reactive protein concentration', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Arterial stenosis', 'Cryoglobulinemia', 'Skin erosion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed:  
The patient presents with cryoglobulinemia, a hallmark of this disease, alongside systemic inflammation (elevated CRP, ESR, ferritin). Rheumatoid factor positivity and complement system abnormalities suggest immune complex deposition, driving vasculitis. Skin erosions, dysesthesia, and arterial stenosis align with small-to-medium vessel inflammation. Elevated hepatic transaminases and alpha-globulins indicate liver involvement, common in cryoglobulinemia. Upper limb/neck pain, limited wrist movement, and hand abnormalities reflect joint and soft tissue damage from vasculitis or cryoglobulin precipitation. Familial mixed type implies a genetic predisposition to mixed cryoglobulin production (IgM-IgG complexes), corroborated by multisystemic features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Recurrent corneal erosions', 'Alacrima', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'Increased serum lactate', 'Gliosis', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Elevated circulating alpha-fetoprotein concentration', 'Prolonged neonatal jaundice', 'Abnormal auditory evoked potentials', 'Chalazion', 'Delayed myelination', 'Dilation of Virchow-Robin spaces', 'Small hand']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A defining feature of the syndrome, directly linked to impaired glycosylation affecting lacrimal gland function.  
2. **Hepatic fibrosis/elevated transaminases/prolonged jaundice**: Reflects liver dysfunction, a core component of the disorder due to defective protein deglycosylation in hepatocytes.  
3. **Seizures/EEG abnormality/hypotonia/global developmental delay/delayed myelination/gliosis**: Indicates severe neurological involvement, consistent with NGLY1 deficiency disrupting neuronal glycoprotein homeostasis.  
4. **Elevated alpha-fetoprotein**: Associated with hepatic injury and impaired glycosylation, common in congenital disorders of deglycosylation.  
5. **Intrauterine growth retardation/short foot/small hand**: Suggests congenital growth restriction, often seen in systemic metabolic disorders.  
6. **Recurrent corneal erosions/chalazion**: Secondary to alacrima-induced dry eye and ocular surface damage.  
7. **Increased serum lactate**: May indicate mitochondrial dysfunction, a known overlap in glycosylation disorders.  
8. **Abnormal auditory evoked potentials/dilation of Virchow-Robin spaces**: Reflects central nervous system abnormalities, including white matter changes.  
9. **Reduced tendon reflexes/constipation**: Autonomic or peripheral nerve involvement due to glycosylation defects.  
10. **Scoliosis**: Often secondary to neuromuscular hypotonia.  
The constellation of alacrima, liver disease, neurodevelopmental deficits, and multi-system involvement aligns pathognomonically with NGLY1-related congenital disorder of deglycosylation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Necrotizing granulomatous inguinal lymphadenopathy is caused by -a) Syphilisb) Granuloma inguinalec) Sarcoidosisd) Tuberculosis
Choices:
A. ad
B. c
C. ac
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is most commonly seen with
Choices:
A. Food with preservatives
B. Home canned food
C. Commercially canned food
D. Unpasteurized milk
Answer: [/INST] Home canned food </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are characteristic of Turner Syndrome EXCEPT:
Choices:
A. Webbing of Neck
B. Cubitus valgus
C. Umbilical Hernia
D. Coarctation of Aorta
Answer: [/INST] Umbilical Hernia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination is given at age of
Choices:
A. 10 weeks
B. 9 months
C. 14 weeks
D. 6 months
Answer: [/INST] 9 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most dangerous Osteogenesis Imperfecta (OI) in utero foetus
Choices:
A. Type 1 OI
B. Type 2 OI
C. Type 3 OI
D. Type 4 OI
Answer: [/INST] Type 3 OI </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis with normal glucose is seen in -
Choices:
A. TB
B. Cryptococcus
C. Coxsackie
D. Listeria
Answer: [/INST] Coxsackie </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine given to contact of measles case exces protective effect within-
Choices:
A. 1 day
B. 3 days
C. 7 days
D. 10 days
Answer: [/INST] 7 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient is diagnosed with HIV and Tuberculosis. How should ATT and c-A.R.T be staed?
Choices:
A. Sta ATT first
B. Sta cA first
C. Sta both simultaneously
D. Sta cA only
Answer: [/INST] Sta ATT first </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Hyperinsulinemia', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Thrombocytopenia', 'Abnormal bleeding', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hyperalbuminemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia, 4-Hydroxyphenylpyruvic aciduria, and Hyperphenylalaninemia**: These indicate a defect in tyrosine metabolism. Tyrosinemia type 1 (HT-1) results from fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine and its metabolites (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (marker of hepatic damage/regeneration), hyperammonemia (impaired urea cycle), hypoglycemia (reduced gluconeogenesis), and hypermethioninemia (secondary to liver failure) align with HT-1’s hepatotoxic effects.  
3. **Coagulopathy**: Prolonged partial thromboplastin time, thrombocytopenia, and abnormal bleeding stem from impaired hepatic synthesis of clotting factors and possible platelet dysfunction.  
4. **Renal and Systemic Toxicity**: Succinylacetone damages renal tubules and inhibits porphobilinogen synthase, explaining abnormal porphyrin levels.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood, and prenatal abnormalities reflect the severe, progressive nature of untreated HT-1.  
6. **Hyperinsulinemia**: May arise from stress-induced hypoglycemia or secondary metabolic dysregulation due to liver failure.  
7. **Elevated Alkaline Phosphatase**: Consistent with cholestatic liver injury, a common feature in HT-1.  

The constellation of liver failure, tyrosine pathway abnormalities, coagulopathy, and succinylacetone-mediated toxicity confirms Tyrosinemia type 1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis mostly affects
Choices:
A. Liver
B. Tounge
C. Colon
D. Hea
Answer: [/INST] Hea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Tremor', 'Death in infancy', 'Leukopenia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Gastroesophageal reflux', 'Pneumonia', 'Increased serum lactate', 'Hyperglycinemia', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Tachypnea', 'Increased blood urea nitrogen', 'Hypertyrosinemia', 'Hyperalaninemia', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperprolinemia', 'Difficulty running', 'Stomatitis', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Abnormalities**: Hyperammonemia, hyperglycinemia, and elevated serum lactate are hallmark features of PA. Propionyl-CoA carboxylase deficiency disrupts the urea cycle (causing hyperammonemia) and mitochondrial function (leading to lactic acidosis).  
2. **Amino Acid Derangements**: Hypertyrosinemia, hyperalaninemia, hyperprolinemia, and hypervalinemia occur due to secondary inhibition of amino acid metabolism by accumulated propionic acid metabolites.  
3. **Hematologic Issues**: Leukopenia and recurrent infections stem from bone marrow suppression, a known complication of PA.  
4. **Neurological Symptoms**: Intellectual disability, seizures, hypotonia, motor delays, and severe hearing impairment result from neurotoxic effects of metabolites (e.g., propionic acid) and energy deficiency.  
5. **Gastrointestinal and Acute Crises**: Vomiting, GER, and tachypnea align with metabolic decompensation episodes. Hyperammonemia and acidosis drive lethargy, drowsiness, and respiratory compensation.  
6. **Early Mortality**: Neonatal/childhood death is typical in severe PA due to metabolic crises or complications like pneumonia.  
7. **Carnitine Abnormalities**: Propionyl-CoA sequesters carnitine, causing secondary carnitine deficiency (abnormal circulating carnitine levels).  
8. **Hyperglycinemia**: Propionyl-CoA inhibits the glycine cleavage system, leading to elevated glycine despite PA not being a primary glycine disorder.  

Key Clinchers: Combined hyperammonemia, metabolic acidosis (elevated lactate), and multisystem involvement (neurologic, hematologic, GI) with early lethality strongly pinpoint PA. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pseudohypoparathyroidism is characterized by:
Choices:
A. Normal serum Ca++ and decreased serum PTH
B. Decreased serum Ca++ and decreased serum PTH
C. Decreased serum Ca++ and Increased serum PTH
D. Normal serum Ca++ and Increased serum PTH
Answer: [/INST] Decreased serum Ca++ and Increased serum PTH </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera is caused by?
Choices:
A. Vibrio cholera.01
B. Enterococcus
C. V. Parahemolyticus
D. E.coli
Answer: [/INST] Vibrio cholera.01 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism causes:
Choices:
A. Descending flaccid paralysis
B. Descending spastic paralysis
C. Ascending paralysis
D. Ascending spastic paralysis
Answer: [/INST] Descending flaccid paralysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Epidermolysis Bullosa simplex is because of defect in:
Choices:
A. Collagen 7
B. Keratin 5 and Keratin 14
C. Laminin
D. BP1 and BP2
Answer: [/INST] Keratin 5 and Keratin 14 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nephrocalcinosis', 'Epistaxis', 'Failure to thrive', 'Death in infancy', 'Pulmonic stenosis', 'Increased serum lactate', 'Hepatomegaly', 'Hypokalemia', 'Hypermagnesemia', 'Hypercholesterolemia', 'High serum calcitriol', 'Elevated circulating alkaline phosphatase concentration', 'Hyperalaninemia', 'Aminoaciduria', 'Increased serum iron', 'Severe short stature', 'Hypouricemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Fanconi-Bickel syndrome  
Reasoning:  
1. **Hepatomegaly** and **failure to thrive** are hallmark features of Fanconi-Bickel syndrome (FBS), caused by hepatic glycogen accumulation and metabolic disturbances.  
2. **Aminoaciduria** and **hypokalemia** indicate proximal renal tubular dysfunction (Fanconi syndrome), a core component of FBS.  
3. **Nephrocalcinosis** arises from chronic renal phosphate wasting and hypercalciuria, exacerbated by **high serum calcitriol** due to dysregulated vitamin D metabolism.  
4. **Severe short stature** and **hypercholesterolemia** reflect impaired glucose metabolism and malnutrition from defective GLUT2-mediated transport.  
5. **Hypouricemia** and **elevated serum lactate** align with proximal tubule dysfunction and glycolytic pathway disruptions.  
6. **Abnormal circulating aspartate family amino acids** and **hyperalaninemia** stem from systemic metabolic dysregulation.  
7. **Increased serum iron** and **hepatomegaly** correlate with hepatic dysfunction and glycogen overload.  
8. **Death in infancy/childhood/adolescence** reflects the severe, progressive nature of untreated FBS.  
9. Atypical features like **pulmonic stenosis** and **epistaxis** may represent comorbidities or secondary complications but do not exclude the diagnosis.  

The collective presentation of hepatorenal glycogen storage disease, Fanconi syndrome, and metabolic derangements confirms Fanconi-Bickel syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Protein implicated in Familial Amyloidosis is
Choices:
A. Serum amyloid A
B. b2-microglobulin
C. Amyloid b peptide
D. Transthyretin
Answer: [/INST] Transthyretin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following may be seen in Multiple Myeloma:
Choices:
A. Decreased Calcium
B. Sclerotic bone lesion
C. Bone deposition
D. Renal failure
Answer: [/INST] Renal failure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Aniridia is associated with -
Choices:
A. Retinoblastoma
B. Hepatoblastoma
C. Nephroblastoma
D. Medulloblastoma
Answer: [/INST] Nephroblastoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Brachycephaly', 'Strabismus', 'Proptosis', 'Shallow orbits', 'Precocious puberty', 'Single transverse palmar crease', 'Seizure', 'Global developmental delay', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Inverted nipples', 'Deep palmar crease', 'Cardiorespiratory arrest', 'Severe muscular hypotonia', 'Infantile muscular hypotonia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe Muscular Hypotonia (Infantile)**: A hallmark of TBCK syndrome, present from birth, aligning with the patient's severe and infantile hypotonia.  
2. **Global Developmental Delay**: Consistent with TBCK’s core phenotype of intellectual disability and psychomotor retardation.  
3. **Seizures/EEG Abnormalities**: Recurrent seizures (tonic-clonic) and abnormal EEG patterns are common due to neuronal dysfunction in TBCK-related disorders.  
4. **Characteristic Facies**:  
   - **Brachycephaly/Shallow Orbits**: Broad, short skull and structural orbital anomalies are typical dysmorphic features.  
   - **Proptosis/Strabismus**: Eye abnormalities linked to shallow orbits and craniofacial dysmorphism.  
5. **Limb Anomalies**:  
   - **Single Transverse Palmar Crease/Deep Palmar Crease**: Frequent in TBCK syndrome as part of connective tissue or developmental hand findings.  
   - **Overlapping Toe**: Minor skeletal anomalies are reported in this syndrome.  
6. **Inverted Nipples**: A noted dysmorphic feature in TBCK cases, supporting the diagnosis.  
7. **Cardiorespiratory Arrest**: Severe hypotonia and neurological instability in TBCK can lead to life-threatening events, especially during infancy.  
8. **Precocious Puberty**: While less common, endocrine dysregulation has been observed in some TBCK patients, potentially explaining this feature.  

The constellation of severe hypotonia, developmental delay, seizures, craniofacial/limb dysmorphism, and supporting features strongly aligns with TBCK syndrome, a disorder caused by biallelic TBCK mutations affecting mTOR signaling and neuronal survival. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperammonemia', 'Hyperglycinemia', 'Hyperalaninemia', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia; PA/Propionic acidemia/Propionic acidemia  
Reasoning:  
1. **Hyperammonemia**: Propionic acidemia disrupts the urea cycle due to accumulation of propionyl-CoA and its derivatives, impairing ammonia detoxification.  
2. **Hyperglycinemia**: Propionyl-CoA inhibits glycine cleavage enzyme activity, reducing glycine catabolism and elevating glycine levels.  
3. **Hyperalaninemia**: Secondary mitochondrial dysfunction and metabolic stress increase protein catabolism, releasing alanine as a byproduct.  
4. **Decreased plasma free carnitine**: Excess propionyl-CoA conjugates with carnitine (forming propionylcarnitine), depleting free carnitine reserves.  
5. **Pathogenic mechanism**: Biallelic mutations in *PCCA* or *PCCB* genes cause propionyl-CoA carboxylase deficiency, blocking valine, isoleucine, methionine, and odd-chain fatty acid metabolism. This results in toxic metabolite accumulation and secondary biochemical disturbances. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spasticity', 'Dysarthria', 'Gait ataxia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Spasticity**: A hallmark of hereditary spastic paraplegias (HSPs), caused by progressive degeneration of corticospinal tracts. SPG76 specifically involves mutations in the *CAPN1* gene, leading to lower limb spasticity.  
2. **Dysarthria**: Indicates brainstem or cerebellar involvement, atypical in ""pure"" HSPs but seen in ""complex"" HSP subtypes like SPG76, where neurodegeneration extends beyond the spinal cord.  
3. **Gait ataxia**: Suggests cerebellar dysfunction, aligning with SPG76's reported phenotype of combined pyramidal (spasticity) and cerebellar (ataxia) features.  
4. **Exclusion of mimics**: Spinocerebellar ataxias (SCAs) were considered, but the triad of spasticity, ataxia, and dysarthria with autosomal recessive inheritance strongly favors SPG76. Genetic testing for *CAPN1* variants would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma characteristically may develop in some cases of
Choices:
A. Osteopetrosis
B. Osteogenesis irnperfecta
C. Acromegaly
D. Osteitis deformans
Answer: [/INST] Osteitis deformans </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Myasthenia Gravis are true, except:
Choices:
A. Anti-AChR antibodies are the most common antibodies in generalized myasthenia gravis
B. The pathogenic Anti-AChR antibodies are IgG antibodies
C. Anti-MuSK antibodies are directed against muscarinic ACh receptors
D. The major defect is a decrease in the number of available ACh receptors
Answer: [/INST] Anti-MuSK antibodies are directed against muscarinic ACh receptors </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Retinoblastoma all are true EXCEPT:
Choices:
A. 13q4p mutation
B. Autosomal dominant
C. 25% Bilateral
D. 40% Heritable forms
Answer: [/INST] 25% Bilateral </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true about Chronic Lymphocytic Leukemia, Except:
Choices:
A. Diagnosed on routine blood tests
B. Leukocytosis is prominent
C. Can present as acute leukemia
D. T lymphocyte CLL is more common
Answer: [/INST] T lymphocyte CLL is more common </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism causes
Choices:
A. Descending flaccid paralysis
B. Descending spastic paralysis
C. Ascending paralysis
D. Ascending spastic paralysis
Answer: [/INST] Descending flaccid paralysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating acylcarnitine concentration', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** and **elevated circulating acylcarnitine concentration** directly indicate a defect in lysine, hydroxylysine, and tryptophan metabolism, characteristic of GA-I due to **glutaryl-CoA dehydrogenase deficiency**.  
2. **Motor delay** and **generalized hypotonia** arise from toxic accumulation of glutaric acid and 3-hydroxyglutaric acid, causing basal ganglia damage and impaired motor neuron function.  
3. **Athetosis** and **dyskinesia** reflect striatal injury, a hallmark of acute encephalopathic crises in GA-I, often triggered by metabolic stressors (e.g., infections).  
4. **Death in infancy** aligns with untreated GA-I, where metabolic crises lead to irreversible neurological damage, cerebral edema, or secondary complications (e.g., rhabdomyolysis).  
5. Elevated acylcarnitine (C5DC) on newborn screening supports the diagnosis, as glutaric acid conjugates with carnitine, depleting free carnitine and increasing acylated forms.  
6. Exclusion of GA-II (MADD): No hypoglycemia, cardiomyopathy, or organic acid profile suggestive of multiple dehydrogenase deficiencies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Enzyme deficiency in Alkaptonuria is
Choices:
A. Tyrosine hydroxylase
B. Homogentisate acid oxidase
C. Phenyl alanine hydroxylase
D. Cystathione synthase
Answer: [/INST] Homogentisate acid oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 37 year old primi Rh negative patient is very concerned above her pregnancy at this age. Her pregnancy is 16 weeks and she is HIV negative, hepatitis B surface Ag neg, Rubella non immune and has no complain.Her triple test report is normal but still due to her age she insists on getting an amniocentesis done.Which of the following is the next best step in management:
Choices:
A. Advise against amniocentesis as it will increase the risk of isoimmunisation
B. Follow Rh titres carefully and give Anti D if evidence of isoimmunisation is present
C. Give Anti D at 28 weeks of pregnancy and after delivery if baby is Rh neg
D. Give Anti D prior to her amniocentesis
Answer: [/INST] Give Anti D prior to her amniocentesis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly explains elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine (due to blocked PAH activity), transient tyrosinemia can occur in neonates with immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome, not the infant’s own PKU, causes congenital anomalies (e.g., microcephaly, heart defects) if the mother had untreated hyperphenylalaninemia during pregnancy. This aligns with prenatal developmental issues in the infant.  
4. **Neonatal death/Death in infancy**: Untreated severe hyperphenylalaninemia can cause acute metabolic crises, seizures, and irreversible neurological damage, potentially leading to early mortality in extreme cases.  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and maternal-fetal transmission of metabolic toxicity strongly supports PKU as the diagnosis, despite atypical tyrosinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a type of chronic Osteomyelitis:
Choices:
A. Garre's Osteomyelitis.
B. Chronic suppurative Osteomyelitis.
C. Condensing osteitis.
D. None of the above.
Answer: [/INST] None of the above. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine levels during pregnancy cause fetal complications (e.g., microcephaly, congenital heart defects).  
3. **Death in infancy/childhood and neonatal death** may occur in untreated severe PKU due to metabolic derangements, neurological deterioration, or secondary infections.  
4. **Hypertyrosinemia** is atypical in PKU (tyrosine levels are usually normal/low). This could indicate a concurrent metabolic disorder, laboratory error, or misreported data, but does not exclude PKU given the strong evidence from other symptoms.  
5. The combination of hyperphenylalaninemia with early mortality and developmental abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** and **recurrent viral infections** suggest a **tetrahydrobiopterin (BH4) deficiency** variant of PKU. BH4 is a cofactor for PAH and tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Immunodeficiency** (recurrent infections) arises from impaired nitric oxide synthesis and neurotransmitter production due to BH4 dependency in immune and neurological pathways.  
4. **Early mortality** (infancy/childhood/adolescence) reflects severe metabolic derangements, neurological deterioration, and susceptibility to infections in untreated BH4-deficient PKU, distinguishing it from classic PAH-deficient PKU.  

This diagnosis aligns with atypical/malignant PKU secondary to BH4 deficiency, explaining the full symptom spectrum. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A known case of Lepromatous Leprosy was initiated on treatment.He developed new painful,erythematous papules over the body along with fever and lymphadenopathy. What is the likely diagnosis?
Choices:
A. Type I lepra reaction
B. Type II lepra reaction
C. Fernandez reaction
D. Mitsuda response
Answer: [/INST] Type II lepra reaction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strain used in Mumps vaccine
Choices:
A. Oka
B. Jeryl Lynn
C. Danish 1331
D. Edmonston Zagreb
Answer: [/INST] Jeryl Lynn </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: CHARGE Syndrome includes?
Choices:
A. Choanal atresia
B. Coloboma of eye
C. Ear anomalies
D. All of above
Answer: [/INST] All of above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Thromboembolism', 'Reduced antithrombin III activity', 'Death in childhood', 'Lipodystrophy', 'Death in adolescence', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Neurological involvement**: Ataxia, cerebellar atrophy/agenesis, motor delay, and intellectual disability align with PMM2-CDG’s hallmark cerebellar and developmental defects due to impaired glycosylation of neural proteins.  
2. **Hepatic manifestations**: Cirrhosis and hepatic fibrosis are consistent with multisystemic involvement, though liver disease is typically milder compared to other CDG subtypes.  
3. **Coagulopathy**: Reduced antithrombin III activity (a glycoprotein) explains thromboembolism, a recognized feature of glycosylation defects.  
4. **Early mortality**: Death in infancy/childhood/adolescence reflects severe phenotypic variability, with fatal outcomes in critical organ dysfunction.  
5. **Hypotonia and strabismus**: Common early signs due to neuromuscular and cranial nerve glycosylation deficits.  
6. **Lipodystrophy**: Rarely reported but plausible in PMM2-CDG, potentially linked to metabolic dysregulation from glycosylation errors.  
7. **Cerebellar agenesis**: Represents an extreme structural anomaly in severe cases, overlapping with cerebellar atrophy spectrum.  

PMM2-CDG is confirmed by genetic testing for *PMM2* mutations and abnormal transferrin glycosylation patterns. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may arise secondary to liver dysfunction or metabolic decompensation in severe untreated cases, though this is rare.  
3. **Abnormality of prenatal development/birth** aligns with maternal PKU syndrome if the mother had uncontrolled hyperphenylalaninemia during pregnancy, causing teratogenic effects (e.g., microcephaly, cardiac defects) in the fetus.  
4. **Neonatal death/Death in infancy** reflects untreated PKU severity, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and metabolic instability, often fatal without early dietary intervention.  
5. While PKU typically presents with **low tyrosine**, confounding factors (e.g., concurrent liver impairment, transient tyrosinemia of the newborn, or laboratory variability) may explain this anomaly. The core diagnostic marker remains hyperphenylalaninemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Increased susceptibility to fractures', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark symptom of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration** occurs because PAH converts phenylalanine to tyrosine; its deficiency reduces tyrosine synthesis, explaining low or dysregulated tyrosine levels.  
3. **Early mortality** (infancy, childhood, adolescence, etc.) aligns with untreated/severe PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Increased susceptibility to fractures** may arise secondary to chronic metabolic derangements, poor bone mineralization, or mobility issues from neurological complications.  
5. Neonatal death is atypical in classical PKU but could indicate rare malignant variants or delayed diagnosis, exacerbating metabolic crises.  

While fractures are not a primary feature of PKU, they may reflect systemic complications of prolonged untreated disease. The combination of hyperphenylalaninemia and tyrosine abnormalities strongly prioritizes PKU over other metabolic disorders (e.g., tyrosinemia). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the least common feature of Multiple Myeloma:
Choices:
A. Bone pain
B. Normocytic Normochromic Anemia
C. Susceptibility to bacterial infection
D. Hyperviscosity syndrome
Answer: [/INST] Hyperviscosity syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vomiting', 'Abdominal pain', 'Death in childhood', 'Recurrent viral infections']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Vomiting and abdominal pain**: Hallmark symptoms of acute porphyria attacks due to autonomic neuropathy and visceral involvement.  
2. **Death in childhood**: Uncommon in AIP (typically adult-onset), but severe cases with untreated neurovisceral crises (e.g., respiratory failure, arrhythmias) could lead to early mortality.  
3. **Recurrent viral infections**: Not classically linked to AIP. May suggest a secondary immunodeficiency or unrelated comorbidity, as porphyria does not directly impair antiviral immunity.  

Disease: Porphyria (General)  
Reasoning:  
1. **Recurrent viral infections**: Could align with congenital erythropoietic porphyria (CEP), a rare subtype causing chronic hemolysis and splenic dysfunction, increasing infection risk.  
2. **Death in childhood**: Severe porphyrias like CEP or ALA dehydratase deficiency porphyria (ADP) present early with multiorgan failure, photosensitivity, and anemia, potentially leading to childhood mortality.  
3. **Abdominal pain/vomiting**: Common to all acute hepatic porphyrias (e.g., AIP, VP, HCP) but less prominent in non-hepatic subtypes like CEP.  

**Conclusion**: Acute intermittent porphyria explains abdominal pain/vomiting but poorly aligns with recurrent infections or early death. A broader porphyria diagnosis (e.g., CEP or ADP) better accounts for childhood severity and infections but requires biochemical/histopathological confirmation (e.g., elevated porphyrins, enzyme assays). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: According to Mc Keown's theory, reduction in moality from Tuberculosis was a consequence of:
Choices:
A. Increased awareness & knowledge
B. Immunization
C. Introduction of Drug Treatment
D. Social and Environmental Factors
Answer: [/INST] Social and Environmental Factors </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Brucellosis, all of these are true except-
Choices:
A. Man to man transmission
B. A zoonosis
C. Blood cultures used in diagnosis
D. B melitensis is the most common cause
Answer: [/INST] Man to man transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Ventricular septal defect', 'Abnormal vertebral morphology', 'Stomatitis', 'Regional abnormality of skin', 'Gangrene']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Seizures**: BTDD disrupts biotin recycling, impairing carboxylase enzymes critical for energy production and neurotransmitter synthesis, leading to metabolic acidosis and neurological manifestations like seizures.  
2. **Generalized hypotonia**: Biotin-dependent carboxylases are essential for mitochondrial metabolism; deficiency causes muscle weakness and hypotonia due to impaired energy metabolism.  
3. **Growth delay**: Chronic metabolic acidosis and malnutrition from defective fatty acid, glucose, and amino acid metabolism result in failure to thrive.  
4. **Death in infancy**: Untreated BTDD causes progressive metabolic crises, irreversible neurological damage, and multi-organ failure, often fatal in early life.  
5. **Ventricular septal defect (VSD)**: Though not a primary feature, severe metabolic stress in BTDD may exacerbate congenital cardiac defects or reflect secondary mitochondrial dysfunction.  
6. **Abnormal vertebral morphology**: Rarely reported in BTDD; may arise from prolonged metabolic disruption affecting skeletal development.  
7. **Stomatitis & regional skin abnormality**: Biotin deficiency leads to dermatitis, mucosal inflammation (e.g., stomatitis), and periorofacial rashes due to impaired keratinocyte function.  
8. **Gangrene**: Severe metabolic acidosis and immunodeficiency in advanced BTDD predispose to tissue necrosis and gangrene.  

**Key confirmatory features**: Neurological symptoms (seizures, hypotonia), mucocutaneous findings (stomatitis, skin rash), and rapid progression without biotin supplementation align with BTDD. Early biotin therapy reverses symptoms, underscoring the urgency of diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Management of a newborn when Mother has active Tuberculosis & is taking ATT -
Choices:
A. BCG + Rifampicin + INH + Breast Feeding
B. BCG + Isolation of baby
C. BCG + INH for 6 week + Breast Feeding
D. BCG + INH + withhold Breast Feeding
Answer: [/INST] BCG + INH for 6 week + Breast Feeding </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Growth delay', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated Branched-Chain Amino Acids (BCAAs)**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate impaired metabolism of BCAAs (valine, leucine, isoleucine), a hallmark of MSUD due to deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic Acidosis**: Accumulation of toxic keto acids (from BCAAs) disrupts acid-base balance.  
3. **Hyperammonemia**: Secondary to metabolic decompensation, as BCAA derivatives interfere with urea cycle function.  
4. **Neurological Symptoms (Seizures, Lethargy, Drowsiness)**: Caused by neurotoxicity from elevated BCAAs and their metabolites.  
5. **Elevated Urinary Carboxylic Acids**: Reflects urinary excretion of branched-chain keto acids (e.g., α-ketoisocaproate, α-keto-β-methylvalerate), pathognomonic for MSUD.  
6. **Early Severe Presentation (Growth Delay, Feeding Difficulties, Death in Infancy)**: Consistent with classic MSUD, which manifests neonatally without treatment.  
7. **Severe Hearing Impairment**: Uncommon but reported in severe metabolic crises due to multisystem toxicity.  
8. **Sleep Disturbances**: Linked to neurological dysfunction from metabolic derangements.  

MSUD is confirmed by biochemical findings (BCAA elevation, urinary keto acids) and clinical features. The absence of maple syrup odor in the description does not exclude the diagnosis, as odor may not always be noted or reported. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy is made non infectious by Rifampicin in:
Choices:
A. 1 week
B. 2 weeks
C. 3 weeks
D. 4 weeks
Answer: [/INST] 3 weeks </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Hyperglycinuria', 'Hyperglutaminemia', 'Argininuria', 'Neonatal death', 'Abnormal circulating arginine concentration', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
Reasoning:  
1. **Hyperammonemia** and **neonatal death**: Core features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS1) deficiency**, impairing ammonia detoxification.  
2. **Elevated plasma citrulline**: Pathognomonic for citrullinemia type I due to citrulline accumulation from ASS1 dysfunction.  
3. **Metabolic acidosis**: Secondary to organic acid accumulation from disrupted urea cycle and alternative nitrogen excretion pathways.  
4. **Hyperglycinuria/Hyperglutaminemia/Argininuria**: Amino acid transport disturbances caused by metabolic stress and renal tubular dysfunction in UCDs.  
5. **Abnormal circulating arginine**: Reduced arginine synthesis (from ASS1 deficiency) and compensatory mechanisms.  
6. **Death in infancy**: Severe neonatal-onset citrullinemia type I often leads to rapid deterioration without early intervention.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
- **Exclusion of type II (SLC25A13 mutation)**: Type II typically presents later (adolescence/adulthood) with episodic hyperammonemia, absent neonatal death, and normal/mildly elevated citrulline.  
- **Biochemical triad**: Hyperammonemia + hypercitrullinemia + metabolic acidosis confirms type I.  
- **Genetic confirmation**: ASS1 gene mutations definitively diagnose classic citrullinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is false regarding Gastroschisis & omphalocele:
Choices:
A. Intestinal obstruction is common in gastroschisis
B. Gastroschisis is associated with multiple anamolies
C. Umbilical cord is attached in normal position in gastroschisis
D. Liver is the content of omphalocele
Answer: [/INST] Gastroschisis is associated with multiple anamolies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Period of infectivity for Measles is:-
Choices:
A. 2 days before to 5 days after appearance of rash
B. 1 day before to 1 day after appearance of rash
C. 4 days before to 5 days after appearance of rash
D. Lifelong
Answer: [/INST] 4 days before to 5 days after appearance of rash </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diagnosis of X linked Agammaglobulinemia should be suspected if:
Choices:
A. Female sex
B. Absent tonsils and no palpable lymph nodes on physical examination
C. High isohemagglutinins titers
D. Low CD3
Answer: [/INST] Absent tonsils and no palpable lymph nodes on physical examination </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In context with Filariasis, all are true except:
Choices:
A. Definitive host is man
B. Worm colonize the lymphatic system
C. Most common causative agent is W. bancrofti
D. Transmitted by Aedes aegypti mosquito
Answer: [/INST] Transmitted by Aedes aegypti mosquito </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acromegaly results due to excessive release of:
Choices:
A. Thyroxine
B. Growth hormone
C. Insulin
D. Glucagon
Answer: [/INST] Growth hormone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Micrognathia', ""Widow's peak"", 'Posteriorly rotated ears', 'Hearing impairment', 'Low-set, posteriorly rotated ears', 'Sensorineural hearing impairment', 'Bulbous nose', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Motor delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Incoordination', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Attention deficit hyperactivity disorder', 'Broad eyebrow', 'Abnormality of fontanelles', 'Feeding difficulties', 'Head-banging', 'Nail-biting', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**:  
   - Global developmental delay, motor delay, absent speech, and hypotonia align with central neurodevelopmental impairments.  
   - Seizures, hyperactivity, ADHD, and atypical behavior (e.g., head-banging) further support neurological dysfunction.  

2. **Ocular Anomalies**:  
   - Structural eye defects (coloboma, microphthalmia, Peters anomaly, optic atrophy) are hallmark features of NEDBEH.  
   - Additional findings (blepharophimosis, downslanted palpebral fissures, deeply set eyes) reinforce craniofacial involvement.  

3. **Cardiac Defects**:  
   - Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" criterion in NEDBEH.  

4. **Craniofacial Dysmorphism**:  
   - Microcephaly/macrocephaly (variable expressivity), frontal bossing, narrow mouth, high palate, micrognathia, and cleft lip are consistent with syndromic facial features.  

5. **Supportive Systemic Features**:  
   - Musculoskeletal anomalies (syndactyly, scoliosis, hip dysplasia) and growth abnormalities (intrauterine growth retardation, short/tall stature) reflect broad developmental disruption.  
   - Gastrointestinal issues (pyloric stenosis, annular pancreas) and renal cysts may represent variable systemic involvement.  

6. **Genetic Overlap**:  
   - Overlapping features (sensorineural hearing loss, café-au-lait spots) suggest genetic heterogeneity but do not exclude NEDBEH, which encompasses phenotypic variability.  

**Conclusion**: The constellation of neurodevelopmental delays, structural eye/heart defects, and multisystem anomalies strongly aligns with NEDBEH, a genetically heterogeneous disorder often linked to de novo variants in genes like *BRPF1* or *UBR1*. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Intellectual disability', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Encephalopathy', 'Failure to thrive', 'Obesity', 'Death in infancy', 'Leukopenia', 'Leukocytosis', 'Hyperammonemia', 'Pyloric stenosis', 'Respiratory insufficiency', 'Hyperglycinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Hyperammonemia, hyperglycinemia, and abnormal circulating amino acids (aspartate family, alanine) align with PA's defect in propionyl-CoA carboxylase, disrupting the urea cycle and glycine metabolism.  
2. **Neurological Symptoms**: Intellectual disability, seizures, encephalopathy, and hypotonia result from toxic metabolite (propionic acid) accumulation and energy deficiency in the brain.  
3. **Gastrointestinal/Feeding Issues**: Failure to thrive, feeding difficulties, and pyloric stenosis correlate with PA-associated metabolic crises and protein intolerance.  
4. **Carnitine Abnormalities**: Abnormal carnitine levels occur due to secondary carnitine depletion from detoxification of propionyl-CoA.  
5. **Infantile/Childhood Mortality**: Neonatal death, death in infancy/childhood/adolescence reflect PA's severity, often triggered by catabolic states (e.g., infections, fasting).  
6. **Infection/Sepsis Risk**: Leukopenia/leukocytosis and sepsis susceptibility stem from metabolic-induced immunosuppression and mitochondrial dysfunction.  
7. **Congenital Anomalies**: Cryptorchidism/hypospadias may arise from prenatal metabolic stress or mitochondrial dysfunction affecting development.  
8. **Respiratory Insufficiency**: Linked to metabolic acidosis or secondary complications (e.g., cardiomyopathy).  
9. **Obesity Paradox**: May result from chronic dietary management with high-calorie, low-protein regimens.  

**Conclusion**: The constellation of metabolic derangements, neurological deficits, and early mortality strongly supports propionic acidemia, confirmed by biochemical markers (hyperammonemia, hyperglycinemia, carnitine/amino acid abnormalities). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: False statement regarding Complex Regional Pain Syndrome (CRPS) is?
Choices:
A. Type 1 CRPS occurs following a nerve injury
B. Type 1 CRPS is also called as Reflex Sympathetic Dystrophy
C. It occurs due to adrenergic sensitivity of afferent nociceptors
D. CRPS Type 1 resolves with symptomatic treatment
Answer: [/INST] Type 1 CRPS occurs following a nerve injury </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are features of Abetalipoproteinemia, EXCEPT:
Choices:
A. Plasma levels of cholesterol and triglyceride are extremely low
B. Manifest in early childhood with diarrhea
C. Progressive pigmented retinopathy seen
D. Neurological manifestation as ataxia in first decade
Answer: [/INST] Neurological manifestation as ataxia in first decade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of female genital tract is commonest is which age group :
Choices:
A. Below 10 yrs
B. 10 - 20 yrs
C. 20 - 30 yrs
D. Above 60 yrs
Answer: [/INST] 20 - 30 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** initially seems conflicting, as PAH deficiency typically reduces tyrosine levels. However, severe phenylalanine elevation may disrupt tyrosine metabolism or reflect a secondary metabolic disturbance.  
3. **Neonatal death/Death in infancy/childhood** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
4. **Abnormality of prenatal development** may stem from maternal PKU syndrome (untreated PKU in the mother during pregnancy), causing congenital anomalies in the fetus, though the patient’s own PKU manifests postnatally.  
5. The absence of early dietary intervention (low-phenylalanine diet) explains the fatal outcomes, emphasizing the critical need for newborn screening in PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 67-year-old man is hospitalized after several days of fever and increasing shortness of breath. Respiratory viral panel returns positive for influenza A and the patient is started on a standard five day course of oseltamivir. Despite therapy, his shortness of breath continues to worsen and his oxygen saturation decreases to the point where ICU transfer and intubation are required. Chest radiograph shows bilateral infiltrates. Clinical criteria are consistent with development of Acute Respiratory Distress Syndrome (ARDS). After several weeks of supportive therapy, the patient improves with lung function returning to near normal. Which of the following processes is involved in the regeneration of alveolar lining after damage to alveoli occurs?
Choices:
A. Squamous cell proliferation.
B. Sweeping of debris out of the alveoli by ciliated cells.
C. Excess mucus production by goblet cells.
D. Proliferation of surfactant-secreting cells.
Answer: [/INST] Proliferation of surfactant-secreting cells. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, leading to **ataxia** and **motor delay** due to impaired cerebellar function.  
2. **Intellectual disability**: Common in PMM2-CDG due to global neurodevelopmental deficits from abnormal glycosylation.  
3. **Strabismus**: Caused by cranial nerve dysfunction or cerebellar-related oculomotor coordination issues.  
4. **Thromboembolism**: Linked to hypoglycosylation of coagulation factors (e.g., antithrombin III deficiency), increasing clotting risk.  
5. **Early mortality (infancy/childhood)**: Severe PMM2-CDG cases involve multi-organ failure, infections, or thromboembolic events.  
6. **Obesity**: Less typical but possible due to endocrine dysregulation or hypothyroidism, which may occur in CDG.  
7. **Supporting evidence**: PMM2-CDG is the most prevalent CDG subtype, characterized by cerebellar abnormalities, neurodevelopmental deficits, and systemic complications. Isoelectric focusing of serum transferrin (abnormal glycosylation pattern) confirms diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Generalized hypotonia', 'Death in infancy', 'Cerebral cortical atrophy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Cerebral cortical atrophy** and **microcephaly** reflect neurodegenerative changes from neurotoxic metabolite accumulation, particularly affecting the basal ganglia (evidenced by **athetosis**) and cortical neurons.  
3. **Generalized hypotonia** aligns with early neurological dysfunction in GA-I, often preceding acute metabolic crises triggered by catabolic stressors.  
4. **Decreased plasma free carnitine** and **abnormal acetylcarnitine** levels occur due to secondary carnitine depletion from conjugating glutaric acid, a hallmark of GA-I.  
5. **Death in infancy/adolescence** correlates with untreated or severe cases, as metabolic crises cause irreversible brain damage, while neonatal death is atypical but possible in profound enzyme deficiency.  
6. The symptom constellation (neurodegeneration, organic aciduria, carnitine derangements) is diagnostic for GA-I, distinguishing it from other organic acidemias. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella is caused by
Choices:
A. Ohomyxovirus
B. Paramyxovirus
C. Toga virus
D. Arbovirus group B
Answer: [/INST] Toga virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is associated frequently with
Choices:
A. Metabolic acidosis
B. Metabolic alkalosis
C. Respiratory acidosis
D. Respiratory alkalosis
Answer: [/INST] Metabolic alkalosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is associated with?
Choices:
A. Decreased NREM sleep
B. Hypnagogic hallucination
C. Late age of onset
D. Normal sleep architecture
Answer: [/INST] Hypnagogic hallucination </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Neonatal death/Death in infancy**: Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, seizures, and failure to thrive. In rare, severe PAH-deficient cases (e.g., ""malignant"" PKU), rapid metabolic deterioration may result in early mortality if undiagnosed.  
3. **Abnormality of prenatal development**: While PKU itself does not directly cause prenatal structural anomalies, *maternal PKU* (untreated hyperphenylalaninemia during pregnancy) can induce fetal teratogenicity (e.g., microcephaly, congenital heart defects). This suggests the patient’s prenatal abnormalities may stem from maternal PKU exposure, compounded by the infant’s own inherited PAH mutation.  
4. **Diagnostic confirmation**: Newborn screening detects hyperphenylalaninemia, and genetic testing identifies PAH mutations. Early dietary intervention (phenylalanine-restricted diet) prevents complications, underscoring the critical link between untreated PKU and the described outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial relapse is seen with which species of Plasmodium?
Choices:
A. P. Falciparum
B. P. Malariae
C. P. Knowlesi
D. P. Ovale
Answer: [/INST] P. Ovale </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true regarding Typhoid in children :
Choices:
A. Leukochyosis is characteristic
B. Encephalitis is common
C. Mild splenomegaly is usual
D. Urine culture is positive in 4 to 6 days
Answer: [/INST] Mild splenomegaly is usual </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Epidural anaesthesia decrease risk of – a) Headacheb) Hypotensionc) Meningitisd) Arachnoiditis
Choices:
A. abc
B. ad
C. bc
D. acd
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Hyperactivity', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Difficulty walking', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency (SSADHD)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: A hallmark of SSADHD due to accumulation of γ-hydroxybutyric acid (GHB), a carboxylic acid, in urine.  
2. **Neurological symptoms**:  
   - **Delayed speech/language development** and **hyperactivity**: Linked to GABA metabolism disruption, affecting neurodevelopment.  
   - **Seizures**: Caused by GHB-mediated excitotoxicity and GABA imbalance.  
   - **Generalized hypotonia**: Reflects impaired motor neuron function from GABAergic dysfunction.  
3. **Motor deficits (walking, stairs, running)**: Secondary to hypotonia, developmental delay, and potential cerebellar involvement.  
4. **Early mortality (infancy/childhood)**: Rare but reported in severe cases due to metabolic crises, refractory seizures, or complications.  
**Conclusion**: Symptom constellation aligns with SSADHD, confirmed by elevated urinary GHB (carboxylic acid). Early death, though atypical, may occur in severe phenotypes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: According to National Leprosy Elimination Programme, elimination of leprosy is defined as prevalence of Leprosy less than or equal to______.
Choices:
A. 1 per 1000 population
B. 1 per 10000 population
C. 1 per 1,00,000 population
D. 2 per 10000 population
Answer: [/INST] 1 per 10000 population </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella vaccination is contraindicated in all except -
Choices:
A. A patient on immunosuppressant
B. Girl with Leukemia
C. Girls between 11-14 years
D. Pregnancy
Answer: [/INST] Girls between 11-14 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Spasticity', 'Motor delay', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: The presence of elevated phenylalanine levels directly indicates a defect in phenylalanine metabolism, the hallmark of PKU.  
2. **Neurological symptoms (intellectual disability, spasticity, motor/speech delay)**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and myelination, leading to developmental delays and neurological damage.  
3. **Early mortality (neonatal/infant/childhood death)**: Severe untreated PKU can result in progressive neurological deterioration, seizures, and susceptibility to infections, contributing to early death.  
4. **Prenatal developmental abnormalities**: While PKU itself does not cause prenatal structural defects, maternal PKU (untreated during pregnancy) can lead to congenital anomalies. The listed symptom may reflect this context or overlap with complications from metabolic instability post-birth.  
5. **Exclusion of alternatives**: Symptoms align with PKU’s pathophysiology; no features suggest other metabolic disorders (e.g., maple syrup urine disease) or syndromes with overlapping symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning: The primary symptom of hyperphenylalaninemia strongly indicates PKU, caused by phenylalanine hydroxylase (PAH) deficiency, impairing phenylalanine-to-tyrosine conversion. Hypertyrosinemia is atypical in classic PKU but may arise from secondary mechanisms, such as excessive dietary tyrosine supplementation or competitive inhibition of tyrosine metabolism by elevated phenylalanine. Death in childhood aligns with untreated PKU, where toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure. This triad of symptoms suggests a severe PKU phenotype with complications driving atypical tyrosine elevation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pierre Robin Sequence includes
Choices:
A. Glossoptosis
B. Airway obstructions
C. Cleft lip
D. Micrognathia
Answer: [/INST] Glossoptosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is due to abnormality in -
Choices:
A. Hypothalamus
B. Neocortex
C. Cerebellum
D. Medullaoblongata
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are complication of Typhoid ulcer except ?
Choices:
A. Perforation
B. Stricture
C. Haemorrhage
D. Sepsis
Answer: [/INST] Stricture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hepatitis D virus (delta agent) is a defective virus that can replicate only in cells already infected with which of the following viruses?
Choices:
A. Hepatitis A virus
B. Epstein-Barr virus
C. Hepatitis G virus
D. Hepatitis B virus
Answer: [/INST] Hepatitis B virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bacillus Anthrax is:
Choices:
A. Gram positive cocci in cluster
B. Gram positive rods with square ends
C. Gram positive bacili with spherical ends
D. Gram negative cocci in cluster
Answer: [/INST] Gram positive rods with square ends </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seborrheic dermatitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Seborrheic dermatitis**: A cutaneous manifestation of metabolic imbalance, commonly seen in untreated PKU due to disrupted amino acid metabolism affecting skin integrity.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has untreated PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU results in severe neurological deterioration, seizures, and organ damage, often leading to early mortality without dietary intervention.  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise secondary to metabolic dysregulation or overlapping conditions (e.g., BH4 deficiency), though PKU typically reduces tyrosine levels due to impaired PAH-mediated conversion of phenylalanine.  

The combination of hyperphenylalaninemia with systemic complications aligns with severe, untreated PKU. Early diagnosis via newborn screening and strict dietary management are critical to prevent these outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is NOT a complication of Congenital Rubella Syndrome (CRS)?
Choices:
A. Retinopathy
B. Spontaneous aboion
C. Cardiac abnormalities
D. Macrocephaly
Answer: [/INST] Macrocephaly </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Cardiac arrest', 'Glutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Death in infancy** aligns with GA-I’s severe early-onset presentation, where metabolic crises (triggered by catabolic stress) lead to acute encephalopathy, striatal necrosis, and irreversible neurological damage, often fatal without prompt intervention.  
3. **Cardiac arrest** is atypical in GA-I but may occur secondary to severe metabolic acidosis or electrolyte imbalances during crises, disrupting cardiac function.  
4. The triad of symptoms suggests undiagnosed/untreated GA-I, where delayed management allows toxic metabolite buildup (glutaric acid, 3-hydroxyglutaric acid), causing multisystem failure.  
5. Differential exclusion: Cardiac arrest more commonly links to fatty oxidation disorders (e.g., GA-II), but glutaric aciduria and striatal pathology prioritize GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis -a) Angio-invasionb) Lymph invasionc) Septate hyphaed) Long term deferoxamine therapy is predisposing factore) It may lead to blindness
Choices:
A. acd
B. ade
C. abd
D. ad
Answer: [/INST] ade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diagnostic of Rabies -
Choices:
A. Guameri bodies
B. Negri bodies
C. Cowdry A body
D. Bollinger bodies
Answer: [/INST] Negri bodies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strategies in National Leprosy Control programme – a) Early detection of casesb) Short course multi drug therapyc) Rehabilitationd) Chemoprophylaxis with dapsonee) All of the above
Choices:
A. ab
B. abc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Lichen Planus all are true, except :
Choices:
A. Hypopigmentation in most residual disease
B. Lymphatic infiltration in supradermal layer
C. Itchy polygonal, purple papule
D. Skin, hair and oral mucosa commonly involved
Answer: [/INST] Hypopigmentation in most residual disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is DOC of Severe Complicated Falciparum Malaria is ?
Choices:
A. Quinine
B. Aemether
C. Aesunate
D. Hydroxychloroquine
Answer: [/INST] Aesunate </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is associated with which of the following infections?
Choices:
A. Herpes simplex
B. Varicella zoster
C. Measles
D. Diphtheria
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The minimum number of polyps necessary for a diagnosis of Familial Adenomatous Polyposis (FAP) is:
Choices:
A. 5
B. 10
C. 50
D. 100
Answer: [/INST] 100 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are used in Alopecia Areata except
Choices:
A. Tacrolimus
B. Acitretin
C. Steroids
D. Phototherapy
Answer: [/INST] Acitretin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is characterized by chronic liver disease, including steatosis and fibrosis, due to impaired glycosylation affecting hepatic function.  
2. **Hypercholesterolemia**: Glycosylation defects disrupt lipid metabolism pathways, leading to elevated cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, common in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests mild myopathy, occasionally observed in this disorder.  
5. **Low ceruloplasmin & copper**: TMEM199-CDG causes hypocupremia and hypoceruloplasminemia secondary to disrupted copper transport (likely via defective glycosylation of COMMD1, a copper metabolism regulator).  
6. **Exclusion of Wilson disease**: While low ceruloplasmin/copper mimic Wilson disease, the absence of neuropsychiatric symptoms and presence of hypercholesterolemia/liver fibrosis favor TMEM199-CDG. Genetic testing for TMEM199 variants confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Leprosy most common renal lesion seen is:
Choices:
A. MGN
B. MPGN
C. Focal glomeruloselerosis
D. Diffuse glomerulosclerosis
Answer: [/INST] MGN </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Giant cells seen in -a)  Osteoclastomab)  Chondroblastomac)  Chordomad)  Osteitis fibrosa cystica
Choices:
A. ac
B. ab
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mode of inheritance forAchondroplasia is -
Choices:
A. Autosomal dominant
B. Autosomal recessive
C. X-linked dominant
D. X- linked recessive
Answer: [/INST] Autosomal dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Exotropia', 'Intellectual disability', 'Seizure', 'Dysarthria', 'Hypoglycemia', 'Hyperammonemia', 'Myopathic facies', 'Apnea', 'Febrile seizure (within the age range of 3 months to 6 years)', 'Developmental regression', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Babinski sign', 'Hyperactive deep tendon reflexes', 'obsolete Loss of ability to walk', 'Focal-onset seizure', 'Arrhythmia', 'Arrhythmia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
- **Metabolic disturbances**: Hypoglycemia and hyperammonemia indicate systemic metabolic dysfunction, consistent with recurrent crises.  
- **Neuromuscular involvement**: Myopathic facies, dysarthria, elevated creatine kinase, myoglobinuria, and rhabdomyolysis suggest severe muscle pathology.  
- **Cardiac arrhythmias**: Repeated mention of arrhythmias highlights cardiac involvement, a hallmark of this syndrome.  
- **Neurological regression**: Developmental regression, seizures (focal-onset, febrile), intellectual disability, Babinski sign, hyperactive reflexes, and loss of ambitation point to progressive neurodegeneration.  
- **Encephalopathic features**: Apnea, microcephaly, and exotropia align with central nervous system deterioration.  
- **Recurrent crises**: The cyclical nature of rhabdomyolysis, metabolic derangements, and neurological decline matches the syndrome’s phenotype of episodic metabolic encephalomyopathy.  
- **Exclusion of mimics**: The combination of hyperammonemia, hypoglycemia, arrhythmias, and rhabdomyolysis distinguishes this from isolated mitochondrial disorders or fatty acid oxidation defects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Urinary incontinence', 'Spastic paraplegia', 'Dysarthria', 'Brisk reflexes', 'Spastic gait', 'Difficulty walking', 'Babinski sign', 'Pes valgus']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core HSP Features**: Spastic paraplegia, spastic gait, difficulty walking, brisk reflexes, and Babinski sign are hallmark signs of hereditary spastic paraplegia (HSP), indicating upper motor neuron dysfunction.  
2. **Urinary Incontinence**: Common in HSP due to spinal cord involvement disrupting bladder control.  
3. **Dysarthria**: Suggests possible bulbar or cerebellar involvement, observed in some HSP subtypes, including SPG76.  
4. **Pes Valgus**: May arise from altered muscle tone or peripheral neuropathy, occasionally linked to HSP.  
5. **Autosomal Recessive Inheritance**: Matches SPG76’s genetic pattern (CAPN1 mutations), distinguishing it from dominant or X-linked HSP subtypes.  
6. **Exclusion of Mimics**: Symptoms align with SPG76’s progressive phenotype, ruling out acquired causes (e.g., spinal cord compression) and other HSP subtypes with overlapping features (e.g., SPG11/SPG15, which often include cognitive decline or thin corpus callosum). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Seizure', 'Death in infancy', 'Anemia', 'Fever', 'Glutaric aciduria', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and related metabolites.  
2. **Macrocephaly**: A hallmark of GA-I, often presenting prenatally or in early infancy due to abnormal brain development or fluid accumulation (e.g., subdural hygromas).  
3. **Seizures**: Result from metabolic crises triggered by catabolic stressors (e.g., fever, infection), causing acute neurotoxicity from accumulating metabolites.  
4. **Death in infancy/childhood**: Untreated GA-I leads to severe encephalopathic crises, irreversible striatal damage, and early mortality without dietary and metabolic management.  
5. **Anemia**: May arise secondary to metabolic disturbances or bone marrow suppression during acute illness.  
6. **Fever**: Often precipitates metabolic decompensation, exacerbating glutaric acid and 3-hydroxyglutaric acid accumulation, worsening neurological symptoms.  
The combination of macrocephaly, metabolic acidosis (implied by glutaric aciduria), and neurological deterioration aligns pathognomonically with GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Allergic Broncho-pulmonary Aspergillosis is commonly a complication of:
Choices:
A. TB
B. Bronchogenic carcinoma
C. Cystic-fibrosis
D. Wegener's granulomatosis
Answer: [/INST] Cystic-fibrosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Average time interval between radiation exposure and genesis of post radiation Osteosarcoma
Choices:
A. 2 yrs
B. 4 yrs
C. 8 yrs
D. 16 yrs
Answer: [/INST] 16 yrs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following treatment is done for Juvenile Onset Recurrent Respiratory Papillomatosis:
Choices:
A. Bevacizumab
B. Aerosol Cidofovir
C. Interferon Beta
D. Steroids
Answer: [/INST] Bevacizumab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine.  
2. **Delayed speech and language development**: Untreated PKU results in neurotoxic effects of elevated phenylalanine, impairing brain development and cognitive/linguistic function.  
3. **Abnormality of prenatal development or birth**: Maternal PKU (untreated during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus due to intrauterine phenylalanine toxicity.  
4. **Neonatal death/Death in infancy/childhood**: Severe untreated PKU causes progressive neurodegeneration, seizures, and failure to thrive, historically leading to early mortality before dietary management became standard.  
5. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to blocked PAH-mediated conversion), transient hypertyrosinemia may occur in critically ill infants with hepatic dysfunction or secondary metabolic disturbances, or as a lab artifact. This symptom is atypical but does not exclude PKU as the primary diagnosis.  

**Note**: The diagnosis assumes classic PKU, with hypertyrosinemia requiring further investigation for coexisting conditions (e.g., tyrosinemia type II) or confounding factors. Confirmatory testing (PAH gene analysis, phenylalanine/tyrosine ratios) is critical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Sinusitis', 'Hypertension', 'Dry skin', 'Pallor', 'Thrombocytosis', 'Anemia', 'Renal artery stenosis', 'Fever', 'Leukocytosis', 'Vomiting', 'Abdominal pain', 'Dyspnea', 'Osteomyelitis', 'Elevated hepatic transaminase', 'Increased blood urea nitrogen', 'Increased circulating IgG level', 'Elevated circulating creatinine concentration', 'Back pain', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Poor appetite', 'Epileptic spasm', 'Elevated circulating C-reactive protein concentration', 'Flank pain', 'Elevated gamma-glutamyltransferase level', 'Elevated carcinoma antigen 125 level', 'obsolete Abnormal fecal test result', 'Abnormality of mesentery morphology', 'Papule', 'Epigastric pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular involvement**: Renal artery stenosis (a hallmark of Takayasu arteritis) explains hypertension, elevated blood urea nitrogen, and creatinine. Flank/back pain may reflect ischemic kidney injury.  
2. **Systemic inflammation**: Fever, leukocytosis, elevated ESR, CRP, and IgG levels align with chronic inflammatory vasculitis.  
3. **Mesenteric ischemia**: Abdominal/epigastric pain, mesentery abnormality, and vomiting suggest compromised mesenteric artery blood flow.  
4. **Anemia/Thrombocytosis**: Common in chronic inflammatory states.  
5. **Autoimmune features**: Antinuclear antibody positivity (non-specific but supportive of autoimmune etiology).  
6. **Exclusion of mimics**: Elevated CA-125 and hepatic enzymes may reflect secondary inflammation; sinusitis and papules are atypical but do not rule out Takayasu.  
**Key omissions**: Angiographic evidence (e.g., aortic/pulmonary artery stenosis) is required for definitive diagnosis, but clinical and lab findings strongly suggest Takayasu arteritis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies free country is:
Choices:
A. China
B. Russia
C. Australia
D. France
Answer: [/INST] Australia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Common antibody in Polymyositis and Dermatomyositis includes
Choices:
A. SS-7
B. SS-8
C. Anti-aminoacyl-tRNA synthetase
D. Anti hystidyl transfer synthetase
Answer: [/INST] Anti-aminoacyl-tRNA synthetase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Hypophosphatemia', 'Hepatomegaly', 'Hypokalemia', 'Prolonged bleeding time', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia & 4-Hydroxyphenylpyruvic aciduria**: Direct biochemical hallmarks of tyrosinemia type I due to fumarylacetoacetate hydrolase (FAH) deficiency, causing toxic accumulation of tyrosine metabolites.  
2. **Hepatomegaly & elevated alpha-fetoprotein (AFP)**: Indicates severe liver dysfunction, a key feature of HT-1. AFP elevation reflects hepatocellular injury/regeneration.  
3. **Hypoglycemia, hypophosphatemia, hypokalemia**: Results from hepatic failure and renal Fanconi syndrome (proximal tubule dysfunction), common in HT-1.  
4. **Prolonged bleeding time**: Secondary to coagulopathy from impaired hepatic synthesis of clotting factors.  
5. **Hyperphenylalaninemia**: May occur due to secondary inhibition of phenylalanine hydroxylase by tyrosine metabolites.  
6. **Abnormality of prenatal development, neonatal/childhood death**: Untreated HT-1 causes rapid progression to liver failure, metabolic crises, and early mortality.  
7. **Neonatal/Infancy onset**: Classic presentation of acute HT-1, aligning with the listed symptoms.  

All findings converge on **tyrosinemia type I**, a disorder of tyrosine metabolism with hepatorenal toxicity. Confirmation requires genetic testing for *FAH* mutations or urinary succinylacetone detection. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Bradycardia', 'Apnea', 'Opisthotonus', 'Neonatal death', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Fatigue', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Amino Acid Elevation**: The triad of *hypervalinemia*, *hyperleucinemia*, and *hyperisoleucinemia* is pathognomonic for MSUD, caused by a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, impairing breakdown of branched-chain amino acids (BCAAs).  
2. **Neurological Manifestations**: *Seizures*, *intellectual disability*, *hypotonia*, and *opisthotonus* arise from neurotoxic accumulation of BCAAs and their keto-acids, disrupting cerebral energy metabolism and myelination.  
3. **Metabolic Crisis**: *Apnea*, *bradycardia*, and *fatigue* reflect acute metabolic decompensation, often triggered by catabolic states (e.g., infections), leading to life-threatening cerebral edema.  
4. **Odor & Early Mortality**: *Body odor* (maple syrup-like scent in urine/sweat) and *neonatal/infant death* align with classic severe MSUD phenotypes, where untreated metabolic crises rapidly progress to coma and death.  
5. **Immunological Vulnerability**: *Recurrent viral infections* may stem from metabolic stress impairing immune cell function, though this is less specific and secondary to the primary metabolic defect.  
**Conclusion**: The combination of BCAA elevation, neurotoxicity, odor, and infantile lethality confirms MSUD. Urgent dietary management (BCAA restriction) is critical to mitigate outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is ?
Choices:
A. AD
B. AR
C. X linked dominant
D. X linked recessive
Answer: [/INST] AR </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Generalized hypotonia', 'Death in infancy', 'Hyperhomocystinemia', 'Abnormal cerebral white matter morphology', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning:  
1. **Methylmalonic aciduria**: Directly listed as a symptom, indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperhomocystinemia**: Specific to defects in cobalamin metabolism (e.g., cblC type), which disrupts homocysteine remethylation to methionine.  
3. **Abnormal cerebral white matter morphology**: Neurological damage from homocystinuria and methylmalonic acid toxicity explains this finding.  
4. **Decreased plasma free carnitine**: Secondary to excessive conjugation with accumulated metabolites (methylmalonic acid/homocysteine).  
5. **Generalized hypotonia and delayed speech**: Neurological manifestations due to combined metabolic toxicity and potential B12 deficiency effects.  
6. **Gastrointestinal inflammation**: Linked to metabolic stress and mitochondrial dysfunction in cblC.  
7. **Neonatal/Infancy/Childhood death**: Severe cblC variants often present with early-life metabolic crises, multiorgan failure, or neurodegeneration.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria**: Primary biochemical hallmark of isolated MMA caused by methylmalonyl-CoA mutase deficiency or cobalamin disorders (e.g., cblA/cblB).  
2. **Decreased plasma free carnitine**: Due to carnitine depletion from conjugating methylmalonic acid.  
3. **Generalized hypotonia and developmental delay**: Common in chronic MMA due to energy deficiency and neurotoxicity.  
4. **Death in infancy/childhood**: Occurs in severe MMA subtypes but **does not explain hyperhomocystinemia or cerebral white matter abnormalities**, making this diagnosis incomplete.  

**Final Diagnosis**: Methylmalonic acidemia with homocystinuria, type cblC (Combined MMA and homocystinuria) is the definitive diagnosis, as it uniquely accounts for **all symptoms**, including the coexistence of methylmalonic aciduria, hyperhomocystinemia, and cerebral white matter pathology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid perforation is diagnosed by-
Choices:
A. Plain X-ray of abdomen in erect posture
B. Rectal examination
C. Gastric aspiration
D. Barium enema
Answer: [/INST] Plain X-ray of abdomen in erect posture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Dysarthria', 'Cerebellar atrophy', 'Dysmetria', 'Babinski sign']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Ataxia, Dysmetria, Cerebellar atrophy**: Core features of cerebellar dysfunction, directly aligning with the syndrome’s progressive cerebellar degeneration.  
2. **Dysarthria**: Commonly associated with cerebellar pathology, consistent with impaired motor coordination of speech.  
3. **Babinski sign**: Indicates upper motor neuron involvement, which may reflect broader neurological dysfunction in the syndrome, including potential spinal cord or pyramidal tract abnormalities.  
4. **Syndrome-specific context**: While pancytopenia (a hallmark of the disorder) is not explicitly listed here, the combination of cerebellar and pyramidal signs strongly suggests a systemic genetic etiology like SAMD9L-related Ataxia-pancytopenia syndrome, which integrates neurological and hematological manifestations. Further hematological evaluation (e.g., CBC) would confirm pancytopenia to solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true about Galactosemia EXCEPT?
Choices:
A. Galactose 1 phosphate and galactitol have toxic effects on various organs
B. Patients are symptomatic immediately after bih
C. Jaundice and liver dysfunction commonly seen
D. E.coli sepsis is an impoant cause of moality
Answer: [/INST] Patients are symptomatic immediately after bih </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy commonly spreads by:
Choices:
A. Milk
B. Droplet
C. Water
D. Mosquitoes
Answer: [/INST] Droplet </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine was first developed by -
Choices:
A. Robert Koch
B. Louis Pasteur
C. Edward Jenner
D. Loeffler
Answer: [/INST] Louis Pasteur </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, impairing neurodevelopment.  
3. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing congenital anomalies (e.g., microcephaly, cardiac defects) in the infant.  
4. **Neonatal death/Death in infancy/childhood** correlates with severe untreated PKU variants (e.g., malignant PKU) or delayed diagnosis, where toxic phenylalanine levels cause irreversible neurological damage or metabolic crises.  
5. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare PAH deficiency variants or secondary metabolic disruptions (e.g., transient tyrosine elevation during metabolic stress).  

PKU explains the core symptom (hyperphenylalaninemia) and associated complications, while hypertyrosinemia warrants further investigation for co-occurring disorders or metabolic instability. Early dietary management (phenylalanine restriction) is critical to prevent adverse outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Agent used for eliciting diagnostic differentiation of Myasthenia Gravis from Cholinergic crisis is
Choices:
A. Neostigmine
B. Ecothiophate
C. Edrophonium
D. Ambenonium
Answer: [/INST] Edrophonium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Fever', 'Leukocytosis', 'Gastroesophageal reflux', 'Hepatomegaly', 'Neoplasm of the liver', 'Elevated hepatic transaminase', 'Back pain', 'Exercise intolerance', 'Shortened PR interval', 'Generalized morning stiffness', 'Abnormal prostate morphology', 'Elevated circulating C-reactive protein concentration', 'Sacroiliac arthritis', 'Fatigue', 'Crackles', 'Elbow pain', 'Knee pain', 'Elevated gamma-glutamyltransferase level', 'Chest tightness', 'Decreased DLCO', 'Serositis', 'Chest pain', 'Skin erosion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The presence of **sacroiliac arthritis**, **generalized morning stiffness**, **back pain**, and **elevated C-reactive protein** strongly suggests inflammatory spondyloarthropathy. Sacroiliitis is a hallmark of axial spondyloarthritis (e.g., ankylosing spondylitis). HLA-B27-associated susceptibility (common in spondyloarthropathies) aligns with genetic predisposition (susceptibility 1). Musculoskeletal symptoms (elbow/knee pain) and systemic inflammation (fever, leukocytosis) further support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: **Serositis** (pleural/pericardial inflammation) and **decreased DLCO** (diffusing capacity of the lungs) indicate extra-articular manifestations, seen in broader autoimmune-driven spondyloarthropathy subtypes. **Skin erosions** and **abnormal prostate morphology** may reflect reactive arthritis or psoriatic spondyloarthropathy overlap, linked to alternative genetic loci (susceptibility 2). Hepatic involvement (steatosis, elevated transaminases) could stem from metabolic syndrome or drug-induced inflammation, common comorbidities in chronic inflammatory arthropathies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Occipital neuralgia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Death in infancy/Neonatal death/Death in childhood**: Untreated PKU leads to severe neurotoxicity from phenylalanine accumulation, resulting in irreversible brain damage, seizures, and early mortality without dietary intervention.  
3. **Hypertyrosinemia**: Atypical but possible in PKU variants (e.g., BH4-deficient PKU), where impaired tyrosine metabolism or secondary metabolic disruptions may elevate tyrosine.  
4. **Occipital neuralgia**: Chronic neurotoxicity in PKU can cause peripheral nerve dysfunction or central pain pathways disruption, though this is a rare manifestation.  

Note: Classic PKU typically presents with *low* tyrosine, but coexisting hypertyrosinemia may suggest a complex metabolic interplay or diagnostic overlap with other tyrosinemia-related disorders. However, hyperphenylalaninemia remains the critical indicator for PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Hypertonia', 'Generalized hypotonia', 'Hyperreflexia', 'Fever', 'Recurrent pneumonia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Krabbe disease  
Reasoning:  
1. **Neurological symptoms** (hypertonia, hyperreflexia, irritability) suggest demyelination, a hallmark of Krabbe disease caused by galactocerebrosidase deficiency.  
2. **Generalized hypotonia** may reflect peripheral neuropathy due to psychosine toxicity, a feature seen in early-infantile Krabbe disease.  
3. **Recurrent pneumonia** aligns with bulbar dysfunction or aspiration risk from impaired swallowing/airway control.  
4. **Fever** is atypical in Krabbe but could stem from secondary infections (e.g., pneumonia) or autonomic dysregulation.  
5. Symptom progression (irritability → spasticity → hypotonia) matches the classic trajectory of infantile-onset Krabbe.  
6. **Combined UMN/LMN signs** (hyperreflexia + hypotonia) point to a neurodegenerative disorder affecting both central and peripheral nervous systems. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Trigeminal Neuralgia are true Except:
Choices:
A. Most commonly involves Ophthalmic Division (V3) of Maxillary Nerve
B. Attacks most commonly occur during the day
C. Affects women more than men
D. More common on the Right Side
Answer: [/INST] Most commonly involves Ophthalmic Division (V3) of Maxillary Nerve </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rapid diagnosis of Rabies in a Rabid living dog is by?
Choices:
A. Fluorescent antibody test
B. Corneal impression
C. Inoculation in mouse
D. None of the above
Answer: [/INST] Fluorescent antibody test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Peripheral pulmonic stenosis is associated with -a) Subaortic stenosis b)  Takayasu's arteritisc) William syndromed) Coarctation of syndromee) Rubella
Choices:
A. ce
B. b
C. ac
D. ae
Answer: [/INST] ce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy spreads by -a) Skin to skin contactb) Blood transfusionc) Droplet spreadd) Ingestion
Choices:
A. a
B. bc
C. ad
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Skin rash', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Neurological Symptoms**: Seizures align with Canavan's progressive leukodystrophy causing neurological deterioration.  
2. **Metabolic Abnormalities**: Elevated N-acetylaspartic acid (NAA) due to ASPA deficiency explains ""abnormal circulating aspartate family amino acid concentration."" Secondary metabolic disruption may contribute to hyperammonemia and aminoaciduria.  
3. **Early Mortality**: Neonatal death or death in infancy is consistent with severe infantile-onset Canavan disease.  
4. **Glycine Irregularity**: Abnormal glycine levels could stem from secondary metabolic disturbances in amino acid homeostasis.  
5. **Skin Manifestations**: Erythematous lesions (plaques, macules, papules) are atypical for Canavan but may reflect concurrent conditions, misreported findings, or cutaneous reactions to metabolic stress.  
6. **Exclusion of Alternatives**: Symptoms lack hallmark features of urea cycle disorders (e.g., vomiting) or organic acidemias (e.g., specific organic acid elevations), reinforcing Canavan as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Low-set ears', 'Rod-cone dystrophy', 'Sparse eyelashes', 'Delayed speech and language development', 'Cafe-au-lait spot', 'Brachydactyly', 'Short stature', 'Sparse hair', 'High anterior hairline', 'Thick vermilion border', 'Delayed ability to walk', 'Sparse eyebrow']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Brachydactyly-short stature-retinitis pigmentosa syndrome/Retinitis pigmentosa with or without skeletal anomalies  
Reasoning:  
1. **Brachydactyly**: Explicitly listed as a symptom, directly aligning with the syndrome's name and diagnostic criteria.  
2. **Short stature**: A core feature of the syndrome, present in the patient.  
3. **Rod-cone dystrophy**: Matches retinitis pigmentosa (RP), a hallmark of the syndrome, characterized by progressive retinal degeneration.  
4. **Sparse hair/eyebrows/eyelashes and high anterior hairline**: Consistent with ectodermal dysplasia-like features reported in some cases of the syndrome.  
5. **Thick vermilion border**: A documented facial dysmorphism in skeletal-RP overlap syndromes.  
6. **Delayed speech/walking**: Developmental delays are part of the phenotypic spectrum, possibly secondary to systemic involvement.  
7. **Cafe-au-lait spot**: While atypical, it does not exclude the diagnosis given the strong alignment of other features; may reflect phenotypic variability.  
8. Exclusion of alternatives: Key symptoms (e.g., brachydactyly, RP) distinguish this from Cohen, Bardet-Biedl, or Alström syndromes.  

Final diagnosis is supported by the triad of brachydactyly, short stature, and RP, alongside supportive dysmorphic and developmental features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Epistaxis', 'Carious teeth', 'Death in infancy', 'Tachycardia', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism is a hallmark of galactosemia, a disorder impairing galactose conversion. Classic galactosemia (GALT deficiency) causes toxic metabolite accumulation, leading to life-threatening complications (neonatal death, death in infancy/childhood). Tachycardia may stem from sepsis or metabolic acidosis, while liver dysfunction (coagulopathy) explains epistaxis. Macrocephaly could reflect cerebral edema, and carious teeth may result from dietary restrictions or metabolic imbalances. Early fatality without galactose restriction aligns with untreated galactosemia. Other symptoms are secondary to systemic toxicity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Dystonia', 'Death in infancy', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Severe short stature', 'Paraplegia/paraparesis', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly linking to the enzyme deficiency (glutaryl-CoA dehydrogenase).  
2. **Neurological symptoms** (seizures, dystonia, athetosis, spastic diplegia/tetraplegia, paraplegia) align with basal ganglia injury caused by toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Motor delay** and **intellectual disability** reflect progressive neurodegeneration from recurrent metabolic crises.  
4. **Severe short stature** may result from chronic metabolic instability and catabolic stress.  
5. **Death in infancy/adolescence** correlates with acute encephalopathic crises triggered by infections or fasting, common in untreated/severe GA-I cases.  
6. **Spasticity** and **paraparesis** indicate corticospinal tract damage, consistent with white matter changes observed in advanced GA-I.  
7. The absence of hepatic symptoms (e.g., hypoglycemia, hyperammonemia) distinguishes GA-I from other organic acidemias, reinforcing specificity.  

This pattern matches GA-I’s pathophysiology, where disrupted lysine/tryptophan metabolism leads to neurotoxicity and multisystemic deterioration. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Leprosy most common renal lesion seen is ?
Choices:
A. MGN
B. MPGN
C. Focal glomeruloselerosis
D. Diffuse glomerulosclerosis
Answer: [/INST] MGN </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Cystinuria, all of the following amino acids are excreted in urine, except:-
Choices:
A. Cystine
B. Ornithine
C. Leucine
D. Arginine
Answer: [/INST] Leucine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Hypothermia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Tachypnea', 'Glycosuria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Recurrent viral infections', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency), hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is the hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Neurological symptoms** (coma, cerebral edema, opisthotonus) result from ammonia toxicity. Elevated ammonia disrupts astrocyte function, causing cerebral edema and brainstem compression (opisthotonus).  
3. **Metabolic acidosis** arises from secondary lactic acidosis due to mitochondrial dysfunction and anaerobic metabolism triggered by hyperammonemia.  
4. **Respiratory issues** (tachypnea, dyspnea) reflect compensatory hyperventilation to counteract acidosis.  
5. **Gastrointestinal symptoms** (vomiting, diarrhea) are nonspecific but common in UCDs due to metabolic stress.  
6. **Hypothermia** and **sepsis** may stem from metabolic instability impairing thermoregulation and immune function.  
7. **Prolonged partial thromboplastin time** suggests liver dysfunction, as CPS1 is hepatocyte-specific; impaired clotting factor synthesis exacerbates bleeding risk.  
8. **Glycosuria** may occur secondary to proximal renal tubular injury from metabolic acidosis.  
9. **Early lethality** (neonatal death, death in infancy) aligns with severe UCDs presenting acutely postpartum when protein intake begins.  
10. **Recurrent infections** could reflect catabolic crises during illness, worsening hyperammonemia, rather than primary immunodeficiency.  

CPS1 deficiency is distinguished from other UCDs by the absence of orotic aciduria (not tested here) and its autosomal recessive inheritance. The symptom constellation, particularly hyperammonemia with metabolic acidosis and rapid neonatal decline, strongly supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not directly cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) in the fetus. This suggests possible maternal PKU contributing to prenatal developmental issues.  
3. **Neonatal death/Death in infancy**: Severe untreated PKU can cause rapid neurological deterioration, seizures, and metabolic instability. In extreme cases, acute complications (e.g., metabolic crises) or secondary infections due to failure to thrive may lead to early mortality.  
4. The combination of hyperphenylalaninemia and early lethality strongly aligns with a classic or severe PKU phenotype, emphasizing the critical need for newborn screening and dietary intervention to prevent outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following vaccine is associated with Toxic Shock Syndrome?
Choices:
A. Infected BCG vaccine
B. Infected DPT vaccine
C. Infected Polio vaccine
D. Infected Measles vaccine
Answer: [/INST] Infected Measles vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which toxin acts by ADP ribosylation-a) Botulinum toxinb)  Shiga toxinc) V.cholerae toxin d) Diphtheria toxine) Pertussis toxin
Choices:
A. cde
B. acd
C. bde
D. ade
Answer: [/INST] cde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine not to be given in case of?
Choices:
A. Rat bite
B. Cat bite
C. Dog bite
D. Monkey bite
Answer: [/INST] Rat bite </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true about Keratoconus, except:
Choices:
A. Increased curvature of cornea
B. Astigmatism
C. K.F ring cornea
D. Thick cornea
Answer: [/INST] Thick cornea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Oral ulcer', 'Sinusitis', 'Abnormal nasal mucosa morphology', 'Thrombocytosis', 'Fever', 'Leukocytosis', 'Dyspnea', 'Abnormality of the knee', 'Elevated circulating alkaline phosphatase concentration', 'Elevated erythrocyte sedimentation rate', 'Increased alpha-globulin', 'Elevated circulating C-reactive protein concentration', 'Erythema nodosum', 'Cervical lymphadenopathy', 'Elevated gamma-glutamyltransferase level', 'Retinitis', 'Aphthous ulcer', 'Mediastinal lymphadenopathy', 'Chest pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral and aphthous ulcers are hallmark features of Behçet’s disease. Erythema nodosum, a skin lesion, further supports this category.  
2. **Ocular Manifestations**: Retinitis aligns with Behçet’s ocular involvement, typically presenting as uveitis or retinal vasculitis.  
3. **Systemic Inflammation**: Elevated ESR, CRP, leukocytosis, and thrombocytosis reflect a systemic inflammatory response, consistent with Behçet’s flares.  
4. **Articular Involvement**: Abnormality of the knee suggests arthritis, commonly non-erosive in Behçet’s.  
5. **Vascular/Thoracic Features**: Dyspnea, chest pain, and mediastinal lymphadenopathy may indicate vasculitis affecting pulmonary or mediastinal vessels, a known complication.  
6. **Lymphatic Involvement**: Cervical lymphadenopathy is occasionally seen during active disease.  
7. **Atypical Overlaps**: Sinusitis and abnormal nasal mucosa are less typical but may occur secondary to inflammation. Elevated liver enzymes (ALP/GGT) are nonspecific but could reflect systemic illness.  
8. **Exclusion of Mimics**: The absence of granulomas (unlike sarcoidosis/GPA) and dominance of mucosal/skin lesions over gastrointestinal symptoms (unlike Crohn’s) solidify Behçet’s as the diagnosis.  

Final diagnosis hinges on the combination of major criteria (oral ulcers, erythema nodosum, ocular lesions) with multisystem inflammation, fulfilling the International Criteria for Behçet’s Disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Tuberculosis in children-
Choices:
A. Commonly sputum negative
B. Incidence 5-15 % of all TB cases
C. Clinically child does not show sign of florid TB
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Disproportionate tall stature', 'Scoliosis', 'Ascending tubular aorta aneurysm', 'High myopia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Marfan syndrome: The patient presents with disproportionate tall stature, a hallmark of Marfan syndrome due to FBN1 gene mutations affecting connective tissue. Scoliosis aligns with skeletal manifestations, while ascending aortic aneurysm reflects cardiovascular involvement, a critical diagnostic criterion. High myopia is consistent with ocular abnormalities seen in this disorder.  
Marfan syndrome type 1: This refers specifically to Marfan syndrome caused by pathogenic variants in the FBN1 gene on chromosome 15, which accounts for >90% of cases. The symptoms described (aortic aneurysm, skeletal features, ocular involvement) are directly linked to FBN1-related connective tissue dysregulation, confirming the subtype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following drug is NOT used to treat Leishmaniasis -
Choices:
A. Cyclosporine
B. Ketoconazole
C. Pentamidine
D. Amphotericin B
Answer: [/INST] Cyclosporine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Osteoporosis', 'Areflexia', 'Tongue fasciculations', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', 'Hypertriglyceridemia', 'Generalized-onset seizure', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Hyponatremia', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Cerebral visual impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neurological & developmental features**: Profound global developmental delay, developmental regression, cerebellar vermis hypoplasia, and cerebral visual impairment align with TBCK syndrome’s hallmark neurodevelopmental deficits. Corpus callosum abnormalities (partial agenesis/hypoplasia) and ventriculomegaly are consistent with brain malformations seen in TBCK.  
2. **Neuromuscular signs**: Severe muscular hypotonia, areflexia, and tongue fasciculations reflect the syndrome’s hypotonia-predominant presentation. Respiratory insufficiency and feeding difficulties are secondary to hypotonia.  
3. **Seizures**: Both generalized-onset and focal-onset seizures are reported in TBCK due to cortical dysgenesis and mTOR pathway dysregulation.  
4. **Craniofacial dysmorphism**: Macroglossia, gingival overgrowth, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, and exaggerated “Cupid’s bow” match the characteristic facies of TBCK-related syndromes.  
5. **Metabolic/Systemic involvement**: Hypertriglyceridemia and osteoporosis may arise from metabolic dysregulation linked to TBCK’s role in mTOR signaling. Hyponatremia could reflect autonomic dysfunction.  
6. **Genetic correlation**: TBCK mutations disrupt kinase activity critical for neuronal survival and metabolism, explaining the multisystemic phenotype.  
The combination of severe hypotonia, distinct facies, brain malformations, and metabolic anomalies strongly supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Q fever is transmitted by -
Choices:
A. Ticks
B. Mites
C. Louse
D. Flea
Answer: [/INST] Ticks </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Lesch Nyhan Syndrome:
Choices:
A. Patient have normal intellectual capacity
B. Pyrimidine overproduction is the cause
C. Uric acid stones are frequently formed
D. X- Linked dominant
Answer: [/INST] Uric acid stones are frequently formed </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true regarding Renal Cell Carcinoma?
Choices:
A. More common in males
B. May cause varicocele
C. May invade the renal vein
D. All the above
Answer: [/INST] All the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Areflexia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Dyspnea', 'Hyperglycinemia', 'Opisthotonus', 'Drowsiness', 'Sleep disturbance', 'Fasciculations', 'Glutaric aciduria', 'Hyperglutaminemia', 'Elevated circulating glutaric acid concentration', 'Abnormal circulating carnitine concentration', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Key metabolic markers**: Elevated glutaric acid (hyperglutaminemia, glutaric aciduria, elevated circulating glutaric acid) directly aligns with GA-I’s pathophysiology due to **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological features**: Dystonia, opisthotonus, seizures, and hypotonia reflect basal ganglia injury, a hallmark of GA-I. These symptoms often manifest during metabolic crises triggered by fever, infection, or fasting.  
3. **Infantile presentation**: Feeding difficulties, lethargy, drowsiness, and risk of early death are consistent with GA-I’s typical onset in infancy. Untreated cases progress to irreversible neurological damage.  
4. **Carnitine abnormalities**: Abnormal carnitine levels occur as the body attempts to conjugate toxic metabolites (e.g., glutaric acid), depleting carnitine reserves.  
5. **Exclusion of mimics**: Hyperglycinemia may suggest glycine encephalopathy, but glutaric aciduria and dystonia strongly favor GA-I. Fasciculations and areflexia could indicate spinal involvement but are secondary to metabolic stress in GA-I.  
6. **Triggers for decompensation**: Fever and dyspnea likely precipitated acute encephalopathy, a common GA-I crisis pattern.  

This constellation of symptoms and biochemical findings is pathognomonic for GA-I, warranting urgent genetic testing (GCDH gene) and metabolic management to mitigate progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Hypoglycemia', 'Hepatomegaly', 'Drowsiness', 'Sleep disturbance', 'Myopathy', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia & Hepatomegaly**: VLCADD disrupts mitochondrial β-oxidation of very long-chain fatty acids, impairing energy production during fasting. This causes hypoglycemia (due to reliance on glucose without ketone alternatives) and hepatomegaly (fatty acid accumulation in the liver).  
2. **Cardiomyopathy & Myopathy**: Cardiac and skeletal muscles depend on fatty acid oxidation for energy. Enzyme deficiency leads to toxic metabolite buildup (e.g., long-chain acylcarnitines), causing cardiomyopathy and muscle weakness.  
3. **Decreased Plasma Free Carnitine & Abnormal Acetylcarnitine**: Carnitine conjugates with unmetabolized fatty acids, reducing free carnitine. Elevated very long-chain acylcarnitines (e.g., C14:1, C14, C16:1) are diagnostic biomarkers.  
4. **Lethargy, Drowsiness, Hypotonia**: Energy deficiency in muscles and the central nervous system explains hypotonia and neurological symptoms.  
5. **Death in Infancy**: Severe phenotypes present early with metabolic crises, cardiac dysfunction, or liver failure, often fatal without dietary intervention (avoidance of fasting, low-fat/high-carbohydrate diet, and medium-chain triglyceride supplementation).  
6. **Sleep Disturbance**: May reflect metabolic instability during prolonged fasting (e.g., overnight), triggering hypoglycemia or acidosis.  
The clinical and biochemical profile aligns with VLCADD, confirmed by genetic testing of *ACADVL* and acylcarnitine analysis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Duane syndrome involves
Choices:
A. Superior oblique
B. Inferior oblique
C. Lateral rectus
D. Superior rectus
Answer: [/INST] Lateral rectus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hepatomegaly', 'Elevated circulating alkaline phosphatase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis and hepatomegaly**: TMEM199-CDG commonly presents with liver involvement, including fatty liver and enlarged liver.  
2. **Reduced antithrombin III activity**: Glycosylation defects impair synthesis of glycoproteins like antithrombin III, leading to functional deficiency.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a hallmark of TMEM199-CDG.  
4. **Decreased ceruloplasmin and copper**: Ceruloplasmin, a copper-binding glycoprotein, requires proper glycosylation for stability. Its deficiency reduces circulating copper levels, distinguishing this from Wilson disease (where copper accumulates in tissues).  
5. **Consistent with TMEM199-CDG pathophysiology**: Mutations in *TMEM199* disrupt Golgi homeostasis, causing secondary glycosylation defects and hepatic/coagulation abnormalities.  

(Note: ""Congenital disorder of glycosylation, type IIP"" and ""TMEM199-CDG"" refer to the same disease, with the latter specifying the genetic cause.) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Immunoprophylaxis of leprosy includes-a)  BCGb)  MMRc)  ICRC bacillusd) Anthrax vaccinee) Mw
Choices:
A. a
B. ac
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Where are the deposits found in IgA Nephropathy?
Choices:
A. Subepithelial
B. Subendocardial
C. Mesangium
D. No deposists
Answer: [/INST] Mesangium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is infectious during -
Choices:
A. After 4 days of rash
B. 4 days before and 5 days after rash
C. Throughout disease
D. Only in incubation period
Answer: [/INST] 4 days before and 5 days after rash </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A newborn of 7 days old presented with meningitis. Most common cause –a)  E.colib)  Streptococcal pneumoniac)  N. Meningitisd)  Streptococcal agalactiae
Choices:
A. b
B. c
C. ac
D. ad
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 22-year-old gravida 1 presents to her physician at 15 weeks gestation for a prenatal appointment. She complains of a rash involving her chest, face, and arms, a watery nasal discharge, and mild bilateral knee pain. She has had these symptoms for about 5 days. The symptoms do not seem to bother her too much, but she is concerned for the baby. She had contact with her younger sister, who also had a rash and was diagnosed with rubella infection about 10 days ago at a family gathering. She cannot confirm her vaccination history. Her vital signs are as follows: blood pressure, 110/70 mmHg; heart rate, 89/min; respiratory rate, 12/min; and temperature, 37.6℃ (99.7℉). Examination shows a moderately dense maculopapular lacy rash spread over the patient’s trunk, extremities, and face. No lymph node, liver, or spleen enlargement is noted. The knee joints appear normal.
Serology performed 1 year ago Current serology
Rubella IgM - negative Rubella IgM - negative
Rubella IgG - 1:128 Rubella IgG - 1:64
Rubella IgG avidity - high Rubella IgG avidity - high
What is the proper next step in the management of this woman?
Choices:
A. Reassure and recommend vaccination against rubella postpartum.
B. Recommend pregnancy termination.
C. Arrange a chorionic villus sampling.
D. Recommend additional serologic testing for parvovirus B19.
Answer: [/INST] Recommend additional serologic testing for parvovirus B19. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In treatment of Osteosarcoma all of the following are used except (REPEAT)
Choices:
A. High dose Methotrexate
B. Cycloohosphamide
C. Vincristine
D. Doxorubicin
Answer: [/INST] Vincristine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pinta is caused by
Choices:
A. Treponema peenue
B. Treponema cerateum
C. Treponema pallidum
D. Treponema endemicum
Answer: [/INST] Treponema cerateum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is not true about Tardive Dyskinesia (TD):
Choices:
A. Clozapine is useful
B. Dopaminergic super sensitivity is the cause
C. Usually seen in perioral area
D. Combining anticholinergics with antipsychotics Prevents TD
Answer: [/INST] Combining anticholinergics with antipsychotics Prevents TD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is NOT seen in Paroxysmal Nocturnal Hemoglobinuria :
Choices:
A. Thrombosis
B. Hemosiderinuria
C. Decreased LDH
D. Thrombocytopenia
Answer: [/INST] Decreased LDH </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Negri bodies are hallmark of Rabies, these Negri bodies are seen in?
Choices:
A. Neurons
B. Microglia
C. Astrocytes
D. Oligodendroglia
Answer: [/INST] Neurons </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine for pre exposure prophylaxis is given at?
Choices:
A. 0, 3, 7 days
B. 0, 3, 7, 14 days
C. 0, 3, 7, 14, 30 days
D. 0, 7, 28 days
Answer: [/INST] 0, 7, 28 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating proline concentration', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and aminoaciduria, which are hallmark features of citrullinemia type I (ASS1 deficiency). Severe neonatal-onset hyperammonemia leads to rapid metabolic decompensation, explaining neonatal death or death in infancy. Aminoaciduria occurs due to overflow excretion of citrulline and other amino acids. Abnormal circulating proline may arise secondarily from metabolic instability or renal tubular stress. Early mortality aligns with the acute urea cycle dysfunction characteristic of this disorder.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Elevated citrulline and hyperammonemia are consistent with citrin deficiency (SLC25A13 mutations). Neonatal intrahepatic cholestasis, though not explicitly listed, is intrinsic to this diagnosis. Abnormal proline levels and aminoaciduria may reflect broader hepatic dysfunction or disrupted mitochondrial transport affecting multiple amino acids. Neonatal death could occur in severe cases with liver failure or metabolic crises, while citrin deficiency’s variable expressivity might also explain childhood mortality in progressive cases. However, the absence of explicit cholestasis-related symptoms (e.g., jaundice, hepatomegaly) makes this diagnosis less definitive. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Autism', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Delayed myelination', 'Thick vermilion border', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Intellectual disability, autism, delayed speech/absent speech, hyperactivity, seizures, and hypotonia align with the core neurodevelopmental phenotype of NEDBEH.  
2. **Brain anomalies**: Abnormal corpus callosum morphology, CNS/cerebral hypomyelination, and delayed myelination reflect the ""brain anomalies"" component, characteristic of SMARCC1-related NEDBEH.  
3. **Eye anomalies**: Coloboma, microphthalmia, Peters anomaly, optic atrophy, and blepharophimosis are hallmark ocular findings in NEDBEH, particularly Peters anomaly (a corneal defect linked to SMARCC1 mutations).  
4. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return satisfy the ""heart anomalies"" criterion.  
5. **Craniofacial/dysmorphic features**: Microcephaly/macrocephaly (variable expressivity), triangular face, micrognathia, high palate, and narrow mouth are consistent with reported facial gestalt.  
6. **Supportive systemic features**: Gastrointestinal anomalies (annular pancreas, duodenal atresia) and genitourinary defects (hypospadias, cryptorchidism) overlap with SMARCC1-related multisystem involvement.  
7. **Exclusion of mimics**: While symptoms like café-au-lait spots or syndactyly might suggest other syndromes (e.g., RASopathies), the triad of neurodevelopmental delay + brain/eye/heart anomalies prioritizes NEDBEH.  

Key confirmatory clues include Peters anomaly, hypomyelination, and congenital heart defects, which collectively distinguish NEDBEH from phenocopies like CHARGE syndrome or chromosomal disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about pyloric stenosisa) Hypokalemiab) Hyponatremiac) Metabolic acidosisd) Hypochloremiae) Hypocalcemia
Choices:
A. abd
B. bcd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cystinuria', 'Argininuria', 'Ornithinuria', 'Abnormal circulating lysine concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cystinuria  
Reasoning:  
1. **Aminoaciduria Pattern**: The patient exhibits cystinuria, argininuria, ornithinuria, and abnormal lysine levels. These four amino acids share a renal transporter system (SLC3A1/SLC7A9 genes) responsible for their reabsorption. A defect in this system leads to their excessive urinary excretion, confirming cystinuria.  
2. **Genetic Basis**: Cystinuria is an autosomal recessive disorder of dibasic amino acid transport. Mutations in *SLC3A1* (Type A) or *SLC7A9* (Type B) disrupt the transporter, causing accumulation of cystine in urine and stone formation.  
3. **Severity and Mortality**: Death in adolescence suggests severe complications, such as recurrent nephrolithiasis leading to chronic kidney disease, infections, or obstructive uropathy. Without aggressive management (hydration, alkalinization, chelators), renal failure could result in early mortality.  
4. **Exclusion of Alternatives**: Lysinuric protein intolerance (LPI) was considered but ruled out due to the absence of hyperammonemia and hepatosplenomegaly, as well as the presence of cystinuria, which is specific to cystinuria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Typhoid except -
Choices:
A. Incubation period 10-14 years
B. Most common among males
C. Carrier are treated by ampicillin
D. Highest incidence occur in 30-40 years age group
Answer: [/INST] Highest incidence occur in 30-40 years age group </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis in sickle cell anemia is due to.
Choices:
A. Salmonella
B. Streptococcus
C. Haemophilus
D. Neisseria
Answer: [/INST] Salmonella </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the kidney', 'Hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Delayed speech and language development', 'Precocious puberty', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Absent speech', 'Abnormal heart morphology', 'Scoliosis', 'Cerebellar dysplasia', 'Intellectual disability, severe', 'Feeding difficulties', 'Frequent temper tantrums']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental features**: Severe intellectual disability, global developmental delay, absent speech, and delayed speech align with the hallmark neurodevelopmental deficits of NEDBEH.  
2. **Hypotonia**: Generalized hypotonia is a common finding in NEDBEH, often linked to HECW2 gene variants.  
3. **Brain anomalies**: Cerebellar dysplasia directly corresponds to structural brain abnormalities associated with the disorder.  
4. **Eye and heart involvement**: Abnormality of the eye and abnormal heart morphology match the ""anomalies of the brain, eye, or heart"" specified in NEDBEH.  
5. **Atypical features**: Choanal atresia and hearing impairment are not classic features but may reflect phenotypic variability. Precocious puberty could arise from hypothalamic dysfunction secondary to brain malformations.  
6. **Supportive findings**: Feeding difficulties, scoliosis, and temper tantrums are consistent with severe developmental delay and hypotonia.  
7. **Exclusion of mimics**: While CHARGE syndrome could explain choanal atresia and heart defects, the absence of coloboma, cranial nerve anomalies, and the presence of severe intellectual disability favor NEDBEH.  

The diagnosis integrates characteristic features (neurodevelopmental delay, brain/eye/heart anomalies) and accommodates less common manifestations (choanal atresia, hearing loss) within the disorder’s phenotypic spectrum. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Demyelination is seen in -a) Multiple sclerosisb) AIDSc) Human leukoencephalopathy d) Leukodystrophy
Choices:
A. ab
B. bc
C. acd
D. abc
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by mutations in the *PAH* gene, impairing phenylalanine hydroxylase activity, leading to phenylalanine accumulation.  
2. **Abnormal circulating tyrosine concentration**: Reduced conversion of phenylalanine to tyrosine results in low tyrosine levels, aligning with ""abnormal tyrosine concentration.""  
3. **Prenatal developmental abnormalities**: Untreated maternal PKU during pregnancy can cause fetal toxicity (microcephaly, congenital heart defects), explaining prenatal anomalies in the patient.  
4. **Neonatal death/Death in infancy**: Severe untreated PKU causes profound neurological damage, seizures, and failure to thrive, which may lead to early mortality without dietary intervention.  
5. **Death in early adulthood**: Chronic complications (e.g., neurocognitive decline, organ damage) from lifelong phenylalanine toxicity, even with partial treatment, may contribute to premature mortality.  

Conclusion: The constellation of hyperphenylalaninemia, tyrosine imbalance, and early mortality aligns with untreated or poorly managed PKU. Maternal PKU syndrome may explain prenatal abnormalities if the mother had uncontrolled phenylalanine levels during gestation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid carriers are detected by following except ?
Choices:
A. Isolation of bacteria from urine
B. Isolation of bacteria from bile
C. Vi antigen
D. Widal test
Answer: [/INST] Widal test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Pneumonia', 'Pregnancy history', 'Neonatal death', 'Death in childhood', 'Hypoargininemia', 'Elevated plasma citrulline', 'Hernia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia, elevated plasma citrulline, and hypoargininemia, hallmark features of urea cycle dysfunction. Death in infancy/childhood, neonatal death, and premature birth align with the severe neonatal-onset form of citrullinemia type I (argininosuccinate synthetase deficiency). This disorder causes rapid ammonia accumulation, leading to metabolic crises, neurological deterioration, and early mortality without intervention. Pneumonia may arise secondary to metabolic instability or immunosuppression during crises.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: Hypoargininemia, hyperammonemia, and elevated citrulline are consistent with citrin deficiency, which disrupts the urea cycle via impaired aspartate transport. Hernia may reflect hepatomegaly or ascites from cholestasis. Premature birth and neonatal death correlate with intrahepatic cholestasis, growth restriction, and liver dysfunction in neonatal-onset type II. Though cholestasis (e.g., jaundice) is not explicitly listed, its inclusion in the disease name and hernia as a potential sign of liver pathology supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Ogilvie syndrome are all except
Choices:
A. It is caused by mechanical obstruction of the colon
B. It involves entire \/ pa of the large colon
C. It occurs after previous surgery
D. It occurs commonly after narcotic use
Answer: [/INST] It is caused by mechanical obstruction of the colon </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Fasciculations', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death', 'Hypoargininemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** and **cerebral edema** are hallmarks of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia detoxification.  
2. **Low plasma citrulline** and **hypoargininemia** indicate a block early in the urea cycle, as citrulline and arginine are downstream metabolites not synthesized when CPS1 is deficient.  
3. **Neonatal death** and **death in infancy** align with the severe, early-onset presentation of CPS1 deficiency, as untreated hyperammonemia rapidly leads to neurological damage and mortality.  
4. **Seizures** and **fasciculations** result from ammonia-induced neurotoxicity and cerebral edema.  
5. **Cyanosis** may arise from metabolic acidosis or respiratory failure secondary to hyperammonemic crisis.  
6. **Oroticaciduria**, though classically linked to ornithine transcarbamylase (OTC) deficiency, can rarely occur in CPS1 deficiency due to compensatory metabolic stress or secondary pyrimidine pathway activation.  
7. The absence of elevated citrulline and arginine distinguishes CPS1 deficiency from later urea cycle defects (e.g., OTC or citrullinemia), solidifying the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This defect results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Hypertyrosinemia**: Classic PKU typically presents with **low/normal tyrosine levels** due to impaired PAH activity. However, this case’s hypertyrosinemia may suggest atypical factors, such as:  
   - Concurrent liver dysfunction (unrelated to PKU) impairing tyrosine metabolism.  
   - Dietary mismanagement (e.g., excessive tyrosine intake in a PKU-specific diet).  
   - A rare PKU variant with secondary metabolic disruptions.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early mortality aligns with untreated or poorly managed cases, compounded by potential complications from hypertyrosinemia (e.g., hepatic/renal stress).  

**Note**: Hypertyrosinemia is atypical for PKU and warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or diagnostic reevaluation. However, hyperphenylalaninemia remains the hallmark feature, prioritizing PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Babesiosis is most commonly transmitted by:
Choices:
A. Pigs
B. Rats
C. Sand fly
D. Ticks
Answer: [/INST] Ticks </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seborrheic dermatitis', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Increased serum lactate', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Seborrheic dermatitis**: A hallmark of biotinidase deficiency due to biotin's role in keratinocyte function and skin health.  
2. **Metabolic acidosis & elevated lactate**: Caused by impaired activity of biotin-dependent carboxylases (e.g., pyruvate carboxylase), disrupting gluconeogenesis and mitochondrial energy metabolism.  
3. **Elevated urinary carboxylic acids**: Accumulation of 3-hydroxyisovaleric acid, 3-methylcrotonylglycine, and propionylglycine due to dysfunctional 3-methylcrotonyl-CoA carboxylase and propionyl-CoA carboxylase.  
4. **Neurological symptoms (seizures, hypotonia)**: Result from lactic acidosis, energy deficiency, and neurotoxic metabolite accumulation.  
5. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic decompensation, respiratory failure, and fatal outcomes.  
6. **Diagnostic confirmation**: Aligns with biochemical findings (low serum biotinidase activity) and rapid clinical improvement with biotin supplementation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Blindness', 'Osteoporosis', 'Ectopia lentis', 'Cardiomyopathy', 'Coronary artery atherosclerosis', 'Abnormal foot morphology', 'Pneumonia', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Hyperalaninemia', 'Abnormal vertebral morphology', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia and Hypermethioninemia**: Hallmark biochemical features of cystathionine beta-synthase (CBS) deficiency, as impaired CBS activity blocks homocysteine conversion to cystathionine, causing homocysteine and methionine accumulation.  
2. **Ectopia lentis**: A pathognomonic sign of classic homocystinuria due to defective collagen cross-linking from homocysteine accumulation, leading to lens dislocation.  
3. **Osteoporosis and Abnormal vertebral/foot morphology**: Homocysteine disrupts bone remodeling and connective tissue integrity, causing skeletal abnormalities.  
4. **Cardiomyopathy and Coronary artery atherosclerosis**: Chronic hyperhomocystinemia damages vascular endothelium, accelerating atherosclerosis and cardiac dysfunction.  
5. **Blindness**: Secondary to ectopia lentis complications (e.g., retinal detachment, glaucoma) or thromboembolic events affecting ocular vasculature.  
6. **Recurrent Pneumonia**: Skeletal chest deformities may impair respiratory function, predisposing to infections.  
7. **Early mortality**: Untreated CBS deficiency leads to thromboembolic events (stroke, myocardial infarction) or severe cardiovascular complications, often causing death in adolescence/early adulthood.  
8. **Hyperalaninemia**: May reflect secondary metabolic disturbances or concurrent stress-induced pyruvate elevation, though less specific to homocystinuria.  

Disease: Homocystinemia/Homocystinuria  
Reasoning:  
- This is a broader diagnostic category encompassing the CBS-deficient subtype. The reasoning aligns with the above, emphasizing the systemic effects of homocysteine toxicity across connective tissue, vascular, and skeletal systems. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ovarian cyst', 'Hepatic steatosis', 'Splenomegaly', 'Fever', 'Arthralgia', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Elevated circulating C-reactive protein concentration', 'Night sweats']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Familial mediterranean fever; FMF (AR)  
Reasoning:  
1. **Fever and elevated CRP**: Hallmark of FMF, reflecting systemic inflammation during attacks.  
2. **Arthralgia/Myalgia**: Common musculoskeletal manifestations in FMF due to serosal inflammation.  
3. **Splenomegaly**: Occurs in severe or chronic FMF due to recurrent inflammatory insults.  
4. **Night sweats**: Associated with febrile episodes.  
5. **Exertional dyspnea/Exercise intolerance**: May stem from subclinical pleuritis (a classic FMF feature) limiting respiratory capacity.  
6. **Hepatic steatosis/Ovarian cyst**: Indirectly linked; chronic inflammation or secondary amyloidosis (a complication of untreated FMF) could contribute to hepatic involvement. Ovarian cysts are not specific but may coexist.  

Disease: Familial Mediterranean fever, AD  
Reasoning:  
1. Overlapping features (fever, arthralgia, elevated CRP) align with AD-FMF, a rare variant with similar but often milder symptoms.  
2. AD inheritance may present with atypical organ involvement (e.g., hepatic steatosis) due to differing genetic modifiers.  
3. Splenomegaly and exercise intolerance are less typical but plausible in prolonged undiagnosed cases.  
4. Requires genetic confirmation (e.g., *MEFV* heterozygous pathogenic variants with AD penetrance).  

**Conclusion**: Both AR and AD forms are plausible. AR-FMF is more likely given the classic triad (fever, serositis, elevated CRP), but AD-FMF should be considered if family history suggests dominant inheritance or genetic testing is inconclusive for biallelic mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Intellectual disability**, **delayed speech/language development**, and **motor delay** align with untreated PKU, as elevated phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Severe short stature** may result from chronic malnutrition due to restrictive dietary management or secondary metabolic disturbances.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low/normal). This may suggest a concurrent metabolic disorder, lab artifact, or a rare PKU variant with secondary tyrosine dysregulation.  
5. **Death in infancy/childhood** is uncommon in isolated PKU but could occur in severe, untreated cases with catastrophic neurological complications or misdiagnosis (e.g., confusion with BH4 deficiency, which has overlapping hyperphenylalaninemia but worse prognosis).  

Note: While PKU explains hyperphenylalaninemia and neurodevelopmental delays, the presence of hypertyrosinemia and early mortality warrants further investigation for comorbid conditions (e.g., tyrosinemia, BH4 deficiency) or diagnostic errors. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Brucellosis, all of these are true except?
Choices:
A. Man to man transmission
B. A zoonosis
C. Blood cultures used in diagnosis
D. B melitensis is the most common cause
Answer: [/INST] Man to man transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for treatment of chloroquine resistant falciparum Malaria is
Choices:
A. Quinine
B. Chloroquine
C. Pyrimethamine
D. Primaquine
Answer: [/INST] Quinine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Alopecia', 'Vomiting', 'Diarrhea', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Vomiting and diarrhea** may occur in untreated PKU due to metabolic instability or secondary effects of phenylalanine toxicity on gastrointestinal function.  
3. **Alopecia** is atypical in classic PKU but could arise from severe malnutrition, micronutrient deficiencies (e.g., biotin), or comorbid autoimmune conditions exacerbated by chronic metabolic stress.  
4. **Death in early adulthood** aligns with untreated/severe PKU, where long-term complications (neurodegeneration, organ damage) or acute metabolic crises reduce life expectancy.  
5. Classic PKU symptoms (e.g., intellectual disability, seizures) may be absent if partially treated, but hyperphenylalaninemia remains critical for diagnosis. Early dietary management failure could explain the atypical progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: To prevent Yellow Fever Aedes aegypti index should be less than
Choices:
A. 0.50%
B. 1%
C. 2%
D. 5%
Answer: [/INST] 1% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Alkaptonuria deficiency is:
Choices:
A. Phosphofructo kinase
B. HMG CoA reductase
C. Homogentisate oxidase
D. Xanthine oxidase
Answer: [/INST] Homogentisate oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with known mutation in the `RB gene' is `disease free' from Retinoblastoma. The patient is at highest risk of developing which of the following malignancies –
Choices:
A. Renal cell carcinoma
B. Osteosarcoma
C. Pinealoblastoma
D. Chondrosarcoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Malaria during pregnancy is ?
Choices:
A. Chloroquine
B. Qunine
C. Primaquine
D. Mepaquine
Answer: [/INST] Chloroquine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Short neck', 'Shield chest', 'Global developmental delay', 'Hypertonia', 'Failure to thrive', 'Small for gestational age', 'Abnormal facial shape', 'Spondyloepiphyseal dysplasia', 'Delayed skeletal maturation', 'Recurrent upper respiratory tract infections', 'Elbow flexion contracture', 'Marked delay in bone age', 'Clinodactyly of the 5th finger', 'Decreased circulating antibody level', 'Short stature', 'Decreased proportion of CD4-positive helper T cells', 'Decreased proportion of CD8-positive T cells', 'Abnormal epiphysis morphology', 'Short 5th finger', 'Limb undergrowth', 'Epileptic spasm', 'Severe global developmental delay', 'Abnormal bone ossification', 'Overweight', 'Increased hepatic echogenicity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Abnormalities**: Microcephaly, spondyloepiphyseal dysplasia, delayed skeletal maturation, clinodactyly of the 5th finger, short 5th finger, limb undergrowth, abnormal epiphysis morphology, and marked delay in bone age align with skeletal dysplasias characteristic of ISDNA.  
2. **Immunodeficiency**: Recurrent infections, decreased antibody levels, and reduced CD4+/CD8+ T cells indicate combined B- and T-cell dysfunction, a hallmark of ISDNA.  
3. **Neurodevelopmental Delays**: Severe global developmental delay, hypertonia, and epileptic spasms reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental phenotype.  
4. **Growth and Metabolic Features**: Short stature, small for gestational age, failure to thrive, and abnormal bone ossification further support a systemic disorder involving skeletal and metabolic pathways.  
5. **Exclusion of Alternatives**: Overlap with other immunooskeletal dysplasias (e.g., Schimke immunoosseous dysplasia) is ruled out by the absence of nephropathy and the presence of severe neurodevelopmental deficits, which are distinctive to ISDNA.  

The triad of skeletal dysplasia, immunodeficiency, and neurodevelopmental abnormalities confirms the diagnosis of ISDNA. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of neonatal death, aminoaciduria, and elevated urinary carboxylic acids align with a defect in leucine catabolism. 3-Methylcrotonyl-CoA carboxylase 1 (MCCC1) deficiency disrupts the breakdown of 3-methylcrotonyl-CoA, leading to accumulation of toxic metabolites like 3-methylcrotonylglycine and 3-hydroxyisovaleric acid, detected as elevated urinary carboxylic acids. Secondary carnitine deficiency occurs due to urinary excretion of carnitine-bound detoxified metabolites. Hyperglycinemia arises from inhibition of the glycine cleavage system by accumulated organic acids. Severe metabolic decompensation in infancy explains early mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses deficiencies in either MCCC1 or MCCC2 subunits of the enzyme. The biochemical hallmarks—abnormal glycine/carnitine levels and urinary carboxylic acid elevation—stem from impaired leucine metabolism. Neonatal death and aminoaciduria reflect acute metabolic crises and renal tubular dysfunction caused by toxic metabolite overload. Both genetic subtypes (MCCC1/MCCC2) present identically clinically, making this a valid diagnosis even if the specific subunit is unspecified. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Brucellosis can be transmitted by all of the following modes, except -
Choices:
A. Contact with infected placenta
B. Ingestion of raw vegatable from infected farms
C. Person to person transmission
D. Inhalation of infected dust or aerosol
Answer: [/INST] Person to person transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Sloping forehead', 'Bulbous nose', 'Intellectual disability', 'Seizure', 'Global brain atrophy', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphisms**: Sloping forehead, bulbous nose, and tented upper lip vermilion align with characteristic facies described in TBCK syndrome.  
2. **Neurological Features**: Severe global developmental delay, intellectual disability, and seizures correlate with TBCK-associated central nervous system involvement.  
3. **Hypotonia**: Severe muscular hypotonia is a hallmark of the disorder, reflecting neuromuscular dysfunction.  
4. **Neuroimaging Findings**: Global brain atrophy supports a progressive neurodegenerative process linked to TBCK mutations.  
5. **Genetic Consistency**: The constellation of symptoms matches the phenotype of TBCK-related syndromes, caused by biallelic loss-of-function variants in the *TBCK* gene, which disrupts mTOR signaling and lysosomal function.  
6. **Exclusion of Mimics**: Features distinguish it from other hypotonia-associated disorders (e.g., Prader-Willi, Rett syndrome) by the unique facial gestalt and absence of metabolic/storage disease markers. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Superantigens area) Erythrotoxin of Staph. aureusb) Clostridium difficile toxinc) Staphyloccocal toxic shock syndrome toxind) Cholera toxin
Choices:
A. a
B. bc
C. ad
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs). CPS1 deficiency disrupts the first step of the urea cycle, preventing ammonia conversion to carbamoyl phosphate, leading to toxic ammonia accumulation.  
2. **Neonatal death** and **death in infancy** align with severe UCDs like CPS1 deficiency, which often presents catastrophically within days of birth due to hyperammonemic coma if untreated.  
3. **Oroticaciduria** is atypical for CPS1 deficiency (typically seen in OTC deficiency). However, severe metabolic stress or liver dysfunction in CPS1 deficiency may secondarily elevate orotic acid via unclear mechanisms, or the finding could reflect a concurrent/overlapping pyrimidine metabolism disturbance.  
4. Key differentiation: CPS1 deficiency classically shows **low citrulline** and **absent oroticaciduria**. The presence of oroticaciduria here is unusual but does not exclude CPS1 deficiency if other features (e.g., hyperammonemia severity, timing) strongly align. Further testing (e.g., genetic analysis, enzyme assays) would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Sensory motor neuropathy is caused by -a) DMb) Lead poisoning c) Arsenicd) Leprosye) AIDS
Choices:
A. abcd
B. bde
C. acde
D. bcde
Answer: [/INST] acde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Reduced antithrombin III activity', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Abnormal circulating copper concentration', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Glycosylation Defects**: Abnormal N-linked and O-linked glycosylation are hallmark features of congenital disorders of glycosylation (CDGs). TMEM199-CDG specifically disrupts both pathways, distinguishing it from CDGs affecting only one type.  
2. **Hepatic Involvement**: Hepatic steatosis, elevated AST/ALT, and alkaline phosphatase indicate liver dysfunction, common in TMEM199-CDG due to impaired glycosylation-dependent hepatic protein trafficking.  
3. **Coagulation Abnormalities**: Reduced antithrombin III activity arises from defective glycosylation of this glycoprotein, critical for its function.  
4. **Cholesterol Dysregulation**: Hypercholesterolemia and elevated LDL stem from disrupted lipid metabolism, linked to hepatic glycosylation defects affecting lipoprotein processing.  
5. **Copper/Ceruloplasmin Abnormalities**: Decreased ceruloplasmin (a glycosylated copper transporter) and abnormal copper levels result from failed glycosylation, mimicking Wilson’s disease but distinct in mechanism.  
6. **Consistent Phenotype**: TMEM199-CDG is specifically associated with combined hepatic, coagulation, lipid, and copper abnormalities, aligning with the patient’s profile.  

(The two diagnoses provided are synonymous: TMEM199-CDG is the molecular designation for CDG type IIP.) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** or **death in infancy** in untreated cases aligns with severe PKU variants or lack of newborn screening/dietary intervention, resulting in metabolic crises, neurological damage, or organ failure.  
3. Classic PKU typically manifests with intellectual disability and seizures, but untreated cases in resource-limited settings may progress rapidly to fatal outcomes due to acute complications (e.g., cerebral edema, infections).  
4. Differential diagnoses (e.g., BH4 deficiency) were excluded as the provided diagnosis specifically lists PKU, and hyperphenylalaninemia alone suffices for PKU classification, even if BH4 defects are clinically distinct. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by a deficiency in phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: While classic PAH-deficient PKU typically results in normal/low tyrosine, this symptom suggests a **tetrahydrobiopterin (BH4) deficiency variant** of PKU. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, explaining the dual elevation.  
3. **Death in early adulthood**: Untreated PKU (especially severe forms or BH4 deficiency) leads to irreversible neurological damage, seizures, and organ dysfunction, contributing to reduced lifespan without early dietary or BH4 supplementation therapy.  

The diagnosis aligns with PKU, with hypertyrosinemia implicating a BH4-deficient subtype as the underlying mechanism. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The heart lesion not found in Congenital Rubella infection is –
Choices:
A. ASD
B. VSD
C. PDA
D. PS
Answer: [/INST] ASD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis lymphadenitis of the cervical lymphnodes is also called:
Choices:
A. Pott's disease
B. Lupus vulgaris
C. Scrofula
D. Ghon's focus
Answer: [/INST] Scrofula </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ulcerative Colitis
? 
Choices:
A. Carries a risk of colonic cancer
B. Can be treated with a LOFFLEX diet
C. Can be caused by small intestinal bacterial overgrowth
D. Can be caused by milk intolerance
Answer: [/INST] Carries a risk of colonic cancer </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true about Mumps: March 2007
Choices:
A. Caused by paramyxovirus
B. Incubation period is less than 14 days
C. Orchitis is a common complication in males
D. Aseptic meningitis is a commoner complication in children
Answer: [/INST] Incubation period is less than 14 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Thrombotic Thrombocytopenic Purpura except:
Choices:
A. Normal ADAMTS levels
B. Microangiopathic hemolytic anemia
C. Thrombocytopenia
D. Thrombosis
Answer: [/INST] Normal ADAMTS levels </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: World Tuberculosis day
Choices:
A. March 1st
B. March 24th
C. April 1st
D. April 24th
Answer: [/INST] March 24th </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Seizures & intellectual disability**: Result from global neurological dysfunction due to glycosylation defects affecting brain structure and signaling.  
3. **Motor delay**: Linked to cerebellar dysfunction and hypotonia, common in PMM2-CDG.  
4. **Obesity**: Observed in some surviving infants due to metabolic dysregulation from glycosylation errors.  
5. **Death in infancy**: Matches severe PMM2-CDG phenotypes, often from multi-organ failure (hepatic, cardiac) or infections.  
6. **Exclusion of mimics**: Symptoms align with PMM2-CDG over Joubert syndrome (lacks glycosylation markers) or Smith-Lemli-Opitz (distinct cholesterol pathway defects).  
7. **Diagnostic confirmation**: Requires phosphomannomutase 2 (PMM2) enzyme testing or genetic analysis for pathogenic variants. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is infective for how many days before the onset of rash -
Choices:
A. 10 days
B. 4 days
C. 1 days
D. on same
Answer: [/INST] 4 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a route of transmission Rabies?
Choices:
A. Bite
B. Lick
C. Aerosol
D. Ingestion
Answer: [/INST] Ingestion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing impairment', 'Epistaxis', 'Gait disturbance', 'Fever', 'Myalgia', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Ear pain', 'Cytoplasmic antineutrophil antibody positivity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic ANCA positivity**: Strongly associated with GPA (specifically c-ANCA/PR3), a hallmark for diagnosis.  
2. **Upper respiratory involvement**: Hearing impairment, ear pain, and epistaxis suggest granulomatous inflammation of the ears and nasal passages, common in GPA.  
3. **Systemic inflammation**: Fever, elevated CRP, fatigue, and myalgia align with systemic vasculitis.  
4. **Musculoskeletal/neurologic symptoms**: Gait disturbance and lower limb pain may reflect peripheral neuropathy, joint involvement, or vascular damage.  
5. **Exclusion of mimics**: Symptoms differentiate GPA from other ANCA-associated vasculitides (e.g., microscopic polyangiitis lacks prominent upper respiratory features; eosinophilic GPA typically includes asthma/eosinophilia).  
6. **Diagnostic consistency**: The triad of vasculitis, granulomatosis, and c-ANCA positivity supports GPA despite absent renal/pulmonary signs in this case. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Egg shell calcification in hilar lymph nodes is seen ina) Sarcoidosisb) Histoplasmosisc) Tuberculosisd) Carcinoma lunge) Silicosis
Choices:
A. bcde
B. abcd
C. abce
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A farmer presenting with fever off and on for the past 4 years was diagnosed to be suffering from chronic Brucellosis. All of the following serological tests would be helpful in the diagnosis at this state except:
Choices:
A. Standard agglutination test
B. 2-mercapto-ethanol test
C. Complement fixation test
D. Coomb's test
Answer: [/INST] Standard agglutination test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common complication of Typhoid:
Choices:
A. Paralytic ileus.
B. Otitis media.
C. Oophoritis.
D. Rheumatic fever.
Answer: [/INST] Paralytic ileus. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal insufficiency', 'Abnormality of the nose', 'Pruritus', 'Hypertrophic cardiomyopathy', 'Dilated cardiomyopathy', 'Pericardial effusion', 'Left ventricular hypertrophy', 'Fever', 'Dyspnea', 'Abnormal circulating protein concentration', 'Decreased glomerular filtration rate', 'Fatigue', 'Reduced left ventricular ejection fraction', 'Cough', 'Myocarditis', 'Sputum eosinophilia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Takayasu arteritis  
Reasoning:  
1. **Vascular Inflammation**: Takayasu arteritis involves large-vessel inflammation, primarily affecting the aorta and its branches. Renal artery stenosis (from vasculitis) can explain **renal insufficiency**, **decreased glomerular filtration rate**, and secondary hypertension, contributing to **left ventricular hypertrophy**.  
2. **Cardiac Manifestations**: Chronic hypertension and inflammatory damage may lead to **hypertrophic cardiomyopathy** and **reduced left ventricular ejection fraction**. Systemic inflammation can cause **myocarditis** and **pericardial effusion**.  
3. **Systemic Inflammation**: **Fever**, **fatigue**, and **abnormal circulating protein concentrations** (e.g., elevated acute-phase reactants like CRP) align with active vasculitis.  
4. **Atypical Features**: **Sputum eosinophilia** and **pruritus** are uncommon in Takayasu but may reflect overlapping autoimmune processes or secondary hypersensitivity reactions. **Abnormality of the nose** (e.g., granulomatous inflammation) could represent rare extrapulmonary involvement.  
5. **Respiratory Symptoms**: **Dyspnea** and **cough** may arise from heart failure (due to cardiomyopathy) or pulmonary artery involvement, a recognized but less common feature of Takayasu.  
6. **Exclusion of Alternatives**: While eosinophilia might suggest Churg-Strauss syndrome, the dominance of large-vessel and cardiac pathology supports Takayasu as the primary diagnosis.  

Note: Coexisting conditions (e.g., secondary amyloidosis) should be ruled out given renal and protein abnormalities, but the clinical picture primarily fits Takayasu arteritis with multisystem complications. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies is identified by -
Choices:
A. Guarnieri bodies
B. Negri bodies
C. Cowdry A bodies
D. Cowdry B bodies
Answer: [/INST] Negri bodies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dose of Rabies immunoglobulin is?
Choices:
A. 10 IU/Kg body weight
B. 15 IU/kg body weight
C. 20 IU/kg body weight
D. 25 IU/kg body weight
Answer: [/INST] 20 IU/kg body weight </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is infectious during –
Choices:
A. After 4 days of rash
B. 4 days before and 5 days after rash
C. Throughout disease
D. Only in incubation period
Answer: [/INST] 4 days before and 5 days after rash </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following investigations is not required in Osteosarcoma?
Choices:
A. MRI
B. Bone marrow biopsy
C. CT chest
D. Bone scan
Answer: [/INST] Bone marrow biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Stomatitis', 'Stridor', 'Abnormal circulating glycine concentration', 'Fatigue', 'Elevated urinary carboxylic acid', 'Gangrene']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Carboxylase Deficiencies**: Decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency directly implicate biotin-dependent carboxylase dysfunction. Biotinidase deficiency prevents biotin recycling, critical for these enzymes.  
2. **Metabolic Acidosis & Lactate Elevation**: Impaired gluconeogenesis (pyruvate carboxylase) and disrupted citric acid cycle lead to lactic acidosis (↑ serum lactate) and metabolic acidosis. Elevated urinary carboxylic acids reflect accumulated metabolites.  
3. **Neurological Symptoms**: Lethargy, drowsiness, hypotonia, and sleep disturbance arise from biotin’s role in neuronal energy metabolism and neurotransmitter regulation.  
4. **Dermatological/Mucosal Involvement**: Stomatitis and gangrene suggest biotin deficiency, as biotin is essential for skin/mucosal integrity.  
5. **Aminoaciduria & Glycine Abnormalities**: Renal tubular acidosis (from metabolic stress) and disrupted amino acid metabolism explain aminoaciduria and abnormal glycine levels.  
6. **Fever & Infant Mortality**: Metabolic crises and susceptibility to infections (due to immune dysfunction) may cause fever. Untreated BTDD leads to fatal metabolic decompensation in infancy.  
7. **Stridor**: Neuromuscular weakness or laryngeal dysfunction secondary to metabolic encephalopathy could manifest as stridor.  
**Conclusion**: The constellation of multi-carboxylase deficiencies, metabolic acidosis, neurological/dermatological signs, and infantile lethality aligns with late-onset BTDD. Biotin supplementation would reverse symptoms if diagnosed early. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Fever', 'Abnormal cerebral morphology', 'Severe hearing impairment', 'L-2-hydroxyglutaric aciduria', 'L-2-hydroxyglutaric acidemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical markers**: The presence of ""L-2-hydroxyglutaric aciduria"" and ""L-2-hydroxyglutaric acidemia"" in the symptom list directly indicates a defect in L-2-hydroxyglutarate dehydrogenase, leading to toxic accumulation of L-2-hydroxyglutaric acid in urine and blood.  
2. **Neurological manifestations**: Macrocephaly, delayed speech, intellectual disability, seizures, and abnormal cerebral morphology align with this disorder’s characteristic progressive encephalopathy and leukoencephalopathy.  
3. **Severe systemic involvement**: Severe hearing impairment and death in infancy suggest advanced disease progression, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Supporting features**: Fever may reflect metabolic decompensation during intercurrent illnesses, exacerbating neurological symptoms.  
5. **Exclusion of mimics**: The combination of biochemical findings, neurodevelopmental regression, and cerebral abnormalities rules out other organic acidurias or leukodystrophies.  

The diagnosis is confirmed by genetic testing (e.g., _L2HGDH_ mutations) and consistent biochemical/neuroimaging findings. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Myxoviruses include -a) Orthomyxovirusb) Influenzac) Measlesd) Polioe) HSV
Choices:
A. ab
B. bc
C. acd
D. abc
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acromegaly is associated with all of the following EXCEPT:
Choices:
A. Nasal sinus enlargement
B. Increased heel pad thickness
C. Diabetes mellitus
D. Muscle hyperophy
Answer: [/INST] Muscle hyperophy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Lymphatic Filariasis except
Choices:
A. Causative agent - Wuchereria bancrofti
B. Intermediate host - Man
C. Main vector in India - Culex quinquefasciatus
D. Most common epidemiological method for detection - thick film preparation
Answer: [/INST] Intermediate host - Man </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Prolactinoma in pregnancy, all are true except
Choices:
A. Most common pituitary tumor but rarely symptomatic
B. Increase in prolactin levels worse prognosis
C. Macroadenoma> 1 cm is associated with bad prognosis
D. Regular visual checkup
Answer: [/INST] Increase in prolactin levels worse prognosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ferritin concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development/birth** and **neonatal death** align with untreated PKU, as elevated phenylalanine is neurotoxic, causing severe developmental disruption if undetected postnatally.  
3. **Death in infancy/childhood** reflects historical untreated PKU outcomes due to progressive neurological damage, seizures, and failure to thrive.  
4. **Hypertyrosinemia** is atypical in classical PKU (which typically shows *low* tyrosine). This may indicate a coexisting condition (e.g., tyrosinemia type II) or secondary metabolic dysregulation from liver stress in severe PKU.  
5. **Decreased ferritin** correlates with PKU dietary management, as low-protein diets may limit iron intake, necessitating monitoring.  
6. PKU diagnosis is prioritized due to **hyperphenylalaninemia** as the pathognomonic feature; other symptoms likely stem from untreated metabolic derangements.  

*Note:* Hypertyrosinemia warrants further investigation to exclude dual diagnoses or enzyme cofactor deficiencies (e.g., tetrahydrobiopterin). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: Biotinidase deficiency disrupts carboxylase function, leading to organic acid accumulation. This forces carnitine to conjugate with toxic metabolites, depleting carnitine stores and causing secondary deficiency.  
2. **Death in childhood/adolescence**: Untreated BTDD results in severe metabolic crises (e.g., ketoacidosis, hyperammonemia), neurological deterioration, and fatal outcomes without early biotin supplementation.  
3. **Obesity**: While atypical, disrupted fatty acid oxidation due to carnitine deficiency may impair energy production, shifting metabolism toward fat storage. Altered acetyl-CoA carboxylase activity (biotin-dependent) could further dysregulate lipid synthesis pathways.  
4. **Consistency with late-onset multiple carboxylase deficiency**: The phenotype aligns with delayed presentations, where partial enzyme activity permits survival into childhood/adolescence before metabolic decompensation occurs. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The best way to manage Dermatitis Herpetiformis is ?
Choices:
A. Gluten free diet with minerals and vitamins
B. Dapsone
C. Acyclovir
D. Steroids
Answer: [/INST] Gluten free diet with minerals and vitamins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: New drug approved for drug-resistant Tuberculosis?
Choices:
A. Bedaquiline
B. Ibalizumab
C. Bectegravir
D. Apalutamide
Answer: [/INST] Bedaquiline </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common cause of Pyogenic Meningitis in 6 month to 2 years of age is
Choices:
A. Staphylococcus aureus
B. Pneumococcus
C. Streptococcus pneumonia
D. H. influeuenzae
Answer: [/INST] Streptococcus pneumonia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is true about Multiple Myeloma?
Choices:
A. M spike increase
B. Direct plasma cell deposition in glomerular capillaries leads to kidney damage
C. IL 8 is a marker for bone lesions
D. Invariablly increase in alkaline Phosphatase
Answer: [/INST] M spike increase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hair on end appearance is seen in X–ray skull in –a)  Thalassemiab)  Hydrocephalusc)  Chronic malariad)  Sickle cell anemia
Choices:
A. ad
B. c
C. ac
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common presentation of Retinoblastoma
Choices:
A. Strabismus
B. Leucocoria
C. Decreased vision
D. Yellowish-white retinal mass.
Answer: [/INST] Leucocoria </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A young patient presented with HTN and VMA 14 mg/24, the causes is/are -a) Medullary carcinoma thyroidb) Von Hippel Lindau syndromec) Graves diseased) Pseudohypoparathyroidisme) Sturge weber syndrome
Choices:
A. abc
B. bcd
C. cde
D. abe
Answer: [/INST] abe </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: NOT seen in Tetralogy of Fallot is
Choices:
A. Pulmonary stenosis
B. Right Ventricular hypertrophy
C. Ventricular septal defect
D. Overriding of Aorta
Answer: [/INST] Pulmonary stenosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Macula involvement is common in -a) Toxoplasmab) Malariac) CMVd) Syphilis
Choices:
A. abc
B. acd
C. bc
D. bde
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is transmitted by -
Choices:
A. Mite
B. Flea
C. Sand fly
D. None
Answer: [/INST] Flea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Pseudohypoparathyroidism are true, except -
Choices:
A. ↓Serum PTH
B. ↓ Serum calcium
C. ↑ Serum phosphate
D. Albright's hereditary osteodystrophy
Answer: [/INST] ↓Serum PTH </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Galactosemia is due to deficiency of the following enzymes
Choices:
A. Galactose-1-phosphate uridyl transferase
B. HGPRT
C. Galactokinase
D. Epimerase
Answer: [/INST] Galactose-1-phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid oral vaccine is given -
Choices:
A. 1, 3, 5 days
B. 1, 2, 3 days
C. 1, 2, 4 days
D. 1, 7, 14 days
Answer: [/INST] 1, 3, 5 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Anemia', 'Hyperhomocystinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal blood folate concentration', 'Abnormal vitamin B12 level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia**: Directly caused by cystathionine beta-synthase (CBS) deficiency, which disrupts homocysteine metabolism, leading to toxic accumulation.  
2. **Anemia**: CBS deficiency indirectly affects folate and vitamin B12 metabolism, both critical for DNA synthesis and erythropoiesis. Abnormal levels of these vitamins can result in megaloblastic anemia.  
3. **Abnormal vitamin B12/folate concentrations**: Homocysteine remethylation to methionine requires B12 and folate. Dysregulation in this pathway alters their utilization, causing abnormal serum levels.  
4. **Death in infancy**: Severe CBS deficiency manifests neonatally with rapid metabolic decompensation, thromboembolic events, or failure to thrive, often fatal without early diagnosis/treatment.  
5. **Abnormal porphyrins**: While not a primary feature of CBS deficiency, secondary oxidative stress from homocysteine toxicity may disrupt heme biosynthesis, elevating porphyrin levels.  

Disease: Homocysteinemia/Homocystinuria (broader category)  
Reasoning:  
1. **Hyperhomocystinemia**: Defines the condition, encompassing both genetic (e.g., CBS deficiency) and acquired causes (e.g., B9/B12 deficiencies).  
2. **Consistent symptoms**: All listed findings (anemia, abnormal B12/folate, porphyrins) align with systemic metabolic disruption from homocysteine toxicity, even if CBS deficiency is the specific etiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Wide nasal bridge', 'Strabismus', 'Recurrent corneal erosions', 'Proptosis', 'Alacrima', 'Oculomotor apraxia', 'Dental crowding', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Short foot', 'Constipation', 'EEG abnormality', 'Highly arched eyebrow', 'Scoliosis', 'Lack of facial subcutaneous fat', 'Small hand']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (NGLY1 deficiency)  
Reasoning:  
1. **Alacrima**: A hallmark feature of NGLY1 deficiency, directly linked to impaired tear production due to glycosylation defects.  
2. **Neurological symptoms** (Seizures, EEG abnormality, Global developmental delay, Hypotonia, Oculomotor apraxia): Reflect systemic neurodegeneration and disrupted glycoprotein metabolism critical for brain function.  
3. **Ocular abnormalities** (Proptosis, Strabismus, Recurrent corneal erosions): Secondary to alacrima (dry eyes causing corneal damage) and neuromuscular dysregulation.  
4. **Growth defects** (Microcephaly, Intrauterine growth retardation, Small hand/Short foot): Consistent with prenatal-onset glycosylation disorder affecting growth pathways.  
5. **Dysmorphic features** (Wide nasal bridge, Highly arched eyebrow, Lack of facial subcutaneous fat): Characteristic craniofacial patterns in congenital glycosylation disorders.  
6. **Musculoskeletal issues** (Scoliosis, Dental crowding): Connective tissue/glycoprotein abnormalities impacting bone and tissue structure.  
7. **Autonomic/Systemic involvement** (Constipation, Reduced tendon reflexes): Dysfunction in glycosylation-dependent autonomic signaling and neuromuscular junctions.  
8. **Absence of noted liver dysfunction**: While liver issues are part of the syndrome’s name, phenotypic variability exists; other symptoms dominate the clinical picture here.  

This constellation aligns with NGLY1 deficiency, a disorder of endoplasmic reticulum-associated degradation (ERAD) due to impaired deglycosylation, disrupting multiple glycoprotein-dependent processes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True statement regarding a 3-week old child with Phenylketonuria is all, except –
Choices:
A. Provocative protein meal tests helps in the diagnosis
B. Tyrosine becomes an Essential amino–acid in diet
C. Serum Phenylalanine is increased and urinary Phenyl Pyruvate level is elevated
D. Phenylalanine should be completely stopped in diet
Answer: [/INST] Phenylalanine should be completely stopped in diet </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Triad of Tuberous Sclerosis includes all, except:
Choices:
A. Epilepsy
B. Low intelligence
C. Hydrocephalus
D. Adenoma sebaceum
Answer: [/INST] Hydrocephalus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial parasite - which statement is false regarding communicability -
Choices:
A. The gematocytes appear in blood 4-6days after a sexual phase in p.vivax
B. The gametocytes appear in blood 10-12 days after a sexual phase in p. Falciparum
C. The number of gametocytes increases in blood with tyme
D. The number of gametocytes increases by 1000 times
Answer: [/INST] The number of gametocytes increases in blood with tyme </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis commonly affects which pa of the intestine: September 2005
Choices:
A. Ileum
B. Jejunum
C. Terminal colon
D. Transverse colon
Answer: [/INST] Ileum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera like diarrhea is associated with?
Choices:
A. Copper poisoning
B. Arsenic poisoning
C. Lead poisoning
D. Mercury poisoning
Answer: [/INST] Arsenic poisoning </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Conjunctivitis', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs in MCADD due to excess conjugation of carnitine to accumulating toxic medium-chain acyl metabolites (e.g., octanoylcarnitine).  
2. **Neonatal/Infancy/Childhood fatality**: MCADD causes life-threatening hypoglycemia and metabolic crises during fasting or illness, often presenting in infancy or early childhood if undiagnosed.  
3. **Prenatal abnormalities**: Though less common, intrauterine metabolic stress from MCADD may contribute to growth restriction or complications, particularly in severe cases.  
4. **Enzyme discrepancy**: The listed ""decreased 3-hydroxyacyl-CoA dehydrogenase level"" may reflect a misreporting. MCADD specifically involves *medium-chain acyl-CoA dehydrogenase* deficiency. If accurate, this could indicate a concurrent or overlapping disorder (e.g., trifunctional protein deficiency), but MCADD remains primary given clinical alignment.  
5. **Conjunctivitis**: Atypical for MCADD; possibly coincidental (e.g., infection) or misdocumented (retinopathy in LCHAD deficiency is a differential but excluded here).  
6. **Key biochemical link**: Hypoketotic hypoglycemia and elevated medium-chain acylcarnitines (C6-C10) on tandem mass spectrometry confirm MCADD, aligning with decreased free carnitine and clinical history. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin -
Choices:
A. Increases the levels of intracellular cylic GMP
B. Acts through the receptor the opiates
C. Causes continued activation of adenylate cyclase
D. Inhibits the enzyme phosphodiesterase
Answer: [/INST] Causes continued activation of adenylate cyclase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Hernia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1  
**Reasoning**:  
1. **Hypertyrosinemia & aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1, caused by deficiency of fumarylacetoacetate hydrolase (FAH), leading to tyrosine accumulation and renal tubular dysfunction (Fanconi syndrome).  
2. **Elevated alpha-fetoprotein (AFP) & abnormal porphyrins**: Succinylacetone (a toxic metabolite in FAH deficiency) inhibits porphobilinogen synthase, causing porphyrin abnormalities. Elevated AFP reflects hepatic injury or regeneration, common in HT-1.  
3. **Hepatic manifestations (ascites, hypoalbuminemia, hypoproteinemia, elevated alkaline phosphatase)**: FAH deficiency causes severe liver dysfunction, progressing to cirrhosis, synthetic failure, and cholestasis. Ascites results from portal hypertension and hypoalbuminemia.  
4. **Thrombocytosis**: Reactive thrombocytosis secondary to chronic liver disease or splenic dysfunction.  
5. **Anemia & pallor**: Due to liver failure (coagulopathy, malnutrition) and/or porphyrin-related hemolysis.  
6. **Hernia**: Increased intra-abdominal pressure from ascites.  
7. **Death in infancy**: Untreated HT-1 often leads to fatal liver failure or neurologic crises in early childhood.  

The constellation of hepatic, renal, and metabolic abnormalities (succinylacetone, tyrosine) is pathognomonic for tyrosinemia type 1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Specific learning disability', 'Feeding difficulties', 'Hypoxemia', 'Posterior rib gap']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cerebrocostomandibular Syndrome:  
1. **Cleft palate & Pierre-Robin sequence**: Cerebrocostomandibular syndrome (CCMS) is characterized by micrognathia (small jaw), glossoptosis, and cleft palate, which collectively define Pierre-Robin sequence. These structural anomalies explain airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: A hallmark feature of CCMS is rib dysplasia, including posterior rib gaps or ""missing"" rib segments. This disrupts thoracic cage integrity, contributing to respiratory insufficiency (hypoxemia).  
3. **Feeding difficulties & hypoxemia**: Micrognathia and cleft palate impair sucking/swallowing, while rib defects reduce lung capacity, exacerbating hypoxemia.  
4. **Specific learning disability**: Chronic hypoxia from respiratory compromise or potential central nervous system involvement (rarely reported in CCMS) may underlie neurodevelopmental delays.  
5. **Exclusion of mimics**: The combination of rib gaps, Pierre-Robin sequence, and neurodevelopmental issues distinguishes CCMS from isolated Pierre-Robin or syndromes like Stickler or Treacher Collins. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella virus belongs to which family ?
Choices:
A. Picornavirus
B. Paramyxoviridae
C. Ohomyxoviridae
D. Togaviridae
Answer: [/INST] Togaviridae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency or abnormal carnitine profiles due to accumulation of toxic metabolites like acylcarnitines (e.g., C8-C10 species).  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes life-threatening metabolic crises triggered by fasting or illness. Hypoketotic hypoglycemia, hepatic dysfunction, and encephalopathy can rapidly progress to coma and death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic instability in utero might contribute to intrauterine growth restriction (IUGR) or prematurity in rare cases.  
4. **Key diagnostic confirmation**: Elevated urinary dicarboxylic acids (C6-C10) and specific acylcarnitines (C8, C6, C10:1) on tandem mass spectrometry (TMS) would confirm MCADD, aligning with the clinical presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Triple deformity of knee is classically seen in -a) Fracture patellab) Tuberculosisc) Rheumatic arthritisd) Rheumatoid arthritis
Choices:
A. c
B. d
C. ab
D. bd
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary site of infection in Cryptococcosis is
Choices:
A. Adrenal glands
B. Bone
C. Central nervous system
D. Lungs
Answer: [/INST] Lungs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The drug of choice in Cryptoccccal Meningitis is:
Choices:
A. Pentostatin
B. Amphotericin B
C. Clotrimazole
D. Zidovudine
Answer: [/INST] Amphotericin B </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Microcephaly is seen in
Beckwith hypoglycaemic syndrome
Fanconi syndrome
Down syndrome
Achondroplasia
Choices:
A. I and iv
B. I and ii
C. ii and iii
D. ii and iv
Answer: [/INST] I and ii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a minor criteria for diagnosis of Rheumatic Fever (RF) according to modified Jones criteria?
Choices:
A. ASO titre
B. Past History of Rheumatic Fever
C. Fever
D. Subcutaneous nodules
Answer: [/INST] Fever </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial parasite in anopheles is
Choices:
A. Propagative
B. Cyclo-Propagative
C. Cyclo-developmental
D. None of the above
Answer: [/INST] Cyclo-Propagative </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is a noveneral form of trephonemal infection – a) Yawsb) Pintac) Syphillisd) GV
Choices:
A. ab
B. a
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the most impoant pa of brain involved in Narcolepsy
Choices:
A. Neocoex
B. Hypothalamus
C. Hippocampus
D. Pons
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinitis Pigmentosa is associated with all except –
Choices:
A. Usher Syndrome
B. Marfan's Syndrome
C. Kearns – Sayre Syndrome
D. Bassen – Kornzweig Syndrome
Answer: [/INST] Marfan's Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diagnostic criteria for Allergic Bronchopulmonary Aspergillosis include all, except
Choices:
A. Peripheral eosinophilia (>0.1 x 109/mm3)
B. Central bronchiectasis
C. Episodic Asthma
D. Detection of Aspergillus in sputum
Answer: [/INST] Peripheral eosinophilia (>0.1 x 109/mm3) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements about Q fever is false -
Choices:
A. Highly infectious zoonotic disease
B. The mode of transmission is by inhalation
C. Arthropods are involved in its transmission to man
D. There is no rash or local lesion
Answer: [/INST] Arthropods are involved in its transmission to man </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Uncooked Fish eating causing Megaloblastic Anemia is due to ?
Choices:
A. H. nana
B. Taenia saginata
C. Echinococcus
D. Diphyllobothrium Latum
Answer: [/INST] Diphyllobothrium Latum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Botulism are true except :
Choices:
A. Botulism is caused by endotoxin
B. Honey ingestion causes infant botulism
C. Constipation is seen
D. Detection of antitoxin in the serum can aid in diagnosis
Answer: [/INST] Botulism is caused by endotoxin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningioma on plain radiography reveals – a) Calcificationb) Erosionc) Sutural diastasis d) Osteosclerosise) Vascular marknig
Choices:
A. ade
B. bde
C. abd
D. ad
Answer: [/INST] ade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cyanosis', 'Seizure', 'Death in infancy', 'Bradycardia', 'Vomiting', 'Dicarboxylic aciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Dicarboxylic aciduria**: A hallmark of impaired fatty acid β-oxidation and ketogenesis. HMG-CoA lyase deficiency disrupts leucine metabolism and ketone body synthesis, leading to urinary excretion of dicarboxylic acids.  
2. **Neonatal death/Death in infancy**: Severe metabolic crises (hypoketotic hypoglycemia, metabolic acidosis) triggered by fasting or catabolism are common in untreated infants.  
3. **Seizures**: Result from acute hypoglycemia and energy depletion in the brain.  
4. **Vomiting and Bradycardia**: Metabolic acidosis and electrolyte imbalances disrupt gastrointestinal and cardiac function.  
5. **Cyanosis**: Secondary to respiratory distress caused by acidosis or poor tissue oxygenation during metabolic decompensation.  
6. **Confirmatory biochemical markers**: Elevated 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-hydroxyisovaleric acids in urine organic acid analysis confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 29-year-old man is seen in the office after returning from a hiking trip in Colorado. He complains of feeling unwell and reports symptoms of fever, myalgia, headache, and nausea. Two days ago, he noticed a rash on his wrists and ankles that has now spread to his body. He recalls having had numerous insect bites during his trip. On examination, his blood pressure is 90/60 mmHg, pulse 100/min, and respirations 20/min. There are multiple 1-5 mm macules on his body and some of them have a hemorrhagic center consistent with a petechia. His neck is supple and fundi are normal. The heart sounds are normal, lungs clear, and legs are edematous. Cranial nerve, motor, and sensory examination is normal. A clinical diagnosis of Rocky Mountain Spotted Fever (RMSF) is made and he is started on appropriate therapy. Which of the following is the most common type of central nervous system (CNS) presentation in this condition?
Choices:
A. hemiplegia
B. cranial nerve abnormalities
C. paraplegia
D. encephalitis
Answer: [/INST] encephalitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are helpful for elimination of Filariasis, except -
Choices:
A. Microfilaris do not multiply in vectors
B. They multiply in humans
C. Larvae are deposited on skin surface where they can't survive
D. NOne
Answer: [/INST] Larvae are deposited on skin surface where they can't survive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma is caused by -a) Fasciola infestationb) Clonorchis infestationc) Paragonimus infestationd) Ascaris infestatione) None of these
Choices:
A. ac
B. ab
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cardiomyopathy', 'Decreased plasma free carnitine', 'Death in adolescence', 'Abnormal circulating acetylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: PCD is caused by mutations in the *SLC22A5* gene, impairing the high-affinity carnitine transporter (OCTN2). This results in renal carnitine wasting and systemic depletion.  
2. **Cardiomyopathy**: Carnitine is critical for fatty acid oxidation (FAO). Its deficiency forces cardiac myocytes to rely on glycolysis, leading to energy depletion, lipid accumulation, and progressive dilated/hypertrophic cardiomyopathy.  
3. **Abnormal circulating acetylcarnitine**: Disrupted carnitine metabolism alters acylcarnitine profiles. While total carnitine is low, acetylcarnitine (C2) may paradoxically rise due to compensatory mitochondrial acetyl-CoA accumulation or secondary FAO disturbances.  
4. **Death in adolescence**: Untreated PCD causes recurrent hypoglycemic/hypoketotic crises, arrhythmias, or heart failure. Mortality peaks in childhood/adolescence due to metabolic stress (e.g., fasting, illness) overwhelming residual FAO capacity.  
5. **Diagnostic confirmation**: PCD is distinguished from secondary carnitine deficiencies (e.g., organic acidemias) by genetic testing (*SLC22A5* mutations) and absence of other FAO disorders. Symptoms resolve with lifelong high-dose carnitine supplementation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Thrombocytopenia', 'Abnormal bleeding', 'Giant platelets', 'Impaired ristocetin-induced platelet aggregation', 'Subdural hemorrhage']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Bernard-Soulier syndrome  
Reasoning:  
1. **Thrombocytopenia**: Low platelet count aligns with Bernard-Soulier syndrome (BSS), as giant platelets are often misclassified or destroyed, reducing measured counts.  
2. **Giant platelets**: Pathognomonic for BSS due to mutations in the *GP1BA*, *GP1BB*, or *GP9* genes, disrupting platelet membrane glycoprotein Ib-IX-V complex formation.  
3. **Impaired ristocetin-induced platelet aggregation**: Specific to BSS, as ristocetin requires functional glycoprotein Ib-IX-V to bind von Willebrand factor (vWF). This defect distinguishes BSS from von Willebrand disease (where ristocetin aggregation is normal or enhanced).  
4. **Abnormal bleeding and subdural hemorrhage**: Reflects severe platelet dysfunction and thrombocytopenia, consistent with BSS’s clinical presentation.  
5. **Exclusion of mimics**: Normal prothrombin time (PT) and activated partial thromboplastin time (aPTT) (implied absence of clotting factor issues) and lack of Döhle bodies (unlike MYH9-related disorders) further support BSS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This aligns with the symptom of elevated blood phenylalanine levels.  
2. **Elevated urinary carboxylic acids**: Untreated PKU results in excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenylacetate), which are carboxylic acids detected in urine.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU can cause progressive neurological deterioration, seizures, and organ failure, potentially leading to early mortality without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (untreated hyperphenylalaninemia during pregnancy) can cause congenital anomalies (e.g., microcephaly) in the fetus, explaining prenatal developmental issues.  
5. **Death in early adulthood**: Chronic complications of untreated PKU, such as intellectual disability, behavioral disorders, and neurodegenerative changes, may reduce life expectancy.  
6. **Hypertyrosinemia discrepancy**: While classic PKU typically causes *low* tyrosine (due to PAH deficiency), this symptom may reflect a concurrent metabolic disorder, lab error, or misclassification of secondary metabolites (e.g., tyrosine elevation from liver dysfunction).  

PKU is the primary diagnosis, with outcomes explained by untreated hyperphenylalaninemia and its systemic effects. Early dietary management (phenylalanine restriction) could prevent most severe complications. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary Tuberculosis most commonly involves
Choices:
A. Lungs
B. Liver
C. Brain
D. Intestine
Answer: [/INST] Lungs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which statement is false regarding Tuberculosis in HIV positive individual :
Choices:
A. Frequent negative sputum smear.
B. False negative tuberculin test result
C. Extra pulmonary tuberculosis more common.
D. Cavitation lesions in lungs as shown by chest X- ray.
Answer: [/INST] Cavitation lesions in lungs as shown by chest X- ray. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are true of Tuberculosis except ?
Choices:
A. For sputum to be positive, (A194) bacilli should be > 1
B. Niacin test differentiates M. tuberculosis and M. bovis
C. Pathogenicity to rabbits differentiates M. tuberculosis and M. bovis
D. All
Answer: [/INST] Pathogenicity to rabbits differentiates M. tuberculosis and M. bovis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Child born to mothers with Phenylketonuria will have all except
Choices:
A. Mental retardation
B. Macrocephaly
C. Growth retardation
D. Congenital heart disease
Answer: [/INST] Macrocephaly </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the lower limb', 'Microscopic hematuria', 'Elevated circulating creatine kinase concentration', 'Paresthesia', 'Elevated erythrocyte sedimentation rate', 'Prolonged prothrombin time', 'Elevated circulating C-reactive protein concentration', 'Macule', 'Decreased circulating complement C4 concentration', 'Skin erosion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (VEXAS)  
Reasoning:  
1. **Elevated inflammatory markers (ESR, CRP)**: Consistent with systemic autoinflammation.  
2. **Skin erosion/macule**: Reflects cutaneous vasculitis, a hallmark of VEXAS.  
3. **Decreased C4**: Suggests complement consumption, potentially linked to immune dysregulation in VEXAS.  
4. **Prolonged prothrombin time**: Aligns with hematologic defects, possibly due to hepatic involvement or clotting factor deficiencies.  
5. **Microscopic hematuria**: May indicate renal inflammation or vasculitic kidney injury.  
6. **Elevated creatine kinase/paresthesia**: Muscle and nerve involvement (myositis/neuropathy) seen in systemic autoinflammatory processes.  
7. **Lower limb abnormalities**: Could stem from arthritis or vasculitis-induced ischemia.  

Disease: Polyarteritis nodosa (PAN)  
Reasoning:  
1. **Microscopic hematuria**: Renal artery vasculitis in PAN can cause glomerular injury.  
2. **Paresthesia**: Mononeuritis multiplex, a classic feature of PAN due to nerve ischemia.  
3. **Skin erosion/macule**: Cutaneous vasculitis manifesting as ulcers or livedo.  
4. **Elevated ESR/CRP**: Non-specific markers of systemic inflammation in vasculitis.  
5. **Elevated creatine kinase**: Muscle ischemia from arterial inflammation.  
6. **Lower limb abnormalities**: Vascular compromise leading to claudication or necrosis.  
**Notable exclusions**: Prolonged PT and low C4 are atypical for PAN, making VEXAS more likely. PAN typically lacks complement abnormalities and coagulopathies.  

**Conclusion**: VEXAS is the primary diagnosis due to hematologic/immunologic features (prolonged PT, low C4), while PAN remains a differential for vasculitis-driven symptoms. Genetic testing for *UBA1* mutations and angiography (for PAN-associated aneurysms) would confirm. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is differentiated from adenocarcinoma by:
Choices:
A. Prescence of long slender microvilli
B. Abundant altered mitochondria
C. Ribosome clumps
D. Dense secretory core granules
Answer: [/INST] Prescence of long slender microvilli </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Neurotropic fungus is/are -a) Cryptococcus neoformansb) Histoplasmosisc) Trichophytond) Candidae) Aspergillosis
Choices:
A. abcd
B. bcde
C. abde
D. ade
Answer: [/INST] abde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Obesity', 'Abdominal pain', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning:  
1. **Abdominal pain** is a hallmark symptom of acute intermittent porphyria (AIP), caused by neurovisceral attacks due to accumulation of porphyrin precursors.  
2. **Death in childhood** aligns with severe, undiagnosed AIP cases, where acute attacks can lead to respiratory failure, seizures, or cardiac arrhythmias.  
3. **Obesity** is atypical for AIP but may reflect metabolic comorbidities, misreported ascites, or steroid use (e.g., during treatment).  
4. AIP typically manifests post-puberty but can occur earlier; childhood mortality suggests a severe genetic variant or delayed diagnosis.  

Disease: Porphyria/Porphyria  
Reasoning:  
1. The term broadly encompasses porphyria disorders, including hepatic (e.g., AIP) or erythropoietic types.  
2. **Abdominal pain** and **death in childhood** could indicate a severe subtype (e.g., congenital erythropoietic porphyria), though cutaneous symptoms would typically dominate.  
3. **Obesity** remains incongruent with classical porphyria phenotypes but may reflect secondary factors (e.g., limited mobility from chronic illness).  
4. Generalized classification allows for atypical presentations but lacks specificity compared to AIP.  

**Conclusion**: Acute intermittent porphyria is the most precise diagnosis, while ""porphyria"" serves as a broader category. Obesity likely represents a confounding factor or comorbidity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Proptosis is seen in – a) Neuroblastoma  b) Meningioma  c) Sympathetic ophthalmia  d) Injuries
Choices:
A. abd
B. abc
C. bcd
D. bde
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine.  
2. **Severe short stature** and **abnormality of prenatal development** may occur in untreated maternal PKU, where high phenylalanine levels during pregnancy disrupt fetal growth.  
3. **Death in infancy/childhood/adolescence** aligns with untreated PKU, as toxic phenylalanine accumulation leads to irreversible neurological damage, seizures, and organ failure.  
4. **Recurrent viral infections** are atypical for classic PKU but could reflect secondary immunodeficiency due to chronic metabolic stress or malnutrition in severe cases.  
5. **Hypertyrosinemia** is unusual in isolated PKU (which typically lowers tyrosine), suggesting a possible comorbid tyrosinemia or BH4 deficiency (a PKU variant affecting both phenylalanine and tyrosine metabolism). However, hyperphenylalaninemia remains the primary diagnostic marker.  
6. Early mortality (**neonatal death**, **death in early adulthood**) underscores the critical need for newborn screening and dietary intervention to prevent complications.  

Note: Hypertyrosinemia may indicate an overlapping disorder (e.g., BH4 deficiency or tyrosinemia), but the dominant feature (hyperphenylalaninemia) strongly prioritizes PKU as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is a characteristic feature of toxicity with:-
Choices:
A. Barium
B. Antimony
C. Copper
D. Iron
Answer: [/INST] Barium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statement are true regarding Q fever except -
Choices:
A. It is zoonotic disease
B. Human disease is characterized by an interstitial pneumonia
C. No rash is seen
D. Weil-felix reaction is very useful for diagnosis
Answer: [/INST] Weil-felix reaction is very useful for diagnosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy involves all except
Choices:
A. Uterus
B. Ovary
C. Nerve
D. Eye
Answer: [/INST] Uterus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Patient diagnosed with HIV and Tuberculosis. How to sta ATT and c-A.R.T
Choices:
A. Sta ATT first
B. Sta cA first
C. Sta both simultaneously
D. Sta cA only
Answer: [/INST] Sta ATT first </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma has been associated with infection by:
Choices:
A. Paragonimus westermani
B. Clonorchis sinensis
C. Loa Loa
D. Schistosoma haematobium
Answer: [/INST] Clonorchis sinensis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is due to -
Choices:
A. Vit-A deficiency
B. Keratoconus
C. Vitamin E deficiency
D. Also seen in retinitis pigmentosa
Answer: [/INST] Vit-A deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Cystic hygroma', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly** and **cystic hygroma** may reflect early cerebral abnormalities or fluid-filled lesions, though cystic hygroma is atypical and warrants further evaluation for comorbidities.  
3. **Neurological symptoms** (lethargy, generalized hypotonia, dystonia, dyskinesia, drowsiness) align with basal ganglia damage, a hallmark of GA-I-induced striatal injury during metabolic crises.  
4. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid, impairing fatty acid metabolism.  
5. **Acute metabolic decompensation** (fever, vomiting, diarrhea, dyspnea) triggers encephalopathic crises, often precipitated by infections or fasting, explaining rapid deterioration and **neonatal/infant death** if untreated.  
6. **Sleep disturbances** may stem from neurochemical imbalances caused by accumulating metabolites.  
7. GA-I’s clinical trajectory—progressive neurological decline and early lethality without dietary/interventional management—matches the symptom constellation.  

*Note: Cystic hygroma is uncommon in GA-I and may suggest a coincidental finding or misdiagnosis; however, the remaining features strongly support GA-I as the primary diagnosis.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the kidney', 'Hypertension', 'Seizure', 'Coma', 'Death in infancy', 'Cardiomyopathy', 'Thrombocytopenia', 'Leukopenia', 'Anemia', 'Leukocytosis', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Increased serum lactate', 'Hyperproteinemia', 'Hyperkalemia', 'Hyperglycinemia', 'Hypertriglyceridemia', 'Skeletal dysplasia', 'Tachypnea', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Hypercholesterolemia', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating parathyroid hormone level', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Hypermethioninemia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Elevated systolic blood pressure', 'Elevated diastolic blood pressure', 'Abnormal circulating porphyrin concentration', 'Hyperhistidinemia', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Methylmalonic acidemia/aciduria** and **decreased methylmalonyl-CoA mutase activity** directly confirm a defect in the methylmalonyl-CoA mutase enzyme, critical for propionate metabolism.  
   - **Hyperammonemia**, **hyperuricemia**, **elevated lactate**, and **hyperglycinemia** reflect secondary metabolic disruptions from toxic metabolite accumulation.  

2. **Acute decompensation features**:  
   - **Seizures**, **coma**, **vomiting**, **tachypnea**, and **feeding difficulties** align with metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
   - **Hyperkalemia**, **hypernatremia**, and **elevated blood urea nitrogen/creatinine** indicate renal dysfunction, a known complication of chronic methylmalonic acid toxicity.  

3. **Chronic multisystem involvement**:  
   - **Cardiomyopathy** and **hypertension** arise from metabolic stress and renal failure.  
   - **Skeletal dysplasia** and **severe short stature** result from chronic acidosis impairing bone mineralization.  
   - **Hematologic abnormalities** (anemia, leukopenia, thrombocytopenia) stem from bone marrow suppression by methylmalonic acid.  

4. **Early mortality**:  
   - **Neonatal death**, **death in infancy/childhood/adolescence**, and **death in early adulthood** reflect the severity of B12-unresponsive MMA, often fatal without aggressive management (dialysis, transplantation).  

5. **Supporting metabolic derangements**:  
   - **Abnormal carnitine**, **hypertriglyceridemia**, and **elevated citrulline/ornithine** highlight disrupted mitochondrial metabolism and urea cycle stress.  
   - **Elevated alkaline phosphatase/PTH** correlate with renal osteodystrophy from chronic kidney disease.  

This constellation of findings conclusively points to **methylmalonyl-CoA mutase deficiency**, a B12-unresponsive form of MMA, explaining both acute crises and progressive organ damage. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Microcephaly', 'Pointed chin', 'Short chin', 'Anteverted nares', 'Torticollis', 'Strabismus', 'Hypermetropia', 'Syndactyly', 'Intellectual disability', 'Hyporeflexia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Bradycardia', 'Apnea', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol metabolism abnormalities**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS) due to defective 7-dehydrocholesterol reductase.  
2. **Craniofacial and physical features**: Microcephaly, pointed/short chin, anteverted nares, syndactyly (classic 2–3 toe fusion), and polydactyly align with SLOS-associated congenital anomalies.  
3. **Urogenital abnormalities**: Cryptorchidism and hypospadias are common in SLOS.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, generalized hypotonia, and hyporeflexia reflect impaired nervous system development linked to cholesterol deficiency.  
5. **Perinatal complications**: Premature birth, feeding difficulties, apnea, bradycardia, and early mortality (neonatal/childhood death) correlate with severe SLOS phenotypes.  
6. **Ocular and musculoskeletal findings**: Strabismus, hypermetropia, and torticollis are consistent with SLOS.  
7. **Immunological vulnerability**: Recurrent viral infections may stem from cholesterol-dependent immune dysfunction.  
8. **Biochemical confirmation**: Elevated 7- and 8-dehydrocholesterol levels confirm the diagnosis, distinguishing SLOS from other syndromic disorders with overlapping features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Psychosis', 'Eczematoid dermatitis', 'Skin rash', 'Intellectual disability', 'Death in infancy', 'Abdominal pain', 'Vertigo', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Occipital neuralgia', 'Elevated urinary carboxylic acid', 'Death in early adulthood', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
**Reasoning**:  
1. **Hyperphenylalaninemia**: Core diagnostic marker for PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability**: Classic feature of untreated PKU from neurotoxic phenylalanine accumulation.  
3. **Skin manifestations (eczema, rash, pustules)**: Caused by metabolic disruption affecting skin integrity; eczema is a well-documented symptom.  
4. **Elevated urinary carboxylic acids**: Reflects excretion of phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate).  
5. **Psychosis**: Late-onset neurological complications in poorly managed cases.  
6. **Early mortality (infancy/adulthood)**: Untreated PKU leads to severe neurological damage, infections, or organ failure.  

**Conflicts/Notes**:  
- **Hypertyrosinemia**: Contradicts PKU (expected low tyrosine). Possible lab error, concurrent condition (e.g., tyrosinemia), or variant PKU with secondary tyrosine dysregulation.  
- **Occipital neuralgia/vertigo/abdominal pain**: Atypical for PKU; may indicate comorbidities or nonspecific systemic effects of metabolic stress.  
- **Death timing**: Aligns with untreated cases; modern neonatal screening and dietary management typically prevent fatal outcomes.  

**Conclusion**: Despite conflicting hypertyrosinemia, hallmark features (hyperphenylalaninemia, intellectual disability, urinary metabolites, and skin findings) overwhelmingly support PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true about Medulloblastoma except
Choices:
A. It arises from medulla
B. It is small round blue Cell tumour
C. It is an embryonal tumour
D. Chang staging system is used
Answer: [/INST] It arises from medulla </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of fallopian tube occurs mainly by -
Choices:
A. Direct spread from uterine cavity
B. Lymphatic spread
C. Hematogenous spread
D. Iatrogenic
Answer: [/INST] Hematogenous spread </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Under Revised National Tuberculosis Control Program, drug used for chemoprophylaxis in children is
Choices:
A. Rifampicin
B. Isoniazid
C. Ethambutol
D. Ciprofloxacin
Answer: [/INST] Isoniazid </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypertension', 'Osteoporosis', 'Lethargy', 'Spastic diplegia', 'Generalized hypotonia', 'Hyperreflexia', 'Tachycardia', 'Abnormal foot morphology', 'Anemia', 'Acute kidney injury', 'Fever', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperkalemia', 'Hyperglycinemia', 'Sparse scalp hair', 'Drowsiness', 'Difficulty walking', 'Sleep disturbance', 'Spastic tetraplegia', 'Hypercalcemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Hypernatremia', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Difficulty climbing stairs', 'Death in childhood', 'Abnormal circulating leucine concentration', 'Recurrent viral infections', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Atransferrinemia', 'Chronic kidney disease', 'Severe hearing impairment', 'Abnormal circulating creatine kinase concentration', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**:  
   - **Decreased methylmalonyl-CoA mutase activity** directly indicates a defect in this enzyme, a hallmark of mutase-deficient MMA.  
   - **Methylmalonic aciduria** and **hyperglycinemia** are diagnostic for MMA, resulting from impaired conversion of methylmalonyl-CoA to succinyl-CoA.  
   - **Hyperammonemia**, **hyperuricemia**, and **hyperkalemia** reflect metabolic toxicity from accumulated organic acids and disrupted urea cycle function.  

2. **Acute metabolic crises**:  
   - **Vomiting**, **lethargy**, **fever**, **drowsiness**, and **acute kidney injury** align with episodic metabolic decompensation triggered by catabolism or protein intake.  
   - **Elevated creatinine**, **increased blood urea nitrogen**, and **hypernatremia** suggest acute-on-chronic kidney dysfunction, common in MMA due to tubular toxicity from methylmalonic acid.  

3. **Chronic multisystem complications**:  
   - **Chronic kidney disease**, **hypertension**, and **osteoporosis** result from long-term renal damage and electrolyte imbalances.  
   - **Spastic diplegia/tetraplegia**, **difficulty walking/climbing stairs**, and **severe short stature** reflect neurodevelopmental impairment from toxic metabolite accumulation.  
   - **Generalized hypotonia** with **hyperreflexia** and **abnormal foot morphology** indicate mixed upper/lower motor neuron damage.  

4. **Hematologic and immune dysfunction**:  
   - **Anemia** and **atransferrinemia** may stem from chronic inflammation or renal failure.  
   - **Recurrent viral infections** suggest secondary immune dysfunction due to metabolic stress.  

5. **Abnormal amino acid/carnitine profiles**:  
   - **Abnormal leucine/isoleucine/valine** levels confirm branched-chain amino acid metabolism disruption.  
   - **Abnormal carnitine** and **creatine kinase** concentrations point to mitochondrial dysfunction and muscle injury.  

6. **Poor prognosis**:  
   - **Death in childhood/adolescence/early adulthood** is consistent with severe mutase-deficient MMA, often refractory to dietary/cofactor therapies.  

This constellation of metabolic derangements, organ damage, and neurodevelopmental deficits, anchored by confirmed enzyme deficiency and methylmalonic aciduria, definitively establishes the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: New RNTCP initiative for Tuberculosis surveillance using case based web based IT system is
Choices:
A. NIKSHAY
B. NISCHAY
C. E-DOTS
D. NIRBHAYA
Answer: [/INST] NIKSHAY </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: High risk lesions for Infective Endocarditis are all except:-
Choices:
A. Prosthetic heart valves
B. Prior history of infective endocarditis
C. Aortic regurgitation
D. Complex cyanotic congenital heart disease
Answer: [/INST] Aortic regurgitation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Brachycephaly', 'Preauricular skin tag', 'Strabismus', 'Proptosis', 'Nystagmus', 'Precocious puberty', 'Single transverse palmar crease', 'Wrist flexion contracture', 'Global developmental delay', 'Generalized hypotonia', 'Overlapping toe', 'Bilateral tonic-clonic seizure', 'EEG abnormality', 'Poor head control', 'Elbow flexion contracture', 'Myoclonic spasms', 'Deep palmar crease', 'Knee flexion contracture', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Infantile muscular hypotonia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Neuromuscular Features**: Severe generalized and infantile hypotonia, poor head control, and flexion contractures (wrist, elbow, knee) align with TBCK’s hallmark neuromuscular involvement.  
2. **Developmental Delay**: Global developmental delay and intellectual disability are core features of TBCK-related syndromes.  
3. **Seizures**: Focal-onset, tonic-clonic, and myoclonic seizures with EEG abnormalities correlate with TBCK’s association with epilepsy.  
4. **Dysmorphic Facies**: Brachycephaly, proptosis, strabismus, nystagmus, and preauricular skin tag match characteristic craniofacial features.  
5. **Skeletal/Physical Anomalies**: Single transverse palmar crease, deep palmar crease, and overlapping toe reflect congenital malformations reported in TBCK cases.  
6. **Supportive Evidence**: TBCK mutations disrupt mTOR signaling, explaining neurodevelopmental and muscular pathology. While precocious puberty is atypical, phenotypic variability is recognized in this disorder.  
7. **Exclusion**: Symptoms collectively distinguish TBCK from mimics like Prader-Willi, Angelman, or Rett syndromes, which lack the full syndromic pattern. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The type of mutation that leads to replacement of Valine for glutamate in Sickle Cell Disease is
Choices:
A. Point mutation
B. Silent mutation
C. Nonsense mutation
D. None
Answer: [/INST] Point mutation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma -
Choices:
A. Obesity
B. Opistorchissinensis infection
C. Salmonella carrier state
D. HBV infection
Answer: [/INST] Opistorchissinensis infection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration** is a hallmark of MCADD, as secondary carnitine deficiency occurs due to impaired fatty acid oxidation and accumulation of toxic metabolites like medium-chain acylcarnitines.  
2. **Neonatal death** and **death in infancy/childhood** align with MCADD’s presentation, where metabolic crises (hypoketotic hypoglycemia) during fasting or illness lead to fatal outcomes if untreated.  
3. **Abnormality of prenatal development** may reflect intrauterine metabolic stress, though MCADD typically manifests postnatally.  
4. MCADD disrupts medium-chain fatty acid oxidation, depriving energy-critical organs (e.g., liver, brain) of fuel during fasting, consistent with the acute lethality described.  
5. The absence of neonatal screening (implied by early death) and delayed diagnosis exacerbates risks, explaining the fatal trajectory. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Revised National Tuberculosis Control programme the silent features are to achieve ?
Choices:
A. Cure rate 85% & diagnosis 85%
B. Cure rate 85% & diagnosis rate 70%
C. Cure rate 80% & diagnosis 85%
D. Cure rate 80% & diagnosis rate 80%
Answer: [/INST] Cure rate 85% & diagnosis rate 70% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: X-ray features of Hypoparathyroidism are the following except
Choices:
A. Osteosclerosis
B. Calvarial thickening
C. Subperiosteal resorption
D. Subcutaneous calcification
Answer: [/INST] Subperiosteal resorption </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leishmaniasis is caused by
Choices:
A. Protozoa
B. Bacteria
C. Virus
D. Prions
Answer: [/INST] Protozoa </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Enzyme defect in Classic Phenylketonuria
Choices:
A. Phenylalanine hydroxylase
B. Dihydrobiopterin reductase
C. Fumarylacetoacetate hydrolase
D. Homogentisate oxidase
Answer: [/INST] Phenylalanine hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur transiently in neonates due to immature liver function or secondary metabolic disruptions from phenylalanine toxicity.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications (e.g., congenital heart defects, microcephaly).  
4. **Upper airway obstruction** and **chronic pulmonary obstruction** are not direct features of PKU but could result from severe neurological impairment (e.g., hypotonia, poor swallowing) leading to aspiration or recurrent infections.  
5. **Neonatal death/Death in infancy** may occur in untreated/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., respiratory failure from aspiration).  

Note: While PKU explains hyperphenylalaninemia and prenatal abnormalities (via maternal PKU), hypertyrosinemia and airway/pulmonary symptoms suggest possible comorbidities (e.g., concurrent metabolic disorders or aspiration-related complications). Further testing (e.g., genetic analysis, BH4 responsiveness, tyrosine metabolite levels) is critical to confirm PKU and exclude overlapping conditions. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Steroids are useful in treating Tuberculosis patient with-
Choices:
A. Endobronchial tuberculosis
B. Tuberculous osteomyelitis
C. Lymphadenitis
D. Pneumonia
Answer: [/INST] Lymphadenitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Under the revised National Tuberculosis Control Programme, schedule of treatment for category I patients is -
Choices:
A. 2 (HRZE)3 + 4(HR)3
B. 2 HRZE+ 4 HRE
C. 2(HRZES)3 + 1(HRZE)3 + 5(HRE)3
D. 2(HRZ)3 + 4 (HR)3
Answer: [/INST] 2 HRZE+ 4 HRE </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true about Rubella?
Choices:
A. Caused by DNA virus of Toga family
B. There is no known carrier state for postnatally acquired rubella
C. Rubella vaccine is live attenuated with strain RA 27/3
D. Risk of transmission and severity maximum in 1st trimester of pregnancy
Answer: [/INST] Caused by DNA virus of Toga family </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera transmission by -a) Food transmitsb) Vaccination gives 90% efficiencyc) Healthy carrierd) Chlorination is not effective
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true regarding Tetralogy of Fallot except
Choices:
A. Ejection systolic murmur in second intercostal space
B. Single second hea sound
C. Predominantly left to right shunt
D. Normal jugular venous pressure
Answer: [/INST] Predominantly left to right shunt </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A pregnant female infected with Rubella. Which of the following immunoglobulin is produced by in-utero infection?
Choices:
A. IgG
B. IgA
C. IgM
D. IgD
Answer: [/INST] IgM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Encephalopathy', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid metabolites**: The presence of glutaric aciduria and elevated circulating glutaric acid directly indicates a defect in glutaric acid metabolism, a hallmark of GA-I caused by deficient glutaryl-CoA dehydrogenase.  
2. **Neurological symptoms**: Seizures, encephalopathy, and opisthotonus align with striatal neurodegeneration triggered by toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
3. **Carnitine depletion**: Decreased plasma free carnitine reflects secondary carnitine deficiency due to excessive conjugation with glutaric acid for renal excretion.  
4. **Urinary carboxylic acid elevation**: Matches the expected excretion of dicarboxylic acids (e.g., glutaric acid) in GA-I.  
5. **Early mortality**: Death in infancy/childhood is consistent with acute metabolic crises (e.g., encephalopathic crises) or progressive neurological damage in untreated GA-I.  
6. **Exclusion of mimics**: Symptoms and biochemical profile rule out other organic acidemias (e.g., type II glutaric aciduria) or mitochondrial disorders, as GA-I uniquely combines these markers with glutaryl-CoA dehydrogenase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is?
Choices:
A. RNA misfolding
B. DNA repair defect
C. Mitochondrial defect
D. Misfolding of protein
Answer: [/INST] Misfolding of protein </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine. This aligns with the symptom ""Hyperphenylalaninemia.""  
2. **Elevated Urinary Carboxylic Acids**: In PKU, excess phenylalanine is metabolized into phenylketones and other derivatives, which may include carboxylic acid byproducts excreted in urine.  
3. **Abnormality of Prenatal Development/Neonatal Death**: Untreated maternal PKU can cause fetal developmental issues (e.g., microcephaly, congenital heart defects) via intrauterine phenylalanine toxicity. Severe neonatal cases (rare in modern screening) could lead to early mortality.  
4. **Death in Infancy/Adolescence**: Historically, untreated PKU causes profound intellectual disability, seizures, and failure to thrive, potentially leading to early death. Modern newborn screening and dietary management prevent this.  
5. **Hypertyrosinemia Discrepancy**: Classic PKU typically results in **low/normal tyrosine** (due to blocked PAH activity). Hypertyrosinemia suggests a secondary issue (e.g., transient tyrosinemia in newborns, co-occurring liver dysfunction, or a BH4 cofactor deficiency, a PKU variant affecting multiple enzymes). This may indicate atypical PKU or comorbid conditions.  

**Conclusion**: The core diagnosis is PKU, supported by hyperphenylalaninemia and urinary anomalies. Hypertyrosinemia and severe outcomes suggest either a rare PKU subtype (e.g., BH4 deficiency) or additional metabolic disruptions requiring further investigation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratoconus is seen in: March 2010
Choices:
A. Patau syndrome
B. Down syndrome
C. Turner syndrome
D. Weber syndrome
Answer: [/INST] Down syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to toxic phenylalanine accumulation in the brain, damaging myelin and neurotransmitters, resulting in neurodevelopmental delays.  
3. **Severe short stature**: Chronic metabolic disruption and malnutrition (due to strict dietary restrictions) contribute to growth failure in untreated cases.  
4. **Death in childhood**: Severe neurological deterioration, seizures, and systemic complications (e.g., cardiac issues) in classic PKU can lead to early mortality if untreated.  
5. **Confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine) and genetic testing for PAH mutations. Early dietary intervention prevents symptoms, but untreated cases align with the described presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Reversible cause of dementia -a) Post encephalitisb) Multi infarctc) Hydrocephalusd) Senile dementia
Choices:
A. a
B. bc
C. ad
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Vomiting', 'Dicarboxylic aciduria', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Abnormal BCAA Levels**: Elevated leucine and isoleucine concentrations align with MSUD's hallmark defect in branched-chain amino acid (BCAA) metabolism due to deficient branched-chain α-keto acid dehydrogenase complex.  
2. **Urinary Metabolites**: Dicarboxylic aciduria and elevated urinary carboxylic acids result from accumulation of toxic keto-acid derivatives (e.g., α-ketoisocaproic acid) from unmetabolized BCAAs.  
3. **Aminoaciduria**: Overflow of excess BCAAs in the blood overwhelms renal reabsorption, causing urinary excretion.  
4. **Clinical Symptoms**: Neonatal death, vomiting, and hypotonia reflect acute metabolic decompensation from BCAA toxicity, leading to cerebral edema and neurological decline.  
5. **Rapid Progression**: Early-onset symptoms and infant mortality are consistent with classical/severe MSUD phenotypes.  
6. **Exclusion of Fatty Acid Disorders**: While dicarboxylic aciduria may suggest fatty acid oxidation defects, the specific BCAA abnormalities and lack of hypoketotic hypoglycemia prioritize MSUD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Open mouth', 'Brachycephaly', 'Sloping forehead', 'Long philtrum', 'Deeply set eye', 'Shallow orbits', 'Reduced eye contact', 'Motor delay', 'Cerebellar atrophy', 'Areflexia', 'Absent septum pellucidum', 'Absent speech', 'Hyperreflexia', 'Microcytic anemia', 'Bilateral tonic-clonic seizure', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Status epilepticus', 'Enlarged cisterna magna', 'Global brain atrophy', 'Hypokinesia', 'Respiratory failure', 'Os odontoideum', 'Severe muscular hypotonia', 'CNS demyelination', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Lipoma', 'Brain atrophy', 'EMG: myokymic discharges']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Features like *brachycephaly*, *sloping forehead*, *long philtrum*, *tented upper lip vermilion*, and *deeply set eyes* align with the facial dysmorphisms described in TBCK syndrome.  
2. **Neurological and developmental deficits**: *Severe muscular hypotonia*, *motor delay*, *absent speech*, *severe global developmental delay*, and *hypokinesia* correlate with the syndrome’s hallmark hypotonia and psychomotor retardation.  
3. **Brain abnormalities**: *Cerebellar atrophy*, *global brain atrophy*, *hypoplasia of the corpus callosum*, *ventriculomegaly*, and *enlarged cisterna magna* reflect widespread CNS involvement, consistent with TBCK’s neurodegenerative features.  
4. **Seizure phenotype**: *Bilateral tonic-clonic seizures* and *status epilepticus* are reported in severe TBCK cases due to cortical and cerebellar dysfunction.  
5. **EMG findings**: *Myokymic discharges* suggest peripheral nerve hyperexcitability, observed in some TBCK patients with neuromuscular involvement.  
6. **Absent septum pellucidum** and **CNS demyelination**: These rare structural anomalies further support a complex neurodevelopmental disorder like TBCK.  
7. **Respiratory failure**: Likely secondary to severe hypotonia and brainstem dysfunction, a known complication in advanced stages.  
8. **Mixed reflex abnormalities**: *Areflexia* (from hypotonia) and *hyperreflexia* (from upper motor neuron involvement) highlight the multisystem neurological impact.  
9. **Lipoma** and **os odontoideum**: While less specific, they may represent connective tissue dysregulation linked to TBCK’s genetic pathway (mTORC1 dysregulation).  

The combination of facial dysmorphism, neurodevelopmental regression, CNS structural defects, and electrophysiological findings strongly points to TBCK-related syndrome. Genetic testing for *TBCK* mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'High palate', 'Large fontanelles', 'Brachycephaly', 'Low-set, posteriorly rotated ears', 'Downslanted palpebral fissures', 'Proptosis', 'Polyhydramnios', 'Atrial septal defect', 'Wide intermamillary distance', '2-4 finger syndactyly', '1-5 toe syndactyly', 'Prominent forehead', 'Midface retrusion']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Apert syndrome  
Reasoning: The patient exhibits craniofacial features (brachycephaly, prominent forehead, midface retrusion, proptosis, downslanted palpebral fissures, low-set ears) consistent with craniosynostosis syndromes. The bilateral 2-4 finger syndactyly and 1-5 toe syndactyly are pathognomonic for Apert syndrome. Additional supportive findings include high palate, atrial septal defect, and polyhydramnios (linked to fetal swallowing difficulties from craniofacial anomalies). Midface hypoplasia explains proptosis and midface retrusion, while wide fontanelles may reflect abnormal calvarial suture dynamics. These collective features strongly align with Apert syndrome, a FGFR2-related disorder. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mallory Weiss Syndrome is caused due to tear in -
Choices:
A. Lower esophageal end.
B. Upper esophageal end.
C. Crico pharyngeal junction.
D. Gastro esophageal junction.
Answer: [/INST] Gastro esophageal junction. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are poor prognostic factors in Multiple Myeloma, Except:
Choices:
A. Azotemia
B. Hypocalcemia
C. LDH
D. High M component production
Answer: [/INST] Hypocalcemia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A6 month old child with Tetralogy of Fallot develops cyanotic spell initiated by crying. Which one of the following drugs you would like to avoid –
Choices:
A. Sodium bicarbonate
B. Propranolol
C. Phenylephrine
D. Isoprenaline
Answer: [/INST] Isoprenaline </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine is not given before:
Choices:
A. 9 months
B. 12 months
C. 15 months
D. 18 months
Answer: [/INST] 9 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in infancy', 'Death in childhood', 'Abnormality of galactoside metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's abnormality of galactoside metabolism directly indicates a defect in galactose processing, a hallmark of galactosemia. Classic galactosemia (GALT deficiency) causes toxic accumulation of galactose metabolites, leading to intellectual disability, delayed speech, and neurobehavioral symptoms (hyperactivity, atypical behavior). Untreated, severe metabolic derangements (e.g., liver failure, sepsis) result in early mortality (infancy/childhood). These findings align with the clinical and biochemical profile of classic galactosemia.   </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Raynaud's phenomenon is seen in -  a) Scleroderma  b) Reiter 's disease   c) Rheumatoid arthritis   d) Behcet's syndrome  e) Mixed connective tissue disease
Choices:
A. ace
B. acd
C. abc
D. cde
Answer: [/INST] ace </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal insufficiency', 'Glomerulonephritis', 'Sinusitis', 'Abnormality of the nose', 'Conjunctivitis', 'Fever', 'Hemoptysis', 'Exercise intolerance', 'Cough', 'Shoulder pain', 'Elbow pain', 'Knee pain', 'Pulmonary hemorrhage', 'Oliguria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Sinusitis and nasal abnormalities (e.g., ulcers, crusting) are classic early signs of GPA.  
2. **Pulmonary manifestations**: Cough, hemoptysis, and pulmonary hemorrhage indicate alveolar capillaritis and vasculitis in the lungs.  
3. **Renal disease**: Glomerulonephritis (often rapidly progressive) with renal insufficiency and oliguria reflects pauci-immune necrotizing glomerulonephritis, a hallmark of GPA.  
4. **Systemic inflammation**: Fever and arthralgias (shoulder, elbow, knee pain) suggest systemic vasculitis.  
5. **Ocular involvement**: Conjunctivitis aligns with GPA-associated ocular inflammation.  
6. **ANCA association**: GPA is strongly linked to c-ANCA/PR3-ANCA, which drives small-vessel vasculitis and granuloma formation.  
7. **Multisystem pattern**: The combination of respiratory, renal, musculoskeletal, and constitutional symptoms is pathognomonic for GPA, distinguishing it from mimics like microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 25 year old boy presents with renal failure. His uncle died of renal failure three years ago. Slit lamp examination reveals Lenticonus / Keratoconus. The likely diagnosis is:
Choices:
A. Autosomal Dominant Polycystic Kidney (ADPCKD)
B. Autosomal Recessive polycystic kidney (ARPCKD)
C. Alpo's syndrome
D. Denysh-Drash Syndrome
Answer: [/INST] Alpo's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: NOT a feature of Classical triad of Congenital Rubella Syndrome is
Choices:
A. Cataract
B. Patent Ductus Arteriosus
C. Microcephaly
D. Deafness
Answer: [/INST] Microcephaly </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Gingival overgrowth', 'High palate', 'Long face', 'Hearing impairment', 'Strabismus', 'Horizontal nystagmus', 'Dental crowding', 'Slender finger', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar hypoplasia', 'Dystonia', 'Hyperreflexia', 'Overgrowth', 'Hypoplasia of the corpus callosum', 'Leukodystrophy', 'Abnormal cerebral white matter morphology', 'Scoliosis', 'Multiple joint contractures', 'CNS hypomyelination', 'Cerebral hypomyelination', 'Generalized hyperreflexia', 'Brain atrophy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Leukodystrophy/CNS hypomyelination**: The presence of leukodystrophy, cerebral/cerebellar hypomyelination, and abnormal white matter morphology directly align with the hallmark hypomyelinating leukodystrophy in NKX6-2 disorders.  
2. **Spastic tetraparesis/hyperreflexia**: Spasticity and hyperreflexia are consistent with corticospinal tract dysfunction due to impaired myelination.  
3. **Cerebellar hypoplasia/brain atrophy**: Explains ataxia, nystagmus, and dystonia, reflecting cerebellar and global CNS involvement.  
4. **Global developmental delay**: Expected in severe neurodevelopmental disorders with hypomyelination and cerebellar defects.  
5. **Hypoplasia of the corpus callosum**: A common associated structural brain anomaly in leukodystrophies.  
6. **Scoliosis/joint contractures**: Secondary to chronic spasticity and reduced mobility.  
7. **Dental/facial features (gingival overgrowth, high palate, long face)**: May represent connective tissue or craniofacial dysregulation linked to NKX6-2's role in development.  
8. **Slender fingers/overgrowth**: Less typical but reported in some genetic leukodystrophies with multisystemic effects.  
9. **Generalized hypotonia**: Early presentation, evolving into spasticity as myelination deficits progress.  

The combination of hypomyelination, spasticity, cerebellar anomalies, and developmental delay strongly supports NKX6-2-related disease, with minor features (e.g., dental crowding) reflecting broader developmental impacts of NKX6-2 mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Recurrent urinary tract infections', 'Gingivitis', 'Facial edema', 'Epistaxis', 'Hyperhidrosis', 'Abnormality of the larynx', 'Weight loss', 'Eosinophilia', 'Microcytic anemia', 'Hemoptysis', 'Pulmonary infiltrates', 'Hyperkalemia', 'Exertional dyspnea', 'Exercise intolerance', 'Adrenal hyperplasia', 'Abnormality of the submandibular glands', 'Facial palsy', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Peripheral edema', 'Cervical lymphadenopathy', 'Nodular pattern on pulmonary HRCT', 'Lagophthalmos', 'Elbow pain', 'Knee pain', 'Decreased thyroid-stimulating hormone level', 'Cutaneous abscess', 'Cytoplasmic antineutrophil antibody positivity', 'Neoplasm of the adrenal gland']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Sarcoidosis/Sarcoidosis, susceptibility to, 1: The patient exhibits multisystem granulomatous involvement, including pulmonary infiltrates, nodular HRCT patterns, cervical lymphadenopathy, and elevated CRP, all hallmarks of sarcoidosis. Facial palsy, lagophthalmos, and laryngeal abnormalities suggest neurosarcoidosis. Cutaneous abscesses, adrenal hyperplasia, and submandibular gland involvement align with extrapulmonary disease. Microcytic anemia, fatigue, and weight loss reflect chronic inflammation. Though cytoplasmic ANCA positivity is atypical, it may occur in overlap syndromes or as a false-positive. Eosinophilia and hyperkalemia could indicate adrenal dysfunction or renal involvement. Genetic susceptibility variants (e.g., HLA-DRB1) may underlie this presentation.  

Sarcoidosis, susceptibility to, 2: The phenotypic overlap with susceptibility type 1 is significant, but genetic distinctions (e.g., BTNL2 gene variants) may explain subtle differences in disease severity or organ tropism. The presence of exertional dyspnea, exercise intolerance, and hemoptysis emphasizes severe pulmonary involvement, potentially linked to specific genetic modifiers. Adrenal neoplasms, though rare in sarcoidosis, may arise from chronic hyperplasia. Persistent UTIs and gingivitis could reflect secondary immune dysregulation from granulomatous inflammation. Thyroid abnormalities (decreased TSH) may indicate concurrent autoimmune thyroiditis or hypothalamic-pituitary involvement. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypoglycemia', 'Death in childhood', 'Decreased plasma free carnitine', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Hypoglycemia**: PCD causes impaired fatty acid oxidation due to defective carnitine transport, reducing energy production during fasting and leading to hypoglycemia.  
2. **Decreased plasma free carnitine**: A hallmark of PCD caused by mutations in the *SLC22A5* gene, resulting in urinary carnitine wasting and low plasma levels.  
3. **Acute/Chronic hepatitis**: Impaired fatty acid oxidation causes toxic metabolite accumulation (e.g., acylcarnitines) in the liver, triggering recurrent hepatitis and eventual chronic liver dysfunction.  
4. **Death in childhood**: Undiagnosed PCD leads to metabolic crises (hypoketotic hypoglycemia, hyperammonemia) or cardiac complications (cardiomyopathy, arrhythmias), often fatal in early life.  
5. **Consistency with PCD**: The triad of hypoketotic hypoglycemia, liver dysfunction, and carnitine deficiency is pathognomonic for PCD, distinguishing it from secondary carnitine deficiencies (e.g., organic acidemias). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following are histopathological features of Extra hepatic Biliary Atresia -
Choices:
A. Bile lakes
B. Hepatocyte ballooning degeneration
C. Marked bile duct proliferation
D. All
Answer: [/INST] Marked bile duct proliferation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about V. Cholerae is -
Choices:
A. One attack of V. Cholerae gives live-long immunity
B. Affects adults and children with equal propensity in non epidemic regions
C. Affects adults and children with equal propensity in non epidemic regions
D. Pathogencity of 0-139 vibrio is due to 0 antigen
Answer: [/INST] Pathogencity of 0-139 vibrio is due to 0 antigen </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Second common malignancy in Patients of Retinoblastoma is:
Choices:
A. Osteoblastoma
B. Osteochondroma
C. Osteoclastoma
D. Osteosarcoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which one of the following is not a strategy under Roll Back Malaria -
Choices:
A. Strengthening of health system
B. Use of insecticide treated bed nets
C. Anti-larval measures
D. Development of new antimalaria drugs
Answer: [/INST] Anti-larval measures </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Xeroderma Pigmentosum except
Choices:
A. It is autosomal dominant inheritance
B. Due to defective DNA repair
C. Associated with squamous cell carcinoma
D. Thymine dimers
Answer: [/INST] It is autosomal dominant inheritance </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lens subluxation', 'Disproportionate tall stature', 'Aortic dissection', 'High myopia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Marfan syndrome  
Reasoning:  
1. **Lens subluxation**: A hallmark of Marfan syndrome due to defective fibrillin-1 (FBN1 gene), weakening zonular fibers that hold the lens.  
2. **Disproportionate tall stature**: Characterized by long limbs (arm span > height) and arachnodactyly, consistent with skeletal manifestations of Marfan.  
3. **Aortic dissection**: Caused by progressive aortic root dilation and connective tissue fragility, a life-threatening feature of Marfan syndrome.  
4. **High myopia**: Associated with elongation of the globe and structural weakness in the eye, common in Marfan-related ocular abnormalities.  

Disease: Marfan syndrome type 1  
Reasoning:  
1. **Genetic confirmation**: Type 1 specifically refers to classic Marfan syndrome caused by pathogenic FBN1 mutations, which explain all listed symptoms.  
2. **Systemic involvement**: The combination of ocular (lens subluxation, myopia), skeletal (tall stature), and cardiovascular (aortic dissection) features aligns with the multisystemic criteria for Marfan syndrome type 1.  
3. **Exclusion of overlap syndromes**: No features of Loeys-Dietz syndrome (e.g., hypertelorism, bifid uvula) or other fibrillinopathies, reinforcing the diagnosis of type 1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Hyperreflexia', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in childhood', 'Abnormal circulating ornithine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **vomiting** are hallmark features of urea cycle disorders (UCDs), including OTCD, due to impaired ammonia detoxification.  
2. **Oroticaciduria** is a critical clue: OTCD disrupts the urea cycle, causing carbamoyl phosphate accumulation, which shunts into pyrimidine synthesis, overproducing orotic acid.  
3. **Cerebral edema** and **seizures** result from ammonia neurotoxicity, exacerbated by **lethargy** and **drowsiness**.  
4. **Abnormal circulating ornithine concentration** aligns with OTCD pathophysiology, as ornithine is a substrate for the deficient OTC enzyme.  
5. **Hyperreflexia** and **sleep disturbances** reflect neurological dysfunction from hyperammonemia.  
6. **Death in childhood** is consistent with severe neonatal-onset OTCD if untreated.  
7. **Fever** may indicate metabolic decompensation triggered by catabolic stressors (e.g., infection), common in UCD crises.  

The absence of citrulline/arginine elevation and the presence of oroticaciduria distinguish OTCD from other UCDs (e.g., citrullinemia, arginase deficiency). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Cerebral edema', 'Neonatal death', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Neonatal death** and **death in infancy** suggest a severe, early-onset UCD, as CPS1 deficiency often manifests within days of life due to complete enzyme dysfunction.  
3. **Feeding difficulties** and **generalized hypotonia** are nonspecific but common neonatal signs of metabolic encephalopathy secondary to hyperammonemia.  
4. **Cerebral edema** arises from ammonia-induced neurotoxicity, disrupting osmotic balance and causing brain swelling.  
5. **Apathy** reflects progressive encephalopathy as ammonia levels rise.  
6. The absence of orotic acid elevation (implied by the diagnosis) distinguishes CPS1 deficiency from ornithine transcarbamylase (OTC) deficiency, another UCD.  
7. CPS1 deficiency is confirmed by genetic testing or enzyme assay, but clinical presentation and hyperammonemia without organic acidemia strongly support this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Abdominal pain', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Metabolic crisis & early mortality**: Symptoms like death in infancy/childhood/adolescence and neonatal death align with IVA's acute metabolic decompensation episodes, often triggered by catabolic stress (e.g., infections).  
2. **Gastrointestinal involvement**: Vomiting, diarrhea, and abdominal pain are classic during crises due to toxic metabolite accumulation (isovaleric acid).  
3. **Characteristic biochemical markers**:  
   - **Abnormal circulating carnitine**: Secondary carnitine depletion occurs as carnitine conjugates isovaleric acid (forming isovalerylcarnitine) for excretion.  
   - **Abnormal glycine**: Elevated glycine due to increased conjugation of isovaleric acid with glycine (isovalerylglycine), a diagnostic urinary marker.  
4. **Body odor**: Distinctive ""sweaty feet"" odor from excess isovaleric acid.  
5. **Immunological vulnerability**: Recurrent viral infections may reflect metabolic instability during illnesses, precipitating crises.  
6. **Inflammatory overlap**: Gastrointestinal inflammation mimics enterocolitis, a known IVA complication.  

IVA is confirmed via elevated isovalerylglycine in urine and genetic testing for *IVD* gene mutations. Early diagnosis enables dietary management (low-protein, leucine-restricted diet) and emergency protocols to prevent fatal metabolic crises. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: NOT a feature of Tetralogy of Fallot among the following
Choices:
A. Cyanosis
B. Ejection Systolic Murmur
C. Pan Systolic murmur
D. Single S2
Answer: [/INST] Pan Systolic murmur </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Jaundice', 'Generalized hypotonia', 'Vomiting', 'Bilateral tonic-clonic seizure', 'Feeding difficulties', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Hypergalactosemia** directly indicates impaired galactose metabolism, a hallmark of galactosemia.  
2. **Feeding difficulties, vomiting, and jaundice** are early-onset symptoms in neonates with classic galactosemia, caused by toxic accumulation of galactose metabolites (e.g., galactitol, galactose-1-phosphate) damaging the liver and gastrointestinal tract.  
3. **Generalized hypotonia** and **seizures** suggest neurological involvement from metabolite toxicity or hypoglycemia secondary to hepatic dysfunction.  
4. **Delayed speech/language development** aligns with long-term neurocognitive sequelae of untreated galactosemia.  
5. **Bilateral tonic-clonic seizures** may result from cerebral edema, metabolic derangements, or direct neurotoxicity.  
6. All symptoms collectively fit the GALT enzyme deficiency (classic galactosemia), which disrupts the Leloir pathway, necessitating immediate lactose/galactose restriction to prevent irreversible complications. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid revaccination is recommended very ___ years in endemic area -
Choices:
A. 1
B. 3
C. 5
D. 10
Answer: [/INST] 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis with rash is seen in
Choices:
A. Neisseria meningitidis
B. Hemophilus influenzae
C. Streptococcus agalactae
D. Pneumococcus
Answer: [/INST] Neisseria meningitidis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diagnosis of Myasthenia Gravis is by using -
Choices:
A. Edrophonium
B. Neostigmine
C. Succinylcholine (SCh)
D. Atropine
Answer: [/INST] Edrophonium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: When is surgery not done in cases of Ulcerative Colitis?
Choices:
A. Toxic megacolon
B. Colonic perforation
C. Colonic obstruction
D. Refractory fistula
Answer: [/INST] Refractory fistula </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The site of occurrence of Subependymal Giant Cell Astrocytoma is
Choices:
A. Cerebellum
B. Pineal gland
C. Foramen of monro
D. Medulla Oblongata
Answer: [/INST] Foramen of monro </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Myocarditis is caused bya) Pertussisb) Measlesc) Diptheriad) Scorpion sting
Choices:
A. bc
B. c
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Pneumocystis Pneumonia
Choices:
A. Cotrimoxazole
B. Penicillin
C. Itraconazole
D. Ivermectin
Answer: [/INST] Cotrimoxazole </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Calcification of intervertebral disc is seen in – a) Goutb) Rheumatoid c) Alkaptonuriad) Psoriasis
Choices:
A. ac
B. bc
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug not given for Prophylaxis of Malaria is:
Choices:
A. Chloroquine
B. Progaunil
C. Aeseunate
D. Doxycycline
Answer: [/INST] Aeseunate </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Periportal fibrosis', 'Hypercholesterolemia', 'Elevated circulating alkaline phosphatase concentration', 'Elevated circulating creatine kinase concentration', 'Decreased circulating ceruloplasmin concentration', 'Decreased circulating copper concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Hepatic steatosis & periportal fibrosis**: TMEM199-CDG is associated with hepatic involvement, including fatty liver and fibrosis due to disrupted glycosylation-dependent hepatic function.  
2. **Hypercholesterolemia**: Impaired glycosylation of lipoproteins (e.g., LDL receptors) disrupts cholesterol metabolism, leading to elevated serum cholesterol.  
3. **Elevated alkaline phosphatase**: Reflects cholestatic liver injury, a common feature in TMEM199-CDG.  
4. **Elevated creatine kinase**: Suggests muscle involvement, occasionally seen in glycosylation disorders due to defective glycoprotein synthesis in muscle tissue.  
5. **Decreased ceruloplasmin & copper**: Ceruloplasmin, a copper-carrying glycoprotein, requires proper glycosylation for stability. Defective glycosylation reduces ceruloplasmin levels, leading to secondary hypocupremia (low serum copper) without copper overload.  
6. **Genetic basis**: TMEM199-CDG is caused by mutations in *TMEM199*, disrupting Golgi glycosylation processes, aligning with the multisystemic symptoms observed. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Skin rash', 'Death in infancy', 'Glycosuria', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: Directly indicates a deficiency in mitochondrial complex IV (COX), a hallmark of this disorder.  
2. **Ethylmalonic aciduria**: Linked to impaired mitochondrial fatty acid oxidation and oxidative phosphorylation, consistent with complex IV dysfunction.  
3. **Death in infancy**: Severe mitochondrial disorders often present with early lethality due to multisystem energy failure.  
4. **Glycosuria**: Suggests renal tubular dysfunction, a known feature of mitochondrial disorders affecting proximal tubule energetics.  
5. **Feeding difficulties & gastrointestinal tract abnormalities**: Reflects high energy demands of the gut, disrupted by mitochondrial ATP deficiency.  
6. **Skin manifestations (rash, plaques, macules, papules)**: May arise from metabolic acidosis, oxidative stress, or secondary inflammation due to mitochondrial dysfunction.  
7. **Abnormal circulating glycine**: Mitochondria play a role in glycine metabolism; dysregulation can occur in respiratory chain defects.  
8. **Nuclear type 1**: Specifies a nuclear DNA mutation (e.g., *COX4I1*, *SURF1*) causing the deficiency, differentiating it from mtDNA-related forms.  

The constellation of metabolic, neuromuscular, and multisystem symptoms aligns with mitochondrial complex IV deficiency, with genetic confirmation targeting nuclear-encoded assembly or catalytic subunits. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is not true about Yaws?
Choices:
A. Spread by sexual transmission
B. Caused by T. peenue
C. Has cross immunity with syphilis
D. Cannot be differentiated serologically from T. pallidum
Answer: [/INST] Spread by sexual transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing abnormality', 'Visual loss', 'Hypertension', 'Hyperhidrosis', 'Gait disturbance', 'Hepatic steatosis', 'obsolete Mood changes', 'Aortic regurgitation', 'Splenomegaly', 'Diarrhea', 'Nausea', 'Constipation', 'Heat intolerance', 'Abnormal intestine morphology', 'Headache', 'Vertigo', 'Abnormality of the lower limb', 'Arthralgia', 'Exertional dyspnea', 'Elevated hepatic transaminase', 'Abnormal EKG', 'Increased LDL cholesterol concentration', 'Elevated circulating creatine kinase concentration', 'Abdominal distention', 'Increased circulating ferritin concentration', 'Back pain', 'Somatic sensory dysfunction', 'Exercise intolerance', 'Gastrointestinal inflammation', 'Ventricular tachycardia', 'Gastritis', 'Premature ventricular contraction', 'Elevated circulating C-reactive protein concentration', 'Right bundle branch block', 'Abnormal metacarpophalangeal joint morphology', 'Constrictive median neuropathy', 'Sacroiliac arthritis', 'Upper limb pain', 'Lower limb pain', 'Dysesthesia', 'Panic attack', 'Neck pain', 'Hip pain', 'Groin pain', 'Unhappy demeanor', 'Low levels of vitamin D', 'Chest pain', 'Insomnia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial skeletal involvement**: Sacroiliac arthritis, back pain, neck pain, hip/groin pain, and abnormal lower limb morphology align with axial spondyloarthritis (e.g., ankylosing spondylitis), a hallmark of spondyloarthropathy.  
2. **Peripheral joint manifestations**: Arthralgia, abnormal metacarpophalangeal joint morphology, and limb pain suggest peripheral arthritis, common in spondyloarthropathies.  
3. **Extra-articular features**:  
   - **Gastrointestinal inflammation**: Diarrhea, constipation, gastritis, and abnormal intestine morphology may indicate inflammatory bowel disease (IBD), frequently comorbid with spondyloarthropathy.  
   - **Cardiac abnormalities**: Aortic regurgitation and conduction defects (right bundle branch block, ventricular tachycardia) are recognized complications of chronic inflammation in HLA-B27-associated diseases.  
   - **Elevated inflammatory markers**: Elevated CRP and ferritin reflect systemic inflammation.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning:  
1. **Genetic predisposition**: Susceptibility loci (e.g., HLA-B27) are strongly linked to spondyloarthropathies, explaining familial clustering and disease severity.  
2. **Neurological and sensory symptoms**: Constrictive median neuropathy, dysesthesia, and somatic sensory dysfunction may stem from enthesitis or nerve compression due to chronic inflammation.  
3. **Dermatological/autonomic features**: Hyperhidrosis and heat intolerance could reflect autonomic dysregulation, occasionally observed in systemic autoimmune disorders.  
4. **Vitamin D deficiency**: Common in chronic inflammatory diseases due to reduced sunlight exposure or malabsorption, exacerbating musculoskeletal pain.  
5. **Psychosocial components**: Unhappy demeanor, panic attacks, and insomnia are consistent with chronic pain syndromes and inflammation-driven neuropsychiatric effects.  

**Key Overlap**: Both diagnoses share core features (axial/peripheral arthritis, IBD association, cardiac involvement) but highlight genetic heterogeneity (e.g., non-HLA genes in susceptibility 2). The breadth of symptoms (musculoskeletal, gastrointestinal, cardiac, neurological) underscores the multisystem nature of spondyloarthropathies, necessitating a holistic diagnostic approach. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: FALSE about Leprosy eradication programme is ?
Choices:
A. Early detection of cases
B. Disability limitation
C. Long term multi drug therapy
D. Health education
Answer: [/INST] Long term multi drug therapy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Encephalopathy', 'Scoliosis', 'CNS hypomyelination']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **CNS hypomyelination**: A hallmark feature of hypomyelinating leukodystrophies, directly linked to NKX6-2 mutations, which disrupt oligodendrocyte function and myelination.  
2. **Encephalopathy**: Common in leukodystrophies due to widespread white matter dysfunction and neuroinflammation.  
3. **Intellectual disability**: Reflects progressive neurological deterioration from impaired myelination and synaptic connectivity.  
4. **Strabismus**: Associated with brainstem/cranial nerve involvement, often seen in leukodystrophies affecting motor coordination pathways.  
5. **Scoliosis**: Secondary to spasticity and axial hypotonia from corticospinal tract degeneration, a feature of spastic ataxia in this disorder.  
6. **Autosomal recessive inheritance**: Matches NKX6-2-related disease etiology, requiring biallelic pathogenic variants.  

The combination of hypomyelination, neurodevelopmental regression, and motor deficits aligns precisely with NKX6-2 dysfunction, distinguishing it from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease) by genetic and phenotypic specificity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Babesiosis is transmitted by -
Choices:
A. Tick
B. Mites
C. Flea
D. Mosquito
Answer: [/INST] Tick </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common drug used in Leprosy is :
Choices:
A. Dapsone
B. Clofazimine
C. Ethionamide
D. Ofloxacin
Answer: [/INST] Dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is regarded as a disease caused by:
Choices:
A. Protozoa
B. Bacteria
C. Virus
D. Prions
Answer: [/INST] Protozoa </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Neonatal death', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly indicates abnormal accumulation of glutaric acid, a hallmark of GA-I due to deficient glutaryl-CoA dehydrogenase activity.  
2. **Metabolic acidosis**: Results from toxic buildup of glutaric acid and related metabolites, disrupting acid-base balance.  
3. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion, reducing free carnitine levels.  
4. **Generalized hypotonia**: Neurotoxic effects of accumulated metabolites impair muscle tone and neuronal function.  
5. **Neonatal death/Death in infancy**: Untreated GA-I causes acute metabolic crises, striatal necrosis, and catastrophic neurological deterioration, often fatal early in life without prompt dietary and metabolic intervention.  
6. **Consistency with GA-I**: The triad of glutaric aciduria, neurologic symptoms, and secondary carnitine deficiency aligns with GA-I pathophysiology, distinguishing it from other organic acidemias (e.g., GA-II involves multiple acyl-CoA dehydrogenases and distinct biochemical markers). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which if the following statements are FALSE regarding Neuroleptic Malignant Syndrome (NMT)?
Choices:
A. Combining Antipsychotics and Antidepressants increased the risk of NMS
B. Increase in Creatinine Phosphokinase (CPK) always indicates NMS
C. First use of Injection anti-psychotic in a risk factor
D. Catatonic symptoms and autonomic dysfunction is a feature of NMS
Answer: [/INST] Increase in Creatinine Phosphokinase (CPK) always indicates NMS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria parasites -a) Has man as its intermediate hostb) Has a life cycle that alternates between man and tse-tse flyc) Has 4 important species in mand) Can be easily cultured in the laboratory
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Indication for surgery in Necrotizing Enterocolitis is?
Choices:
A. Pneumatosis intestinalis- Stage IIA of NEC
B. Pneumoperitoneum- Stage IIIB of NEC
C. Poal Vein gas- Stage IIB of NEC
D. Peritonitis- Stage IIIA of NEC
Answer: [/INST] Pneumoperitoneum- Stage IIIB of NEC </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Retinopathy', 'Cataract', 'Hypertension', 'Congestive heart failure', 'Myocardial infarction', 'Acute kidney injury', 'Progressive neurologic deterioration', 'Glycosuria', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] MODY: The patient presents with elevated hemoglobin A1c and glycosuria, indicative of chronic hyperglycemia. MODY, a monogenic form of diabetes, often manifests in early adulthood with autosomal dominant inheritance. Retinopathy, cataracts, and chronic kidney disease align with long-term diabetic complications. Hypertension and cardiovascular events (myocardial infarction, congestive heart failure) suggest accelerated vascular damage from prolonged hyperglycemia. Acute kidney injury and sepsis may result from diabetes-related susceptibility to infections and renal stress. Progressive neurologic deterioration could stem from metabolic derangements (e.g., uremia, hypoglycemia) or microvascular damage. Early adulthood mortality reflects severe, untreated diabetic complications, consistent with delayed MODY diagnosis or inadequate management. While MODY is typically milder, type 1 (HNF4A mutation) can lead to significant morbidity if glycemic control is poor. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, historically causing early mortality without dietary intervention.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies, though this is not a direct symptom of the patient’s PKU. The inclusion may reflect severe metabolic disruption or comorbid factors.  
4. **Gastrointestinal inflammation**: Less typical but possible in metabolic crises or secondary to protein-restricted diet complications (e.g., nutrient deficiencies).  

PKU is confirmed by elevated blood phenylalanine and genetic testing for PAH mutations. Early diagnosis and phenylalanine-restricted diet prevent severe outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Aniridia is associated with:
Choices:
A. Retinoblastoma
B. Hepatoblastoma
C. Nephroblastoma
D. Medulloblastoma
Answer: [/INST] Nephroblastoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningioma arises from-
Choices:
A. Extra dural arteries
B. Extra cranial muscles
C. Venous sinuses
D. Arachnoid cap cells
Answer: [/INST] Arachnoid cap cells </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Autistic behavior', 'Self-mutilation', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Motor delay', 'Obesity', 'Death in infancy', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased serum iron']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia** and **hyperphenylalaninemia** directly indicate a defect in tyrosine metabolism, a hallmark of Tyrosinemia type 1 (HT-1) caused by fumarylacetoacetate hydrolase deficiency.  
2. **Elevated circulating alpha-fetoprotein (AFP)** and **alkaline phosphatase** suggest liver damage, consistent with HT-1’s hepatotoxic effects.  
3. **Seizures**, **intellectual disability**, **motor delay**, and **autistic behavior** align with neurotoxic effects of tyrosine byproducts (e.g., succinylacetone).  
4. **Self-mutilation** and **hyperactivity** may reflect neurological dysfunction or peripheral neuropathy from metabolite accumulation.  
5. **Abnormal aspartate/alanine concentrations** and **decreased serum iron** reflect disrupted amino acid metabolism and secondary liver dysfunction.  
6. **Death in infancy/childhood** and **neonatal death** correlate with HT-1’s acute and chronic forms, often due to liver failure or metabolic crises.  
7. **Obesity** is atypical but may arise from metabolic dysregulation or dietary management complications.  
8. **Elevated AFP** and liver-related symptoms differentiate HT-1 from other amino acid disorders (e.g., PKU), which lack severe hepatic involvement.  

This constellation of hepatic, neurological, and metabolic abnormalities strongly supports Tyrosinemia type 1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague epidemic in Surat in 1995 has occurred after a 'silence period' of
Choices:
A. 18 years
B. 23 years
C. 28 years
D. 30 years
Answer: [/INST] 28 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Jaundice', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Conjugated hyperbilirubinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine metabolism.  
2. **Hypertyrosinemia** may occur secondarily in PKU due to competitive inhibition of tyrosine metabolism by accumulated phenylalanine, though this is atypical and suggests severe metabolic disruption.  
3. **Neonatal/Infancy/Childhood death** aligns with untreated PKU, where toxic phenylalanine levels cause irreversible neurodevelopmental damage.  
4. **Jaundice/Conjugated hyperbilirubinemia/Elevated alkaline phosphatase** are unusual in classic PKU but could indicate comorbid liver dysfunction (e.g., prematurity-related immaturity or secondary metabolic stress).  
5. **Abnormality of prenatal development** is inconsistent with PKU (symptoms manifest postnatally), suggesting potential misdiagnosis or overlapping conditions (e.g., maternal PKU syndrome if the mother had untreated PKU during pregnancy).  

**Note:** The diagnosis of PKU primarily rests on persistent hyperphenylalaninemia. The atypical liver-related symptoms warrant investigation for additional disorders (e.g., tyrosinemia type I, biliary atresia) or confounding factors (e.g., sepsis, prematurity). Confirmatory testing (PAH gene analysis, BH4 loading) is critical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bone scan of a patient with Multiple Myeloma shows
Choices:
A. Diffusely increased uptake
B. Diffusely decreased uptake
C. Hot spots
D. Cold spots
Answer: [/INST] Cold spots </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria affects all the following organs except -
Choices:
A. Brain
B. Heart
C. Liver
D. Spleen
Answer: [/INST] Heart </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal sternum morphology', 'Leukocytosis', 'Dyspnea', 'Osteomyelitis', 'Osteoarthritis', 'Elevated erythrocyte sedimentation rate', 'Elevated circulating C-reactive protein concentration', 'Chest pain', 'Hyperostosis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: SAPHO syndrome  
Reasoning: The patient presents with a combination of osteoarticular and inflammatory symptoms.  
1. **Hyperostosis** and **abnormal sternum morphology** are hallmark features of SAPHO, often involving the anterior chest wall.  
2. **Osteomyelitis** (non-infectious osteitis) and **osteoarthritis** align with the synovitis-hyperostosis-osteitis triad in SAPHO.  
3. **Elevated ESR/CRP** and **leukocytosis** reflect systemic inflammation, consistent with SAPHO’s inflammatory pathophysiology.  
4. **Chest pain** and **dyspnea** correlate with sternocostoclavicular joint involvement, a common site in SAPHO.  
5. Exclusion of infectious osteomyelitis is supported by the lack of cited fever or microbiological evidence, favoring sterile inflammation.  
6. The constellation of musculoskeletal and inflammatory markers, without dermatologic symptoms (e.g., palmoplantar pustulosis), still fits SAPHO’s variable presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Oral ulcer', 'Goiter', 'Arthritis', 'Abnormality of the larynx', 'Anemia', 'Palpitations', 'Gastroesophageal reflux', 'Headache', 'Fasciculations', 'Paraparesis', 'Abnormality of the knee', 'Arthralgia', 'Myalgia', 'EMG: neuropathic changes', 'Somatic sensory dysfunction', 'Antinuclear antibody positivity', 'Decreased circulating complement C3 concentration', 'Abnormal phalangeal joint morphology of the hand', 'Abnormal circulating protein concentration', 'Right bundle branch block', 'Atrioventricular reentrant tachycardia', 'Abnormal metacarpophalangeal joint morphology', 'Upper limb pain', 'Dysesthesia', 'Neck pain', 'Elbow pain', 'Finger pain', 'Knee pain', 'Increased tear production', 'Aphthous ulcer', 'Abnormality of nail color', 'Dyspepsia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune Features**: Antinuclear antibody positivity and decreased complement C3 strongly suggest an autoimmune etiology.  
2. **Myositis Overlap**: Myalgia, EMG neuropathic changes, and somatic sensory dysfunction align with inflammatory muscle involvement, a hallmark of antisynthetase syndrome.  
3. **Articular Manifestations**: Arthritis, arthralgia, and joint abnormalities (knee, hand phalanges, MCP joints) are consistent with the polyarthritis seen in this syndrome.  
4. **Systemic Involvement**: Gastroesophageal reflux, dyspepsia, and dysesthesia reflect multisystemic inflammation, commonly seen in antisynthetase syndrome.  
5. **Extramuscular Signs**: Oral/aphthous ulcers and abnormal nail color may correlate with cutaneous manifestations of the disease.  
6. **Laboratory Clues**: Abnormal circulating protein concentration supports chronic inflammation.  
7. **Exclusion of Mimics**: While cardiac abnormalities (bundle branch block, tachycardia) are atypical, they are occasionally reported in antisynthetase syndrome, and other diseases (e.g., lupus, Sjögren’s) are less likely given the symptom constellation.  

The combination of myositis, arthritis, autoantibodies, and systemic involvement strongly supports antisynthetase syndrome, particularly with anti-Jo-1 antibodies (implied by ANA positivity in this context). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ichthyosis linearis circumflexa is the characteristic skin lesion seen in:
Choices:
A. Netheon syndrome
B. Progeria
C. Lamellar ichthyosis
D. Harlequin ichthyosis
Answer: [/INST] Netheon syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mode of transmission of Q fever is
Choices:
A. Bite of infected louse
B. Bite of infected tick
C. Bite of infected mite
D. Inhalation of aerosol
Answer: [/INST] Inhalation of aerosol </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Abnormal myelination']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Abnormal myelination**: Canavan disease is a leukodystrophy caused by aspartoacylase deficiency, leading to defective myelin synthesis due to toxic accumulation of N-acetylaspartic acid (NAA) in the brain.  
2. **Abnormal circulating aspartate family amino acid concentration**: Elevated NAA in blood/urine is pathognomonic for Canavan disease, directly linked to the enzyme deficiency.  
3. **Feeding difficulties and death in infancy**: Early-onset symptoms (3–6 months) include hypotonia, poor feeding, and failure to thrive, progressing to severe neurodegeneration and typically fatal outcomes in infancy/early childhood.  
4. **Hyperactivity**: Neurological deterioration in Canavan disease may manifest as irritability or hyperexcitability due to cerebral dysfunction, though spasticity and developmental regression are more common.  
5. **Exclusion of other leukodystrophies**: The biochemical profile (NAA elevation) and clinical progression distinguish Canavan from other disorders like Tay-Sachs or Krabbe disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma is differentiated from myositis ossificans by radiology by:
Choices:
A. Location
B. Absence of osteomyelitic changes
C. Shape of swelling
D. Peripheral field of differentiation
Answer: [/INST] Peripheral field of differentiation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria in pregnancy doesn't cause?
Choices:
A. HELLP
B. IUGR
C. IUD
D. Preterm
Answer: [/INST] HELLP </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Smallpox vaccine was introduced by:
Choices:
A. Paul Ehrlich
B. Robert Koch
C. Louis Pasteur
D. Edward Jenner
Answer: [/INST] Edward Jenner </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the classical CSF finding seen in Tubercular Meningitis?
Choices:
A. Increased protein, decreased sugar, increased lymphocytes
B. Increased protein, sugar and lymphocytes
C. Decreased protein, increased sugar and lymphocytes
D. Increased sugar, protein and neutrophils
Answer: [/INST] Increased protein, decreased sugar, increased lymphocytes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: FALSE about Leprosy eradication programme is -
Choices:
A. Early detection of cases
B. Disability limitation
C. Long term multi drug therapy
D. Health education
Answer: [/INST] Long term multi drug therapy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing the conversion of phenylalanine to tyrosine. This aligns with the listed symptom.  
2. **Abnormality of prenatal development or birth** may reflect maternal PKU syndrome (untreated phenylalanine elevation during pregnancy) rather than the infant’s own PKU, though severe neonatal metabolic instability could contribute.  
3. **Death in infancy/childhood and neonatal death** are rare in treated PKU but plausible in undiagnosed/severe cases due to metabolic crises, neurological deterioration, or secondary complications (e.g., seizures, failure to thrive).  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually normal/low). This could suggest a comorbid condition (e.g., transient tyrosinemia in liver immaturity) or a BH4-deficient PKU variant, where disrupted tyrosine metabolism may occur alongside phenylalanine accumulation.  
5. The combination of **hyperphenylalaninemia + early lethality** strongly prioritizes PKU as the primary diagnosis, with hypertyrosinemia requiring further investigation for confounding factors. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Severe, untreated maternal PKU can disrupt fetal development due to phenylalanine toxicity, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia**: While PKU classically results in *low* tyrosine (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia may occur in neonates with liver immaturity or secondary metabolic disturbances.  
4. **Neonatal death/Death in infancy**: Untreated PKU can cause rapid neurological deterioration, seizures, and failure to thrive, particularly in rare severe variants (e.g., ""malignant"" PKU with near-complete PAH deficiency).  
5. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe early-life outcomes aligns with PKU, though hypertyrosinemia suggests possible comorbid factors (e.g., transient neonatal tyrosinemia) or misdiagnosis of lab values.  

**Note**: Hypertyrosinemia is atypical for classic PKU and warrants investigation for alternative/additional disorders (e.g., tyrosinemia types I–III, BH4 deficiencies) or confirmatory genetic testing for PAH mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to acute hyperammonemic crises.  
3. **Neurological symptoms** (seizures, spasticity, lethargy, drowsiness, intellectual disability) result from ammonia-induced neurotoxicity and cerebral edema.  
4. **Generalized hypotonia** and **microcephaly** reflect chronic energy deprivation and impaired brain development from persistent metabolic dysfunction.  
5. **Sleep disturbances** correlate with encephalopathic phases of hyperammonemia.  
6. CPS1 deficiency is distinguished from other UCDs (e.g., OTC deficiency) by autosomal recessive inheritance and absence of orotic acid elevation, though confirmatory genetic/enzymatic testing is definitive. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the kidney', 'High palate', 'Hearing impairment', 'Sensorineural hearing impairment', 'Choanal atresia', 'Abnormality of the eye', 'Deeply set eye', 'Ptosis', 'Esotropia', 'Compulsive behaviors', 'Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Cyanosis', 'Spatulate thumbs', 'Intellectual disability', 'Ataxia', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Bilateral ptosis', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Hyperconvex nail', 'Myopathic facies', 'Hypoplasia of the corpus callosum', 'Apnea', 'Abnormal brainstem morphology', 'Language impairment', 'Expressive language delay', 'Aortic root aneurysm', 'Scoliosis', 'Myopathy', 'Sleep apnea', 'Abnormal eye morphology', 'Choking episodes']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental Core Features**: Intellectual disability, global developmental delay, delayed speech/language development, expressive language delay, and compulsive behaviors with abnormal repetitive mannerisms align with the neurodevelopmental axis of NEDBEH.  
2. **Brain Anomalies**: Hypoplasia of the corpus callosum and abnormal brainstem morphology directly correspond to structural brain abnormalities in NEDBEH.  
3. **Ocular Involvement**: Abnormality of the eye, deeply set eyes, bilateral ptosis, esotropia, and abnormal eye morphology satisfy the ""eye anomalies"" criterion.  
4. **Cardiac Defects**: Atrial septal defect, abnormal cardiac septum morphology, and aortic root aneurysm reflect cardiac anomalies associated with NEDBEH.  
5. **Systemic Features**: Hypotonia, ataxia, myopathy, scoliosis, hyperconvex nails, spatulate thumbs, and myopathic facies suggest multisystem involvement, common in genetic neurodevelopmental disorders.  
6. **Auxiliary Symptoms**: Cyanosis, apnea, choking episodes, and sensorineural hearing impairment are secondary to neuromuscular, cardiac, or brainstem dysfunction.  
7. **Exclusion of Overlap**: The constellation of symptoms (brain-eye-heart triad) is distinct from isolated syndromes (e.g., CHARGE, Cornelia de Lange), favoring NEDBEH’s broader diagnostic scope.  

This synthesis of neurodevelopmental delays, structural brain/eye/cardiac defects, and supportive systemic features confirms NEDBEH as the unifying diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is false about Alkaptonuria?
Choices:
A. Genitourinary system not involved
B. Hemogentistic oxidase deficiency
C. Black urine
D. Calcification in veebral bodies
Answer: [/INST] Genitourinary system not involved </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hepatic Encephalopathy is predisposed by all, Except:
Choices:
A. Hyperkalemia
B. Dehydration
C. Constipation
D. GI Bleeding
Answer: [/INST] Hyperkalemia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Radiologic feature suggestive of Achalasia cardia is-
Choices:
A. Absence of gastric air bubble
B. Air fluid level in mediastinum
C. Sigmoid ecophagus
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine at a primary health care centre should be stored at which temperature?
Choices:
A. .-20 oC
B. 0 oC
C. .+2 o C to 8 oC
D. Any temperature not exceeding room temperature
Answer: [/INST] .+2 o C to 8 oC </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Intrahepatic cholestasis is seen in – a)  Galactosemiab)  Hypercalcemiac)  Haemoclu–omatosisd)  Cystic fibrosis
Choices:
A. ad
B. c
C. ac
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Leukopenia', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Abnormal basal ganglia morphology', 'Hyperuricemia', 'Hyperglycinemia', 'Hepatomegaly', 'Difficulty walking', 'Methylmalonic acidemia', 'Hypoproteinemia', 'Increased blood urea nitrogen', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Periventricular cysts', 'Difficulty running', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Methylmalonic aciduria', 'Abnormal myelination']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical markers**: Methylmalonic acidemia (MMA) and methylmalonic aciduria are hallmarks of this disorder, directly indicating a defect in methylmalonyl-CoA mutase, the enzyme responsible for converting methylmalonyl-CoA to succinyl-CoA. Vitamin B12-unresponsiveness confirms mutations in the *MUT* gene encoding this enzyme.  
2. **Metabolic disturbances**: Metabolic acidosis, hyperammonemia, hypoglycemia, and hyperglycinemia arise due to disrupted propionate metabolism, leading to toxic accumulation of methylmalonic acid and secondary inhibition of multiple metabolic pathways (e.g., urea cycle dysfunction).  
3. **Hematologic abnormalities**: Leukopenia and abnormal erythrocyte morphology reflect bone marrow suppression caused by toxic metabolites.  
4. **Neurological involvement**: Generalized hypotonia, motor delays, intellectual disability, abnormal myelination, and periventricular cysts correlate with neurotoxic effects of methylmalonic acid and impaired energy metabolism in the basal ganglia.  
5. **Systemic complications**: Hepatomegaly, hypoproteinemia, and increased blood urea nitrogen result from hepatic/renal stress. Severe short stature and early mortality (infancy/childhood/adolescence) reflect chronic metabolic decompensation.  
6. **Exclusion of secondary causes**: Abnormal carnitine/porphyrin levels are secondary to mitochondrial dysfunction, not primary disorders. Hyperuricemia may stem from renal tubular damage.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Clinical confirmation**: Overlapping features (metabolic acidosis, hyperammonemia, methylmalonic aciduria) fulfill diagnostic criteria for MMA.  
2. **Phenotypic spectrum**: The inclusion of both neonatal death and death in adolescence aligns with MMA’s variable severity, depending on residual enzyme activity.  
3. **Supportive biomarkers**: Abnormal myelination, hypoglycemia, and hepatomegaly are consistent with long-term complications of MMA, even if not disease-specific.  
4. **Disease categorization**: This broader diagnosis encapsulates the genetic and biochemical heterogeneity of MMA, including subtypes beyond *MUT* mutations (e.g., cobalamin metabolism defects), though the B12-unresponsive subtype is prioritized here based on clinical severity.  

**Final Diagnosis**: The patient has **vitamin B12-unresponsive methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency**, a severe form of MMA with poor prognosis, as evidenced by early lethality, metabolic instability, and neurological sequelae. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Autosomal recessive spastic paraplegia type 76 (SPG76): The patient exhibits lower and upper limb spasticity, consistent with hereditary spastic paraplegia (HSP). The additional cerebellar features (gait ataxia, limb ataxia, dysmetria, dysarthria) indicate a complex HSP subtype. SPG76, caused by CAPN1 mutations, is characterized by progressive spastic paraplegia, cerebellar ataxia, dysarthria, and dysphagia. While keratoconus is not a classic feature of SPG76, the combination of spasticity, cerebellar dysfunction, and autosomal recessive inheritance strongly supports this diagnosis. Keratoconus may represent an atypical or coincidental manifestation in this case. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Malaria, histopathological examination of liver would show:
Choices:
A. Microabscess formation
B. Kupffer's cell hyperplasia with macrophage infiltration around peripoal area laden with pigments
C. Non caseating granuloma
D. Non specific finding of neutrophilic infiltration
Answer: [/INST] Kupffer's cell hyperplasia with macrophage infiltration around peripoal area laden with pigments </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis in Pott's disease involves: September 2010
Choices:
A. Hip Joint
B. Knee Joint
C. Spine
D. Wrist Joint
Answer: [/INST] Spine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Global developmental delay', 'Generalized hypotonia', 'Abnormal facial shape', 'Delayed skeletal maturation']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Intellectual disability and global developmental delay** align with TBCK syndrome’s hallmark neurodevelopmental impairments caused by TBC1 domain-containing kinase (TBCK) gene mutations.  
2. **Generalized hypotonia** is a core feature of this disorder, reflecting neuromuscular dysfunction.  
3. **Abnormal facial shape** corresponds to characteristic facies (e.g., coarse features, hypertelorism, broad nasal tip) linked to TBCK syndrome.  
4. **Delayed skeletal maturation** matches reported skeletal anomalies, including bone age delay and scoliosis.  
5. The absence of seizures or progressive neurodegeneration (common in other hypotonia-linked disorders) supports TBCK syndrome, which is typically non-degenerative.  
6. Genetic testing for TBCK mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma can arise from:
Choices:
A. Diaphysis
B. Epiphysis
C. Metaphysis
D. All of the above
Answer: [/INST] Metaphysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is false about Botulism?
Choices:
A. It is a type food poisoning
B. Botulinum toxin is a potent neurotoxin
C. It is an infection and not intoxication
D. The causative organism is Clostridium botulinum
Answer: [/INST] It is an infection and not intoxication </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Hearing impairment', 'Cataract', 'Proptosis', 'Growth delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cockayne syndrome A  
Reasoning:  
1. **Microcephaly**: A hallmark of Cockayne syndrome (CS), caused by progressive neurodegeneration and impaired brain development.  
2. **Hearing impairment**: Sensorineural hearing loss is common in CS due to neurological and cochlear degeneration.  
3. **Cataract**: Ocular abnormalities, including cataracts, arise from DNA repair defects impacting lens transparency.  
4. **Proptosis**: Facial atrophy and sunken eyes in CS can create an illusion of protruding eyes, though true proptosis may occur due to orbital fat loss.  
5. **Growth delay**: Severe postnatal growth failure is a cardinal feature, driven by cellular sensitivity to UV-induced DNA damage and metabolic dysfunction.  

The combination of neurodevelopmental, sensory, and growth abnormalities aligns with Cockayne syndrome type A (CSA), an autosomal recessive disorder caused by mutations in *ERCC8*. Differentiated from other subtypes (e.g., CSB) by earlier onset and severity, CSA typically manifests in infancy with these core features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertension', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability** aligns with untreated PKU, as excess phenylalanine disrupts neurotransmitter synthesis and myelination.  
3. **Elevated urinary carboxylic acid** reflects phenylalanine metabolism via alternative pathways (e.g., phenylpyruvate), excreted as phenylketones.  
4. **Obesity and hypertension** may result from carbohydrate-rich diets used to restrict phenylalanine intake, leading to metabolic complications.  
5. **Early mortality** correlates with untreated PKU complications, including neurological decline and metabolic instability.  
6. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine is typically low) but may arise from dietary tyrosine supplementation or secondary metabolic adaptations.  

Note: Hypertyrosinemia and hyperphenylalaninemia coexistence suggests potential diagnostic complexity (e.g., BH4 deficiency or tyrosinemia overlap), but PKU remains the primary diagnosis based on core features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which favor face presentation:a) Anencephalyb) Contracted pelvisc) Placenta praevia d) Thyroid swellinge) Bicornuate uterus
Choices:
A. abd
B. bcd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cause of secondary dysmenorrhea in a young female:a) Tuberculosisb) Adenomyosisc) CINd) Endometriosise) Subserous fibroid
Choices:
A. acd
B. bde
C. abd
D. ade
Answer: [/INST] ade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following age group is most severely affected by Rubella infection –
Choices:
A. Females aged 25–35 Year
B. Young girls
C. Adolescent girls
D. Unborn child
Answer: [/INST] Unborn child </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Duchenne Muscular Dystrophy is a disease of –
Choices:
A. Neuromuscular junction
B. Sarcolemmal proteins
C. Muscle contractile proteins
D. Disuse atrophy due to muscle weakness
Answer: [/INST] Sarcolemmal proteins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A multigravida came for routine antenatal check up. She had a history of medical termination of pregnancy due to fetus with anencephaly. Anencephaly is best diagnosed in the present pregnancy by using:
Choices:
A. Maternal Alpha fetoprotein
B. Amniotic fluid beta hCG
C. USG
D. X-ray
Answer: [/INST] USG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids** align with phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted via alternative pathways in untreated PKU.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence) reflects severe, untreated PKU complications: irreversible neurotoxicity, seizures, and failure to thrive prior to modern dietary management.  
4. **Hypertyrosinemia** is atypical in classic PKU (tyrosine levels are usually low due to PAH deficiency). This may suggest a coexisting condition (e.g., tyrosinemia) or a reporting error, but PKU remains the primary diagnosis given hyperphenylalaninemia and urinary findings.  
5. Neonatal screening and dietary restriction of phenylalanine typically prevent progression, but historical cases without intervention explain the fatal trajectory described. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormal erythrocyte morphology', 'Thrombocytosis', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating porphyrin concentration', 'Abnormality of vitamin D metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning:  
1. **Abnormality of galactoside metabolism**: Directly aligns with galactosemia, a disorder of galactose metabolism due to GALT enzyme deficiency.  
2. **Neonatal death/Death in infancy/Death in childhood**: Untreated galactosemia causes severe complications (e.g., liver failure, sepsis) leading to early mortality.  
3. **Abnormal erythrocyte morphology**: Hemolysis from toxic galactitol accumulation can alter red blood cell structure.  
4. **Thrombocytosis**: May arise secondary to liver dysfunction or splenic dysfunction from chronic hemolysis.  
5. **Abnormal circulating porphyrin concentration**: Hepatic impairment disrupts heme biosynthesis pathways.  
6. **Abnormality of vitamin D metabolism**: Liver damage reduces 25-hydroxylation of vitamin D, impairing activation.  
7. **Abnormality of prenatal development or birth**: Though galactosemia is not congenital in structural development, metabolic stress in utero may contribute to prenatal abnormalities.  

All symptoms collectively point to **classic galactosemia**, where toxic galactose metabolites drive multi-organ dysfunction, consistent with the patient’s presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Fever', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity. This enzyme converts phenylalanine to tyrosine, and its absence leads to toxic phenylalanine accumulation.  
2. **Hypertyrosinemia**: While atypical in classic PKU (which typically shows normal/low tyrosine), this may indicate a rare variant (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting liver dysfunction from chronic metabolic stress.  
3. **Abnormal urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate) may mimic carboxylic acid excretion patterns, though organic acidemias should be ruled out.  
4. **Decreased ferritin**: Chronic dietary restriction (low-protein PKU management) or malabsorption could contribute to iron deficiency.  
5. **Recurrent infections**: Untreated PKU causes severe neurological decline and immunosuppression due to metabolic derangements, increasing infection susceptibility.  
6. **Early mortality (infancy/childhood/adolescence)**: Reflects untreated/severe PKU, where toxic phenylalanine levels lead to neurodegeneration, seizures, and organ failure. Neonatal screening often prevents this, but delayed diagnosis results in fatal outcomes.  

Note: Hypertyrosinemia and porphyrin abnormalities are not classic PKU features, suggesting potential comorbidities (e.g., secondary mitochondrial dysfunction) or misattributed lab findings. However, hyperphenylalaninemia remains the diagnostic anchor. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Common spinal cord tumor with intradural but extramedullary situation -a)  Meningiomab)  Neurofibromac)  Ependymomad) Astrocytoma
Choices:
A. ab
B. a
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The Clinical incubation period of Filariasis is
Choices:
A. 10 to 20 days
B. 3 to 6 months
C. 8 to 16 months
D. 6 to 12 months
Answer: [/INST] 8 to 16 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vit A deficiency produces -a) Bitots Spotsb) Trantas spotsc) Keratomalaciad) Xerophthalmia e) Color blindness
Choices:
A. abc
B. ad
C. bc
D. acd
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Respiratory insufficiency', 'Neonatal death', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Uraciluria** and **abnormal circulating pyrimidine concentration** are hallmark biochemical features of dihydropyrimidine dehydrogenase (DPD) deficiency, as the enzyme catalyzes the first step in pyrimidine degradation.  
2. DPD deficiency leads to accumulation of uracil and thymine in body fluids, which correlates with the observed metabolic abnormalities.  
3. **Respiratory insufficiency** and **neonatal death** are consistent with severe presentations of DPD deficiency, often due to neurological dysfunction or metabolic crises.  
4. **Death in infancy** aligns with the life-threatening nature of this autosomal recessive disorder, particularly in cases with complete enzyme deficiency.  
5. The combination of metabolic derangements and catastrophic early clinical course strongly supports this diagnosis over other rare pyrimidine metabolism disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Retrognathia', 'Abnormality of prenatal development or birth', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Apnea', 'Opisthotonus', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Neurological symptoms (Seizure, Hypotonia, Apnea, Opisthotonus)**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting neurotransmitter synthesis and causing severe neurological damage.  
3. **Poor prognosis (Death in infancy/childhood, Neonatal death)**: Without early dietary intervention, progressive neurodegeneration results in fatal outcomes.  
4. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to blocked PAH-mediated conversion of phenylalanine to tyrosine. This may indicate a coexisting metabolic disorder, lab error, or atypical PKU variant.  
5. **Retrognathia/prenatal abnormalities**: Uncommon in classic PKU but could suggest maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting fetal development.  

Key confirmation: Hyperphenylalaninemia + neurological decline aligns with PKU. Early diagnosis via newborn screening and dietary management are critical to prevent symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma –
Choices:
A. Is inherited in 50% of cases
B. Is caused by deletion of 11q14
C. Rosettes suggest good prognosis
D. Causes death in 60% of sufferers in the UK
Answer: [/INST] Rosettes suggest good prognosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statement about Renal Cell Carcinoma (Hypemephroma) is false:
Choices:
A. Originate in the coex
B. Histologically are usually Adenocarcinomas
C. May present with varicocele
D. Radiosensitive
Answer: [/INST] Radiosensitive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis is characterized by the acute onset of fever and stiff neck. Aseptic meningitis may be caused by a variety of microbial agents. During the initial 24 h of the course of aseptic meningitis, an affected person's cerebrospinal fluid is characterized by
Choices:
A. Decreased protein content
B. Elevated glucose concentration
C. Lymphocytosis
D. Polymorphonuclear leukocytosis
Answer: [/INST] Polymorphonuclear leukocytosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vaccine which must be stored in the freezer compartment of a fridge is/are -a)  BCGb)  OPVc)  Measlesd)  Smallpoxe)  All of the above
Choices:
A. ce
B. bc
C. cde
D. eb
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Dystonia', 'Death in infancy', 'Glutaric aciduria', 'Paraplegia/paraparesis', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Elevated urinary glutaric acid is a hallmark biochemical marker of GA-I, directly caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Seizures & Dystonia**: Neurotoxic accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia, leading to acute/subacute striatal injury, manifesting as dystonia and secondary seizures.  
3. **Feeding difficulties**: Infants may exhibit poor feeding due to metabolic instability, encephalopathic crises, or oromotor dysfunction linked to neurological impairment.  
4. **Paraplegia/paraparesis**: Chronic neurodegeneration and corticospinal tract involvement can result in progressive spastic paraparesis.  
5. **Death in infancy**: Untreated GA-I often leads to life-threatening metabolic crises (e.g., during catabolic stress), with striatal necrosis causing irreversible neurological decline and early mortality.  
6. **Temporal consistency**: Symptom onset aligns with GA-I’s typical presentation in infancy (3-36 months), especially following triggers like infections.  
The triad of macrocephaly (often present), movement disorders, and organic aciduria strongly supports GA-I, distinguishing it from other organic acidemias with overlapping features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Meningitis in immunocompromised host is frequently caused by
Choices:
A. Candida tropicalis
B. Cryptococcus neoformans
C. Trichophyton rubrum
D. Epidermophyton flocculosum
Answer: [/INST] Cryptococcus neoformans </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 4-month-old infant with Tetralogy of Fallot presents with fever and loose stools. Which of the following is compatible with the diagnosis of Tetralogy spells?
Choices:
A. O2 saturation < 70% in room air
B. Inability to hear a murmur
C. Hepatomegaly
D. S3 gallop rhythm
Answer: [/INST] Inability to hear a murmur </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following is/are true about Rubella in pregnancy except
Choices:
A. Diagnosed when IgM antibodies are present in the neonatal serum
B. Diagnosed when IgG antibodies persist for more than 6 months
C. Most common defects are cataracts, deafness and hea defects
D. Maternal infection after 16 weeks of gestation result in major congenital defects
Answer: [/INST] Maternal infection after 16 weeks of gestation result in major congenital defects </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating leucine concentration', 'Abnormal circulating isoleucine concentration', 'Abnormal circulating valine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of abnormal circulating concentrations of branched-chain amino acids (leucine, isoleucine, valine), aminoaciduria, and severe neonatal symptoms (seizures, death in infancy/neonatal period) strongly suggests MSUD. This autosomal recessive disorder results from a deficiency in the branched-chain alpha-keto acid dehydrogenase complex, impairing BCAA catabolism. Accumulation of BCAAs and their toxic keto-acid derivatives leads to metabolic decompensation, neurotoxicity (seizures), and rapid progression to lethality in untreated classic MSUD. Aminoaciduria reflects renal excretion of excess BCAAs, consistent with the biochemical profile. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following antibodies is most frequently seen in Antiphospholipid Syndrome?
Choices:
A. Beta 2 microglobulin antibody
B. Anti-nuclear antibody
C. Anti-centromere antibody
D. Anti- beta 2 glycoprotein antibody
Answer: [/INST] Anti- beta 2 glycoprotein antibody </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Oral ulcer', 'Sinusitis', 'Tinnitus', 'Hearing impairment', 'Visual loss', 'Diplopia', 'Nephrolithiasis', 'Hematuria', 'Keratoconjunctivitis sicca', 'Abnormality of the hand', 'Syncope', 'Arthritis', 'Eosinophilia', 'Renal tubular acidosis', 'Nausea', 'Abdominal pain', 'Hypercalciuria', 'Headache', 'Vertigo', 'Bone pain', 'Exertional dyspnea', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'Paresthesia', 'Back pain', 'Somatic sensory dysfunction', 'Hypouricemia', 'Deviated nasal septum', 'Generalized morning stiffness', 'Limb pain', 'Decreased urinary urate', 'Fatigue', 'Mild proteinuria', 'Oral cavity bleeding', 'Neck pain', 'Wrist pain', 'Ankle pain', 'Aphthous ulcer', 'Chest pain', 'Lymphocytosis', 'Papule', 'Pustule', 'Epigastric pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Behçet disease/Behcet syndrome  
Reasoning:  
1. **Mucocutaneous Involvement**: Recurrent oral ulcers (""Oral ulcer,"" ""Aphthous ulcer"") and genital ulcers (implied by Behçet’s diagnostic criteria) are hallmark features. ""Oral cavity bleeding"" aligns with ulcerative mucosal damage. Skin lesions (""Papule,"" ""Pustule"") correlate with Behçet’s papulopustular eruptions.  
2. **Ocular Manifestations**: ""Visual loss"" and ""Diplopia"" suggest posterior uveitis, retinal vasculitis, or optic neuritis, common in Behçet’s. ""Keratoconjunctivitis sicca"" may indicate secondary dryness from inflammation.  
3. **Neurological Involvement**: ""Headache,"" ""Vertigo,"" ""Syncope,"" ""Paresthesia,"" and ""Somatic sensory dysfunction"" point to neuro-Behçet’s, which can cause meningoencephalitis or vascular CNS lesions.  
4. **Musculoskeletal Symptoms**: ""Arthritis,"" ""Wrist pain,"" ""Ankle pain,"" and ""Generalized morning stiffness"" reflect Behçet’s-associated non-erosive oligoarthritis.  
5. **Vascular Inflammation**: ""Chest pain"" may indicate pericarditis or vasculitis. ""Exertional dyspnea"" could stem from pulmonary artery aneurysms, a rare but severe Behçet’s complication.  
6. **Gastrointestinal Involvement**: ""Abdominal pain,"" ""Nausea,"" and ""Epigastric pain"" align with intestinal ulcers, a mimic of Crohn’s disease in Behçet’s.  
7. **Atypical Associations**: While ""Renal tubular acidosis"" and ""Hypercalciuria"" are uncommon in Behçet’s, secondary autoimmune tubulointerstitial nephritis or overlapping syndromes could explain these.  
8. **Inflammatory Markers**: ""Eosinophilia"" and ""Lymphocytosis"" suggest systemic inflammation, consistent with Behçet’s flares.  

**Key Exclusions**:  
- Sjögren’s syndrome (keratoconjunctivitis sicca) is less likely without anti-SSA/SSB antibodies or prominent sicca symptoms.  
- Sarcoidosis (hypercalciuria, lymphocytosis) lacks typical granulomas or hilar adenopathy here.  
- Vasculitides like GPA (sinusitis, renal issues) are excluded by the absence of ANCA or necrotizing glomerulonephritis.  

**Conclusion**: The constellation of mucocutaneous, ocular, neurological, and vascular symptoms strongly supports Behçet’s syndrome, despite atypical renal findings. Further evaluation with pathergy testing, HLA-B51 testing, and imaging (e.g., angiography for vasculitis) would solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Jaundice', 'Generalized hypotonia', 'Anemia', 'Hyperhomocystinemia', 'Progressive neurologic deterioration', 'Hypomethioninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating porphyrin concentration', 'Abnormality of folate metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Hyperhomocystinemia** is the hallmark of homocystinuria, caused by impaired cystathionine beta-synthase (CBS) activity, blocking homocysteine-to-cystathionine conversion.  
2. **Hypomethioninemia** is atypical for CBS deficiency (typically *elevated* methionine), but may occur in rare variants or secondary folate metabolism disturbances affecting remethylation pathways.  
3. **Progressive neurologic deterioration** aligns with untreated homocystinuria, as excess homocysteine is neurotoxic, causing seizures, intellectual disability, and neurodegeneration.  
4. **Abnormality of folate metabolism** may exacerbate remethylation defects, worsening homocysteine accumulation and methionine depletion.  
5. **Recurrent viral infections** and **anemia** could stem from immune dysfunction due to metabolic stress or folate-related hematologic abnormalities.  
6. **Jaundice** and **abnormal porphyrins** suggest hepatic involvement, possibly from oxidative stress or secondary porphyrin pathway disruption.  
7. **Death in childhood** correlates with severe, untreated CBS deficiency, often due to thromboembolic events or neurologic complications.  

Disease: Homocysteinemia/Homocystinuria (general)  
Reasoning:  
1. **Hyperhomocystinemia** directly defines this disorder, encompassing both CBS deficiency and remethylation defects (e.g., MTHFR deficiency).  
2. **Hypomethioninemia** suggests a remethylation defect (e.g., MTHFR or cobalamin disorders), where homocysteine cannot recycle to methionine, but this overlaps with CBS deficiency in clinical presentation.  
3. **Abnormal folate metabolism** supports a broader homocysteinemia diagnosis, as folate is critical for homocysteine remethylation.  
4. **Neurologic deterioration** and **hypotonia** are nonspecific but consistent with systemic metabolic dysfunction from homocysteine toxicity.  
5. **Recurrent infections** and **anemia** may reflect multisystemic failure or secondary nutritional deficiencies (e.g., B12/folate).  

**Final Diagnosis**: Classic homocystinuria (CBS deficiency) is prioritized due to progressive neurologic decline and hyperhomocystinemia, though hypomethioninemia suggests a complex presentation, possibly with coexisting folate pathway disruption. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements are true about Congenital Rubella, EXCEPT:
Choices:
A. It is diagnosed when the infant has IgM antibodies at bih
B. It is diagnosed when IgG antibodies persist from more than 6 months
C. Most common congenital defects are deafness, cardiac malformations and cataract
D. Infection after 16 weeks of gestation results in major congenital defects
Answer: [/INST] Infection after 16 weeks of gestation results in major congenital defects </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cerebellar atrophy', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy**: PMM2-CDG is characterized by progressive neurological deterioration. Cerebellar atrophy is a hallmark of the disease due to disrupted glycosylation, impairing cerebellar development and function.  
2. **Death in childhood**: PMM2-CDG type Ia is a severe, multisystem disorder. Mortality in early life is common due to complications such as liver failure, infections, or severe neurological decline.  
3. **Cerebellar agenesis**: While ""agenesis"" implies complete absence (rare in PMM2-CDG), severe cerebellar hypoplasia (underdevelopment) is frequently reported. This may reflect variability in phenotypic terminology or extreme cerebellar malformation secondary to glycosylation defects.  
4. **Consistency with PMM2-CDG**: The triad of cerebellar structural anomalies, early lethality, and systemic involvement aligns with PMM2-CDG’s clinical spectrum. Confirmatory testing (e.g., phosphomannomutase activity, genetic analysis for *PMM2* mutations) would solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary pleural tumor is -a)  Mesotheliomab)  Myxomac)  Lipomad)  Fibroma
Choices:
A. b
B. c
C. ac
D. ad
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements about Yaws is not TRUE?
Choices:
A. Spread by sexual transmission
B. Caused by T. peenue
C. Has cross immunity with syphilis
D. Cannot be differentiated serologically from T. pallidum
Answer: [/INST] Spread by sexual transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient of Scleroderma presents with acute respiratory distress. Chest X-ray shows B/L reticular basilar shadows. What is the next line of investigation in this patient?
Choices:
A. Echocardiography to look for Cor pulmonale
B. High resolution CT
C. Pulmonary function test
D. Contrast enhanced CT scan
Answer: [/INST] High resolution CT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Epistaxis', 'Weight loss', 'Migraine', 'Vertigo', 'Vasculitis', 'Myalgia', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Ear pain', 'Neck pain', 'Carotid artery stenosis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Takayasu arteritis  
Reasoning:  
1. **Vasculitis**: Takayasu arteritis is a large-vessel vasculitis, directly aligning with the patient's vasculitis diagnosis.  
2. **Carotid artery stenosis**: Inflammation in large arteries (e.g., carotids) leads to stenosis, a hallmark of Takayasu.  
3. **Elevated ESR**: Indicates systemic inflammation, consistent with active arteritis.  
4. **Weight loss, Exercise intolerance**: Systemic inflammatory responses and reduced blood flow to muscles.  
5. **Migraine, Vertigo, Neck pain**: Caused by compromised cerebral blood flow due to carotid/vertebral artery involvement.  
6. **Myalgia**: Muscle pain from ischemia or systemic inflammation.  
7. **Epistaxis, Ear pain**: Rare but possible with vascular compromise in nasal or auricular arteries.  
8. **Demographic context**: While age is unspecified, symptom clusters (vascular stenosis + systemic inflammation) are classic for Takayasu.  

Exclusion of mimics (e.g., Giant Cell Arteritis) hinges on carotid involvement and lack of temporal artery symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Visual impairment', 'Seizure', 'Cerebellar vermis hypoplasia', 'Hypoplasia of the corpus callosum', 'Respiratory insufficiency', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Highly arched eyebrow', 'Peripheral axonal neuropathy', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial Dysmorphism**: ""Narrow forehead,"" ""Prominent nasal bridge,"" ""Anteverted nares,"" ""Exaggerated cupid's bow,"" and ""Highly arched eyebrow"" align with the characteristic facies of TBCK syndrome, which includes midface hypoplasia and distinct lip morphology.  
2. **Neurological Abnormalities**: ""Cerebellar vermis hypoplasia,"" ""Hypoplasia of the corpus callosum,"" and ""Small basal ganglia"" are consistent with brain malformations reported in TBCK-related disorders. ""Ventriculomegaly"" further supports structural CNS involvement.  
3. **Developmental and Motor Deficits**: ""Profound global developmental delay"" and ""Peripheral axonal neuropathy"" correlate with the syndrome’s hallmark hypotonia, psychomotor retardation, and progressive neurological decline.  
4. **Seizures/EEG Abnormalities**: ""Seizure"" and ""EEG abnormality"" match the epileptic phenotypes observed in TBCK patients, often linked to cortical dysfunction.  
5. **Systemic Involvement**: ""Feeding difficulties"" and ""Respiratory insufficiency"" reflect the multisystem impact of TBCK mutations, including bulbar weakness and respiratory muscle compromise.  
6. **Ocular and Genetic Consistency**: ""Visual impairment"" may stem from cortical or optic nerve abnormalities, while the genetic basis (biallelic TBCK loss) explains the syndromic clustering of these features.  
**Conclusion**: The constellation of craniofacial, neurological, and systemic findings strongly supports a diagnosis of TBCK-related intellectual disability syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mumps most commonly affects the: March 2004
Choices:
A. Parotid gland
B. Submandibular gland
C. Sublingual gland
D. Lacrimal gland
Answer: [/INST] Parotid gland </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Efficacy of BCG vaccine for Pulmonary Tuberculosis
Choices:
A. 0%
B. 25%
C. 33%
D. 50%
Answer: [/INST] 0% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Death in infancy', 'Sudden death', 'Hypoglycemia', 'Vomiting', 'Elevated circulating alkaline phosphatase concentration', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Increased circulating lactate dehydrogenase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by mutations in the *SLC22A5* gene impairing carnitine transport.  
2. **Hypoglycemia** occurs due to defective fatty acid oxidation (FAO), forcing reliance on glucose metabolism and depleting glycogen stores, particularly during fasting or metabolic stress.  
3. **Sudden death in infancy** and **coma** result from metabolic crises triggered by hypoglycemia and hyperammonemia, exacerbated by the inability to utilize fatty acids for energy in critical tissues (e.g., heart, liver).  
4. **Elevated lactate dehydrogenase (LDH)** and **abnormal alanine/aspartate family amino acids** reflect secondary mitochondrial dysfunction and anaerobic glycolysis activation under energy-deficient states.  
5. **Vomiting** and **hepatic involvement** (elevated alkaline phosphatase) stem from hepatic steatosis and impaired hepatic FAO.  
6. PCD aligns with the acute metabolic decompensation pattern in infancy, distinguishing it from other FAO disorders (e.g., MCAD deficiency lacks carnitine deficiency). Genetic testing for *SLC22A5* variants would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following clinical presentation qualify for the term ""Severe Falciparum Malaria"" EXCEPT
Choices:
A. Severe anemia
B. Acidosis
C. Pulmonary oedema
D. High grade fever with rigors
Answer: [/INST] High grade fever with rigors </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cyanosis', 'Seizure', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', '3-hydroxydicarboxylic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glycogen storage disease Ia  
Reasoning:  
1. **Hyperammonemia and 3-hydroxydicarboxylic aciduria**: In GSD Ia, impaired gluconeogenesis and glycogenolysis lead to reliance on fatty acid oxidation, generating dicarboxylic acids (e.g., 3-hydroxydicarboxylic acids) and secondary hyperammonemia due to disrupted urea cycle function from liver stress.  
2. **Cyanosis and seizures**: Severe hypoglycemia (hallmark of GSD Ia) triggers seizures, while lactic acidosis (from excess lactate production) reduces oxygen delivery, causing peripheral cyanosis.  
3. **Neonatal death/infant mortality**: Untreated GSD Ia results in metabolic crises (hypoglycemia, acidosis) shortly after birth, often fatal without rapid diagnosis and glucose stabilization.  
4. **Consistency with GSD Ia**: Symptoms align with glucose-6-phosphatase deficiency, though hyperammonemia and dicarboxylic aciduria are atypical but explainable through metabolic cascades and hepatic dysfunction. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Congenital diaphragmatic hernia', 'Intellectual disability', 'Motor delay', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Cerebral atrophy', 'Lipodystrophy', 'Abnormal muscle physiology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] PMM2-CDG/Congenital disorder of glycosylation, type Ia:  
- **Congenital diaphragmatic hernia (CDH)** and **hiatus hernia** align with PMM2-CDG’s multisystem involvement, as glycosylation defects impair tissue integrity, including diaphragmatic and connective tissue development.  
- **Intellectual disability**, **motor delay**, and **cerebral atrophy** reflect the neurological hallmarks of PMM2-CDG, caused by abnormal glycosylation of brain proteins and neuronal migration defects.  
- **Failure to thrive** and **death in infancy** are common due to systemic complications (e.g., liver dysfunction, protein-losing enteropathy) and metabolic instability.  
- **Lipodystrophy** and **abnormal muscle physiology** stem from disrupted lipid metabolism and glycosylation-dependent muscle protein function.  
- The constellation of visceral, neurological, and metabolic symptoms, alongside early lethality, strongly supports PMM2-CDG as the unifying diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles virus is -
Choices:
A. Paramyxovirus
B. Ohomyxovirus
C. Poxvirus
D. Picornavirus
Answer: [/INST] Paramyxovirus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The MOST common enzyme deficiency responsible for Galactosemia is related to which of the following enzymes?
Choices:
A. UDP galactose epimerase
B. Galactokinase
C. Galactosidase
D. Galactose-l-phosphate uridyl transferase
Answer: [/INST] Galactose-l-phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a treatment modality for Keratoconus
Choices:
A. Spectacle
B. Prism
C. Contact lens
D. INTACS
Answer: [/INST] Prism </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the inheritance pattern of Familial Hypercholesterolemia?
Choices:
A. Autosomal dominant
B. Autosomal recessive
C. X Linked dominant
D. X Linked recessive
Answer: [/INST] Autosomal dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma differs from pseudoglioma by
Choices:
A. Decreasing Intraocular pressure
B. Blurring of vision
C. Enlargement of optic foramen
D. All the above
Answer: [/INST] Enlargement of optic foramen </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal renal tubule morphology', 'Enlarged kidney', 'Nephritis', 'Hematuria', 'Hypertension', 'Seizure', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Polydipsia', 'Vomiting', 'Anorexia', 'Hepatomegaly', '4-Hydroxyphenylpyruvic aciduria', 'Abdominal distention', 'Aminoaciduria', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating tyrosine concentration', 'Abdominal mass']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type I  
Reasoning:  
1. **Hepatic and Renal Involvement**: Symptoms like cirrhosis, hepatic fibrosis, hepatomegaly, abnormal renal tubule morphology, and nephritis indicate combined liver and kidney dysfunction, a hallmark of Tyrosinemia type I (HT-1).  
2. **Metabolic Abnormalities**: Elevated 4-hydroxyphenylpyruvic aciduria and abnormal tyrosine levels directly point to a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
3. **Infant/Childhood Fatality**: Death in infancy or childhood aligns with the severe, progressive nature of untreated HT-1, which causes liver failure and renal tubular damage.  
4. **Secondary Manifestations**: Hypertension (renal origin), seizures (neurotoxicity from metabolites like succinylacetone), aminoaciduria (renal tubular dysfunction), and elevated alpha-fetoprotein (hepatocyte regeneration/cancer risk) are consistent with HT-1 complications.  
5. **Gastrointestinal Symptoms**: Vomiting, anorexia, and abdominal distention reflect metabolic acidosis and liver dysfunction.  
6. **Diagnostic Confirmation**: The combination of hepatic fibrosis, renal Fanconi-like syndrome (aminoaciduria), and specific tyrosine pathway abnormalities excludes other metabolic disorders (e.g., galactosemia, Wilson disease) and confirms HT-1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Characteristic of Borderline Leprosy is
Choices:
A. Inveed Saucer appearance
B. Erythema Nodosum Leprosum
C. 1-lypopigmented macules/plaques all over the body
D. Glove and Stocking Anesthesia
Answer: [/INST] Inveed Saucer appearance </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is cutaneous Tuberculosis secondary to underlying tissue lymph node called
Choices:
A. Scrofuloderma
B. Lupus vulgaris
C. Spina ventosa
D. None of the above
Answer: [/INST] Scrofuloderma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The earliest Cranial nerve involved in Acoustic Neuroma is:
Choices:
A. V
B. VI
C. VII
D. X
Answer: [/INST] V </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hepatitis C virus is associated with -a) Anti LKM - I antibodyb)  Sclerodermac) Cryoglobulinemiad) Polyarteritis nodosa
Choices:
A. a
B. ac
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is transmitted by –  a) Anopheles stephensi  b) Anopheles culicifacies  c) Culex  d) Phlebotomus
Choices:
A. ab
B. ac
C. bd
D. cd
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: An infectious disease investigator is evaluating the diagnostic accuracy of a new interferon-gamma-based assay for diagnosing tuberculosis in patients who have previously received a Bacillus Calmette-Guérin (BCG) vaccine. Consenting participants with a history of BCG vaccination received an interferon-gamma assay and were subsequently evaluated for tuberculosis by sputum culture. Results of the study are summarized in the table below.
Tuberculosis, confirmed by culture No tuberculosis Total
Positive interferon-gamma assay 90 6 96
Negative interferon-gamma assay 10 194 204
Total 100 200 300
Based on these results, what is the sensitivity of the interferon-gamma-based assay for the diagnosis of tuberculosis in this study?""
Choices:
A. 194/200.
B. 90/100.
C. 90/96.
D. 100/300.
Answer: [/INST] 90/100. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles elimination criteria-
Choices:
A. <1/1000
B. <1/10000
C. < 1/100000
D. <1/100
Answer: [/INST] < 1/100000 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Key Metabolic Marker**: ""Decreased 3-hydroxyacyl-CoA dehydrogenase level"" directly indicates a defect in medium-chain acyl-CoA dehydrogenase (MCAD), a critical enzyme in mitochondrial β-oxidation of fatty acids.  
2. **Carnitine Abnormality**: ""Abnormal circulating carnitine concentration"" aligns with secondary carnitine deficiency in MCADD due to disrupted fatty acid metabolism and accumulation of toxic acyl-CoA intermediates.  
3. **Early Lethality**: Symptoms like ""neonatal death,"" ""death in infancy,"" and ""death in childhood"" reflect MCADD’s presentation during metabolic stress (e.g., fasting), causing hypoketotic hypoglycemia, hepatic dysfunction, and fatal energy crises if untreated.  
4. **Prenatal/Developmental Signs**: ""Abnormality of prenatal development"" may correlate with intrauterine metabolic stress or placental insufficiency secondary to fetal fatty acid oxidation defects.  
5. **Exclusion of Alternatives**: Symptoms are specific to a fatty acid oxidation disorder, and MCADD is the most common in this category, distinguished by the enzyme deficiency stated. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements regarding drugs used in Leprosy is false
Choices:
A. Single intramuscular injections of acedapsone maintain inhibitory levels of dapsone in tissues for up to 3 months
B. Monthly doses of rifampicin delay the emergency of resistance to dapsone
C. Clofazimine should not be given to patients who are intolerant to dapsone or who fail to improve during treatment with dapsone
D. Clofazimine may cause changes in skin colour
Answer: [/INST] Clofazimine should not be given to patients who are intolerant to dapsone or who fail to improve during treatment with dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation. This directly aligns with the symptom of hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While PKU typically reduces tyrosine levels (due to impaired conversion of phenylalanine to tyrosine), transient hypertyrosinemia can occur in neonates due to immature enzyme systems. This may resolve but could compound metabolic stress in untreated PKU.  
3. **Prenatal abnormalities**: Maternal PKU (untreated high phenylalanine during pregnancy) can cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus, explaining ""abnormality of prenatal development.""  
4. **Early mortality**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, leading to neonatal/infant/childhood death. Without dietary intervention, toxic phenylalanine levels are fatal.  
5. **Consistency with symptoms**: The combination of hyperphenylalaninemia, developmental issues, and early mortality strongly supports PKU as the primary diagnosis, with hypertyrosinemia as a secondary or transient finding. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Coma', 'Generalized hypotonia', 'Encephalopathy', 'Cardiomyopathy', 'Anemia', 'Hypoglycemia', 'Vomiting', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary carnitine deficiency (PCD)  
Reasoning:  
1. **Decreased plasma free carnitine**: A hallmark of PCD due to defective carnitine transporter (OCTN2), impairing cellular carnitine uptake.  
2. **Hypoglycemia**: Carnitine is essential for fatty acid oxidation (FAO); its deficiency forces reliance on glucose, depleting reserves and causing hypoglycemia, especially during fasting/metabolic stress.  
3. **Cardiomyopathy and generalized hypotonia**: Impaired FAO reduces ATP production in cardiac and skeletal muscles, leading to energy-deficient states.  
4. **Hepatomegaly and elevated hepatic transaminases**: Hepatic fat accumulation (steatosis) from defective fat metabolism causes liver enlargement and inflammation.  
5. **Encephalopathy, irritability, coma**: Hypoglycemia and potential hyperammonemia (secondary to disrupted urea cycle intermediates) induce neurotoxicity.  
6. **Abnormal circulating amino acids (aspartate family, alanine)**: Dysregulated gluconeogenesis and Krebs cycle intermediates alter amino acid metabolism.  
7. **Anemia**: Chronic energy deprivation affects erythropoiesis; mitochondrial dysfunction in bone marrow may contribute.  
8. **Abnormal porphyrins**: Secondary disruption of heme biosynthesis pathways due to hepatic mitochondrial dysfunction.  
9. **Death in childhood**: Untreated PCD causes recurrent metabolic crises, cardiac failure, or sudden death, consistent with the natural history of severe cases.  

PCD unifies all symptoms via disrupted fatty acid metabolism, energy deficiency, and multi-organ dysfunction. Confirmatory testing would involve genetic analysis of *SLC22A5* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: It is probable that physician have a higher index of suspicion for tuberculosis in children without BCG scar that those with BCG scar. If this is so and an association is found between Tuberculosis and not having BCG due to -scar, the association may be
Choices:
A. Selection bias
B. Interviewer bias
C. Surveillance bias
D. Non-response bias
Answer: [/INST] Interviewer bias </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Neonatal death', 'Recurrent viral infections', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Hyperammonemia and elevated plasma citrulline** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in **argininosuccinate synthetase (ASS1)**, a urea cycle enzyme. This blocks the conversion of citrulline to argininosuccinate, leading to citrulline accumulation.  
2. **Oroticaciduria** occurs due to secondary diversion of carbamoyl phosphate into pyrimidine synthesis when the urea cycle is disrupted, a phenomenon seen in urea cycle disorders.  
3. **Neonatal death/death in infancy** aligns with the severe, early-onset presentation of classic citrullinemia, often triggered by protein feeding after birth.  
4. **Lethargy, drowsiness, and sleep disturbances** reflect neurotoxicity from hyperammonemia, which disrupts cerebral metabolism.  
5. **Fever** may arise secondary to metabolic stress or intercurrent illnesses exacerbating the underlying defect.  
6. **Recurrent viral infections** are atypical for urea cycle disorders but could stem from prolonged hospitalization or metabolic instability impairing immune responses.  

The combination of urea cycle dysfunction (hyperammonemia), specific metabolite abnormalities (citrulline, orotic acid), and life-threatening neonatal course strongly supports citrullinemia type I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is most commonly seen in
Choices:
A. Maturity onset DM
B. Type1DM
C. Type2DM
D. Equally seen with all forms of DM
Answer: [/INST] Type2DM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination to all 9 months - 14 years children is a pa of which WHO strategy?
Choices:
A. Mop up
B. Catch up
C. Keep up
D. Follow up
Answer: [/INST] Catch up </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Epicanthus', 'Low-set ears', 'Wide nasal bridge', 'Anteverted nares', 'Ptosis', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Vomiting', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Polydactyly', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol with hypocholesterolemia are pathognomonic for SLOS, caused by a deficiency in 7-dehydrocholesterol reductase.  
2. **Craniofacial features**: Microcephaly, epicanthus, ptosis, wide nasal bridge, anteverted nares, and low-set ears align with SLOS-associated dysmorphism.  
3. **Limb anomalies**: Syndactyly (classically 2nd–3rd toe webbing) and polydactyly (often postaxial) are hallmark signs.  
4. **Neurodevelopmental issues**: Intellectual disability, motor delay, and generalized hypotonia reflect neurological involvement.  
5. **Systemic/growth complications**: Feeding difficulties, failure to thrive, vomiting, and early mortality (neonatal/infant/childhood death) correlate with severe SLOS phenotypes.  
6. **Rule-out**: Biochemical findings exclude other syndromes (e.g., trisomy 13/18), while cholesterol abnormalities confirm SLOS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Increased serum lactate', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Metabolic acidosis**: Elevated serum lactate aligns with impaired mitochondrial energy production due to deficient carboxylases (e.g., pyruvate carboxylase), a hallmark of BTDD.  
2. **Neurological manifestations**: Opisthotonus (severe hypertonia) and feeding difficulties suggest neurological dysfunction from accumulated toxic metabolites (e.g., lactate, ammonia) or disrupted neurotransmitter synthesis.  
3. **Amino acid abnormalities**: Abnormal aspartate family amino acids (e.g., elevated aspartate) and alanine stem from defective amino acid metabolism via biotin-dependent enzymes (e.g., propionyl-CoA carboxylase).  
4. **Hearing impairment**: Cochlear dysfunction due to chronic metabolic stress or oxidative damage is a recognized feature of untreated BTDD.  
5. **Infantile lethality**: Untreated BTDD causes progressive metabolic crises, leading to early death.  
6. **Diagnostic confirmation**: BTDD explains all symptoms under the umbrella of ""late-onset multiple carboxylase deficiency,"" where biotin recycling failure triggers multi-system dysfunction. Biotin supplementation reverses symptoms if initiated early. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Neonatal death', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Methylmalonic aciduria is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA. Generalized hypotonia aligns with metabolic energy deficits in MMA, while neonatal death and death in infancy reflect the severe, early-onset phenotype of the disorder due to toxic metabolite accumulation and metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The B12-unresponsive subtype specifically implicates mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. Neonatal lethality and lack of response to B12 supplementation distinguish this form from B12-responsive variants. The absence of improvement with B12 therapy exacerbates metabolic instability, leading to rapid clinical decline and early mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Untreated PKU** results in severe neurological damage, seizures, and developmental failure. Historically, before newborn screening and dietary management, infants with classic PKU often faced **death in infancy** due to progressive neurodegeneration or complications like infections.  
3. **Neonatal death** (within the first 28 days) is less typical but could occur in rare, severe variants (e.g., malignant PKU) or if metabolic derangements (e.g., electrolyte imbalances) compound critical organ dysfunction.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, where hyperphenylalaninemia precedes irreversible systemic collapse. Modern screening mitigates this outcome, but the historical context explains the listed presentation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 生物素酶缺乏症/Biotinidase deficiency (BTDD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Neonatal death/Death in infancy**: Untreated BTDD causes progressive metabolic crises (e.g., lactic acidosis, hyperammonemia) due to impaired carboxylase function. Without biotin supplementation, these crises lead to neurological deterioration, respiratory failure, and early mortality.  
   - **Abnormality of prenatal development or birth**: While BTDD typically manifests postnatally, severe maternal biotin deficiency (rarely) or fetal metabolic stress in utero may contribute to intrauterine growth restriction (IUGR) or preterm birth, indirectly linking to prenatal abnormalities.  

2. **Pathophysiology**:  
   - Biotinidase deficiency prevents recycling of biotin, a cofactor for carboxylases critical in fatty acid synthesis, gluconeogenesis, and amino acid catabolism.  
   - Postnatal biotin deprivation results in metabolic instability, with symptoms escalating within weeks to months after birth if untreated.  

3. **Diagnostic Confirmation**:  
   - Neonatal screening (bloodspot assay for biotinidase activity) or genetic testing (BTD gene mutations) would confirm the diagnosis.  
   - Absence of treatment explains the fatal trajectory described in the symptoms.  

4. **Exclusion of Alternatives**:  
   - Early-onset holocarboxylase synthetase deficiency presents similarly but typically manifests within days of birth, whereas BTDD is ""late-onset"" (weeks to months).  
   - Other lethal metabolic disorders (e.g., organic acidemias) were likely ruled out via the provided diagnosis.  

**Conclusion**: The triad of symptoms aligns with untreated BTDD, where biotin dependency post-birth leads to irreversible metabolic dysfunction and early death. Prenatal abnormalities may reflect secondary effects of metabolic instability or comorbid factors. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly is best diagnosed using:
Choices:
A. Maternal serum alpha feto protein
B. Amniotic fluid alpha feto protein
C. USG
D. X-ray
Answer: [/INST] USG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid Vi polysaccharide vaccine is usually administered in children above the age of-
Choices:
A. 6 months
B. 1 year
C. 2 years
D. 1 year 6 months
Answer: [/INST] 2 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Methylmalonic aciduria** is a cardinal biochemical marker of MMA, directly indicating impaired metabolism of methylmalonyl-CoA.  
2. **Hyperammonemia** and **increased serum lactate** arise due to disrupted urea cycle function and secondary mitochondrial dysfunction from toxic metabolite accumulation (methylmalonic acid, propionic acid).  
3. **Vomiting** and **weight loss** reflect metabolic decompensation triggered by catabolic stress (e.g., infections, fasting), common in organic acidemias.  
4. **Generalized hypotonia** results from energy deficiency in muscles/nerves and neurotoxicity of accumulated metabolites.  
5. **Death in infancy** aligns with the severe neonatal/early infantile presentation of MMA, often exacerbated by delayed diagnosis or metabolic crises.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. The **B12-unresponsive subtype** is confirmed by persistent methylmalonic aciduria despite adequate B12 levels, pointing to a defect in the mutase enzyme itself (MUT gene).  
2. **Severe clinical course** (death in infancy) correlates with complete loss of methylmalonyl-CoA mutase activity (mut⁰ mutation), leaving no residual enzyme function to alleviate metabolic blockades.  
3. **Hyperammonemia** and **lactic acidosis** are more pronounced in mutase deficiency compared to B12-responsive forms, as the metabolic block is irreversible without enzyme replacement.  
4. Absence of hematologic abnormalities (not listed in symptoms) further supports mutase deficiency over defects involving B12 metabolism (e.g., cblC), which often include megaloblastic anemia.  

Both diagnoses are consolidated by the triad of methylmalonic aciduria, life-threatening metabolic acidosis (lactate↑), and hyperammonemia in infancy, with subtype differentiation based on B12 responsiveness and genetic etiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy affects all the following except:
Choices:
A. Testes
B. Ovaries
C. Eyes
D. Nerves
Answer: [/INST] Ovaries </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis of paranasal sinus is most common in?
Choices:
A. HIV
B. Diabetes
C. Those on immuno suppressants
D. Post surgical
Answer: [/INST] Diabetes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is bilateral in:
Choices:
A. 1% of cases
B. 50% of cases
C. 100% of cases
D. 30% of cases
Answer: [/INST] 30% of cases </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment of choice for Kawasaki Disease is:
Choices:
A. IV Immunoglobulins
B. Steroids
C. Dapsone
D. Methotrexate
Answer: [/INST] IV Immunoglobulins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin acts by -
Choices:
A. Na ATPase inhibition
B. Adenylate cyclase stimulation
C. Opening of chloride channel
D. Stimulation of Ca' channel
Answer: [/INST] Adenylate cyclase stimulation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Clinical features of anicteric Leptospirosis are all EXCEPT: March 2013
Choices:
A. Influenza like illness like fever, hepatosplenomegaly, nausea, headache etc.
B. Muscle pain
C. High moality
D. Conjuctival suffusion is MC finding on physical examination
Answer: [/INST] High moality </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True of 8th Pandemic of Cholera
Choices:
A. Originated in 2012
B. Started in Bangladesh
C. Due to O139 El Tor
D. Low attack rate
Answer: [/INST] Started in Bangladesh </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Best indicator of trend of Tuberculosis unaffected by current control measures is:-
Choices:
A. Annual risk of infection
B. Prevalence of TB infection
C. % of primary drug resistance
D. % of multidrug resistance
Answer: [/INST] Annual risk of infection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Self-mutilation', 'Delayed speech and language development', 'Cyanosis', 'Abnormality of skin pigmentation', 'Abnormality of prenatal development or birth', 'Seizure', 'Death in infancy', 'Dehydration', 'Fever', 'Hyperkalemia', 'Hypokalemia', 'Hyponatremia', 'Neonatal death', 'Death in childhood', 'Pigmentation of the sclera', 'Severe hearing impairment', 'Elevated circulating 17-hydroxyprogesterone concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency  
Reasoning:  
1. **Elevated 17-hydroxyprogesterone (17-OHP)**: This is the hallmark biochemical marker of 21-hydroxylase deficiency (21-OHD), as the enzyme defect blocks cortisol synthesis, causing precursor accumulation.  
2. **Salt-wasting features**: Hyponatremia, hyperkalemia, dehydration, and neonatal/childhood death align with aldosterone deficiency, leading to electrolyte imbalances and adrenal crises.  
3. **Skin/scleral pigmentation**: Elevated ACTH (due to cortisol deficiency) stimulates melanocytes, causing hyperpigmentation.  
4. **Cryptorchidism and prenatal abnormalities**: Androgen imbalances in utero may disrupt genital development in males, though ambiguous genitalia (more typical in females) is absent here.  
5. **Seizures and developmental delays**: Likely secondary to recurrent metabolic derangements (e.g., hyponatremia, hypoglycemia) during adrenal crises.  
6. **Fever, cyanosis, death**: Reflect acute adrenal insufficiency crises, which can cause hypovolemic shock and multi-organ failure if untreated.  
7. **Hypokalemia discrepancy**: May represent transient fluctuations or misclassification; hyperkalemia is pathognomonic for salt-wasting 21-OHD.  
8. **Severe hearing impairment**: Uncommon in 21-OHD but could indicate a coincidental finding or atypical presentation.  

Other symptoms (e.g., self-mutilation) are atypical for 21-OHD and may suggest comorbidities, but the biochemical and cardinal clinical features strongly confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common drug used in Leprosy is:
Choices:
A. Dapsone
B. Clofazimine
C. Ethionamide
D. Ofloxacin
Answer: [/INST] Dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Dementia', 'Hallucinations', 'Delusions', 'Dysarthria', 'Gait disturbance', 'Parkinsonism', 'Dystonia', 'Tremor', 'Rigidity', 'Micrographia', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: The presence of tremor, rigidity, gait disturbance, and micrographia aligns with core parkinsonian features. Autosomal recessive early-onset Parkinson’s disease (PARK23) typically manifests before age 40.  
2. **Neuropsychiatric symptoms**: Dementia, hallucinations, and delusions suggest atypical cognitive/psychiatric involvement, which is reported in DNAJC6-related PD23 due to broader neuronal dysfunction.  
3. **Movement abnormalities**: Dystonia and dyskinesia are common in early-onset genetic parkinsonism, often exacerbated by dopaminergic therapy or intrinsic basal ganglia pathology.  
4. **Dysarthria and gait disturbance**: Reflects progressive neurodegeneration affecting both motor and extrapyramidal pathways.  
5. **Genetic correlation**: DNAJC6 mutations impair chaperone-mediated neuroprotection, leading to early synaptic dysfunction and multisystemic degeneration, consistent with the symptom profile.  
6. **Exclusion of mimics**: The combination of parkinsonism, cognitive decline, and psychiatric features distinguishes PD23 from other early-onset forms (e.g., PARK2/Parkin) that lack prominent neuropsychiatric signs. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid investigation of choice in 1st week
Choices:
A. Blood culture
B. Widal test
C. Stool culture
D. Urine culture
Answer: [/INST] Blood culture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Atrial septal defect', 'Respiratory insufficiency', 'Hyperechogenic kidneys', 'Feeding difficulties', 'Posterior rib gap', '10 pairs of ribs']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cerebrocostomandibular syndrome (CCMS):  
1. **Rib anomalies**: The patient exhibits **posterior rib gaps** and **10 pairs of ribs** (vs. the normal 12 pairs). These defects are pathognomonic for CCMS, characterized by ""missing"" or maldeveloped ribs with costovertebral discontinuities.  
2. **Pierre-Robin sequence (PRS)**: The **cleft palate** and associated PRS (micrognathia, glossoptosis) align with CCMS, as mandibular hypoplasia and airway/respiratory challenges are common.  
3. **Respiratory insufficiency**: Likely secondary to rib defects (restrictive lung disease) and PRS-related airway obstruction.  
4. **Additional features**: **Atrial septal defect** and **hyperechogenic kidneys** are occasionally reported in CCMS, supporting multisystem involvement. **Feeding difficulties** correlate with PRS and orofacial structural abnormalities.  
5. **Exclusion**: Other rib-gap syndromes (e.g., cerebro-costo-mandibular-like syndrome) lack full phenotypic overlap, making CCMS the definitive diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
- **Hyperphenylalaninemia**: This is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic accumulation of phenylalanine.  
- **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital abnormalities (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the fetus.  
- **Hypertyrosinemia**: While classic PKU typically causes **low** tyrosine (due to blocked PAH-dependent conversion of phenylalanine to tyrosine), transient or secondary hypertyrosinemia may occur in severe metabolic crises or liver dysfunction, often seen in critically ill infants with metabolic decompensation.  
- **Death in infancy/childhood/neonatal death**: Untreated PKU causes irreversible neurotoxicity, seizures, and failure to thrive, which can lead to early mortality. Neonatal screening and dietary management prevent these outcomes, but untreated cases historically resulted in fatal complications.  

**Note**: Hypertyrosinemia is atypical in PKU and suggests possible comorbid conditions (e.g., tyrosinemia type II) or diagnostic overlap. However, hyperphenylalaninemia and the clinical trajectory strongly prioritize PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies virus
Choices:
A. Cytotropic
B. Dermatotropic
C. Chromophilic
D. Neurotropic
Answer: [/INST] Neurotropic </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following clinical signs seen in Keratoconus except:
Choices:
A. Fleischer ring
B. Rizutti sign
C. Haab's striae
D. Oil droplet reflex
Answer: [/INST] Haab's striae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hydrocephalus', 'Death in infancy', 'Anemia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Directly linked to **glutaryl-CoA dehydrogenase deficiency**, the hallmark of GA-I, which disrupts lysine and tryptophan metabolism, causing toxic accumulation of glutaric acid.  
2. **Decreased plasma free carnitine**: Carnitine binds to glutaric acid to form glutarylcarnitine for excretion, depleting free carnitine.  
3. **Hydrocephalus/macrocephaly**: GA-I causes frontotemporal atrophy and subdural fluid collections, often mistaken for hydrocephalus. Metabolic crises may exacerbate cerebral edema.  
4. **Anemia**: Chronic metabolic stress or carnitine deficiency can impair erythropoiesis.  
5. **Death in infancy**: Untreated GA-I leads to severe encephalopathy, dystonia, and metabolic decompensation, often fatal early in life without dietary and carnitine therapy.  
The combination of biochemical findings (glutaric aciduria, low carnitine) and clinical features (neurological abnormalities, early mortality) confirms GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is infective for: March 2009
Choices:
A. One day before and 4 days after rash
B. Four days before and five days after rash
C. Entire incubation period
D. Only during scabs falling
Answer: [/INST] Four days before and five days after rash </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Agent used for eliciting diagnostic differentiation of Myasthenia Gravis from Cholinergic crisis is:-
Choices:
A. Ecothiophate
B. Edrophonium
C. Neostigmine
D. Ambenonium
Answer: [/INST] Edrophonium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cataract', 'Abnormality of prenatal development or birth', 'Hepatic failure', 'Death in infancy', 'Atrial septal defect', 'Hyperammonemia', 'Conjugated hyperbilirubinemia', 'Increased total bilirubin', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Death in childhood', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient's symptoms of hypergalactosemia, conjugated hyperbilirubinemia, 4-hydroxyphenylacetic aciduria, and hepatic failure directly align with the pathophysiology of classic galactosemia (GALT deficiency). Accumulation of galactose metabolites (e.g., galactitol) explains cataracts, while liver dysfunction causes coagulopathy (prolonged PTT) and hyperammonemia. Neonatal death and infant mortality are typical in untreated cases due to metabolic crisis. Abnormal galactoside metabolism and amino acid derangements further support this diagnosis.  

Disease: Galactosemia  
Reasoning: The broader diagnosis of galactosemia encompasses the patient's prenatal abnormalities, neonatal death, and metabolic markers (e.g., hyperbilirubinemia, hyperammonemia). The systemic toxicity from galactose-1-phosphate accumulation explains multi-organ failure (liver, brain, eyes). Atrial septal defect, though less common, may occur due to metabolic stress during embryogenesis. The constellation of symptoms across hepatic, ocular, and developmental domains confirms galactosemia as the unifying etiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is what type of zoonosis?
Choices:
A. Cyclozoonosis
B. Direct zoonosis
C. Sapro-zoonosis
D. Meta Zoonosis
Answer: [/INST] Meta Zoonosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Rod-cone dystrophy', 'Ophthalmoplegia', 'Abnormality of visual evoked potentials', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Death in infancy', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar abnormalities (atrophy/agenesis)**: Central to PMM2-CDG, causing ataxia, motor delay, and hypotonia due to disrupted cerebellar development.  
2. **Neurological involvement**: Intellectual disability and abnormal visual evoked potentials align with global neurodevelopmental defects from impaired glycosylation.  
3. **Ocular symptoms**: Rod-cone dystrophy and ophthalmoplegia stem from glycosylation-dependent retinal and neuromuscular dysfunction.  
4. **Systemic severity**: Death in infancy reflects severe multisystem failure, consistent with classic PMM2-CDG presentations.  
5. **Diagnostic alignment**: The constellation of cerebellar, ocular, and developmental features distinguishes PMM2-CDG from other CDG subtypes or cerebellar malformation syndromes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: ECG changes in Hypokalemia are?
Choices:
A. Tall T wave
B. Poor P wave
C. Sho QT interval
D. Presence of U wave
Answer: [/INST] Presence of U wave </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Cystic hygroma', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Key Biochemical Markers**: Elevated glutaric acid in urine (glutaric aciduria) and blood, combined with decreased plasma free carnitine, strongly suggest a defect in lysine, hydroxylysine, and tryptophan metabolism. GA-I is caused by mutations in the *GCDH* gene, leading to glutaryl-CoA dehydrogenase deficiency and subsequent toxic accumulation of glutaric acid.  
2. **Neurological Symptoms**: Macrocephaly (often due to frontotemporal atrophy), dystonia, dyskinesia, generalized hypotonia, and lethargy align with striatal degeneration caused by neurotoxic metabolites (e.g., glutaric acid, 3-hydroxyglutaric acid) during metabolic crises.  
3. **Acute Metabolic Crises**: Fever, vomiting, diarrhea, dyspnea, and metabolic acidosis are triggered by catabolic stressors (e.g., infections), characteristic of GA-I decompensation.  
4. **Poor Prognosis**: Neonatal death or death in childhood is common if untreated, as crises cause irreversible brain damage.  
5. **Supporting Features**: Hyperhidrosis and sleep disturbances may reflect autonomic dysfunction, while drowsiness and lethargy correlate with encephalopathic phases.  
6. **Exclusion of Cystic Hygroma**: While cystic hygroma is listed, it is likely incidental or a prenatal finding unrelated to GA-I, which primarily affects metabolic and neurological systems.  

The constellation of metabolic acidosis, glutaric acid accumulation, neurological deterioration, and carnitine deficiency confirms GA-I as the definitive diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma most common metastasis is to -
Choices:
A. Lung
B. CNS
C. Liver
D. Spleen
Answer: [/INST] CNS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Vomiting', 'Increased total bilirubin', 'Neonatal death', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Galactosemia; GAL/Galactosemia  
Reasoning: Hypergalactosemia (elevated galactose in blood) is a hallmark of galactosemia, a rare metabolic disorder caused by impaired galactose metabolism. The symptoms of vomiting, jaundice (elevated bilirubin), and neonatal death align with the rapid deterioration seen in untreated galactosemia, as infants cannot process galactose from lactose in breast milk or formula, leading to toxic accumulation and multi-organ failure.  

Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: Classic galactosemia (GALT deficiency, Type I) is the most severe form. Neonatal death and infant mortality are typical without early dietary intervention. Increased bilirubin reflects liver damage, a key feature, while vomiting and hypergalactosemia directly result from the inability to metabolize galactose. This subtype is distinguished by complete GALT enzyme deficiency, consistent with the acute presentation described. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nephrotic syndrome', 'Abnormality of the nose', 'Hematuria', 'Membranoproliferative glomerulonephritis', 'Purpura', 'Wrist swelling', 'Dyspnea', 'Hypertriglyceridemia', 'Hypercholesterolemia', 'Increased body weight', 'Pedal edema', 'Peripheral edema', 'Moderate proteinuria', 'Heavy proteinuria', 'Foamy urine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoglobulin A vasculitis (IgAV), also known as Henoch-Schönlein purpura (HSP)  
Reasoning:  
1. **Purpura**: A hallmark of IgAV, presenting as non-thrombocytopenic palpable purpura, typically on dependent areas (e.g., lower limbs).  
2. **Renal Involvement**:  
   - **Nephrotic syndrome** (heavy proteinuria, hypoalbuminemia-induced hypercholesterolemia/hypertriglyceridemia, edema) and **hematuria** align with IgA-mediated glomerulonephritis.  
   - **Membranoproliferative glomerulonephritis (MPGN)** on biopsy is consistent with IgAV nephritis, characterized by IgA-dominant immune deposits.  
3. **Arthritis**: Wrist swelling reflects IgAV-associated arthritis, commonly affecting large joints.  
4. **Systemic Features**:  
   - **Dyspnea** may arise from fluid overload due to nephrotic syndrome or rare pulmonary vasculitis.  
   - **Abnormality of the nose** (e.g., mucosal vasculitis or epistaxis) suggests small-vessel involvement.  
5. **Exclusion of Mimics**: Symptoms collectively rule out isolated nephrotic syndrome, lupus nephritis, or infection-driven glomerulonephritis, reinforcing IgAV as the unifying diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is NOT seen in furious Rabies -
Choices:
A. Hyperexcitability
B. Aerophobia
C. Hypertension
D. Constriction of pupil
Answer: [/INST] Constriction of pupil </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tularemia belongs to which category of bioterrorism agents -
Choices:
A. A
B. B
C. C
D. D
Answer: [/INST] A </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statement are true regarding Q fever except-
Choices:
A. it is zoonotic disease
B. Human disease is characterized by an interstitial pneumonia
C. No rash is seen
D. Weil felix reaction is very useful for diagnosis
Answer: [/INST] Weil felix reaction is very useful for diagnosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is most commonly due to -
Choices:
A. Egg
B. Milk
C. Meat
D. Canned vegetables
Answer: [/INST] Canned vegetables </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true regarding Typhoid in children -
Choices:
A. Leukochyosis is characteristic
B. Encephalitis is common
C. Mild splenomegaly is usual
D. Urine culture is positive in 4 to 6 days
Answer: [/INST] Mild splenomegaly is usual </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Areflexia', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like hyperammonemia, elevated urinary carboxylic acids, and abnormal circulating amino acids (aspartate family, alanine) suggest a metabolic disorder disrupting amino acid catabolism.  
2. **BCAA Accumulation**: MSUD specifically involves defective breakdown of branched-chain amino acids (BCAAs—leucine, isoleucine, valine), leading to toxic buildup of keto acids (detected as urinary carboxylic acids) and secondary ammonia elevation.  
3. **Neurological Manifestations**: Seizures, hypotonia, and areflexia align with neurotoxicity from BCAA-derived metabolites, which impair brain function and myelination.  
4. **Infantile Fatality**: Neonatal death or death in infancy is characteristic of severe, untreated MSUD due to rapid metabolic decompensation post-protein ingestion (feeding difficulties).  
5. **Diagnostic Confirmation**: Abnormal BCAA levels (not explicitly listed but inferred from ""abnormal aspartate family amino acids"") and urinary alpha-keto-acids confirm MSUD, distinguishing it from urea cycle defects or organic acidemias. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism characterised by  a) Seizure  b) Fever  c) Ascending paralysis  d) Descending symmetrical paralysis  e) Blurring of vision
Choices:
A. abc
B. bd
C. cde
D. de
Answer: [/INST] de </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Spasticity', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hypoglycemia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key biochemical markers**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in branched-chain amino acid (BCAA) metabolism, the hallmark of MSUD.  
2. **Neurological symptoms**: Spasticity, generalized hypotonia, and apathy arise from neurotoxicity caused by accumulated BCAAs and their ketoacid derivatives.  
3. **Early mortality**: Neonatal death, death in infancy, or early adulthood aligns with severe MSUD phenotypes, where metabolic crises lead to rapid deterioration without dietary intervention.  
4. **Hypoglycemia**: Reflects metabolic instability during catabolic states (e.g., infections or fasting), common in MSUD due to disrupted energy metabolism.  
5. **Obesity**: May result from high-calorie dietary regimens used to manage MSUD or secondary metabolic dysfunction.  
6. **Exclusion of mimics**: The triad of elevated BCAAs rules out isolated hypervalinemia or other aminoacidurias, solidifying MSUD as the diagnosis.  

(Note: Classic MSUD also features a maple syrup odor in bodily fluids, which may not have been reported here but is not essential for diagnosis when biochemical and clinical criteria are met.) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Obesity', 'Hyperalaninemia', 'Abnormal circulating glycine concentration', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isovaleric acidemia (IVA)  
Reasoning:  
1. **Hyperleucinemia**: IVA results from isovaleryl-CoA dehydrogenase deficiency, impairing leucine catabolism. This leads to accumulation of isovaleric acid and its precursors, including elevated leucine.  
2. **Abnormal circulating carnitine**: Isovaleric acid conjugates with carnitine to form isovaleryl-carnitine, depleting free carnitine and altering its circulating levels.  
3. **Abnormal glycine concentration**: Isovaleric acid is detoxified via glycine conjugation (forming isovalerylglycine), which may reduce free glycine levels, explaining the abnormal glycine profile.  
4. **Intellectual disability**: Untreated IVA causes recurrent metabolic crises, leading to neurotoxicity and intellectual impairment.  
5. **Hyperalaninemia**: Metabolic stress from catabolism during crises increases protein breakdown, elevating alanine as a byproduct.  
6. **Obesity**: May arise from high-calorie dietary interventions to prevent catabolism or metabolic dysregulation.  
7. **Hyperisoleucinemia**: Likely a secondary effect due to metabolic decompensation or analytical overlap with leucine metabolites.  
8. **Death in adolescence**: Reflects severe, poorly managed IVA with life-threatening metabolic acidosis or organ failure during crises.  

The combination of branched-chain amino acid disturbances (leucine), glycine/carnitine abnormalities, and clinical progression aligns with IVA pathophysiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts β-oxidation of medium-chain fatty acids, leading to secondary carnitine deficiency due to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines like C8, C10), which are excreted, depleting free carnitine.  
2. **Neonatal death/Death in infancy**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (common in newborns/infants), leading to encephalopathy, liver failure, or cardiac arrest if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe fetal metabolic stress or maternal metabolic disturbances during pregnancy (e.g., maternal fasting) may contribute to subtle prenatal abnormalities.  
4. **Supporting biochemical hallmarks**: MCADD is confirmed by elevated C6-C10 acylcarnitines on tandem mass spectrometry and genetic testing for *ACADM* gene mutations.  
5. **Exclusion of alternatives**: Symptoms align with MCADD rather than other fatty acid oxidation disorders (e.g., VLCADD presents with cardiomyopathy, LCHADD with retinopathy) or organic acidemias (e.g., distinct organic aciduria). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis most commonly affects -
Choices:
A. Liver
B. Tongue
C. Colon
D. Hea
Answer: [/INST] Hea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Central to PKU, caused by deficient phenylalanine hydroxylase (PAH), impairing phenylalanine (Phe) metabolism.  
2. **Abnormal circulating tyrosine concentration**: PAH deficiency reduces tyrosine synthesis, leading to low tyrosine levels (hypotyrosinemia), consistent with PKU.  
3. **Elevated urinary carboxylic acid**: Excess Phe is metabolized via alternative pathways, producing phenylketones (e.g., phenylpyruvate) excreted in urine.  
4. **Neonatal death/Death in infancy**: Untreated PKU causes severe metabolic derangements, neurological damage, and organ failure, often fatal without early dietary intervention.  
5. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies (e.g., microcephaly) in the fetus.  
6. **Obesity**: May arise from high-calorie, low-Phe dietary management or metabolic dysregulation secondary to chronic Phe imbalance.  
7. **Death in early adulthood**: Long-term complications (e.g., cardiovascular issues, neurological decline) in poorly managed cases or late-diagnosed patients.  

PKU aligns with the biochemical markers (hyperphenylalaninemia, tyrosine deficiency, urinary phenylketones) and clinical progression described, emphasizing untreated or severe disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bone forming tumors are -a) Osteosarcomab) Osteoid osteomac) Giant cell tumourd) Osteoblastomae) Chondrosarcoma
Choices:
A. abd
B. bcd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Broad philtrum', 'Long philtrum', 'Anteverted nares', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol (8-DHC) paired with hypocholesterolemia are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in the *DHCR7* gene, which disrupts cholesterol synthesis.  
2. **Craniofacial features**: Broad, long, and deep philtrum, along with anteverted nares, are classic dysmorphic findings in SLOS.  
3. **Limb anomalies**: Syndactyly (often of toes 2-3) is a hallmark congenital malformation in SLOS.  
4. **Neurological and systemic issues**: Generalized hypotonia and feeding difficulties align with the severe metabolic dysfunction and neurodevelopmental deficits seen in SLOS.  
5. **Lethality**: Neonatal death or death in infancy correlates with severe forms of SLOS, where cholesterol deficiency critically impacts organogenesis and cellular function.  

The combination of biochemical abnormalities (elevated 7-DHC/8-DHC), dysmorphic features, syndactyly, and life-threatening metabolic dysfunction confirms SLOS as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strategies in National Leprosy Control programme?
Choices:
A. Early detection of cases
B. Sho course multi drug therapy
C. Rehabilitation
D. All
Answer: [/INST] All </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with metabolic acidosis and decreased methylmalonyl-CoA mutase activity, hallmark features of methylmalonic acidemia (MMA). MMA is caused by impaired metabolism of methylmalonyl-CoA, leading to toxic accumulation of methylmalonic acid. The enzyme deficiency directly disrupts the propionate pathway, resulting in metabolic decompensation, which manifests as life-threatening acidosis. Early lethality (infancy/childhood) aligns with severe forms of MMA, where crises trigger multisystem failure.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The specific mention of decreased methylmalonyl-CoA mutase activity confirms a defect in the MUT gene, encoding the mutase enzyme. This subtype is unresponsive to vitamin B12 therapy, as the mutation directly affects the enzyme’s structure/function rather than cofactor (adenosyl-B12) metabolism. Persistent enzyme dysfunction exacerbates metabolic instability, explaining the poor prognosis (death in infancy/childhood) despite standard interventions. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chordoma commonly involves -a) Dorsal spineb) Clivusc) Lumbar spined) Sacrume) Cervical spine
Choices:
A. bd
B. d
C. ab
D. ac
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination is given at
Choices:
A. 9 months
B. At bih
C. 4 weeks
D. 8 weeks
Answer: [/INST] 9 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Subacute Sclerosing Panencephalitis is a rare and dangerous complication of;
Choices:
A. Measles
B. Mumps
C. Rubella
D. Varicella
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Poland Syndrome is
Choices:
A. Congenital absence of Pectoralis minor
B. Acquired Weakness and disuse atrophy of Pectoralis minor
C. Acquired Weakness and disuse atrophy of Pectoralis major
D. Congenital absence of Pectoralis major
Answer: [/INST] Congenital absence of Pectoralis major </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Post exposure immunization is given in -a)  Rabiesb)  Pertussisc)  Measlesd)  Yellow fever
Choices:
A. b
B. ac
C. ab
D. bd
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Babesiosis is transmitted by bite of:
Choices:
A. Mosquito
B. Sandfly
C. Reduviid bug
D. Tick
Answer: [/INST] Tick </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the genitourinary system', 'Entropion', 'Cutis laxa', 'Generalized hypotonia', 'Flexion contracture', 'Hip dysplasia', 'Disproportionate tall stature', 'Abnormal heart morphology', 'Abnormal facial shape', 'Pneumothorax', 'Vascular dilatation', 'Kyphoscoliosis', 'Aortic aneurysm']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cutis laxa, autosomal recessive, type IIC  
Reasoning: The patient presents with cutis laxa, a hallmark of this disorder, alongside multisystemic manifestations. Generalized hypotonia and flexion contractures align with neuromuscular involvement. Kyphoscoliosis and hip dysplasia reflect skeletal abnormalities tied to connective tissue defects. Vascular dilatation, aortic aneurysm, and pneumothorax indicate severe vascular and pulmonary fragility, characteristic of ATP6V0A2 gene mutations. Abnormal heart morphology and facial shape, entropion, and genitourinary anomalies further support systemic connective tissue dysfunction. Disproportionate tall stature may arise from skeletal disproportions rather than growth acceleration, consistent with ARCL2C's phenotypic spectrum. This constellation of symptoms, particularly the combination of cutaneous, vascular, skeletal, and developmental features, strongly points to autosomal recessive cutis laxa type IIC. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is bilateral in
Choices:
A. 100 % of cases
B. 1 % of cases
C. 50 % of cases
D. 30 % of cases
Answer: [/INST] 30 % of cases </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Intellectual disability', 'Seizure', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core feature of PKU due to deficient phenylalanine hydroxylase (PAH), causing phenylalanine accumulation.  
2. **Intellectual disability & Hyperactivity**: Untreated PKU results in neurotoxic phenylalanine buildup, impairing brain development and function.  
3. **Seizures**: Neurological damage from elevated phenylalanine can manifest as seizures.  
4. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) excreted in urine, classified as carboxylic acids.  
5. **Severe short stature & Obesity**: Less typical but possible in poorly managed cases due to metabolic dysregulation or restrictive diets altering growth/weight.  
6. **Early mortality (childhood/adolescence/adulthood)**: Historically, untreated PKU led to severe complications (e.g., neurodegeneration, infections), but modern neonatal screening and dietary management mitigate this.  

**Conflicts/Discordant Symptoms**:  
- **Hypertyrosinemia**: PKU classically causes *low* tyrosine (PAH converts phenylalanine to tyrosine). This symptom suggests possible comorbid tyrosinemia type II or lab error.  
- **Obesity**: Rare in PKU; may reflect dietary adjustments (high-carb/low-protein intake) or unrelated factors.  

**Conclusion**: Dominant PKU features (hyperphenylalaninemia, neurodevelopmental issues, urinary metabolites) align with the diagnosis. Discordant symptoms may require further investigation for comorbidities or testing inaccuracies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of skin is called as – a) Lupus vulgarisb) Lupus pernioc) Lupus profundusd) Scrofuloderma
Choices:
A. b
B. c
C. ad
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is the commonest ocular manifestation of Tuberculosis?
Choices:
A. Phlyctenular conjunctivitis
B. Choroiditis
C. Eales' disease
D. Acute Retinal necrosis
Answer: [/INST] Choroiditis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. Untreated PKU leads to toxic phenylalanine accumulation, causing severe neurological damage, which explains **neonatal death**, **death in infancy**, or **childhood** due to metabolic crisis or complications.  
3. **Hypertyrosinemia** may appear contradictory (as PAH deficiency typically reduces tyrosine levels), but secondary metabolic disturbances or overlapping enzyme dysfunction (e.g., transient tyrosine elevation during metabolic decompensation) could explain this finding.  
4. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, though this is context-dependent.  
5. PKU is confirmed via newborn screening; untreated cases match the described fatal trajectory. Other tyrosinemia types are excluded due to the primary hyperphenylalaninemia and lack of liver/kidney symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Lowe syndrome, all of the following are seen except: September 2007
Choices:
A. Undescended testes in males
B. Cataract
C. Hypeonia
D. Low IQ
Answer: [/INST] Hypeonia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bone marrow in Amyloid Lightchain Amyloidosis shows which of the following features?
Choices:
A. Bone marrow plasmacytosis
B. Granulomatous reaction
C. Fibrosis
D. Giant cell formation
Answer: [/INST] Bone marrow plasmacytosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nephritis', 'Failure to thrive', 'Growth delay', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Abnormal circulating tyrosine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Hawkinsinuria  
Reasoning:  
1. **Abnormal Tyrosine Metabolism**: The presence of abnormal circulating tyrosine concentration suggests a defect in tyrosine catabolism, a hallmark of Hawkinsinuria.  
2. **Urinary Carboxylic Acid Elevation**: Elevated urinary carboxylic acids (specifically hawkinsin, a cyclic keto-enol ether derived from 4-hydroxyphenylpyruvate) are pathognomonic for this disorder.  
3. **Infantile Presentation**: Symptoms like vomiting, diarrhea, failure to thrive, and growth delay align with metabolic crises in infancy caused by tyrosine derivative accumulation.  
4. **Renal Involvement**: Nephritis may arise due to tubular damage from toxic metabolites, though this is less common and typically milder compared to other tyrosine metabolism disorders.  
5. **Severity Spectrum**: Death in infancy is rare but reported in severe, untreated cases due to metabolic acidosis or complications from chronic renal dysfunction.  
6. **Exclusion of Other Tyrosinemias**: Unlike tyrosinemia types I/II, Hawkinsinuria lacks severe liver dysfunction or neurological symptoms, focusing the diagnosis on urinary hawkinsin excretion and milder clinical progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Causes of polyhydraminos include:a) Diabetes mellitusb) Preeclampsiac) Esophageal atresiad) Renal agenesise) Anencephaly
Choices:
A. acd
B. bde
C. cde
D. ace
Answer: [/INST] ace </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Oral ulcer', 'Headache', 'Memory impairment', 'Osteomyelitis', 'Osteoarthritis', 'Kyphosis', 'Obstructive sleep apnea', 'Abnormality of the ankle', 'Back pain', 'Intervertebral disc degeneration', 'Ankle pain', 'Aphthous ulcer', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: SAPHO syndrome  
Reasoning:  
1. **Osteomyelitis and Osteoarthritis**: Core features of SAPHO syndrome, which involves osteitis and hyperostosis, explaining bone inflammation and joint degeneration.  
2. **Pustule and Aphthous/Oral Ulcers**: Align with cutaneous manifestations (pustulosis) and occasional mucosal involvement seen in SAPHO.  
3. **Spinal Abnormalities (Kyphosis, Back Pain, Disc Degeneration)**: Reflects axial skeleton hyperostosis, a hallmark of SAPHO, leading to structural changes and pain.  
4. **Ankle Pain/Abnormality**: Synovitis and joint inflammation in SAPHO can target peripheral joints like the ankle.  
5. **Obstructive Sleep Apnea**: Potential secondary effect from spinal kyphosis altering airway mechanics.  
6. **Headache/Memory Impairment**: Likely indirect (e.g., chronic pain, sleep disruption) rather than direct neurological involvement.  
7. **Exclusion of Alternatives**: Behçet’s disease lacks bone involvement; CRMO lacks pustular lesions. The triad of bone, joint, and skin symptoms strongly supports SAPHO. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute Myeloid Leukemia is a malignant cancer in which myeloid progenitor cells become rapidly dividing and retain their semi-stem cell state. Under normal circumstances, which of the following cell types would arise from this stem cell?? 
Choices:
A. NK cell
B. Platelet
C. T cell
D. Lymphoid progenitor
Answer: [/INST] Platelet </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macroglossia', 'Microcephaly', 'Coarse facial features', 'Long eyelashes', 'Synophrys', 'Decreased response to growth hormone stimulation test', 'Hirsutism', 'Seizure', 'Hyporeflexia', 'Motor delay', 'Absent speech', 'Cerebral cortical atrophy', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Corneal opacity', 'Severe global developmental delay', 'Central adrenal insufficiency']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Core phenotypic features**: Severe muscular hypotonia, severe global developmental delay, and motor delay align with the syndrome’s hallmark triad. Absent speech reflects profound neurodevelopmental impairment.  
2. **Characteristic facies**: Coarse facial features, long eyelashes, and synophrys (fused eyebrows) are classic dysmorphic traits in TBCK-related disorders.  
3. **Neurological abnormalities**: Cerebral cortical atrophy explains seizures, hyporeflexia, and developmental regression (linked to progressive brain changes, though not classically neurodegenerative). Microcephaly further supports central nervous system involvement.  
4. **Endocrine dysfunction**: Decreased growth hormone response and central adrenal insufficiency correlate with TBCK’s role in mTOR signaling, affecting endocrine pathways.  
5. **Musculoskeletal findings**: Scoliosis and hypotonia are secondary to chronic low muscle tone and motor deficits.  
6. **Ancillary features**: Hirsutism and corneal opacity, while less common, are documented in some cases, reflecting multisystemic impact of TBCK mutations.  
7. **Exclusion of mimics**: The combination of hypotonia, adrenal/growth hormone deficits, and facial dysmorphism distinguishes this from lysosomal storage disorders or mitochondrial diseases.  
The constellation of symptoms strongly supports a TBCK-related diagnosis, confirmed by genetic testing for pathogenic variants in the TBCK gene. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spasticity', 'Death in infancy', 'Premature birth', 'Ileus', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased circulating ferritin concentration', 'Hypoxemia', 'Peritoneal effusion', 'Abnormal vitamin B12 level', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts fatty acid oxidation, leading to carnitine depletion as it conjugates to unmetabolized medium-chain fatty acids.  
2. **Neonatal/childhood death**: Untreated MCADD causes life-threatening hypoglycemia and metabolic crises during fasting, common in infancy/early childhood.  
3. **Spasticity & hypoxemia**: Metabolic acidosis from MCADD crises can induce neurological damage (spasticity) and respiratory compromise (hypoxemia).  
4. **Ileus & peritoneal effusion**: Secondary to metabolic instability affecting gastrointestinal function or organ dysfunction.  
5. **Premature birth**: Though not a direct feature, metabolic stress in utero might contribute to early delivery.  
6. **Abnormal vitamin B12/ferritin**: Non-specific markers of systemic metabolic disruption or organ involvement.  
7. **Decreased 3-hydroxyacyl-CoA dehydrogenase**: May reflect downstream disruption in β-oxidation due to MCAD enzyme deficiency.  

Key biochemical hallmarks (e.g., hypoketotic hypoglycemia, elevated C8-C10 acylcarnitines) are absent in the listed symptoms but inferred from clinical context. Early mortality and carnitine abnormalities strongly align with MCADD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly can be diagnosed by USG at –
Choices:
A. 10–12 weeks of gestation
B. 14–18 weeks of gestation
C. 20–24 weeks of gestation
D. 24–28 weeks of gestation
Answer: [/INST] 10–12 weeks of gestation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy affects all organs except
Choices:
A. Eyes
B. Nerves
C. Uterus
D. Ovary
Answer: [/INST] Uterus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mutation of which of the following gene is most impoant in Paroxysmal Nocturnal Hemoglobinuria
Choices:
A. Decay accelerating factor (DAF)
B. Membrane inhibitor of reactive lysis (MIRL)
C. Glycosyl phosphatidyl inositol (GPI)
D. CD8 binding protein
Answer: [/INST] Glycosyl phosphatidyl inositol (GPI) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Death in infancy', 'Premature birth', 'Metabolic acidosis', 'Hypoglycemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Death in adolescence', 'Hypoxemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia and metabolic acidosis**: MCADD impairs mitochondrial β-oxidation of medium-chain fatty acids, leading to insufficient ketone production during fasting. This results in hypoglycemia (due to reliance on glucose without alternative energy sources) and metabolic acidosis (from accumulating toxic metabolites like medium-chain acylcarnitines).  
2. **Decreased plasma free carnitine**: Unmetabolized medium-chain acyl-CoA intermediates bind to carnitine, forming acylcarnitines that accumulate and deplete free carnitine.  
3. **Life-threatening crises and early mortality**: Prolonged fasting or metabolic stress (e.g., infections) triggers acute decompensation, causing coma, hypoxemia (secondary to respiratory failure), and multi-organ dysfunction. Untreated cases often result in neonatal death or death in infancy/childhood/adolescence.  
4. **Gastrointestinal inflammation**: May arise during metabolic crises due to tissue hypoxia or direct toxicity from metabolites.  
5. **Premature birth**: Not a primary feature of MCADD but may reflect prenatal stress or comorbid factors contributing to early presentation.  

The constellation of hypoglycemia, metabolic acidosis, carnitine deficiency, and catastrophic outcomes aligns pathognomonically with MCADD, a disorder of fatty acid oxidation. Confirmatory testing would include plasma acylcarnitine profile (elevated C6-C10 species) and genetic analysis of *ACADM* gene variants. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is due to abnormality in
Choices:
A. Hypothalamus
B. Neocoex
C. Cerebellum
D. Medulla oblongata
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cardiac condition requiring Antibiotic Prophylaxis for Infective Endocarditis?
Choices:
A. Coronary Heart Disease
B. Rheumatic Heart Disease
C. Cardiac Pacemakers
D. Hypertensive Heart Disease
Answer: [/INST] Rheumatic Heart Disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Urinary urgency', 'Sinusitis', 'Tachycardia', 'Fever', 'Leukocytosis', 'Hemoptysis', 'Pleural effusion', 'Abnormal EKG', 'Atrial fibrillation', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Reduced haptoglobin level', 'Nodular pattern on pulmonary HRCT', 'Episcleritis', 'Chest pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Granulomatosis with polyangiitis (GPA):  
1. **Upper respiratory involvement**: Chronic sinusitis is a hallmark of GPA, often preceding systemic manifestations.  
2. **Pulmonary features**: Hemoptysis, cough, chest pain, nodular pattern on HRCT, and pleural effusion align with necrotizing granulomatous inflammation and vasculitis in the lungs.  
3. **Renal involvement**: Urinary urgency may indicate early kidney disease (glomerulonephritis), though hematuria/proteinuria are more typical; renal biopsy would confirm.  
4. **Ocular manifestation**: Episcleritis is a common ocular manifestation of GPA.  
5. **Systemic inflammation**: Fever, leukocytosis, and elevated CRP reflect active vasculitis.  
6. **Cardiac complications**: Atrial fibrillation and abnormal EKG suggest cardiac involvement (rare but reported in GPA due to inflammation or secondary effects).  
7. **Hematologic abnormalities**: Reduced haptoglobin hints at microangiopathic hemolysis (occurs in severe vasculitis).  
8. **Multisystem pattern**: The combination of respiratory, renal, ocular, and systemic symptoms strongly supports GPA, a small-to-medium vessel ANCA-associated vasculitis.  

**Definitive diagnosis** requires ANCA testing (PR3-ANCA positivity), biopsy (necrotizing granulomas), and exclusion of mimics (e.g., infections, other vasculitides). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is:
Choices:
A. Occurs due to Vit-A deficiency
B. Relatively benign condition
C. First feature of Vit-A deficiency
D. Also seen in retinitis pigmentosa
Answer: [/INST] Occurs due to Vit-A deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles virus is
Choices:
A. Paramyxovirus
B. Ohomyxovirus
C. Poxvirus
D. Picornavirus
Answer: [/INST] Paramyxovirus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Index of operational efficiency of Malaria ?
Choices:
A. API
B. ABER
C. Infant parasite rate
D. Spleen rate
Answer: [/INST] ABER </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements about Leptospirosis is true
Choices:
A. Rats are prime reservoirs
B. Fluoroquinolones are the drug of choice
C. Person to person Transmission is common
D. Hepatorenal syndrome may occur in upto 50% of patients.
Answer: [/INST] Rats are prime reservoirs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin is due to -
Choices:
A. Chromosome
B. Plasmid
C. Phage
D. Transposons
Answer: [/INST] Phage </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In the Rabies vaccine schedule of 0,3,7,14,30,90,0 means -
Choices:
A. Day of dog bite
B. Day of first injection
C. Day of symptom onset
D. Day of dog death
Answer: [/INST] Day of first injection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Generalized hypotonia** aligns with Canavan disease, a leukodystrophy causing progressive brain tissue degeneration and impaired motor function.  
2. **Death in infancy** is consistent with the severe, rapidly progressive nature of Canavan disease, often fatal by early childhood.  
3. **Abnormal circulating aspartate family amino acid concentration** directly links to the disease’s hallmark biochemical defect: aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA) in blood/urine.  
4. Confirmatory evidence includes genetic testing for ASPA gene mutations and neuroimaging showing leukodystrophy (e.g., diffuse white matter degeneration).  
5. Exclusion of other leukodystrophies (e.g., Tay-Sachs, Krabbe) or amino acid metabolism disorders (e.g., citrullinemia) via clinical and biochemical differentiation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy does not involve –
Choices:
A. CNS
B. Testis
C. Skin
D. Cornea
Answer: [/INST] CNS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Incubation period of Mumps is
Choices:
A. 7 days
B. 18 days
C. 10 days
D. 14 days
Answer: [/INST] 18 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertension', 'Secondary hyperparathyroidism', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Cardiomyopathy', 'Anemia', 'Acute kidney injury', 'Hyperammonemia', 'Vomiting', 'Hyperuricemia', 'Hyperglycinemia', 'Tachypnea', 'Methylmalonic acidemia', 'Increased blood urea nitrogen', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Key biochemical markers**:  
   - Decreased methylmalonyl-CoA mutase activity directly confirms a defect in this enzyme, a hallmark of MMA caused by *MUT* gene mutations.  
   - Methylmalonic acidemia/aciduria, hyperammonemia, hyperglycinemia, and hyperalaninemia reflect disrupted propionate metabolism, leading to toxic metabolite accumulation.  

2. **Systemic manifestations**:  
   - **Renal**: Acute/chronic kidney injury, elevated creatinine, and increased blood urea nitrogen result from nephrotoxic metabolites (methylmalonic acid, ammonia).  
   - **Neuromuscular**: Hypotonia, motor delay, and feeding difficulties arise from energy deficiency and neurotoxicity.  
   - **Metabolic crises**: Vomiting, tachypnea (compensatory for metabolic acidosis), and hyperuricemia occur during acute decompensation.  

3. **Complications**:  
   - Cardiomyopathy and anemia are linked to mitochondrial dysfunction and carnitine depletion (decreased plasma free carnitine).  
   - Growth failure (severe short stature) and recurrent infections stem from chronic metabolic stress and protein catabolism.  
   - Early mortality (infancy/childhood/adolescence) aligns with severe B12-unresponsive MMA due to multiorgan failure.  

4. **Exclusion of B12-responsive forms**:  
   - Absence of hematologic features (e.g., megaloblastic anemia) and confirmed enzyme deficiency (not responsive to B12 supplementation) distinguish this from B12-responsive subtypes.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
- This is the broader diagnostic category encompassing the specific mutase-deficient subtype. The term ""methylmalonic aciduria"" explicitly references urinary excretion of methylmalonic acid, a diagnostic criterion confirmed via organic acid analysis. All clinical and biochemical findings (e.g., hyperammonemia, metabolic acidosis) are secondary to the primary defect in methylmalonate metabolism. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True precocious puberty can occur in all, except –a) McCune Albright syndromeb) Craniopharyngiomac) Congenital adrenal hyperplasiad) Hypothalamic hamartoma
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Earliest pathological change is X-ray in Ulcerative Colitis -
Choices:
A. Loss of haustration
B. Aphthous ulcerattions
C. Mucosal granularity
D. Skip tensions
Answer: [/INST] Mucosal granularity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following drug is an inverse agonist at H3 receptors used for Narcolepsy?
Choices:
A. Dexmedetomidine
B. Pitolisant
C. Icatibont
D. Secukinumab
Answer: [/INST] Pitolisant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 30 year old male patient was on Isoniazid therapy for Tuberculosis.He developed rashes on exposed pas of body.He has disoriented memory. Family members gives history of diarrhea also.What is the diagnosis?
Choices:
A. Isoniazid neuropathy
B. Tuberculosis skin lesions
C. Niacin deficiency
D. Some other drugs has caused this
Answer: [/INST] Niacin deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following are orbital tumours a) Glioma    b) Lymphoma   c) Chloroma  d) Meningioma  e) Schwannoma
Choices:
A. abcde
B. abd
C. abc
D. acd
Answer: [/INST] abcde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids. Unmetabolized fatty acids conjugate with carnitine, forming acylcarnitines excreted in urine, leading to secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: MCADD causes metabolic crises triggered by fasting (e.g., prolonged sleep, illness). Hypoketotic hypoglycemia, hyperammonemia, and toxic metabolite accumulation (e.g., octanoylcarnitine) result in encephalopathy, seizures, and sudden death if untreated.  
3. **Abnormality of prenatal development or birth**: While MCADD primarily manifests postnatally, severe fetal metabolic stress or maternal fatty acid metabolism disturbances during pregnancy may contribute to subtle prenatal complications (e.g., intrauterine growth restriction).  
4. **Diagnostic confirmation**: Newborn screening detects elevated medium-chain acylcarnitines (C6-C10). Genetic testing identifies *ACADM* gene mutations, confirming MCADD. Early intervention (avoiding fasting, glucose supplementation) prevents mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is due to deficiency of -
Choices:
A. Factor VIII
B. Factor VII
C. Factor IX
D. factor X
Answer: [/INST] Factor IX </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Intellectual disability** arises from untreated phenylalanine toxicity, damaging brain development postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which typically causes *low* tyrosine). This may suggest a PAH deficiency variant, secondary metabolic disruptions, or a co-occurring tyrosinemia (e.g., type II), though PKU remains primary due to hyperphenylalaninemia dominance.  
4. **Neonatal death/Death in infancy/adolescence** reflects severe metabolic complications (e.g., seizures, organ failure) in untreated or late-diagnosed cases.  
5. **Abnormality of prenatal development** is inconsistent with isolated PKU (as fetal PAH is inactive; symptoms manifest postnatally). This may indicate maternal PKU syndrome (untreated maternal hyperphenylalaninemia during pregnancy) affecting the fetus, aligning with the patient’s congenital anomalies.  

Note: Hypertyrosinemia and prenatal anomalies require further investigation for overlapping metabolic disorders, but hyperphenylalaninemia and clinical progression prioritize PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is more frequently seen in Churg Strauss Syndrome in comparison to Wegener's Granulomatosis
Choices:
A. Renal involvement
B. Lower Respiratory Tract involvement
C. Eye involvement
D. Upper Respiratory Tract involvement
Answer: [/INST] Lower Respiratory Tract involvement </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macular degeneration', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Lethargy', 'Spasticity', 'Dystonia', 'Hyperreflexia', 'Growth delay', 'Death in infancy', 'Fever', 'Leukocytosis', 'Cerebral atrophy', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Abnormality of limb bone morphology', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Paraplegia/paraparesis', 'Uraciluria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Dihydropyrimidine dehydrogenase deficiency (DPYD deficiency)  
Reasoning:  
1. **Metabolic hallmarks**: The presence of **uraciluria** and **abnormal circulating pyrimidine concentration** directly links to DPYD deficiency, as this enzyme is critical for pyrimidine catabolism. Deficiency causes accumulation of uracil, thymine, and their metabolites.  
2. **Neurological involvement**:  
   - **Seizures**, **spasticity**, **hyperreflexia**, **dystonia**, and **paraplegia/paraparesis** align with neurotoxicity from elevated pyrimidines and their derivatives (e.g., dihydropyrimidines).  
   - **Cerebral atrophy** and **abnormal cerebral white matter morphology** reflect progressive neurodegeneration due to metabolic dysfunction.  
3. **Developmental delays**: **Intellectual disability**, **delayed speech**, and **growth delay** are consistent with impaired neurodevelopment in severe metabolic disorders.  
4. **Systemic manifestations**: **Lethargy**, **drowsiness**, and **sleep disturbance** may arise from energy metabolism disruption. **Leukocytosis** and **fever** could indicate secondary infections or inflammatory responses triggered by metabolic stress.  
5. **Early mortality**: **Death in infancy/childhood** is typical in severe DPYD deficiency due to metabolic crises and neurological deterioration.  
6. **Bone abnormalities**: **Abnormality of limb bone morphology** is occasionally reported in metabolic disorders affecting nucleotide homeostasis.  

The combination of pyrimidine metabolism derangements (uraciluria), neurological deficits, and developmental delays strongly supports DPYD deficiency, distinguishing it from other neurometabolic disorders (e.g., mitochondrial diseases or leukodystrophies). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteonecrosis of femoral head seen in -a) Sickle cell diseaseb) Gaucher's diseasec) Polycythemiad) Hyperparathyroidisme) Fracture
Choices:
A. bcde
B. abcd
C. acde
D. abce
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common type of pathological changes seen in Rabies are
Choices:
A. Meningitis
B. Cranial aeritis
C. Ventriculitis
D. Brain stem encephalitis
Answer: [/INST] Brain stem encephalitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low) but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or transient neonatal tyrosinemia overlapping with PKU.  
3. **Abnormality of prenatal development** aligns with maternal PKU syndrome, where elevated maternal phenylalanine crosses the placenta, causing fetal microcephaly, congenital heart defects, or growth restriction.  
4. **Neonatal death/Death in infancy** suggests severe, untreated PKU with acute metabolic crises (e.g., profound neurological toxicity, seizures) or comorbid complications (e.g., cardiac defects from maternal PKU).  
5. PKU is confirmed via newborn screening (elevated phenylalanine, low tyrosine), though rapid progression to neonatal demise implies extreme enzyme deficiency or delayed diagnosis.  
Note: Hypertyrosinemia warrants investigation for co-occurring disorders (e.g., tyrosinemia type II) but does not exclude PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had untreated PKU during pregnancy, causing congenital anomalies in the infant.  
3. **Death in infancy/childhood and neonatal death** correlate with severe, untreated PKU. Without dietary intervention, toxic phenylalanine levels cause irreversible neurological damage, seizures, and failure to thrive, often leading to early mortality.  
4. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually normal or low due to PAH deficiency). However, this could indicate a comorbid condition (e.g., transient tyrosinemia in newborns) or a secondary metabolic disruption from liver dysfunction in critical cases.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU as the primary diagnosis, emphasizing the critical need for newborn screening and dietary management to prevent severe outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Myopia', 'Nystagmus', 'Abnormally large globe', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, dysplasia, cysts, and dilated fourth ventricle align with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome.  
2. **Ocular manifestations**: Strabismus, myopia, nystagmus, and absent retinal pigment epithelium reflect the syndrome’s retinal dystrophy and high myopia phenotype. The abnormally large globe (megalophthalmos) further supports congenital ocular abnormalities.  
3. **Neurological deficits**: Motor delay correlates with cerebellar dysfunction and ataxia, a core feature of the syndrome.  
4. **Exclusion of mimics**: The absence of ""molar tooth sign"" (Joubert syndrome), liver involvement (COACH syndrome), or severe muscular/lissencephaly findings (Walker-Warburg syndrome) strengthens the diagnosis.  
5. **Genetic confirmation**: While not explicitly stated, Poretti-Boltshauser syndrome is linked to LAMA1 mutations, which underlie the observed neuro-ocular developmental defects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drugs that can be used in Kernicterus
Choices:
A. Barbiturates
B. Benzodiazepines
C. Phenytoin
D. Chlorpromazine
Answer: [/INST] Barbiturates </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pseudoglioma differs from Retinoblastoma in that pseudoglioma is associated with
Choices:
A. Decreased intraocular pressure
B. Blurring of vision
C. Enlargement of the optic foramen
D. All of the above
Answer: [/INST] Decreased intraocular pressure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Confirmatory test for the diagnosis of Amyloidosis is:
Choices:
A. Diagnostic peritoneal lavage
B. Tongue biopsy
C. Rectal biopsy
D. Whole body CT scan
Answer: [/INST] Rectal biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Egg shell calcifications can be seen in Sarcoidosis Silicosis Aspergillosis Pulmonary aery hypeension Amyloidosis scleroderma
Choices:
A. 1,2,3,4
B. 1,2,4,5
C. 1,2,3,6
D. 1,2,5,6
Answer: [/INST] 1,2,5,6 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine levels are usually low), but could arise from concurrent tyrosine supplementation, secondary metabolic dysregulation, or a comorbid condition (e.g., tyrosinemia). However, the primary diagnostic focus remains on elevated phenylalanine.  
3. **Death in childhood** aligns with untreated/severe PKU, as toxic phenylalanine accumulation leads to neurodevelopmental failure, seizures, and early mortality without dietary intervention.  
4. While Hypertyrosinemia creates ambiguity, PKU is prioritized due to the pathognomonic Hyperphenylalaninemia. Further testing (e.g., BH4 responsiveness, tyrosine metabolite analysis) would clarify coexisting disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Permethrin is used in treatment of – a) Scabiesb) Leprosyc) Body Loused) Leishmaniasis
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Vomiting', 'Hyperglutaminemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Feeding difficulties', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark of MMA, alongside key features like **vomiting, feeding difficulties, generalized hypotonia, and developmental delays (intellectual disability, motor delay)**. These symptoms reflect impaired methylmalonyl-CoA metabolism, leading to toxic metabolite accumulation. **Hyperleucinemia** and **hyperglutaminemia** may arise from secondary metabolic disruptions in amino acid catabolism. **Recurrent viral infections** could stem from metabolic stress impairing immune function. **Death in childhood** aligns with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is strongly supported by the severity of symptoms (e.g., **early mortality**) and biochemical findings. This form results from mutations in the *MUT* gene, causing **methylmalonyl-CoA mutase deficiency**, which bypasses B12-dependent pathways. Lack of response to B12 therapy exacerbates metabolic crises, explaining **refractory acidosis, progressive neurological damage**, and poor prognosis. The absence of B12-responsiveness differentiates this from cobalamin metabolism defects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macroglossia', 'Bifid uvula', 'Craniosynostosis', 'Patent foramen ovale', 'Lymphopenia', 'Hypoglycemia', 'Abnormal facial shape', 'Recurrent respiratory infections', 'Skeletal dysplasia', 'Hyperbilirubinemia', 'Lumbar kyphosis', 'Cleft anterior mitral valve leaflet']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal dysplasia** and **lumbar kyphosis**: Core features of ISDNA, linked to EXTL3 gene mutations affecting glycosaminoglycan synthesis and skeletal development.  
2. **Lymphopenia** and **recurrent respiratory infections**: Reflect immunodeficiency, a hallmark of ISDNA due to abnormal lymphopoiesis and T-cell dysfunction.  
3. **Craniosynostosis** and **abnormal facial shape**: Align with craniofacial anomalies reported in ISDNA, though less common than other skeletal findings.  
4. **Patent foramen ovale** and **cleft anterior mitral valve leaflet**: Suggest connective tissue/cardiac involvement, potentially secondary to dysregulated extracellular matrix remodeling.  
5. **Hypoglycemia** and **hyperbilirubinemia**: May indicate metabolic dysregulation, occasionally observed in ISDNA due to systemic glycosylation defects.  
6. **Macroglossia** and **bifid uvula**: Less typical but possible in syndromic craniofacial dysmorphism.  
7. **Neurodevelopmental abnormalities** (implied in diagnosis name): Consistent with ISDNA’s phenotype, though not explicitly listed in symptoms.  

The combination of skeletal, immune, and subtle craniofacial/cardiac anomalies strongly supports ISDNA, despite atypical symptoms like macroglossia. Genetic testing for EXTL3 variants is critical for confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following drugs are used for managing Status Epilepticus except :-
Choices:
A. Phenytoin
B. Diazepam
C. Thiopentone sodium
D. Carbamazepine
Answer: [/INST] Carbamazepine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinitis Pigmentosa is associated with all except -
Choices:
A. Usher Syndrome
B. Marfan's Syndrome
C. Kearns- Sayre Syndrome
D. Bussen - Kornzweig Syndrome
Answer: [/INST] Marfan's Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is due to:
Choices:
A. Factor VII deficiency
B. Factor IX deficiency
C. Platelet deficiency
D. Vit C deficiency
Answer: [/INST] Factor IX deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed cranial suture closure', 'Dental malocclusion', 'Delayed eruption of permanent teeth', 'Joint laxity', 'Wormian bones', 'Hypoplastic iliac wing', 'Depressed nasal bridge', 'Aplastic clavicle', 'Delayed pubic bone ossification', 'Supernumerary tooth']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cleidocranial dysplasia/Cleidocranial dysplasia:  
1. **Aplastic clavicle** is a hallmark feature of cleidocranial dysplasia (CCD), often leading to hypermobile shoulders.  
2. **Delayed cranial suture closure** and **Wormian bones** reflect impaired intramembranous ossification, characteristic of CCD.  
3. **Dental malocclusion**, **delayed eruption of permanent teeth**, and **supernumerary tooth** stem from defective dental development and abnormal tooth formation, common in CCD.  
4. **Hypoplastic iliac wing** and **delayed pubic bone ossification** indicate skeletal dysplasia affecting pelvic bone development.  
5. **Depressed nasal bridge** aligns with midface hypoplasia seen in CCD.  
6. **Joint laxity** may result from connective tissue involvement in skeletal development.  
This constellation of craniofacial, dental, and skeletal anomalies is pathognomonic for CCD, typically caused by mutations in the *RUNX2* gene. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis deposition most commonly occurs in:
Choices:
A. Renal vessels
B. Knee joints
C. Skin
D. Cornea
Answer: [/INST] Renal vessels </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following antibodies is most frequently seen in Antiphospholipid Syndrome? -
Choices:
A. Anti- beta 2 glycoprotein antibody
B. Beta 2 microglobulin antibody
C. Anti-nuclear antibody
D. Anti-centromere antibody
Answer: [/INST] Anti- beta 2 glycoprotein antibody </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The strain used in Mumps vaccine is
Choices:
A. Jeryl Lynn
B. Edmonston Zagreb
C. RA 27/3
D. Oka
Answer: [/INST] Jeryl Lynn </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are features of Scleroderma except-
Choices:
A. Dysphagia
B. Raynand's phenomenon
C. Skin contracture
D. Clacification in all the long bones
Answer: [/INST] Clacification in all the long bones </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Failure to thrive', 'Death in infancy', 'Hepatomegaly', 'Elevated hepatic transaminase', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Aminoaciduria', '4-hydroxyphenylacetic aciduria', 'Prolonged partial thromboplastin time', 'Hyperphenylalaninemia', 'Abnormal circulating alanine concentration', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Tyrosinemia, type I: The patient presents with hepatomegaly, elevated hepatic transaminases, and acute/chronic hepatitis, indicating severe liver dysfunction. Hypertyrosinemia, hypermethioninemia, and hyperphenylalaninemia directly reflect impaired tyrosine metabolism due to fumarylacetoacetate hydrolase (FAH) deficiency. The accumulation of toxic metabolites (4-hydroxyphenylpyruvate, 4-hydroxyphenylacetate) in urine (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) confirms a block in the tyrosine degradation pathway. Prolonged partial thromboplastin time suggests secondary coagulopathy from hepatic synthetic failure. Aminoaciduria and abnormal alanine levels indicate renal tubular damage, consistent with the hepatorenal phenotype. Early-onset liver failure (""death in infancy"" and ""failure to thrive"") is pathognomonic for untreated Tyrosinemia type I. The biochemical and clinical triad (liver disease, renal dysfunction, neurological crises) aligns exclusively with this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological impairment, seizures, and developmental failure. In extreme cases (e.g., undiagnosed or untreated), metabolic derangements and complications like cerebral edema or infections may contribute to **neonatal death** or **death in infancy**.  
3. While neonatal lethality is uncommon in PAH-deficient PKU, it aligns with severe variants (e.g., complete PAH deficiency) or delayed diagnosis in resource-limited settings without newborn screening.  
4. Other causes of hyperphenylalaninemia (e.g., BH4 deficiency) were considered but excluded due to the explicit diagnosis provided and lack of additional symptoms (e.g., neurotransmitter deficiencies). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Dementia', 'Skin rash', 'Spasticity', 'Areflexia', 'Death in infancy', 'Fever', 'Hyperammonemia', 'Diarrhea', 'Cerebral edema', 'Hepatomegaly', 'Progressive neurologic deterioration', 'Hyperlysinuria', 'Hypoargininemia', 'Abnormal circulating methionine concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating alanine concentration', 'Elevated plasma citrulline', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Classic)  
Reasoning:  
1. **Elevated plasma citrulline** and **hyperammonemia** are hallmark biochemical features of citrullinemia type I, caused by a deficiency in argininosuccinate synthetase (ASS1), a urea cycle enzyme.  
2. **Progressive neurologic deterioration**, **cerebral edema**, **spasticity**, and **dementia** align with ammonia neurotoxicity and urea cycle dysfunction.  
3. **Hypoargininemia** occurs due to impaired arginine synthesis in the urea cycle, while **hyperlysinuria** reflects secondary amino acid transport disruptions.  
4. **Hepatomegaly** and **abnormal circulating amino acids** (methionine, glutamine, alanine) suggest metabolic liver stress and secondary mitochondrial dysfunction.  
5. **Death in infancy** is consistent with the severe neonatal-onset form of classic citrullinemia.  
6. Cutaneous manifestations (**rash, erythematous plaques/macules/papules**) may result from metabolic acidosis or ammonia-induced inflammation.  
7. **Areflexia** and **fever** are nonspecific but compatible with acute metabolic decompensation.  

Disease: Citrullinemia type II (excluded)  
Reasoning:  
- Type II (citrin deficiency) typically presents later (adult/childhood) with **different amino acid abnormalities** (e.g., hyperthreonine, hypermethionine) and lacks classic neonatal lethality. Elevated citrulline is milder compared to type I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Coma', 'Reduced tendon reflexes', 'Alopecia', 'Metabolic acidosis', 'Cerebral edema', 'Abnormal cerebral white matter morphology', 'Death in childhood', 'Recurrent viral infections', 'Hyperleucinemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Hyperleucinemia** is pathognomonic for MSUD, caused by impaired branched-chain α-ketoacid dehydrogenase (BCKDH) complex activity, leading to accumulation of leucine, isoleucine, and valine.  
2. **Neurological symptoms** (Ataxia, Coma, Cerebral edema, Abnormal cerebral white matter morphology) stem from leucine-induced neurotoxicity, disrupting neurotransmitter synthesis and causing cerebral osmotic imbalance.  
3. **Metabolic acidosis** results from secondary inhibition of the citric acid cycle by accumulating α-ketoacids.  
4. **Reduced tendon reflexes** correlate with acute metabolic decompensation and axonal dysfunction.  
5. **Death in childhood/adolescence** aligns with classic/severe MSUD phenotypes if untreated; cerebral edema and metabolic crises are often fatal.  
6. **Alopecia** and **recurrent viral infections** are atypical but may reflect nutritional deficiencies or secondary immune dysregulation during metabolic stress.  
7. **Abnormal cerebral white matter morphology** on imaging corresponds with delayed myelination and vacuolization due to leucine toxicity.  

*Note: While recurrent infections and alopecia are not classic MSUD features, the core biochemical and neurological findings dominate the diagnostic rationale.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Ataxia', 'Tremor', 'Death in infancy', 'Cerebral atrophy', 'Abnormal basal ganglia morphology', 'Neonatal death', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Biochemical confirmation**: The symptom ""L-2-hydroxyglutaric aciduria"" directly indicates elevated levels of L-2-hydroxyglutaric acid in bodily fluids, a hallmark diagnostic marker.  
2. **Neurological symptoms**: Intellectual disability, ataxia, and tremor align with progressive neurodegeneration caused by toxic metabolite accumulation.  
3. **Neuroimaging findings**: Cerebral atrophy and abnormal basal ganglia morphology are characteristic radiological features of this disorder, explaining motor and cognitive deficits.  
4. **Severe clinical course**: Neonatal death, death in infancy, and death in childhood suggest a severe phenotypic variant, consistent with early-onset, rapidly progressing forms of the disease.  
5. **Exclusion of mimics**: The combination of biochemical, clinical, and imaging features differentiates L-2-HGA from other organic acidurias or mitochondrial disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Slow saccadic eye movements', 'Dysarthria', 'Hypertonia', 'Spastic tetraparesis', 'Bilateral talipes equinovarus', 'Limb ataxia', 'Unsteady gait']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Core spastic paraplegia features**: Spastic tetraparesis (spasticity in all four limbs) and hypertonia align with hereditary spastic paraplegia (HSP).  
2. **Cerebellar involvement**: Limb ataxia, dysarthria, and unsteady gait suggest cerebellar dysfunction, consistent with *complex HSP*.  
3. **Ocular abnormality**: Slow saccadic eye movements indicate brainstem/cerebellar pathology, reported in SPG76 due to CAPN1 mutations affecting neuronal signaling.  
4. **Congenital musculoskeletal anomaly**: Bilateral talipes equinovarus (clubfoot) may reflect early-onset neuromuscular dysfunction or developmental anomalies linked to SPG76.  
5. **Genetic confirmation**: Autosomal recessive inheritance matches SPG76’s etiology (CAPN1 mutations), which combines spasticity, ataxia, and variable neuro-ophthalmic signs.  
6. **Exclusion of mimics**: Symptoms differentiate SPG76 from pure HSP subtypes (no cerebellar signs) or spinocerebellar ataxias (less prominent spasticity). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is due to deficiency of:
Choices:
A. Factor VIII
B. Factor VII
C. Factor IX
D. Factor X
Answer: [/INST] Factor IX </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Galactosemia commonly is due to deficiency of
Choices:
A. Galactose-1 phosphate uridyl transferase
B. Galactose-1 phosphatase
C. Glucose-1 phosphatase
D. Glucose-6 phosphatase
Answer: [/INST] Galactose-1 phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Seizure', 'Absent speech', 'Hypoplasia of the corpus callosum', 'Developmental regression', 'Areflexia of lower limbs', 'Severe muscular hypotonia', 'Periventricular leukomalacia', 'Severe global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and areflexia**: Core features of TBCK syndrome, reflecting neuromuscular involvement due to TBCK gene mutations affecting mTOR signaling.  
2. **Intellectual disability, absent speech, and severe global developmental delay**: Consistent with neurodevelopmental deficits characteristic of TBCK syndrome.  
3. **Hypoplasia of the corpus callosum**: A hallmark neuroimaging finding in TBCK-related disorders, linked to disrupted neuronal connectivity.  
4. **Seizures and developmental regression**: Observed in severe TBCK cases, possibly due to progressive neuronal dysfunction or epileptic encephalopathy.  
5. **Macrocephaly**: Reported in some patients, though nonspecific, it aligns with brain structural anomalies.  
6. **Ocular abnormalities (strabismus, nystagmus)**: Common in neurogenetic syndromes, supporting central nervous system involvement.  
7. **Periventricular leukomalacia**: May overlap with white matter abnormalities seen in TBCK, though typically associated with preterm injury; here, it likely reflects dysmyelination from the genetic defect.  
8. **Exclusion of mimics**: Features distinguish it from similar disorders (e.g., Prader-Willi, Rett syndrome) by the absence of dysmorphism, metabolic markers, or specific regression patterns. Genetic testing for TBCK mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment of Alkaptonuria:
Choices:
A. Vitamin A
B. Vitamin C
C. Vitamin D
D. Vitamin K
Answer: [/INST] Vitamin C </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is characterized by?
Choices:
A. Increased REM sleep
B. Increased day time sleep
C. Increased night time sleep
D. Normal sleep architecture
Answer: [/INST] Increased day time sleep </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy does NOT affect axilla, groin and scalp because
Choices:
A. They are warmer regions of the body
B. They are colder regions of the body
C. Less blood supply in the body
D. Less sensory nerve supply in the body
Answer: [/INST] They are warmer regions of the body </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following represents the earliest ECG changes in a patient with Hypokalemia?
Choices:
A. Pseudo-P-Pulmonale
B. Flattening of T wave
C. Development of U wave
D. Fusion of TU waves
Answer: [/INST] Flattening of T wave </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hydrocephalus', 'High forehead', 'Spasticity', 'Generalized hypotonia', 'Death in infancy', 'Cerebral atrophy', 'Athetosis', 'Glutaric aciduria', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity.  
2. **Neurological symptoms (Spasticity, Athetosis, Cerebral atrophy)**: Accumulation of glutaric acid and 3-hydroxyglutaric acid damages the basal ganglia and white matter, leading to dystonia, movement disorders, and progressive neurodegeneration.  
3. **Macrocephaly/High forehead**: Often presents in infancy due to transient subdural hemorrhages or pseudohydrocephalus secondary to brain atrophy.  
4. **Generalized hypotonia**: Early manifestation before metabolic crises or neurological deterioration.  
5. **Death in infancy/childhood**: Severe metabolic decompensation (e.g., during infections) or irreversible brain injury in untreated cases.  
6. **Cerebral atrophy**: Chronic neurotoxicity from toxic metabolites results in progressive loss of brain tissue.  
The combination of characteristic organic aciduria, striatal injury patterns, and clinical progression aligns definitively with GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True statement regarding Achondroplasia is :
Choices:
A. AR inheritance
B. Shortened spine
C. Increased risk of pathological fracture
D. Diagnosed at birth by X-ray
Answer: [/INST] Diagnosed at birth by X-ray </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is due to deficiency of-
Choices:
A. Factor VIII
B. Factor VII
C. Factor IX
D. factor X
Answer: [/INST] Factor IX </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug resistance in Tuberculosis is due to ?
Choices:
A. Transformation
B. Transduction
C. Conjugation
D. Mutation
Answer: [/INST] Mutation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Fever', 'Diarrhea', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Abnormal circulating aspartate family amino acid concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: The hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Hypertyrosinemia**: Secondary elevation of tyrosine may occur due to competitive inhibition of tyrosine metabolism by excess phenylalanine or dietary protein restrictions.  
3. **Delayed speech/development**: Untreated PKU results in neurotoxic effects of phenylalanine, impairing cognitive and language development.  
4. **Abnormal prenatal development/Neonatal death**: Severe PAH deficiency can manifest prenatally; untreated cases may lead to metabolic instability and early mortality.  
5. **Elevated urinary carboxylic acids**: Phenylalanine metabolites (e.g., phenylpyruvate, phenyllactate) may appear in urine as alternative degradation products.  
6. **Recurrent infections/Diarrhea/Fever**: Possible secondary to dietary management (low-protein diets affecting immune function) or metabolic stress.  
7. **Abnormal aspartate family amino acids**: Disruption in amino acid metabolism pathways due to phenylalanine excess may indirectly alter aspartate-related metabolites.  

*Note:* While some symptoms (e.g., recurrent infections) are atypical for classic PKU, they may reflect complications of severe/prolonged metabolic derangement or comorbidities. Confirmatory testing (PAH gene variants, phenylalanine levels, neonatal screening results) is critical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Craniopharyngioma except?
Choices:
A. Derived from Rathke's pouch
B. Contains epithelial cells
C. Present in temporal or parietal lobes
D. Causes visual disturbances
Answer: [/INST] Present in temporal or parietal lobes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hepatic steatosis', 'Elevated hepatic transaminase', 'Death in childhood', 'Hyperphenylalaninemia', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Decreased circulating copper concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Hepatolenticular degeneration; Wilson disease  
Reasoning:  
1. **Decreased circulating ceruloplasmin concentration** and **increased urinary copper concentration** are hallmark biochemical features of Wilson disease, caused by mutations in the *ATP7B* gene, impairing copper transport and biliary excretion.  
2. **Hepatic steatosis** and **elevated hepatic transaminase** reflect copper accumulation in the liver, leading to hepatocyte injury and fatty degeneration.  
3. **Decreased circulating copper concentration** occurs paradoxically due to reduced ceruloplasmin (a copper-binding protein), despite systemic copper overload.  
4. **Abnormal circulating aspartate family amino acids** and **alanine** may arise from secondary mitochondrial dysfunction or liver damage disrupting amino acid metabolism.  
5. **Hyperphenylalaninemia** could result from hepatic insufficiency impairing phenylalanine hydroxylase activity, though this is atypical and suggests severe liver involvement.  
6. **Death in childhood** aligns with early-onset Wilson disease variants presenting as acute liver failure, a rapid and fatal manifestation without timely intervention.  
The constellation of copper metabolism derangements, liver pathology, and ceruloplasmin deficiency strongly supports Wilson disease as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Pallor', 'Intellectual disability', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Drowsiness', 'Sleep disturbance', 'Hyperalaninemia', 'Death in childhood', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating carnitine concentration', 'Atransferrinemia', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia (PA)  
Reasoning:  
1. **Metabolic Findings**: Hyperammonemia, hyperglycinemia, hyperalaninemia, and elevated urinary carboxylic acids align with PA's hallmark organic acidemia due to propionyl-CoA carboxylase deficiency, causing toxic metabolite accumulation.  
2. **Hematologic Abnormalities**: Leukopenia and anemia reflect bone marrow suppression from metabolic toxicity, common in PA crises.  
3. **Neurological Symptoms**: Intellectual disability, lethargy, generalized hypotonia, and delayed speech result from neurotoxic effects of ammonia/glycine and energy deficiency.  
4. **Early Mortality**: Death in infancy/childhood is typical in severe, untreated PA due to metabolic decompensation.  
5. **Carnitine Abnormalities**: Abnormal carnitine levels occur as carnitine is depleted to conjugate propionyl-CoA for excretion.  
6. **Atypical Features**: Atransferrinemia and hearing impairment are less common but may arise from chronic metabolic stress or secondary complications.  
7. **Sleep/Drowsiness**: Hyperammonemia disrupts CNS function, explaining drowsiness and sleep disturbances.  
8. **Porphyrin Anomalies**: Likely secondary to mitochondrial dysfunction affecting heme synthesis pathways.  

PA integrates metabolic, hematologic, and neurologic symptoms, with key biochemical markers (hyperammonemia, hyperglycinemia, elevated carboxylic acids) confirming the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Following are radiological evidence of Achalasia cardia except not related -radiology
Choices:
A. Smooth narrowing of esophagus
B. Dilated touous esophagus
C. Absence of air in the fundus
D. Exaggerated peristalsis
Answer: [/INST] Exaggerated peristalsis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Metabolic acidosis', 'Tachypnea', '3-Methylglutaric aciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia**: CPS1 deficiency disrupts the urea cycle, impairing ammonia detoxification. Elevated ammonia levels cause neurological symptoms (seizures) and contribute to neonatal lethality.  
2. **Respiratory Findings (Tachypnea)**: Hyperammonemia stimulates the respiratory drive, leading to tachypnea as a compensatory mechanism for associated metabolic acidosis.  
3. **Metabolic Acidosis**: Secondary mitochondrial dysfunction from hyperammonemia or energy depletion may cause lactic acidosis. Concurrent organic aciduria (3-methylglutaric aciduria) suggests disrupted mitochondrial metabolism, potentially due to metabolic stress from ammonia toxicity.  
4. **3-Methylglutaric Aciduria**: Likely a secondary marker of mitochondrial dysfunction, as hyperammonemia can impair leucine catabolism or other pathways, leading to organic acid accumulation.  
5. **Neonatal/Infantile Death**: Severe urea cycle defects like CPS1 deficiency often manifest catastrophically in neonates due to rapid ammonia accumulation, metabolic derangements, and neurological deterioration.  

This diagnosis aligns with the clinical triad of hyperammonemia, metabolic acidosis, and respiratory compensation, alongside the rare but plausible association with 3-methylglutaric aciduria in mitochondrial stress states. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 7 yr old boy underwent neurosurgery for Craniopharyngioma following which pituitary functions were lost. Which of the following hormone should be replaced first?
Choices:
A. Hydrocoisone
B. Thyroxine
C. Growth hormone
D. Prolactin
Answer: [/INST] Hydrocoisone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy bacillus is cultured by using:-
Choices:
A. Bordet Gengou medium
B. LJ medium
C. Loeffler's serum slope
D. None of the above
Answer: [/INST] None of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Alopecia', 'Increased serum lactate', 'Increased CSF lactate']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Eczematoid dermatitis/Skin rash**: Biotinidase deficiency impairs biotin recycling, leading to biotin-dependent carboxylase dysfunction. This disrupts fatty acid synthesis and skin barrier integrity, causing dermatitis and rashes.  
2. **Alopecia**: Biotin is critical for keratinocyte function and hair follicle health. Deficiency results in hair loss due to impaired protein synthesis and cellular repair.  
3. **Increased serum/CSF lactate**: Dysfunctional carboxylases (e.g., pyruvate carboxylase) disrupt gluconeogenesis and the tricarboxylic acid cycle, causing lactic acidosis from pyruvate accumulation. Elevated lactate in both serum and CSF reflects systemic metabolic dysfunction.  
4. **Death in infancy**: Untreated biotinidase deficiency leads to progressive metabolic crises (acidosis, hyperammonemia), seizures, and neurologic deterioration, often fatal in early childhood without biotin supplementation.  
5. **Consistency with late-onset multiple carboxylase deficiency**: The term ""late-onset"" refers to partial enzyme activity delaying symptom onset, but severe cases (as implied by infant mortality) align with complete biotinidase deficiency.  

This constellation of dermatologic, metabolic, and neurologic features is pathognomonic for biotinidase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The classic triad of congenital Rubella includes all except:
Choices:
A. Cataract
B. Deafness
C. Retinal detachment
D. CHD
Answer: [/INST] Retinal detachment </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Hypercholesterolemia', 'Increased LDL cholesterol concentration', 'Elevated circulating alkaline phosphatase concentration', 'Infantile muscular hypotonia', 'Decreased circulating ceruloplasmin concentration', 'Abnormal protein N-linked glycosylation', 'Abnormal protein O-linked glycosylation', 'Elevated circulating aspartate aminotransferase concentration', 'Elevated circulating alanine aminotransferase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Congenital disorder of glycosylation, type IIP (TMEM199-CDG)  
Reasoning:  
1. **Abnormal N-linked and O-linked glycosylation**: Indicates a Golgi-associated glycosylation defect (Type II CDG), consistent with TMEM199-CDG, which disrupts Golgi homeostasis.  
2. **Hepatic involvement**: Elevated AST, ALT, and alkaline phosphatase reflect liver dysfunction, a hallmark of TMEM199-CDG due to impaired glycosylation-dependent hepatic protein secretion.  
3. **Hypotonia/developmental delay**: Common in CDGs due to systemic glycosylation defects affecting neurological and muscular development.  
4. **Hypercholesterolemia/increased LDL**: Linked to disrupted LDL receptor glycosylation or altered lipid metabolism regulation in the liver.  
5. **Decreased ceruloplasmin**: Ceruloplasmin is a glycoprotein; improper glycosylation reduces its stability, leading to low circulating levels.  
6. **TMEM199 gene association**: Confirms CDG-Type IIP, as TMEM199 mutations specifically impair Golgi manganese transport, critical for glycosylation enzymes.  

(Note: The two diagnoses provided are synonymous, as ""Congenital disorder of glycosylation, type IIP"" is the clinical term for TMEM199-CDG.) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The enzyme deficient in Galactosemia is:-
Choices:
A. Sphingomyelinase
B. Hexosaminidase
C. Galactose 1- phosphate uridyl transferase
D. Glucocerebrosidase
Answer: [/INST] Galactose 1- phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Leptospirosis are true, except:
Choices:
A. Infection acquired by direct contact with infected urine
B. Moality is 5-15% in severe cases
C. Antibodies are usually detectable in the first week
D. IV penicillin is recommended for treatment of severe cases
Answer: [/INST] Antibodies are usually detectable in the first week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Low-set ears', 'Ptosis', 'Coloboma', 'Optic nerve hypoplasia', 'Iris coloboma', 'Diabetes mellitus', 'Hypertension', 'Cyanosis', 'Edema', 'Generalized hypotonia', 'Bilateral ptosis', 'Polyhydramnios', 'Ventricular septal defect', 'Atrial septal defect', 'Congestive heart failure', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Large forehead', 'Dyspnea', 'Apnea', 'Ventriculomegaly', 'Gray matter heterotopia', 'Bilateral choanal atresia', 'Right ventricular dilatation', 'Depressed nasal bridge', 'Redundant neck skin', 'Wide intermamillary distance', 'Ocular anterior segment dysgenesis', 'Corneal opacity', 'Microtia', 'Axial hypotonia', 'Infantile axial hypotonia', 'Maternal diabetes', 'Simplified gyral pattern', 'Prominent forehead', 'Flexion contracture of finger', 'Pulmonary edema']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/Brain anomalies**: Simplified gyral pattern, gray matter heterotopia, ventriculomegaly, generalized hypotonia, and axial hypotonia indicate central nervous system involvement.  
2. **Ocular anomalies**: Coloboma (iris/optic nerve), optic nerve hypoplasia, corneal opacity, and anterior segment dysgenesis are hallmark eye findings in NEDBEH.  
3. **Cardiac defects**: Ventricular/atrial septal defects, patent foramen ovale, abnormal cardiac septum morphology, and congestive heart failure align with the cardiac spectrum of this disorder.  
4. **Supportive features**: Dysmorphic traits (low-set ears, depressed nasal bridge, microtia, redundant neck skin) and maternal diabetes (a known risk factor for congenital anomalies) further support the diagnosis.  
5. **Exclusion of mimics**: Choanal atresia and pulmonary edema may arise secondary to structural or functional abnormalities linked to the primary disorder. Polyhydramnios correlates with hypotonia-related fetal swallowing issues.  
6. **Syndromic coherence**: The triad of neurodevelopmental delay, brain/eye malformations, and congenital heart defects is pathognomonic for NEDBEH, often caused by de novo variants in genes like *BRD4* or *SMARCA2*. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is recommended for culture sampling in Infective Endocarditis:
Choices:
A. 2 culture sets separated by at-least 1 hour over 24 hours
B. 2 culture sets separated by at-least 2 hours over 24 hours
C. 3 culture sets separated by at-least 1 hour over 24 hours
D. 3 culture sets separated by at-least 2 hours over 24 hours
Answer: [/INST] 3 culture sets separated by at-least 1 hour over 24 hours </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'Delayed CNS myelination', 'EEG abnormality', 'Developmental regression', 'Inability to walk', 'Bruxism', 'Secondary microcephaly', 'Hypoplasia of the frontal lobes']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Developmental regression**: A hallmark of Rett syndrome, though the congenital variant often lacks the classic period of normal development before regression.  
2. **Secondary microcephaly**: Reflects postnatal slowing of head growth, consistent with Rett-associated neurological degeneration.  
3. **Seizures and EEG abnormality**: Common in Rett due to cortical hyperexcitability and disrupted neuronal connectivity.  
4. **Hypoplasia of the corpus callosum and frontal lobes**: Aligns with FOXG1-related congenital Rett variant, which disrupts forebrain development.  
5. **Delayed CNS myelination**: Supports a neurodevelopmental disorder affecting white matter maturation.  
6. **Hypotonia and inability to walk**: Indicates severe motor dysfunction, typical of early-onset/congenital forms.  
7. **Bruxism and repetitive mannerisms**: Stereotypic movements are classic in Rett spectrum disorders.  
8. **Delayed speech/development**: Reflects global neurodevelopmental impairment.  
*Conclusion*: The constellation of structural brain anomalies, regression, microcephaly, and movement abnormalities strongly suggests a FOXG1-related congenital Rett variant rather than classic MECP2-linked Rett syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Encephalopathy', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Increased serum lactate', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', '3-Methylglutaric aciduria', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase deficiency (HMGCL deficiency)  
Reasoning:  
1. **Organic Acidurias**: Elevated urinary 3-methylglutaric acid and glutaric acid are hallmark biochemical markers of HMGCL deficiency due to impaired leucine catabolism and ketogenesis.  
2. **Metabolic Crisis Features**: Hypoglycemia (from defective ketogenesis), hyperammonemia (secondary to metabolic stress), and lactic acidosis (mitochondrial dysfunction) align with acute decompensation episodes in this disorder.  
3. **Neurological Involvement**: Encephalopathy, abnormal cerebral white matter morphology, and delayed development reflect neurotoxic effects of accumulated metabolites (e.g., 3-hydroxy-3-methylglutaric acid).  
4. **Early Lethality**: Neonatal death or death in infancy/childhood is common in severe cases due to metabolic instability and susceptibility to infections.  
5. **Carnitine/Carboxylic Acid Abnormalities**: Secondary carnitine deficiency and elevated monocarboxylic acids occur due to excessive conjugation/excretion of toxic intermediates.  
6. **Systemic Symptoms**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections stem from chronic metabolic dysfunction and energy deficiency.  
7. **Exclusion of Mimics**: Glutaric aciduria type I is ruled out by the absence of striatal necrosis and presence of 3-methylglutaric aciduria, which is specific to HMGCL deficiency.  

The combination of biochemical findings (urinary acids, hyperammonemia, hypoglycemia) and clinical features (neurodegeneration, early mortality) confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding syphilis, all are true, except -a) VDRL titre decreases or even absent after treatmentb) VDRL becomes positive after 10-14 days of infectionc) Earliest serological test to become positive in untreated primary syphilis is TPHAd) Yaws and Pinta cannot be differentiated
Choices:
A. bc
B. c
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pre-exposure prophylaxis for Rabies is given on
Choices:
A. Days 0, 3, 7, 14, 28, 90
B. Days 0, 3, 7, 28, 90
C. Days 0, 3
D. Days 0, 7, 28
Answer: [/INST] Days 0, 7, 28 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hip dysplasia', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or secondary metabolic disruptions (e.g., transient tyrosine elevation due to hepatic immaturity in premature infants).  
3. **Elevated urinary carboxylic acids** could reflect phenylalanine metabolites (e.g., phenylpyruvate) excreted in urine, misclassified as carboxylic acids.  
4. **Severe short stature** and **neonatal death** might indicate untreated or late-diagnosed PKU, leading to metabolic crises and growth failure.  
5. **Premature birth** and **hip dysplasia** are not directly linked to PKU but may coexist as unrelated complications or reflect syndromic forms (e.g., maternal PKU effects on fetal development).  
6. **Death in infancy/adolescence** aligns with severe metabolic derangements if phenylalanine-restricted diets are absent, causing neurodegeneration and multi-organ failure.  

*Note: Hypertyrosinemia and skeletal abnormalities (e.g., hip dysplasia) are atypical for PKU and suggest further investigation for coexisting disorders (e.g., tyrosinemia, skeletal dysplasias) or diagnostic inconsistencies.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hypoglycemia**: MCADD impairs fatty acid β-oxidation, limiting energy production during fasting. This results in hypoketotic hypoglycemia (reduced ketones despite low glucose).  
2. **Hyperammonemia**: Secondary to metabolic decompensation; impaired urea cycle function from energy depletion or accumulated toxic metabolites.  
3. **Decreased plasma free carnitine**: Excess medium-chain acyl-CoA intermediates bind carnitine, forming acyl-carnitine conjugates (e.g., C8, C10), depleting free carnitine.  
4. **Lethargy/Drowsiness/Vomiting**: Manifestations of acute metabolic crises triggered by fasting or infection, causing encephalopathy.  
5. **Generalized hypotonia**: Chronic energy deficiency in muscles and nervous system.  
6. **Sleep disturbance**: Neurological dysfunction from hypoglycemia or hyperammonemia.  
7. **Death in infancy/childhood**: Untreated MCADD leads to rapid metabolic collapse during catabolic states (e.g., illness, prolonged fasting).  
8. **Key diagnostic clues**: Hypoketotic hypoglycemia + hyperammonemia + low free carnitine with elevated medium-chain acylcarnitines on tandem mass spectrometry.  
**Conclusion**: Symptom constellation and biochemical profile (hypoglycemia, hyperammonemia, carnitine deficiency) strongly indicate MCADD, a fatty acid oxidation disorder. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is due to the deficiency of:
Choices:
A. Phenylalanine
B. Phenylalanine hydroxylase (PAH)
C. Phenylene
D. All of these
Answer: [/INST] Phenylalanine hydroxylase (PAH) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the followings are true about Narcolepsy; except:
Choices:
A. Strong association with HLA class II
B. Sudden loss of voluntary muscle tone
C. NREM abnormality
D. Irresistible desire to sleep
Answer: [/INST] NREM abnormality </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on?
Choices:
A. Chromosome 6
B. Chromosome 9
C. Chromosome 13
D. Chromosome 2l
Answer: [/INST] Chromosome 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which form of asbestos is most commonly associated with maximum risk of Mesothelioma?
Choices:
A. Chrysolite
B. Amosite
C. Anthophyllite
D. Crocidolite
Answer: [/INST] Crocidolite </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Intellectual disability', 'Obesity', 'Death in infancy', 'Splenomegaly', 'Hyperammonemia', 'Vomiting', 'Hyperlysinemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Elevated circulating glutaric acid concentration', 'Low plasma citrulline', 'Prolonged partial thromboplastin time', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Abnormal circulating ornithine concentration', 'Uraciluria', 'Abnormal circulating creatine kinase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** + **vomiting** + **hepatomegaly**: Core features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Oroticaciduria** + **uraciluria**: Pathognomonic for OTCD. OTC deficiency causes carbamoyl phosphate accumulation, which enters pyrimidine synthesis, producing excess orotic acid/uracil.  
3. **Low citrulline**: OTC catalyzes ornithine + carbamoyl phosphate → citrulline; deficiency blocks this step, reducing citrulline synthesis.  
4. **Abnormal ornithine/arginine**: Secondary disruption of urea cycle intermediates.  
5. **Elevated glutamine/alanine/lysine**: Amino acid imbalances from alternative ammonia scavenging pathways (e.g., glutamine synthesis) and metabolic stress.  
6. **Hepatosplenomegaly** + **elevated liver enzymes**: Hepatic dysfunction due to toxic metabolite accumulation.  
7. **Prolonged PTT** + **recurrent infections**: Possible secondary coagulopathy/immune dysfunction from liver involvement.  
8. **Neurodevelopmental features** (apathy, intellectual disability) + **early mortality**: Reflects severe hyperammonemic crises causing irreversible neurological damage.  
OTCD aligns with the biochemical profile (orotic aciduria, citrulline depletion) and clinical progression of neonatal/infantile-onset UCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 27-year-old G3P2002 presents to the clinic for follow up after her initial prenatal visit. Her last period was 8 weeks ago. Her medical history is notable for obesity, hypertension, type 2 diabetes, and eczema. Her current two children are healthy. Her current pregnancy is with a new partner after she separated from her previous partner. Her vaccinations are up to date since the delivery of her second child. Her temperature is 98°F (37°C), blood pressure is 110/60 mmHg, pulse is 85/min, and respirations are 18/min. Her physical exam is unremarkable. Laboratory results are shown below:

Hemoglobin: 14 g/dL
Hematocrit: 41%
Leukocyte count: 9,000/mm^3 with normal differential
Platelet count: 210,000/mm^3

Blood type: O
Rh status: Negative

Urine:
Epithelial cells: Rare
Glucose: Positive
WBC: 5/hpf
Bacterial: None

Rapid plasma reagin: Negative
Rubella titer: > 1:8
HIV-1/HIV-2 antibody screen: Negative

Gonorrhea and Chlamydia NAAT: negative
Pap smear: High-grade squamous intraepithelial lesion (HGSIL)

What is the best next step in management?
Choices:
A. Colposcopy and biopsy after delivery.
B. Colposcopy and biopsy now.
C. Cryosurgical excision.
D. Loop electrosurgical excision procedure (LEEP).
Answer: [/INST] Colposcopy and biopsy now. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Micropenis', 'Gingival overgrowth', 'Long philtrum', 'Micrognathia', 'Anteverted nares', 'Proptosis', 'Bifid ribs', 'Bicuspid aortic valve', 'Frontal bossing', 'Hemivertebrae', 'Elbow dislocation', 'Acromesomelia', 'Short stature', 'Depressed nasal bridge', 'Eversion of lateral third of lower eyelids', 'Microtia', 'Short finger', 'Limb undergrowth', 'Cleft lower lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive Robinow syndrome/Robinow syndrome, autosomal recessive  
Reasoning:  
1. **Craniofacial Features**: Micrognathia (small jaw), long philtrum, anteverted nares, depressed nasal bridge, frontal bossing (prominent forehead), proptosis (bulging eyes), and eversion of the lateral third of the lower eyelids align with the characteristic facial dysmorphology of Robinow syndrome.  
2. **Skeletal Anomalies**: Bifid ribs, hemivertebrae (spinal malformations), elbow dislocation, acromesomelia (shortened distal limbs), limb undergrowth, and short fingers are hallmark skeletal defects in autosomal recessive Robinow syndrome.  
3. **Genitourinary/Genital Involvement**: Micropenis is a key feature of the autosomal recessive form, distinguishing it from the milder dominant type.  
4. **Oral/Dental Abnormalities**: Gingival overgrowth and cleft lower lip are frequently observed in recessive Robinow syndrome.  
5. **Auxiliary Findings**: Short stature, microtia (small ears), and bicuspid aortic valve (cardiac anomaly) further support the diagnosis, as these are common systemic manifestations.  
6. **Exclusion of Differential Diagnoses**: The combination of severe skeletal, craniofacial, and genital abnormalities differentiates this from other acromesomelic dysplasias or syndromes with overlapping features (e.g., Simpson-Golabi-Behmel or Cornelia de Lange syndrome).  
7. **Genetic Basis**: Autosomal recessive inheritance (linked to *ROR2* gene mutations) correlates with the severity of observed symptoms, including pronounced skeletal defects and genital hypoplasia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which substance gets accumulated in abnormal amounts in Alkaptonuria
Choices:
A. Acetoacetate
B. Oxalate
C. Homogentisate
D. Phenylacetic acid
Answer: [/INST] Homogentisate </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological symptoms**: Delayed speech, hyperactivity, intellectual disability, and seizures align with SSADHD, a disorder disrupting GABA metabolism, leading to neurodevelopmental deficits.  
2. **Metabolic markers**: Decreased plasma free carnitine and elevated urinary carboxylic acids (e.g., 4-hydroxybutyric acid) are pathognomonic for SSADHD due to impaired GABA degradation.  
3. **Hypotonia and mortality**: Generalized hypotonia reflects neuromuscular dysfunction from metabolite accumulation. Early death, though rare, may occur in severe cases due to metabolic crises or refractory seizures.  
4. **Monocarboxylic acid abnormalities**: Elevated GHB (a monocarboxylic acid) in blood/urine directly results from succinic semialdehyde dehydrogenase enzyme deficiency.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidurias (e.g., glutaric aciduria) by specific biochemical profile (GHB elevation, carnitine depletion). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis of the jaw can be cured by
Choices:
A. Resection
B. Physiotherapy
C. Sequestrectomy with antibiotic treatment
D. Drainage
Answer: [/INST] Sequestrectomy with antibiotic treatment </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma exclusively occurs in the:-
Choices:
A. Medulla
B. Cerebellum
C. Cerebral hemisphere
D. Spinal cord
Answer: [/INST] Cerebellum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Brachydactyly', 'Delayed ossification of carpal bones', 'Abnormal facial shape', 'Waddling gait', 'Flared femoral metaphysis', 'Genu varum', 'Metaphyseal irregularity', 'Short long bone', 'Hypoplasia of the capital femoral epiphysis', 'Flat acetabular roof', 'Short stature', 'Beaking of vertebral bodies', 'Mucopolysacchariduria', 'Irregular acetabular roof', 'Disproportionate short-limb short stature', 'Irregular epiphyses', 'Lower limb pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Pseudoachondroplasia  
**Reasoning**:  
1. **Disproportionate short-limb short stature** and **short long bones** are hallmark features of pseudoachondroplasia, a skeletal dysplasia caused by *COMP* gene mutations.  
2. **Metaphyseal irregularity**, **flared femoral metaphysis**, and **hypoplasia of the capital femoral epiphysis** align with characteristic metaphyseal/epiphyseal dysplasia seen radiographically.  
3. **Genu varum** and **waddling gait** result from abnormal lower limb alignment and hip dysplasia, exacerbated by **flat/irregular acetabular roof**.  
4. **Beaking of vertebral bodies** reflects vertebral anomalies common in pseudoachondroplasia, though less severe than in mucopolysaccharidoses (MPS).  
5. **Delayed ossification of carpal bones** and **brachydactyly** correlate with delayed skeletal maturation and shortened bones.  
6. **Mucopolysacchariduria** is atypical but may represent a coincidental finding or lab overlap; dominant skeletal features outweigh this.  
7. **Lower limb pain** stems from early-onset joint degeneration, a known complication.  
8. **Abnormal facial shape** is mild/nonspecific in pseudoachondroplasia, contrasting with coarse facies in MPS, reinforcing the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), the enzyme that converts phenylalanine to tyrosine. This deficiency results in the accumulation of phenylalanine, consistent with hyperphenylalaninemia.  
2. **Hypertyrosinemia**: While classic PKU typically presents with *low* tyrosine due to impaired synthesis, hypertyrosinemia in this case could suggest:  
   - **Atypical PKU variant**: Residual PAH activity or compensatory dietary tyrosine supplementation.  
   - **Secondary metabolic disruption**: Severe liver dysfunction (e.g., due to untreated PKU complications) impairing tyrosine catabolism.  
3. **Death in early adulthood**: Untreated PKU leads to severe neurological damage, seizures, and organ failure. Early demise aligns with delayed diagnosis or poor adherence to dietary restrictions (e.g., low-phenylalanine diet).  
4. **Exclusion of alternatives**: Tyrosinemia type I/II or BH4 deficiency were considered but ruled out due to the prominence of hyperphenylalaninemia and lack of hallmark features (e.g., liver failure in tyrosinemia, neurotransmitter deficits in BH4 disorders).  

Conclusion: PKU is the primary diagnosis, with hypertyrosinemia attributed to atypical metabolic adjustments or concurrent factors. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Under extended sickness benefit of ESI act, Tuberculosis benefit is given for duration of:
Choices:
A. 6 months
B. 1 year
C. 2 years
D. 4 years
Answer: [/INST] 2 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid ulcer perforation mostly occurs in: March 2005, March 2013
Choices:
A. 1 -2 week
B. 2 -3week
C. 3-4 week
D. 4 -5week
Answer: [/INST] 3-4 week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not a feature of Achondroplasia
Choices:
A. Tombstone iliac bone
B. Champagne glass pelvis
C. Acromelic dwarfism
D. Bullet shaped veebra
Answer: [/INST] Acromelic dwarfism </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Drowsiness', 'Sleep disturbance', 'Bone pain', 'Hypertyrosinemia', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical finding in PKU, caused by a deficiency of phenylalanine hydroxylase (PAH), which prevents the conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia** is atypical in classical PKU but may occur due to exogenous tyrosine supplementation (common in PKU management) or overlapping metabolic disturbances.  
3. **Neurological symptoms** (lethargy, drowsiness, sleep disturbances) align with untreated PKU, as phenylalanine accumulation disrupts neurotransmitter synthesis (e.g., dopamine, serotonin).  
4. **Bone pain** is not classic for PKU but could stem from long-term nutritional deficiencies (e.g., calcium/vitamin D) in poorly managed dietary therapy.  
5. The absence of liver dysfunction or severe tyrosine-related symptoms (e.g., keratitis, skin lesions) argues against primary tyrosinemia, reinforcing PKU as the primary diagnosis.  
6. Hypertyrosinemia may reflect secondary metabolic adaptations or testing artifacts, but hyperphenylalaninemia remains the critical diagnostic marker for PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rapid diagnostic test for gram negative bacterial Meningitis is
Choices:
A. CSF - Latex agglutination
B. Nasopharyngeal swab culture
C. CSF - Culture
D. Limulus amebocyte lysate assay
Answer: [/INST] Limulus amebocyte lysate assay </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Clinical features of Botulism are all Except
Choices:
A. Diarrhea
B. Dysarthria
C. Ocular nerve paralysis
D. Blurring of vision
Answer: [/INST] Diarrhea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common mutation in Hereditary Spherocytosis is
Choices:
A. Band 3
B. Ankyrin
C. Spectrin
D. Band 4.2
Answer: [/INST] Ankyrin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts medium-chain fatty acid oxidation, leading to accumulation of medium-chain acylcarnitines and secondary carnitine deficiency.  
2. **Neonatal death/Death in infancy/childhood**: Untreated MCADD causes hypoketotic hypoglycemia during fasting, triggering metabolic crises that can be fatal, especially in early life.  
3. **Delayed speech/language development**: Neurological damage from prior hypoglycemic episodes or metabolic instability may impair development in undiagnosed cases.  
4. **Abnormality of prenatal development or birth**: Though atypical, severe metabolic stress *in utero* or maternal factors (e.g., placental insufficiency) might contribute to prenatal abnormalities.  
5. **Decreased 3-hydroxyacyl-CoA dehydrogenase level**: Likely reflects misinterpretation of acylcarnitine profile data or secondary metabolic disruption; MCADD primarily involves MCAD enzyme deficiency (not 3-hydroxyacyl-CoA dehydrogenase).  

Key confirmation relies on genetic testing for *ACADM* mutations and characteristic acylcarnitine profile (elevated C6-C10 species, notably C8). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Tuberculosis HIV patientsa) ↑ Sputum positivityb) INH prophyaxis prevent development of T.Bc) Lack characteristics feature of T.Bd) Highly positive PPD reactione) Atypical radiological features
Choices:
A. ce
B. b
C. ac
D. ae
Answer: [/INST] ce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid revaccination is recommended every ... years in endemic area-
Choices:
A. 1
B. 3
C. 5
D. 10
Answer: [/INST] 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vasculitis involving the Aoic arch is
Choices:
A. Takayasu aeritis
B. Polyaeritis nodosa
C. Kawasaki disease
D. Churg-Strauss syndrome
Answer: [/INST] Takayasu aeritis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Mental deterioration', 'Slurred speech', 'Spastic tetraplegia', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Mental deterioration**: Observed in DNAJC6-related PARK23 due to rapid neurodegeneration and early cognitive decline.  
2. **Slurred speech**: Linked to dysarthria from basal ganglia dysfunction and possible pyramidal tract involvement.  
3. **Spastic tetraplegia**: Reflects pyramidal tract damage (spasticity), atypical in classic Parkinson’s but characteristic of PARK23’s broader neurological pathology.  
4. **Dyskinesia**: Arises from basal ganglia dysfunction and may occur earlier in genetic forms, independent of levodopa therapy.  
The combination of parkinsonism, pyramidal signs, cognitive decline, and dyskinesia aligns with PARK23’s phenotype caused by biallelic DNAJC6 mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is the commonest complication of Mumps in adults ?
Choices:
A. Encephalitis
B. Orchitis
C. Pancreatitis
D. Carditis
Answer: [/INST] Orchitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A newlywed couple comes to your office for genetic counseling. Both potential parents are known to be carriers of the same Cystic Fibrosis (CF) mutation. What is the probability that at least one of their next three children will have CF if they are all single births?
Choices:
A. 0.
B. 1/64.
C. 27/64.
D. 37/64.
Answer: [/INST] 37/64. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient's elevated urinary carboxylic acids (e.g., 3-hydroxyisovaleric acid and 3-methylcrotonylglycine) stem from a defect in leucine catabolism due to MCCC1 gene mutations. This disrupts 3-methylcrotonyl-CoA carboxylase activity, causing metabolite accumulation. Aminoaciduria arises from proximal tubule dysfunction secondary to toxic organic acids, while abnormal glycine levels may reflect increased conjugation with 3-methylcrotonyl-CoA, altering its circulating concentration.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Broadly, this deficiency (encompassing MCCC1/MCCC2 mutations) disrupts leucine breakdown, leading to urinary excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine (explaining elevated carboxylic acids). Aminoaciduria occurs due to renal tubular damage from acidic metabolites. Glycine abnormalities may result from metabolic diversion to conjugate accumulated intermediates, reducing free glycine or altering its homeostasis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Strabismus', 'Delayed speech and language development', 'Seizure', 'Ataxia', 'Lethargy', 'Death in infancy', 'Abnormal cerebral morphology', 'Increased serum lactate', 'Drowsiness', 'Progressive neurologic deterioration', 'Sleep disturbance', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Macrocephaly**: A hallmark of Canavan disease due to spongiform degeneration of white matter and brain swelling.  
2. **Neurological Symptoms (Ataxia, Seizures, Progressive Deterioration)**: Caused by leukodystrophy disrupting myelination and neuronal function.  
3. **Abnormal Cerebral Morphology**: MRI typically shows diffuse white matter abnormalities and cyst-like changes.  
4. **Delayed Speech/Language Development**: Reflects global developmental delay from neurodegeneration.  
5. **Increased Serum Lactate & Abnormal Aspartate Metabolism**: Linked to ASPA gene mutations impairing N-acetylaspartate (NAA) breakdown, causing toxic accumulation and secondary mitochondrial dysfunction.  
6. **Lethargy/Drowsiness/Sleep Disturbance**: Result from cerebral energy deficits and neurochemical imbalances.  
7. **Fatal Early Course (Infancy/Childhood)**: Severe infantile-onset Canavan disease leads to rapid neurodegeneration and early mortality.  
8. **Strabismus**: Occurs due to optic nerve atrophy or impaired brainstem coordination.  

The combination of macrocephaly, leukodystrophy features, aspartate metabolism abnormalities, and early fatality strongly supports Canavan disease, confirmed by genetic testing for ASPA mutations or elevated NAA in urine/CSF. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not seen in Narcolepsy:
Choices:
A. Sleep paralysis
B. Sleep attack
C. Catalepsy
D. Cataplexy
Answer: [/INST] Catalepsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased serum lactate', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Increased serum lactate**: Biotinidase deficiency disrupts carboxylase enzymes (dependent on biotin), impairing gluconeogenesis and fatty acid synthesis. This leads to lactic acidosis, a hallmark of the disorder.  
2. **Neonatal death/Death in infancy**: Untreated BTDD causes severe metabolic crises, neurological deterioration (seizures, hypotonia), and respiratory failure, often fatal in early life.  
3. **Abnormality of prenatal development or birth**: While structural birth defects are rare, metabolic dysfunction *in utero* may contribute to intrauterine distress or growth abnormalities. Maternal biotin deficiency (if present) could exacerbate fetal vulnerability.  
4. **Diagnostic alignment**: Symptoms match the ""late-onset"" form of multiple carboxylase deficiency (caused by BTDD), where symptoms emerge postnatally but rapidly progress without biotin supplementation. Early mortality underscores the critical need for newborn screening and prompt treatment. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Causative agent of Yaws is:
Choices:
A. Treponema peenue
B. Treponema carateum
C. Treponema pallidum
D. Treponema endemicum
Answer: [/INST] Treponema peenue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dracunculosis is most common in-
Choices:
A. Gujarat
B. Rajasthan
C. Madhya Pradesh
D. Orissa
Answer: [/INST] Rajasthan </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Myopia', 'Exotropia', 'Ectopia lentis', 'Arachnodactyly', 'Intellectual disability', 'Ataxia', 'Dysarthria', 'Gait disturbance', 'Abnormal pyramidal sign', 'Brain atrophy', 'Scleral staphyloma', 'Flushing']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective collagen cross-linking due to cystathionine beta-synthase (CBS) deficiency.  
2. **Arachnodactyly and Myopia**: Connective tissue abnormalities from disrupted sulfur metabolism, mimicking Marfan-like features but with distinct metabolic etiology.  
3. **Intellectual disability, Ataxia, Dysarthria, Gait disturbance**: Reflect chronic CNS involvement due to homocysteine neurotoxicity, vascular insults, or secondary folate deficiency.  
4. **Brain atrophy and Abnormal pyramidal signs**: Long-standing metabolic derangement leads to neuronal loss and corticospinal tract damage.  
5. **Exotropia and Scleral staphyloma**: Ocular connective tissue weakness and lens displacement contribute to strabismus and scleral thinning.  
6. **Flushing**: Potentially linked to endothelial dysfunction from elevated homocysteine levels affecting vasoregulation.  
7. **Exclusion of mimics**: Differentiated from Marfan syndrome (no aortic root dilation) and other metabolic disorders (e.g., sulfite oxidase deficiency) by the combination of biochemical, ocular, and neuropsychiatric features.  
**Conclusion**: The constellation of connective, ocular, neurological, and vascular symptoms aligns with CBS-deficient homocystinuria, confirmed by elevated plasma homocysteine and low methionine levels. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Polycystic ovaries', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Hypertyrosinemia', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash** and **eczematoid dermatitis** align with PKU’s dermatologic manifestations due to metabolite accumulation and impaired skin barrier function.  
3. **Gastrointestinal inflammation**, **vomiting**, and **diarrhea** may reflect dietary protein intolerance or metabolic stress from phenylalanine toxicity.  
4. **Generalized hypotonia** and **obesity** correlate with untreated PKU’s neurologic sequelae and restrictive dietary management (high-carbohydrate diets).  
5. **Recurrent viral infections** could stem from secondary immune dysfunction due to chronic metabolic imbalance.  
6. **Death in infancy/childhood/adolescence/early adulthood** reflects untreated PKU’s natural history, involving severe neurodegeneration, organ failure, or complications like seizures.  
7. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants (e.g., PAH deficiency with secondary tyrosine dysregulation) or coexisting metabolic stressors.  
8. **Polycystic ovaries** and **pustules** are less specific but may arise from hormonal disruptions or inflammatory responses linked to chronic metabolic derangement.  

Note: While some symptoms (e.g., hypertyrosinemia) suggest overlap with tyrosinemia or BH4 deficiency, the definitive diagnosis of PKU is prioritized due to **hyperphenylalaninemia** as the central finding. Early fatality timelines emphasize untreated/severe disease progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Transitional cell carcinoma of bladder is associated with -a) Schistosomiasisb) Naphthylaminec) Smokingd) Tuberculosis of bladder
Choices:
A. ab
B. abc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Causes of Nephrogenic Diabetes Insipidus all except
Choices:
A. Sheehan's syndrome
B. Amyloidosis
C. Polycystic kidney Disease
D. Lithium
Answer: [/INST] Sheehan's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Coma', 'Hyporeflexia', 'Generalized hypotonia', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Hyperammonemia', 'Respiratory distress', 'Cerebral edema', 'Fasciculations', 'Increased total bilirubin', 'Prolonged partial thromboplastin time', 'Neonatal death', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating glutamine concentration', 'Abnormal circulating citrulline concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Classic Citrullinemia)  
Reasoning:  
1. **Hyperammonemia** and **metabolic acidosis** are hallmark features of urea cycle disorders (UCDs). Citrullinemia type I results from **argininosuccinate synthetase (ASS) deficiency**, disrupting the urea cycle.  
2. **Abnormal circulating citrulline concentration** (severely elevated) directly reflects the enzyme defect, as citrulline cannot be converted to argininosuccinate.  
3. **Abnormal glutamine** (elevated) and **aspartate family amino acids** (disrupted) align with urea cycle dysfunction, as glutamine acts as an ammonia buffer.  
4. **Cerebral edema** and **coma** are secondary to ammonia neurotoxicity. **Respiratory distress** may arise from ammonia-induced central hyperventilation or metabolic acidosis compensation.  
5. **Generalized hypotonia**, **hyporeflexia**, and **fasciculations** reflect acute neurological injury from hyperammonemia.  
6. **Neonatal death** and **death in infancy** are typical in untreated classic citrullinemia due to rapid ammonia accumulation and multiorgan failure.  
7. **Prolonged PTT** and **increased bilirubin** suggest hepatic dysfunction, a known complication of UCDs.  
8. **Tachycardia** and **metabolic acidosis** correlate with systemic metabolic decompensation.  

The absence of liver-specific markers (e.g., citrin deficiency in type II) and the neonatal presentation confirm **Citrullinemia type I**. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Erythroderma', 'Global developmental delay', 'Hyperreflexia', 'Opisthotonus', 'Generalized-onset seizure', 'Short stature', 'Disproportionate short-limb short stature', 'Fetal distress', 'Oligoclonal T cell expansion', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Skeletal Features**: Disproportionate short-limb short stature and short stature align with skeletal dysplasia, a hallmark of ISDNA.  
2. **Neurodevelopmental Abnormalities**: Global developmental delay, hyperreflexia, opisthotonus, and generalized-onset seizures indicate severe neurological involvement, consistent with ISDNA's neurodevelopmental phenotype.  
3. **Immune Dysregulation**: Oligoclonal T cell expansion and sepsis suggest immunodeficiency, while erythroderma may reflect inflammatory T-cell dysregulation, all characteristic of ISDNA's immune pathology.  
4. **Prenatal Onset**: Fetal distress supports a congenital disorder, fitting ISDNA's genetic etiology (EXOC6B mutations).  
5. **Integration**: The triad of skeletal, neurological, and immune abnormalities distinguishes ISDNA from isolated skeletal dysplasias, neurodevelopmental disorders, or primary immunodeficiencies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Elevated plasma citrulline', 'Uraciluria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The combination of **hyperammonemia**, **elevated plasma citrulline**, and **uraciluria** strongly indicates a urea cycle disorder (UCD). Citrullinemia is characterized by a defect in **argininosuccinate synthetase (ASS1)**, which prevents the conversion of citrulline to argininosuccinate. This results in citrulline accumulation (elevated plasma citrulline) and ammonia buildup (hyperammonemia). Uraciluria occurs due to secondary pyrimidine metabolism disruption. Neonatal lethality and early childhood death align with severe metabolic decompensation in untreated UCDs.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Type I (classic citrullinemia) is distinguished by **neonatal-onset** symptoms, including rapid neurological decline, hyperammonemic crises, and biochemical features like extreme citrulline elevation (often >1,000 µmol/L). The prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality (infancy/childhood) correlate with the severe enzymatic deficiency in ASS1. Type II (citrin deficiency) typically presents later in life and lacks uraciluria, ruling it out here. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Elevated urinary carboxylic acid** is a hallmark of impaired carboxylase function. Biotinidase deficiency prevents biotin recycling, a coenzyme required for carboxylases (propionyl-CoA carboxylase, pyruvate carboxylase), leading to accumulation of unmetabolized substrates (e.g., lactic acid, 3-hydroxyisovaleric acid) in urine.  
2. **Neonatal death/Death in infancy** aligns with untreated BTDD, as biotin-dependent metabolic pathways (e.g., fatty acid synthesis, gluconeogenesis) are disrupted, causing metabolic acidosis, seizures, and organ failure.  
3. **Late-onset multiple carboxylase deficiency** refers to BTDD’s postnatal presentation (vs. holocarboxylase synthetase deficiency, which manifests prenatally). Without biotin supplementation, rapid decompensation in early infancy is typical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperalaninemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Hyperalaninemia**: Elevated alanine levels suggest disrupted amino acid metabolism, often secondary to energy crises from impaired fatty acid oxidation (FAO). MCADD disrupts medium-chain fatty acid breakdown, forcing reliance on glycolysis, increasing pyruvate (converted to alanine).  
2. **Abnormal circulating carnitine**: MCADD causes secondary carnitine deficiency due to accumulation of medium-chain acylcarnitines, which are excreted in urine, depleting free carnitine.  
3. **Neonatal/infant/childhood death**: MCADD presents with life-threatening hypoglycemia and metabolic decompensation during fasting (e.g., infections), leading to sudden death if untreated.  
4. **Small for gestational age (SGA)**: Impaired placental fatty acid metabolism in MCADD may restrict fetal energy supply, causing growth restriction.  
5. **Severe hearing impairment**: Rarely reported in MCADD but may occur due to metabolic acidosis or energy deficits affecting cochlear function during crises.  
6. **Exclusion of alternatives**: Symptoms align with FAO disorders (not urea cycle defects or mitochondrial diseases). MCADD is the most common FAO defect with this phenotype.  

Key diagnostic confirmation would require plasma acylcarnitine profiling (elevated C6-C10 species, especially C8) and genetic testing for *ACADM* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dracunculosis infection occurs through?
Choices:
A. Ingestion of water containing cyclops
B. Ingestion of water containing the parasite
C. Ingestion of fish
D. Penetration of skin
Answer: [/INST] Ingestion of water containing cyclops </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Galactosemia enzyme defect:
Choices:
A. Fructokinase
B. Glucokinase
C. Galactose 1 Phosphate Uridyl transferase
D. Glucose 6 Phosphatase
Answer: [/INST] Galactose 1 Phosphate Uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Trophic ulcers are seen in a/e -a) Poliob) Syringomyeliac) Leprosyd) TB. Meningitis
Choices:
A. b
B. c
C. ad
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Micropenis', 'Microretrognathia', 'Incomplete partition of the cochlea type II', 'Retinal coloboma', 'Generalized hypotonia', 'Congestive heart failure', 'Dysphagia', 'Gastroesophageal reflux', 'Poor suck', 'Neonatal respiratory distress', 'Respiratory failure', 'Facial palsy', 'Aplasia of the semicircular canal']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: CHARGE syndrome/Charge syndrome  
Reasoning:  
1. **Coloboma**: Retinal coloboma is a hallmark feature of CHARGE syndrome, directly aligning with the ""C"" in the acronym.  
2. **Heart defects**: Congestive heart failure suggests congenital heart anomalies, corresponding to the ""H"" (Heart defects).  
3. **Genital hypoplasia**: Cryptorchidism and micropenis fulfill the ""G"" (Genital anomalies) criterion.  
4. **Ear abnormalities**: Incomplete partition of the cochlea type II and aplasia of the semicircular canal are characteristic inner ear malformations linked to the ""E"" (Ear anomalies).  
5. **Cranial nerve dysfunction**: Facial palsy and dysphagia/poor suck indicate cranial nerve involvement (CN VII, IX, X), common in CHARGE.  
6. **Multi-system involvement**: Neonatal respiratory distress, hypotonia, gastroesophageal reflux, and microretrognathia reflect the syndrome’s broad impact on respiratory, neuromuscular, and craniofacial systems.  
7. **Diagnostic criteria**: While choanal atresia (""A"") is not explicitly listed, the combination of major features (coloboma, semicircular canal hypoplasia) and minor features (heart defects, facial palsy) meets clinical diagnostic criteria for CHARGE syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Seizure', 'Spasticity', 'Death in infancy', 'Alopecia', 'Dyspnea', 'Fatigue', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acid**: Directly links to impaired carboxylase function (propionyl-CoA carboxylase, pyruvate carboxylase, etc.), which require biotin as a cofactor. Deficiency reduces enzyme activity, causing organic acid accumulation.  
2. **Seizures & spasticity**: Neurological manifestations arise from metabolic acidosis, hyperammonemia, or disrupted neurotransmitter synthesis due to defective biotin-dependent enzymes.  
3. **Alopecia**: Biotin is critical for keratin synthesis; deficiency leads to hair fragility and loss.  
4. **Dyspnea & fatigue**: Metabolic acidosis from accumulated organic acids triggers respiratory compensation (Kussmaul breathing) and systemic energy depletion.  
5. **Apathy**: Reflects global encephalopathy secondary to metabolic derangements.  
6. **Death in infancy**: Untreated BTDD causes progressive neurological decline, metabolic crises, and fatal outcomes without biotin supplementation.  
7. **Late-onset presentation**: Aligns with partial biotinidase deficiency, where symptoms manifest after the neonatal period but escalate rapidly without intervention.  

The constellation of metabolic, neurological, and dermatological signs, coupled with urinary carboxylic acid elevation, is pathognomonic for biotinidase deficiency. Early biotin replacement reverses symptoms, underscoring the urgency of diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is NOT a common cause of Meningitis in adults?
Choices:
A. Group B streptococcus
B. Mycobacterium tuberculosis
C. Staph. aureus/H. influenza
D. Str. pyogenes -- Group A
Answer: [/INST] Str. pyogenes -- Group A </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy commonly affects all organs except:
Choices:
A. Ovary
B. Skin
C. Nerves
D. Eye
Answer: [/INST] Ovary </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Dystonia', 'Abnormal cerebral morphology', 'Glutaric aciduria', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal myelination']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Directly links to GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Neurological symptoms (Ataxia, Dystonia)**: Toxic metabolites damage the basal ganglia and striatum, causing movement disorders.  
3. **Abnormal cerebral morphology**: Macrocephaly (often seen in infancy) and frontotemporal atrophy due to metabolic injury.  
4. **Decreased plasma free carnitine**: Secondary carnitine deficiency occurs as carnitine binds to glutaric acid for excretion.  
5. **Abnormal myelination**: Delayed or disrupted white matter development from neurotoxic metabolites.  
6. **Death in childhood**: Untreated GA-I leads to irreversible neurological damage, metabolic crises, and early mortality.  
7. **Consistency with GA-I**: Symptom constellation (organic aciduria, neurological deficits, imaging findings) is pathognomonic for this disorder. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mode of transmission of Q fever:
Choices:
A. Ticks
B. Mites
C. Aerosols
D. Mosquito
Answer: [/INST] Ticks </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis complex include all except -
Choices:
A. M. tuberculosis
B. M. bovis
C. M. kansasii
D. M. microti
Answer: [/INST] M. kansasii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following are histopathological features of Extra hepatic Biliary Atresia -a) Bile lakesb) Hepatocyte ballooning degenerationc) Marked bile duct proliferationd) Fibrosis of hepatic ducte) Parenchymal cholestasis
Choices:
A. cde
B. acd
C. bde
D. ade
Answer: [/INST] cde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid ulcer ruptures at
Choices:
A. 1st week
B. 2nd week
C. 3rd week
D. 4th week
Answer: [/INST] 3rd week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death/Death in infancy** aligns with untreated severe PKU, where elevated phenylalanine levels cause irreversible neurological damage, seizures, and metabolic crises if undiagnosed and unmanaged (e.g., absent newborn screening).  
3. **Abnormality of prenatal development or birth** may reflect complications in maternal PKU (uncontrolled phenylalanine levels during pregnancy), but here it likely indicates postnatal developmental failure due to early metabolic dysfunction in the infant.  
4. PKU is typically asymptomatic at birth but manifests progressively after feeding; rapid deterioration without dietary intervention (low-phenylalanine diet) explains the fatal outcomes listed.  

*Note:* Confirmation requires genetic testing (PAH gene mutations) and newborn screening results (elevated phenylalanine with normal tyrosine). Early treatment prevents severe outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is closely associated with which of the following: September 2011, March 2013 (f, h)
Choices:
A. Silicosis
B. Anthracosis
C. Byssinosis
D. Asbestosis
Answer: [/INST] Asbestosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is enrichment media for Vibrio Cholera?
Choices:
A. Venkatraman-Ramakrishnan medium
B. Cary-Blair medium
C. Autoclaved sea water
D. Alkaline peptone water
Answer: [/INST] Alkaline peptone water </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria causing nephrotic syndrome -
Choices:
A. P. vivax
B. P. Falciparum
C. P. malariae
D. P. Ovale
Answer: [/INST] P. malariae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Allergic bronchopulmonary Aspergillosis is commonly a complication of:
Choices:
A. TB
B. Bronchogenic carcinoma
C. Cystic fibrosis
D. Wegener's granulomatosis
Answer: [/INST] Cystic fibrosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Micrognathia', 'Delayed eruption of primary teeth', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cleidocranial dysplasia/Cleidocranial dysplasia  
Reasoning:  
1. **Cranial and Skull Abnormalities**: Large fontanelles, parietal/frontal bossing, Wormian bones, and metopic depression align with CCD's hallmark delayed cranial suture closure and defective ossification.  
2. **Dental Manifestations**: Delayed eruption of primary teeth and enamel hypoplasia are classic CCD features due to disrupted osteoclast activity and dental follicle abnormalities.  
3. **Clavicular Defects**: Short clavicles (often hypoplastic/aplastic) explain the ""abnormal facility in opposing the shoulders.""  
4. **Skeletal Dysplasia**: Hypoplastic iliac wings, short stature, scoliosis, broad femoral heads, and short femoral necks reflect generalized skeletal hypoplasia and abnormal bone growth.  
5. **Facial Dysmorphism**: Midface retrusion, depressed nasal bridge, hypertelorism, and micrognathia result from craniofacial bone underdevelopment.  
6. **Pelvic and Pubic Involvement**: Delayed pubic bone ossification and hypoplastic iliac wings are consistent with CCD's pelvic radiographic findings.  
7. **Rule-Out Considerations**: While some features (e.g., Wormian bones) overlap with osteogenesis imperfecta, the combination of clavicular, dental, and cranial defects is pathognomonic for CCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis first occurs in :-
Choices:
A. Metaphysis
B. Epiphysis
C. Diaphysis
D. All of above
Answer: [/INST] Metaphysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia A is caused due to deficiency of
Choices:
A. Factor X
B. Factor XI
C. Factor IX
D. Factor VIII
Answer: [/INST] Factor VIII </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cysticercosis is caused by:
Choices:
A. T. Solium
B. T. Saginata
C. A. duodenale
D. E. granulosus
Answer: [/INST] T. Solium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is?
Choices:
A. Sleep walking
B. Sleeptalking
C. Increased day time sleep
D. Sleep terrors
Answer: [/INST] Increased day time sleep </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are a complication of Typhoid ulcer, EXCEPT -
Choices:
A. Perforation
B. Stricture
C. Haemorrhage
D. Sepsis
Answer: [/INST] Stricture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Two days after delivery, a 4300-g (9-lb 8-oz) newborn has difficulty feeding and has become increasingly lethargic. His cry has become weak. He was born at term. His mother has a history of intravenous drug use. His temperature is 36.4°C (96.5°F), pulse is 170/min, respirations are 62/min, and blood pressure is 70/48 mm Hg. Examination shows midfacial hypoplasia, diaphoresis, and tremor of the lower extremities. Macroglossia is present. There are folds in the posterior auricular cartilage. The left lower extremity is larger than the right lower extremity. Abdominal examination shows an umbilical hernia. The liver is palpated 4 cm below the right costal margin. Neurological examination shows decreased tone in all extremities. Which of the following is the most appropriate intervention?
Choices:
A. Administer thyroxine.
B. Administer 3% saline.
C. Administer glucose.
D. Administer ampicillin and gentamicin.
Answer: [/INST] Administer glucose. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Hypertyrosinemia** is atypical in classic PKU but may occur in **tetrahydrobiopterin (BH4) deficiency**, a PKU variant. BH4 is a cofactor for PAH *and* tyrosine hydroxylase; its deficiency disrupts both phenylalanine and tyrosine metabolism, leading to dual accumulation.  
3. **Death in early adulthood** aligns with severe, untreated PKU or BH4 deficiency, where neurological damage, metabolic crises, or secondary complications (e.g., cardiac, hepatic) lead to premature mortality.  
4. The combined symptoms suggest **malignant PKU (BH4 deficiency)**, classified under PKU spectrum disorders due to shared hyperphenylalaninemia and clinical overlap.  

Disease: BH4 Deficiency (as a subtype of PKU)  
Reasoning:  
1. Directly links elevated phenylalanine *and* tyrosine via dual enzyme disruption (PAH and tyrosine hydroxylase).  
2. Explains rapid progression and early mortality due to neurotransmitter synthesis defects and systemic metabolic failure.  
3. Often grouped with PKU in diagnostic frameworks despite distinct molecular pathology.  

**Final Diagnosis**: PKU (with BH4 deficiency as the underlying subtype). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Petechiae', 'Thrombocytopenia', 'Leukocytosis', 'Headache', 'Vasculitis', 'Elevated hepatic transaminase', 'Smooth muscle antibody positivity', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Decreased circulating complement C3 concentration', 'Viral hepatitis', 'Peripheral neuropathy', 'Pedal edema', 'Elevated circulating C-reactive protein concentration', 'Fatigue', 'Lower limb pain', 'Foot pain', 'Antimitochondrial antibody positivity', 'Decreased circulating complement C4 concentration', 'Abnormality of nail color', 'Cryoglobulinemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cryoglobulinemic vasculitis/Cryoglobulinemia, familial mixed  
Reasoning:  
1. **Cryoglobulinemia**: Directly listed as a symptom, indicating abnormal immunoglobulin complexes precipitating in cold temperatures.  
2. **Vasculitis**: Present and central to the diagnosis; explains petechiae, peripheral neuropathy, and organ involvement (e.g., liver via elevated transaminases).  
3. **Complement consumption**: Decreased C3/C4 levels suggest immune complex deposition, a hallmark of cryoglobulinemic vasculitis.  
4. **Autoimmune markers**: Smooth muscle antibody (SMA), antinuclear antibody (ANA), and antimitochondrial antibody (AMA) positivity indicate autoimmune dysregulation, though AMA may overlap with viral hepatitis.  
5. **Viral hepatitis**: A common trigger for mixed cryoglobulinemia (often hepatitis C), linking liver injury and cryoglobulin production.  
6. **Inflammation**: Elevated ESR, CRP, leukocytosis, and fatigue align with systemic inflammation from vasculitis.  
7. **Cutaneous/neurologic involvement**: Petechiae, nail discoloration, peripheral neuropathy, and limb pain reflect small-vessel damage.  
8. **Familial component**: ""Familial mixed"" suggests genetic predisposition, though viral cofactors (hepatitis) may drive disease expression.  
9. **Renal/edema**: Pedal edema hints at possible renal involvement (glomerulonephritis) secondary to cryoglobulin deposition.  

The constellation of immune complexes, vasculitis, hepatitis, and complement abnormalities confirms **cryoglobulinemic vasculitis**, with familial mixed type indicating hereditary susceptibility. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Nystagmus', 'Intellectual disability', 'Ataxia', 'Hyporeflexia', 'Motor delay', 'Cerebellar atrophy', 'Generalized hypotonia', 'Encephalopathy', 'Growth delay', 'Death in infancy', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: Core feature of PMM2-CDG, caused by impaired glycosylation critical for cerebellar development.  
2. **Ataxia, motor delay, hypotonia, hyporeflexia**: Directly linked to cerebellar dysfunction and neuromuscular involvement.  
3. **Strabismus/nystagmus**: Ocular motor abnormalities due to cerebellar/brainstem malformations.  
4. **Encephalopathy**: Metabolic instability from glycosylation defects affecting multiple organ systems.  
5. **Intellectual disability/growth delay**: Result from systemic glycosylation failure impacting neurodevelopment and metabolism.  
6. **Death in infancy**: Severe PMM2-CDG phenotypes often lead to early mortality due to multiorgan failure.  
7. **Consistency with PMM2-CDG**: The triad of cerebellar anomalies, neurodevelopmental deficits, and multisystem involvement aligns with type Ia CDG pathophysiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis of hea presents with -
Choices:
A. Arrhythmia
B. AV block
C. |Ed mass/voltage
D. AS
Answer: [/INST] Arrhythmia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Reduced eye contact', 'Seizure', 'Hypotonia', 'Hypoplasia of the corpus callosum', 'EEG abnormality', 'Sleep disturbance', 'Bruxism', 'Hypoplasia of the frontal lobes', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Core symptoms of Rett syndrome**: Abnormal repetitive mannerisms (e.g., hand stereotypies), delayed speech/language development, and reduced eye contact align with Rett syndrome's hallmark features.  
2. **Neurological involvement**: Seizures, EEG abnormalities, and hypotonia are common in Rett syndrome due to mutations in *MECP2* or related genes, affecting neuronal function.  
3. **Structural brain anomalies**: Hypoplasia of the corpus callosum and frontal lobes is consistent with congenital variants of Rett syndrome, where severe neurodevelopmental abnormalities occur early.  
4. **Supportive features**: Sleep disturbances, bruxism, and feeding difficulties are frequently observed in Rett syndrome due to autonomic dysfunction and oral-motor challenges.  
5. **Differentiation from classic Rett**: The congenital variant lacks the typical regression phase, presenting with severe delays and structural brain defects from infancy, matching the patient’s profile.  
6. **Exclusion of mimics**: CDKL5 deficiency or Angelman syndrome could overlap but are less likely given corpus callosum hypoplasia and frontal lobe involvement, which strongly suggest Rett spectrum disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abdominal pain', 'Elevated urinary delta-aminolevulinic acid', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Acute intermittent porphyria/Porphyria, acute intermittent  
Reasoning: Abdominal pain is a hallmark of acute neurovisceral attacks in acute intermittent porphyria (AIP). Elevated urinary delta-aminolevulinic acid (ALA) aligns with AIP’s pathophysiology, where a deficiency in porphobilinogen deaminase (PBGD) causes accumulation of ALA and porphobilinogen (PBG). While AIP typically manifests post-puberty, severe childhood-onset cases can lead to fatal complications like respiratory paralysis or electrolyte imbalances, explaining early mortality.  

Disease: Porphyria/Porphyria  
Reasoning: Elevated urinary ALA is nonspecific and occurs in multiple porphyrias. If PBG levels were not measured, broader porphyria classification is appropriate. Death in childhood could suggest rare, severe forms like ALAD-deficiency porphyria (ADP), which also elevates ALA but lacks PBG elevation. However, ADP is not explicitly listed, so ""porphyria"" serves as a general diagnosis when subtype confirmation is incomplete. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Q fever is caused by -
Choices:
A. Pseudomonas
B. Francisella
C. Coxiella burnetii
D. Rickettsia typhi
Answer: [/INST] Coxiella burnetii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following inclusion body is seen in a patient with Rabies?
Choices:
A. Cowdry-B
B. Negri bodies
C. Guarneri bodies
D. Bollinger bodies
Answer: [/INST] Negri bodies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Abnormality of urine homeostasis', 'Neonatal death', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Delayed speech and language development**: Biotinidase deficiency causes neurological impairments, including developmental delays, due to disrupted biotin-dependent carboxylase activity, affecting myelination and neurotransmitter synthesis.  
2. **Abnormality of prenatal development or birth**: While BTDD is typically postnatal in presentation, severe metabolic instability from untreated disease may manifest as perinatal complications or nonspecific congenital anomalies.  
3. **Death in infancy/Neonatal death/Death in childhood**: Untreated BTDD leads to progressive metabolic acidosis, hyperammonemia, and organic aciduria, culminating in fatal metabolic crises or sepsis. Neonatal death may occur if diagnosis is delayed.  
4. **Abnormality of urine homeostasis**: Accumulation of organic acids (e.g., 3-hydroxyisovaleric acid) disrupts renal acid-base regulation, causing metabolic acidosis and abnormal urinary organic acid profiles.  

**Conclusion**: The constellation of metabolic instability, neurological regression, and fatal outcomes aligns with biotinidase deficiency. Early-onset symptoms (e.g., urine abnormalities, developmental delays) and rapid progression without biotin supplementation explain the listed features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A Child presented with Adenoma sebaceum and intractable seizures. MRI showed sub ependymal giant cell Astrocytomas. Cause is
Choices:
A. Tuberous sclerosis
B. Neurofibromatosis
C. Sturge Weber syndrome
D. Von-Hippel Lindau syndrome
Answer: [/INST] Tuberous sclerosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratoconus is associated with all except-
Choices:
A. Down's syndrome
B. Ehlers-Danlos' syndrome
C. Marfan's syndrome
D. Usher's syndrome
Answer: [/INST] Usher's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Enzyme deficiency in Galactosemia:
Choices:
A. Galactose 1 phosphate uridyl transferase
B. Aldolase B
C. UDP galactose 4 epimerase
D. Fructokinase
Answer: [/INST] Galactose 1 phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Death in infancy', 'Dehydration', 'Fever', 'Diarrhea', 'Opisthotonus', 'Athetosis', 'Progressive neurologic deterioration', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating acetylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Core biochemical markers**: Elevated glutaric acid (glutaric aciduria, elevated circulating glutaric acid) and carnitine deficiency (decreased plasma free carnitine, abnormal acetylcarnitine) directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
2. **Neurological features**: Ataxia, opisthotonus, athetosis, and progressive neurologic deterioration align with basal ganglia damage, a hallmark of GA-I due to toxic metabolite accumulation (glutaric acid, 3-hydroxyglutaric acid).  
3. **Metabolic crises**: Fever, dehydration, and diarrhea are typical triggers of acute metabolic decompensation in GA-I, exacerbating neurological injury.  
4. **Early mortality**: Death in infancy/childhood reflects untreated GA-I’s severe natural course, as crises lead to irreversible brain damage.  
5. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., GA-II lacks prominent basal ganglia injury) and confirm GA-I’s distinct phenotype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Multiple Sclerosis is associated with all of the following, Except
Choices:
A. Hydrocephalus
B. Optic Neuritis
C. Spasticity
D. Spinal cord involvement
Answer: [/INST] Hydrocephalus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The drug of choice in Cryptococcal Meningitis is -
Choices:
A. Pentostatin
B. Amphotericin B
C. Clotrimazole
D. Zidovudine
Answer: [/INST] Amphotericin B </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dense calcification is found in -a) Osteosarcomab) Chondroblastomac) Synovial sarcomad) Osteoblastoma
Choices:
A. abd
B. bcd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dracunculosis infection occurs through -
Choices:
A. Ingestion of water containing cyclops
B. Ingestion of water containing the parasite
C. Ingestion of fish
D. Penetration of skin
Answer: [/INST] Ingestion of water containing cyclops </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Radiologic feature suggestive of Achalasia cardia is?
Choices:
A. Absence of gastric air bubble
B. Air fluid level in mediastinum
C. Sigmoid ecophagus
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal paranasal sinus morphology', 'Epistaxis', 'Abnormal nasal mucosa morphology', 'Hemoptysis', 'Sneeze', 'Elbow pain', 'Knee pain', 'Ankle pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis  
**Reasoning**:  
1. **Upper respiratory involvement**: Symptoms like *abnormal paranasal sinus morphology*, *epistaxis*, and *abnormal nasal mucosa morphology* are hallmarks of GPA, which commonly causes necrotizing granulomatous inflammation in the sinuses and nasal passages.  
2. **Lower respiratory tract involvement**: *Hemoptysis* suggests alveolar hemorrhage due to pulmonary vasculitis, a critical feature of GPA.  
3. **Systemic vasculitis**: Joint pain (*elbow, knee, ankle*) reflects systemic inflammation affecting small- to medium-sized vessels, consistent with GPA’s multisystemic nature.  
4. **Exclusion of mimics**: The absence of asthma/eosinophilia (ruling out eosinophilic GPA) and the prominence of upper respiratory + joint symptoms distinguish GPA from other vasculitides (e.g., microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis).  
5. **Triad alignment**: GPA classically presents with necrotizing granulomas of the respiratory tract, vasculitis, and glomerulonephritis (not listed here, but not all features are required for diagnosis). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cerebellar atrophy', 'Generalized hypotonia', 'Tachycardia', 'Cardiac arrest', 'Skeletal muscle atrophy', 'Death in childhood', 'Recurrent viral infections', 'Aplasia/Hypoplasia involving the musculature of the extremities', 'Cerebellar agenesis', 'Increased urinary glycerol']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Isolated glycerol kinase deficiency/Glycerol kinase deficiency  
Reasoning:  
1. **Increased urinary glycerol** is pathognomonic for glycerol kinase deficiency (GKD), as the enzyme deficiency prevents glycerol metabolism, leading to its urinary excretion.  
2. **Skeletal muscle atrophy** and **generalized hypotonia** align with impaired energy production due to disrupted glycerol utilization in muscle tissue.  
3. **Aplasia/Hypoplasia of extremity musculature** suggests developmental metabolic dysfunction affecting muscle formation.  
4. **Cardiac arrest** and **tachycardia** may result from metabolic crises or cardiomyopathy secondary to energy deficits in cardiac tissue.  
5. **Recurrent viral infections** could reflect episodic metabolic decompensation weakening immune resilience.  
6. **Death in childhood** correlates with severe metabolic instability or cardiac complications in untreated GKD.  
7. **Cerebellar atrophy/agenesis** is atypical for isolated GKD but may represent a phenotypic variant or comorbid condition, though the primary diagnosis is anchored by urinary glycerol elevation and metabolic features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the kidney', 'Overfolded helix', 'Macrotia', 'Choanal atresia', 'Abnormality of the eye', 'Strabismus', 'Visual impairment', 'Hypermetropia', 'Upslanted palpebral fissure', 'Delayed speech and language development', '11 pairs of ribs', 'Brachydactyly', 'Hypotonia', 'Global developmental delay', 'Generalized hypotonia', 'Obesity', 'Atrial septal defect', 'Short foot', 'Asthma', 'Scoliosis', 'Tracheomalacia', 'Hypoventilation', 'Short stature', 'Preauricular pit', 'Central hypoventilation', 'Abnormal eye morphology', 'Abnormality of brain morphology', 'Hyperconvex toenail', 'Cerebral visual impairment', 'Small hand', 'Menometrorrhagia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart  
Reasoning:  
1. **Neurodevelopmental features**: Global developmental delay, delayed speech and language development, hypotonia, and cerebral visual impairment align with core neurodevelopmental deficits.  
2. **Brain morphology abnormality**: Hypotonia, central hypoventilation, and cerebral visual impairment suggest central nervous system involvement.  
3. **Eye anomalies**: Visual impairment, strabismus, hypermetropia, abnormal eye morphology, and upslanted palpebral fissures indicate structural and functional ocular defects.  
4. **Cardiac involvement**: Atrial septal defect directly correlates with the ""heart"" component of the diagnosis.  
5. **Craniofacial/skeletal features**: Overfolded helix, macrotia, preauricular pit, brachydactyly, short foot, small hand, and 11 pairs of ribs reflect multisystem congenital anomalies typical of syndromic neurodevelopmental disorders.  
6. **Systemic associations**: Obesity, short stature, tracheomalacia, and choanal atresia further support a genetic syndrome affecting multiple organ systems.  
7. **Exclusion of alternatives**: The constellation of symptoms (e.g., absence of pathognomonic signs for Rett, Down, or CHARGE syndromes) and the specificity of brain-eye-heart anomalies prioritize this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: TSS (Toxic Shock Syndrome) is caused mainly by:
Choices:
A. Streptococci
B. Staphylococci
C. Pneumococci
D. Pseudomonas
Answer: [/INST] Staphylococci </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not true about Osteosarcoma
Choices:
A. Associated with Hyperglycemia
B. Sun burst appearance on x-ray
C. Pulsatile bone tumor
D. Osteitis imperfecta has increased risk of transforming into osteosarcoma
Answer: [/INST] Osteitis imperfecta has increased risk of transforming into osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Intellectual disability', 'Ataxia', 'Motor delay', 'Cerebellar atrophy', 'Obesity', 'Death in infancy', 'Thromboembolism', 'Death in childhood', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: A hallmark of PMM2-CDG, caused by abnormal glycosylation critical for cerebellar development and function.  
2. **Ataxia and motor delay**: Directly linked to cerebellar dysfunction and neurodevelopmental deficits.  
3. **Intellectual disability**: Reflects global neurological impairment due to glycosylation defects affecting brain development.  
4. **Strabismus**: Common in PMM2-CDG due to oculomotor control abnormalities from cerebellar/brainstem involvement.  
5. **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
6. **Obesity**: Observed in some cases, potentially from hypothalamic-pituitary dysfunction or metabolic dysregulation.  
7. **Death in infancy/childhood**: Severe multisystemic involvement (liver failure, cardiomyopathy, infections) can lead to early mortality.  
8. **Supporting specificity**: The combination of neurodevelopmental, cerebellar, and coagulation abnormalities is pathognomonic for PMM2-CDG-Ia, distinguishing it from other CDG subtypes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis most commonly affects
Choices:
A. Liver
B. Tongue
C. Colon
D. Hea
Answer: [/INST] Hea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by deficient activity of phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth**: Untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) due to phenylalanine toxicity to the developing fetus.  
3. **Death in infancy/childhood**: Severe, untreated PKU causes irreversible neurological damage, seizures, and failure to thrive. Historically, before newborn screening and dietary management, elevated phenylalanine levels led to early mortality.  
4. **Consistency with PKU**: The combination of hyperphenylalaninemia and severe outcomes aligns with classic PKU pathophysiology. Early diagnosis via newborn screening and strict dietary intervention prevent these complications. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the site of Venous Thrombosis in Budd Chiari Syndrome?
Choices:
A. Infrahepatic inferior vena cava
B. Infrarenal inferior vena cava
C. Hepatic vein
D. Poal vein
Answer: [/INST] Hepatic vein </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the inheritance of Incontinentia Pigmenti
Choices:
A. AD
B. AR
C. X-linked dominant
D. X-linked recessive
Answer: [/INST] X-linked dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Microcephaly', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Smith-Lemli-Opitz syndrome:  
1. **Biochemical markers**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol, along with hypocholesterolemia, are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS). These result from a deficiency in 7-dehydrocholesterol reductase (DHCR7), which blocks cholesterol synthesis.  
2. **Congenital anomalies**: Hypospadias and microcephaly align with SLOS-associated malformations caused by disrupted cholesterol-dependent embryogenesis.  
3. **Neurological features**: Generalized hypotonia and motor delay reflect abnormal neurodevelopment due to cholesterol deficiency, critical for myelination and synaptic function.  
4. **Feeding difficulties and lethality**: Poor feeding, neonatal death, and infant mortality are common in severe SLOS cases, often due to multiorgan failure or metabolic instability from critically low cholesterol.  
5. **Consistency with phenotype**: The combination of dysmorphic features, biochemical abnormalities, and early lethality strongly supports SLOS as the definitive diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cleft lip, polydactyly, Holoprosencephaly are characteristic feature of?
Choices:
A. Down syndrome
B. Edward syndrome
C. Patau syndrome
D. Turners syndrome
Answer: [/INST] Patau syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: National Leprosy Eradication Programme was staed in -
Choices:
A. 1949
B. 1955
C. 1973
D. 1983
Answer: [/INST] 1983 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Distant metastasis in Retinoblastoma is commonly seen in: September 2012
Choices:
A. Long bones
B. Lungs
C. Brain
D. Liver
Answer: [/INST] Brain </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vectors for Plague transmission
Choices:
A. X. cheopis
B. X. astia
C. Pulex irritans
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia may be a feature of all following diseases, except -
Choices:
A. Addison's disease
B. Cushing's syndrome
C. Barter's syndrome
D. Gitelman's syndrome
Answer: [/INST] Addison's disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: False about Q fever
Choices:
A. Causative agent is Coxiella burnetii
B. Incubation period is 2-3 weeks
C. Vector is louse
D. Mode of transmission is inhalation of infected dust
Answer: [/INST] Vector is louse </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Hypertelorism', 'Downslanted palpebral fissures', 'Spasticity', 'Morphological central nervous system abnormality', 'Chorea', 'Restrictive ventilatory defect', 'Posterior rib gap']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cerebrocostomandibular Syndrome: The patient presents with cleft palate and Pierre-Robin sequence (micrognathia, glossoptosis, airway obstruction), which are hallmark craniofacial features of CCMS. Posterior rib gaps and restrictive ventilatory defect correlate with the syndrome’s characteristic costovertebral anomalies (missing or malformed posterior rib segments), leading to thoracic insufficiency. Spasticity, chorea, and morphological CNS abnormalities align with neurological involvement seen in severe CCMS cases. Hypertelorism and downslanted palpebral fissures further support the syndromic craniofacial dysmorphism. The combination of these structural and neurological findings strongly points to CCMS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Increased total bilirubin', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative metabolism of excess phenylalanine, forming phenylketones excreted in urine.  
3. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome if the mother has uncontrolled phenylalanine levels during pregnancy, though this symptom is secondary.  
4. **Death in infancy/childhood/neonatal death** aligns with untreated PKU, as toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure without early dietary intervention.  
5. **Increased total bilirubin** is atypical for classic PKU but could indicate transient neonatal jaundice, a common comorbidity in newborns, not directly linked to PKU pathology.  
The combination of hyperphenylalaninemia and phenylketonuria-confirming urinary metabolites strongly supports PKU, with poor outcomes reflecting lack of newborn screening or treatment. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Motor delay and generalized hypotonia**: These are hallmark neurological symptoms of SSADHD, caused by disrupted GABA metabolism. Accumulation of GABA and its metabolite gamma-hydroxybutyrate (GHB) leads to excessive neuronal inhibition, impairing motor development and muscle tone.  
2. **Elevated urinary carboxylic acid**: SSADHD results in elevated GHB, a carboxylic acid, in urine due to the enzyme deficiency blocking succinic semialdehyde conversion to succinate. This biochemical marker is specific to the disorder.  
3. **Pneumonia**: Hypotonia increases aspiration risk, predisposing infants to recurrent respiratory infections like pneumonia.  
4. **Death in infancy**: While SSADHD is typically non-lethal, severe metabolic instability, respiratory complications (e.g., pneumonia), or delayed diagnosis may contribute to early mortality in rare cases.  

The combination of neurological deficits, characteristic urinary metabolite elevation, and secondary respiratory complications aligns conclusively with SSADHD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Increased serum lactate', 'Fasciculations', 'Tachypnea', 'Neonatal death', 'Abnormal circulating citrulline concentration', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia (Citrullinemia type I/Citrullinemia, classic)  
**Reasoning**:  
1. **Hyperammonemia** and **abnormal circulating citrulline concentration** are hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency, disrupting the urea cycle.  
2. **Metabolic acidosis** and **increased serum lactate** result from compensatory anaerobic metabolism due to mitochondrial dysfunction from ammonia toxicity.  
3. **Seizures** and **fasciculations** arise from neurotoxicity secondary to hyperammonemia.  
4. **Tachycardia** and **tachypnea** are physiological responses to acidosis (respiratory compensation) and systemic stress.  
5. **Feeding difficulties**, **neonatal death**, and **death in infancy** reflect the severe, early-onset nature of classic citrullinemia, typically manifesting within days of life due to protein intolerance and rapid ammonia accumulation.  
6. **Fever** may occur secondary to metabolic decompensation or intercurrent illness triggering crisis.  

Both listed diagnoses refer to the same entity: **Citrullinemia type I** (OMIM #215700), distinguished by citrulline elevation in serum/urine and confirmatory genetic testing for *ASS1* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial parasite was discovered by -
Choices:
A. Ronald Ross
B. Paul muller
C. Laveran
D. Pampania
Answer: [/INST] Laveran </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Gene involved in Retinoblastoma
Choices:
A. 12P13
B. 13P14
C. 12Q13
D. 13Q14
Answer: [/INST] 13Q14 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination is given at -
Choices:
A. 9 months
B. At birth
C. 4 weeks
D. 8 weeks
Answer: [/INST] 9 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following drugs is not recommended for the treatment of Multiple Sclerosis:
Choices:
A. Interferon p-1 a
B. Interferon p-lb
C. Glatiramer Acetate
D. Mycophenolate
Answer: [/INST] Interferon p-lb </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements regardingGamma-Release-Assays for diagnosis of Tuberculosis is true -
Choices:
A. First Generation Quanti FERON-TB assay used ESAT-6
B. Second Generation Quanti FERON-TB (Gold) assay used ESAT-6 and CPF-10
C. These tests can distinguish between M. tuberculosis and M. bovis
D. None of the non-tuberculosis mycobacteria give a positive reaction with the test
Answer: [/INST] Second Generation Quanti FERON-TB (Gold) assay used ESAT-6 and CPF-10 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
**Reasoning**:  
1. **Key biochemical markers**:  
   - **Glutaric aciduria** and **elevated circulating glutaric acid** directly indicate a defect in glutaryl-CoA dehydrogenase, the enzyme deficient in GA-I.  
   - **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from binding excess glutaric acid.  

2. **Neurological manifestations**:  
   - **Dystonia**, **dyskinesia**, and **athetosis** result from striatal injury and basal ganglia degeneration, classic in GA-I.  
   - **Generalized hypotonia** and **lethargy** are early signs of metabolic encephalopathy.  

3. **Acute metabolic crises**:  
   - **Vomiting**, **diarrhea**, **fever**, and **drowsiness** often precede or accompany acute crises triggered by catabolic stress (e.g., infections).  
   - **Dyspnea** may reflect metabolic acidosis or neurological respiratory control disruption.  

4. **Macrocephaly**:  
   - A hallmark of GA-I, caused by frontotemporal atrophy or delayed myelination, often evident before symptom onset.  

5. **Poor prognosis**:  
   - **Death in infancy/childhood** and **neonatal death** align with untreated GA-I, as crises cause irreversible neurological damage or cerebral edema.  

6. **Sleep disturbance**:  
   - Linked to basal ganglia dysfunction or neurochemical imbalances from accumulated metabolites.  

**Conclusion**: The triad of macrocephaly, movement disorders, and biochemical evidence (glutaric acid elevation, low carnitine) confirms GA-I. Acute crises exacerbate symptoms, leading to fatal outcomes without early intervention. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are seen in McCune Albright Syndrome Except
Choices:
A. Polyostotic fibrous dysplasia
B. Cafe-au-lait spots
C. GnRH-independent sexual precocity
D. GnRH-dependent sexual precocity
Answer: [/INST] GnRH-dependent sexual precocity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Premature birth', 'Hyperammonemia', 'Respiratory distress', 'Apnea', 'Neonatal death', 'Respiratory acidosis', 'Elevated plasma citrulline', 'Hypoxemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The patient presents with hyperammonemia and markedly elevated plasma citrulline, hallmark features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. Neonatal respiratory distress, apnea, and respiratory acidosis align with metabolic decompensation from ammonia toxicity, leading to neurological depression and respiratory failure. Premature birth and neonatal death are consistent with the severe, rapid progression of untreated urea cycle disorders.  

Disease: Neonatal intrahepatic cholestasis due to citrin deficiency/Citrullinemia, type II, neonatal-onset  
Reasoning: While cholestasis is not explicitly listed, citrin deficiency (type II) can present with neonatal hyperammonemia and elevated citrulline due to secondary urea cycle dysfunction. Respiratory distress and hypoxemia may reflect metabolic stress or hepatic involvement. Neonatal death and prematurity overlap with acute metabolic crises, though citrin deficiency often includes transient cholestasis or amino acid imbalances (e.g., high threonine), which may not be documented here. Differentiation from type I requires genetic testing or additional biomarkers (e.g., citrin protein analysis). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation. This aligns with the patient’s elevated phenylalanine levels.  
2. **Hypertyrosinemia**: While atypical for classic PKU (where tyrosine is typically low), this could indicate a secondary metabolic disruption, transient neonatal tyrosinemia, or a coexisting condition (e.g., liver dysfunction). Alternatively, it may reflect a diagnostic error in symptom reporting.  
3. **Neonatal death/Death in infancy**: Severe, untreated PKU (or BH4-deficient variants) can cause rapid neurological deterioration, seizures, and organ failure, potentially leading to early mortality.  
4. **Prenatal abnormalities**: Unlikely from infantile PKU itself but may arise if the mother had untreated maternal PKU during pregnancy, indirectly affecting fetal development.  
5. **Exclusion of alternatives**: Tyrosinemias or BH4 deficiencies were considered but excluded due to the primary hallmark of hyperphenylalaninemia and the specified diagnosis of PKU.  

Conclusion: PKU explains the core biochemical anomaly (hyperphenylalaninemia) and aligns with severe outcomes when untreated, despite atypical hypertyrosinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute Pyogenic Meningitis true is/are -
Choices:
A. Purulent exudates within leptomeninges
B. CSF cloudy with PMN
C. Causes ventricular enlargements.
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Oral ulcer', 'Xerostomia', 'Tinnitus', 'Hearing impairment', 'Proptosis', 'Visual loss', 'Decreased lacrimation', 'Diplopia', 'Nephrolithiasis', 'Abnormal finger morphology', 'Hemiparesis', 'Gait disturbance', 'Arthritis', 'Mitral regurgitation', 'Renal tubular acidosis', 'Leukocytosis', 'Migraine', 'Vertigo', 'Arthralgia', 'Exertional dyspnea', 'Elevated circulating thyroid-stimulating hormone concentration', 'Somatic sensory dysfunction', 'Hypouricemia', 'Exercise intolerance', 'Decreased urinary urate', 'Neck pain', 'Aphthous ulcer', 'Low levels of vitamin D', 'Skin vesicle', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Behçet disease/Behcet syndrome  
Reasoning: The patient presents with recurrent oral/aphthous ulcers, a hallmark of Behçet disease. Ocular involvement (proptosis, visual loss, diplopia) aligns with uveitis or retinal vasculitis. Skin vesicles/pustules suggest pathergy or cutaneous manifestations. Neurological symptoms (hemiparesis, gait disturbance, somatic sensory dysfunction) indicate possible neuro-Behçet. Arthritis and arthralgia are common systemic features. While atypical symptoms like xerostomia, renal tubular acidosis, and hypouricemia are not classic for Behçet, the core criteria (oral ulcers + multisystem inflammation) strongly support this diagnosis.  

Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: Arthritis, neck pain, and uveitis (implied by visual loss) are consistent with spondyloarthropathy (SpA). Elevated leukocytosis and HLA-B27 susceptibility (inferred from ""susceptibility to, 1"") may predispose to axial involvement. However, oral ulcers, neurological deficits, and cutaneous symptoms are less typical, suggesting incomplete alignment with SpA.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Similar to SpA-1, arthritic and axial symptoms (neck pain) are present. However, the absence of hallmark SpA features (e.g., enthesitis, sacroiliitis) and prominence of non-SpA symptoms (oral ulcers, renal/metabolic abnormalities) reduce confidence. Genetic susceptibility (e.g., ERAP1 variants in SpA-2) may contribute but does not override the stronger evidence for Behçet syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Hyperactivity', 'Intellectual disability', 'Death in childhood', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency (SSADH deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acid**: SSADH deficiency disrupts GABA metabolism, leading to accumulation of gamma-hydroxybutyric acid (GHB), a carboxylic acid excreted in urine.  
2. **Neurodevelopmental symptoms**: Delayed speech, hyperactivity, and intellectual disability align with GABAergic dysfunction, as GABA is critical for neuronal regulation and brain development.  
3. **Early mortality**: Severe cases may involve life-threatening complications (e.g., seizures, respiratory failure, or neuroregressive crises) contributing to death in childhood/adolescence.  
4. **Metabolic confirmation**: The triad of neurobehavioral abnormalities, elevated urinary GHB, and genetic testing confirms SSADH deficiency, distinguishing it from other organic acidurias. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on:
Choices:
A. Chromosome 5
B. Chromosome 8
C. Chromosome 13
D. Chromosome 16
Answer: [/INST] Chromosome 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Virus causing acute onset sensorineural deafness -a) Corona virusb) Rubella, measlesc) Mumpsd) Adeno viruse) Rota virus
Choices:
A. a
B. bc
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leptospirosis, all are true except
Choices:
A. Faeces & urine of rodents is the cause
B. onset of IgM in 2 days
C. Incubation period is 10 days
D. It is sensitive to penicillin
Answer: [/INST] onset of IgM in 2 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Cardiomegaly', 'Hypoglycemia', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Hypoglycemia and increased serum lactate**: Impaired mitochondrial β-oxidation of very long-chain fatty acids deprives the body of energy during fasting, forcing reliance on glycolysis (causing hypoglycemia) and anaerobic metabolism (elevating lactate).  
2. **Dicarboxylic aciduria**: VLCADD disrupts fatty acid breakdown, leading to alternative ω-oxidation of fatty acids in the endoplasmic reticulum, producing dicarboxylic acids excreted in urine.  
3. **Hepatomegaly and cardiomegaly**: Toxic accumulation of long-chain acylcarnitines and fatty acid metabolites in the liver and heart causes organ damage and hypertrophy.  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to excessive conjugation of carnitine with unmetabolized long-chain acyl-CoA species.  
5. **Recurrent viral infections and tachypnea**: Metabolic crises during catabolic states (e.g., infections) exacerbate energy deficits, triggering respiratory compensation (tachypnea) and susceptibility to infections.  
6. **Death in infancy/childhood**: Severe VLCADD phenotypes present neonatally with cardiomyopathy or hepatic failure, often leading to early mortality without prompt diagnosis and dietary management (e.g., avoidance of fasting, medium-chain triglyceride supplementation).  

The combination of fatty acid oxidation disorder markers (dicarboxylic aciduria, hypoglycemia, carnitine abnormalities) with multi-organ involvement (heart, liver) and early lethality is pathognomonic for VLCADD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What are the minimum number bacilli for Sputum positive Tuberculosis?
Choices:
A. 10
B. 102
C. 103
D. 104
Answer: [/INST] 104 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Proteinuria', 'Ascites', 'Acute pancreatitis', 'Splenomegaly', 'Pancytopenia', 'Fever', 'Diarrhea', 'Abdominal pain', 'Peritonitis', 'Arthralgia', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Myalgia', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Hypovolemia', 'Fatigue', 'Increased circulating lactate dehydrogenase concentration', 'Hydrometrocolpos', 'Epigastric pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Systemic lupus erythematosus  
Reasoning: The patient presents with multisystem involvement, including renal (proteinuria), hematologic (pancytopenia), musculoskeletal (myalgia, arthralgia, elevated creatine kinase), and immunologic (ANA positivity) manifestations. Fever, fatigue, and abdominal pain with serositis (ascites, peritonitis) further support SLE. Elevated LDH and muscle weakness may indicate lupus-related myositis or hemolysis. Acute pancreatitis and splenomegaly are rare but documented in SLE.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: While age is unspecified, symptoms like hydrometrocolpos (a congenital anomaly sometimes associated with pediatric autoimmune conditions) and pancytopenia could suggest early-onset SLE. Pediatric SLE often presents with severe renal and hematologic involvement, aligning with proteinuria and pancytopenia.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: Genetic susceptibility loci like SLEB6 (ITGAM gene) are linked to renal and hematologic phenotypes. Proteinuria, pancytopenia, and ANA positivity align with this genetic predisposition, though confirmatory testing would be required.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: While vitiligo is not explicitly listed, overlapping autoimmune features (ANA positivity, pancreatitis, myositis) could suggest polyautoimmunity. However, this diagnosis is less definitive without vitiligo or confirmed genetic markers.  

Disease: Systemic lupus erythematosus 16  
Reasoning: Linked to DNASE1L3 mutations, causing severe renal and serosal inflammation (proteinuria, ascites, peritonitis). Elevated LDH and creatine kinase may reflect tissue damage from impaired apoptotic clearance, a hallmark of this subtype.  

**Note:** Hydrometrocolpos is an outlier; it may indicate a concurrent congenital anomaly (e.g., Müllerian duct obstruction) unrelated to SLE, necessitating further evaluation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypercholesterolemia', 'Hypertyrosinemia', 'Aminoaciduria', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to impaired conversion of phenylalanine to tyrosine.  
2. **Hypertyrosinemia**: Unusual in classic PKU (where tyrosine is typically low), but may occur in rare PKU variants or secondary metabolic disruptions (e.g., dietary interventions or overlapping enzyme deficiencies).  
3. **Aminoaciduria**: Excess phenylalanine excretion in urine due to overflow from elevated blood levels, consistent with PKU.  
4. **Hypercholesterolemia**: Not directly linked to PKU but potentially secondary to high-fat/low-protein dietary management required for PKU.  
5. **Early mortality**: Untreated PKU causes severe neurological damage, seizures, and organ failure, explaining death in adolescence/early adulthood if undiagnosed or unmanaged.  
**Conclusion**: Despite atypical hypertyrosinemia and hypercholesterolemia, hyperphenylalaninemia and aminoaciduria strongly align with PKU, with secondary factors explaining discrepancies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine metabolism.  
2. **Untreated Severe PKU**: In classic PKU, complete PAH deficiency leads to rapid phenylalanine accumulation. Without early dietary intervention, toxic levels cause irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Neonatal/Infant Death**: In unscreened or untreated cases, severe metabolic derangements (e.g., cerebral edema, metabolic crises) or complications like infections in neurologically compromised infants may result in neonatal death or death within the first year.  
4. **Diagnostic Link**: The triad of hyperphenylalaninemia, neonatal deterioration, and infant mortality aligns with untreated PKU, particularly in settings lacking newborn screening or access to phenylalanine-restricted diets. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing impairment', 'Tachycardia', 'Splenomegaly', 'Fever', 'Hyperkalemia', 'Vertigo', 'Decreased circulating total IgM', 'Hypercalcemia', 'Abnormal EKG', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Elevated circulating C-reactive protein concentration', 'Increased circulating free T3', 'Foot pain', 'Elbow pain', 'Wrist pain', 'Hip pain', 'Knee pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning:  
1. **Hearing impairment** aligns with Muckle-Wells syndrome’s hallmark sensorineural hearing loss due to chronic inflammation.  
2. **Fever**, **elevated ESR**, and **high CRP** reflect systemic inflammation, consistent with autoinflammatory syndromes like MWS.  
3. **Arthralgias** (joint pain in elbows, wrists, hips, knees, feet) are common in MWS, driven by IL-1-mediated inflammation.  
4. **Abnormality of the complement system** and **splenomegaly** suggest chronic inflammation and immune dysregulation.  
5. **Hyperkalemia** and **abnormal EKG** may indicate early renal amyloidosis, a complication of untreated MWS.  
6. **Hypercalcemia** could stem from cytokine-driven bone resorption or renal dysfunction.  
7. **Vertigo** may relate to inner ear inflammation, supporting cochlear involvement.  
8. **Decreased IgM** is atypical but could result from chronic inflammation or secondary immune dysregulation.  

Excluded other familial cold syndromes (FCAS 1-4, familial cold urticaria) due to lack of documented cold triggers and presence of hearing loss. CINCA syndrome was excluded due to absence of severe neurological/developmental features (e.g., chronic meningitis, bony overgrowth). Elevated free T3 is a confounding factor but may reflect inflammation-associated thyroid test abnormalities rather than primary thyroid disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies can be confirmed in patients early in illness by: March 2013 (b, e)
Choices:
A. Antigen detection by corneal smears immunofluorescence
B. Antigen detection by immunofluorescence of skin biopsy
C. Demonstration of neutralizing antibodies
D. Demonstration of Negri bodies in hippocampus
Answer: [/INST] Antigen detection by immunofluorescence of skin biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Whihc of the following is true about meningococcal Meningitis-
Choices:
A. Case fatality less than 10% in untreated cases
B. Cases are main source of infection
C. Rifampicin is the Drug of choice
D. Treatment in the first 2 days can save the life of 95% cases
Answer: [/INST] Treatment in the first 2 days can save the life of 95% cases </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Xerostomia', 'Irregular menstruation', 'Keratoconjunctivitis sicca', 'Leukopenia', 'Diarrhea', 'Reduced haptoglobin level', 'Autoimmune antibody positivity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary Sjögren syndrome/Sjogren syndrome  
Reasoning: Xerostomia and keratoconjunctivitis sicca are hallmark symptoms of Sjögren syndrome, directly reflecting exocrine gland dysfunction. Autoimmune antibody positivity (e.g., anti-SSA/Ro or anti-SSB/La) supports this diagnosis. While leukopenia and reduced haptoglobin suggest systemic involvement, these can occur in Sjögren syndrome due to secondary autoimmune processes or overlap with other conditions.  

Disease: Systemic lupus erythematosus  
Reasoning: Leukopenia, autoimmune antibody positivity (e.g., ANA, anti-dsDNA), and reduced haptoglobin (indicating potential hemolytic anemia) align with SLE diagnostic criteria (SLICC or ACR). Irregular menstruation may reflect SLE-related hormonal or inflammatory effects. Diarrhea could stem from autoimmune enteritis or vasculitis, though further evaluation is needed. While sicca symptoms suggest Sjögren overlap, SLE is prioritized due to broader systemic features.  

Disease: Systemic lupus erythematosus, susceptibility to, 6  
Reasoning: If genetic testing reveals variants in *ITGAM* or other loci linked to SLE susceptibility 6, this could explain predisposition. However, clinical diagnosis of SLE is already supported by symptoms, making this a secondary genetic risk annotation rather than a primary diagnosis.  

Disease: Vitiligo-Associated multiple autoimmune disease susceptibility 1  
Reasoning: This applies if vitiligo is present (unstated here) and polyautoimmunity is confirmed. Current symptoms lack vitiligo-specific features, making this less likely unless additional findings are reported.  

Disease: Pediatric systemic lupus erythematosus  
Reasoning: Pediatric SLE is considered if the patient is under 18, but age is unspecified. Symptoms overlap with adult SLE, so this diagnosis is conditional on demographic context.  

Disease: Systemic lupus erythematosus 16  
Reasoning: This refers to a specific genetic susceptibility locus (e.g., *TNFAIP3*). Like susceptibility 6, it requires genetic confirmation and does not replace the clinical diagnosis of SLE.  

**Final Prioritization**: Primary Sjögren syndrome and Systemic lupus erythematosus are the most clinically relevant diagnoses based on symptoms and criteria. Overlap syndrome (SLE-Sjögren) should be considered if both sets of criteria are fully met. Genetic susceptibilities (e.g., SLE 6/16) are secondary findings. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Simplex type of Epidermolysis Bullosa involves mutations in
Choices:
A. Keratin 5
B. Lamina lucida
C. Type vII collagen
D. Dystrophin
Answer: [/INST] Keratin 5 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Pendred Syndrome
Choices:
A. Blindness
B. Conductive deafness
C. Sensorineural deafness
D. All of the above
Answer: [/INST] Sensorineural deafness </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypospadias', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Esophageal atresia', 'Upper airway obstruction', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Phenylketonuria (PKU): The patient's hyperphenylalaninemia is pathognomonic for PKU, an autosomal recessive disorder caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine-to-tyrosine conversion. Chronic phenylalanine accumulation leads to neurotoxicity, explaining potential early mortality due to untreated metabolic crises and severe neurological deterioration. Hypertyrosinemia is atypical in classical PKU but could arise from secondary metabolic disruptions or concurrent hepatic dysfunction. Structural anomalies (e.g., hypospadias, esophageal atresia) may reflect maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing teratogenic effects on fetal development. While PKU itself does not directly cause congenital malformations, these findings highlight the critical interplay between maternal metabolic control and fetal outcomes. Chronic pulmonary/airway obstruction and early mortality across life stages align with complications of untreated PKU, including susceptibility to infections, neurorespiratory failure, or comorbid conditions exacerbated by metabolic instability. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: If a claw hand develops in a patient with Leprosy, th deformity is ?
Choices:
A. Grade 0
B. Grade I
C. Grade II
D. Grade III
Answer: [/INST] Grade II </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cataract', 'Global developmental delay', 'Choreoathetosis', 'Motor delay', 'Generalized hypotonia', 'Anal atresia', 'Cerebral atrophy', 'Lower limb spasticity', 'Abnormal circulating amino acid concentration', 'Increased serum pyruvate', 'Short stature', 'Generalized tonic seizure', 'Abnormal circulating creatine kinase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: CODAS syndrome  
Reasoning: The patient presents with cataracts (ocular anomaly), global developmental delay, motor delay, cerebral atrophy (cerebral anomalies), and short stature (skeletal anomaly), aligning with core features of CODAS syndrome. Generalized hypotonia and lower limb spasticity suggest neuromuscular involvement, while abnormal circulating amino acids and increased serum pyruvate indicate mitochondrial dysfunction, consistent with LONP1 gene mutations affecting mitochondrial protein homeostasis. Choreoathetosis and seizures may arise from cerebral atrophy or metabolic disturbances. Although anal atresia is atypical for CODAS, the constellation of cerebral, ocular, metabolic, and skeletal findings strongly supports this diagnosis over other mitochondrial or peroxisomal disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the dentition', 'Alopecia', 'Increased susceptibility to fractures', 'Low alkaline phosphatase', 'Short stature', 'Miscarriage', 'Fatigue', 'Lower limb pain', 'Ectopic pregnancy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Hypophosphatasia; HPP/Hypophosphatasia  
Reasoning:  
1. **Low alkaline phosphatase**: A pathognomonic feature of HPP due to mutations in the *ALPL* gene, causing deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity.  
2. **Increased susceptibility to fractures** and **lower limb pain**: Impaired bone mineralization from accumulated inorganic pyrophosphate (PPi) leads to osteomalacia, fragility fractures, and bone pain.  
3. **Abnormality of the dentition**: Premature loss of deciduous teeth (especially incisors) due to defective cementum formation.  
4. **Short stature**: Result of skeletal hypomineralization and growth plate abnormalities.  
5. **Fatigue**: Linked to muscle weakness or chronic pain secondary to skeletal pathology.  
6. **Miscarriage** and **ectopic pregnancy**: HPP may disrupt placental calcification or uterine environment, increasing pregnancy complications (reported in severe or perinatal forms).  

Disease: Hypophosphatasia, adult  
Reasoning:  
1. **Persistent low alkaline phosphatase**: Confirms ongoing TNSALP deficiency in adulthood.  
2. **Recurrent fractures** and **limb pain**: Adult-onset HPP often manifests with stress fractures, pseudofractures, and musculoskeletal pain.  
3. **Dental abnormalities**: Adult patients may retain childhood dental issues (e.g., tooth loss) or develop periodontitis.  
4. **Fatigue**: Chronic bone and muscle involvement contribute to systemic symptoms.  
5. **Reproductive complications**: While less common in adult HPP, metabolic disturbances could theoretically predispose to ectopic pregnancy or miscarriage.  

**Note**: Alopecia is atypical for HPP and may suggest a comorbid condition, requiring further evaluation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Skin rash', 'Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Decreased plasma free carnitine', 'Erythematous plaque', 'Erythematous macule', 'Erythematous papule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD; excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Neurological symptoms (lethargy, drowsiness, vomiting, sleep disturbance)**: Reflect ammonia neurotoxicity.  
4. **Death in infancy**: Severe neonatal-onset OTCD causes rapid metabolic collapse without intervention.  
5. **Decreased plasma free carnitine**: Secondary carnitine depletion due to disrupted metabolism or renal loss.  
6. **Skin lesions (rash, plaques, macules/papules)**: Less specific but may arise from metabolic stress or ammonia-induced inflammation.  
7. **Gastrointestinal symptoms (diarrhea, vomiting)**: Common in metabolic crises due to systemic toxicity.  
**Key differentiators**: Oroticaciduria distinguishes OTCD from other urea cycle defects. X-linked inheritance (though de novo mutations occur) and hyperammonemia severity further support the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: NOT seen in Narcolepsy
Choices:
A. Sleep paralysis
B. Ataxia
C. Catalepsy
D. Abnormal REM sleep
Answer: [/INST] Catalepsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Pointed chin', 'Short chin', 'Strabismus', 'Ptosis', 'Hyperactivity', 'Syndactyly', 'Intellectual disability', 'Ataxia', 'Generalized hypotonia', 'Hyperreflexia', 'Failure to thrive', 'Death in infancy', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Metabolic markers**: Elevated 7-dehydrocholesterol (7-DHC) and hypocholesterolemia are pathognomonic for SLOS, caused by mutations in *DHCR7*, which disrupts cholesterol synthesis. Elevated 8-dehydrocholesterol may also occur due to secondary biochemical instability.  
2. **Craniofacial features**: Microcephaly, pointed chin, short chin, ptosis, and strabismus align with SLOS-associated dysmorphism.  
3. **Neurological/developmental**: Intellectual disability, generalized hypotonia, hyperreflexia, ataxia, and hyperactivity reflect neurodevelopmental deficits typical of SLOS.  
4. **Growth/feeding issues**: Failure to thrive, feeding difficulties, and fatigue correlate with metabolic dysfunction and poor cholesterol-dependent growth.  
5. **Congenital anomalies**: Syndactyly (often 2-3 toe) is a hallmark structural defect in SLOS.  
6. **Severity/mortality**: Death in infancy or childhood occurs in severe cases due to metabolic instability or organ malformations.  

All findings coalesce into a diagnosis of Smith-Lemli-Opitz syndrome, confirmed by biochemical/genetic testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Pneumonia', 'Hepatomegaly', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Abnormal circulating acetylcarnitine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Metabolic acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective HMG-CoA lyase.  
2. **Hypoglycemia**: Impaired ketogenesis (HMG-CoA lyase is critical for ketone body synthesis) leads to energy deficits during fasting.  
3. **Hyperammonemia**: Secondary inhibition of the urea cycle by organic acid metabolites.  
4. **Hepatomegaly**: Fatty liver from disrupted lipid metabolism and mitochondrial dysfunction.  
5. **Dicarboxylic aciduria**: Increased fatty acid oxidation (compensatory energy pathway) produces dicarboxylic acids.  
6. **3-Methylglutaconic aciduria**: Direct result of HMG-CoA lyase deficiency, as 3-methylglutaconate cannot be metabolized to acetoacetate.  
7. **Decreased plasma free carnitine**: Carnitine is consumed conjugating toxic metabolites (e.g., 3-hydroxy-3-methylglutarate) for urinary excretion.  
8. **Abnormal acetylcarnitine**: Reflects disrupted mitochondrial acyl-CoA metabolism.  
9. **Elevated urinary carboxylic acids**: Excretion of 3-hydroxy-3-methylglutarate, 3-methylglutaconate, and other intermediates.  
10. **Apathy/Death in infancy**: Neurological sequelae of metabolic crises (hypoglycemia, acidosis) if untreated.  
11. **Vomiting/Pneumonia**: Common triggers (infection, fasting) for acute decompensation in metabolic disorders.  
12. **Abnormal glycine**: Potential secondary disturbance from mitochondrial dysfunction.  

**Conclusion**: The constellation of metabolic acidosis, hypoglycemia, hyperammonemia, specific urinary metabolites (3-methylglutaconic acid, dicarboxylic acids), and carnitine abnormalities is pathognomonic for HMG-CoA lyase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Hydrocephalus ex vacuo, the compensatory enlargement of ventricles and an increase in CSF volume due to brain atrophy is seen in-
Choices:
A. Alzheimers diseae
B. Picks diseases
C. Both
D. None of the above
Answer: [/INST] Both </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia ECG changes all except
Choices:
A. Tall T wave
B. Prolonged QRS interval
C. Depressed ST segment
D. Prominent U waves
Answer: [/INST] Tall T wave </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Coma', 'Hepatic steatosis', 'Death in infancy', 'Hypoglycemia', 'Hyperammonemia', 'Vomiting', 'Gastrointestinal hemorrhage', 'Hypokalemia', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating glycine concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-Coa lyase deficiency (HMG-CoA lyase deficiency)  
Reasoning:  
1. **Hypoglycemia + Hyperammonemia + Hepatic steatosis**: Core triad of HMG-CoA lyase deficiency, caused by impaired ketogenesis and leucine catabolism, leading to energy deficits and toxic metabolite accumulation.  
2. **Dicarboxylic aciduria + 3-Methylglutaric aciduria**: Direct biochemical hallmarks due to defective breakdown of HMG-CoA into acetoacetate, resulting in elevated 3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids in urine.  
3. **Abnormal amino acids (glycine, aspartate family, alanine)**: Secondary to metabolic decompensation, disrupting amino acid homeostasis and urea cycle function.  
4. **Seizures + Coma + Death in infancy**: Result from severe hypoglycemia, hyperammonemia, and metabolic acidosis during metabolic crises, typical in untreated HMG-CoA lyase deficiency.  
5. **Elevated hepatic transaminases + GI hemorrhage**: Hepatic dysfunction from steatosis and metabolic stress, compounded by coagulopathy from hyperammonemia.  
6. **Hypokalemia**: Likely due to renal losses from acidosis or vomiting.  
7. **Abnormal porphyrins**: Possible secondary disruption of heme synthesis pathways during metabolic instability.  

The constellation of fatty acid oxidation defects, organic aciduria, and neonatal lethality confirms HMG-CoA lyase deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Diarrhea', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptoms of metabolic crisis**: Vomiting and diarrhea are common during acute episodes due to the inability to metabolize medium-chain fatty acids, leading to energy depletion and toxic metabolite accumulation.  
2. **Gastrointestinal inflammation**: Secondary to metabolic stress and mitochondrial dysfunction in gastrointestinal cells.  
3. **Abnormal carnitine levels**: MCADD causes secondary carnitine deficiency as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine) for urinary excretion.  
4. **Early mortality**: Neonatal/childhood death aligns with untreated MCADD, as prolonged fasting (e.g., during infections) triggers hypoglycemia, hepatopathy, and encephalopathy.  
5. **Prenatal/developmental abnormalities**: Subtle intrauterine metabolic stress may affect growth, though MCADD typically manifests postnatally.  
6. **Exclusion of other disorders**: Symptoms overlap with long-chain fatty acid oxidation defects (e.g., VLCAD), but gastrointestinal predominance and carnitine pattern favor MCADD.  
**Diagnostic confirmation**: Elevated C6-C10 acylcarnitines (especially C8) on newborn screening, genetic testing for *ACADM* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Polyuria', 'Visual loss', 'Hematuria', 'Dry skin', 'Keratoconjunctivitis sicca', 'Tremor', 'Diarrhea', 'Constipation', 'Heat intolerance', 'Migraine', 'Exertional dyspnea', 'Myalgia', 'Exercise intolerance', 'Inflammatory abnormality of the skin', 'Fatigue', 'Cough', 'Abnormal systemic blood pressure', 'Increased circulating IgG4 level', 'Dyspepsia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: IgG4 related disease; IgG4-RD  
Reasoning: The patient exhibits elevated IgG4 levels, a hallmark of IgG4-RD, alongside multi-organ involvement. Ocular symptoms (visual loss, keratoconjunctivitis sicca) suggest lacrimal or orbital inflammation. Renal manifestations (polyuria, hematuria) may indicate tubulointerstitial nephritis or retroperitoneal fibrosis causing ureteral obstruction. Cutaneous (dry skin, inflammatory skin changes), respiratory (cough, exertional dyspnea), and gastrointestinal symptoms (dyspepsia, diarrhea/constipation) reflect systemic inflammation and fibrosis. Systemic features (fatigue, myalgia, exercise intolerance) align with chronic inflammatory states. Migraine and blood pressure abnormalities may arise from secondary effects of organ compression or systemic inflammation.  

Disease: IgG4-related retroperitoneal fibrosis  
Reasoning: A subtype of IgG4-RD, retroperitoneal fibrosis explains hematuria and polyuria via ureteral obstruction or renal parenchymal involvement. Abdominal symptoms (dyspepsia, constipation/diarrhea) could stem from retroperitoneal mass effects on adjacent organs. Elevated IgG4 levels and association with other IgG4-RD features (e.g., ocular, cutaneous) further support this diagnosis.  

Disease: Multifocal fibrosclerosis  
Reasoning: This term describes fibrosis across multiple sites, now recognized as part of the IgG4-RD spectrum. The patient’s diverse symptoms (ocular, renal, cutaneous, respiratory) indicate fibroinflammatory lesions in various organs. Increased IgG4 levels and systemic involvement confirm multifocal fibrosclerosis as a manifestation of underlying IgG4-RD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Scleroderma involves:
Choices:
A. Tightening of oraL mucosa and periodontal involvement
B. Multiple palmar keratosis
C. Raynaud's phenomenon
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Asbestosis is usually related to -a) Small cell carcinoma lungb) Large cell carcinoma lungc) Mesotheliomad) Squamous cell carcinoma lung
Choices:
A. cd
B. bc
C. bd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Wrist swelling', 'Joint hypermobility', 'Abnormality of the gluteal musculature', 'Thrombocytosis', 'Leukocytosis', 'Low back pain', 'Foot pain', 'Neck pain', 'Shoulder pain', 'Elbow pain', 'Wrist pain', 'Knee pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning:  
1. **Axial Involvement**: Low back pain and neck pain suggest inflammatory spinal involvement, a hallmark of spondyloarthropathy.  
2. **Peripheral Arthritis**: Wrist swelling and pain in multiple joints (shoulder, elbow, knee, foot) align with asymmetric peripheral arthritis seen in spondyloarthropathies.  
3. **Systemic Inflammation**: Thrombocytosis and leukocytosis indicate an active inflammatory process, consistent with immune-mediated arthropathies.  
4. **Enthesitis**: Abnormality of the gluteal musculature may reflect enthesitis (inflammation at tendon/ligament insertions) near the pelvis or hips, common in this disease group.  
5. **Genetic Predisposition**: The diagnosis code implies HLA-B27 or other genetic markers linked to spondyloarthropathy susceptibility.  
6. **Exclusion of Alternatives**: Symptoms lack symmetry (unlike rheumatoid arthritis) or overt infection (unlike reactive arthritis), favoring spondyloarthropathy. Joint hypermobility may be incidental or secondary to chronic inflammation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Macroglossia is seen in following except -
Choices:
A. Amyloidosis
B. Acromegaly
C. Hyperthyroidism
D. Down's syndrome
Answer: [/INST] Hyperthyroidism </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where elevated phenylalanine during pregnancy disrupts fetal development.  
3. **Hypertyrosinemia** may occur secondarily if tyrosine metabolism is overwhelmed or due to co-existing hepatic dysfunction, though this is atypical in classic PKU.  
4. **Neonatal death/Death in infancy/childhood** reflects untreated severe PKU, leading to neurotoxicity, seizures, and organ failure without early dietary intervention.  
5. The absence of tyrosinemia-specific symptoms (e.g., liver/kidney dysfunction) prioritizes PKU over primary tyrosinemia.  
6. Neonatal screening for hyperphenylalaninemia strongly supports PKU diagnosis, even with atypical hypertyrosinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Multicystic kidney dysplasia', 'Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Hypotelorism', 'Iris coloboma', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Hip dysplasia', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Postnatal growth retardation', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, hypotonia, seizures, spastic tetraparesis, ADHD, and cerebral hypomyelination/delayed myelination align with core neurodevelopmental deficits. Structural brain abnormalities (hypoplastic corpus callosum, ventriculomegaly, cerebellar/pons malformations) further support this.  
2. **Ocular anomalies**: Microphthalmia, iris coloboma, Peters anomaly, optic atrophy, and blepharophimosis are hallmark features of NEDBEH-associated eye involvement.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return match the cardiac spectrum of the disorder.  
4. **Dysmorphic features**: Triangular face, micrognathia, high palate, hypertelorism, and epicanthus are consistent with reported craniofacial patterns. Conflicting micro/macrocephaly may reflect variable expressivity.  
5. **Multisystem involvement**: Urogenital (cryptorchidism, hypospadias, renal dysplasia), gastrointestinal (pyloric stenosis, annular pancreas), and skeletal (syndactyly, scoliosis) anomalies align with NEDBEH’s systemic nature.  
6. **Growth abnormalities**: Intrauterine and postnatal growth retardation, alongside tall stature (paradoxical but possible in genetic mosaicism or metabolic dysregulation).  
7. **Overlap with RAC1-related phenotype**: NEDBEH is linked to RAC1 mutations, which can manifest with brain-eye-heart anomalies, hypotonia, and variable dysmorphism, as seen here.  
8. **Exclusion of mimics**: While café-au-lait spots or hypertrichosis might suggest RASopathies, the triad of neurodevelopmental delay, structural brain/eye/heart defects, and absence of pathognomonic features of other syndromes (e.g., NF1, Noonan) favors NEDBEH.  

Key confirmatory features include the combination of neurodevelopmental delay, cerebellar/pontine malformations, Peters anomaly, and congenital heart defects, which collectively prioritize NEDBEH over isolated organ-system diagnoses. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella vaccination is contraindicated in all except-
Choices:
A. Patient on immunosuppressant
B. Girl with Leukemia
C. Girls between 11-14 years
D. Pregnancy
Answer: [/INST] Girls between 11-14 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Absolute lymphocytosis is seen in -a)  SLEb)  T.B.c) CLLd)  Brucellosis
Choices:
A. abc
B. bcd
C. ac
D. bd
Answer: [/INST] bcd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is false regarding Multiple Sclerosis (MS)?
Choices:
A. More common in women and age of onset is between 20-40 years of age
B. Risk factors include vitamin D deficiency and cigarette smoking
C. Pathological hallmark is axonal degeneration
D. HLA DRB1 in MHC class II is associated with 10% of disease risk
Answer: [/INST] Pathological hallmark is axonal degeneration </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Failure to thrive', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, severe metabolic disturbances in utero (e.g., maternal fasting-induced stress) may contribute to prenatal complications.  
2. **Failure to thrive**: Impaired fatty acid β-oxidation limits energy production during fasting, leading to poor weight gain and growth.  
3. **Neonatal death/Death in infancy/Death in childhood**: Untreated MCADD causes life-threatening hypoglycemia, hyperammonemia, and metabolic crises triggered by catabolic stress (e.g., infections, fasting).  
4. **Abnormal circulating carnitine concentration**: Secondary carnitine deficiency occurs due to urinary loss of acylcarnitines (e.g., octanoylcarnitine), a hallmark of MCADD.  

Key biochemical link: MCADD disrupts medium-chain fatty acid oxidation, leading to toxic metabolite accumulation (e.g., medium-chain acylcarnitines), hypoglycemia, and energy deficiency, aligning with the clinical and metabolic features described. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pruritus', 'Tachycardia', 'Ankle swelling', 'Weight loss', 'Lymphopenia', 'Anemia', 'Fever', 'Leukocytosis', 'Abnormality of the knee', 'Hypoalbuminemia', 'Abnormal EKG', 'Elevated circulating creatine kinase concentration', 'Myalgia', 'EMG: myopathic abnormalities', 'Antinuclear antibody positivity', 'Exercise intolerance', 'Elevated erythrocyte sedimentation rate', 'Generalized morning stiffness', 'Increased alpha-globulin', 'Enlarged metacarpophalangeal joints', 'Erythema', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Lower limb pain', 'Cough', 'Finger swelling', 'Antimitochondrial antibody positivity', 'Increased circulating creatine kinase MB isoform', 'Myositis', 'Abnormality of nail color', 'Increased circulating troponin T concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Antisynthetase syndrome  
Reasoning:  
1. **Myositis**: Supported by myalgia, elevated creatine kinase, EMG myopathic abnormalities, and exercise intolerance.  
2. **Interstitial lung disease**: Cough and potential respiratory involvement align with antisynthetase-related ILD.  
3. **Inflammatory arthritis**: Swollen metacarpophalangeal joints, finger swelling, and morning stiffness suggest polyarthritis.  
4. **Systemic inflammation**: Fever, leukocytosis, neutrophilia, elevated ESR/CRP, and hypoalbuminemia indicate a systemic inflammatory process.  
5. **Autoimmune markers**: Antinuclear antibody (ANA) positivity is common, though antisynthetase antibodies (e.g., anti-Jo1) are pathognomonic (implied in the diagnosis).  
6. **Cutaneous features**: Erythema, pruritus, and nail abnormalities may reflect ""mechanic’s hands,"" a classic sign.  
7. **Cardiac involvement**: Elevated troponin T, CK-MB, and abnormal EKG suggest myocarditis or subclinical cardiac inflammation.  
8. **Hematologic abnormalities**: Anemia and lymphopenia are consistent with chronic inflammation.  
9. **Exclusion of mimics**: Elevated alpha-globulin and antimitochondrial antibody positivity are nonspecific but do not override the syndromic pattern.  

The triad of myositis, ILD, and inflammatory arthritis with autoimmune serology strongly supports antisynthetase syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Narrow mouth', 'Microcephaly', 'Nystagmus', 'Hypertrichosis', 'Erythroderma', 'Brachydactyly', 'Preaxial hand polydactyly', 'Seizure', 'Hypertonia', 'Atrial septal defect', 'Abnormal cardiac septum morphology', 'Postaxial foot polydactyly', 'Eosinophilia', 'Abnormal facial shape', 'Delayed gross motor development', 'Limb hypertonia', 'Hypsarrhythmia', 'Skeletal dysplasia', 'Spondyloepiphyseal dysplasia', 'Elbow flexion contracture', 'Severe combined immunodeficiency', 'Generalized hypertrichosis', 'Combined immunodeficiency', 'Absence of CD8-positive T cells', 'Axial hypotonia', 'Profound global developmental delay', 'Abnormal natural killer cell count', 'Enlarged uterus']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (ISDNA)  
Reasoning:  
1. **Immunodeficiency**: Severe combined immunodeficiency (SCID), combined immunodeficiency, absence of CD8+ T cells, and abnormal NK cell count align with ISDNA’s hallmark immune dysfunction due to EXTL3 mutations affecting lymphocyte development.  
2. **Skeletal Abnormalities**: Brachydactyly, preaxial/postaxial polydactyly, spondyloepiphyseal dysplasia, and elbow contractures match ISDNA’s skeletal dysplasia phenotype, characterized by defective bone growth and limb anomalies.  
3. **Neurodevelopmental Features**: Profound global developmental delay, seizures, hypertonia (limb), axial hypotonia, and hypsarrhythmia reflect central nervous system involvement, consistent with ISDNA’s neurodevelopmental defects.  
4. **Dysmorphic Traits**: Microcephaly, narrow mouth, and abnormal facial shape are typical craniofacial findings in ISDNA.  
5. **Additional Features**: Hypertrichosis and erythroderma may overlap with immune dysregulation, while eosinophilia could signal aberrant immune activity. Cardiac septal defects and enlarged uterus, though less common, may represent variable expressivity of the disorder.  
6. **Genetic Basis**: ISDNA is caused by biallelic EXTL3 mutations, which disrupt glycosaminoglycan synthesis, explaining multisystem involvement (immune, skeletal, neural).  
**Conclusion**: The constellation of severe immunodeficiency, skeletal dysplasia, neurodevelopmental delay, and dysmorphism strongly supports ISDNA, necessitating EXTL3 gene testing for confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is caused by a
Choices:
A. Single stranded RNA enveloped virus
B. Single stranded RNA non-enveloped virus
C. Double stranded RNA enveloped virus
D. Double stranded RNA non-enveloped virus
Answer: [/INST] Single stranded RNA enveloped virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis and decreased methylmalonyl-CoA mutase activity are hallmark features of methylmalonic acidemia (MMA), an autosomal recessive disorder impairing methylmalonyl-CoA metabolism. Accumulation of methylmalonic acid leads to systemic toxicity, explaining early mortality. The presentation aligns with MMA’s severe neonatal/early infantile form, where rapid metabolic decompensation causes death in infancy or childhood if untreated.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Directly linked to the documented **decreased methylmalonyl-CoA mutase activity**, this subtype involves mutations in the *MUT* gene, rendering the enzyme nonfunctional. Unlike B12-responsive forms, supplementation is ineffective, resulting in refractory metabolic acidosis and poor prognosis. Early death reflects the severity of enzyme deficiency, as residual activity <1% is typically incompatible with long-term survival. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A child suffering from Rubella, presented with rose colored lesion in Oropharynx. This is know as __________
Choices:
A. Koplik spots
B. Nagayama spots
C. Forcheimer spots
D. None of the above
Answer: [/INST] None of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is seen in which type of pneumoconiosis:
Choices:
A. Anthracosis
B. Byssinosis
C. Asbestosis
D. Silicosis
Answer: [/INST] Asbestosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Phenylketonuria the main aim of first-line therapy is
Choices:
A. Replacement of the defective enzymes
B. Replacement of the deficient product
C. Limiting the substrate for deficient enzyme
D. Giving the missing amino acid by diet
Answer: [/INST] Limiting the substrate for deficient enzyme </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The differential diagnosis of Retinoblastoma include all of the following except
Choices:
A. Persistent hyperplastic primary vitreous
B. Coats disease
C. Retinal astrocytoma
D. Retinal detachment
Answer: [/INST] Retinal detachment </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Feeding difficulties', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Key Symptom - Body Odor**: The presence of a distinctive sweet, maple syrup-like odor (often noted in urine, sweat, or cerumen) is pathognomonic for MSUD, caused by accumulation of branched-chain keto acids.  
2. **Neonatal Onset & Severe Outcomes**: Symptoms like feeding difficulties, lethargy, and generalized hypotonia appearing in infancy, alongside neonatal death or death in infancy, align with the classic severe form of MSUD, which manifests within days of birth if untreated.  
3. **Neurological Involvement**: Drowsiness, sleep disturbances, and hypotonia result from neurotoxicity due to elevated branched-chain amino acids (leucine, isoleucine, valine) and their keto-acid derivatives, which disrupt cerebral function.  
4. **Hyperammonemia**: Though not a primary feature of MSUD, secondary hyperammonemia can occur during metabolic crises due to liver dysfunction or catabolic stress overwhelming urea cycle capacity.  
5. **Metabolic Crisis**: The combination of lethargy, feeding difficulties, and rapid deterioration reflects acute metabolic decompensation, a hallmark of untreated MSUD.  

This pattern of symptoms, especially the characteristic odor and neonatal presentation, strongly supports MSUD as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A child has received full Rabies vaccination in December 2018 and now presented with oozing wound on Great toe and the pet had vaccination also. Next line of management is
Choices:
A. No vaccine required
B. RIG + 5 doses of vaccine
C. 5 doses of vaccines only
D. 2 doses of Rabies vaccine
Answer: [/INST] 2 doses of Rabies vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: According to Bismuth classification, type IV Cholangiocarcinoma involves
Choices:
A. Common hepatic duct
B. Bifurcation only
C. Bifurcation and bilateral secondary intrahepatic ducts
D. Bifurcation and unilateral secondary intrahepatic ducts
Answer: [/INST] Bifurcation and bilateral secondary intrahepatic ducts </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Hernia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, leading to fetal complications (e.g., congenital defects, microcephaly).  
3. **Death in infancy/childhood and neonatal death** reflect untreated PKU’s natural progression, as toxic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure.  
4. **Hypertyrosinemia** is atypical in classic PKU but may arise in rare variants (e.g., BH4-deficient PKU) or secondary metabolic disruptions from liver dysfunction.  
5. **Hernia** is likely incidental, though malnutrition or connective tissue weakness from metabolic stress could contribute.  

Note: Hypertyrosinemia warrants further investigation for overlapping disorders (e.g., tyrosinemia), but hyperphenylalaninemia prioritizes PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common site of metastases in case of Osteosarcoma DELETE
Choices:
A. Brain
B. Lungs
C. Liver
D. Bladder
Answer: [/INST] Lungs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not an association for Keratoconus:
Choices:
A. Marfans Syndroma
B. Leber congenital amaurosis
C. Vernal kerato conjunctivitis
D. Senile Cataract
Answer: [/INST] Senile Cataract </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis control is achieved when -
Choices:
A. Tuberculosis conversion index in infants is <1%
B. Prevalence on natural infection in age group 0-14 years is in order of 10%
C. Annual infection rate <5%
D. Prevalence of natural infection in 0-14 years is <1%
Answer: [/INST] Prevalence of natural infection in 0-14 years is <1% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Major fibril protein in Primary Amyloidosis is?
Choices:
A. AL
B. AA
C. Transthyretin
D. Procalcitonin
Answer: [/INST] AL </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Dehydration', 'Hyperammonemia', 'Hyperhomocystinemia', 'Drowsiness', 'Sleep disturbance', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits hallmark biochemical features of methylmalonic acidemia (MMA), including **methylmalonic acidemia**, **methylmalonic aciduria**, and **decreased plasma free carnitine**. These findings result from impaired methylmalonyl-CoA mutase activity or cobalamin metabolism, leading to toxic accumulation of methylmalonic acid. Symptoms like **lethargy**, **generalized hypotonia**, **hyperammonemia**, and **dehydration** align with acute metabolic decompensation seen in MMA. **Death in infancy** and **delayed speech/development** reflect the severe, early-onset nature of untreated cases.  

Disease: Methylmalonic aciduria, vitamin B12-responsive, cblB type  
Reasoning: The presence of **hyperhomocystinemia** alongside methylmalonic aciduria suggests a cobalamin (vitamin B12) metabolism defect. The cblB type specifically involves mutations in the *MMAB* gene, disrupting adenosylcobalamin synthesis, which is critical for methylmalonyl-CoA mutase function. While cblB typically spares methionine synthase (thus homocysteine is usually normal), **hyperhomocystinemia** here may indicate secondary folate cycle disruption or overlapping metabolic stress. The inclusion of **vitamin B12-responsive** in the diagnosis is supported by MMA cases showing partial biochemical improvement with B12 supplementation, a hallmark of cblB/cblA subtypes. Symptoms like **drowsiness** and **sleep disturbances** further correlate with chronic neurometabolic dysfunction in this subtype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Inflammation of nerve is seen in -a) Leprosyb) Diabetes c) Guillain Barre Syndrome d) Diphtheria
Choices:
A. abc
B. acd
C. bc
D. bde
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Hydrocephalus exvacuo, the compensatory enlargement of ventricles and increase in CSF volume due to brain atrophy is seen in-
Choices:
A. Alzheimers diseae
B. Picks diseases
C. Both
D. None of the above
Answer: [/INST] Both </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tetralogy of Fallot's present with one of the following?
Choices:
A. Cenral cyanosis with clubbing
B. Cardiomegaly
C. Left ventricular hyperophy
D. Normal ECG and Chest x-ray
Answer: [/INST] Cenral cyanosis with clubbing </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Indicator for the outbreak of Plague epidemic is
Choices:
A. Rat burrow index
B. Total flea
C. Specific flea index
D. Cheopis index
Answer: [/INST] Cheopis index </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Brachycephaly', 'Hearing impairment', 'Recurrent otitis media', 'Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Global developmental delay', 'Motor delay', 'Generalized hypotonia', 'Truncal obesity', 'Sleep disturbance', 'Scoliosis', 'Short stature', 'Midface retrusion', 'Self-injurious behavior']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Magenis syndrome  
**Reasoning**:  
1. **Craniofacial features**: Brachycephaly (short skull) and midface retrusion align with the characteristic facial dysmorphism in Smith-Magenis syndrome (SMS).  
2. **Neurodevelopmental delays**: Global developmental delay, intellectual disability, motor delay, and speech/language delays are hallmark features of SMS, often linked to *RAI1* gene haploinsufficiency.  
3. **Behavioral phenotype**: Self-injurious behavior (e.g., head-banging, nail-pulling) is pathognomonic for SMS, alongside sleep disturbances (inverted melatonin rhythm causing fragmented sleep).  
4. **Musculoskeletal findings**: Hypotonia in infancy, scoliosis, and short stature are common due to connective tissue and skeletal involvement.  
5. **Otolaryngologic issues**: Recurrent otitis media and hearing impairment stem from craniofacial abnormalities (e.g., Eustachian tube dysfunction).  
6. **Metabolic features**: Truncal obesity emerges in late childhood/adolescence, likely due to hormonal dysregulation and behavioral factors.  
7. **Ocular involvement**: Strabismus is frequently observed in SMS due to craniofacial and neuromuscular factors.  

This constellation of symptoms, particularly the triad of developmental delay, self-injury, and circadian rhythm-driven sleep disturbances, strongly supports SMS, typically caused by a 17p11.2 deletion or *RAI1* mutation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is diagnostic of Rabies?
Choices:
A. Guarneri bodies
B. Negri bodies
C. Cowdry A body
D. Bollinger bodies
Answer: [/INST] Negri bodies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome, where high maternal phenylalanine disrupts fetal development (e.g., microcephaly, congenital heart defects).  
3. **Neonatal death/Death in infancy** occurs in severe, untreated PKU due to rapid neurotoxicity from extreme phenylalanine levels, causing metabolic encephalopathy.  
4. **Hypertyrosinemia** is atypical in classic PKU (expected hypotyrosinemia), but may reflect transient neonatal tyrosinemia, liver dysfunction, or a coexisting metabolic disturbance.  
5. The combination of hyperphenylalaninemia with early lethality strongly prioritizes PKU over other tyrosinemia disorders, despite the tyrosine elevation anomaly. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Cyanosis', 'Ataxia', 'Hyperreflexia', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Vomiting', 'Hypothermia', 'Hyperglycinemia', 'Methylmalonic acidemia', 'Decreased methylmalonyl-CoA mutase activity', 'Hyperalaninemia', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating arginine concentration', 'Hypervalinemia', 'Abnormal circulating carnitine concentration', 'Elevated plasma citrulline', 'Hyperornithinemia', 'Methylmalonic aciduria', 'Decreased circulating ferritin concentration', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Metabolic acidosis, hypoglycemia, vomiting, and hyperglycinemia** are hallmark features of methylmalonic acidemia (MMA), a disorder of branched-chain amino acid metabolism.  
2. **Methylmalonic acidemia/aciduria** directly indicates impaired methylmalonyl-CoA mutase function, critical for converting methylmalonyl-CoA to succinyl-CoA.  
3. **Decreased methylmalonyl-CoA mutase activity** confirms an enzymatic defect in this pathway.  
4. **Hypothermia, apathy, ataxia, dyskinesia, and hyperreflexia** reflect neurological toxicity from accumulating methylmalonic acid and other metabolites.  
5. **Abnormal carnitine levels** and **hypervalinemia/hyperalaninemia** suggest secondary disturbances in fatty acid and amino acid metabolism.  
6. **Death in infancy/childhood** aligns with severe, untreated MMA phenotypes.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Vitamin B12-unresponsiveness** is implied by **decreased methylmalonyl-CoA mutase activity** (direct enzyme defect) without features of B12 metabolism defects (e.g., homocystinuria).  
2. **Persistent metabolic acidosis, hyperglycinemia, and methylmalonic aciduria** despite B12 supplementation are diagnostic of this subtype.  
3. **Recurrent viral infections** and **abnormal arginine/citrulline/ornithine** levels may stem from secondary mitochondrial dysfunction or protein catabolism.  
4. **Decreased ferritin** could indicate oxidative stress or nutritional complications from chronic illness.  
5. **Neurological symptoms (ataxia, hyperreflexia)** correlate with basal ganglia injury seen in mutase-deficient MMA.  

Both diagnoses are consolidated under the primary disorder: **mutase-deficient MMA**, distinguished by B12-unresponsiveness and enzyme assay confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common manifestation of congenital Rubella syndrome is
Choices:
A. Cataract
B. Chorioretinitis
C. Deafness
D. Patent ductus arteriosus
Answer: [/INST] Deafness </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperphenylalaninemia', 'Abnormal circulating tyrosine concentration', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormal tyrosine concentration** (likely low) directly results from PAH dysfunction, as tyrosine synthesis is blocked.  
3. **Death in early adulthood** aligns with untreated/severe PKU, where chronic phenylalanine accumulation causes irreversible neurological damage, seizures, and organ failure. Early dietary management mitigates symptoms, but lack of treatment leads to reduced life expectancy.  
4. Alternative disorders (e.g., BH4 deficiency, tyrosinemia) are excluded due to the absence of specific features (e.g., neurotransmitter deficits, liver/kidney dysfunction). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Causes of breech presentation are:a) Hydrocephalusb) Oligohydramniosc) Pelvic contracture d) Placenta praevia
Choices:
A. acd
B. ad
C. bc
D. bde
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma most commonly metastases to-
Choices:
A. Liver
B. Bones
C. Lung
D. Pancrease
Answer: [/INST] Liver </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood** align with severe, untreated PKU, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
3. **Hypertyrosinemia** is atypical for classical PKU (which typically results in *low* tyrosine due to blocked PAH-dependent conversion). However, this could indicate:  
   - A comorbid condition (e.g., transient tyrosinemia of the newborn) or secondary metabolic disruption.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia is expected in PKU).  
4. The fatal outcomes emphasize the critical need for early newborn screening and dietary intervention in PKU to prevent catastrophic complications. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nephrotic syndrome', 'Tremor', 'Death in childhood', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **L-2-hydroxyglutaric aciduria** is explicitly listed as a biochemical finding, confirming excessive excretion of L-2-hydroxyglutaric acid in urine, a hallmark of this disorder.  
2. **Tremor** aligns with the neurological manifestations of L-2-HGA, which include ataxia, dystonia, and seizures due to cerebral organic acid accumulation.  
3. **Death in childhood** reflects the severe, progressive nature of the disease, often linked to neurodegeneration, metabolic crises, or complications like respiratory failure.  
4. **Nephrotic syndrome**, though atypical for classic L-2-HGA, may arise secondary to metabolic toxicity or mitochondrial dysfunction affecting renal podocytes, or indicate an overlapping/atypical variant of the disorder.  
The diagnosis prioritizes the biochemical marker (aciduria) and core neurological features, with nephrotic syndrome interpreted as a rare or comorbid complication in this case. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Modified plan of operation for Malaria is based on
Choices:
A. API
B. ABER
C. Spleen rate
D. Infant parasite rate
Answer: [/INST] API </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is most commonly caused by?
Choices:
A. Asbestosis
B. Silicosis
C. Anthracosis
D. Coal workers pneumoconiosis
Answer: [/INST] Asbestosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Weight loss', 'Leukopenia', 'Dyspnea', 'Vertigo', 'Elevated circulating creatine kinase concentration', 'Exercise intolerance', 'Ground-glass opacification', 'Foot pain', 'Autoimmune antibody positivity', 'Decreased DLCO']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Antisynthetase syndrome  
Reasoning:  
1. **Autoimmune antibody positivity**: A hallmark of antisynthetase syndrome (e.g., anti-Jo-1 antibodies).  
2. **Ground-glass opacification & decreased DLCO**: Indicates interstitial lung disease (ILD), a core feature of antisynthetase syndrome.  
3. **Elevated creatine kinase & exercise intolerance**: Suggests inflammatory myositis, another key component of the syndrome.  
4. **Foot pain**: May reflect inflammatory arthritis, part of the clinical triad (myositis, ILD, arthritis).  
5. **Dyspnea**: Correlates with ILD severity.  
6. **Weight loss & leukopenia**: Systemic inflammation or autoimmune-driven processes.  
7. **Vertigo**: Less specific but possible in autoimmune-mediated neuroinflammation or comorbidities.  

The constellation of ILD, myositis, and autoimmune serology strongly supports antisynthetase syndrome. Confirmatory testing for anti-synthetase antibodies (e.g., anti-Jo-1) and imaging/pulmonary function tests would solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Investigation of choice for Hydrocephalus in infants ?
Choices:
A. Cranial USG
B. CT Scan
C. MRI
D. X-ray skull
Answer: [/INST] Cranial USG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Conductive hearing impairment', '11 pairs of ribs', 'Thin ribs', 'Scoliosis', 'Posterior rib gap']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cerebrocostomandibular syndrome:  
1. **Pierre-Robin sequence and cleft palate**: Core features of CCMS, involving micrognathia (small jaw), glossoptosis (tongue displacement), and cleft palate.  
2. **Rib anomalies**: Pathognomonic findings include reduced rib count (11 pairs), thin ribs, posterior rib gaps, and scoliosis secondary to thoracic skeletal defects.  
3. **Conductive hearing impairment**: Linked to recurrent middle ear dysfunction, often associated with craniofacial malformations.  
4. **Exclusion of mimics**: Rib gaps and specific rib count abnormalities distinguish CCMS from other syndromes (e.g., Stickler or Treacher Collins).  
The constellation of craniofacial, auditory, and severe rib defects confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Decreased plasma free carnitine', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Metabolic Crisis Indicators**: Symptoms like vomiting and gastrointestinal inflammation align with metabolic decompensation during fasting, a hallmark of MCADD due to impaired fatty acid oxidation.  
2. **Fatality Timeline**: Neonatal/infant/childhood death correlates with untreated MCADD, where prolonged fasting triggers hypoglycemia, lethargy, and fatal metabolic crises.  
3. **Biochemical Markers**: Decreased plasma free carnitine occurs as carnitine binds to unmetabolized medium-chain acyl-CoA derivatives. Reduced 3-hydroxyacyl-CoA dehydrogenase activity (if misreported or a related enzyme) may reflect MCADD’s specific enzyme defect (MCAD).  
4. **Infection Susceptibility**: Recurrent viral infections may stem from energy deprivation impairing immune responses during metabolic stress.  
5. **Prenatal Abnormalities**: While MCADD typically lacks structural birth defects, severe metabolic dysfunction in utero could manifest as growth abnormalities or prenatal distress.  

Key confirmation would require genetic testing for *ACADM* mutations or elevated C6-C10 acylcarnitines on newborn screening. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Kernicterus', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Neonatal death', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation. While PKU classically presents with intellectual disability, seizures, and musty odor, severe untreated cases can result in **neonatal death** or **death in adolescence** due to profound neurological damage. **Obesity** may arise from a high-carbohydrate, low-protein diet used to manage PKU. However, **hypertyrosinemia** and **elevated urinary carboxylic acids** are atypical for PKU and suggest a coexisting metabolic disorder (e.g., tyrosinemia or organic acidemia). **Kernicterus** (bilirubin encephalopathy) and **recurrent infections** are not directly linked to PKU and may indicate additional hepatic or immune dysfunction. Further testing (e.g., BH4 responsiveness, tyrosine metabolites, urinary organic acids) is critical to address these inconsistencies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is least likely to be associated with Infective Endocarditis -
Choices:
A. Small ASD
B. Small VSD
C. Mild MR
D. Mild MS
Answer: [/INST] Small ASD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following conditions, Aniridia and Hemihyperophy are most likely present?
Choices:
A. Neuroblastoma
B. Wilms' tumour
C. Non-Hodgkin's lymphoma
D. Germ cell tumour
Answer: [/INST] Wilms' tumour </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Small intestinal biopsy is diagnostic in :a) Whipple's diseaseb) Abetalipoproteinemiac) Celiac diseased) Agammaglobulinemia
Choices:
A. acd
B. bcd
C. abd
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid Vi polysaccharide vaccine is usually administered in children above the age of :
Choices:
A. 6 months
B. 1 year
C. 2 years
D. 1 year 6 months
Answer: [/INST] 2 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which one of the following is the treatment of choice for Dermatitis Herpetiformis?
Choices:
A. Corticosteroids
B. Dapsone
C. Methotrexate
D. Retinoids
Answer: [/INST] Dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Abnormal circulating pyrimidine concentration', 'Decreased plasma free carnitine', 'Hyperprolinemia', 'Abnormal circulating arginine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria & Uraciluria**: Pathognomonic for OTCD. Accumulated carbamoyl phosphate diverts to pyrimidine synthesis, overproducing orotic acid and uracil.  
3. **Hyperglutaminemia**: Excess ammonia is converted to glutamine as an alternative detoxification pathway.  
4. **Elevated plasma citrulline**: Uncommon in classic OTCD but may occur in partial deficiencies or compensatory mechanisms, though typically low. This could reflect atypical presentation or overlapping metabolic stress.  
5. **Aminoaciduria/Hyperalaninemia/Hyperprolinemia**: Secondary to generalized amino acid overflow from impaired urea cycle function.  
6. **Metabolic acidosis**: Likely due to secondary organic acid accumulation or renal tubular dysfunction from ammonia toxicity.  
7. **Decreased plasma carnitine**: Carnitine depletion from increased acylcarnitine formation during metabolic crises.  
8. **Early mortality**: Aligns with severe urea cycle defects; untreated hyperammonemia leads to neurological damage and death.  

The triad of **hyperammonemia, oroticaciduria, and uraciluria** is diagnostic for OTCD, overriding atypical citrulline elevation. Other amino acid abnormalities and clinical outcomes further support this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Optic disc pallor', 'Spasticity', 'Dysphagia', 'Delayed gross motor development', 'Mutism', 'Poor head control', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Gastrostomy tube feeding in infancy', 'Pendular nystagmus']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and motor deficits**: Spasticity, delayed gross motor development, and poor head control align with hypomyelinating leukodystrophies, which disrupt white matter integrity, impairing motor neuron signaling.  
2. **Optic pathway involvement**: Optic disc pallor, reduced visual acuity, and pendular nystagmus suggest optic nerve hypomyelination, a hallmark of NKX6-2-related disorders due to oligodendrocyte dysfunction.  
3. **Developmental trajectory**: Infantile muscular hypotonia progressing to spasticity reflects the evolving nature of myelination defects, where initial low tone transitions to hypertonia as myelination fails.  
4. **Bulbar dysfunction**: Dysphagia and gastrostomy tube dependence indicate brainstem involvement, common in severe leukodystrophies affecting cranial nerve nuclei.  
5. **Mutism**: Likely secondary to severe motor dysfunction (anarthria) or corticobulbar tract damage, rather than cognitive impairment, typical in NKX6-2-related disease.  
6. **Genetic consistency**: Autosomal recessive NKX6-2 mutations disrupt transcriptional regulation of myelination, correlating with the observed hypomyelination phenotype.  
7. **Differential exclusion**: Overlap with Pelizaeus-Merzbacher disease is ruled out by the absence of PLP1 mutations and the presence of gastrostomy dependence/mutism, more specific to NKX6-2 pathology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Kernicterus is invariably associated with
Choices:
A. Crigler-Najjar syndrome type-I
B. Crigler-Najjar syndrome type-II
C. Dubin Johnson syndrome
D. Rotor syndrome
Answer: [/INST] Crigler-Najjar syndrome type-I </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which one of the following is not a feature of Phenylketonuria?
Choices:
A. Severe mental retardation
B. Reduced tendon reflexes
C. Enamel hypoplasia
D. Vomiting in early infancy
Answer: [/INST] Reduced tendon reflexes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The earliest manifestation of Alkaptonuria is -
Choices:
A. Ankylosis of lumbodorsal spine
B. Ochronotic arthritis
C. Prostatic calculi
D. Pigmentation of tympanic membrane
Answer: [/INST] Ochronotic arthritis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not a Cholera vaccine?
Choices:
A. Ty21a
B. CVD-103-HgR
C. WC-rBS
D. mORC-Vax
Answer: [/INST] Ty21a </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Babesiosis -
Choices:
A. Caused by Babesia microtia
B. Resides in RBC
C. Resides in WBC
D. Chloroquine is the treatment of choice
Answer: [/INST] Caused by Babesia microtia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Confirmatory investigation for Acromegaly is:
Choices:
A. Insulin induced GH suppression
B. Glucose induced GH suppression
C. Random GH assay
D. IGF - I level
Answer: [/INST] Glucose induced GH suppression </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Atypical behavior', 'Hyperactivity', 'Intellectual disability', 'Coma', 'Motor delay', 'Hepatic failure', 'Weight loss', 'Fever', 'Hyperammonemia', 'Vomiting', 'Cerebral cortical atrophy', 'Difficulty walking', 'Hyperglutaminemia', 'Oroticaciduria', 'Difficulty climbing stairs', 'Death in childhood', 'Difficulty running', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** indicate a urea cycle defect, as ammonia detoxification relies on this pathway.  
2. **Oroticaciduria** is pathognomonic for OTCD. Carbamoyl phosphate accumulates due to OTC enzyme deficiency, diverting into pyrimidine synthesis and generating excess orotic acid.  
3. **Hepatic failure** aligns with OTCD’s liver-specific urea cycle dysfunction.  
4. **Cerebral cortical atrophy**, **coma**, and **neurological symptoms** (motor delay, difficulty walking/running) stem from chronic neurotoxicity due to hyperammonemia.  
5. **Abnormal aspartate/alanine concentrations** reflect metabolic disruption in urea/amino acid metabolism.  
6. **Death in childhood/adolescence** is consistent with severe, untreated OTCD, as hyperammonemic crises are life-threatening.  
7. **Vomiting**, **fever**, and **weight loss** are nonspecific but common during metabolic decompensation.  
8. **Intellectual disability** and **atypical behavior** result from recurrent ammonia-induced brain injury.  

OTCD is the only diagnosis explaining all symptoms, particularly the triad of hyperammonemia, oroticaciduria, and hepatic involvement. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: McKneown’s Theory states that reduced prevalence of Tuberculosis occurs due to
Choices:
A. Enhanced knowledge and awareness
B. Medical advancements
C. Behavioural modification
D. Social and environmental factors
Answer: [/INST] Enhanced knowledge and awareness </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Obesity', 'Death in infancy', 'Hyperalaninemia', 'Aminoaciduria', 'Increased total bilirubin', 'Abnormality of galactoside metabolism', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating tyrosine concentration', 'Death in adolescence', 'Hypergalactosemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient exhibits hypergalactosemia and an abnormality of galactoside metabolism, directly implicating impaired galactose processing. Classic galactosemia (GALT deficiency) results in toxic accumulation of galactose-1-phosphate, leading to liver dysfunction (elevated bilirubin, hyperalaninemia, aminoaciduria) and metabolic derangements (abnormal tyrosine/aspartate family amino acids). Neonatal/infant mortality and adolescent death align with untreated cases due to liver failure, sepsis, or chronic complications. Delayed speech may reflect neurological damage from metabolite toxicity. Obesity is atypical but could arise from dietary adjustments or metabolic dysregulation.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This term encompasses broader galactose metabolism defects, including GALT, GALK1, or GALE deficiencies. The patient’s hypergalactosemia, galactoside metabolism abnormalities, and liver-related symptoms (increased bilirubin, aminoaciduria) are consistent with this category. Abnormal tyrosine/aspartate levels may reflect secondary disruptions in hepatic amino acid handling. Early mortality and developmental delays further support a severe, systemic galactosemia variant. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to deficient phenylalanine hydroxylase activity and impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth**: While PKU itself does not cause structural birth defects, untreated maternal PKU during pregnancy can result in congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. The symptom may reflect complications from maternal hyperphenylalaninemia affecting prenatal development.  
3. **Neonatal death/Death in infancy/Death in adolescence**: Severe, untreated PKU causes progressive neurotoxicity due to phenylalanine accumulation. Early death may occur from acute metabolic crises, seizures, or irreversible neurological damage. In classic PKU, death in adolescence is rare with modern screening and dietary management, but historically, untreated cases led to fatal outcomes.  

The constellation of symptoms aligns with severe, undiagnosed/untreated PKU, exacerbated by maternal PKU effects if applicable. Confirmation requires genetic testing and phenylalanine level analysis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is NOT seen in Paroxysmal Nocturnal Hemoglobinuria -
Choices:
A. Hypocellular bone marrow
B. Hemosiderinuria
C. Increased LAP score
D. Pancytopenia
Answer: [/INST] Increased LAP score </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are features of Scleroderma except
Choices:
A. Dysphagia
B. Raynaud's phenomenon
C. Skin contracture
D. Calcification in all the long bones
Answer: [/INST] Calcification in all the long bones </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: MCADD is an autosomal recessive disorder caused by mutations in the *ACADM* gene, which may manifest as subtle prenatal or neonatal metabolic instability.  
2. **Death in infancy/Neonatal death**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to hypoketotic hypoglycemia and metabolic crises during fasting. Untreated, this can rapidly progress to coma, seizures, or sudden death in infancy.  
3. **Abnormal circulating carnitine concentration**: MCADD causes secondary carnitine deficiency due to urinary loss of acylcarnitine adducts (e.g., C8, C10:1), while elevated medium-chain acylcarnitines (C6-C10) on newborn screening are pathognomonic.  
4. **Key biochemical correlation**: The combination of hypoglycemia, low free carnitine (C0), and elevated C8/C10:1 acylcarnitines strongly supports MCADD, distinguishing it from other fatty acid oxidation disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal hypoplasia', 'Focal segmental glomerulosclerosis', 'Nephrocalcinosis', 'Hepatic steatosis', 'Hepatic cysts', 'Splenomegaly', 'Thrombocytopenia', 'Diarrhea', 'Hyperuricemia', 'Hyperkalemia', 'Abnormal shoulder morphology', 'Increased blood urea nitrogen', 'Hyperuricosuria', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatinine concentration', 'Increased circulating ferritin concentration', 'Antinuclear antibody positivity', 'Elevated erythrocyte sedimentation rate', 'Abnormality of complement system', 'Constrictive median neuropathy', 'Decreased glomerular filtration rate', 'Upper limb pain', 'Lower limb pain', 'obsolete Increased urinary urate', 'Reduced haptoglobin level', 'Elevated prostate-specific antigen level', 'Neck pain', 'Shoulder pain', 'Anti-centromere antibody positivity', 'Abnormal blood phosphate concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: CREST syndrome  
Reasoning: The patient's anti-centromere antibody positivity is a hallmark of CREST syndrome. While classic CREST features (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasia) are not explicitly listed, secondary manifestations align with systemic involvement. Elevated ESR, ANA positivity, and complement abnormalities suggest autoimmune activity. Renal hypoplasia, glomerulosclerosis, and nephrocalcinosis may reflect chronic kidney damage from vascular or metabolic complications. Constrictive median neuropathy (carpal tunnel) and musculoskeletal pain could stem from fibrosis or inflammation. Elevated PTH and abnormal phosphate hint at metabolic bone disease, potentially linked to renal dysfunction.  

Disease: Scleroderma, familial progressive  
Reasoning: Familial progressive scleroderma encompasses broader systemic involvement. The patient’s hepatic steatosis, cysts, splenomegaly, and thrombocytopenia may indicate portal hypertension or liver fibrosis. Hyperuricemia, hyperuricosuria, and elevated creatinine correlate with progressive renal impairment, possibly due to scleroderma renal crisis (though atypical here). Elevated ferritin and reduced haptoglobin suggest chronic inflammation or hemolysis. Anti-centromere antibodies overlap with CREST, but familial progression implies genetic predisposition. Musculoskeletal pain, neuropathy, and elevated PSA (potentially inflammation-driven) further support diffuse connective tissue disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Facial palsy', 'Dark urine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Alkaptonuria:  
1. **Dark urine** is the hallmark symptom of alkaptonuria, caused by the accumulation and oxidation of homogentisic acid in urine. This is often the first sign noticed in infancy.  
2. **Generalized hypotonia** and **growth delay** may occur secondary to metabolic stress or systemic effects of chronic homogentisic acid accumulation, though these are not classic features of alkaptonuria and could indicate comorbid conditions.  
3. **Facial palsy** and **death in infancy** are atypical for alkaptonuria, which usually has a later-onset presentation (e.g., ochronosis, arthritis). These symptoms likely point to additional complications or misdiagnosis, but the presence of dark urine strongly prioritizes alkaptonuria as the primary diagnosis.  

*Note: While alkaptonuria explains the dark urine, the combination with severe infantile symptoms (e.g., death in infancy) suggests either an unusual presentation, coexisting disorders, or potential misalignment in the case details. Further testing for homogentisic acid in urine and genetic analysis for* HGD *gene mutations would confirm alkaptonuria.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles elimination criteria?
Choices:
A. < 1/1000
B. < 1/10000
C. <1/100000
D. <1/100
Answer: [/INST] <1/100000 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin irreversibly stimulates the cAMP-dependent pump in intestinal cells resulting in
Choices:
A. Cl- rich watery diarrhea
B. K+ rich watery diarrhea
C. Na+ rich watery diarrhea
D. Ca+ rich watery diarrhea
Answer: [/INST] Cl- rich watery diarrhea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: False about Leishmaniasis is
Choices:
A. Aldehyde Test of Napier is a good test for diagnosis
B. Indian Leishmaniasis is a non-zoonotic infection with man as the sole reservoir
C. Co-infection with AIDS is now emerging
D. There are no drugs for personal prophylaxis
Answer: [/INST] Aldehyde Test of Napier is a good test for diagnosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Ataxia', 'Coma', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Increased serum lactate', 'Stroke-like episode', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the branched-chain α-keto acid dehydrogenase (BCKDH) complex, the hallmark of MSUD.  
2. **Neurological symptoms**: Ataxia, irritability, coma, and stroke-like episodes arise from neurotoxicity caused by elevated leucine and its metabolites.  
3. **Metabolic decompensation**: Hyperammonemia and increased serum lactate reflect mitochondrial dysfunction and energy failure during metabolic crises.  
4. **Gastrointestinal involvement**: Vomiting and diarrhea are common during acute metabolic stress.  
5. **Early lethality**: Death in infancy/adolescence aligns with severe classical/intermediate MSUD phenotypes if untreated.  
6. **Secondary vulnerabilities**: Recurrent viral infections may stem from metabolic instability impairing immune responses.  
7. **Pathognomonic biochemical profile**: Combined elevation of valine, leucine, and isoleucine (with alloisoleucine) is unique to MSUD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hyperammonemia', 'Dyspnea', 'Abnormality of urine homeostasis', 'Neonatal death', 'Abnormal nervous system physiology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency)  
Reasoning:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), particularly CPS1 deficiency, as CPS1 catalyzes the first and rate-limiting step of ammonia detoxification.  
2. **Neonatal death** and **death in infancy** align with severe UCDs, which often present catastrophically in the first days of life due to ammonia toxicity.  
3. **Dyspnea** may reflect respiratory alkalosis from hyperventilation, a compensatory response to ammonia-induced cerebral edema.  
4. **Abnormality of urine homeostasis** (e.g., orotic acid absence in urine) distinguishes CPS1 deficiency from other UCDs (e.g., OTC deficiency), as CPS1 defects do not cause orotic aciduria.  
5. **Abnormal nervous system physiology** (lethargy, seizures, coma) results from ammonia crossing the blood-brain barrier, causing neurotoxicity.  
6. The absence of secondary markers like elevated orotic acid confirms CPS1 deficiency over other UCDs, matching the biochemical profile of the diagnosed disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following true regarding Hemophilia A
Choices:
A. Serum levels of factor VIII are decreased
B. Deficiency of factor IX
C. PT increased
D. FIT decreased
Answer: [/INST] Serum levels of factor VIII are decreased </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Group B (flaviviruses) Arboviruses is/are-a) Dengue feverb) Rift valley feverc) Chikungunya feverd) J.E.e) Yellow fever
Choices:
A. acd
B. bde
C. ade
D. ad
Answer: [/INST] ade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The immunoglobulin most commonly involved in Multiple Myeloma is :
Choices:
A. IgG
B. IgM
C. IgA
D. IgD
Answer: [/INST] IgG </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: DOC for management of visceral Leishmaniasis:
Choices:
A. Parenteral Sodium stibogluconate
B. Liposomal Amphotericin B
C. Miltefosine
D. Pentamidine
Answer: [/INST] Liposomal Amphotericin B </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Trisomy 18 is known as -
Choices:
A. Edward Syndrome
B. Patau sundrome
C. Cat eye syndrome
D. Down's syndrome
Answer: [/INST] Edward Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella causes all except
Choices:
A. Microcephaly
B. VSD
C. PDA
D. AS
Answer: [/INST] AS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: National health policy which started before 1960 is/are – a) National Filaria Control Programmeb) National Malaria Control Programmec) National Leprosy Control Programmed) National Tuberculosis Programmee) Goitre Control Programme
Choices:
A. ab
B. abc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: MMR (Measles, mumps, rubella) vaccine is an example of:
Choices:
A. Live attenuated vaccine
B. Conjugated vaccine
C. Polysaccharide vaccine
D. Killed vaccine
Answer: [/INST] Live attenuated vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid intestinal perforation is usually occurs in which week of typhoid fever?
Choices:
A. 2nd - 3rd week
B. 4th - 5th week
C. 5th - 7th week
D. 6th - 8th week
Answer: [/INST] 2nd - 3rd week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is a disease of
Choices:
A. Neural transmission caused by the toxin of the bacterium clostridium botulinum
B. Muscular transmission caused by the toxin of the bacterium clostridium botulinum
C. Neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum
D. Non neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum
Answer: [/INST] Neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Hypoglycemia', 'Drowsiness', 'Sleep disturbance', 'Glycosuria', 'Death in childhood', 'Impairment of fructose metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Fructose-1,6-bisphosphatase deficiency  
Reasoning:  
1. **Hypoglycemia** and **metabolic acidosis** are hallmark features of fructose-1,6-bisphosphatase deficiency due to impaired gluconeogenesis, leading to glucose production failure during fasting and compensatory fat breakdown (causing ketosis and acidosis).  
2. **Impairment of fructose metabolism** arises because fructose ingestion exacerbates metabolic stress by depleting intracellular phosphate, worsening hypoglycemia and acidosis.  
3. **Glycosuria** may occur during metabolic crises, potentially from transient renal dysfunction or altered glucose homeostasis despite systemic hypoglycemia.  
4. **Lethargy**, **drowsiness**, **apathy**, and **sleep disturbances** reflect neurological impacts of hypoglycemia and acidosis.  
5. **Death in infancy/childhood** aligns with untreated metabolic decompensation during fasting or illness, which is life-threatening without prompt glucose supplementation and fructose/sucrose avoidance.  
6. Exclusion of hereditary fructose intolerance (HFI) is critical, as HFI primarily causes liver/kidney damage post-fructose ingestion but lacks fasting-induced hypoglycemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Congenital Rubella syndrome may have the following clinical features, except
Choices:
A. Intrauterine growth retardation
B. Neonatal hepatitis
C. Congenital cataract
D. Hydrocephalus
Answer: [/INST] Hydrocephalus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: keinbock Osteonecrosis, all true except
Choices:
A. Tenderness over base of 3rd metacarpall is present
B. Pain is more on wrist flexion than wrist extension
C. Is the osteochondritis of lunate
D. common age group 20-40
Answer: [/INST] Pain is more on wrist flexion than wrist extension </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which type ofAmyloidosis is caused by mutation of the transthyretin protein ?
Choices:
A. Familial Mediterranean fever
B. Familial amyloidotic polyneuropathy
C. Dialysis associated amyloidosis
D. Prion protein associated amyloidosis
Answer: [/INST] Familial amyloidotic polyneuropathy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Petechiae', 'Abnormality of skin pigmentation', 'Death in infancy', 'Thrombocytopenia', 'Hypoglycemia', 'Hyperammonemia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Hypermethioninemia', 'Prolonged partial thromboplastin time', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Pigmentation of the sclera', 'Ichthyosis', 'Abnormal circulating porphyrin concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1 (HT-1)  
Reasoning:  
1. **Metabolic abnormalities**: Hypertyrosinemia, hypermethioninemia, hyperphenylalaninemia, and 4-hydroxyphenylpyruvic aciduria directly indicate a defect in tyrosine metabolism, specifically a deficiency of fumarylacetoacetate hydrolase (FAH) in HT-1.  
2. **Liver dysfunction**: Hypoglycemia, hyperammonemia, elevated alpha-fetoprotein, and hypermethioninemia reflect hepatic injury and impaired tyrosine catabolism.  
3. **Coagulopathy**: Thrombocytopenia, prolonged partial thromboplastin time, and petechiae result from liver failure reducing clotting factor synthesis.  
4. **Skin manifestations**: Ichthyosis, abnormal pigmentation, and scleral pigmentation arise from tyrosine deposition and secondary metabolic disruptions (e.g., porphyrin abnormalities).  
5. **Early fatality**: Death in infancy/childhood aligns with acute HT-1’s rapid progression due to liver failure, renal tubular dysfunction, and metabolic crises.  
6. **Biochemical markers**: Elevated alkaline phosphatase (cholestasis) and hyperammonemia (urea cycle stress) further support hepatorenal involvement.  
**Exclusion**: Other tyrosinemia types (II/III) lack severe liver/kidney phenotypes. HT-1 uniquely combines hepatic, neurologic, and dermatologic features with specific amino acid abnormalities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements about Mallory Weiss Syndrome are true:
Choices:
A. Presents with hemoptysis
B. Shows transmural rupture
C. Chest pain and shoness of breath
D. Shows mucosal tear
Answer: [/INST] Shows mucosal tear </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of male external genitalia', 'Hearing impairment', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Absent speech', 'Abnormality of the cardiovascular system', 'Feeding difficulties', 'Heart murmur']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Stankiewicz-Isidor syndrome  
Reasoning:  
1. **Abnormality of male external genitalia**: A hallmark feature of Stankiewicz-Isidor syndrome, often due to urogenital anomalies like hypospadias or cryptorchidism.  
2. **Hearing impairment**: Reported in some cases, though less common, possibly linked to neurodevelopmental deficits.  
3. **Neurodevelopmental delays (absent speech, motor delay, intellectual disability)**: Core features of the syndrome, driven by pathogenic *PACS1* gene variants affecting neuronal development.  
4. **Seizures**: Observed in affected individuals, consistent with neurological involvement.  
5. **Autistic behavior/atypical behavior**: Aligns with the syndrome’s behavioral phenotype, including social communication challenges.  
6. **Cardiovascular abnormalities/heart murmur**: Congenital heart defects (e.g., septal defects) are recurrent findings.  
7. **Feeding difficulties**: Common in infancy due to hypotonia or oromotor dysfunction.  
The combination of genitourinary, cardiac, and severe neurodevelopmental symptoms strongly supports Stankiewicz-Isidor syndrome, with *PACS1* testing recommended for confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the eye', 'Arachnodactyly', 'Peripheral arterial stenosis', 'Death in adolescence', 'Abnormal nervous system physiology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Abnormality of the eye**: Homocystinuria commonly causes ectopia lentis (dislocation of the ocular lens), leading to visual impairment.  
2. **Arachnodactyly**: Elevated homocysteine disrupts collagen cross-linking, resulting in Marfanoid habitus, including long, slender fingers.  
3. **Peripheral arterial stenosis**: Vascular damage from homocysteine-induced endothelial injury and thromboembolism predisposes to arterial stenosis and occlusion.  
4. **Death in adolescence**: Untreated homocystinuria carries high mortality from thromboembolic events (e.g., stroke, pulmonary embolism) or cardiovascular complications in early life.  
5. **Abnormal nervous system physiology**: Homocysteine neurotoxicity and thromboembolic strokes cause seizures, intellectual disability, or psychiatric manifestations.  

The combination of ocular, skeletal, vascular, and neurological features with early mortality strongly supports **cystathionine beta-synthase (CBS) deficiency**, the most common form of homocystinuria. Biochemical confirmation via elevated plasma homocysteine and methionine, with reduced cystathionine, would be definitive. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy causes?
Choices:
A. Rapidly progressive GN
B. Focal glomerulosclerosis
C. Membranoproliferative GN
D. Acute glomerulonephritis
Answer: [/INST] Focal glomerulosclerosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Alopecia', 'Fasciculations', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD/Biotinidase deficiency  
Reasoning:  
1. **Seizures & Hypotonia**: Biotinidase deficiency disrupts biotin recycling, impairing carboxylase enzymes critical for energy metabolism and neurotransmitter synthesis, leading to neurological dysfunction.  
2. **Elevated Urinary Carboxylic Acids**: Biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase) malfunction, causing organic acid accumulation (e.g., 3-hydroxyisovaleric acid), detectable in urine.  
3. **Alopecia**: Biotin is essential for keratin synthesis; deficiency results in hair loss.  
4. **Growth Delay & Death in Infancy**: Metabolic crises from untreated acidosis, hyperammonemia, and catabolism impair growth and are fatal without biotin supplementation.  
5. **Fasciculations**: Secondary to neuronal hyperexcitability from metabolic disturbances.  
6. **Diagnostic Confirmation**: The term ""late-onset multiple carboxylase deficiency"" refers to partial biotinidase deficiency, but severe infantile forms present acutely with this symptom cluster. Early biotin treatment reverses symptoms, underscoring urgency in diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is transmitted in Rural areas by ?
Choices:
A. Anopheles stephensi
B. Anopheles dirus
C. Anopheles culicifacies
D. None
Answer: [/INST] Anopheles culicifacies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Homocysteinemia; Homocystinuria  
Reasoning: The presence of **hyperhomocystinemia** and **aminoaciduria** directly indicates impaired homocysteine metabolism, a hallmark of homocystinuria. Elevated homocysteine levels disrupt connective tissue, vascular, and nervous systems, which aligns with **abnormality of prenatal development** and early mortality (**neonatal death**, **death in infancy/childhood**).  

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** is specific to cystathionine beta-synthase (CBS) deficiency, as methionine cannot be converted to homocysteine in this disorder. CBS deficiency causes accumulation of both homocysteine and methionine, explaining the biochemical findings. Severe forms of this autosomal recessive condition lead to life-threatening complications (e.g., thromboembolism, organ failure) during early life, consistent with **death in infancy/childhood** and developmental abnormalities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Achondroplasia except
Choices:
A. Antosomal dominant
B. Acral osteolysis
C. Trident hand
D. Champaigne glass pelvis
Answer: [/INST] Acral osteolysis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: When should you perform Widal test in a case of Typhoid?
Choices:
A. 1st week
B. 2nd week
C. 3rd week
D. 4th week
Answer: [/INST] 2nd week </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Torticollis', 'Vertical supranuclear gaze palsy', 'Hypometric saccades', 'Supranuclear gaze palsy', 'Nystagmus', 'Ataxia', 'Dysarthria', 'Motor delay', 'Cerebellar atrophy', 'Dystonia', 'Morphological abnormality of the pyramidal tract', 'Spastic ataxia', 'Inability to walk', 'CNS hypomyelination', 'Somatic sensory dysfunction', 'Demyelinating peripheral neuropathy', 'Peripheral neuropathy', 'Abnormal involuntary eye movements', 'Titubation']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8  
Reasoning:  
1. **Hypomyelination**: The presence of **CNS hypomyelination** and **demyelinating peripheral neuropathy** indicates a leukodystrophy with combined central and peripheral nervous system involvement, a hallmark of NKX6-2-related disorders.  
2. **Spastic ataxia**: **Ataxia**, **spasticity**, **cerebellar atrophy**, and **morphological pyramidal tract abnormalities** align with the ""spastic ataxia"" phenotype linked to NKX6-2 mutations.  
3. **Oculomotor deficits**: **Vertical supranuclear gaze palsy**, **hypometric saccades**, and **abnormal eye movements** are consistent with brainstem and cerebellar dysfunction seen in this disorder.  
4. **Motor dysfunction**: **Inability to walk**, **dystonia**, **titubation**, and **motor delay** reflect progressive cerebellar and pyramidal tract degeneration.  
5. **Peripheral neuropathy**: **Somatic sensory dysfunction** and **peripheral neuropathy** support the dual central-peripheral hypomyelination pattern unique to NKX6-2-related disease.  
6. **Exclusion of mimics**: The combination of central hypomyelination, spastic ataxia, and peripheral neuropathy distinguishes this from other leukodystrophies (e.g., Pelizaeus-Merzbacher disease, 4H syndrome) or isolated spinocerebellar ataxias. Genetic confirmation of NKX6-2 mutations would be definitive. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma histologically resembles
Choices:
A. Squamous cell type
B. Colloid cell type
C. Schirrhous type
D. Columnar type
Answer: [/INST] Schirrhous type </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acid**: MSUD is caused by a defect in branched-chain α-keto acid dehydrogenase, leading to accumulation of branched-chain amino acids (leucine, isoleucine, valine) and their toxic keto-acid derivatives (carboxylic acids) in urine.  
2. **Body odor**: The distinctive maple syrup or burnt sugar odor in bodily fluids is pathognomonic for MSUD due to urinary excretion of sotolone, a compound derived from accumulated keto-acids.  
3. **Feeding difficulties & vomiting**: Acute metabolic decompensation from protein intake overwhelms the impaired enzymatic pathway, causing gastrointestinal distress.  
4. **Generalized hypotonia & growth delay**: Neurotoxic effects of elevated leucine disrupt cerebral metabolism and myelination, impairing neuromuscular function and growth.  
5. **Neonatal death/death in infancy**: Classic severe MSUD manifests within days of birth; untreated hyperleucinosis causes cerebral edema, seizures, and rapid neurological decline.  
6. **Consistency with metabolic crisis**: Symptom triad of encephalopathy, feeding refusal, and odor aligns with acute neonatal-onset MSUD, distinguishing it from other organic acidurias (e.g., propionic acidemia lacks the maple syrup odor). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which one of the following is not a feature of Phenylketonuria ?
Choices:
A. Severe mental retardation
B. Reduced tendon reflexes
C. Enamel hypoplasia
D. Vomiting in early infancy
Answer: [/INST] Reduced tendon reflexes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following are causes of face presentation in a foetus? 1. Anencephaly 2. Multiparity 3. Hydraminos 4. Contracted Pelvis 5. Placenta prae
Choices:
A. 1, 2, 3 - False & 4, 5 - True
B. 2, 3, 4 - True & 1, 5 - False
C. 2, 3, 4 - False & 1, 5 - True
D. 1, 2, 4 - True & 3, 5 - False
Answer: [/INST] 1, 2, 4 - True & 3, 5 - False </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Delayed speech and language development**: Untreated PKU causes neurotoxicity from elevated phenylalanine, impairing cognitive and language development.  
3. **Abnormality of prenatal development or birth**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though neonatal PKU itself may present with nonspecific metabolic instability.  
4. **Hypertyrosinemia**: Secondary tyrosine elevation is atypical in classic PKU but may occur transiently due to metabolic dysregulation or overlap with other tyrosine metabolism disorders (e.g., tyrosinemia type II), though PKU remains primary here.  
5. **Early mortality (infancy/childhood/adulthood)**: Untreated PKU leads to severe neurological deterioration, seizures, and organ damage, historically causing premature death. Neonatal death is rare unless compounded by acute metabolic crises or misdiagnosis.  

**Conclusion**: Symptoms align with severe, untreated PKU, exacerbated by delayed diagnosis or lack of dietary management. Hypertyrosinemia may indicate a complex metabolic interplay but does not override the primary PKU diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment of Congenital Hydrocephalus is
Choices:
A. Stereotactic Surgery
B. Diuretics
C. Radiotherapy
D. VP shunt
Answer: [/INST] VP shunt </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma of the jaw:
Choices:
A. Occurs mostly in the maxilla
B. Seen in old age
C. Highly malignant tumour which shows early metastasis
D. Shows a soap bubble type of radiolucency in radiographs
Answer: [/INST] Highly malignant tumour which shows early metastasis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: FALSE about Leprosy eradication programme is –
Choices:
A. Early detection of cases
B. Disability limitation
C. Long term multi drug therapy
D. Health education
Answer: [/INST] Long term multi drug therapy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are features of SVC Syndrome except-
Choices:
A. Facial swelling
B. Dilatation and congestion of neck veins
C. Headache
D. Hoarseness of voice
Answer: [/INST] Hoarseness of voice </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strain used for production of Measles vaccine is:
Choices:
A. Jeryl Lynn strain
B. 17 - D strain
C. Ankara strain
D. Edmonston Zagreb strain
Answer: [/INST] Edmonston Zagreb strain </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following antibodies is most frequently seen in Antiphospholipid Syndrome ? -
Choices:
A. Beta 2 microglobulin antibody
B. Anti-nuclear antibody
C. Anti-centromere antibody
D. Anti- beta 2 glycoprotein antibody
Answer: [/INST] Anti- beta 2 glycoprotein antibody </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a feature of Phenylketonuria?
Choices:
A. Loss of deep tendon reflexes
B. Mental retardation
C. Macrocephaly
D. All
Answer: [/INST] Mental retardation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Leukopenia', 'Metabolic acidosis', 'Hyperammonemia', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Biotinidase deficiency impairs the activity of biotin-dependent carboxylases (e.g., propionyl-CoA carboxylase, pyruvate carboxylase), disrupting amino acid catabolism and urea cycle function. This leads to accumulation of organic acids (e.g., lactate, propionate) and ammonia.  
2. **Leukopenia**: Secondary to bone marrow suppression from metabolic toxins (e.g., organic acids) or biotin-dependent immune dysfunction.  
3. **Generalized hypotonia**: Caused by energy deficiency in muscles/nerves due to defective mitochondrial carboxylases and hyperammonemia-induced neurotoxicity.  
4. **Neonatal death/death in infancy**: Untreated BTDD causes progressive metabolic crises, seizures, and cardiorespiratory failure. Neonatal-onset cases often present with rapid deterioration without early biotin supplementation.  
5. **Exclusion of mimics**: Symptoms overlap with organic acidemias (e.g., propionic acidemia), but leukopenia and biotin-responsiveness distinguish BTDD.  

**Conclusion**: The triad of metabolic acidosis, hyperammonemia, and leukopenia in a critically ill neonate aligns with late-onset multiple carboxylase deficiency due to biotinidase deficiency. Early mortality reflects delayed diagnosis and lack of biotin therapy. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about 'Tetralogy of Fallot' (TOF) are all of the following EXCEPT?
Choices:
A. It is the most common congenital cyanotic hea disease in children
B. Severity of disease depends on the severity of pulmonary stenosis
C. Atrial septal defect is one of the components of TOF
D. Boot shaped hea is seen on chest X ray
Answer: [/INST] Atrial septal defect is one of the components of TOF </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Millary shadow on chest X-ray is seen in – a) Tuberculosisb) Rheumatoid arthritisc) Pneumoconiosisd) COPDe) Metastasis
Choices:
A. bcde
B. abcd
C. abce
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ichthyosis may be associated with: September 2003
Choices:
A. Carcinoma lung
B. Carcinoma breast
C. Leukemia
D. Lymphoma
Answer: [/INST] Lymphoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high maternal phenylalanine levels disrupt fetal development, though neonatal PKU itself typically manifests postnatally.  
3. **Hypertyrosinemia** is atypical in classic PKU (which usually causes *hypo*tyrosinemia). This may suggest a concurrent metabolic defect (e.g., transient tyrosinemia in neonates or a secondary pathway disruption) or a severe PAH variant affecting tyrosine metabolism indirectly.  
4. **Neonatal death/Death in infancy** correlates with untreated or severe PKU variants, where toxic phenylalanine levels cause irreversible neurological damage, seizures, and organ failure.  
5. The combination of hyperphenylalaninemia and early lethality strongly prioritizes PKU, though hypertyrosinemia warrants investigation for comorbid conditions (e.g., tyrosinemia type II) or BH4 metabolism disorders.  

Note: Hypertyrosinemia is incongruent with classic PKU and may indicate a complex case requiring additional biochemical/genetic analysis (e.g., BH4 deficiency or dual enzyme defects). However, hyperphenylalaninemia remains the primary diagnostic anchor. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cutaneous (skin) Tuberculosis secondary to underlying tissue eg lymph node is called as
Choices:
A. Lupus Vulgaris
B. Scrofuloderma
C. Spina Ventosa
D. Tuberculous Verrucosa Cutis
Answer: [/INST] Scrofuloderma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are used in the treatment of Thrombotic Thrombocytopenic Purpura, Except.
Choices:
A. Plasmapharesis
B. Coicosteroids
C. Immunotherapy
D. Heparin
Answer: [/INST] Heparin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Dyspnea', 'Apnea', 'Opisthotonus', 'Spastic tetraplegia', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Body odor']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (BCAAs):** Hypervalinemia, hyperleucinemia, and hyperisoleucinemia are pathognomonic for MSUD, as the disease disrupts the breakdown of BCAAs due to a deficiency in the branched-chain α-keto acid dehydrogenase complex.  
2. **Metabolic acidosis:** Accumulation of toxic keto acids (from BCAAs) overwhelms buffering systems, leading to acidosis.  
3. **Neurological symptoms:** Seizures, spastic diplegia/tetraplegia, motor delay, and opisthotonus result from neurotoxicity caused by elevated leucine and its metabolites.  
4. **Respiratory and feeding issues:** Dyspnea, apnea, and feeding difficulties arise from metabolic decompensation and neurological dysfunction.  
5. **Odor and fatal course:** The characteristic ""maple syrup"" body odor (due to alloisoleucine) and neonatal death/infant mortality align with classic severe MSUD phenotypes.  
6. **Generalized hypotonia:** Reflects acute metabolic encephalopathy and impaired energy metabolism in neurons.  

The combination of BCAA elevation, metabolic derangements, and rapid neurological decline confirms MSUD as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are WHO classified Myelodysplastic Syndromes except:
Choices:
A. CML
B. Refractory anemia with excess blasts
C. Refractory anemia with ringed sideroblasts
D. Refractory anemia
Answer: [/INST] CML </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid Mary his known in history to cause more than 1300 cases in her lifetime. This is an example of which of the following epidemic?
Choices:
A. Common source single exposure epidemic
B. Common source continuous or repeated exposure epidemic
C. Long term or secular trend epidemic
D. Propagated epidemic
Answer: [/INST] Common source continuous or repeated exposure epidemic </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acalculus cholecystitis caused by:a) DMb) TPNc) Leptospirosisd) Estrogen therapy
Choices:
A. abc
B. bc
C. acd
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies can be transmitted by all the following routes except -
Choices:
A. Aerosol
B. Bites
C. Ingestion
D. Ingestion
Answer: [/INST] Ingestion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Major fibril protein in Primary Amyloidosis is ?
Choices:
A. AL
B. AA
C. Transthyretin
D. Procalciton
Answer: [/INST] AL </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Dystonia', 'Cerebral atrophy', 'Glutaric aciduria', 'Subdural hemorrhage']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: Often presents in infancy due to frontotemporal atrophy or benign external hydrocephalus, a common early sign of GA-I.  
3. **Dystonia**: Results from striatal neurodegeneration (especially caudate/putamen damage), triggered by metabolic crises during catabolic states (e.g., infections), a hallmark of GA-I.  
4. **Cerebral atrophy**: Progressive neurodegeneration in basal ganglia and white matter, exacerbated by untreated metabolic decompensation.  
5. **Subdural hemorrhage**: Secondary to cerebral atrophy and vascular fragility, sometimes mimicking non-accidental trauma in infants.  

The combination of neurodevelopmental regression, characteristic biochemical markers, and neuroimaging findings aligns definitively with GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Increased Monocytic count is seen in Typhoid and which of the following conditions?
Choices:
A. Parasitic infections
B. Sub-Acute Bacterial Endocarditis
C. Hodgkin's Lymphoma
D. None of the above
Answer: [/INST] Sub-Acute Bacterial Endocarditis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true regarding Typhoid carrier?
Choices:
A. Convalescent carriers excrete the organism for 6 - 8 weeks
B. Chronic carriers excrete bacilli for many years
C. Chronic carrier state is associated with presence of bacilli in gall bladder
D. Urinary carrier is more common than fecal carrier
Answer: [/INST] Urinary carrier is more common than fecal carrier </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is seen in all except?
Choices:
A. Barter syndrome
B. Hypokalemic periodic paralysis
C. 21 hydroxylase deficiency
D. Reninoma (JG cell tumour)
Answer: [/INST] 21 hydroxylase deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is characterized by all of the folowing except -
Choices:
A. Sleep paralys is
B. Cataplexy
C. Hallucination
D. Snoring
Answer: [/INST] Snoring </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Arsenic is assocaited with increased risk of   a) Mesothelioma   b) Melanoma     c) Basal cell carcinoma  d) Squamous cell carcinoma
Choices:
A. ad
B. bd
C. cd
D. ab
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Clinical features of Botulism are all EXCEPT:
Choices:
A. Diarrhoea
B. Constipation
C. Ocular nerve paralysis
D. Blurring of vision
Answer: [/INST] Diarrhoea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Autistic behavior', 'Delayed speech and language development', 'Intellectual disability', 'Absent speech', 'Sleep apnea', 'Enuresis nocturna']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Core neurodevelopmental symptoms**: Autistic behavior, delayed speech/absent speech, and intellectual disability are hallmark features of NEDBEH, a disorder linked to DIDO1 gene mutations. These align with its characteristic developmental delays.  
2. **Sleep apnea**: Could reflect brainstem dysfunction or structural airway anomalies, which fall under the ""brain anomalies"" spectrum of NEDBEH.  
3. **Enuresis nocturna**: Often secondary to neurodevelopmental delays in bladder control maturation, consistent with global intellectual disability.  
4. **Absence of specified eye/heart anomalies**: The diagnosis accommodates presentations without these features, focusing on the neurodevelopmental core.  
5. **Exclusion of mimics**: Symptoms collectively fit NEDBEH better than isolated autism spectrum disorder or other syndromic intellectual disabilities due to the combination with sleep-disordered breathing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are true about Kernicterus EXCEPT:
Choices:
A. Kernicterus is due to Unconjugated Hyperbilirubinemia
B. Yellowish staining of Basal Ganglia is seen
C. Prematurity is a risk factor
D. Not associated with increased morbidity
Answer: [/INST] Not associated with increased morbidity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning: Hyperphenylalaninemia is the defining biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine-to-tyrosine conversion.  
Reasoning: Untreated PKU leads to toxic phenylalanine accumulation, resulting in severe neurological damage, developmental failure, and early mortality (death in infancy/childhood).  
Reasoning: Hypertyrosinemia is atypical in classic PKU but may indicate a co-occurring BH4 deficiency (a PKU variant), where impaired tyrosine hydroxylase activity disrupts tyrosine metabolism, causing its accumulation.  
Reasoning: Pustules could reflect secondary skin manifestations from tyrosine-derived metabolites or oxidative stress due to systemic metabolic dysfunction. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Dicarboxylic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Seizures**: Result from impaired mitochondrial energy production in the brain, causing neuronal hyperexcitability due to ATP deficiency.  
2. **Motor delay and generalized hypotonia**: Caused by defective oxidative phosphorylation in skeletal muscles, leading to weakness and delayed motor milestones.  
3. **Death in infancy**: Severe forms of complex IV deficiency (e.g., SURF1-related Leigh syndrome) cause rapid neurodegeneration and metabolic crises, often fatal within the first years of life.  
4. **Dicarboxylic aciduria**: Secondary to inefficient fatty acid β-oxidation, as mitochondrial dysfunction forces reliance on alternative energy pathways, producing dicarboxylic acids.  
5. **Complex IV (cytochrome c oxidase) deficiency**: Confirmed by biochemical findings (e.g., elevated lactate, reduced enzyme activity) and genetic variants in nuclear genes (e.g., SURF1) critical for complex IV assembly.  
This constellation aligns with nuclear-encoded mitochondrial complex IV deficiency type 1, typically presenting with Leigh-like symptoms and metabolic derangements. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma arises from
Choices:
A. Layer of rods & cones
B. Layer of bipolar cells
C. External limiting membrane
D. Any nucleated retinal layer
Answer: [/INST] Any nucleated retinal layer </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is seen in therapy with
Choices:
A. Digitalis
B. Ibuprufen
C. Corticosteroids
D. Diazepam
Answer: [/INST] Digitalis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid is treated by all except
Choices:
A. Erythromycin
B. Ceftriaxone
C. Amikacin
D. Ciprofloxacin
Answer: [/INST] Erythromycin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Recurrent corneal erosions', 'Alacrima', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Intrauterine growth retardation', 'Constipation', 'Increased serum lactate', 'EEG abnormality', 'Scoliosis', 'Elevated hepatic transaminase', 'Peripheral neuropathy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Alacrima**: A core diagnostic feature of CDDG1, explaining the absence of tears.  
2. **Recurrent corneal erosions**: Secondary to alacrima due to lack of tear lubrication and corneal protection.  
3. **Elevated hepatic transaminase**: Reflects liver dysfunction, a key component of the syndrome.  
4. **Global developmental delay & Hypotonia**: Consistent with neurological involvement in CDDG1, linked to defective deglycosylation affecting brain development.  
5. **Microcephaly & Intrauterine growth retardation (IUGR)**: Aligns with congenital growth and neurodevelopmental deficits in CDDG1.  
6. **Increased serum lactate**: Suggests mitochondrial dysfunction, common in metabolic disorders like CDDG1.  
7. **EEG abnormality & Peripheral neuropathy**: Indicates central and peripheral nervous system abnormalities, typical of deglycosylation defects.  
8. **Reduced tendon reflexes**: Likely due to peripheral neuropathy or hypotonia.  
9. **Scoliosis**: May arise from neuromuscular hypotonia or connective tissue involvement.  
10. **Constipation**: Gastrointestinal dysmotility, often seen in CDGs due to autonomic or muscular dysfunction.  

The triad of **alacrima, liver dysfunction, and neurological deficits** (developmental delay, hypotonia, neuropathy), alongside supportive features (IUGR, metabolic derangements), confirms CDDG1, typically caused by *NGLY1* mutations impairing deglycosylation pathways. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles elimination criteria are all except ?
Choices:
A. Absence of endemic measles
B. For more than 12 months
C. Incidence < 1 per 1 lac population
D. Transmission at low level
Answer: [/INST] Transmission at low level </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A young female presents with a history of fever and nodular lesion over the shin. Histopathology reveals foamy histiocytes with neutrophilic infiltration. There is no evidence of Vasculitis. Most probable diagnosis is:
Choices:
A. Sweet's Syndrome
B. Erythema nodosum
C. Erythema nodosum leprosum
D. Behcet's syndrome
Answer: [/INST] Erythema nodosum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Alkaptonuria is due to deficiency of
Choices:
A. Alkaptonase
B. Tyrosinase
C. Phenylalanine hydroxylase
D. Homogentisic acid oxidase
Answer: [/INST] Homogentisic acid oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which among the following country is a 'Rabies free country'?
Choices:
A. USA
B. Russia
C. Australia
D. France
Answer: [/INST] Australia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Opisthotonus', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Death in childhood', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic Acidosis**: Caused by accumulation of toxic metabolites (3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid) due to defective leucine catabolism and impaired ketogenesis.  
2. **Seizures & Hypotonia**: Result from energy deficiency in the brain (lack of ketone bodies during fasting) and neurotoxicity from organic acid buildup.  
3. **Opisthotonus**: Reflects severe neurological dysfunction from metabolic crisis.  
4. **Dicarboxylic Aciduria**: Occurs due to compensatory omega-oxidation of fatty acids when ketogenesis fails, producing dicarboxylic acids.  
5. **3-Methylglutaconic Aciduria**: Secondary to enzyme deficiency, as 3-methylglutaconyl-CoA cannot be processed, leading to urinary excretion.  
6. **Elevated Urinary Carboxylic Acids**: Includes 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, pathognomonic for this disorder.  
7. **Early Mortality (Neonatal/Infancy/Childhood)**: Untreated metabolic crises cause rapid decompensation, hypoglycemia, and cerebral edema.  
8. **Irritability**: Early sign of metabolic stress during fasting or illness.  
The combination of these biochemical and clinical features distinguishes HMG-CoA lyase deficiency from other organic acidemias. Confirmatory testing involves genetic analysis of *HMGCL* or enzyme activity assays. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strategies in National Leprosy Control programme include-
Choices:
A. Early detection of cases
B. Sho course multi drug therapy
C. Rehabilitation
D. Chemoprophylaxis with dapsone
Answer: [/INST] Early detection of cases </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya is transmitted by -
Choices:
A. Aedes
B. Culex
C. Mansonia
D. Anopheles
Answer: [/INST] Aedes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is the least common feature of Multiple Myeloma -
Choices:
A. Bone pain
B. Normocytic Normochromic Anemia
C. Susceptibility to bacterial Infection
D. Hyperviscosity syndrome
Answer: [/INST] Hyperviscosity syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Craniopharyngioma arises from -
Choices:
A. Pituitary stalk
B. Posterior pituitary
C. Pineal gland
D. Cerebellum
Answer: [/INST] Pituitary stalk </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A mother brings her 1-year-old daughter to the physician. She says that for the last 2 days her daughter has been fussy and crying more than usual. She also refuses formula. The patient has a fever of 39.4degC (102.9degF). Meningitis is suspected, and a lumbar puncture is per- formed. Analysis of the cerebrospinal fluid shows an opening pressure of 98 mm H2O, a leukocyte count of 1256/mm3, a protein level of 210 mg/dL, and a glucose level of 31 mg/dL.. The mother says that the patient has received no immunizations. Which of the following organisms is most likely responsible for this patient's illness?
Choices:
A. Clostridium botulinum
B. Haemophilus influenza
C. Neisseria meningitides
D. Streptococcus pneumoniae
Answer: [/INST] Haemophilus influenza </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is not seen in Polycythemia Vera?
Choices:
A. Ocular congestion
B. Increase RBC count
C. Increase erythropoietin level
D. Increased Vit B12 binding capacity
Answer: [/INST] Increase erythropoietin level </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a recently approved monoclonal antibody for treatment of Hemophilia A?
Choices:
A. Emicizumab
B. Sarilumab
C. Abaloparatide
D. Durvalumab
Answer: [/INST] Emicizumab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial parasite was discovered by-
Choices:
A. Ronald ross
B. Paul muller
C. Laveran
D. Pampania
Answer: [/INST] Laveran </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which level of Prolactin definitely suggest Prolactinoma?
Choices:
A. >50 mg/L
B. >100 mg/L
C. >150 mg/L
D. >200 mg/L
Answer: [/INST] >200 mg/L </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Irritability', 'Spasticity', 'Hyperreflexia', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to toxic phenylalanine accumulation.  
2. **Neurological symptoms** (irritability, spasticity, hyperreflexia) arise from phenylalanine-induced brain damage in untreated cases.  
3. **Early mortality** (neonatal/infancy/childhood/adolescence death) aligns with severe untreated PKU variants or complications like metabolic crises or seizures.  
4. **Hypertyrosinemia inconsistency**: Typically, PKU causes *low* tyrosine (due to blocked PAH activity). This symptom suggests a possible comorbid condition (e.g., tyrosinemia type II) or diagnostic error.  
5. **Recurrent viral infections** are atypical for PKU and may indicate an unrelated immunodeficiency.  
6. PKU diagnosis is confirmed by elevated blood phenylalanine and genetic testing for *PAH* mutations, but conflicting hypertyrosinemia warrants further metabolic investigation.  

Note: Hypertyrosinemia and recurrent infections are not classic PKU features; additional workup is critical to rule out overlapping disorders (e.g., BH4 deficiencies, tyrosinemias). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Intellectual disability, delayed speech/motor development** align with untreated PKU, as excess phenylalanine disrupts myelination and neurotransmitter synthesis, damaging the central nervous system.  
3. **Hypertyrosinemia** may initially seem contradictory (PAH deficiency typically reduces tyrosine), but secondary tyrosine supplementation in PKU management or coexisting hepatic dysfunction could elevate levels.  
4. **Abnormal circulating porphyrin** might reflect secondary metabolic stress or liver involvement, though not a classic PKU feature.  
5. **Early mortality** (infancy/childhood/adolescence) suggests severe, untreated PKU with complications like seizures, neurodegeneration, or infections due to compromised immunity.  
6. While some symptoms (e.g., porphyrin abnormalities) are atypical, they may arise from systemic metabolic derangements or comorbidities. PKU remains the primary diagnosis due to the central role of hyperphenylalaninemia and its neurodevelopmental consequences. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient came to a private practitioner and was diagnosed Tuberculosis. Within how many days he has to inform or register to district health officer?
Choices:
A. 1 day
B. 7 day
C. 30 days
D. 1 year
Answer: [/INST] 30 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma can occur bilaterally in how many percentage of the cases?
Choices:
A. 10-15%
B. 15-20%
C. 20-25%
D. 25-30%
Answer: [/INST] 25-30% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cardiomyopathy', 'Fever', 'Abnormality of urine homeostasis', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary carnitine deficiency; PCD/Systemic primary carnitine deficiency/Carnitine deficiency, systemic primary  
Reasoning:  
1. **Decreased plasma free carnitine** is the hallmark biochemical feature of PCD, caused by defective carnitine transport due to mutations in the *SLC22A5* gene.  
2. **Cardiomyopathy** arises from impaired fatty acid oxidation in cardiac muscle due to carnitine deficiency, leading to energy depletion and cardiac dysfunction.  
3. **Gastrointestinal inflammation** and **fever** may reflect metabolic decompensation episodes triggered by fasting or infection, causing hypoketotic hypoglycemia and secondary systemic stress.  
4. **Abnormality of urine homeostasis** correlates with renal carnitine wasting (reduced tubular reabsorption) and potential electrolyte imbalances during metabolic crises.  
5. **Death in childhood** aligns with untreated PCD's natural history, where cardiac failure, hypoglycemic encephalopathy, or arrhythmias prove fatal without carnitine supplementation.  
6. Symptom constellation matches PCD's multisystemic presentation: hepatic, cardiac, muscular, and metabolic manifestations from disrupted lipid metabolism. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: An adolescent male presents with Hypokalemia, Metabolic Alkalosis, Hypercalciuria and Nephrocalcinosis. His Blood Pressure is normal. The likely diagnosis is:
Choices:
A. Bater Syndrome
B. Gitelman's Syndrome
C. Liddle's Syndrome
D. Renal Tubular Acidosis
Answer: [/INST] Bater Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Sinusitis', 'Abnormality of the nose', 'Otitis media', 'Fever', 'Headache', 'Exercise intolerance', 'Elbow pain', 'Knee pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Upper respiratory involvement**: Chronic sinusitis and nasal abnormalities (e.g., ulcers, crusting) are hallmark features of GPA, caused by granulomatous inflammation.  
2. **Otitis media**: Secondary to Eustachian tube dysfunction from nasopharyngeal inflammation or vasculitis.  
3. **Systemic inflammation**: Fever and headache reflect systemic vasculitis and granulomatosis.  
4. **Musculoskeletal symptoms**: Elbow and knee pain (arthralgia/arthritis) occur in 50-70% of GPA patients due to inflammatory joint involvement.  
5. **Exercise intolerance**: May indicate subclinical pulmonary or renal involvement (common in GPA) or anemia of chronic disease.  
6. **Exclusion of mimics**: Symptoms align with GPA over other vasculitides (e.g., absence of asthma/eosinophilia rules out EGPA; PR3-ANCA positivity would further support diagnosis).  
7. **Triad correlation**: Combines upper/lower respiratory tract and potential renal involvement (even if not overtly stated), consistent with GPA pathology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Sloping forehead', 'Bulbous nose', 'Abnormality of eye movement', 'Upslanted palpebral fissure', 'Delayed speech and language development', 'Eczema', 'Intellectual disability', 'Seizure', 'Generalized hypotonia', 'Absent speech', 'Decreased fetal movement', 'Oligohydramnios', 'Asthma', 'Global brain atrophy', 'Developmental regression', 'Ventilator dependence with inability to wean', 'Severe muscular hypotonia', 'Tented upper lip vermilion', 'Severe global developmental delay', 'Brain atrophy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Facial dysmorphism**: ""Sloping forehead,"" ""bulbous nose,"" ""upslanted palpebral fissure,"" and ""tented upper lip vermilion"" align with the characteristic facies of TBCK syndrome, which often includes coarse facial features and distinct lip morphology.  
2. **Neurological/developmental features**: ""Severe global developmental delay,"" ""intellectual disability,"" ""absent speech,"" and ""developmental regression"" correlate with the syndrome’s hallmark psychomotor retardation. ""Seizure"" and ""global brain atrophy"" are consistent with progressive neurological involvement.  
3. **Hypotonia**: ""Severe muscular hypotonia"" and ""generalized hypotonia"" are cardinal features of TBCK-related disorders, often leading to respiratory complications like ""ventilator dependence with inability to wean.""  
4. **Prenatal/neonatal history**: ""Decreased fetal movement"" and ""oligohydramnios"" suggest congenital onset, reported in severe TBCK cases.  
5. **Comorbidities**: ""Eczema"" and ""asthma"" are common immune-related associations in TBCK syndrome.  
6. **Exclusion of mimics**: The combination of hypotonia, distinct facies, brain atrophy, and developmental regression differentiates TBCK from other neurogenetic disorders (e.g., Rett syndrome or mitochondrial disorders). Genetic testing for TBC1-domain-containing kinase (TBCK) mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most Common Valve Not involved in Rheumatic Fever:
Choices:
A. Mitral
B. Aoic
C. Pulmonary
D. Tricuspid
Answer: [/INST] Tricuspid </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Narcolepsy is due to abnormality in ?
Choices:
A. Hypothalamus
B. Neocoex
C. Cerebellum
D. Medulla oblongata
Answer: [/INST] Hypothalamus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Urinary incontinence', 'Depression', 'Hallucinations', 'Apathy', 'Mental deterioration', 'Confusion', 'Dystonia', 'Slurred speech', 'Dysphagia', 'Cerebral atrophy', 'Abnormality of speech or vocalization', 'Postural instability', 'Falls', 'Cachexia', 'Hyperactive deep tendon reflexes', 'Abnormal pyramidal sign', 'Freezing of gait', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Parkinson disease 23, autosomal recessive early-onset  
Reasoning:  
1. **Early-onset parkinsonism**: Symptoms like dystonia, dyskinesia, freezing of gait, and postural instability align with early-onset Parkinsonian features.  
2. **Neuropsychiatric and cognitive decline**: Depression, apathy, hallucinations, mental deterioration, and confusion suggest rapid neurodegeneration beyond typical Parkinson’s disease, consistent with severe genetic forms.  
3. **Pyramidal involvement**: Hyperactive deep tendon reflexes and abnormal pyramidal signs (e.g., Babinski) indicate upper motor neuron dysfunction, atypical in idiopathic Parkinson’s but reported in PARK23 (VPS13C-related).  
4. **Bulbar and autonomic dysfunction**: Dysphagia, slurred speech, and urinary incontinence point to widespread neurodegeneration, including brainstem and autonomic systems.  
5. **Structural CNS changes**: Cerebral atrophy on imaging supports progressive neurodegenerative pathology.  
6. **Systemic progression**: Cachexia and frequent falls reflect advanced disease severity, typical of rapidly progressive autosomal recessive forms like PARK23.  
7. **Genetic consistency**: Autosomal recessive inheritance (implied by diagnosis) matches VPS13C mutations, which cause early-onset, aggressive parkinsonism with pyramidal and cognitive features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Hypoglycemia', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormality of acid-base homeostasis', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency  
Reasoning:  
1. **Hypoglycemia & Seizures**: Impaired ketogenesis due to HMG-CoA lyase deficiency prevents energy production during fasting, leading to hypoglycemia and subsequent seizures.  
2. **Hepatomegaly & Elevated Transaminases**: Toxic accumulation of metabolites (e.g., 3-hydroxy-3-methylglutaric acid) causes hepatic stress and mitochondrial dysfunction.  
3. **Dicarboxylic Aciduria**: Secondary to defective fatty acid β-oxidation, prompting ω-oxidation of fatty acids as an alternative pathway.  
4. **3-Methylglutaric Aciduria**: Direct consequence of blocked leucine catabolism at the HMG-CoA lyase step, causing buildup of upstream metabolites.  
5. **Acid-Base Homeostasis Abnormality**: Metabolic acidosis from excess organic acids (e.g., 3-hydroxy-3-methylglutaric acid) overwhelms buffering systems.  
6. **Decreased Plasma Free Carnitine**: Organic acids bind carnitine, forming acylcarnitines excreted in urine, depleting free carnitine reserves.  
7. **Elevated Urinary Carboxylic Acids**: Reflects systemic excretion of toxic intermediates (3-hydroxy-3-methylglutaric, 3-methylglutaric, and dicarboxylic acids).  
8. **Death in Infancy**: Untreated episodes of metabolic decompensation (hypoglycemia, acidosis) lead to fatal outcomes early in life.  

The constellation of findings aligns pathognomonically with HMG-CoA lyase deficiency, a leucine catabolism and ketogenesis disorder. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Multidrug (MDT) regimen under the National Leprosy Eradication Program for treatment of all Multibacillary Leprosy would include:-
Choices:
A. Clofazimine, Thiacetazone and Dapsone
B. Clofazimine, Rifampicin and Dapsone
C. Ethionamide, Rifampicin and Dapsone
D. Propionamide, Rifampicin and Dapsone
Answer: [/INST] Clofazimine, Rifampicin and Dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis in children true is
Choices:
A. Commonly sputum negative
B. Incidence < 5% of all TB cases
C. Clinically child does not show sign of florid TB
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vomiting', 'Ethylmalonic aciduria', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Short chain acyl-CoA dehydrogenase deficiency/Acyl-CoA dehydrogenase, short-chain, deficiency of  
Reasoning:  
1. **Ethylmalonic aciduria**: A hallmark of short-chain acyl-CoA dehydrogenase (SCAD) deficiency, as impaired short-chain fatty acid oxidation leads to accumulation of ethylmalonic acid.  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: SCAD deficiency disrupts mitochondrial β-oxidation, indirectly affecting enzymes in the pathway, including 3-hydroxyacyl-CoA dehydrogenase.  
3. **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to excessive acylcarnitine excretion and disrupted fatty acid metabolism.  
4. **Vomiting**: Common during metabolic decompensation triggered by fasting or illness when energy demand exceeds defective fatty acid oxidation capacity.  
5. **Early mortality (childhood/adolescence)**: Severe SCAD deficiency causes life-threatening metabolic crises (hypoketotic hypoglycemia, encephalopathy) if untreated, leading to premature death.  
6. **Consistency with biochemical profile**: The triad of ethylmalonic aciduria, carnitine imbalance, and enzyme abnormalities aligns pathognomonically with SCAD deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The multidrug regimen under the National Leprosy Eradication Programme for the treatment of all multibacillary leprosy would include-
Choices:
A. Clofazimine, thiacetazone and dapsone
B. Clofazimine, rifampicin and dapsone
C. Ethionamide, rifampicin and dapsone
D. Propionamide, rifampicin and dapsone
Answer: [/INST] Clofazimine, rifampicin and dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) arise from alternative phenylalanine metabolism via transamination, a pathognomonic feature of PKU.  
3. **Eczematoid dermatitis/skin rash** correlates with tyrosine deficiency (due to blocked PAH activity), impairing melanin and protein synthesis, causing skin manifestations.  
4. **Abnormality of prenatal development** aligns with maternal PKU syndrome if the mother had uncontrolled phenylalanine levels during pregnancy, causing fetal complications like microcephaly or cardiac defects.  
5. **Death in infancy/childhood/neonatal death** reflects untreated PKU’s severe neurological sequelae (seizures, intellectual disability) and metabolic instability, historically fatal before dietary management.  
6. **Hypertyrosinemia** may appear contradictory (PAH deficiency typically lowers tyrosine), but transient elevations can occur due to metabolic stress or overlapping pathways in severe cases.  

The collective symptoms strongly indicate PKU, emphasizing untreated metabolic dysfunction and its systemic consequences. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Gold standard Investigation for Achalasia cardia is :
Choices:
A. Esophageal manometry
B. Barium swallow
C. Endoscopy
D. Endoscopic ultrasound
Answer: [/INST] Esophageal manometry </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Langerhans Cell Histiocytosis, the characteristic abnormality seen is:
Choices:
A. Foamy macrophages
B. Giant cell
C. Plasma cell
D. Birbeck's granules
Answer: [/INST] Birbeck's granules </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the major histocompatibility antigens is associated with an increased risk of Multiple Sclerosis?
Choices:
A. A3
B. B27
C. DR2
D. DR3
Answer: [/INST] DR2 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vomiting', 'Abdominal pain', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Acute intermittent porphyria  
Reasoning: The symptoms of vomiting and severe abdominal pain align with acute attacks characteristic of acute intermittent porphyria (AIP). AIP is caused by a deficiency in hydroxymethylbilane synthase, leading to accumulation of neurotoxic porphyrin precursors. While AIP typically manifests after puberty, severe cases or undiagnosed episodes in childhood can result in fatal neurological complications (e.g., respiratory paralysis, seizures) or electrolyte imbalances (e.g., hyponatremia), explaining early mortality.  

Disease: Porphyria  
Reasoning: Porphyria encompasses a group of disorders affecting heme biosynthesis. The patient’s gastrointestinal symptoms and early fatality suggest an acute hepatic porphyria. While AIP is the most likely subtype, other severe forms (e.g., ALAD-deficiency porphyria or homozygous variants) may present in childhood with rapid progression. Lack of cutaneous symptoms rules out cutaneous porphyrias, narrowing the diagnosis to acute hepatic types. Genetic testing would confirm the specific subtype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Man is the only reservoir of -a) Rabiesb) Measlesc) Typhoidd) Japanese B encephalitis
Choices:
A. a
B. bc
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spastic diplegia', 'Death in infancy', 'Spastic tetraplegia', 'Dark urine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alkaptonuria  
Reasoning: While dark urine (due to homogentisic acid oxidation) is a hallmark of alkaptonuria, the neurological symptoms (spastic diplegia/tetraplegia) and early mortality are atypical. Alkaptonuria primarily manifests with ochronosis, arthritis, and cardiac complications in adulthood. The listed symptoms suggest a severe neurometabolic disorder (e.g., leukodystrophy, mitochondrial disease) rather than alkaptonuria. This mismatch highlights a potential error in the provided diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Management of a newborn when mother has active Tuberculosis and is not taking ATT:
Choices:
A. BCG + Rifampicin + INH + Breastfeeding
B. BCG + Isolation of baby
C. BCG + INH for 6 week + Breastfeeding
D. BCG + INH + withhold Breastfeeding
Answer: [/INST] BCG + INH + withhold Breastfeeding </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common Morphological difference between Ulcerative Colitis and Crohn's disease
Choices:
A. Mucosal edema
B. Crypt abscess
C. Diffuse polyps
D. Lymphoid aggregates
Answer: [/INST] Crypt abscess </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is detected in peripheral blood smear -a) Malariab) Toxoplasmac) Babesiad) Brucellae) Filaria
Choices:
A. acd
B. bde
C. cde
D. abce
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Alkaptonuria an inherited metabolic disorder is due to the deficiency of
Choices:
A. Homogentisate oxidase
B. Cystathionase
C. Pheylalanine hydroxylase
D. Tyrosine transaminase
Answer: [/INST] Homogentisate oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine at a primary health centre should be stored at which temperature ?
Choices:
A. -20°C
B. 0°C
C. +2°C to 8°C
D. Any temperature not exceeding room temperature
Answer: [/INST] +2°C to 8°C </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies can be transmitted by all EXCEPT: March 2013 (d)
Choices:
A. Bite of rabid dog
B. Bite of bats
C. Bite of fox
D. Bite of squirrel
Answer: [/INST] Bite of squirrel </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following oral structures are not effected in Leprosy
Choices:
A. Gingiva
B. Tongue
C. Hard Palate
D. Soft Palate
Answer: [/INST] Gingiva </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Polyuria', 'Hyperactivity', 'Abnormality of prenatal development or birth', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Tachycardia', 'Hypoglycemia', 'Hypophosphatemia', 'Hyperglycinemia', 'Hypokalemia', 'Hyponatremia', 'Hypomagnesemia', 'Hypochloremia', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hyperglutaminemia', 'Hypertyrosinemia', 'Hypermethioninemia', 'Paresthesia', 'Elevated calcitonin', '4-hydroxyphenylacetic aciduria', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated circulating alpha-fetoprotein concentration', 'Paraplegia/paraparesis', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia Type I (HT-1)  
Reasoning:  
1. **Hypertyrosinemia and Tyrosine Metabolites**: Elevated tyrosine levels and metabolites (4-Hydroxyphenylpyruvic aciduria, 4-hydroxyphenylacetic aciduria) directly indicate a defect in tyrosine catabolism. HT-1 involves a deficiency of fumarylacetoacetate hydrolase (FAH), causing toxic metabolite accumulation (e.g., succinylacetone).  
2. **Liver Dysfunction**: Elevated alpha-fetoprotein (AFP) and alkaline phosphatase suggest hepatic damage, a hallmark of HT-1. Hypoglycemia and hypermethioninemia further support liver impairment.  
3. **Renal Tubular Dysfunction**: Electrolyte imbalances (hypophosphatemia, hypokalemia, hyponatremia, hypomagnesemia, hypochloremia) point to Fanconi syndrome, a renal complication of HT-1 due to succinylacetone toxicity.  
4. **Neurological and Systemic Symptoms**: Tachycardia, hyperactivity, and paresthesia may stem from metabolic crises or electrolyte disturbances. Generalized hypotonia aligns with systemic metabolic dysfunction.  
5. **Early Mortality**: Neonatal death, death in infancy/childhood/adolescence reflects the severe, progressive nature of untreated HT-1, often due to liver failure or neurological crises.  
6. **Prenatal/Developal Abnormalities**: Congenital enzyme deficiency explains prenatal growth issues and multisystemic involvement.  
7. **Biochemical Markers**: Elevated calcitonin and hyperglycinemia are less specific but may occur secondary to metabolic stress.  

**Conclusion**: The constellation of tyrosine metabolism derangements, liver/krenal pathology, and early lethality confirm Tyrosinemia Type I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis pleural effusion is characterized by all EXCEPT: March 2013 (d)
Choices:
A. LDH > 60% of serum LDH
B. Hemorrhagic fluid
C. Increased mesothelial cells
D. Increased deaminase
Answer: [/INST] Increased mesothelial cells </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Enzyme-deficient in Alkaptonuria
Choices:
A. Phenylalanine hydroxylase
B. Cystathionine synthase
C. Homogentisic acid oxidase
D. Tyrosinase
Answer: [/INST] Homogentisic acid oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Congenital diaphragmatic hernia', 'Motor delay', 'Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Hiatus hernia', 'Lipodystrophy', 'Abnormal muscle physiology', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and motor delay**: Hallmark neurological features of PMM2-CDG due to impaired glycosylation of proteins critical for cerebellar development and neuronal function.  
2. **Failure to thrive and death in infancy**: Common in severe PMM2-CDG cases due to multi-organ dysfunction, feeding difficulties, and metabolic instability.  
3. **Congenital diaphragmatic hernia (CDH) and hiatus hernia**: Rare but reported in PMM2-CDG, linked to abnormal connective tissue and muscle physiology from glycosylation defects.  
4. **Lipodystrophy and abnormal muscle physiology**: Reflect systemic metabolic disturbances caused by disrupted glycosylation of enzymes and structural proteins.  
5. **Consistent multisystem involvement**: Matches PMM2-CDG’s presentation, which combines neurological, gastrointestinal, musculoskeletal, and metabolic abnormalities.  

This pattern aligns with PMM2-CDG’s pathophysiology of defective N-glycosylation, confirmed by genetic testing for *PMM2* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Decreased plasma free carnitine**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to accumulation of toxic metabolites (e.g., medium-chain acylcarnitines). Carnitine becomes sequestered as these conjugates, causing secondary carnitine deficiency.  
2. **Gastrointestinal inflammation**: Metabolic crises in MCADD induce vomiting, diarrhea, and hepatic dysfunction, mimicking gastrointestinal inflammation.  
3. **Neonatal/infant/childhood death**: Untreated MCADD causes life-threatening hypoglycemia, encephalopathy, and multiorgan failure during fasting or illness, often fatal in early life without prompt diagnosis.  
4. **Prenatal abnormalities**: While MCADD typically manifests postnatally, severe intrauterine metabolic stress (e.g., maternal fasting) might theoretically contribute to growth abnormalities.  
5. **Exclusion of alternatives**: Symptoms align with MCADD over other fatty acid oxidation disorders (e.g., VLCAD, LCHAD) due to the absence of cardiomyopathy or retinopathy and the specific carnitine profile. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Achalasia is associated with increased risk of ...... malignancy:
Choices:
A. Squamous cell carcinoma esophagus
B. Adenocarcinoma esophagus
C. Bronchogenic carcinoma
D. Bronchial adenoma
Answer: [/INST] Squamous cell carcinoma esophagus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Ventricular septal defect', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Abnormality of prenatal development/birth, VSD, and neonatal/infant death** may reflect **maternal PKU syndrome**, where untreated maternal hyperphenylalaninemia during pregnancy induces teratogenic effects (e.g., congenital heart defects like VSD) in the fetus.  
3. **Hypertyrosinemia** is atypical for classic PKU (where tyrosine levels are usually low/normal) and suggests a potential secondary metabolic disturbance, co-occurring liver dysfunction, or misdiagnosis of tyrosine levels.  
4. **Death in childhood** aligns with severe, untreated PKU, as neurological damage and metabolic complications (seizures, failure to thrive) can be fatal without dietary intervention.  
5. While **hypertyrosinemia** creates ambiguity, the dominant hyperphenylalaninemia and clinical context prioritize PKU as the primary diagnosis. Further evaluation of tyrosine metabolism (e.g., BH4 deficiency, tyrosinemia) would be warranted to address this discrepancy. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles epidemic can be anticipated when proportion of suceptible children in a community
Choices:
A. 20%
B. 40%
C. 60%
D. 80%
Answer: [/INST] 40% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Emergency or reemergence seen in which of the following organisms -a)  Polio virusb)  Measles virusc)  Nipah virusd)  West Nile viruse)  Hepatitis B virus
Choices:
A. abd
B. cde
C. bde
D. ade
Answer: [/INST] cde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Strain used in Mumps vaccine?
Choices:
A. Edmonsten Zagreb
B. Urabe
C. Jeryl Lynn
D. Danish 1331
Answer: [/INST] Jeryl Lynn </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diffuse esophageal dilatation on barium swallow is seen in – a) Achlasiab) Trypanosomiasisc) Etidronate therapyd) Scleroderma
Choices:
A. ac
B. ab
C. ad
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria ?
Choices:
A. Propagative
B. Cyclopropagative
C. Cyclodevelopmental
D. None of the above
Answer: [/INST] Cyclopropagative </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cysticercosis present as  a) Seizure  b) Neuropathy  c) Encephalitis  d) Muscular hypertrophy
Choices:
A. abc
B. abd
C. bcd
D. bd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Microcephaly', 'Epicanthus', 'Low-set ears', 'Anteverted nares', 'Strabismus', 'Ptosis', 'Nystagmus', 'Delayed speech and language development', 'Nevus flammeus', 'Syndactyly', 'Intellectual disability', 'Lethargy', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Death in infancy', 'Athetosis', 'Drowsiness', 'Sleep disturbance', 'Hypercholesterolemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Key Craniofacial and Structural Features**: Cleft palate, microcephaly, low-set ears, anteverted nares, syndactyly (classic 2-3 toe webbing), and nevus flammeus align with SLOS phenotypic hallmarks.  
2. **Ocular Abnormalities**: Strabismus, ptosis, nystagmus, and epicanthus are consistent with SLOS-associated eye findings.  
3. **Neurodevelopmental Delays**: Intellectual disability, delayed speech/motor development, generalized hypotonia, and lethargy reflect impaired cholesterol-dependent neurodevelopment.  
4. **Growth and Survival Issues**: Failure to thrive, feeding difficulties, neonatal/childhood death correlate with severe SLOS phenotypes.  
5. **Biochemical Signature**: Hypocholesterolemia, elevated 7-dehydrocholesterol (7-DHC), and elevated 8-dehydrocholesterol confirm defective cholesterol biosynthesis due to DHCR7 mutations.  
6. **Pathophysiologic Link**: SLOS is caused by deficient 7-DHC reductase, leading to toxic sterol accumulation (7-DHC, 8-DHC) and cholesterol deficiency, directly explaining metabolic and clinical features.  
7. **Exclusion of Mimics**: Syndactyly + cholesterol abnormalities distinguish SLOS from other syndromes (e.g., Cornelia de Lange, Rubinstein-Taybi) lacking sterol defects.  

The constellation of dysmorphia, neurodevelopmental deficits, syndactyly, and characteristic sterol profile is diagnostic of SLOS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: TRUE statements concerning malaria includea) Malaria caused by each of the  four plasmodial species can relapse after initial illnessb) Red cells negative for the Duffy blood group antigen are resistant to Plasmodium vivaxc) Renal impairment is a grave prognostic sign in falciparum malariad) Plasmodium malariae can cause immune-mediated nephropathy
Choices:
A. ac
B. bd
C. c
D. d
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine given to contact of measles case exes protective effect within -
Choices:
A. 1 day
B. 3 days
C. 7 days
D. 10 days
Answer: [/INST] 7 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Abnormality of the outer ear', 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Single transverse palmar crease', 'Cafe-au-lait spot', 'Hypertrichosis', 'Brachydactyly', 'Syndactyly', 'Seizure', 'Hypotonia', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Hypoglycemia', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Intellectual disability, moderate', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Temperature instability', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Broad thumb', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental features**: Symptoms like *moderate intellectual disability*, *hyperactivity*, *attention deficit hyperactivity disorder (ADHD)*, and *atypical behavior* align with the neurodevelopmental core of NEDBEH.  
2. **Brain anomalies**: Structural CNS abnormalities such as *cerebellar vermis hypoplasia*, *CNS hypomyelination*, *hypoplasia of the corpus callosum*, and *ventriculomegaly* directly match the ""brain anomalies"" criterion.  
3. **Eye anomalies**: Multiple ocular findings (*coloboma*, *microphthalmia*, *blepharophimosis*, *optic atrophy*, *Peters anomaly*, *abnormality of iris morphology*) satisfy the ""eye"" component.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, *patent foramen ovale*, and *anomalous pulmonary venous return* fulfill the ""heart"" criterion.  
5. **Supportive systemic features**:  
   - Growth issues (*intrauterine growth retardation*, *short stature*, *growth delay*) and craniofacial dysmorphism (*triangular face*, *micrognathia*, *high palate*, *cleft lip*) are common in NEDBEH.  
   - Additional congenital anomalies (*choanal atresia*, *duodenal atresia*, *annular pancreas*) and neurological signs (*hypotonia*, *seizures*, *spastic tetraparesis*) reinforce multisystem involvement.  
6. **Exclusion of mimics**: Overlapping features with syndromes like CHARGE or chromosomal disorders are ruled out by the absence of pathognomonic signs (e.g., absent CHARGE coloboma-choanal atresia triad) and the broad spectrum of NEDBEH-specific gene associations (e.g., *BRPF1*, *KAT6B*).  

The combination of neurodevelopmental delay, brain malformations, ocular defects, and congenital heart anomalies provides a definitive match for NEDBEH. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Hypotonia', 'Reduced tendon reflexes', 'Abnormal facial shape', 'Ventriculomegaly', 'Developmental regression', 'Severe global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Hypotonia and reduced tendon reflexes** are hallmark features of TBCK syndrome, reflecting neuromuscular involvement.  
2. **Severe global developmental delay** and **intellectual disability** align with the syndrome’s core neurocognitive phenotype.  
3. **Macrocephaly** and **ventriculomegaly** correlate with reported structural brain anomalies, including cortical atrophy or white matter changes.  
4. **Seizures** are commonly observed due to underlying neuronal dysfunction.  
5. **Abnormal facial shape** (e.g., coarse facies, hypertelorism, broad nasal tip) matches the characteristic dysmorphology.  
6. **Delayed speech/language development** and **developmental regression** (in some cases) reflect progressive neurological deterioration or static encephalopathy.  
7. Genetic confirmation would identify biallelic *TBCK* mutations, but clinical consistency suffices for preliminary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Cataract', 'Amblyopia', 'Autistic behavior', 'Delayed speech and language development', 'Abnormally large globe', 'Retinal atrophy', 'Motor delay', 'Cerebellar vermis hypoplasia', 'Dilated fourth ventricle', 'Cerebellar cyst', 'Abnormal midbrain morphology', '2-3 toe syndactyly', 'Cerebellar dysplasia', 'Absent retinal pigment epithelium', 'High myopia', 'Splayed superior cerebellar peduncle']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar anomalies**: Cerebellar vermis hypoplasia, cerebellar cysts, dilated fourth ventricle, and cerebellar dysplasia are hallmark features of Poretti-Boltshauser syndrome (PTBHS).  
2. **Ocular abnormalities**: High myopia, retinal atrophy, absent retinal pigment epithelium, strabismus, and cataracts align with PTBHS-associated retinal dystrophy and structural eye defects.  
3. **Neurodevelopmental delays**: Motor delay, delayed speech, and autistic behavior correlate with intellectual disability and cerebellar dysfunction in PTBHS.  
4. **Midbrain/cerebellar peduncle anomalies**: Splayed superior cerebellar peduncles and abnormal midbrain morphology are consistent with PTBHS neuroimaging findings.  
5. **Syndactyly**: 2-3 toe syndactyly is a rare but reported skeletal feature in PTBHS, supporting the diagnosis.  
6. **Exclusion of mimics**: The absence of nephronophthisis (Joubert syndrome) or liver fibrosis (COACH syndrome), combined with cerebellar cysts and retinal changes, distinguishes PTBHS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Seizure', 'Lethargy', 'Death in infancy', 'Metabolic acidosis', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Neonatal death', 'Methylmalonic aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, alongside metabolic acidosis, vomiting, lethargy, and neurological symptoms (seizures, drowsiness, apathy). Neonatal death and death in infancy align with severe MMA presentations. These findings collectively indicate impaired methylmalonyl-CoA metabolism.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **B12-unresponsive subtype** is inferred due to the severity (neonatal death) and lack of improvement with B12 therapy. Mutations in the *MUT* gene disrupt methylmalonyl-CoA mutase activity, exacerbating acid accumulation. Persistent metabolic acidosis and early lethality are characteristic of this subtype, distinguishing it from B12-responsive forms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA lyase deficiency (HMGCLD)  
Reasoning:  
1. **Biochemical Pathway Context**: HMG-CoA lyase is critical in ketogenesis (fatty acid breakdown) and leucine catabolism. Deficiency disrupts conversion of HMG-CoA to acetoacetate and acetyl-CoA, causing toxic metabolite accumulation.  
2. **3-Methylglutaric Aciduria**: Directly linked to impaired leucine degradation. The enzyme deficiency leads to buildup of 3-methylglutaconyl-CoA, which is converted to 3-methylglutaric acid, excreted in urine.  
3. **Dicarboxylic Aciduria**: Secondary to defective ketogenesis. During fasting, increased fatty acid oxidation overwhelms β-oxidation, producing dicarboxylic acids (e.g., adipic, suberic acids) due to alternative ω-oxidation pathways.  
4. **Elevated Urinary Carboxylic Acids**: Reflects systemic metabolic dysfunction, with spillage of 3-hydroxy-3-methylglutaric acid (primary marker), 3-methylglutaric acid, and 3-methylcrotonylglycine.  
5. **Exclusion of Mimics**: Differentiated from other organic acidurias (e.g., glutaric acidemia type I, multiple carboxylase deficiency) by the specific triad of metabolites and absence of key markers like glutaric acid or holocarboxylase synthetase defects.  
6. **Clinical Correlation**: Patients typically present with hypoglycemia, metabolic acidosis, and lethargy during catabolic stress (fasting/illness), aligning with the biochemical findings. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Self-mutilation', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Death in infancy', 'Hypertyrosinemia', 'Severe short stature', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH), leading to phenylalanine accumulation.  
2. **Intellectual disability**, **microcephaly**, and **delayed speech** are classic neurodevelopmental consequences of untreated PKU due to toxic phenylalanine levels damaging the brain.  
3. **Seizures** and **self-mutilation** correlate with severe neurological impairment from chronic phenylalanine toxicity.  
4. **Severe short stature** may result from metabolic disruption and poor protein utilization.  
5. **Death in infancy/adolescence** reflects untreated or poorly managed PKU, causing acute metabolic crises or irreversible neurological damage.  
6. **Hypertyrosinemia** is atypical for classic PKU but may occur in rare variants (e.g., BH4 deficiency) or secondary metabolic disturbances.  
7. The combination of **hyperphenylalaninemia** with neurodevelopmental deficits strongly prioritizes PKU, even with atypical features like hypertyrosinemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Botulism are true except
Choices:
A. Botulism is caused by endotoxin
B. Honey ingestion causes infant botulism
C. Constpation is seen
D. Detection of antitoxin in the serum can aid in diagnosis
Answer: [/INST] Botulism is caused by endotoxin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Hemophilia B what is most common cause of death?
Choices:
A. Hemorrhage
B. HIV, HBV, HCV due to transfusions
C. Transfusion reactions
D. Deep vein thrombosis
Answer: [/INST] Hemorrhage </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Thrombocytopenia', 'Leukopenia', 'Metabolic acidosis', 'Apnea', 'Decreased methylmalonyl-CoA mutase activity', 'Neonatal death', 'Feeding difficulties', 'Methylmalonic aciduria', 'Abnormal nervous system physiology']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria** and **decreased methylmalonyl-CoA mutase activity**, hallmark biochemical features of MMA. Symptoms like **metabolic acidosis**, **apnea**, **feeding difficulties**, and **abnormal nervous system physiology** align with MMA's pathophysiology, where toxic methylmalonic acid accumulates, disrupting energy metabolism and causing multi-organ dysfunction. **Thrombocytopenia** and **leukopenia** may result from bone marrow suppression secondary to metabolic stress. **Neonatal death** and **death in infancy** are consistent with severe, untreated MMA.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **decreased methylmalonyl-CoA mutase activity** directly indicates a defect in the MUT gene, causing the B12-unresponsive subtype of MMA. This subtype does not improve with vitamin B12 supplementation, distinguishing it from B12-responsive forms. Symptoms such as **generalized hypotonia**, **metabolic acidosis**, and **methylmalonic aciduria** are classic for this genetic enzyme deficiency. Early lethality (**neonatal death**, **death in infancy**) is characteristic of severe mutase deficiency (mut⁰ or mut⁻ variants), where residual enzyme activity is minimal or absent. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly is earliest diagnosed at :
Choices:
A. 6 weeks
B. 10 weeks
C. 14 weeks
D. 18 weeks
Answer: [/INST] 10 weeks </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Motor delay', 'Obesity', 'Death in infancy', 'Premature birth', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
**Reasoning**:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Motor delay** aligns with untreated PKU, as elevated phenylalanine disrupts myelination and neurotransmitter synthesis, leading to neurodevelopmental deficits.  
3. **Elevated urinary carboxylic acids** may reflect secondary metabolic disturbances from phenylalanine accumulation or dietary management (e.g., high protein substitutes).  
4. **Obesity** could arise from high-carbohydrate/low-protein diets used to manage PKU, promoting caloric imbalance.  
5. **Premature birth** and early mortality (**infancy/childhood/adolescence death**) suggest severe, untreated PKU with metabolic crises or complications like cerebral edema.  
6. **Hypertyrosinemia** is atypical in classic PKU but may occur in rare variants or due to concurrent metabolic stress affecting tyrosine metabolism.  
7. **Recurrent viral infections** are not directly linked to PKU but may stem from compromised health in severe cases or nutritional deficiencies.  

**Note**: Hypertyrosinemia and elevated urinary carboxylic acids are unusual for classic PKU, suggesting possible comorbid conditions (e.g., tyrosinemia, organic acidemias) or atypical PKU variants. However, hyperphenylalaninemia remains the primary diagnostic anchor. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy is not yet eradicated because
Choices:
A. No effective vaccine
B. Highly Infectious but low pathogenicity
C. Only humans are reservoir
D. Long incubation period
Answer: [/INST] No effective vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dracunculosis is most common in -
Choices:
A. Gujarat
B. Rajasthan
C. Madhya Pradesh
D. Orissa
Answer: [/INST] Rajasthan </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common symptom of Orthostatic Hypotension is
Choices:
A. Vertigo
B. Light headedness
C. Palpitations
D. Blurred vision
Answer: [/INST] Light headedness </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya virus belongs to which family:
Choices:
A. Enterovirus
B. Herpes virus
C. Toga virus
D. None of the above
Answer: [/INST] Toga virus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Broad philtrum', 'Long philtrum', 'Wide nasal bridge', 'Anteverted nares', 'Glaucoma', 'Cataract', 'Abnormal external genitalia', 'Syndactyly', 'Generalized hypotonia', 'Death in infancy', 'Deep philtrum', 'Vomiting', 'Pyloric stenosis', 'High, narrow palate', 'Hypocholesterolemia', 'Abdominal distention', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Elevated 7-dehydrocholesterol', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Cholesterol biosynthesis defect**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in *DHCR7* leading to impaired cholesterol synthesis.  
2. **Craniofacial features**: Cleft palate, broad/deep philtrum, wide nasal bridge, anteverted nares, and high/narrow palate align with SLOS-associated dysmorphism.  
3. **Ocular anomalies**: Glaucoma and cataracts are linked to abnormal cholesterol-dependent eye development.  
4. **Genital/skeletal abnormalities**: Abnormal external genitalia and syndactyly (classically 2-3 toe syndactyly) are hallmark features.  
5. **Gastrointestinal issues**: Feeding difficulties, vomiting, pyloric stenosis, and abdominal distention reflect cholesterol-dependent digestive dysfunction.  
6. **Poor prognosis**: Neonatal death or death in infancy correlates with severe SLOS phenotypes.  
7. **Hypocholesterolemia**: Directly ties to the biochemical defect in cholesterol synthesis.  
8. **Generalized hypotonia**: Common in SLOS due to disrupted membrane cholesterol in neuromuscular function.  

The combination of sterol abnormalities, syndromic malformations, and metabolic features confirms SLOS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis of paranasal sinus is most common in
Choices:
A. HIV
B. Diabetes
C. Those on immuno suppressants
D. Post surgical
Answer: [/INST] Diabetes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Mucormycosis is
Choices:
A. Angioinvasion
B. Lymph invasion
C. Septate hyphae
D. Long term deferoxamine therapy is predisposing factor
Answer: [/INST] Angioinvasion </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mesothelioma is -
Choices:
A. Benign
B. Rarely malignant
C. Mostly malignant
D. Always malignant
Answer: [/INST] Mostly malignant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hyperammonemia', 'Oroticaciduria', 'Short stature']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: OTCD disrupts the urea cycle, impairing ammonia detoxification. This leads to toxic ammonia accumulation, a hallmark of urea cycle disorders.  
2. **Oroticaciduria**: The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid, which is excreted in urine.  
3. **Death in infancy**: Severe neonatal-onset OTCD often results in life-threatening hyperammonemic crises without prompt treatment.  
4. **Short stature**: Chronic metabolic stress and recurrent hyperammonemia impair growth and development over time.  
OTCD aligns uniquely with this symptom cluster, distinguishing it from other urea cycle defects (e.g., citrullinemia) through the presence of oroticaciduria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Sinusitis', 'Eosinophilia', 'Dyspnea', 'Pulmonary infiltrates', 'Increased circulating IgE level', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Nasal polyposis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Eosinophilic granulomatosis with polyangiitis (EGPA)  
Reasoning:  
1. **Sinusitis and Nasal Polyposis**: Common ENT manifestations in EGPA, reflecting granulomatous inflammation.  
2. **Eosinophilia**: A hallmark of EGPA, driven by eosinophil-rich tissue infiltration.  
3. **Dyspnea and Pulmonary Infiltrates**: Indicates asthma-like airway involvement and eosinophilic pneumonitis.  
4. **Nodular Pattern on HRCT**: Suggests granulomatous lesions or vasculitic damage in the lungs.  
5. **Increased IgE Levels**: Linked to allergic/atopic predisposition, often seen in EGPA.  
6. **Autoimmune Antibody Positivity**: ANCA (typically MPO-ANCA) may be present, supporting vasculitic pathology.  
7. **Triphasic Disease Progression**: Aligns with allergic, eosinophilic, and vasculitic phases typical of EGPA.  
**Exclusion**: Other eosinophilic disorders (e.g., ABPA) lack vasculitis, while GPA lacks prominent eosinophilia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pseudoglioma differs from Retinoblastoma in that pseudoglioma is associated with –
Choices:
A. Decreased intraocular pressure
B. Blurring of vision
C. Enlargement of the optic foramen
D. All of the above
Answer: [/INST] Decreased intraocular pressure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin-
Choices:
A. Increases the levels of intracellular cylic GMP
B. Acts through the receptor the opiates
C. Causes continued activation of adenylate cyclase
D. Inhibits the enzyme phosphodiesterase
Answer: [/INST] Causes continued activation of adenylate cyclase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Growth delay', 'Death in infancy', 'Tachycardia', 'Anemia', 'Tachypnea', 'Neonatal death', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease; MSUD  
Reasoning:  
1. **Elevated urinary carboxylic acids**: MSUD disrupts branched-chain amino acid (BCAA) metabolism, leading to accumulation of branched-chain keto acids (e.g., ketoisocaproic acid), which are carboxylic acids excreted in urine.  
2. **Abnormal nervous system physiology** and **generalized hypotonia**: Neurotoxicity from elevated BCAAs and their derivatives damages neurons, impairing motor function and muscle tone.  
3. **Tachycardia** and **tachypnea**: Metabolic acidosis triggers compensatory mechanisms (e.g., increased respiratory rate to expel CO₂, tachycardia to maintain circulation).  
4. **Growth delay** and **anemia**: Chronic metabolic stress and protein catabolism impair nutrient utilization, affecting growth and red blood cell production.  
5. **Neonatal death/death in infancy**: Untreated classic MSUD causes rapid metabolic decompensation, cerebral edema, and fatal outcomes without early intervention (e.g., dietary BCAA restriction).  
6. **Absence of maple syrup odor**: While a hallmark, this may not be immediately apparent in neonatal screening or masked by acute crisis management.  
Key biochemical confirmation involves detecting elevated plasma BCAAs (leucine, isoleucine, valine) and urinary branched-chain keto acids. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dose of Human Rabies Immunoglobulin is:
Choices:
A. 10 IU/kg
B. 20 IU/kg
C. 30 IU/kg
D. 40 IU/kg
Answer: [/INST] 20 IU/kg </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Neurogenic bladder', 'Macroglossia', 'Macrocephaly', 'Coarse facial features', 'Thick eyebrow', 'Hyperthyroidism', 'Intellectual disability', 'Seizure', 'Reduced tendon reflexes', 'Absent speech', 'Developmental regression', 'Scoliosis', 'Severe muscular hypotonia', 'Severe global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Severe muscular hypotonia and reduced tendon reflexes**: Core features of TBCK syndrome, reflecting neuromuscular dysfunction.  
2. **Severe global developmental delay and intellectual disability**: Consistent with the syndrome’s hallmark neurocognitive impairments.  
3. **Coarse facial features, macrocephaly, thick eyebrows, and macroglossia**: Align with characteristic dysmorphic findings in TBCK-related disorders.  
4. **Seizures and developmental regression**: Reported in severe cases, possibly linked to progressive neurological involvement.  
5. **Neurogenic bladder and scoliosis**: Suggestive of autonomic and skeletal muscle involvement, common in neuromuscular genetic disorders.  
6. **Absent speech**: Expected in severe developmental delay associated with TBCK mutations.  
7. **Hyperthyroidism**: Atypical but may represent a comorbid condition or phenotypic expansion; primary diagnosis remains anchored to neuromuscular and dysmorphic features.  
8. **Exclusion of mimics**: Differentiated from lysosomal storage disorders (no organomegaly/ocular findings) and Rett syndrome (no regression pattern or typical hand stereotypies). Genetic testing for TBCK mutations would confirm. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Werner Syndrome, the most common site of Gastrinoma is?
Choices:
A. Pancreas
B. Stomach
C. Small Intestine
D. Colon
Answer: [/INST] Small Intestine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following immune hypersensitivity reaction is resonsible for Myasthenia Gravis -
Choices:
A. Type I Hypersensitivity
B. Type II Hypersensitivity
C. Type III Hypersensitivity
D. Type IV Hypersensitivity
Answer: [/INST] Type II Hypersensitivity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratoconus is associated with all except –
Choices:
A. Down's syndrome
B. Ehlers–Danlo's syndrome
C. Marfan's syndrome
D. Usher's syndrome
Answer: [/INST] Usher's syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Pancytopenia', 'Spinocerebellar tract degeneration', 'Decreased circulating IgA level', 'Decreased circulating total IgM', 'Decreased circulating IgG level', 'Cellular immunodeficiency', 'Bone marrow hypocellularity', 'Lower limb muscle weakness', 'Leg muscle stiffness']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia and bone marrow hypocellularity**: Central features of the syndrome, directly linked to bone marrow dysfunction.  
2. **Spinocerebellar tract degeneration**: Explains ataxia (implicit in the syndrome name) and neurological symptoms like nystagmus and lower limb muscle weakness/stiffness.  
3. **Immunodeficiency**: Decreased IgA, IgM, IgG levels and cellular immunodeficiency align with the syndrome’s hallmark humoral and T-cell defects.  
4. **Exclusion of mimics**: Lack of telangiectasia (rules out ataxia-telangiectasia) and absence of physical anomalies/DNA repair defects (rules out Fanconi anemia).  
5. **Symptom coherence**: The triad of ataxia, pancytopenia, and immunodeficiency is pathognomonic for APS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma originates from which type of cells
Choices:
A. Osteocytes
B. Osteoblasts
C. Chondrocytes
D. Osteoclast
Answer: [/INST] Osteoblasts </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: If both husband and wife are suffering with Achondroplasia, what are their chances of having a normal child?
Choices:
A. 0%
B. 25%
C. 50%
D. 100%
Answer: [/INST] 25% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is caused by deficiency of
Choices:
A. Tyrosine transminase
B. Tyrosine hydroxylase
C. Phenylalanine transaminase
D. Phenylalanine hydroxylase
Answer: [/INST] Phenylalanine hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following organs may be involved in Leprosy except -
Choices:
A. Uterus
B. Ovary
C. Testes
D. Eye
Answer: [/INST] Uterus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Weight loss', 'Fever', 'Dyspnea', 'Oroticaciduria', 'Neonatal death', 'Inappropriate crying']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria**: A hallmark of OTCD due to secondary pyrimidine synthesis disruption. Accumulated carbamoyl phosphate is diverted to orotic acid production.  
2. **Hyperammonemia (implied)**: Neonatal death, hypotonia, and inappropriate crying suggest metabolic encephalopathy from elevated ammonia (unmeasured but pathognomonic in OTCD).  
3. **Neonatal/Infantile lethality**: Severe OTCD manifests shortly after birth with rapid metabolic decompensation, consistent with ""death in infancy"" and ""neonatal death.""  
4. **Respiratory and systemic symptoms**: Dyspnea and fever may reflect secondary metabolic acidosis or triggering infections (common precipitants of urea cycle crises).  
5. **Neuromuscular signs**: Generalized hypotonia aligns with hyperammonemia-induced CNS toxicity.  
6. **Weight loss**: Poor feeding and catabolism during metabolic stress.  

OTCD is strongly supported by the triad of oroticaciduria, neonatal hyperammonemia features, and rapid fatal course. Other urea cycle disorders lack oroticaciduria, while acquired causes (e.g., liver failure) do not explain neonatal onset. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Symptom Alignment**:  
   - **Abnormality of prenatal development or birth**: While MCADD typically manifests postnatally, intrauterine metabolic stress or placental insufficiency from maternal fasting (due to fetal inability to oxidize medium-chain fatty acids) may contribute to subtle prenatal abnormalities.  
   - **Death in infancy/Neonatal death**: MCADD causes life-threatening hypoglycemia and metabolic crises triggered by fasting (e.g., delayed feeding in neonates). Untreated, this leads to coma, cardiorespiratory failure, and early mortality.  
   - **Abnormal circulating carnitine**: Secondary carnitine deficiency occurs due to sequestration of carnitine by accumulating toxic metabolites (e.g., medium-chain acylcarnitines), reducing free carnitine levels.  

2. **Pathophysiological Link**:  
   - MCADD disrupts β-oxidation of medium-chain fatty acids (C6-C12), impairing energy production during fasting. Neonates/infants are highly vulnerable due to high metabolic demands and limited glycogen reserves.  

3. **Diagnostic Confirmation**:  
   - Elevated C8-C10 acylcarnitines on newborn screening (tandem mass spectrometry) and genetic testing for *ACADM* mutations confirm MCADD.  

4. **Exclusion of Alternatives**:  
   - Symptoms overlap with other fatty acid oxidation disorders (e.g., VLCADD, LCHADD), but abnormal medium-chain acylcarnitines and carnitine profile specifically localize to MCADD.  

**Conclusion**: The constellation of neonatal metabolic instability, carnitine derangements, and early mortality strongly supports MCADD. Early intervention (avoidance of fasting, glucose supplementation) can prevent fatal outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient who is 21 weeks pregnant came to you with fever and chills. You make a diagnosis of Malaria. What is the next line of management?
Choices:
A. Wait till term and sta treatment for malaria
B. Terminate pregnancy and treat the patient for malaria
C. Sta antimalarial treatment immediately and continue the pregnancy
D. Treat only if it is falciparum malaria otherwise wait till term
Answer: [/INST] Sta antimalarial treatment immediately and continue the pregnancy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is the characterstic of Poland Syndrome ?
Choices:
A. Amastia with the absence of the Pectoralis major
B. Athelia with the absence of the Pectoralis major
C. Amastia with the absence of the Pectoralis minor
D. Athelia with the absence of the Pectoralis minor
Answer: [/INST] Amastia with the absence of the Pectoralis major </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal insufficiency', 'Renal cyst', 'Visual loss', 'Hypertension', 'Purpura', 'Hepatic steatosis', 'Hepatic cysts', 'Tubulointerstitial nephritis', 'Nausea', 'Abnormal lung morphology', 'Dyspnea', 'Headache', 'Microscopic hematuria', 'Nephrosclerosis', 'Pyuria', 'Fatigue', 'Peripheral edema', 'Bacteriuria', 'Moderate albuminuria', 'Cough', 'Nitrituria', 'Mediastinal lymphadenopathy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Sarcoidosis/Sarcoidosis, susceptibility to, 1:  
The patient presents with **mediastinal lymphadenopathy**, **abnormal lung morphology**, **dyspnea**, and **cough**, which are hallmark features of pulmonary sarcoidosis. **Tubulointerstitial nephritis**, **microscopic hematuria**, and **moderate albuminuria** align with renal sarcoidosis, a common extrapulmonary manifestation. **Visual loss** suggests ocular involvement (e.g., uveitis), while **hepatic steatosis** and elevated liver enzymes (implied by hepatic cysts) may reflect hepatic granulomas. **Hypertension** and **nephrosclerosis** could result from chronic kidney injury secondary to sarcoidosis. **Fatigue** and **headache** are systemic inflammatory symptoms. Although **renal/hepatic cysts** and **purpura** are atypical, they may coexist due to secondary complications or genetic predisposition.  

Sarcoidosis, susceptibility to, 2:  
The genetic susceptibility variants (e.g., HLA-DRB1 or BTNL2 mutations) could explain the multi-organ involvement and severity. The overlapping features—**lymphadenopathy**, **interstitial lung disease**, **uveitis**, and **renal inflammation**—are consistent with a systemic granulomatous process. **Bacteriuria** and **nitrituria** likely reflect unrelated UTIs, while **peripheral edema** and **nausea** stem from renal insufficiency. The atypical **hepatic cysts** might indicate concurrent metabolic dysfunction or incidental findings, but the core phenotype strongly supports sarcoidosis susceptibility. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Intellectual disability', 'Motor delay', 'Generalized hypotonia', 'Failure to thrive', 'Small for gestational age', 'Death in infancy', 'Splenomegaly', 'Anemia', 'Acute kidney injury', 'Metabolic acidosis', 'Hypoglycemia', 'Dehydration', 'Fever', 'Hyperammonemia', 'Hypothermia', 'Pneumonia', 'Hyperuricemia', 'Increased serum lactate', 'Hyperglycinemia', 'Hepatomegaly', 'Methylmalonic acidemia', 'Hyperglycinuria', 'Increased blood urea nitrogen', 'Elevated circulating alkaline phosphatase concentration', 'Decreased methylmalonyl-CoA mutase activity', 'Elevated circulating creatinine concentration', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating homocysteine concentration', 'Elevated circulating C-reactive protein concentration', 'Feeding difficulties', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Key biochemical markers**: Elevated methylmalonic acid in blood (methylmalonic acidemia) and urine (methylmalonic aciduria), decreased methylmalonyl-CoA mutase activity, hyperammonemia, metabolic acidosis, and increased serum lactate directly indicate a defect in methylmalonyl-CoA metabolism.  
2. **Clinical features**: Neonatal death, failure to thrive, intellectual disability, motor delay, and generalized hypotonia align with severe mitochondrial energy deficiency caused by MMA.  
3. **Metabolic instability**: Hypoglycemia, hyperuricemia, hyperglycinemia, and abnormal amino acid profiles (e.g., aspartate, alanine, homocysteine) reflect disrupted intermediary metabolism and secondary mitochondrial dysfunction.  
4. **Organ involvement**: Hepatomegaly, splenomegaly, acute/chronic kidney injury, and elevated creatinine/blood urea nitrogen suggest toxic metabolite accumulation (methylmalonic acid) damaging organs.  
5. **Systemic complications**: Feeding difficulties, gastrointestinal inflammation, and recurrent infections (pneumonia) are consistent with chronic metabolic stress and immune dysfunction.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Enzyme deficiency confirmation**: Decreased methylmalonyl-CoA mutase activity explicitly identifies the molecular defect, distinguishing it from B12-responsive forms (e.g., cblA/cblB defects).  
2. **B12-unresponsiveness**: Persistence of methylmalonic acidemia despite B12 supplementation (implied by classification) and severe phenotypes (neonatal death, death in childhood) are hallmarks of mutase deficiency.  
3. **Carnitine depletion**: Decreased plasma free carnitine occurs due to excessive conjugation with toxic metabolites (e.g., propionyl-CoA derivatives), exacerbating energy crisis.  
4. **Chronic multisystem disease**: Chronic kidney disease, severe short stature, and abnormal porphyrin metabolism indicate long-term sequelae of uncontrolled MMA.  
5. **Laboratory correlations**: Elevated CRP, hyperlactatemia, and abnormal urinary carboxylic acids further support chronic metabolic decompensation and oxidative stress.  

Both diagnoses are intrinsically linked, with the second specifying the mutase-deficient, B12-unresponsive subtype underlying the patient’s catastrophic clinical course. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Low-set ears', 'Wide nasal bridge', 'Strabismus', 'Delayed speech and language development', 'Syndactyly', 'Intellectual disability', 'Motor delay', 'Death in infancy', 'Difficulty walking', 'Elevated 8-dehydrocholesterol', 'Severe short stature', 'Difficulty climbing stairs', 'Neonatal death', 'Death in childhood', 'Difficulty running', 'Elevated 7-dehydrocholesterol', 'Severe hearing impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
Reasoning:  
1. **Biochemical Markers**: Elevated 7-dehydrocholesterol and 8-dehydrocholesterol are pathognomonic for Smith-Lemli-Opitz syndrome (SLOS), caused by a defect in the *DHCR7* gene, which disrupts cholesterol biosynthesis.  
2. **Craniofacial Features**: Microcephaly, low-set ears, and wide nasal bridge are classic dysmorphic traits in SLOS.  
3. **Limb Anomalies**: Syndactyly (often of toes 2-3) is a hallmark of SLOS.  
4. **Neurodevelopmental Delays**: Intellectual disability, motor delays, and speech/language delays align with impaired cholesterol-dependent myelination and synaptic function.  
5. **Growth and Survival**: Severe short stature, neonatal/childhood death, and early mortality correlate with severe SLOS phenotypes.  
6. **Sensory and Motor Issues**: Strabismus, severe hearing impairment, and difficulty walking/climbing stairs reflect multisystem involvement from cholesterol deficiency.  
7. **Consistency with Severity**: The combination of life-threatening outcomes (infancy/childhood death) and biochemical abnormalities confirms a severe SLOS diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Delayed speech and language development', 'Intellectual disability', 'Cirrhosis', 'Hepatic fibrosis', 'Death in infancy', 'Hyperuricemia', 'Neoplasm of the liver', 'Elevated circulating alkaline phosphatase concentration', '4-Hydroxyphenylpyruvic aciduria', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating ferritin concentration', 'Decreased serum iron']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hepatic involvement**: Cirrhosis, hepatic fibrosis, and liver neoplasms align with HT-1’s hallmark liver damage due to toxic tyrosine metabolites (e.g., succinylacetone). Elevated α-fetoprotein reflects hepatocellular injury or malignancy.  
2. **Metabolic abnormalities**: Hypertyrosinemia and 4-hydroxyphenylpyruvic aciduria directly indicate a tyrosine catabolism defect, specifically fumarylacetoacetate hydrolase (FAH) deficiency in HT-1.  
3. **Renal and systemic effects**: Hyperuricemia and abnormal porphyrins stem from succinylacetone inhibiting renal tubular function and δ-ALA dehydratase, disrupting heme synthesis.  
4. **Early mortality**: Neonatal/childhood death is typical in untreated HT-1 due to acute liver failure or complications like hepatocellular carcinoma.  
5. **Neurological features**: Delayed development and intellectual disability may arise from chronic metabolic instability or secondary neurological damage.  
6. **Iron anomalies**: Decreased ferritin/iron could reflect liver dysfunction impairing storage, though this is less specific.  
7. **Exclusion of mimics**: Symptoms collectively localize to FAH deficiency, distinguishing HT-1 from other tyrosinemias (e.g., HT-2/3 lack severe liver disease) or porphyria (porphyrin abnormalities here are secondary). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Galactosemia is due to the deficiency of:
Choices:
A. Galactose-1-Phosphatase
B. Glucose-1-Phosphatase
C. Galcatose-1-Phosphate uridyl transferase
D. Glucose-6-Phosphatase
Answer: [/INST] Galcatose-1-Phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Pneumonia', 'Hepatomegaly', 'Decreased plasma free carnitine', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Succinic semialdehyde dehydrogenase deficiency  
Reasoning:  
1. **Neurological Symptoms**: Seizures, motor delay, and generalized hypotonia align with SSADHD, a disorder disrupting GABA metabolism. Accumulation of γ-aminobutyric acid (GABA) and γ-hydroxybutyrate (GHB) causes neurotoxicity.  
2. **Elevated Urinary Carboxylic Acid**: SSADHD is characterized by elevated urinary GHB, often reported as a carboxylic acid in screening tests.  
3. **Decreased Plasma Free Carnitine**: Secondary carnitine deficiency may occur due to conjugation of carnitine with accumulating metabolites (e.g., GHB derivatives), reducing free carnitine levels.  
4. **Hepatomegaly**: Could stem from metabolic stress or carnitine deficiency impairing fatty acid oxidation, leading to hepatic lipid accumulation.  
5. **Pneumonia/Death in Infancy**: Severe hypotonia and seizures increase aspiration risk, predisposing to pneumonia. Early mortality reflects complications like refractory seizures or respiratory infections.  
6. **Exclusion of Other Disorders**: While hepatomegaly and carnitine deficiency suggest fatty acid oxidation disorders, the combination with elevated GHB (via urinary carboxylic acids) and neurological symptoms specifically points to SSADHD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pandemic are caused by -a)  Hepatitis Bb)  Influenza-Ac)  Influenza-Bd)  Influenza-Ce) Cholera
Choices:
A. bd
B. be
C. bcd
D. da
Answer: [/INST] be </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Early surgery is indicated in -a) Amoebiasis peritonitisb) Biliary peritonitisc) Typhoid peritonitisd) All
Choices:
A. a
B. bc
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Vomiting', 'Neonatal death', 'Abnormal circulating carnitine concentration', 'Decreased 3-hydroxyacyl-CoA dehydrogenase level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts medium-chain fatty acid β-oxidation, leading to secondary carnitine depletion as carnitine conjugates with accumulating toxic metabolites (e.g., medium-chain acylcarnitines).  
2. **Decreased 3-hydroxyacyl-CoA dehydrogenase activity**: While MCADD primarily involves medium-chain acyl-CoA dehydrogenase (MCAD), impaired β-oxidation indirectly affects downstream enzymes like 3-hydroxyacyl-CoA dehydrogenase due to metabolic bottlenecking.  
3. **Vomiting, neonatal/infant death**: MCADD causes hypoglycemia and metabolic crises triggered by fasting (e.g., missed feeds), resulting in vomiting, encephalopathy, and rapid deterioration in neonates/infants.  
4. **Prenatal abnormalities**: Severe MCADD may manifest as intrauterine growth restriction or prematurity due to chronic energy deficiency from impaired fatty acid metabolism.  
5. **Diagnostic confirmation**: The clinical triad of hypoketotic hypoglycemia, elevated C6-C10 acylcarnitines, and genetic testing for *ACADM* mutations aligns with the symptoms and biochemical findings. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Lethargy', 'Coma', 'Encephalopathy', 'Abnormal cerebellum morphology', 'Dystonia', 'Tachycardia', 'Acute kidney injury', 'Fever', 'Leukocytosis', 'Hyperammonemia', 'Abnormal cerebral morphology', 'Abnormality of extrapyramidal motor function', 'Hyperkalemia', 'Drowsiness', 'Sleep disturbance', 'Elevated hepatic transaminase', 'Hypernatremia', 'Death in childhood', 'Fatigue', 'Chronic kidney disease', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Hyperammonemia** and **encephalopathy**: Hallmark features of urea cycle disorders (UCDs). Citrullinemia type I (argininosuccinate synthetase deficiency) disrupts the urea cycle, leading to ammonia accumulation, neurotoxicity, and cerebral edema.  
2. **Neurological symptoms** (lethargy, coma, dystonia, dyskinesia, extrapyramidal abnormalities): Result from ammonia-induced neuronal damage, particularly in the basal ganglia and cerebellum, explaining **abnormal cerebral/cerebellar morphology**.  
3. **Acute/chronic kidney injury** and **hyperkalemia**: Metabolic acidosis and dehydration during hyperammonemic crises impair renal function. Chronic hyperammonemia may also cause tubular injury.  
4. **Elevated hepatic transaminases**: Secondary to metabolic stress or liver involvement in ammonia detoxification.  
5. **Hypernatremia**: Often due to dehydration during acute crises or inappropriate fluid management.  
6. **Death in childhood**: Untreated neonatal-onset citrullinemia type I is fatal within days to weeks without urgent ammonia-lowering therapy (e.g., dialysis).  
7. **Supporting features**: Leukocytosis and fever (inflammatory response to metabolic crisis), sleep disturbances, and fatigue (neurological dysfunction).  

Disease: Citrullinemia  
Reasoning:  
- This is the Chinese term for Citrullinemia type I. The reasoning aligns identically with the above, as it refers to the same disorder. The symptoms collectively match the classic presentation of this autosomal recessive urea cycle defect. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Anal atresia', 'Clonus', 'Focal clonic seizure', 'Cloverleaf skull', 'Severe combined immunodeficiency', 'Developmental stagnation', 'Fetal distress']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoskeletal dysplasia with neurodevelopmental abnormalities (EXTL3-related)  
Reasoning:  
1. **Skeletal anomalies**: ""Cloverleaf skull"" (craniosynostosis) strongly suggests a skeletal dysplasia, a hallmark of EXTL3 mutations.  
2. **Immunodeficiency**: ""Severe combined immunodeficiency (SCID)"" aligns with EXTL3's role in heparan sulfate biosynthesis, critical for immune cell development.  
3. **Neurodevelopmental issues**: ""Nystagmus,"" ""clonus,"" and ""focal clonic seizures"" indicate neurological dysfunction, consistent with EXTL3's impact on brain development.  
4. **Congenital anomalies**: ""Anal atresia"" and ""fetal distress"" suggest multisystem involvement, common in syndromic disorders like EXTL3-related disease.  
5. **Developmental stagnation**: Reflects global developmental delays due to combined skeletal, immune, and neurological defects.  
6. **Exclusion of mimics**: Overlap with other immunoskeletal disorders (e.g., Schimke immuno-osseous dysplasia) is ruled out by the unique triad of cloverleaf skull, SCID, and seizures. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine contains the following as a preservative:
Choices:
A. Streptomycin
B. Cholramphenicol
C. Neomycin
D. Thiomersal
Answer: [/INST] Neomycin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Thromboembolism', 'Hyperhomocystinemia', 'Hypermethioninemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Homocysteinemia; Homocystinuria  
Reasoning: The patient exhibits **hyperhomocystinemia**, a hallmark of homocystinuria, alongside **intellectual disability** and **thromboembolism**, which are classic complications of elevated homocysteine levels. Hyperhomocystinemia directly indicates impaired homocysteine metabolism, a core feature of this disorder. The presence of **hypermethioninemia** suggests a defect in the transsulfuration pathway, where homocysteine accumulates due to enzyme deficiencies. Early mortality aligns with severe vascular complications (e.g., strokes, thromboses) from chronic homocysteine toxicity.

Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning: **Hypermethioninemia** specifically points to cystathionine beta-synthase (CBS) deficiency, as this enzyme converts homocysteine to cystathionine. Its deficiency traps homocysteine in the methionine cycle, elevating both homocysteine and methionine. **Thromboembolism** and **intellectual disability** are consistent with CBS-deficient homocystinuria, where vascular and connective tissue damage are prominent. **Death in adolescence/early adulthood** reflects the life-threatening thromboembolic events and multisystemic progression seen in untreated or severe cases of CBS deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: No chemoprophylaxis for - a)  Typhoidb)  Chicken poxc)  Influenzad)  Cholera
Choices:
A. b
B. ab
C. ab
D. bd
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hydrocephalus is detailed best antenatally by –
Choices:
A. X-ray abdomen
B. Amniocentesis
C. Clinical examination
D. Ultrasonography
Answer: [/INST] Ultrasonography </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis deposition most commonly occurs in
Choices:
A. Renal vessels
B. Knee joints
C. Skin
D. Cornea
Answer: [/INST] Renal vessels </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Osteosarcoma which one is true
Choices:
A. Affects people in 5th or 6th decade
B. Occurs due to proliferation of osteoclast
C. Lymphatic metastasis is most common
D. Sunray appearance indicates new bone-formation
Answer: [/INST] Sunray appearance indicates new bone-formation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements are true regarding Q fever except:
Choices:
A. It is a zoonotic disease
B. Human disease is characterized by an interstitial pneumonia
C. No rash is seen
D. Weil-Felix reactions is very useful for diagnosis
Answer: [/INST] Weil-Felix reactions is very useful for diagnosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia A results due to deficiency of which of the factors:
Choices:
A. II
B. VII
C. VIII
D. XI
Answer: [/INST] VIII </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macroglossia', 'Turricephaly', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Deeply set eye', 'Esotropia', 'Optic atrophy', '11 pairs of ribs', 'Hypertrichosis', 'Seizure', 'Areflexia', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', ""Exaggerated cupid's bow"", 'EEG abnormality', 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Feeding difficulties', 'Right aortic arch', 'Small basal ganglia', 'Profound global developmental delay']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Macroglossia, turricephaly, coarse facial features, narrow forehead, prominent nasal bridge, anteverted nares, deeply set eyes, highly arched eyebrows, and ""exaggerated cupid's bow"" align with the dysmorphic facial phenotype described in TBCK syndrome.  
2. **Neurological/developmental hallmarks**: Severe muscular hypotonia, profound global developmental delay, developmental regression, seizures, EEG abnormality, and areflexia match the core features of TBCK-related disorders, which involve progressive neurodegeneration and psychomotor impairment.  
3. **Brain malformations**: Cerebellar vermis hypoplasia, hypoplasia/agenesis of the corpus callosum, ventriculomegaly, and small basal ganglia are recurrent neuroimaging findings in TBCK syndrome, linked to disrupted neuronal development and maintenance.  
4. **Systemic features**: Feeding difficulties (due to hypotonia), hypertrichosis, and right aortic arch (vascular anomaly) are consistent with multisystem involvement reported in TBCK cases.  
5. **Genetic correlation**: The combination of hypotonia, intellectual disability, characteristic facies, and brain anomalies strongly suggests a monogenic disorder like TBCK syndrome, caused by biallelic pathogenic variants in the *TBCK* gene affecting mTOR signaling and autophagy.  
6. **Exclusion of mimics**: Features such as optic atrophy and 11 pairs of ribs (likely a typo for rib anomalies) do not contradict the diagnosis and may represent variable expressivity of TBCK-related disease. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormal circulating carnitine concentration**: MCADD disrupts mitochondrial β-oxidation of medium-chain fatty acids, leading to secondary carnitine depletion as carnitine conjugates with unmetabolized acyl-CoA intermediates (e.g., octanoylcarnitine), reducing free carnitine levels.  
2. **Neonatal death/Death in infancy**: MCADD typically manifests during fasting or metabolic stress (e.g., infections), causing hypoketotic hypoglycemia, encephalopathy, and hepatic dysfunction. Untreated, this rapidly progresses to coma or fatal metabolic crisis, especially in infancy.  
3. **Abnormality of prenatal development or birth**: While MCADD does not cause structural congenital anomalies, biochemical abnormalities (e.g., elevated C8-C10 acylcarnitines) may be detectable prenatally or at birth via newborn screening. Severe undiagnosed cases may present as sudden infant death syndrome (SIDS), aligning with ""abnormality of birth.""  
4. **Supporting evidence**: MCADD is included in newborn screening panels globally due to its preventable morbidity/mortality. The symptom constellation aligns with impaired energy metabolism during catabolic states, hallmark of fatty acid oxidation disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leptospirosis is transmitted by -
Choices:
A. Rat
B. Cat
C. Dog
D. Fish
Answer: [/INST] Rat </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Weight loss', 'Dehydration', 'Hyperammonemia', 'Pneumonia', 'Dyspnea', 'Opisthotonus', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Tachypnea', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Abnormal circulating pyrimidine concentration', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating proline concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Uraciluria', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD, a urea cycle disorder impairing ammonia detoxification.  
2. **Oroticaciduria/Uraciluria**: Pathognomonic for OTCD; excess carbamoyl phosphate diverts to pyrimidine synthesis, producing orotic acid and uracil.  
3. **Neurological symptoms (cerebral edema, opisthotonus, drowsiness)**: Result from ammonia-induced neurotoxicity.  
4. **Early lethality (neonatal/infant/childhood death)**: Characteristic of severe urea cycle defects due to rapid metabolic decompensation.  
5. **Hyperglutaminemia/Hyperalaninemia**: Alternative nitrogen accumulation from impaired urea cycle.  
6. **Respiratory signs (tachypnea, dyspnea)**: Compensatory respiratory alkalosis to counteract acidosis from ammonia.  
7. **Elevated plasma citrulline discrepancy**: While atypical for OTCD (typically low citrulline), possible partial enzyme activity, analytical variability, or concurrent metabolic stressors may explain this finding.  
8. **Recurrent infections/GI inflammation**: Catabolic states and metabolic instability predispose to immune dysfunction and mucosal injury.  
9. **Abnormal amino acid/carnitine profiles**: Secondary to disrupted nitrogen metabolism and mitochondrial dysfunction.  

Key confirmatory features: Oroticaciduria + hyperammonemia + X-linked inheritance pattern (severe males), despite citrulline elevation, strongly prioritize OTCD over other urea cycle disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cell culture Rabies vaccine is given at: September 2005
Choices:
A. Medial pa of thigh
B. Deltoid muscle
C. Anterior Abdomen
D. Lateral pa of thigh
Answer: [/INST] Deltoid muscle </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: To prevent Yellow Fever Aedes aegypti index should be less than?
Choices:
A. 0.50%
B. 1%
C. 2%
D. 5%
Answer: [/INST] 1% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma has been associated with infection by
Choices:
A. Paragonimus westermani
B. Clonorchis sinensis
C. Loa Loa
D. Schistosoma haematobium
Answer: [/INST] Clonorchis sinensis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is detected by which urine test:
Choices:
A. Guthrie test
B. Sodium nitroprusside test
C. Blot test
D. FeCl3
Answer: [/INST] Guthrie test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypomelanosis of Ito is associated with?
Choices:
A. Mental retardation
B. Seizures
C. Visual abnormalities
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chordoma can occur over all the following sites, except -
Choices:
A. Rib
B. Clivus
C. Sacrum
D. Vertebral body
Answer: [/INST] Rib </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Small for gestational age', 'Death in infancy', 'Hyperammonemia', 'Aminoaciduria', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with hyperammonemia, aminoaciduria, and elevated urinary carboxylic acids, indicative of a leucine metabolism disorder. Decreased plasma free carnitine aligns with secondary carnitine depletion due to conjugation with toxic metabolites like 3-methylcrotonylglycine. Neonatal death and growth issues correlate with metabolic crises from enzyme deficiency (MCCC1 gene), impairing 3-methylcrotonyl-CoA conversion.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: Symptoms overlap with the broader enzyme deficiency (MCCC1 or MCCC2 subunits). Elevated urinary 3-hydroxyisovaleric acid and abnormal glycine levels are hallmark biochemical findings. Death in infancy/childhood reflects acute decompensation episodes triggered by catabolic stressors. Small for gestational age suggests prenatal metabolic dysfunction. The combined features confirm disrupted branched-chain amino acid catabolism due to 3-MCC deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following genetic syndromes are associated with Acute Myeloid Leukemia, except:
Choices:
A. Down's Syndrome
B. Klinefelter's Syndrome
C. Patau Syndrome
D. Turner's Syndrome
Answer: [/INST] Turner's Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Dysarthria', 'Cerebellar atrophy', 'Dysphagia', 'Gait ataxia', 'Paraparesis', 'Scoliosis', 'Ankle clonus']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Paraparesis** and **ankle clonus** are hallmark signs of upper motor neuron dysfunction, consistent with hereditary spastic paraplegia (HSP).  
2. **Cerebellar atrophy** and **gait ataxia** indicate cerebellar involvement, aligning with ""complicated"" HSP subtypes like SPG76, where CAPN1 mutations cause combined pyramidal and cerebellar pathology.  
3. **Dysarthria** and **dysphagia** suggest brainstem or cerebellar dysfunction, often seen in HSPs with extended neurological features.  
4. **Scoliosis** may arise secondary to chronic neuromuscular imbalance, a known skeletal complication in progressive HSPs.  
5. SPG76’s autosomal recessive inheritance and phenotypic overlap with spasticity-plus syndromes (e.g., cerebellar degeneration) distinguish it from pure motor HSPs (e.g., SPG4). The constellation of pyramidal, cerebellar, and bulbar symptoms strongly supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following conditions Aniridia and help hyperophy6 are most likely present
Choices:
A. Nerublastoma
B. Wilms tumor
C. Non Hodgkin's lymphoma
D. Germ cell tumor
Answer: [/INST] Wilms tumor </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccine given to contact of measles case exerts protective effect within -
Choices:
A. 1 day
B. 3 days
C. 7 days
D. 10 days
Answer: [/INST] 7 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment of choice for Kawasaki Disease
Choices:
A. Immunoglobulins
B. Coicosteroids
C. Azathioprine
D. Methotrexate
Answer: [/INST] Immunoglobulins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The cause of the severe hemorrhage in Acute Promyelocytic Leukemia is?
Choices:
A. Disseminated intravascular coagulation
B. Immune complex deposits on blood vessels
C. Thrombocytopenia
D. Thrombocytosis
Answer: [/INST] Disseminated intravascular coagulation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Chordee', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Low-set ears', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic nerve hypoplasia', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Dysarthria', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Hip dysplasia', 'Intrauterine growth retardation', 'Small for gestational age', 'Premature birth', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Dysphagia', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Duodenal atresia', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Mild neurosensory hearing impairment', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Abnormality of fontanelles', 'Placental infarction', 'Unilateral microphthalmos', 'Hypoplasia of the pons', 'Delayed myelination', 'Thick vermilion border', 'Anisometropia', 'Abnormal hippocampus morphology', 'Clinodactyly', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
**Reasoning**:  
1. **Neurodevelopmental and CNS anomalies**: Global developmental delay, seizures, hypotonia, dysarthria, spastic tetraparesis, ADHD, and abnormal hippocampus morphology align with core neurodevelopmental dysfunction. Structural brain abnormalities (hypoplasia of the corpus callosum, ventriculomegaly, pontine hypoplasia, cerebral hypomyelination) are hallmark features of NEDBEH.  
2. **Ocular anomalies**: Coloboma, Peters anomaly, optic nerve hypoplasia, and unilateral microphthalmos directly correlate with the ""eye"" component of NEDBEH, particularly given the specificity of Peters anomaly (a rare anterior segment defect).  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and anomalous pulmonary venous return fulfill the ""heart"" criterion, common in NEDBEH.  
4. **Craniofacial dysmorphism**: Microcephaly/macrocephaly (variable expressivity), triangular face, epicanthus, hypertelorism, smooth philtrum, and cleft lip reflect the syndromic facial gestalt seen in neurodevelopmental genetic disorders.  
5. **Multi-system involvement**: Choanal atresia, duodenal atresia, renal cysts, and genitourinary anomalies (cryptorchidism, hypospadias) support a systemic genetic disorder, consistent with NEDBEH’s broad phenotypic spectrum.  
6. **Growth anomalies**: Intrauterine growth restriction (IUGR), small for gestational age, and short stature (contradicts ""tall stature,"" possibly an error) align with prenatal-onset growth issues seen in NEDBEH.  
7. **Supportive features**: Hypotonia, hypertrichosis, and café-au-lait spots, while non-specific, are reported in NEDBEH cases. Delayed myelination and hypoplastic corpus callosum further strengthen the diagnosis.  

**Exclusion Notes**: Overlap with CHARGE syndrome is considered (coloboma, choanal atresia), but the absence of arhinia, semicircular canal defects, and the prominence of brain malformations favor NEDBEH. Peters anomaly and hypomyelination are more characteristic of NEDBEH. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Strabismus', 'Hypothyroidism', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Constipation', 'Elevated circulating thyroid-stimulating hormone concentration', 'Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Core biochemical marker of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Intellectual disability, seizures, microcephaly, motor delay**: Classic neurological consequences of untreated PKU due to phenylalanine neurotoxicity.  
3. **Death in infancy/childhood**: Occurs in severe, untreated cases from metabolic derangements and complications.  
4. **Strabismus/Constipation**: Secondary neurological/gastrointestinal effects of elevated phenylalanine.  
5. **Hypertyrosinemia discrepancy**: Unusual in PKU (typically low tyrosine), possibly reflects testing artifacts, dietary factors, or overlapping metabolic conditions (e.g., transient tyrosinemia in neonates).  
6. **Elevated TSH/hypothyroidism**: Likely coincidental or comorbid (e.g., congenital hypothyroidism), as PKU does not directly disrupt thyroid function.  

**Conclusion**: Dominant features (hyperphenylalaninemia, neurodevelopmental deficits) align with PKU. Atypical findings (hypertyrosinemia, hypothyroidism) warrant further investigation but do not override the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Honeycombimg of lung in C.X.R. is seen in – a) R.A.b) T.B.c) Sclerodermad) Carcinomae) Interstitial lung disease
Choices:
A. bcde
B. abce
C. acde
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatable causes of dementia are -a) Alzheimer's ds.b) Hypothyroidismc) Multi-infarct dementia d) SDH (subdural h'ge) e) Hydrocephalus
Choices:
A. abc
B. ade
C. bde
D. bce
Answer: [/INST] bde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Tall stature', 'Narrow mouth', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Astigmatism', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormality of the ear', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Microdontia', 'Atypical behavior', 'Autistic behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Seizure', 'Hypotonia', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Abnormal cerebellum morphology', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Poor suck', 'Ventriculomegaly', 'Duodenal atresia', 'Tetraparesis', 'Abnormal cerebellar vermis morphology', 'Sleep disturbance', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Delayed fine motor development', 'Laterally extended eyebrow', 'Abnormality of fontanelles', 'Abdominal colic', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  

**Reasoning:**  
1. **Neurodevelopmental Core Features:**  
   - *Autistic behavior, delayed speech, hyperactivity, ADHD, absent speech, delayed fine motor development* align with the ""neurodevelopmental disorder"" component.  
   - *Abnormal corpus callosum, cerebellar/pons/hippocampus anomalies, CNS hypomyelination* indicate structural brain abnormalities.  

2. **Ocular Involvement:**  
   - *Coloboma, microphthalmia, Peters anomaly, optic atrophy, astigmatism, deeply set eyes* reflect the ""eye anomalies"" criterion.  

3. **Cardiac Defects:**  
   - *Ventricular septal defect, patent ductus arteriosus, anomalous pulmonary return* satisfy the ""heart anomalies"" spectrum.  

4. **Craniofacial & Systemic Features:**  
   - *Microcephaly/macrocephaly, triangular face, micrognathia, high palate, bulbous nose* are common in genetic neurodevelopmental syndromes.  
   - *Growth delay, hypotonia, seizures, GI anomalies (pyloric stenosis, duodenal atresia)* support multisystem involvement.  

5. **Exclusion of Overlap Syndromes:**  
   - While features like *café-au-lait spots* or *syndactyly* may suggest RASopathies or chromosomal disorders, the triad of neurodevelopmental delay + brain/eye/heart anomalies is pathognomonic for NEDBEH (OMIM 618733).  

6. **Genetic Consistency:**  
   - NEDBEH is linked to *CABP4* or *UBR3* mutations, which disrupt neurodevelopment and organogenesis, explaining the observed phenotypic variability.  

**Conclusion:** The convergence of neurodevelopmental delays, structural brain/eye/heart defects, and variable dysmorphism strongly supports NEDBEH. Genetic testing for causative variants is recommended for confirmation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Intellectual disability', 'Lethargy', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Apnea', 'Cerebral edema', 'Drowsiness', 'Sleep disturbance', 'Hypotension', 'Hyperglutaminemia', 'Low plasma citrulline', 'Neonatal death', 'Recurrent viral infections']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia**: Central to diagnosis, as CPS1 deficiency disrupts the urea cycle’s first step, preventing ammonia detoxification.  
2. **Low plasma citrulline**: CPS1 deficiency blocks carbamoyl phosphate synthesis, reducing citrulline production (unlike OTC deficiency, where citrulline is also low but orotic acid is elevated).  
3. **Hyperglutaminemia**: Excess ammonia is metabolized via alternative pathways, forming glutamine as a compensatory mechanism.  
4. **Neurological symptoms (Microcephaly, Intellectual disability, Cerebral edema, Lethargy, Drowsiness)**: Result from ammonia neurotoxicity, impairing brain development and function.  
5. **Apnea, Hypotension, Bradycardia**: Systemic effects of hyperammonemia and cerebral edema impacting autonomic regulation.  
6. **Neonatal death/Death in infancy**: Severe CPS1 deficiency often presents catastrophically in infancy due to rapid ammonia accumulation.  
7. **Recurrent viral infections**: Likely secondary to metabolic instability and critical illness rather than a primary immune defect.  
8. **Sleep disturbance**: Reflects neurological irritation from hyperammonemia.  

The combination of hyperammonemia, low citrulline, and hyperglutaminemia distinguishes CPS1 deficiency from other urea cycle disorders. The absence of elevated orotic acid or other intermediates further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria parasite was discovered by:
Choices:
A. Ronald Ross
B. Paul Muller
C. Laveran
D. Pampania
Answer: [/INST] Laveran </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Tachycardia', 'Metabolic acidosis', 'Vomiting', 'Hepatomegaly', 'Tachypnea', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Metabolic Acidosis**: A hallmark of urea cycle disorders (UCDs) due to hyperammonemia and secondary organ dysfunction.  
2. **Vomiting & Hepatomegaly**: Common in UCDs; hepatomegaly specifically linked to argininosuccinic aciduria due to liver involvement from toxic metabolite accumulation.  
3. **Tachypnea & Tachycardia**: Compensatory responses to metabolic acidosis and hyperammonemia-induced encephalopathy.  
4. **Neonatal Death/Infant Mortality**: Severe UCDs like argininosuccinic aciduria often present acutely in infancy with rapid deterioration if untreated.  
5. **Distinguishing from Other UCDs**: Elevated argininosuccinic acid in blood/urine (pathognomonic) and hepatomegaly differentiate it from ornithine transcarbamylase (OTC) deficiency.  
6. **Exclusion of Organic Acidemias**: Lack of pronounced ketosis and presence of hepatomegaly favor urea cycle dysfunction over organic acidemias.  
7. **Liver Dysfunction**: Contributes to metabolic acidosis via impaired ammonia detoxification and potential lactic acidosis.  

Conclusion: Symptom constellation aligns with argininosuccinic aciduria, confirmed by biochemical markers (argininosuccinic acid elevation) and clinical progression. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy do not involve:
Choices:
A. CNS
B. Testis
C. Skin
D. Cornea
Answer: [/INST] CNS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following conditions, uniform dilation of esophagus is seen -a)  Sclerodermab)  Achalasia cardiac) Dermatomyositisd) Trypanosoma cruzi infection
Choices:
A. c
B. bd
C. ab
D. ac
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Acne', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia**: Uncommon in classic PKU but may occur in atypical variants or secondary metabolic disruptions (e.g., tyrosine supplementation or overlapping enzyme deficiencies).  
3. **Neonatal death/Death in infancy/Death in adolescence**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality in unscreened or unmanaged cases.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU) can cause congenital anomalies, though this symptom is atypical for infantile PKU.  
5. **Acne**: May arise from tyrosine metabolism imbalances or secondary skin effects of chronic metabolic stress.  
6. **Diagnostic alignment**: While hypertyrosinemia and prenatal abnormalities are atypical, hyperphenylalaninemia and the mortality pattern strongly suggest PKU with severe complications from delayed diagnosis/treatment. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Drowsiness', 'Sleep disturbance', 'Abnormal cerebral white matter morphology', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Death in childhood', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria and elevated glutaric acid**: Direct biochemical markers of GA-I, caused by **glutaryl-CoA dehydrogenase deficiency**, impairing lysine and tryptophan metabolism.  
2. **Neurological symptoms (ataxia, hypotonia, drowsiness)**: Accumulated glutaric acid and neurotoxic metabolites (e.g., 3-hydroxyglutaric acid) damage the basal ganglia and white matter, consistent with **abnormal cerebral white matter morphology** on imaging.  
3. **Feeding difficulties and lethargy**: Common early signs in infants with GA-I due to metabolic instability.  
4. **Acute crises and neurodegeneration**: Untreated GA-I leads to metabolic decompensation (often triggered by infections/stress), causing irreversible brain injury, **sleep disturbance**, and **death in childhood**.  
5. **Exclusion of mimics**: Symptoms align with GA-I’s hallmark triad (encephalopathy, movement disorders, white matter changes) and biochemical profile, distinguishing it from other organic acidemias. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Respiratory insufficiency', 'Opisthotonus', 'Neonatal death', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Feeding difficulties', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Elevated branched-chain amino acids (Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia)**: MSUD is caused by a defect in the branched-chain alpha-keto acid dehydrogenase complex, leading to toxic accumulation of leucine, isoleucine, and valine. These lab findings are pathognomonic.  
2. **Neurological symptoms (Seizure, Opisthotonus)**: Excess leucine is neurotoxic, causing cerebral edema and severe neurological dysfunction, manifesting as seizures and abnormal posturing (opisthotonus).  
3. **Metabolic decompensation (Feeding difficulties, Respiratory insufficiency)**: Infants develop poor feeding, vomiting, and lethargy due to metabolic acidosis. Respiratory failure may arise from central nervous system depression or muscle weakness.  
4. **Early lethality (Neonatal death, Death in infancy)**: Untreated classic MSUD progresses rapidly to coma and death within weeks to months due to irreversible neurological damage.  
5. **Sepsis mimicry**: Metabolic crises in MSUD can mimic sepsis (lethargy, respiratory distress), and secondary infections may occur due to immune dysfunction from metabolic stress.  

The combination of BCAA elevation, acute neurological decline, and neonatal onset confirms MSUD as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are precancerous for carcinoma bladder except -a) Tuberculosis bladderb) Aniline dyesc) Schistosomiasisd) Chronic ulcer
Choices:
A. b
B. ad
C. ac
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which condition is associated with Congenital Adrenal Hyperplasia?
Choices:
A. Male pseudohermaphroditism
B. Female pseudohermaphroditism
C. Female true hermaphroditism
D. Sequential pseudohermaphroditism
Answer: [/INST] Female pseudohermaphroditism </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ichthyosis is associated with –
Choices:
A. Hodgkins disease
B. AIDS
C. Hypothyroidism
D. All
Answer: [/INST] All </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is due to deficiency of:
Choices:
A. Phenylalanine
B. Phenylalanine hydroxylase (PAH)
C. Galactokinase
D. Tyrosinase
Answer: [/INST] Phenylalanine hydroxylase (PAH) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pinta is caused by:
Choices:
A. Treponema peenue
B. Treponema carateum
C. Treponema pallidum
D. Treponema endemicum
Answer: [/INST] Treponema carateum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly can be diagnosed by ultrasound at:
Choices:
A. 14-18 week of gestation
B. 20-24 week of gestation
C. 24-37 weeks of gestation
D. 10-12 week of gestation
Answer: [/INST] 10-12 week of gestation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common presentation of Cryptococcosis is
Choices:
A. Meningitis
B. Pulmonary cryptococcosis
C. SKin lesions
D. Osteomyelitis
Answer: [/INST] Pulmonary cryptococcosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Ataxia', 'Lethargy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency causes impaired ammonia detoxification.  
2. **Oroticaciduria**: Pathognomonic for OTCD due to carbamoyl phosphate shunting into pyrimidine synthesis, producing excess orotic acid.  
3. **Neurological symptoms** (Apathy, Ataxia, Lethargy, Drowsiness): Reflect hyperammonemic encephalopathy from ammonia neurotoxicity.  
4. **Gastrointestinal symptoms** (Vomiting): Common during metabolic decompensation episodes.  
5. **Sleep disturbance**: Linked to circadian disruption from ammonia accumulation.  
6. **Death in adolescence**: Consistent with late-onset OTCD complications if untreated (e.g., cerebral edema, coma).  

The triad of **hyperammonemia, oroticaciduria, and neurological decline** confirms OTCD, a urea cycle disorder with X-linked inheritance (though females may manifest due to skewed lyonization). Urgent ammonia reduction and long-term protein restriction/ammonia scavengers are critical. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Tremor', 'Athetosis', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Ataxia** (impaired coordination), **tremor** (rhythmic shaking), and **athetosis** (slow, writhing movements) align with the progressive neurodegenerative effects of the disease, caused by toxic accumulation of L-2-hydroxyglutaric acid in the central nervous system.  
3. **Disease Progression**: The **death in adolescence or early adulthood** is consistent with the disorder’s natural history, as complications like seizures, respiratory infections, or severe neurological decline often lead to early mortality.  
4. **Genetic Basis**: Autosomal recessive mutations in *L2HGDH* disrupt lysine metabolism, leading to systemic and neurological manifestations.  
5. **Exclusion of Mimics**: Symptoms overlap with other organic acidurias or mitochondrial disorders, but the specific biochemical marker (L-2-hydroxyglutaric aciduria) and clinical course confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute complication of PEM – a)  Hypothermiab)  Hypoglycemiac)  Hypokalemiad)  Hypermagnesaemiae)  Eosinophilia
Choices:
A. ab
B. bc
C. abc
D. bcd
Answer: [/INST] abc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine schedule is:
Choices:
A. 0,3,7,14,28
B. 8,0,4,0,1,1
C. 8,0,0,4,1,1
D. 8,0,4,0,0,1
Answer: [/INST] 8,0,4,0,1,1 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Prolactinoma in pregnancy, all are true except:
Choices:
A. Most common pituitary tumor but rarely symptomatic
B. Increase in prolactin levels worse prognosis
C. Macroadenoma> 1 cm is associated with bad prognosis
D. Regular visual checkup
Answer: [/INST] Increase in prolactin levels worse prognosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Strabismus', 'Apathy', 'Delayed speech and language development', 'Seizure', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Abdominal distention', 'Propionyl-CoA carboxylase deficiency', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Key biochemical marker**: Propionyl-CoA carboxylase deficiency is a hallmark of biotinidase deficiency (BTDD), as biotin is a cofactor for multiple carboxylases, including propionyl-CoA carboxylase.  
2. **Metabolic abnormalities**: Elevated urinary carboxylic acids (e.g., propionate, 3-hydroxyisovalerate) and abnormal aspartate/alanine concentrations align with impaired carboxylase activity due to biotin depletion.  
3. **Dermatological features**: Alopecia (hair loss) is a classic sign of biotin deficiency, as biotin is critical for keratin synthesis.  
4. **Neurological symptoms**: Seizures, motor delay, apathy, and severe hearing impairment reflect biotin’s role in neuronal function and myelination. Untreated BTDD causes progressive neurodegeneration.  
5. **Immune dysfunction**: Recurrent viral infections may stem from biotin’s role in immune regulation and leukocyte function.  
6. **Early mortality**: Death in infancy/childhood is typical in severe, untreated cases due to metabolic crises or infections.  
7. **Abdominal distention**: Likely secondary to metabolic acidosis or hepatic dysfunction from toxic metabolite accumulation.  
8. **Late-onset presentation**: Symptoms like delayed speech and hypotonia manifest after the neonatal period, distinguishing BTDD from holocarboxylase synthetase deficiency (early-onset).  
**Conclusion**: The constellation of carboxylase deficiency, neurological decline, alopecia, and metabolic derangements confirms BTDD. Immediate biotin supplementation is critical to reverse symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leukodystrophy with Bilateral occipital lobe involvement is seen in
Choices:
A. MELAS
B. Canavan disease
C. Alexander disease
D. Adrenoleucodystrophy
Answer: [/INST] Adrenoleucodystrophy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis begins as an inflammation of
Choices:
A. Cortical bone
B. Periosteum
C. Medullary bone
D. Periosteum and inner cortex
Answer: [/INST] Medullary bone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bleeding disorder with ↑ a PTT is/are -a) Hemophilia Ab) Hemophilia Bc) Henoch-schonlein purpurad) Bernard-soulier syndromee) Von-Willebrand disease
Choices:
A. abe
B. bcd
C. cde
D. acd
Answer: [/INST] abe </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Smallpox vaccine was discovered by:
Choices:
A. Edward Jenner
B. Louis pasteur
C. Salk
D. Sabin
Answer: [/INST] Edward Jenner </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Killing of Thyroid Cancer cells By I-131 is mainly by
Choices:
A. Alpha Rays
B. X rays
C. Beta Rays
D. Gamma Rays
Answer: [/INST] Beta Rays </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are features of Scleroderma are following except
Choices:
A. Diffuse periosteal reaction
B. Esophageal dysmotility
C. Erosion of tip of phalanges
D. Lung Nodular infiltrates
Answer: [/INST] Diffuse periosteal reaction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis of kidney may be seen in the following except -
Choices:
A. Enteric fever
B. Ulcerative colitis
C. Suppurative lung disease
D. Hansen's disease
Answer: [/INST] Enteric fever </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Multiple carboxylase involvement**: Symptoms like decreased pyruvate carboxylase activity and propionyl-CoA carboxylase deficiency indicate a global defect in biotin-dependent carboxylases, which require holocarboxylase synthetase (HLCS) for activation.  
2. **Metabolic derangements**:  
   - **Hyperammonemia** and **metabolic acidosis** arise due to impaired urea cycle function (via propionyl-CoA accumulation) and excessive organic acids (e.g., lactic acid, 3-hydroxypropionic acid).  
   - **Elevated urinary carboxylic acids** and **aminoaciduria** reflect disrupted amino acid catabolism and mitochondrial dysfunction.  
3. **Biotin dependency**: HLCS deficiency prevents biotin incorporation into carboxylases, explaining the multi-enzyme dysfunction.  
4. **Neonatal severity**: Symptoms like **feeding difficulties**, **tachypnea** (compensatory respiratory alkalosis), and **neonatal death** align with the rapid metabolic decompensation seen in untreated HLCS deficiency.  
5. **Glycine abnormalities**: Propionyl-CoA accumulation inhibits glycine cleavage, leading to **abnormal circulating glycine**.  
6. **Exclusion of isolated deficiencies**: Concurrent pyruvate and propionyl-CoA carboxylase deficiencies rule out isolated defects (e.g., propionic acidemia), pointing to a shared biotinylation defect. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Oroticaciduria** is a hallmark of OTCD, caused by carbamoyl phosphate accumulation due to the enzyme defect, shunting into pyrimidine synthesis and producing excess orotic acid.  
2. **Abnormal circulating ornithine concentration** aligns with disrupted urea cycle dynamics, as ornithine is not efficiently converted to citrulline.  
3. **Lethargy, drowsiness, and sleep disturbances** reflect hyperammonemia-induced neurotoxicity, a critical feature of urea cycle disorders.  
4. **Death in infancy** is consistent with severe neonatal-onset OTCD, where hyperammonemia rapidly progresses without intervention.  
5. OTCD’s X-linked inheritance explains severe male presentations, though symptomatic females may also occur due to skewed X-inactivation.  
6. Exclusion of other urea cycle disorders (e.g., citrullinemia) is supported by the absence of specific amino acid elevations (e.g., citrulline) and the presence of oroticaciduria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypoglycemia', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Abnormal nervous system physiology', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient’s **hypoglycemia**, **elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine), and **abnormal carnitine levels** align with 3-MCC1 deficiency, which disrupts leucine catabolism. **Aminoaciduria** may stem from renal tubular dysfunction secondary to metabolic stress. **Abnormal nervous system physiology** and **neonatal death** reflect severe metabolic crises from toxic metabolite accumulation (e.g., 3-methylcrotonyl-CoA). The **abnormal glycine concentration** could result from secondary metabolic disturbances. Prenatal abnormalities and infant mortality are consistent with acute presentations of this autosomal recessive disorder.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis includes deficiencies in either the MCCC1 or MCCC2 subunits. The patient’s **hypoglycemia** and **elevated urinary carboxylic acids** directly correlate with impaired 3-methylcrotonyl-CoA metabolism. **Abnormal carnitine levels** arise from excessive acyl-carnitine conjugation to clear toxic intermediates. **Aminoaciduria** and **abnormal glycine** suggest systemic metabolic dysregulation. **Neonatal death** and **nervous system abnormalities** indicate a severe phenotype, typical of untreated cases. The absence of hyperammonemia or ketosis differentiates it from other organic acidemias, further supporting 3-MCC deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diagnostic criterion for Infective Endocarditis include all, Except:
Choices:
A. Positive Echocardiogram
B. Positive Blood culture
C. Raised ESR
D. Positive Rheumatoid Factor
Answer: [/INST] Raised ESR </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Acute kidney injury', 'Methylmalonic acidemia', 'Decreased plasma free carnitine', 'Abnormal circulating porphyrin concentration', 'Death in adolescence', 'Abnormal circulating creatinine concentration', 'Methylmalonic aciduria', 'Chronic kidney disease', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning:  
1. **Core biochemical findings**: Methylmalonic acidemia/aciduria confirms impaired methylmalonyl-CoA mutase function, a hallmark of MMA.  
2. **B12-unresponsiveness**: The diagnosis specifies a B12-unresponsive subtype, which aligns with a mutase (MUT gene) deficiency, as B12 supplementation cannot bypass the defective enzyme.  
3. **Renal complications**: Chronic kidney disease, acute kidney injury, and abnormal creatinine reflect long-term metabolic acidosis and hypermethylmalonic acid toxicity, common in severe, treatment-resistant MMA.  
4. **Carnitine deficiency**: Decreased plasma free carnitine occurs due to excessive urinary excretion of methylmalonyl-carnitine, a compensatory mechanism to eliminate toxic metabolites.  
5. **Early mortality**: Death in adolescence/early adulthood is typical in mutase-deficient MMA due to metabolic crises, renal failure, or secondary organ damage.  
6. **Porphyrin abnormalities**: Likely secondary to renal dysfunction or mitochondrial toxicity disrupting heme biosynthesis pathways.  

Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning:  
1. **Symptomatic confirmation**: The presence of methylmalonic acidemia and aciduria directly establishes the broad diagnosis of MMA.  
2. **Overlap with subtype**: This general diagnosis encompasses all forms of MMA, including the specific mutase-deficient subtype, which is further refined by the second diagnosis.  
3. **Metabolic derangements**: All listed symptoms (kidney injury, carnitine deficiency) are consistent with the systemic effects of MMA, regardless of subtype.  
4. **Terminology clarification**: ""Methylmalonic aciduria"" is synonymous with MMA, emphasizing urinary excretion of methylmalonic acid as a diagnostic feature.  

The two diagnoses are hierarchically linked: the second (mutase deficiency) specifies the etiology and subtype of the first (general MMA). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: According to American hea association & world hea federation 2015 criteria, low risk is defined as having An Acute Rheumatic Fever incidence <---------- per 100,000 school aged children per year?
Choices:
A. 1
B. 2
C. 0.1
D. 0.01
Answer: [/INST] 2 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Conjunctivitis', 'Delayed speech and language development', 'Growth delay', 'Obesity', 'Small for gestational age', 'Death in infancy', 'Premature birth', 'Abnormal erythrocyte morphology', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Abnormal circulating porphyrin concentration', 'Hypoxemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: This is the hallmark biochemical finding in PKU, caused by deficient phenylalanine hydroxylase activity, impairing phenylalanine metabolism.  
2. **Delayed speech and language development**: Untreated PKU leads to neurotoxic phenylalanine accumulation, resulting in intellectual disability and developmental delays.  
3. **Growth delay/Obesity**: Poorly managed PKU can disrupt metabolic processes, while obesity may arise from restrictive diets favoring low-protein, high-carbohydrate intake.  
4. **Premature birth/Small for gestational age/Neonatal death**: Maternal PKU during pregnancy causes fetal exposure to high phenylalanine, leading to intrauterine growth restriction, prematurity, and congenital anomalies (if untreated).  
5. **Death in infancy/childhood**: Historically occurs in untreated PKU due to severe neurological damage and metabolic complications.  

**Atypical symptoms (e.g., hypertyrosinemia, abnormal erythrocyte morphology)**: Likely represent comorbidities, laboratory artifacts, or secondary effects (e.g., oxidative stress from chronic metabolic imbalance). PKU primarily explains the core features (hyperphenylalaninemia, neurodevelopmental deficits, and prenatal complications). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Clumsiness', 'Drowsiness', 'Sleep disturbance', 'Poor coordination', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The patient presents with lethargy, drowsiness, feeding difficulties, and decreased plasma free carnitine, consistent with a metabolic disorder. 3-Methylcrotonyl-CoA carboxylase (3-MCC) deficiency disrupts leucine catabolism, leading to toxic metabolite accumulation (e.g., 3-methylcrotonylglycine), which sequesters carnitine, causing secondary deficiency. Symptoms like poor coordination, clumsiness, and sleep disturbances align with metabolic encephalopathy. Severe forms can trigger life-threatening metabolic crises, explaining neonatal/childhood death if untreated.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This broader diagnosis encompasses both MCCC1 and MCCC2 gene defects. The patient’s symptoms—lethargy, feeding difficulties, and early mortality—reflect acute metabolic decompensation. Decreased carnitine results from organic acid conjugation and renal loss. Neonatal death suggests a severe phenotype with rapid progression, often due to delayed diagnosis or metabolic stressors (e.g., fasting, infection). The clinical overlap between subtypes makes biochemical/genetic testing critical, but the symptom profile strongly supports 3-MCC deficiency as the underlying etiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Ventricular septal defect', 'Atrial septal defect', 'Anemia', 'Hypoglycemia', 'Hepatomegaly', 'Tachypnea', 'Dicarboxylic aciduria', '3-Methylglutaconic aciduria', 'Neonatal death', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMGCLD)  
Reasoning:  
1. **Hypoglycemia and Hepatomegaly**: Central to HMGCLD, as the enzyme deficiency impairs ketogenesis and leucine metabolism, leading to energy crises during fasting.  
2. **Dicarboxylic Aciduria and 3-Methylglutaconic Aciduria**: Pathognomonic findings due to accumulation of 3-hydroxy-3-methylglutaric acid, 3-methylglutaconic acid, and dicarboxylic acids from disrupted fatty acid oxidation.  
3. **Seizures and Neonatal Death**: Result from severe hypoglycemia, metabolic acidosis, and hyperammonemia during metabolic crises, often fatal without intervention.  
4. **Feeding Difficulties and Tachypnea**: Reflect acute decompensation (vomiting, lethargy) and compensatory respiratory alkalosis from metabolic acidosis.  
5. **Elevated Urinary Carboxylic Acids**: Direct consequence of defective organic acid metabolism.  
6. **Anemia**: May arise secondary to bone marrow suppression or metabolic stress.  
7. **Cardiac Defects (VSD/ASD)**: Uncommon but reported in rare cases, possibly linked to mitochondrial dysfunction or metabolic stress during embryogenesis.  
**Note**: While cardiac anomalies are atypical for HMGCLD, the biochemical markers (3-methylglutaconic/dicarboxylic aciduria) and metabolic profile are diagnostic. Early neonatal demise underscores the severity of untreated metabolic crises. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Following are spontaneous resolution tumours except-a) Malignant melanomab) Osteogenic sarcomac) Cholangio carcinomad) Retinoblastoma
Choices:
A. a
B. c
C. bc
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma ?
Choices:
A. Obesity
B. Opistorchissinensis infection
C. Salmonella carrier state
D. HBV infection
Answer: [/INST] Opistorchissinensis infection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following immune hypersensitivity reaction is resonsible for Myasthenia Gravis ?
Choices:
A. Type I Hypersensitivity
B. Type II Hypersensitivity
C. Type III Hypersensitivity
D. Type IV Hypersensitivity
Answer: [/INST] Type II Hypersensitivity </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera like symptoms is produced by which of the following poisons
Choices:
A. Arsenic
B. Organophosphorus
C. Lead
D. Rat killer
Answer: [/INST] Arsenic </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Metabolic acidosis', 'Glutaric aciduria', 'Decreased plasma free carnitine', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** and **metabolic acidosis** are hallmark biochemical features of GA-I, caused by deficient glutaryl-CoA dehydrogenase activity, leading to toxic accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Decreased plasma free carnitine** occurs due to secondary carnitine depletion from conjugation with glutaric acid for urinary excretion.  
3. **Neurological symptoms (ataxia, dystonia, dyskinesia)** arise from striatal injury and basal ganglia degeneration triggered by neurotoxic metabolites during metabolic crises.  
4. **Generalized hypotonia** in infancy reflects acute or progressive motor dysfunction, often preceding irreversible neurological damage.  
5. **Death in infancy** aligns with severe, untreated GA-I, where metabolic decompensation (e.g., triggered by infections) causes encephalopathy, cerebral edema, or multiorgan failure.  
6. Symptom constellation excludes other organic acidemias (e.g., methylmalonic/propionic acidemia) due to specific metabolite profile (glutaric aciduria) and characteristic neuroimaging findings (frontotemporal atrophy, basal ganglia lesions). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common cause of Pseudomyxoma Peritonei is
Choices:
A. Mucinous tumour of appendix
B. Ovarian tumour
C. Colorectal carcinoma
D. None of the above
Answer: [/INST] Mucinous tumour of appendix </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Abnormality of prenatal development or birth', 'Motor delay', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Death in adolescence', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Elevated plasma citrulline and hyperammonemia are hallmark biochemical features of citrullinemia type I, caused by argininosuccinate synthetase (ASS1) deficiency. This disrupts the urea cycle, leading to ammonia accumulation. Neonatal death, death in infancy/childhood, and hypotonia align with acute neonatal-onset presentations of classic citrullinemia, where rapid ammonia toxicity causes severe neurological compromise. Motor and speech delays reflect chronic neurodevelopmental damage from recurrent hyperammonemia. Obesity may arise from metabolic dysregulation or dietary management strategies. Prenatal abnormalities (e.g., intrauterine growth restriction) and early mortality underscore the disease’s severity.  

Disease: Citrullinemia  
Reasoning: This term broadly encompasses urea cycle disorders with citrulline accumulation. The patient’s elevated citrulline, hyperammonemia, and life-threatening neonatal/childhood course are consistent with the general diagnosis. However, the specificity of neonatal death and classic biochemical profile narrows it further to type I. The inclusion of “abnormality of prenatal development” supports a congenital metabolic disorder like citrullinemia, where intrauterine ammonia exposure may affect fetal development. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Gastroschisis is associated with :
Choices:
A. Younger maternal age
B. Maternal obesity
C. Elderly primi
D. Anaemia
Answer: [/INST] Younger maternal age </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is associated with which chromosome?
Choices:
A. 13
B. 11
C. 17
D. 15
Answer: [/INST] 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Culex mosquito is associated with the transmission of-a) Malariab) Filariasisc) Dengued) Japanese encephalitise) Typhus
Choices:
A. c
B. d
C. bd
D. ac
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning: The symptoms of neonatal death, death in infancy, and abnormal circulating carnitine concentration align with MCADD, a fatty acid oxidation disorder. MCADD impairs the breakdown of medium-chain fatty acids, leading to energy deficits during fasting. Hypoglycemia and metabolic crises in infancy can result in sudden death. Abnormal carnitine levels occur due to secondary carnitine depletion from conjugation with accumulating toxic acyl-CoA intermediates. While prenatal abnormalities are less typical, severe metabolic stress in utero or delayed postnatal adaptation may contribute to complications. MCADD is a common cause of metabolic emergencies in neonates and is detectable via newborn screening (elevated C8-C10 acylcarnitines). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Phenylketonuria is due to deficiency of -
Choices:
A. Phenylalanine transaminase
B. Phenylalanine hydroxylase
C. Tyrosine transaminase
D. Tyrosine hydroxylase
Answer: [/INST] Phenylalanine hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Typhoid in 1st week is best diagnosed by
Choices:
A. Blood culture
B. Antigenic test
C. Stool culture
D. Urine culture
Answer: [/INST] Blood culture </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All except one are deformities associated with Leprosy
Choices:
A. Claw hand
B. Lag ophthalmos
C. Clutton's joint
D. Foot drop
Answer: [/INST] Clutton's joint </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Coicosteroids are absolutely contraindicated in the following type of Tuberculosis
Choices:
A. Miliary
B. Meningeal
C. Intestinal
D. Renal
Answer: [/INST] Intestinal </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Neurofibromatosis 1 criteria except
Choices:
A. Brain tumor
B. Acoustic neuromas
C. Pseudoarthrosis
D. Café-au-lait spots
Answer: [/INST] Acoustic neuromas </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 12-year-old boy has sudden onset of fever, headache, and stiff neck. Two days earlier, he swam in a lake that is believed to have been contaminated with dog excreta. Leptospirosis is suspected. Which of the following laboratory tests is most appropriate to determine whether he has been infected with leptospira?
Choices:
A. Agglutination test for leptospiral antigen
B. Counter immune-electrophoresis of urine sample
C. Gram stain of urine specimen
D. Spinal fluid for dark-field microscopy and culture in Fletcher serum medium
Answer: [/INST] Spinal fluid for dark-field microscopy and culture in Fletcher serum medium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypeension with Hypokalemia is seen in:
Choices:
A. Bater Syndrome
B. Liddle's Syndrome
C. Gitelman's Syndrome
D. All of the above
Answer: [/INST] Liddle's Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anencephaly is best diagnosed at 12 weeks by :
Choices:
A. Serum alpha fetoprotein
B. Ultrasonogram
C. Radiography
D. Amniography
Answer: [/INST] Ultrasonogram </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Petechiae', 'Seizure', 'Lethargy', 'Generalized hypotonia', 'Reduced tendon reflexes', 'Death in infancy', 'Increased serum lactate', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Skeletal muscle atrophy', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Aplasia/Hypoplasia involving the musculature of the extremities']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Mitochondrial complex IV deficiency, nuclear type 1  
Reasoning:  
1. **Cytochrome C oxidase (COX)-negative muscle fibers**: A hallmark of complex IV deficiency, directly implicating dysfunction in mitochondrial respiratory chain complex IV.  
2. **Increased serum lactate and ethylmalonic aciduria**: Reflects impaired oxidative phosphorylation, leading to anaerobic metabolism and accumulation of toxic metabolites due to defective fatty acid/amino acid oxidation.  
3. **Neurological symptoms (seizures, lethargy, drowsiness)**: Result from energy deprivation in the brain, a high-energy-demand organ vulnerable to mitochondrial dysfunction.  
4. **Muscular involvement (hypotonia, reduced reflexes, atrophy, extremity musculature hypoplasia)**: Caused by deficient ATP production in skeletal muscle, leading to weakness, atrophy, and developmental defects.  
5. **Glutaric aciduria**: May arise secondary to disrupted mitochondrial metabolism, affecting organic acid pathways.  
6. **Death in infancy**: Consistent with severe infantile-onset forms of mitochondrial disorders due to multisystem energy failure.  
7. **Nuclear type 1 classification**: Indicates an autosomal recessive mutation (e.g., *SURF1* gene) affecting complex IV assembly, distinguishing it from mitochondrial DNA-related defects.  

This constellation of metabolic, muscular, and neurological findings, anchored by COX-negative fibers and elevated lactate/ethylmalonic acid, confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Fracture of talus without displacement in x-ray would lead to -a) Osteoarthritis of ankleb) Osteonecrosis of head of talusc) Avascular necrosis of body of talusd) Avascular necrosis of neck of taluse) Non union
Choices:
A. ac
B. bc
C. ad
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Seizure', 'Coma', 'Global developmental delay', 'Absent speech', 'Torsade de pointes', 'Hypoglycemia', 'Ketosis', 'Lower limb spasticity', 'Status epilepticus', 'Increased serum lactate', 'Myoglobinuria', 'Ketonuria', 'Elevated circulating thyroid-stimulating hormone concentration', 'Lactic acidosis', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Acute encephalopathy', 'Axial hypotonia', 'Arrhythmia', 'Brain atrophy', 'Dicarboxylic acidemia', 'Elevated circulating acylcarnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Metabolic Dysregulation**: Hypoglycemia, ketosis, ketonuria, dicarboxylic acidemia, and elevated acylcarnitine suggest impaired fatty acid oxidation and mitochondrial dysfunction.  
2. **Neurological Crises**: Acute encephalopathy, seizures, status epilepticus, coma, and lactic acidosis align with recurrent metabolic encephalopathic episodes.  
3. **Muscle Involvement**: Rhabdomyolysis, myoglobinuria, and elevated creatine kinase indicate severe myopathy, consistent with ""encephalomyopathic"" features.  
4. **Cardiac Arrhythmias**: Torsade de pointes and arrhythmia reflect systemic metabolic toxicity affecting cardiac ion channels.  
5. **Neurodegeneration**: Microcephaly, brain atrophy, global developmental delay, absent speech, axial hypotonia, and spasticity imply progressive neurodegeneration.  
6. **Thyroid Dysregulation**: Elevated TSH may indicate secondary endocrine disruption due to chronic metabolic stress.  
7. **Consistency with Syndrome**: The triad of recurrent encephalopathy, rhabdomyolysis, and arrhythmias, combined with neurodegeneration and metabolic biomarkers, uniquely matches this ultra-rare syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: WhiCh of the following drugs is most likely to be effective against multi drug resistant strains big M. Tuberculosis including those resistant to Streptomycin
Choices:
A. Amikacin
B. Claruthromycin
C. Gentamicin
D. Spectinomycin
Answer: [/INST] Amikacin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Loeys-Dietz Syndrome is characterized by all of the following Except
Choices:
A. Aerial aneurysms
B. Hypeelorism
C. Bifid uvula
D. Mutations in the gene encoding filamin A (FLNA)
Answer: [/INST] Mutations in the gene encoding filamin A (FLNA) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles has been controlled in many countries by which of the following?? 
Choices:
A. By hygiene
B. By MMR vaccine
C. By new molecular peptide vaccines
D. By humanised monoclonal antibodies to F protein
Answer: [/INST] By MMR vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Cerebral cortical atrophy', 'Death in adolescence', 'Methylmalonic aciduria', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient presents with **methylmalonic aciduria**, a hallmark biochemical finding of methylmalonic acidemia (MMA). MMA is an autosomal recessive disorder of branched-chain amino acid metabolism, caused by defects in methylmalonyl-CoA mutase or its cofactor adenosylcobalamin (vitamin B12). The presence of **seizures** and **cerebral cortical atrophy** aligns with chronic neurotoxicity from accumulated methylmalonic acid and metabolic instability, leading to progressive neurological damage. **Death in adolescence/early adulthood** reflects the severe natural history of untreated or unresponsive MMA, often due to metabolic crises, renal failure, or neurological complications.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: The **lack of response to vitamin B12** (implied by the diagnostic term ""B12-unresponsive"") points specifically to mutations in the *MUT* gene encoding methylmalonyl-CoA mutase. This subtype accounts for ~60% of MMA cases and is associated with severe phenotypes. Cerebral cortical atrophy and seizures indicate irreversible neurological injury from chronic metabolite accumulation. Early mortality (adolescence/early adulthood) is typical in mutase-deficient MMA due to treatment-refractory metabolic decompensation, multiorgan dysfunction, and limited therapeutic options beyond supportive care. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following agent is least likely to cause Meningitis in the elderly?
Choices:
A. Listeria Monocytogenes
B. Streptococcus pneumonia
C. Gram Negative bacteria
D. Herpes Simplex Virus - 2 (HSV 2)
Answer: [/INST] Herpes Simplex Virus - 2 (HSV 2) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Fox Fordyce Disease effects:
Choices:
A. Sebaceous glands
B. Eccrine Glands
C. Apocrine glands
D. Any gland
Answer: [/INST] Apocrine glands </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are false regarding Ataxia Telangiectasia EXCEPT:
Choices:
A. Autosomal dominant
B. Prone for Development of Squamous Cell Carcinoma of Skin
C. Gene repair defect
D. Most common seen in adults
Answer: [/INST] Gene repair defect </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Following are radiological evidence of Achalasia cardia Except
Choices:
A. Beak like appearance
B. Dilated touous esophagus
C. Presence of air-fluid level
D. Exaggerated peristalsis
Answer: [/INST] Exaggerated peristalsis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Caudal Regression Syndrome is seen in babies of mothers suffering from which of the following condition?
Choices:
A. PIH
B. Anaemia
C. Cardiac disease
D. Gestational diabetes
Answer: [/INST] Gestational diabetes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of following statements are true regarding Q fever except.
Choices:
A. It is a zoonotic infection.
B. Human disease is characterized by an interstitial pneumonia
C. No rash is seen
D. Weil Felix reaction is very useful for diagnosis.
Answer: [/INST] Weil Felix reaction is very useful for diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following disorder of mother leads to microcephaly in baby –a)  SLEb)  Hepatitis A c) Phenylketonuriad)  Rubella
Choices:
A. ab
B. cd
C. bd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Intellectual disability', 'Seizure', 'Motor delay', 'Death in infancy', 'Anemia', 'Hyperammonemia', 'Hyperglycinemia', 'Hepatomegaly', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Hypoglycinemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Dysregulation**: Propionic acidemia (PA) is caused by defective propionyl-CoA carboxylase, leading to toxic accumulation of propionate. This disrupts amino acid (isoleucine, valine, methionine, threonine) and fatty acid metabolism.  
2. **Hyperammonemia & Hyperglycinemia**: Propionate overload inhibits the urea cycle (causing hyperammonemia) and disrupts glycine metabolism, resulting in elevated glycine (hyperglycinemia).  
3. **Carnitine Abnormalities**: Secondary carnitine deficiency occurs as carnitine conjugates with propionate for excretion, explaining ""abnormal circulating carnitine concentration.""  
4. **Neurological Symptoms**: Intellectual disability, seizures, and motor delay arise from neurotoxic metabolites (e.g., propionate, ammonia) and energy deficiency.  
5. **Hepatomegaly & Anemia**: Liver enlargement stems from metabolic stress; anemia results from bone marrow suppression by toxic metabolites.  
6. **Early Mortality**: Neonatal/infant/childhood death aligns with acute metabolic crises (acidosis, hypoglycemia) in untreated PA.  
7. **Prenatal Abnormalities**: Intrauterine accumulation of metabolites may cause growth restriction or structural defects.  
*Note*: The listed ""hypoglycinemia"" may be an inconsistency, as PA typically elevates glycine. This could reflect transient fluctuations or a documentation error. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on –
Choices:
A. Chromosome 5
B. Chromosome 8
C. Chromosome 13
D. Chromosome 16
Answer: [/INST] Chromosome 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following characteristics of Disseminated Intravascular Coagulation (DIC) makes it distinguished from Thrombotic Thrombocytopenic Purpura (TTP)?
Choices:
A. Brisk Reticulocytosis
B. The Number of Schistocytes
C. Reduction of Coagulation Factor
D. Significant Thrombocytopenia
Answer: [/INST] Reduction of Coagulation Factor </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Keratoconus', 'Dysarthria', 'Dysmetria', 'Lower limb spasticity', 'Gait ataxia', 'Limb ataxia', 'Upper limb spasticity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Lower and upper limb spasticity**: Core features of hereditary spastic paraplegias (HSPs), including SPG76, caused by *CAPN1* mutations. Spasticity reflects corticospinal tract dysfunction.  
2. **Gait ataxia, limb ataxia, dysmetria**: Indicate cerebellar involvement, consistent with SPG76’s reported association with cerebellar degeneration.  
3. **Dysarthria**: Aligns with cerebellar or bulbar dysfunction, seen in complex HSP subtypes like SPG76.  
4. **Keratoconus**: Less typical but plausible in SPG76, as calpain dysfunction (from *CAPN1* mutations) may disrupt corneal structural integrity. Calpains regulate cytoskeletal proteins critical in corneal homeostasis.  
5. **Exclusion of mimics**: Other HSPs (e.g., SPG7) or ataxia syndromes lack this specific combination of spasticity, ataxia, and keratoconus. Genetic testing for *CAPN1* variants would confirm SPG76. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholangiocarcinoma histologically resembles -
Choices:
A. Sq. cell type
B. Colloid cell type
C. Schirrhous type
D. Columnar cell type
Answer: [/INST] Schirrhous type </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug used in Acute Intermittent Porphyria is
Choices:
A. Opioids
B. Phenobarbitone
C. Primidone
D. Blood tranfusion
Answer: [/INST] Opioids </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Blindness', 'Motor delay', 'Hyperreflexia', 'Death in infancy', 'Opisthotonus', 'Abnormal circulating aspartate family amino acid concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Canavan disease  
Reasoning:  
1. **Abnormal circulating aspartate family amino acid concentration**: Directly links to Canavan disease, a leukodystrophy caused by aspartoacylase deficiency, leading to elevated N-acetylaspartic acid (NAA).  
2. **Motor delay and hyperreflexia**: Reflects progressive white matter degeneration, causing spasticity and upper motor neuron dysfunction.  
3. **Blindness**: Optic nerve atrophy due to demyelination is common in Canavan disease.  
4. **Opisthotonus**: Severe neurological damage from toxic NAA accumulation leads to abnormal posturing.  
5. **Death in infancy**: While typically fatal in early childhood, severe infantile forms can result in earlier demise.  
6. **Exclusion of alternatives**: Symptoms align with Canavan’s biochemical profile (aspartate-related metabolic error), distinguishing it from other leukodystrophies or aminoacidopathies. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency / 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** (e.g., 3-hydroxyisovaleric acid, 3-methylcrotonylglycine) arise due to impaired leucine catabolism from deficient 3-methylcrotonyl-CoA carboxylase (3-MCC), a biotin-dependent enzyme.  
2. **Abnormal circulating carnitine concentration** (secondary carnitine deficiency) occurs as carnitine conjugates with toxic metabolites (e.g., 3-methylcrotonyl-CoA) for urinary excretion, depleting free carnitine.  
3. **Aminoaciduria** may result from renal tubular dysfunction caused by accumulated metabolites or secondary mitochondrial stress.  
4. **Abnormal circulating glycine concentration** (often elevated) stems from glycine conjugation with excess organic acids (e.g., 3-methylcrotonylglycine formation), altering glycine homeostasis.  
*Note: Both terms refer to the same disorder, with the nomenclature difference reflecting gene-specific (MCCC1) vs. enzymatic classification.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dracunculosis infection occurs through-
Choices:
A. Ingestion of water containing cyclops
B. Ingestion of water containing the parasite
C. Ingestion of fish
D. Penetration of skin
Answer: [/INST] Ingestion of water containing cyclops </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 26 year old man is critically ill, with multisystem organ failure, and he has not been able to give a clear history of respiratory distress. You suspect Acute Respiratory Distress Syndrome (ARDS). 1. The lung injury may be direct, as occurs in sepsis, or indirect, as occurs in Toxic inhalation 2. The aerial (a) PO2 (in mmHg)/FIO2 (inspiratory O2 fraction) > 200 mmHg is characteristic of ARDS 3. Ventilator-induced injury will be more with low tidal volume ventilation in ARDS 4. Moality was significantly lower in the high tidal volume ventilation, compared to the conventional tidal volume ventilated patients 5. High-dose glucocoicoids are useful in the care of ARDS patients
Choices:
A. 1,2,5-True & 3,4-False
B. All True
C. All False
D. 3,4-True & 1,2,5-False
Answer: [/INST] All False </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Brucellosis can be transmitted by all of the following modes, except:
Choices:
A. Contact with infected placenta
B. Ingestion of raw vegetables from infected farms
C. Person to person transmission
D. Inhalation of infected dust or aerosol
Answer: [/INST] Person to person transmission </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Congenital Adrenal Hyperplasia is due to deficiency of:
Choices:
A. 21 beta hydroxylase
B. 17 alpha hydroxylase
C. 5 alpha reductase
D. 17 beta reductase
Answer: [/INST] 21 beta hydroxylase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Hyperammonemia', 'Cerebral edema', 'Oroticaciduria', 'Hypoargininemia', 'Hyperprolinemia', 'Elevated plasma citrulline', 'Citrullinuria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning:  
1. **Elevated plasma citrulline and citrullinuria**: These are hallmark findings of argininosuccinate synthetase (ASS) deficiency, which prevents the conversion of citrulline to argininosuccinate in the urea cycle.  
2. **Hyperammonemia**: Caused by impaired urea cycle function, leading to toxic ammonia accumulation.  
3. **Hypoargininemia**: Reduced arginine production due to the enzymatic block at ASS, limiting downstream arginine synthesis.  
4. **Oroticaciduria**: Likely secondary to partial carbamoyl phosphate spillover into pyrimidine synthesis, triggered by urea cycle dysfunction or mitochondrial stress from hyperammonemia.  
5. **Cerebral edema and seizures**: Result from ammonia toxicity and osmotic effects of accumulated glutamine in the brain.  
6. **Hyperprolinemia**: May arise from disrupted arginine-proline metabolic crosstalk or compensatory mechanisms in urea cycle failure.  

This constellation of findings—urea cycle disruption, citrulline accumulation, and secondary metabolic effects—confirms the diagnosis of Citrullinemia type I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma best evaluated by -
Choices:
A. Ultrasonography
B. CT SCAN
C. CT SCAN + MRI
D. MRI
Answer: [/INST] CT SCAN + MRI </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Duchenne Muscular Dystrophy is a disease of-
Choices:
A. Neuromuscularj unction
B. Sarcolemmal proteins
C. Muscle contractile proteins
D. Disuse atrophy due to muscle weakness
Answer: [/INST] Sarcolemmal proteins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine was first developed by ?
Choices:
A. Robe Koch
B. Louis Pasteur
C. Edward Jenner
D. Loeffler
Answer: [/INST] Louis Pasteur </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the genitourinary system', 'Hydrocephalus', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Arachnoid cyst']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-pancytopenia syndrome  
Reasoning:  
1. **Pancytopenia & Bone Marrow Hypocellularity**: Core features of APS, caused by SAMD9L mutations disrupting hematopoiesis.  
2. **Immunodeficiency**: Secondary to pancytopenia (neutropenia, lymphopenia).  
3. **Hydrocephalus & Arachnoid Cyst**: Neurological structural anomalies (e.g., cerebellar defects, CSF flow issues) align with APS-associated CNS abnormalities.  
4. **Growth Delay**: Common in multisystem genetic disorders like APS.  
5. **Genitourinary Abnormalities**: Reported in some APS cases, though less typical, suggesting phenotypic variability.  
6. **Ataxia (implied)**: While not explicitly listed, hydrocephalus/cysts may indicate cerebellar dysfunction, a hallmark of APS.  

The constellation of hematologic, neurologic, and developmental symptoms strongly supports APS diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria is transmitted in Rural areas by -
Choices:
A. Anopheles stephensi
B. Anopheles dirus
C. Anopheles culicifacies
D. None
Answer: [/INST] Anopheles culicifacies </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The specific laboratory finding often reflect the clinical manifestations of Neuroleptic Malignant Syndrome (NMS) is
Choices:
A. Elevated Creatine kinase
B. Hypocalcemia
C. Increased Alkaline phosphatase
D. Leukocytosis
Answer: [/INST] Elevated Creatine kinase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Renal hypoplasia', 'Renal cyst', 'Xerostomia', 'Hepatic cysts', 'Ankle swelling', 'Palpitations', 'Dysphagia', 'Nausea', 'Gastroesophageal reflux', 'Abdominal pain', 'Hiatus hernia', 'Bronchiectasis', 'Vertigo', 'Increased blood urea nitrogen', 'Elevated circulating parathyroid hormone level', 'Elevated circulating creatine kinase concentration', 'Elevated circulating creatinine concentration', 'Back pain', 'Elevated erythrocyte sedimentation rate', 'Premature ventricular contraction', 'Chronic oral candidiasis', 'Elevated circulating C-reactive protein concentration', 'Neutrophilia', 'Decreased glomerular filtration rate', 'Fatigue', 'Bronchitis', 'Lower limb pain', 'Ground-glass opacification', 'Nodular pattern on pulmonary HRCT', 'Autoimmune antibody positivity', 'Crackles', 'Reduced FEV1/FVC ratio', 'Sputum eosinophilia', 'Decreased DLCO', 'Abnormality of nail color', 'Epigastric pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Primary Sjögren Syndrome  
**Reasoning**:  
1. **Exocrine Gland Dysfunction**:  
   - **Xerostomia** (dry mouth) and **chronic oral candidiasis** are hallmark features of Sjögren syndrome, reflecting salivary gland involvement and secondary fungal infection due to reduced saliva.  
   - **Dysphagia**, **gastroesophageal reflux**, and **hiatus hernia** may arise from decreased saliva production and esophageal dysmotility linked to autonomic dysfunction.  

2. **Autoimmune Features**:  
   - **Autoimmune antibody positivity** (e.g., anti-SSA/Ro or anti-SSB/La) is diagnostic for Sjögren syndrome.  
   - **Elevated ESR**, **CRP**, and **neutrophilia** indicate systemic inflammation.  

3. **Pulmonary Involvement**:  
   - **Bronchiectasis**, **crackles**, **ground-glass opacities**, and **nodular patterns on HRCT** suggest interstitial lung disease (ILD), a common extraglandular manifestation.  
   - **Reduced DLCO** and **FEV1/FVC ratio** reflect restrictive/obstructive patterns from lymphocytic infiltration or bronchiolitis.  

4. **Renal Abnormalities**:  
   - **Renal hypoplasia**, **decreased GFR**, and elevated **creatinine/urea nitrogen** align with tubulointerstitial nephritis, a frequent renal complication.  
   - **Elevated parathyroid hormone** may indicate secondary hyperparathyroidism due to chronic kidney disease.  

5. **Musculoskeletal and Systemic Inflammation**:  
   - **Back pain**, **lower limb pain**, and **elevated creatine kinase** suggest inflammatory myopathy or arthralgias.  
   - **Fatigue** and **abdominal/epigastric pain** correlate with systemic autoimmune activity and possible gastrointestinal dysmotility.  

6. **Extraglandular Manifestations**:  
   - **Hepatic cysts** are atypical but may coexist with autoimmune liver disease.  
   - **Vertigo** and **palpitations/premature ventricular contractions** could stem from autonomic neuropathy or electrolyte imbalances (e.g., hypercalcemia from hyperparathyroidism).  

**Conclusion**: The constellation of sicca symptoms, systemic inflammation, multi-organ involvement (renal, pulmonary, hepatic), and autoimmune markers strongly supports **primary Sjögren syndrome**. Overlapping features (e.g., ILD, nephritis) are consistent with its extraglandular manifestations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements is TRUE about Rabies Virus:
Choices:
A. It is double stranded RNA virus
B. Contains a DNA-dependent RNA polymerase
C. Negative sense RNA Genome
D. Affects motor neurons
Answer: [/INST] Negative sense RNA Genome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Bejel is caused by -
Choices:
A. T. pallidum
B. T. endemicum
C. T. pertenue
D. T. carateum
Answer: [/INST] T. endemicum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chromophilic Renal Cell Carcinoma is associated with
Choices:
A. 3p
B. Trisomy 7 and 17
C. 6q
D. t(3, 11)
Answer: [/INST] Trisomy 7 and 17 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Select false statement regarding Rabies infection Rabies is dead end infection in man Can be transmitted by aerosols Suturing is usually recommended on local wound Human Rabies immunoglobulin dose - 10 IU/kg Human bite can transmit Rabies infection
Choices:
A. 2, 3, 4, 5
B. 2, 3, 4
C. 4, 5
D. 3, 4, 5
Answer: [/INST] 3, 4, 5 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spastic diplegia', 'Death in infancy', 'Cerebral cortical atrophy', 'Opisthotonus', 'Athetosis', 'Spastic tetraplegia', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Elevated glutaric acid & Glutaric aciduria**: Direct biochemical markers of GA-I due to deficient glutaryl-CoA dehydrogenase enzyme activity, impairing lysine and tryptophan metabolism.  
2. **Decreased plasma free carnitine**: Secondary carnitine depletion occurs as carnitine binds to accumulating glutaric acid, forming glutarylcarnitine for excretion.  
3. **Cerebral cortical atrophy**: Neurotoxic effects of glutaric acid and its derivatives (e.g., 3-hydroxyglutaric acid) cause striatal and cortical neuronal damage.  
4. **Spastic diplegia/tetraplegia, Opisthotonus, Athetosis**: Result from basal ganglia and corticospinal tract injury, characteristic of GA-I-associated encephalopathic crises.  
5. **Death in infancy**: Untreated GA-I leads to acute metabolic decompensation (often triggered by infections), severe neurological damage, and early mortality.  
The triad of macrocephaly (not listed here but common), striatal necrosis, and organic acidemia strongly supports GA-I. Early-onset neurological deterioration with specific biochemical abnormalities confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Causative agent of Yaws is?
Choices:
A. Treponema pertenue
B. Treponema carateum
C. Treponema pallidum
D. Treponema endemicum
Answer: [/INST] Treponema pertenue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin effects are mediated by stimulation of which of the following second messengers
Choices:
A. cAMP
B. cGMP
C. Ca44 -calmodulim
D. IP3/ DAG
Answer: [/INST] cAMP </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following Bacteria are most often associated with Acute Neonatal Meningitis except
Choices:
A. Escherichia coli
B. Streptococcus agalactiae
C. Neisseria meningitidis
D. Listeria monocytogenes
Answer: [/INST] Neisseria meningitidis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria** is a hallmark laboratory finding directly linked to GA-I, caused by deficient glutaryl-CoA dehydrogenase enzyme activity.  
2. **Metabolic acidosis** aligns with organic acidemia pathophysiology due to toxic accumulation of glutaric acid and derivatives.  
3. **Neurological symptoms (Ataxia, Lethargy, Drowsiness, Generalized hypotonia)** reflect basal ganglia and white matter injury from metabolic crises, characteristic of GA-I.  
4. **Death in infancy** underscores the severe, early-onset nature of untreated GA-I, often triggered by catabolic stressors (e.g., infections).  
5. **Sleep disturbances** may arise from neurotoxicity or secondary complications (e.g., electrolyte imbalances).  
6. Symptom combination excludes other organic acidemias (e.g., GA-II) or mitochondrial disorders, as GA-I uniquely associates with glutaric aciduria and striatal degeneration. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia in an infant may be due to all of the following except -
Choices:
A. Adrenal tumor
B. Adrenal tumor
C. Thiazide therapy
D. Diarrhea
Answer: [/INST] Adrenal tumor </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing impairment', 'Gait disturbance', 'Hepatic steatosis', 'Hepatic cysts', 'Pericardial effusion', 'Splenomegaly', 'Abnormal lung morphology', 'Hepatomegaly', 'Paraparesis', 'Somatic sensory dysfunction', 'Rhinitis', 'Lower limb pain', 'Splenic cyst', 'Cytoplasmic antineutrophil antibody positivity', 'Insomnia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
Reasoning:  
1. **Cytoplasmic antineutrophil antibody (c-ANCA) positivity**: Highly specific for GPA, supporting an autoimmune vasculitis diagnosis.  
2. **Rhinitis and hearing impairment**: Reflect upper respiratory tract involvement, common in early GPA due to granulomatous inflammation.  
3. **Abnormal lung morphology**: GPA often causes pulmonary nodules, cavities, or infiltrates.  
4. **Paraparesis and somatic sensory dysfunction**: Indicates neurologic involvement, possibly from vasculitic neuropathy or CNS inflammation.  
5. **Pericardial effusion**: Suggests systemic vasculitis affecting serous membranes.  
6. **Hepatomegaly, hepatic steatosis, and splenomegaly**: Less common but documented in systemic GPA due to granulomatous infiltration or secondary inflammation.  
7. **Splenic/hepatic cysts**: Rare manifestations, potentially linked to chronic inflammation or ischemic injury.  
8. **Lower limb pain and gait disturbance**: May result from neuropathy, myositis, or joint involvement.  
9. **Insomnia**: Likely secondary to chronic pain or systemic illness.  

While hepatic/splenic cysts are atypical, the combination of c-ANCA positivity, multi-organ involvement (respiratory, renal, neurologic), and classic vasculitic features strongly aligns with GPA. Differential diagnoses (e.g., eosinophilic granulomatosis with polyangiitis) are less likely given the absence of eosinophilia or asthma. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is seen with -
Choices:
A. Frusemide
B. Coisol
C. Metabolic acidosis
D. Amiloride
Answer: [/INST] Frusemide </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: What is not a part of triad of Renal Cell Carcinoma?
Choices:
A. Loin Mass
B. Hematuria
C. Loin Pain
D. Oliguria
Answer: [/INST] Oliguria </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Efficacy of Measles vaccine after second dose:-
Choices:
A. 90%
B. 95%
C. 99%
D. 100%
Answer: [/INST] 99% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not used for diagnosis of Leptospirosis:
Choices:
A. Microscopic agglutination test
B. Dark field illumination
C. Macroscopic agglutination test
D. Weil-Felix reaction
Answer: [/INST] Weil-Felix reaction </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute Infective Endocarditis with abscess formation is most commonly associated with
Choices:
A. Listeria
B. Staphylococcus
C. Streptococcus
D. Enterococcus
Answer: [/INST] Staphylococcus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Splenomegaly', 'Hepatomegaly', 'Elevated hepatic transaminase', 'Death in childhood', 'Decreased circulating ceruloplasmin concentration', 'Increased urinary copper concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Death in adolescence', 'Decreased circulating copper concentration', 'Copper accumulation in liver']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Wilson disease (Hepatolenticular degeneration)  
Reasoning:  
1. **Copper metabolism abnormalities**:  
   - **Decreased circulating ceruloplasmin** and **copper concentrations** indicate impaired copper transport due to ATP7B gene mutations.  
   - **Increased urinary copper excretion** and **hepatic copper accumulation** reflect the body’s compensatory mechanism to eliminate excess copper, which overwhelms hepatic storage capacity.  

2. **Hepatic involvement**:  
   - **Hepatomegaly**, **elevated hepatic transaminases**, and **copper accumulation in the liver** are hallmarks of Wilson disease-induced liver damage.  
   - Progressive liver dysfunction leads to **splenomegaly** (via portal hypertension) and **abnormal amino acid concentrations** (due to impaired hepatic metabolism).  

3. **Neuromuscular and systemic features**:  
   - **Generalized hypotonia** may arise from early neurological involvement or metabolic encephalopathy secondary to liver failure.  

4. **Prognosis**:  
   - **Death in childhood/adolescence** aligns with untreated or advanced Wilson disease, where liver failure or neurological complications become fatal without timely intervention (e.g., chelation therapy or liver transplantation).  

5. **Diagnostic confirmation**:  
   - The triad of **low ceruloplasmin**, **high urinary copper**, and **Kayser-Fleischer rings** (not listed but often present) is pathognomonic. Genetic testing for ATP7B mutations would definitively confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: WHO considerations regarding Dracunculosis eradication, all are true except
Choices:
A. DDT
B. Drinking piped water and installation of hand pumps
C. Health education and awareness of public
D. Control of Cyclops
Answer: [/INST] DDT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is a poor prognostic factor in Acute Myeloid Leukemia (AML)
Choices:
A. Monosomy
B. Deletion of X or Y chromosome
C. t (8; 21) translocation
D. Nucleophosphin mutation
Answer: [/INST] Monosomy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Recurrent viral infections', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid accumulation**: Hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicate a defect in the metabolism of valine, leucine, and isoleucine—the branched-chain amino acids (BCAAs). This triad is pathognomonic for MSUD, caused by a deficiency in the branched-chain α-keto acid dehydrogenase (BCKDH) complex.  
2. **Early mortality**: Death in infancy, childhood, adolescence, or early adulthood aligns with severe MSUD phenotypes (e.g., classic or intermediate forms). Untreated, toxic BCAA accumulation leads to metabolic decompensation, cerebral edema, and multisystem failure.  
3. **Gastrointestinal inflammation**: Metabolic crises in MSUD cause vomiting, feeding difficulties, and mucosal injury, explaining gastrointestinal symptoms.  
4. **Recurrent infections and pustules**: Chronic metabolic stress and ketoacidosis impair immune function, increasing susceptibility to infections. Skin pustules may arise from secondary bacterial infections or inflammatory responses to metabolic byproducts.  
5. **Neonatal death**: Severe MSUD manifests within days of birth if undiagnosed, as BCAA levels rise rapidly post-feeding, causing acute neurological decline.  

This constellation of symptoms and biochemical findings is specific to MSUD, with no other disorder combining these features. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Hypertrichosis', 'Intellectual disability', 'Spasticity', 'Coma', 'Generalized hypotonia', 'Obesity', 'Death in infancy', 'Hyperammonemia', 'Pneumonia', 'Oroticaciduria', 'Ornithinuria', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Abnormal circulating glutamine concentration', 'Abnormal circulating arginine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Elevated plasma citrulline', 'Feeding difficulties', 'Hyperornithinemia', 'Uraciluria', 'Hypoammonemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: The patient exhibits **elevated plasma citrulline**, a hallmark of citrullinemia, caused by defects in the urea cycle. Key symptoms like **hyperammonemia** (ammonia accumulation), **oroticaciduria**, and **uraciluria** indicate a urea cycle disruption, as excess carbamoyl phosphate is diverted to pyrimidine synthesis. **Intellectual disability**, **spasticity**, and **coma** align with neurotoxicity from hyperammonemia. **Feeding difficulties** and **neonatal death** are consistent with severe neonatal-onset forms. Abnormal amino acid concentrations (**glutamine**, **arginine**) further reflect urea cycle dysfunction.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia type I (argininosuccinate synthetase deficiency) is confirmed by **elevated citrulline** and **hyperornithinemia**. **Acute/chronic hepatitis** and **hypertrichosis** suggest liver involvement, common in type I. **Recurrent infections** and **pneumonia** may stem from metabolic instability impairing immunity. **Death in infancy/childhood** correlates with the severe prognosis of untreated type I. **Oroticaciduria** and **ornithinuria** directly link to urea cycle blockage, while **hypoammonemia** (if confirmed) could indicate late-stage liver failure. The biochemical triad of citrullinemia (high citrulline, orotic aciduria, hyperammonemia) and early lethality solidify this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Seizure', 'Death in infancy', 'Opisthotonus', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid**: The hallmark biochemical finding in GA-I is elevated circulating glutaric acid due to deficient glutaryl-CoA dehydrogenase enzyme activity, disrupting lysine and tryptophan metabolism.  
2. **Macrocephaly**: Characteristic frontotemporal atrophy with subdural fluid accumulation in infancy often leads to macrocephaly.  
3. **Neurological symptoms (Seizures, Opisthotonus)**: Accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid) damages basal ganglia, causing dystonia, seizures, and posturing (e.g., opisthotonus).  
4. **Glutaric aciduria**: Urinary excretion of glutaric acid is a diagnostic marker.  
5. **Early mortality**: Untreated GA-I causes metabolic crises triggered by catabolic stress (e.g., infections), leading to irreversible neurological damage, encephalopathy, and death in infancy/neonatal periods if severe.  
6. **Consistency with phenotype**: The combination of macrocephaly, dystonia, metabolic derangements, and rapid progression aligns definitively with GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common inheritance of Achondroplasia is
Choices:
A. Sporadic
B. Autosomal dominant
C. Autosomal recessive
D. X-linked recessive
Answer: [/INST] Autosomal dominant </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is associated with, which of the following tumors
Choices:
A. Osteoclastoma
B. Hepatocellular carcinoma
C. Squamous cell carcinoma
D. Osteosarcoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Commonest metastasis in Renal Cell Carcinoma is to
Choices:
A. Lung
B. Bone
C. Adrenal
D. Liver
Answer: [/INST] Lung </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The type of necrosis seen in Tuberculosis:
Choices:
A. Gummatous
B. Coagulative
C. Caseation
D. Liquefactive
Answer: [/INST] Caseation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. Untreated **classic PKU** results in severe neurological damage, seizures, and intellectual disability. In extreme cases, metabolic instability or secondary complications (e.g., infections, failure to thrive) may contribute to **death in infancy** or **neonatal death**, especially in resource-limited settings lacking newborn screening and dietary management.  
3. **Neonatal death** is atypical in well-managed PKU but could occur in severe variants (e.g., BH4-deficient forms) with additional neurotransmitter deficiencies or acute metabolic crises.  
4. The triad of symptoms aligns with undiagnosed/untreated PKU, emphasizing the critical need for early detection via newborn screening to prevent fatal outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Anteverted nares', 'Strabismus', 'Abnormality of the ear', 'Syndactyly', 'Ataxia', 'Coma', 'Motor delay', 'Death in infancy', 'Hypoglycemia', 'Hypocholesterolemia', 'Elevated 8-dehydrocholesterol', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Elevated 7-dehydrocholesterol']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Smith-Lemli-Opitz syndrome  
**Reasoning**:  
1. **Biochemical hallmarks**: Elevated 7-dehydrocholesterol (7-DHC) and 8-dehydrocholesterol are pathognomonic for SLOS due to mutations in *DHCR7*, which disrupts cholesterol biosynthesis.  
2. **Hypocholesterolemia**: Low cholesterol levels align with the metabolic defect in SLOS.  
3. **Dysmorphic features**: Anteverted nares, syndactyly (classically 2nd-3rd toe), microcephaly, and ear abnormalities are consistent with SLOS-associated congenital malformations.  
4. **Neurological symptoms**: Ataxia, motor delay, and coma reflect severe neurological impairment from cholesterol deficiency, critical for myelination and brain development.  
5. **Poor prognosis**: Neonatal death, death in infancy/childhood, and recurrent infections (immune dysfunction linked to cholesterol deficiency) characterize severe SLOS phenotypes.  
6. **Hypoglycemia**: May arise due to adrenal insufficiency (cholesterol is a precursor for steroid hormones).  

The combination of dysmorphia, neurodevelopmental regression, and specific sterol abnormalities confirms SLOS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of taste sensation', 'Membranoproliferative glomerulonephritis', 'Petechiae', 'Headache', 'Fatigue']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Immunoglobulin A vasculitis  
Reasoning:  
1. **Petechiae**: A hallmark of IgA vasculitis (Henoch-Schönlein purpura), caused by small-vessel inflammation and IgA-mediated immune complex deposition in the skin.  
2. **Membranoproliferative glomerulonephritis (MPGN)**: While IgA nephropathy is more typical, MPGN can occur in severe IgA vasculitis due to chronic immune complex deposition in renal glomeruli, leading to histopathological overlap.  
3. **Fatigue and Headache**: Non-specific systemic symptoms linked to inflammation, cytokine release, and potential renal dysfunction.  
4. **Abnormality of taste sensation**: Likely secondary to uremia from renal impairment (due to glomerulonephritis), causing dysgeusia (metallic taste), rather than a direct feature of vasculitis.  
5. **Consistent diagnostic framework**: The triad of cutaneous vasculitis (petechiae), renal involvement, and systemic symptoms aligns with IgA vasculitis, despite atypical MPGN histology. Differential diagnoses (e.g., cryoglobulinemia, lupus nephritis) were excluded based on IgA dominance and clinical context. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Death in childhood** aligns with untreated/severe PKU, as neurological damage and complications (e.g., seizures, intellectual disability) may result in early mortality without dietary intervention.  
3. **Hypertyrosinemia** is atypical in classical PKU (where tyrosine levels are usually low/normal due to blocked PAH activity). This may indicate:  
   - A concurrent condition (e.g., tyrosinemia type II) or metabolic overlap.  
   - Potential misreporting of symptoms (e.g., hypotyrosinemia expected in PKU).  
   - Rare variants or secondary metabolic disruptions (e.g., liver dysfunction).  

Final diagnosis prioritizes hyperphenylalaninemia and clinical severity, consistent with PKU, while acknowledging the atypical tyrosine elevation as a confounding factor requiring further investigation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ectopia lentis', 'Arachnodactyly', 'Global developmental delay', 'Disproportionate tall stature']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic homocystinuria/Homocystinuria due to cystathionine beta-synthase deficiency  
Reasoning:  
1. **Ectopia lentis**: A hallmark feature of homocystinuria, caused by defective cysteine metabolism weakening zonular fibers that secure the lens.  
2. **Arachnodactyly and disproportionate tall stature**: Marfanoid habitus (long limbs, slender fingers) arises from disrupted collagen cross-linking due to homocysteine accumulation.  
3. **Global developmental delay**: Elevated homocysteine levels are neurotoxic, impairing myelination and neuronal function, leading to intellectual/developmental deficits.  
4. **Exclusion of Marfan syndrome**: While Marfan shares arachnodactyly and ectopia lentis, it lacks metabolic abnormalities or developmental delay, directing suspicion toward homocystinuria.  
5. **Biochemical confirmation**: Suspected diagnosis aligns with cystathionine beta-synthase deficiency, confirmed via elevated plasma homocysteine, low methionine, and genetic testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which grade of ROP (Retinopathy of Prematurity) shows a ridge with retinal fibrovascular proliferation and neovasularisation?
Choices:
A. ROP 1
B. ROP 2
C. ROP 3
D. ROP 4
Answer: [/INST] ROP 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypermetropia', 'Uveitis', 'Keratoconjunctivitis sicca', 'Abnormality of the gluteal musculature', 'Kyphosis', 'Microscopic hematuria', 'Back pain', 'Generalized morning stiffness', 'Low levels of vitamin D']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Spondyloarthropathy, susceptibility to, 1  
Reasoning: The patient’s back pain, morning stiffness, and kyphosis align with axial spondyloarthropathy, which commonly involves spinal inflammation and postural changes. Uveitis is a hallmark extra-articular manifestation of SpA, strongly supporting this diagnosis. HLA-B27 (a genetic marker for susceptibility 1) is frequently associated with these features. The gluteal musculature abnormality may reflect enthesitis or chronic compensatory postural adjustments.  

Disease: Spondyloarthropathy, susceptibility to, 2  
Reasoning: Microscopic hematuria could indicate renal involvement, potentially linked to IgA nephropathy, which has been sporadically associated with SpA. Keratoconjunctivitis sicca may suggest secondary autoimmune overlap, though less typical. Low vitamin D may exacerbate skeletal inflammation and contribute to kyphosis. Susceptibility 2 might involve non-HLA-B27 genetic variants (e.g., ERAP1/IL23R), which could explain broader immune dysregulation and atypical features like renal or ocular surface involvement. Hypermetropia is likely incidental but underscores the need for multidisciplinary evaluation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma best evaluated by-
Choices:
A. Ultrasonography
B. CT SCAN
C. CT SCAN + MRI
D. MRI
Answer: [/INST] CT SCAN + MRI </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements about Leptospirosis is true?
Choices:
A. Rats are prime reservoirs
B. Fluoroquinolones are the drug of choice
C. Person to person Transmission is common
D. Hepatorenal syndrome may occur in upto 50% of patients
Answer: [/INST] Rats are prime reservoirs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common enzyme deficiency responsible for Galactosemia is?
Choices:
A. UDP galactose epimerase
B. Galaktokinase
C. Galactosidase
D. Galactose-l-phosphate uridyl transferase
Answer: [/INST] Galactose-l-phosphate uridyl transferase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is a hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Abnormality of prenatal development or birth** aligns with untreated maternal PKU, where high phenylalanine levels during pregnancy cause fetal developmental issues.  
3. **Death in infancy/Neonatal death/Death in childhood** reflects severe untreated PKU, leading to neurotoxicity, seizures, and metabolic crises without early dietary intervention.  
4. **Hypertyrosinemia** initially seems contradictory (classic PKU typically shows *low* tyrosine), but may indicate:  
   - Coexisting tyrosinemia type II/III (unlikely without specific hepatic/ocular symptoms),  
   - Secondary tyrosine elevation due to liver dysfunction or metabolic stress in critical illness,  
   - A rare PKU variant with atypical tyrosine dynamics (e.g., partial PAH activity with compensatory pathways).  
5. PKU remains the primary diagnosis due to **hyperphenylalaninemia** and clinical progression, with hypertyrosinemia requiring further investigation for comorbidities or metabolic complexities. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Q fever is caused by-
Choices:
A. R Quintana
B. C. burnetii
C. R typhi
D. R akari
Answer: [/INST] C. burnetii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: World Tuberculosis Day is celebrated on ?
Choices:
A. 24th March
B. 7th April
C. 22nd April
D. 1st December
Answer: [/INST] 24th March </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about pituitary tumor?a) It is present in 10% of brain tumors b) Erodes the sella and extends into surrounding areac) Prolactinoma is least commond) It is differentiated by reticulin stain
Choices:
A. acd
B. abd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is associated with-
Choices:
A. Osteosarcoma
B. Hepatocellular
C. SCC
D. Osteoclastoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following may not be used as candidate vaccine(s) in Leprosy
Choices:
A. BCG Vaccine
B. Killer M.leprae + BCG Vaccine
C. M.indicus pranii
D. BCG Vaccine + M.vaccae
Answer: [/INST] BCG Vaccine + M.vaccae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: X-rays findings of Fibrous Dysplasia is:
Choices:
A. Ground glass density
B. Calcifications
C. Coical thickening
D. Bony expansion
Answer: [/INST] Ground glass density </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following conditions, Aniridia and Hemihyperophy are most likely present ?
Choices:
A. Neuroblastoma
B. Wilms' tumour
C. Non-Hodgkin's lymphoma
D. Germ cell tumour
Answer: [/INST] Wilms' tumour </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pinta disease is caused by
Choices:
A. Treponema pallidum
B. Treponema carateum
C. Leptospira interrogans
D. None of the above
Answer: [/INST] Treponema carateum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Conjunctivitis', 'Death in infancy', 'Neonatal death', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline is a hallmark of urea cycle disorders, specifically citrullinemia. Neonatal death or death in infancy aligns with severe metabolic decompensation due to argininosuccinate synthetase (ASS1) deficiency, which causes toxic ammonia accumulation. While conjunctivitis is atypical for urea cycle disorders, it may reflect secondary infections from metabolic instability or unrelated comorbidities.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: Classic citrullinemia (type I) presents neonatally with hyperammonemia, vomiting, and lethargy progressing to coma. Elevated citrulline levels confirm ASS1 enzyme deficiency. Early mortality correlates with the rapid progression of untreated hyperammonemia. Conjunctivitis is not pathognomonic but may occur due to systemic illness or incidental factors. Type II (citrin deficiency) typically involves liver dysfunction and later onset, making type I the definitive diagnosis here. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Platyspondyly', 'Broad metacarpals', 'Abnormal facial shape', 'Apnea', 'Hypoplastic iliac wing', 'Metaphyseal irregularity', 'Flat acetabular roof', 'Thoracic hypoplasia', 'Broad phalanx', 'Six lumbar vertebrae', 'Rhizomelia', 'Short metacarpal', 'Arrhythmia', '11 thoracic vertebrae']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Spondylometaphyseal dysplasia, Sedaghatian type  
Reasoning:  
1. **Platyspondyly** and **six lumbar vertebrae/11 thoracic vertebrae** indicate vertebral abnormalities, consistent with ""spondylo"" (spinal) involvement in SMD.  
2. **Metaphyseal irregularity**, **broad/short metacarpals**, **broad phalanx**, and **rhizomelia** reflect metaphyseal and skeletal dysplasia, core features of SMD.  
3. **Hypoplastic iliac wing** and **flat acetabular roof** align with pelvic dysplasia seen in skeletal dysplasias.  
4. **Thoracic hypoplasia** and **apnea** suggest respiratory compromise, typical in severe neonatal forms like Sedaghatian type.  
5. **Arrhythmia** correlates with reported cardiac anomalies in Sedaghatian type.  
6. **Abnormal facial shape** supports craniofacial dysmorphism associated with skeletal dysplasias.  
7. The combination of lethal skeletal dysplasia, metaphyseal/spinal defects, and cardiac involvement distinguishes this subtype from other SMDs. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya is transmitted by ?
Choices:
A. Aedes
B. Culex
C. Mansonoides
D. Anopheles
Answer: [/INST] Aedes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Smallpox eradication was declared by WHO in 1980. All of the following epidemiological factors are have a role in eradication of smallpox, EXCEPT:
Choices:
A. Patients with subclinical infections did not transmit the disease
B. Vaccine was highly effective
C. Cross-immunity from other animal poxviruses
D. Life-long immunity
Answer: [/INST] Cross-immunity from other animal poxviruses </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera prophylaxis is by -
Choices:
A. Doxycycline 300mg OD
B. Cephalosporin
C. Streptomycin
D. Cotrimoxazole
Answer: [/INST] Doxycycline 300mg OD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Carious teeth', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Spastic diplegia', 'Motor delay', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Diarrhea', 'Respiratory insufficiency', 'Difficulty walking', 'Spastic tetraplegia', 'Difficulty climbing stairs', 'Excessive salivation', 'Neonatal death', 'Death in childhood', 'Recurrent viral infections', 'Difficulty running', 'Hypervalinemia', 'Hyperleucinemia', 'Hyperisoleucinemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning:  
1. **Branched-chain amino acid elevation**: Presence of hypervalinemia, hyperleucinemia, and hyperisoleucinemia directly indicates a defect in the branched-chain α-keto acid dehydrogenase complex, the hallmark of MSUD.  
2. **Neurological manifestations**: Spastic diplegia/tetraplegia, seizures, intellectual disability, and motor delays align with neurotoxicity from accumulated amino acids.  
3. **Metabolic crises**: Hyperammonemia, vomiting, diarrhea, and respiratory insufficiency correlate with acute metabolic decompensation, common in MSUD.  
4. **Early mortality**: Neonatal death, death in infancy/childhood/adolescence, and early adulthood are consistent with severe or untreated MSUD variants.  
5. **Supporting features**: Excessive salivation, recurrent infections, and carious teeth may arise from chronic metabolic dysregulation and dietary management challenges.  
6. **Exclusion of mimics**: Symptoms collectively rule out other organic acidemias (e.g., no mention of hypoglycemia or fatty acid oxidation defects) or urea cycle disorders (though hyperammonemia occurs, it is secondary in MSUD). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Severe hearing impairment', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase deficiency (3-MCC deficiency)  
Reasoning:  
1. **Elevated urinary carboxylic acids**: 3-MCC deficiency disrupts leucine catabolism, causing accumulation of 3-methylcrotonyl-CoA and its derivatives (3-hydroxyisovaleric acid, 3-methylcrotonylglycine), which are excreted in urine.  
2. **Death in infancy**: Severe metabolic crises (hypoglycemia, acidosis, hyperammonemia) triggered by catabolic stressors (e.g., fasting, infection) can lead to fatal outcomes if untreated.  
3. **Severe hearing impairment**: While not a hallmark, sensorineural hearing loss may occur due to neurotoxic metabolite effects or secondary neurological damage during metabolic decompensation.  

Note: The two listed diagnoses refer to the same disorder. 3-MCC deficiency involves mutations in *MCCC1* or *MCCC2* genes, encoding subunits of the enzyme. Clinical variability exists, with some cases showing atypical features like hearing impairment. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is not present in :
Choices:
A. Vomiting
B. Diarrhoea
C. Patient on diuretics
D. Chronic renal failure
Answer: [/INST] Chronic renal failure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Phenylketonuria, the first line therapy is:
Choices:
A. Replacement of the defective enzyme
B. Replacement of the deficient product
C. Limiting the substrate for deficient enzyme
D. Giving the missing amino acid by diet
Answer: [/INST] Limiting the substrate for deficient enzyme </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not seen in'Hereditary Spherocytosis:
Choices:
A. Direct Coomb's Positive
B. Increased Osmotic Fragility
C. Splenomegaly
D. Gall Stones
Answer: [/INST] Direct Coomb's Positive </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Plague is transmitted by the bite of -
Choices:
A. Culex mosquito
B. Rat flea
C. Body louse
D. Tse-Tse fly
Answer: [/INST] Rat flea </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following antibodies is most frequently seen in Antiphospholipid Syndrome ?
Choices:
A. Beta 2 microglobulin antibody
B. Anti-nuclear antibody
C. Anti-centromere antibody
D. Anti- beta 2 glycoprotein antibody
Answer: [/INST] Anti- beta 2 glycoprotein antibody </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Tuberculosis of spine best diagnostic modality is:
Choices:
A. Clinical
B. X-ray
C. MRI
D. CT guided biopsy
Answer: [/INST] CT guided biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Epicanthus', 'Hypotonia', 'Global developmental delay', 'Hepatic fibrosis', 'Intrauterine growth retardation', 'EEG abnormality', 'Short nose', 'Prolonged neonatal jaundice', 'Lateral ventricle dilatation', 'Abnormality of movement']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1 (CDDG1)  
Reasoning:  
1. **Hepatic fibrosis** and **prolonged neonatal jaundice** align with the liver dysfunction characteristic of CDDG1.  
2. **Abnormality of movement** (e.g., choreoathetosis) and **EEG abnormality** reflect neurological involvement, consistent with the syndrome’s choreoathetosis phenotype.  
3. **Global developmental delay**, **hypotonia**, and **lateral ventricle dilatation** indicate widespread neurological dysfunction, typical of deglycosylation disorders affecting brain development.  
4. **Microcephaly** and **intrauterine growth retardation** suggest congenital origins, fitting CDDG1’s presentation of prenatal-onset growth and structural defects.  
5. Dysmorphic features (**epicanthus**, **short nose**) are common in congenital glycosylation disorders due to disrupted glycoprotein synthesis.  
6. While alacrimia (absent tears) is not explicitly listed, the combination of hepatic, neurological, and developmental abnormalities strongly supports CDDG1, as phenotypic variability is recognized.  
7. CDDG1 is caused by *NGLY1* mutations, impairing deglycosylation and leading to multi-organ dysfunction, as seen in this patient’s hepatic, neurological, and growth-related symptoms. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: National Tuberculosis institute is in
Choices:
A. Chennai
B. Bangalore
C. Agra
D. Bhopal
Answer: [/INST] Bangalore </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Locking of knee joint can be caused by -a) Osgood shalterb) Loose body in knee jointc) Tuberculosis of kneed) Medial meniscal partial tear
Choices:
A. c
B. d
C. bd
D. ac
Answer: [/INST] bd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Prognosis of Gestational Trophoblastic Disease depends on all, except :
Choices:
A. Number of living children
B. Blood group
C. Parity
D. Previous HCG titre
Answer: [/INST] Number of living children </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Dermatomyositis test of choice -
Choices:
A. CPK
B. 24hr urine creat
C. SGOT
D. SGPT
Answer: [/INST] CPK </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true regarding Congenital Syphilis except:
Choices:
A. Procaine Penicillin can prevent it satisfactorily
B. Infection of the fetus most commonly occurs in 1st trimester
C. Neurological damage with mental retardation can be a serious consequence
D. If mother has late syphilis, chances of transmission decreases
Answer: [/INST] Infection of the fetus most commonly occurs in 1st trimester </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Obesity', 'Large for gestational age', 'Death in infancy', 'Abnormal cerebral morphology', 'Neonatal death', 'Death in childhood', 'Abnormal circulating lysine concentration', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key biochemical marker**: The presence of **L-2-hydroxyglutaric aciduria** directly indicates a defect in the metabolism of L-2-hydroxyglutarate, typically due to mutations in the *L2HGDH* gene, which encodes the enzyme L-2-hydroxyglutarate dehydrogenase.  
2. **Neurological and developmental symptoms**: **Macrocephaly**, **delayed speech**, **intellectual disability**, and **seizures** align with the progressive neurodegenerative features of L-2-HGA, caused by toxic accumulation of L-2-hydroxyglutarate in the central nervous system.  
3. **Abnormal cerebral morphology**: MRI findings (e.g., leukoencephalopathy, subcortical cysts, or basal ganglia abnormalities) are hallmark features of this disorder.  
4. **Metabolic derangement**: **Abnormal circulating lysine concentration** reflects disrupted lysine metabolism, a pathway linked to L-2-HGA.  
5. **Early mortality**: **Death in infancy/childhood** and **neonatal death** suggest severe forms of the disease, often due to metabolic decompensation or refractory seizures.  
6. **Large for gestational age (LGA)**: While less common, LGA may occur in metabolic disorders due to prenatal metabolic dysregulation.  
7. **Obesity**: May arise secondary to mitochondrial dysfunction or disrupted energy metabolism associated with the disease.  

**Conclusion**: The combination of neurodevelopmental regression, characteristic biochemical findings (L-2-hydroxyglutaric aciduria), cerebral abnormalities, and metabolic disturbances confirms the diagnosis of **L-2-hydroxyglutaric aciduria**. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Alkaptonuria is a metabolic disease caused by a defect in or lack of homogentisic acid oxidase which lead to
Choices:
A. Absent patella
B. Blue sclera
C. Darkly pigmented sclera cornea & ear
D. Absent radii
Answer: [/INST] Darkly pigmented sclera cornea & ear </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Not a feature of Ulcerative Colitis?
Choices:
A. Fine mucosal granularity
B. Pseudopolyps
C. String sign of Kantor
D. lead Pipe Appearance
Answer: [/INST] String sign of Kantor </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark biochemical feature of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Neonatal death** and **death in infancy/childhood/adolescence** align with untreated PKU, where severe neurological damage, seizures, and organ failure occur due to metabolic toxicity.  
3. **Obesity** may arise from restrictive dietary management (low-protein, high-carbohydrate diets) or metabolic dysregulation in poorly controlled cases.  
4. **Abnormality of prenatal development** is atypical for PKU itself but could reflect maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the offspring.  
5. The progression to early mortality underscores delayed diagnosis or lack of newborn screening, preventing timely dietary intervention to lower phenylalanine levels.  

Key confirmation requires genetic testing for *PAH* mutations and blood phenylalanine monitoring. Early treatment prevents severe outcomes, but untreated cases match the fatal trajectory described. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following characterizes Q fever?
Choices:
A. Has an incubation period of four to six weeks
B. is an acute febrile illness caused by Coxiella Burnetii
C. Is an illness confined to the upper respiratory tract
D. Is most commonly found in tropical region
Answer: [/INST] is an acute febrile illness caused by Coxiella Burnetii </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Rabies  a) Bats Transmit disease in some parts of the world  b) Brainstem encephalitis is characteristic c)  Negri bodies commonly found in thalamus and anterior pituitary  d) Paraesthesia is not seen  e) Recovery is the usual course
Choices:
A. ab
B. abc
C. abd
D. bcd
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with known mutation in the 'Rb gene' is 'disease free' from Retinoblastoma. The patient is at highest risk of developing which of the following malignancies
Choices:
A. Renal cell carcinoma
B. Osteosarcoma
C. Pinealoblastoma
D. Chondrosarcoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Non-specific esterase is positive in all the categories of Acute Myeloid Leukemia, EXCEPT:
Choices:
A. M3
B. M4
C. M5
D. M6
Answer: [/INST] M3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Treatment of acute phase of Kawasaki Disease is -
Choices:
A. Aspirin
B. IV steroids
C. IV immunoglobins
D. Cyclophosphamide
Answer: [/INST] IV immunoglobins </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most potential route for transmission of Meningitis from CNS to Inner ear is:
Choices:
A. Cochlear Aqueduct
B. Endolymphatic sac
C. Vestibular Aqueduct
D. Hyl's fissure
Answer: [/INST] Cochlear Aqueduct </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya is trasmittedb ?
Choices:
A. Aedes
B. Culex
C. Mansonoides
D. Anopheles
Answer: [/INST] Aedes </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypoparathyroidism occurs as a result ofa) Idiopathic atrophy of parathyroidsb) Following surgeryc) Thyroditis with secondary atrophy of parathyroidsd) All of the above
Choices:
A. ac
B. a
C. ab
D. bc
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following condition does odynohagia occur? 1. Achalasia 2. Herpes esophagitis 3. Monilial esophagitis 4. Barrett's esophagus
Choices:
A. 1 & 2
B. 2 & 3
C. 1,2 & 3
D. 1,2,3 & 4
Answer: [/INST] 2 & 3 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hydrocephalus', 'Microcephaly', 'Strabismus', 'Nystagmus', 'Intellectual disability', 'Death in infancy', 'Premature birth', 'Respiratory insufficiency', 'Hyperhomocystinemia', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration', 'Methylmalonic aciduria', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: The patient exhibits **methylmalonic aciduria**, a hallmark of MMA, caused by defects in methylmalonyl-CoA mutase or cobalamin (B12) metabolism. Symptoms like **respiratory insufficiency**, **neonatal death**, **death in childhood**, and **abnormal carnitine levels** align with MMA’s metabolic crises. However, **hyperhomocystinemia** and **neurological features** (e.g., intellectual disability, strabismus, nystagmus) suggest a **combined disorder** involving homocysteine, prompting consideration of a cobalamin metabolism defect.  

Disease: Methylmalonic acidemia with homocystinuria, type cblC/Methylmalonic aciduria and homocystinuria, Cblc type  
Reasoning: The **co-occurrence of methylmalonic aciduria and hyperhomocystinemia** is pathognomonic for **cblC type**, the most common inborn error of cobalamin metabolism. This disorder explains **neurological symptoms** (hydrocephalus, microcephaly, dyskinesia, nystagmus), **premature birth**, and **early mortality** due to multisystem decompensation. **Abnormal carnitine levels** and **respiratory insufficiency** further support severe metabolic dysfunction. The combination of MMA and homocystinuria distinguishes cblC from isolated MMA or homocystinuria alone. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Ataxia', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Stroke-like episode', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis and ataxia**: PMM2-CDG commonly presents with cerebellar hypoplasia/atrophy due to impaired glycosylation of proteins critical for cerebellar development, leading to motor dysfunction (ataxia).  
2. **Intellectual disability**: Global neurodevelopmental deficits are a hallmark of PMM2-CDG, resulting from disrupted glycosylation-dependent brain maturation.  
3. **Thromboembolism/stroke-like episodes**: Hypoglycosylation of coagulation factors (e.g., antithrombin III, protein C/S) causes a hypercoagulable state, predisposing to thrombotic events and vascular insults mimicking strokes.  
4. **Death in infancy**: Severe multisystem involvement (hepatic, cardiac, and neurologic) in classic PMM2-CDG often leads to early mortality.  
5. **Exclusion of mimics**: The combination of cerebellar structural anomalies, coagulopathy, and infantile lethality distinguishes PMM2-CDG from isolated metabolic disorders or mitochondrial diseases. Genetic testing for PMM2 mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia (REPEATED question)
Choices:
A. Occurs due to vitamin A deficiency
B. Relatively benign condition
C. First feature of vitamin A deficiency
D. Also seen in retinitis pigmentosa
Answer: [/INST] Occurs due to vitamin A deficiency </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Large fontanelles', 'Parietal bossing', 'Hypertelorism', 'Delayed eruption of primary teeth', 'Narrow chest', 'Short clavicles', 'Frontal bossing', 'Wormian bones', 'Scoliosis', 'Hypoplastic iliac wing', 'Short stature', 'Abnormal facility in opposing the shoulders', 'Depressed nasal bridge', 'Enamel hypoplasia', 'Delayed pubic bone ossification', 'Broad femoral head', 'Metopic depression', 'Midface retrusion', 'Short femoral neck']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cleidocranial dysplasia  
Reasoning:  
1. **Cranial/Facial Features**:  
   - **Large fontanelles**, **frontal/parietal bossing**, **metopic depression**, and **midface retrusion** indicate defective membranous bone ossification, a hallmark of CCD due to *RUNX2* gene mutations.  
   - **Hypertelorism** and **depressed nasal bridge** align with midface hypoplasia characteristic of CCD.  
   - **Wormian bones** (extra sutural bones) further support calvarial dysplasia.  

2. **Dental Abnormalities**:  
   - **Delayed eruption of primary teeth** and **enamel hypoplasia** result from impaired osteoblast differentiation and abnormal dental follicle development.  

3. **Clavicular/Skeletal Defects**:  
   - **Short clavicles** (or aplasia) explain **abnormal facility in opposing the shoulders** and **narrow chest**.  
   - **Hypoplastic iliac wings**, **delayed pubic bone ossification**, **broad femoral head**, and **short femoral neck** reflect pelvic and long bone dysplasia.  

4. **Growth and Axial Skeleton**:  
   - **Short stature** and **scoliosis** stem from generalized skeletal involvement.  

5. **Exclusion of Alternatives**:  
   - Overlap with hypophosphatasia or osteogenesis imperfecta is excluded by the absence of biochemical abnormalities (e.g., low alkaline phosphatase) or fragility fractures.  

This constellation of craniofacial, dental, clavicular, and pelvic abnormalities is pathognomonic for cleidocranial dysplasia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is defined as a plasma potassium concentration of
Choices:
A. < 3.5 mmol/L
B. < 3.6 mmol/L
C. < 3.7 mmol/L
D. < 3.8 mmol/L
Answer: [/INST] < 3.5 mmol/L </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Pityriasis Rosea, true is:
Choices:
A. Self-limiting
B. Chronic relapsing
C. Life threatening infection
D. Caused by dermatophytes
Answer: [/INST] Self-limiting </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed gross motor development', 'Gray matter heterotopia', 'Cerebellar dysplasia', 'Aplasia/Hypoplasia of the optic nerve']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Delayed gross motor development**: Common in Poretti-Boltshauser syndrome due to cerebellar dysfunction, which disrupts coordination and motor skill acquisition.  
2. **Gray matter heterotopia**: Reflects neuronal migration defects, a hallmark of neurodevelopmental disorders; while not pathognomonic, it aligns with the spectrum of brain malformations in this syndrome.  
3. **Cerebellar dysplasia**: A core feature of Poretti-Boltshauser syndrome, characterized by structural cerebellar abnormalities (e.g., cysts, dysplasia) contributing to ataxia and motor delays.  
4. **Aplasia/Hypoplasia of the optic nerve**: Observed in this syndrome due to congenital optic nerve defects, differentiating it from other cerebellar ataxias (e.g., Joubert syndrome, which typically involves retinal dystrophy instead).  
The combination of cerebellar dysplasia, optic nerve hypoplasia, and neurodevelopmental delays strongly supports this diagnosis, especially when genetic testing confirms pathogenic variants in *LAMA1* or *COL4A1*, genes implicated in the syndrome. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity', 'Death in childhood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), as impaired methylmalonyl-CoA mutase activity disrupts propionate metabolism, leading to toxic accumulation of methylmalonic acid. The clinical severity (death in childhood) aligns with acute or neonatal-onset MMA, which often presents with life-threatening metabolic decompensation.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene, which encodes this enzyme. This subtype is vitamin B12-unresponsive because the mutation affects the enzyme itself, not its cofactor (adenosylcobalamin, derived from vitamin B12). Early mortality underscores the severe biochemical dysfunction caused by the enzyme deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Yaws is caused by -
Choices:
A. Treponema pallidum
B. Treponema carateum
C. Treponema refringens
D. Treponema pertenue
Answer: [/INST] Treponema pertenue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is seen in -
Choices:
A. Children
B. Adults
C. Old age
D. At any age
Answer: [/INST] Children </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most immunogenic Typhoid antigen
Choices:
A. O antigen
B. H antigen
C. Vi antigen
D. Somatic antigen
Answer: [/INST] H antigen </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Vomiting', 'Migraine', 'Hyperglutaminemia', 'Oroticaciduria', 'Hyperalaninemia', 'Low plasma citrulline', 'Death in childhood', 'Death in adolescence', 'Uraciluria', 'Decreased circulating ferritin concentration', 'Abnormal vitamin B12 level']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Urea Cycle Dysregulation**: OTCD disrupts the urea cycle, impairing ammonia detoxification. While hyperammonemia is not explicitly listed, symptoms like vomiting and migraines align with episodic ammonia toxicity.  
2. **Hyperglutaminemia**: Excess ammonia drives glutamine synthesis via glutamine synthetase, explaining elevated glutamine levels.  
3. **Oroticaciduria/Uraciluria**: Urea cycle blockage shunts carbamoyl phosphate into pyrimidine synthesis, overproducing orotic acid and uracil, excreted in urine.  
4. **Low Plasma Citrulline**: OTCD prevents carbamoyl phosphate and ornithine from forming citrulline, reducing its plasma levels.  
5. **Hyperalaninemia**: Alternative nitrogen disposal via alanine transamination elevates alanine.  
6. **Secondary Metabolic Abnormalities**: Decreased ferritin and abnormal B12 may reflect liver dysfunction or metabolic stress from chronic hyperammonemia.  
7. **Early Mortality**: Untreated OTCD causes lethal hyperammonemic crises, consistent with death in childhood/adolescence.  
**Key Differentiators**: Oroticaciduria and low citrulline distinguish OTCD from other urea cycle disorders (e.g., citrullinemia, where citrulline is elevated). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Animal to man transmission (zoonosis) is seen in -a) Rabiesb) Japanese encephalitisc) HIVd) Plaguee)  Measles
Choices:
A. acd
B. bcd
C. abc
D. abd
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common translocation seen in patients with Multiple Myeloma is
Choices:
A. t(11;14)
B. t(4;14)
C. t(14;16)
D. t(14;20)
Answer: [/INST] t(11;14) </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on chromosome -
Choices:
A. 6
B. 9
C. 13
D. 21
Answer: [/INST] 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In which of the following conditions, Aniridia and Hemihypertrophy are most likely present -
Choices:
A. Neuroblastoma
B. Wilm's tumour
C. Non-Hodgkin's lymphoma
D. Germ cell tumour
Answer: [/INST] Wilm's tumour </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Neurofibromatosis 1 criteria include all except:
Choices:
A. Brain tumor
B. Acoustic neuromas
C. Dysplasia of the sphenoidal and tibial bone
D. Cafe-au-lait spots
Answer: [/INST] Acoustic neuromas </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements regarding-Gamma-Release-Assays for diagnosis of Tuberculosis is true -
Choices:
A. First Generation Quanti FERON-TB assay used ESAT-6
B. Second Generation Quanti FERON-TB (Gold) assay used ESAT-6 and CPF-10
C. These tests can distinguish between M. tuberculosis and M. bovis
D. None of the non-tuberculosis mycobacteria give a positive reaction with the test
Answer: [/INST] Second Generation Quanti FERON-TB (Gold) assay used ESAT-6 and CPF-10 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is most commonly seen in ?
Choices:
A. Maturity onset DM
B. Type I DM
C. Type H DM
D. HTN
Answer: [/INST] Type H DM </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies free country is
Choices:
A. China
B. Australia
C. France
D. Russia
Answer: [/INST] Australia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Hypohidrosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Alopecia', 'Metabolic acidosis', 'Neonatal death', 'Arrhythmia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency; BTDD  
Reasoning:  
1. **Metabolic acidosis and elevated urinary carboxylic acids**: Biotinidase deficiency impairs biotin recycling, critical for carboxylase enzymes (propionyl-CoA, 3-methylcrotonyl-CoA, pyruvate, and acetyl-CoA carboxylases). Dysfunction leads to accumulation of organic acids (e.g., lactate, 3-hydroxyisovalerate) in blood and urine, explaining metabolic acidosis and elevated urinary carboxylic acids.  
2. **Dermatological manifestations (eczematoid dermatitis, skin rash, alopecia)**: Biotin is essential for keratinocyte function and fatty acid synthesis. Deficiency causes periorificial dermatitis, alopecia, and rashes, mimicking zinc deficiency or seborrheic dermatitis.  
3. **Neurological features (hypotonia, macrocephaly)**: Organic acid accumulation disrupts energy metabolism, leading to hypotonia. Macrocephaly may arise from cerebral edema or leukodystrophy due to untreated metabolic crises.  
4. **Hypohidrosis**: Autonomic dysfunction from metabolic stress or direct sweat gland impairment secondary to biotin-dependent processes.  
5. **Arrhythmia**: Electrolyte imbalances (e.g., hyperammonemia, hypokalemia) from metabolic acidosis or cardiac energy depletion can trigger arrhythmias.  
6. **Infant mortality**: Untreated BTDD causes progressive neurological decline, metabolic decompensation, and fatal outcomes in infancy. Neonatal death may occur in severe, undiagnosed cases.  
**Diagnostic confirmation**: Low serum biotinidase activity and genetic testing for *BTD* gene mutations. Prompt biotin supplementation reverses symptoms, underscoring urgency in identification. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies is diagnosed by ?
Choices:
A. Hair follicle smear
B. Corneal smear
C. Isolation from blood
D. Nerve biopsy
Answer: [/INST] Corneal smear </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Yaws is caused by
Choices:
A. T.pallidum
B. T. Endemicum
C. T. Peenue
D. T. Carateum
Answer: [/INST] T. Peenue </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Intellectual disability', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) enzyme activity, impairing phenylalanine-to-tyrosine conversion.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are excreted in urine as carboxylic acids.  
3. **Intellectual disability**: Untreated PKU leads to neurotoxic phenylalanine accumulation, disrupting brain development.  
4. **Neonatal/childhood death**: Severe metabolic derangements (e.g., seizures, failure to thrive) in untreated cases may result in early mortality.  
5. **Hypertyrosinemia (atypical for PKU)**: While classic PKU reduces tyrosine levels, secondary factors (e.g., transient liver dysfunction, dietary intake, or metabolic stress) may explain elevated tyrosine.  
6. **Prenatal abnormalities**: Maternal PKU during pregnancy can cause congenital anomalies, though postnatal PKU diagnosis aligns with neonatal symptoms.  

Note: Hypertyrosinemia warrants further investigation for coexisting disorders (e.g., tyrosinemia), but PKU remains the primary diagnosis based on hyperphenylalaninemia and phenylketonuria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Medium chain acyl-CoA dehydrogenase deficiency (MCADD)  
Reasoning:  
1. **Abnormality of prenatal development or birth**: While MCADD typically does not cause structural birth defects, maternal fatty acid oxidation disorders (e.g., in an undiagnosed mother) may indirectly affect fetal energy supply, potentially leading to intrauterine distress.  
2. **Death in infancy/Neonatal death/Death in childhood**: MCADD causes an inability to metabolize medium-chain fatty acids during fasting. Neonates/children with MCADD are at high risk of hypoketotic hypoglycemia, metabolic acidosis, and encephalopathy triggered by catabolic states (e.g., infections, prolonged fasting), leading to sudden death if untreated.  
3. **Decreased plasma free carnitine**: MCADD results in accumulation of medium-chain acylcarnitines (e.g., C6-C10), which are renally excreted, depleting free carnitine. This contrasts with long-chain fatty acid oxidation defects where carnitine is often normal or elevated.  
4. **Diagnostic confirmation**: Elevated C6-C10 acylcarnitines on newborn screening or plasma acylcarnitine analysis, combined with genetic testing confirming *ACADM* gene mutations, solidify the diagnosis. Early intervention with fasting avoidance and emergency protocols prevents mortality. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is a disease of ?
Choices:
A. Neural transmission caused by the toxin of the bacterium clostridium botulinum
B. Muscular transmission caused by the toxin of the bacterium clostridium botulinum
C. Neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum
D. Non neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum
Answer: [/INST] Neuromuscular transmission caused by the toxin of the bacterium clostridium botulinum </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Ventricular septal defect', 'Cardiomyopathy', 'Leukocytosis', 'Vomiting', 'Respiratory distress', 'Hypoproteinemia', 'Abnormal circulating porphyrin concentration', 'Abnormal circulating aspartate family amino acid concentration', 'Feeding difficulties', 'Increased circulating lactate dehydrogenase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency/Glycogen storage disease type IXb  
Reasoning:  
1. **Metabolic Dysfunction**: The enzyme phosphorylase kinase deficiency impairs glycogen breakdown, leading to glycogen accumulation in the liver and muscles. This disrupts glucose release, causing metabolic crises (vomiting, feeding difficulties) and secondary stress responses (leukocytosis).  
2. **Hepatic Involvement**: Hypoproteinemia and abnormal porphyrin levels indicate liver dysfunction, as impaired hepatic glycogenolysis affects protein synthesis and heme metabolism.  
3. **Muscle/Cardiac Manifestations**: Deficiency in muscle phosphorylase kinase results in glycogen accumulation in cardiac tissue, explaining cardiomyopathy. Increased lactate dehydrogenase (LDH) reflects muscle damage and metabolic stress.  
4. **Respiratory Distress**: Likely due to metabolic acidosis from lactate accumulation or respiratory muscle weakness secondary to glycogen storage.  
5. **Amino Acid Abnormalities**: Altered aspartate family amino acids suggest disrupted liver metabolism, a secondary effect of chronic hepatic dysfunction.  
6. **Ventricular Septal Defect (VSD)**: While not a classic feature of GSD IXb, severe metabolic stress in infancy may exacerbate congenital cardiac anomalies or reflect a syndromic presentation.  
7. **Infant Mortality**: Severe metabolic and cardiac complications in infancy align with the rapid progression of untreated GSD IXb, particularly with multi-organ involvement.  

The constellation of hepatic, muscular, and metabolic symptoms, coupled with enzyme-specific pathophysiology, confirms Glycogen Storage Disease Type IXb. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Criteria included in AIDS surveillance definition include -a) Extrapulmonary TB b) Cryptococcosisc)  Candidiasisd)  Leptospirosis e)  Kaposi sarcoma
Choices:
A. bcde
B. abce
C. acde
D. abde
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hearing impairment', 'Delayed speech and language development', 'Obesity', 'Death in infancy', 'Fever', 'Hypertyrosinemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase activity, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids** (e.g., phenylpyruvate, phenyllactate) result from alternative phenylalanine metabolism, a key diagnostic feature of PKU.  
3. **Delayed speech and language development** and **hearing impairment** align with neurotoxic effects of phenylalanine accumulation in untreated PKU.  
4. **Severe short stature** and **obesity** may reflect metabolic dysregulation and dietary challenges in managing phenylalanine intake.  
5. **Hypertyrosinemia** is atypical for classic PKU but could suggest a comorbid condition, secondary metabolic disruption, or a variant (e.g., BH4-deficient PKU).  
6. **Neonatal death/Death in infancy/childhood/adolescence** might indicate severe, untreated PKU complications (e.g., neurodegeneration, metabolic crises) or a lethal variant (e.g., malignant PKU with dihydropteridine reductase deficiency).  
7. **Fever** could signal intercurrent infections exacerbated by metabolic instability.  
8. While other organic acidemias or tyrosinemias are considered, **hyperphenylalaninemia** and urinary phenylketones strongly prioritize PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis is found in the following except ?
Choices:
A. Multiple myeloma
B. Hypernephroma
C. Thymoma
D. Lymphoma
Answer: [/INST] Thymoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Epicanthus', 'Strabismus', 'Alacrima', 'Oculomotor apraxia', 'Tapered finger', 'Hypotonia', 'Global developmental delay', 'Reduced tendon reflexes', 'Clinodactyly of the 5th toe', 'Frontal bossing', 'Constipation', 'Hypoplastic nipples', 'Elevated hepatic transaminase', 'Prominent metopic ridge', 'Prolonged neonatal jaundice', 'Chalazion', 'Tented upper lip vermilion', 'Clinodactyly of the 4th toe']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alacrimia-choreoathetosis-liver dysfunction syndrome/Congenital disorder of deglycosylation 1  
Reasoning:  
1. **Alacrima**: A hallmark feature of this disorder, directly referenced in its name.  
2. **Liver dysfunction**: Supported by *prolonged neonatal jaundice* and *elevated hepatic transaminases*.  
3. **Neurological involvement**: *Global developmental delay*, *hypotonia*, *oculomotor apraxia*, and *reduced tendon reflexes* align with the syndrome’s neurological and movement-related manifestations (choreoathetosis, though not explicitly listed, is often part of the phenotype).  
4. **Dysmorphic features**: *Microcephaly*, *frontal bossing*, *prominent metopic ridge*, *epicanthus*, *tented upper lip vermilion*, *tapered fingers*, and *clinodactyly of the 4th/5th toes* are consistent with craniofacial and skeletal anomalies seen in congenital disorders of glycosylation.  
5. **Systemic involvement**: *Hypoplastic nipples*, *chalazion*, and *constipation* reflect multisystemic pathology typical of glycosylation defects.  
6. **Exclusion of mimics**: The combination of alacrima, liver dysfunction, and neurodevelopmental abnormalities is pathognomonic for this disorder, distinguishing it from other CDG subtypes or syndromes like Smith-Lemli-Opitz or NGLY1 deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles shows age distribution. It is found most commonly in which age group?
Choices:
A. 9 months to 3 years
B. 6 months to 2 years
C. 9 months to 2 years
D. 6 months to 3 years
Answer: [/INST] 6 months to 3 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vasculitis is seen in-a)  Burger's diseaseb)  HSPc)  Goutd)  Reiteres diseasee)  Behcets syndrome
Choices:
A. abcd
B. bcde
C. acde
D. abde
Answer: [/INST] abde </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mode of transmisstion of Q fever -
Choices:
A. Bite of infected louse
B. Bite of infected tick
C. Inhalation of aerosol
D. Bite of infected mice
Answer: [/INST] Inhalation of aerosol </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin:
Choices:
A. Increases the levels of intracellular cylic GMP
B. Acts through the receptor the opiates
C. Causes continued activation of adenylate cyclase
D. Inhibits the enzyme phosphodiesterase
Answer: [/INST] Causes continued activation of adenylate cyclase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia in an infant may be due to all of the following except –
Choices:
A. Adrenal tumor
B. Acute renal failure
C. Thiazide therapy
D. Diarrhea
Answer: [/INST] Acute renal failure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Splenomegaly', 'Respiratory insufficiency']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cystinuria: Cystinuria is a genetic disorder characterized by impaired transport of cystine and other amino acids in the kidneys, leading to recurrent kidney stone formation. However, the listed symptoms—seizures, death in infancy, splenomegaly, and respiratory insufficiency—do not align with cystinuria. Cystinuria primarily manifests with urinary tract symptoms (e.g., nephrolithiasis, hematuria) and is not associated with neurological deficits, splenomegaly, or life-threatening respiratory failure in infancy. The diagnosis provided is inconsistent with the clinical presentation.  

**Likely Alternative Diagnosis (not cystinuria):**  
The symptoms suggest a severe metabolic or lysosomal storage disorder, such as:  
- **Niemann-Pick disease type A (ASMD):** Presents with hepatosplenomegaly, progressive neurodegeneration, seizures, and respiratory failure in infancy.  
- **Gaucher disease type 2:** Features splenomegaly, neurological deterioration, and respiratory complications, though seizures are less common.  
- **Mitochondrial respiratory chain disorders:** May cause multisystem involvement, including seizures, respiratory insufficiency, and organomegaly due to energy deficiency.  

**Conclusion:** The provided diagnosis of cystinuria is incorrect for this clinical scenario. Further evaluation (e.g., enzyme assays, genetic testing, imaging) is critical to identify the underlying condition. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Abnormal bleeding', 'Hyperammonemia', 'Vomiting', 'Oroticaciduria', 'Abnormality of the coagulation cascade']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency  
Reasoning:  
1. **Hyperammonemia** is a cardinal feature of urea cycle disorders (UCDs), specifically implicating OTCD as ornithine transcarbamylase (OTC) is critical for ammonia detoxification in the urea cycle.  
2. **Oroticaciduria** is pathognomonic for OTCD. The enzyme deficiency causes carbamoyl phosphate to divert into pyrimidine synthesis, overproducing orotic acid.  
3. **Vomiting** and **death in infancy** align with acute neonatal-onset OTCD, where hyperammonemic crises trigger neurological deterioration and multi-organ failure.  
4. **Abnormal bleeding/coagulation cascade abnormalities** arise from hyperammonemia-induced platelet dysfunction and potential secondary liver impairment (reduced clotting factor synthesis).  
5. Exclusion of other UCDs (e.g., CPS1 deficiency lacks oroticaciduria; arginase deficiency presents later). The symptom constellation is specific to OTCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Amyloidosis shown in Cardiac muscle is mainly due to …….. fibril
Choices:
A. AL
B. AA
C. AANF
D. ATTR
Answer: [/INST] ATTR </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypoparathyroidism is seen in all of the following except
Choices:
A. DiGeorge syndrome
B. Chronic renal failure
C. Wilson's disease
D. Haemochromatosis
Answer: [/INST] Chronic renal failure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera patient having stool output 1000-1500 mL/day is known as:
Choices:
A. Cholera mitis
B. Cholera dumdum
C. Cholera magna
D. Cholera gravis
Answer: [/INST] Cholera gravis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hydrocephalus in the fetus is diagnosed by all except :
Choices:
A. Large fontanelle with widely separated sutures as felt on PV examination
B. High floating head
C. Serial ultrasound
D. CPD
Answer: [/INST] CPD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Hypomelanotic macule', 'Shagreen patch', 'Fibroma', 'Macule', 'Profound global developmental delay', 'Ungual fibroma']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tuberous sclerosis-1  
Reasoning:  
1. **Seizures**: Common in tuberous sclerosis complex (TSC) due to cortical tubers or subependymal nodules disrupting brain function.  
2. **Hypomelanotic macules (ash leaf spots)**: A major diagnostic criterion for TSC, appearing as depigmented skin patches.  
3. **Shagreen patch**: A connective tissue nevus (typically on the lower back), a major diagnostic feature of TSC.  
4. **Ungual fibroma**: Fibrous growths around/under nails, a major diagnostic criterion when multiple are present.  
5. **Profound global developmental delay**: Linked to severe neurological involvement in TSC, often from cortical tubers or epilepsy burden.  
6. **Fibromas**: Benign tumors (e.g., facial angiofibromas) are hallmark lesions in TSC.  
7. **Macule**: General term; here, likely referencing hypomelanotic macules or other TSC-associated skin lesions.  

The combination of ≥2 major features (hypomelanotic macules, shagreen patch, ungual fibroma, seizures) and developmental delay strongly supports **TSC1** (mutations in the *TSC1* gene on chromosome 9q34), a subtype of tuberous sclerosis complex. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following tumours present with proptosis  a) Neuroblastoma  b) Nephroblastoma  c) Germ cell tumour  d) Medulloblastoma  e) Meningioma
Choices:
A. abe
B. acd
C. cde
D. abd
Answer: [/INST] abe </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Medulloblastoma most common metastasis is to ?
Choices:
A. Lung
B. CNS
C. Liver
D. Spleen
Answer: [/INST] CNS </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Rod-cone dystrophy', 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
- **Rod-cone dystrophy**: PMM2-CDG commonly causes retinal abnormalities, including progressive vision loss due to rod-cone dystrophy, linked to defective glycosylation of photoreceptor proteins.  
- **Intellectual disability**: A hallmark of PMM2-CDG due to impaired glycosylation critical for neurodevelopment, leading to global developmental delays and cognitive deficits.  
- **Cerebellar atrophy/agenesis**: Structural cerebellar defects (atrophy or agenesis) arise from disrupted glycosylation during brain development, contributing to hypotonia, ataxia, and motor deficits.  
- **Death in infancy**: Severe PMM2-CDG cases often result in early mortality from multiorgan failure, infections, or complications like liver disease and thromboembolism.  
- **Thromboembolism**: Coagulation factor glycosylation defects (e.g., antithrombin III deficiency) predispose to thrombotic events.  
- **Abnormal facial shape/calvaria morphology**: Characteristic dysmorphic features (e.g., high forehead, large ears) and skull abnormalities stem from glycosylation-dependent craniofacial development disruptions.  
- **Lipodystrophy**: Subcutaneous fat redistribution or loss may occur due to metabolic dysregulation from glycosylation defects in adipose tissue signaling.  
- **Acute/chronic hepatitis**: Persistent liver dysfunction (elevated transaminases, hepatomegaly) is common, progressing to fibrosis in severe cases, driven by glycosylation-dependent hepatic protein misfolding.  

**Conclusion**: The multisystemic presentation—neurological, hepatic, coagulopathic, and dysmorphic—aligns pathognomonically with PMM2-CDG, a disorder of N-linked glycosylation caused by PMM2 mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Rabies, the characteristic pathological manifestation is -
Choices:
A. Ventriculitis
B. Encephalitis
C. Basal ganglia affection
D. Meningitis
Answer: [/INST] Encephalitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Paresthesia', 'Hyperphenylalaninemia', 'Death in early adulthood', 'Acute hepatitis', 'Chronic hepatitis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are pathognomonic for PKU, caused by deficient phenylalanine hydroxylase (PAH) activity.  
2. **Intellectual disability**: Untreated PKU leads to toxic phenylalanine accumulation, disrupting brain development and function.  
3. **Paresthesia**: Chronic neurotoxicity from phenylalanine may cause peripheral neuropathy, manifesting as sensory disturbances.  
4. **Death in early adulthood**: Historically, untreated PKU results in severe neurological decline and systemic complications, though modern dietary management improves prognosis.  
5. **Acute/Chronic hepatitis**: Atypical for classic PKU. May suggest comorbid conditions (e.g., viral hepatitis, metabolic liver disease) or secondary effects from prolonged metabolic stress. PKU itself does not directly cause hepatitis, necessitating further investigation for liver-specific etiologies.  

Key PKU hallmarks (hyperphenylalaninemia, neurocognitive deficits) dominate the diagnosis, while liver abnormalities likely indicate a coexisting or unrelated condition. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Roll back Malaria program is -
Choices:
A. Encourage the development of more effective and new anti malarial drugs and vaccines
B. Encourage the proper and expanded use of insecticide treated mosquito nets
C. Training of villages health workers and mother on early and appropriate treatment of malaria
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Feature of Achalasia cardia (cardiospasm) include all of the following except-
Choices:
A. Increasing dificulty in swallowing more for liquids than for soilds
B. Regurgitant vomiting
C. Dilated & turtuous esophagus
D. Filling defect on barium study
Answer: [/INST] Filling defect on barium study </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Hypospadias', 'Vesicoureteral reflux', 'Renal hypoplasia', 'Tall stature', 'Renal cyst', 'Hydronephrosis', 'Narrow mouth', 'Abnormality of the dentition', 'Broad alveolar ridges', 'High palate', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Abnormal pinna morphology', 'Prominent antihelix', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Deeply set eye', 'Downslanted palpebral fissures', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Abnormal choroid morphology', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Hyperactivity', 'Cafe-au-lait spot', 'Abnormal thumb morphology', 'Hypotonia', 'Global developmental delay', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Hip dysplasia', 'Growth delay', 'Growth delay', 'Intrauterine growth retardation', 'Polyhydramnios', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Hypoplasia of the corpus callosum', 'Ventriculomegaly', 'Generalized non-motor (absence) seizure', 'Duodenal atresia', 'Tetraparesis', 'Hypoplastic nipples', 'Scoliosis', 'Neoplasm of the liver', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', '3-4 finger syndactyly', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormal choroid plexus morphology', 'Postnatal growth retardation', 'Anterior creases of earlobe', 'Abnormal fifth toe morphology', '1-2 finger syndactyly', 'Anomalous pulmonary venous return', 'Expanded terminal portion of crus of helix', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental/core features**: Global developmental delay, hypotonia, spastic tetraparesis, generalized non-motor seizures, ADHD, and cerebellar vermis hypoplasia align with central nervous system involvement. Delayed myelination, cerebral hypomyelination, and hypoplastic corpus callosum further support brain structural anomalies.  
2. **Ocular anomalies**: Microphthalmia, coloboma, Peters anomaly, optic atrophy, and abnormal iris morphology are hallmark eye abnormalities in NEDBEH.  
3. **Cardiac defects**: Ventricular septal defect, patent ductus arteriosus, and abnormal cardiac septum morphology match the ""heart"" component of the disorder.  
4. **Craniofacial/Systemic dysmorphism**: Microcephaly/macrocephaly, triangular face, micrognathia, hypertelorism, smooth philtrum, and high palate are consistent with reported facial gestalt. Renal hypoplasia, hydronephrosis, and annular pancreas reflect multi-organ involvement.  
5. **Supportive features**: Growth retardation (pre/postnatal), sensorineural hearing impairment, limb anomalies (syndactyly, clinodactyly), and café-au-lait spots overlap with phenotypic variability in NEDBEH.  
6. **Exclusion**: While features like choanal atresia or duodenal atresia may suggest other syndromes (e.g., CHARGE), the combination of neurodevelopmental, eye, and heart anomalies without a primary skeletal dysplasia or metabolic disorder strongly favors NEDBEH.  

Key triad: Neurodevelopmental delay + structural brain/eye anomalies + congenital heart defects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Toxic Shock Syndrome is most commonly caused by: March 2005
Choices:
A. Sterptococcus pneumoniae
B. Staphylococcus aureus
C. Vibrio cholerae
D. Clostridium tetani
Answer: [/INST] Staphylococcus aureus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cyanosis', 'Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Death in infancy', 'Anemia', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Holocarboxylase synthetase deficiency (HLCS deficiency)  
Reasoning:  
1. **Enzyme Dysfunction**: HLCS deficiency impairs biotin-dependent activation of multiple carboxylases (propionyl-CoA, pyruvate, β-methylcrotonyl-CoA, and acetyl-CoA carboxylases).  
2. **Metabolic Acidosis & Hyperammonemia**: Propionyl-CoA carboxylase deficiency leads to propionic acid accumulation, disrupting the urea cycle (hyperammonemia) and causing metabolic acidosis.  
3. **Skin Manifestations**: Eczematoid dermatitis and rash arise from functional biotin deficiency, impairing fatty acid synthesis and skin barrier function.  
4. **Neuromuscular Symptoms**: Generalized hypotonia stems from energy deficits (pyruvate carboxylase deficiency) and toxic metabolite accumulation.  
5. **Respiratory & Gastrointestinal Signs**: Tachypnea compensates for acidosis; diarrhea reflects intestinal metabolic dysfunction.  
6. **Laboratory Abnormalities**:  
   - **Aminoaciduria/Abnormal Glycine**: Disrupted amino acid catabolism due to carboxylase deficiencies.  
   - **Elevated Urinary Carboxylic Acids**: Propionate, 3-hydroxypropionate, and methylcitrate accumulate from blocked propionyl-CoA metabolism.  
   - **Decreased Pyruvate Carboxylase Activity**: Confirms multi-carboxylase involvement (lactic acidosis risk).  
7. **Early Lethality**: Neonatal death or infantile mortality occurs in untreated cases due to metabolic crises (acidosis, hyperammonemia).  
8. **Diagnostic Confirmation**: Combined propionyl-CoA and pyruvate carboxylase deficiencies (vs. isolated carboxylase defects) and abnormal glycine/monocarboxylic acid profiles pinpoint HLCS deficiency.  
**Conclusion**: The constellation of multi-carboxylase dysfunction, metabolic derangements, and neonatal presentation aligns definitively with HLCS deficiency. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles vaccination is given at-
Choices:
A. 9 months
B. At birth
C. 4 weeks
D. 8 weeks
Answer: [/INST] 9 months </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is least likely to be associated with Infective Endocarditis:
Choices:
A. Small ASD
B. Small VSD
C. Mild MR
D. Mild MS
Answer: [/INST] Small ASD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies virus is inactivated by
Choices:
A. Phenol
B. UV radiation
C. BPL
D. All
Answer: [/INST] All </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pallor', 'Death in infancy', 'Ascites', 'Thrombocytosis', 'Anemia', 'Hepatomegaly', 'Hypoalbuminemia', 'Hypoproteinemia', 'Elevated circulating alkaline phosphatase concentration', 'Hypertyrosinemia', 'Aminoaciduria', 'Elevated circulating alpha-fetoprotein concentration', 'Abnormal circulating porphyrin concentration', 'Pustule']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Tyrosinemia type 1  
Reasoning:  
1. **Hypertyrosinemia & Aminoaciduria**: Direct biochemical hallmarks of tyrosinemia type 1 (HT-1), caused by fumarylacetoacetate hydrolase (FAH) deficiency, leading to toxic tyrosine metabolite accumulation.  
2. **Hepatomegaly & Hypoalbuminemia/Hypoproteinemia**: Severe liver dysfunction due to tyrosine metabolite toxicity, impairing synthetic function and causing edema/ascites.  
3. **Elevated AFP**: Reflects hepatocyte regeneration or malignancy risk, a key marker in HT-1.  
4. **Abnormal circulating porphyrins**: Secondary to succinylacetone accumulation (a tyrosine metabolite), inhibiting δ-aminolevulinic acid dehydratase, disrupting heme synthesis.  
5. **Thrombocytosis & Anemia/Pallor**: Thrombocytosis may arise from splenic dysfunction or inflammation; anemia results from bone marrow suppression or bleeding complications.  
6. **Elevated alkaline phosphatase**: Indicates cholestatic liver injury.  
7. **Ascites**: Due to hypoalbuminemia and portal hypertension from cirrhosis.  
8. **Pustules**: Rare cutaneous manifestations of metabolic toxicity.  
9. **Death in infancy**: Untreated HT-1 causes acute liver failure, renal tubular dysfunction, and neurologic crises, often fatal in early childhood.  

The constellation of liver failure, tyrosine metabolism derangements, and secondary biochemical abnormalities confirms HT-1. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ulcerative Colitis and Crohn's diseases are associated with all EXCEPT?
Choices:
A. Wiskott Aldrich Syndrome
B. Turner's syndrome
C. Glycogen storage diseases Type III
D. Hermansky Pudlak Syndrome
Answer: [/INST] Glycogen storage diseases Type III </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies virus is inactivated by -
Choices:
A. Phenol
B. UV radiation
C. BPL
D. ALL
Answer: [/INST] ALL </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following statements regarding diagnosis of Malaria are true?
Choices:
A. Thin blood film is used to determine parasite concentration.
B. Thick blood film is used to detect plasmodium species causing infection.
C. Jaswant Singh Bhattacharya (JSB) Stain is used.
D. As the sensitivity of microscopy is low, it is useful to detect parasite load at high concentrations only.
Answer: [/INST] Jaswant Singh Bhattacharya (JSB) Stain is used. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Open mouth', 'Mandibular prognathia', 'Broad forehead', 'Hearing impairment', 'Bulbous nose', 'Atypical behavior', 'Generalized hypotonia', 'Absent speech', 'Abnormal facial shape', 'Developmental regression', 'Delayed skeletal maturation', 'Severe global developmental delay', 'Thick vermilion border']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facial features**: ""Broad forehead,"" ""bulbous nose,"" ""thick vermilion border,"" ""open mouth,"" and ""mandibular prognathia"" align with the distinct facies described in TBCK syndrome, including midface hypoplasia and a prominent upper lip.  
2. **Neuromuscular involvement**: ""Generalized hypotonia"" is a hallmark of the disorder, often presenting in infancy.  
3. **Developmental delays**: ""Severe global developmental delay,"" ""absent speech,"" and ""delayed skeletal maturation"" correlate with the syndrome’s core features of psychomotor retardation and growth deficits.  
4. **Atypical behavior**: Observed in TBCK cases due to intellectual disability and potential autism spectrum traits.  
5. **Hearing impairment**: Documented in some patients, possibly linked to sensorineural or conductive abnormalities.  
6. **Developmental regression**: While less common, stagnation or regression may occur in severe cases, overlapping with neurodegenerative-like presentations.  
7. **Genetic confirmation**: Although not explicitly stated, the symptom constellation strongly suggests biallelic TBCK mutations, which impair mTORC1 signaling and lysosomal function.  

The absence of key features of phenocopies (e.g., Coffin-Siris or Angelman syndromes) further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: It is probable that physician have a higher index of suspicion for tuberculosis in children without BCG scar that those with BCG scar. If this is so and an association is found between Tuberculosis and not having BCG scar, the association may be due to-
Choices:
A. Selection bias
B. Interviewer bias
C. Surveillance bias
D. Non-response bias
Answer: [/INST] Interviewer bias </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: About Achalasia Cardia: 1. Dysphagia is a presenting symptom 2. The cause is the absence of Auerbach's plexus 3. Esophagectomy is the treatment 4. Motility improving agents are used in treatment 5. Barium swallow shows irregular filling defects in lower esophagus
Choices:
A. 1,2,3 False & 4,5 True
B. 1,2,4 True & 3,5 False
C. 2,3,4 True &1,5 False
D. 1,3,5 True & 2,4 False
Answer: [/INST] 1,2,4 True & 3,5 False </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mycobacterium causing lung infection are   a) Mycobacterium Tuberculosis   b) Mycobacterium Kansasii  c) Mycobacterium Fortuitum  d) Mycobacterium avium intracellularae  e) Mycobacterium Scrofuloceuml
Choices:
A. abd
B. abc
C. acd
D. bcd
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following tests can help in the diagnosis of Galactosemia EXCEPT?
Choices:
A. GALT assay
B. Mutation analysis
C. Benedicts test
D. Guthrie's test
Answer: [/INST] Guthrie's test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Neurogenic bladder', 'Macroglossia', 'Gingival overgrowth', 'Coarse facial features', 'Narrow forehead', 'Prominent nasal bridge', 'Anteverted nares', 'Ptosis', 'Cataract', 'Osteoporosis', 'Areflexia', 'Stroke', 'Cerebellar vermis hypoplasia', 'Partial agenesis of the corpus callosum', 'Respiratory insufficiency', 'Hypertriglyceridemia', ""Exaggerated cupid's bow"", 'Developmental regression', 'Highly arched eyebrow', 'Severe muscular hypotonia', 'Focal-onset seizure', 'Multifocal epileptiform discharges', 'Feeding difficulties', 'Small basal ganglia', 'Profound global developmental delay', 'Periauricular skin pits', 'Subdural hemorrhage', 'Cerebral visual impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: TBCK-related intellectual disability syndrome/Hypotonia, infantile, with psychomotor retardation and characteristic facies 3  
Reasoning:  
1. **Characteristic facies**: Coarse facial features, macroglossia, gingival overgrowth, narrow forehead, prominent nasal bridge, anteverted nares, ptosis, highly arched eyebrows, and ""exaggerated Cupid's bow"" align with the distinct craniofacial phenotype described in TBCK syndrome.  
2. **Neurological and neuromuscular deficits**: Severe muscular hypotonia, areflexia, profound global developmental delay, developmental regression, and cerebellar vermis hypoplasia reflect the central and peripheral nervous system involvement typical of TBCK mutations.  
3. **Epilepsy**: Focal-onset seizures and multifocal epileptiform discharges correlate with the seizure phenotype observed in TBCK-related disorders.  
4. **Neuroimaging findings**: Partial agenesis of the corpus callosum, small basal ganglia, and subdural hemorrhage (likely secondary to hypotonia/falls) are consistent with structural brain anomalies reported in TBCK patients.  
5. **Systemic features**: Osteoporosis, hypertriglyceridemia, respiratory insufficiency, and cataracts match the multisystemic manifestations of TBCK syndrome, involving metabolic and connective tissue dysfunction.  
6. **Supportive features**: Periauricular skin pits, feeding difficulties, and cerebral visual impairment further reinforce the diagnosis, as these are recurrently observed in TBCK-related cases.  
7. **Exclusion of mimics**: The absence of organomegaly, skeletal dysplasia, or specific storage material distinguishes this from lysosomal disorders (e.g., mucopolysaccharidoses), while the combination of hypotonia, facial dysmorphism, and brain anomalies differentiates it from other neurodevelopmental syndromes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypoglycemia', 'Vomiting', 'Diarrhea', 'Elevated hepatic transaminase', 'Abnormal circulating carnitine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Medium chain acyl-CoA dehydrogenase deficiency (MCADD):  
1. **Hypoglycemia**: MCADD impairs the breakdown of medium-chain fatty acids, a critical energy source during fasting. This leads to hypoglycemia due to the inability to generate ketones as an alternative fuel.  
2. **Vomiting/Diarrhea**: Metabolic decompensation during fasting or infection triggers gastrointestinal symptoms.  
3. **Elevated hepatic transaminases**: Accumulation of toxic metabolites (e.g., medium-chain acylcarnitines) causes hepatocellular damage.  
4. **Abnormal carnitine profile**: Secondary carnitine deficiency occurs due to urinary loss of carnitine bound to unmetabolized fatty acids (elevated C8-C10 acylcarnitines on bloodspot analysis).  
5. **Death in infancy**: Untreated MCADD carries high mortality from hypoglycemia, encephalopathy, and liver failure during catabolic stress. Neonatal screening and avoidance of fasting are lifesaving. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The Multidrug (MDT) regimen under the National Leprosy Eradication Program for the treatment of all Multibacillary Leprosy would include:-
Choices:
A. Clofazimine, Thiacetazone and Dapsone
B. Clofazimine, Rifampicin and Dapsone
C. Ethionamide, Rifampicin and Dapsone
D. Propionamide, Rifampicin and Dapsone
Answer: [/INST] Clofazimine, Rifampicin and Dapsone </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal retinal morphology', 'Myopia', 'Oculomotor apraxia', 'Delayed speech and language development', 'Motor delay', 'Generalized hypotonia', 'Dilated fourth ventricle', 'Cerebellar dysplasia', 'Inferior cerebellar vermis hypoplasia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome/Poretti-Boltshauser syndrome  
Reasoning:  
1. **Cerebellar Abnormalities**: The presence of *dilated fourth ventricle*, *cerebellar dysplasia*, and *inferior cerebellar vermis hypoplasia* aligns with the hallmark cerebellar structural defects in Poretti-Boltshauser syndrome, often including cerebellar cysts or dysplasia.  
2. **Oculomotor Apraxia**: Directly matches the defining feature of the syndrome, explaining difficulties in initiating voluntary eye movements.  
3. **Neurodevelopmental Delays**: *Motor delay*, *delayed speech and language development*, and *generalized hypotonia* correlate with the intellectual disability and ataxia characteristic of the disorder.  
4. **Ocular Findings**: *Abnormal retinal morphology* and *myopia* are consistent with reported ocular anomalies linked to LAMA1 mutations, the genetic cause of the syndrome.  
5. **Exclusion of Alternatives**: The combination of cerebellar vermis hypoplasia, oculomotor apraxia, and retinal changes distinguishes it from similar disorders (e.g., Joubert syndrome, which typically shows a ""molar tooth sign"" absent here). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The Earliest feature Tuberculosis is:
Choices:
A. Caseation
B. Lymphocytosis
C. Giant calls (Langerhans)
D. Granuloma
Answer: [/INST] Lymphocytosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The mechanism of the development of Acute Rheumatic Fever is which of the following?
Choices:
A. Cross reactivity with exogenous antigen
B. Innocent bystander effect
C. Due to toxin secretion by streptococci
D. Release of pyrogenic cytokines
Answer: [/INST] Cross reactivity with exogenous antigen </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria card test for P. Falciparum detects
Choices:
A. LDH
B. Aldolase
C. Histidine rich protein
D. None of the above
Answer: [/INST] Histidine rich protein </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, leading to phenylalanine accumulation.  
2. **Elevated urinary carboxylic acids**: PKU causes excess phenylalanine to be metabolized into phenylketones (e.g., phenylpyruvate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy/childhood**: Untreated PKU results in severe neurological damage, seizures, and metabolic instability, often fatal in early life without dietary intervention.  
4. **Abnormality of prenatal development**: Maternal PKU syndrome (if the mother has uncontrolled PKU during pregnancy) can cause congenital anomalies like microcephaly or cardiac defects in the infant.  
5. **Hypertyrosinemia**: While classic PKU typically reduces tyrosine levels (due to blocked PAH), transient hypertyrosinemia may occur in metabolic crises or overlapping disorders (e.g., BH4 deficiency), though this is atypical and suggests possible complex metabolic interplay.  
6. **Obesity**: May arise from high-calorie, low-protein diets used to manage PKU or secondary metabolic dysregulation.  

While hypertyrosinemia is not a classic PKU feature, the dominant hyperphenylalaninemia and urinary carboxylic acids strongly support PKU as the primary diagnosis, with other symptoms explained by untreated disease or maternal effects. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Apraxia is a disorder of:
Choices:
A. Cerebellum
B. Sensory system
C. Motor system
D. Initiating and planning movement
Answer: [/INST] Initiating and planning movement </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Lethargy', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Abnormal circulating ornithine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ornithine transcarbamylase deficiency (OTCD)  
Reasoning:  
1. **Hyperammonemia**: Central to OTCD diagnosis, as the urea cycle enzyme deficiency prevents ammonia detoxification.  
2. **Oroticaciduria**: Excess carbamoyl phosphate shunts into pyrimidine synthesis, producing orotic acid.  
3. **Hyperglutaminemia**: Secondary to ammonia accumulation, as glutamine synthesis increases to sequester excess ammonia.  
4. **Abnormal ornithine**: Reduced ornithine due to impaired conversion to citrulline in the urea cycle.  
5. **Neurological symptoms** (lethargy, drowsiness, vomiting, sleep disturbance): Caused by ammonia neurotoxicity.  
6. **Death in infancy**: Severe neonatal-onset OTCD leads to rapid metabolic decompensation without intervention.  
7. **X-linked inheritance**: Males typically present earlier and more severely, aligning with infant mortality risk.  

This constellation of urea cycle dysfunction, biochemical markers, and clinical presentation confirms OTCD. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: TRUE about Gestational Trophoblastic Disease is?
Choices:
A. Most common site of metastasis is vagina
B. Presence of Lung metastasis classifies as stage 4 GTN
C. Liver metastasis carries a poor prognosis similar to brain metastasis
D. GTN following a term pregnancy has a better prognosis than that with previous molar pregnancy
Answer: [/INST] Liver metastasis carries a poor prognosis similar to brain metastasis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by a deficiency in phenylalanine hydroxylase (PAH), leading to toxic accumulation of phenylalanine in the blood.  
2. **Elevated urinary carboxylic acids**: Excess phenylalanine is metabolized into phenylketones (e.g., phenylpyruvate, phenyllactate), which are carboxylic acids excreted in urine.  
3. **Neonatal death/Death in infancy**: Untreated PKU results in severe neurological damage, seizures, and failure to thrive, often fatal in early life without dietary intervention.  
4. **Death in early adulthood**: Chronic complications (e.g., intellectual disability, behavioral issues, osteoporosis) in untreated individuals may reduce lifespan.  
5. **Abnormality of prenatal development**: Maternal PKU during pregnancy (if the mother is untreated) causes fetal exposure to high phenylalanine, leading to congenital anomalies (e.g., microcephaly, cardiac defects).  
6. **Hypertyrosinemia discrepancy**: Typically, PKU causes *low* tyrosine due to impaired PAH activity. This symptom may reflect a coexisting condition (e.g., tyrosinemia), laboratory error, or misreporting but does not exclude PKU as the primary diagnosis.  

Note: Hypertyrosinemia is atypical for PKU and warrants further investigation for overlapping metabolic disorders (e.g., BH4 deficiency or tyrosinemia), but the core symptoms align conclusively with PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Ataxia', 'Lethargy', 'Generalized hypotonia', 'Death in infancy', 'Drowsiness', 'Sleep disturbance', 'Abnormal circulating pyrimidine concentration', 'Uraciluria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Dihydropyrimidine dehydrogenase deficiency  
Reasoning:  
1. **Abnormal Pyrimidine Metabolism**: The presence of **abnormal circulating pyrimidine concentration** and **uraciluria** directly points to a defect in pyrimidine catabolism, as uracil accumulation occurs due to impaired breakdown.  
2. **Enzyme Deficiency**: Dihydropyrimidine dehydrogenase (DPD) is responsible for the first step in pyrimidine degradation. Deficiency leads to elevated uracil and thymine in blood/urine.  
3. **Neurological Symptoms**: **Ataxia**, **lethargy**, **drowsiness**, and **generalized hypotonia** align with neurotoxicity caused by excess pyrimidines or their metabolites disrupting CNS function.  
4. **Severe Infantile Presentation**: **Death in infancy** and **sleep disturbance** are consistent with severe neonatal-onset forms of the disorder, where metabolic crises and neurological decline are common.  
5. **Confirmatory Biomarkers**: The combination of uraciluria and abnormal pyrimidine levels is pathognomonic for DPD deficiency, distinguishing it from other metabolic disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Select inappropriate statement regarding Cholera
Choices:
A. Incubation period 1-2 days
B. Rice - watery diarrhoea
C. Azithromycin is treatment of choice in adults
D. It is a notifiable disease locally, nationally and internationally
Answer: [/INST] Azithromycin is treatment of choice in adults </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Drug of choice for Falciparum Malaria is
Choices:
A. Chloroquine
B. Mefloquine
C. ACT
D. Proguanil
Answer: [/INST] ACT </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: 40 years old Bank officer was told to be having illeocecal Tuberculosis (Bovine after thorough investigation. He told the physician that he had no body infected with tuberculosis in the family, but he was told by the Doctor that he acquired this infection from
Choices:
A. Infected milk
B. Infected client
C. Contaminated vessel
D. Polluted water
Answer: [/INST] Infected milk </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about meningococcal Meningitis -
Choices:
A. Case fatality less than 10% in untreated cases
B. Cases are the main source of infection
C. Rifampicin is the drug of choice
D. Treatment in the first 2 days can save the life of 95% cases
Answer: [/INST] Treatment in the first 2 days can save the life of 95% cases </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Elevated circulating glutaric acid concentration', 'Recurrent viral infections', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Elevated glutaric acid and glutaric aciduria**: Direct biochemical markers of glutaryl-CoA dehydrogenase deficiency, which disrupts lysine and tryptophan metabolism.  
2. **Generalized hypotonia and feeding difficulties**: Common early signs of metabolic decompensation due to toxic metabolite accumulation.  
3. **Athetosis**: Reflects basal ganglia injury (e.g., striatal necrosis) from acute encephalopathic crises triggered by metabolic stressors like infections or fasting.  
4. **Death in infancy**: Untreated GA-I leads to irreversible neurological damage or fatal metabolic crises.  
5. **Recurrent viral infections**: Likely act as triggers for metabolic decompensation rather than indicating primary immune dysfunction.  
6. **Consistency with GA-I phenotype**: Macrocephaly, movement disorders, and episodic crises align with classic GA-I presentation, though immune dysfunction is not a core feature. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Glutaric aciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I; GA-I/Glutaryl-CoA dehydrogenase deficiency/Glutaric acidemia I  
Reasoning:  
1. **Glutaric aciduria** is pathognomonic for GA-I, caused by deficient glutaryl-CoA dehydrogenase, leading to toxic accumulation of glutaric acid.  
2. **Neonatal death** and **death in infancy** align with severe GA-I phenotypes, where absent enzyme activity triggers acute metabolic crises (e.g., acidosis, encephalopathy) shortly after birth.  
3. GA-I’s biochemical hallmark—elevated urinary glutaric acid—directly correlates with the symptom list, excluding other organic acidurias (e.g., propionic/methylmalonic acidemia) that present with distinct metabolites.  
4. Early lethality in untreated cases supports this diagnosis, as delayed management exacerbates neurotoxicity and multisystem failure. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A pregnant mother presents with history of delivery of a previous child with Congenital Adrenal Hyperplasia (CAH). The best management protocol for the current pregnancy is:
Choices:
A. To sta prednisolone after establishing whether fetus is affected by Chorionic Villous Sampling
B. To sta dexamethasone as soon as pregnancy is confirmed
C. To sta dexamethasone after determining sex of the fetus by Karyotyping
D. To sta prednisolone after determining sex of the fetus with USG
Answer: [/INST] To sta dexamethasone as soon as pregnancy is confirmed </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria predominantly cause which type of nephrotic syndrome
Choices:
A. MPGN
B. Membranous
C. FSGS
D. Minimal change disease
Answer: [/INST] MPGN </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperhidrosis', 'Death in infancy', 'Cardiomyopathy', 'Cardiomegaly', 'Hypotension', 'Tachypnea', 'Aminoaciduria', 'Death in childhood', 'Abnormal circulating glycine concentration', 'Feeding difficulties', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning:  
1. **Aminoaciduria and elevated urinary carboxylic acids** align with impaired leucine catabolism due to 3-MCC deficiency, leading to accumulation of 3-methylcrotonyl-CoA and derivatives like 3-hydroxyisovaleric acid.  
2. **Cardiomyopathy/Cardiomegaly** may result from energy deficiency in cardiac tissue due to disrupted mitochondrial fatty acid oxidation and ketogenesis.  
3. **Hypotension/Tachypnea** suggests metabolic acidosis, a hallmark of organic acidemias, triggering respiratory compensation.  
4. **Feeding difficulties/Hyperhidrosis** are nonspecific but common in metabolic crises from toxic metabolite buildup.  
5. **Death in infancy/childhood** reflects severe metabolic decompensation episodes typical in untreated 3-MCC deficiency.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency (general)  
Reasoning:  
1. **Abnormal circulating glycine concentration** (secondary to glycine conjugation with accumulated metabolites) and **aminoaciduria** are biochemical hallmarks of this disorder.  
2. **Elevated urinary carboxylic acids** (e.g., 3-methylcrotonylglycine) directly indicate a block in 3-MCC enzyme activity.  
3. **Cardiac manifestations** (cardiomyopathy, cardiomegaly) stem from disrupted energy production and possible secondary carnitine depletion.  
4. **Early mortality** correlates with acute metabolic crises triggered by catabolic stressors (e.g., infections, fasting), common in this autosomal recessive disorder.  
5. Overlap with subtype 1 deficiency is expected, as MCCC1 gene mutations account for the majority of 3-MCC deficiency cases. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperreflexia', 'Lower limb spasticity', 'Spastic ataxia', 'Diffuse cerebral atrophy', 'Ankle clonus']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Hyperreflexia** and **ankle clonus** indicate upper motor neuron dysfunction, consistent with hereditary spastic paraplegias (HSPs).  
2. **Lower limb spasticity** is a hallmark of HSPs, reflecting corticospinal tract degeneration.  
3. **Spastic ataxia** suggests combined pyramidal (spasticity) and cerebellar (ataxia) involvement, aligning with SPG76’s phenotypic overlap between HSP and spinocerebellar ataxia.  
4. **Diffuse cerebral atrophy** supports a complex HSP subtype, as SPG76 (linked to *CAPN1* mutations) often involves cerebellar and cerebral degeneration.  
5. Autosomal recessive inheritance matches SPG76’s genetic pattern, distinguishing it from dominant HSPs or other ataxias with similar features (e.g., SPG11/SPG15 may also show atrophy but typically include additional manifestations like neuropathy or retinopathy).  
6. Symptom triad (spasticity, ataxia, cerebral atrophy) and exclusion of mimics confirm SPG76. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteomyelitis of spine is caused by most common organism ?
Choices:
A. Staphylococcus aureus
B. Pseudomonas
C. Tuberculosis
D. Streptococcus
Answer: [/INST] Staphylococcus aureus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Apathy', 'Death in infancy', 'Oroticaciduria', 'Neonatal death', 'Feeding difficulties', 'Sepsis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Argininosuccinic aciduria  
Reasoning:  
1. **Urea Cycle Dysfunction**: Argininosuccinic aciduria is a urea cycle disorder (UCD) caused by argininosuccinate lyase deficiency, impairing ammonia detoxification.  
2. **Hyperammonemia Manifestations**: Neonatal death, feeding difficulties, and apathy align with hyperammonemia-induced encephalopathy and multi-organ failure.  
3. **Oroticaciduria**: Accumulated carbamoyl phosphate shunts into pyrimidine synthesis, producing excess orotic acid, a hallmark of proximal UCDs.  
4. **Sepsis Mimicry**: Hyperammonemia in UCDs often mimics sepsis due to lethargy, vomiting, and metabolic instability, delaying correct diagnosis.  
5. **Early Lethality**: Severe UCDs like argininosuccinic aciduria typically present neonatally with rapid deterioration, explaining infant mortality without prompt treatment.  
6. **Biochemical Confirmation**: Elevated argininosuccinic acid in blood/urine and genetic testing would definitively confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma arises from:
Choices:
A. Layer of rods and cones
B. Layer of bipolar cells
C. Ganglion cells layers
D. Any nucleated retinal layer
Answer: [/INST] Any nucleated retinal layer </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A child with Acute Myeloid Leukemia presents with hyperleukocytosis. Treatment includes all of the following except ?
Choices:
A. IV fluid
B. Allopurinol
C. Alkalinization
D. Immediately sta induction chemotherapy
Answer: [/INST] Immediately sta induction chemotherapy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia with hypeension is seen in?
Choices:
A. Bater syndrome
B. Primary hyperaldosteronism
C. Primary hyperparathyroidism
D. Diuretic therapy
Answer: [/INST] Primary hyperaldosteronism </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cerebellar atrophy', 'Failure to thrive', 'Death in infancy', 'Thromboembolism', 'Neonatal death', 'Cerebellar agenesis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PMM2-CDG/Congenital disorder of glycosylation, type Ia  
Reasoning:  
1. **Cerebellar atrophy/agenesis**: PMM2-CDG commonly causes cerebellar hypoplasia or atrophy due to impaired protein glycosylation, critical for cerebellar development.  
2. **Failure to thrive**: A hallmark of PMM2-CDG, resulting from multisystem dysfunction (e.g., gastrointestinal, hepatic, endocrine) disrupting nutrient absorption and metabolism.  
3. **Thromboembolism**: Glycosylation defects impair coagulation factor synthesis (e.g., antithrombin III, protein C/S), predisposing to thrombotic events.  
4. **Neonatal death/Death in infancy**: Severe PMM2-CDG cases often lead to early mortality due to organ failure, metabolic crises, or recurrent infections.  
5. **Consistency with type Ia**: PMM2-CDG (type Ia) is the most prevalent subtype, characterized by neurologic deficits, coagulopathy, and infantile lethality in severe presentations.  
The constellation of neurologic, growth, and coagulation abnormalities strongly aligns with PMM2-CDG-Ia, confirmed by genetic testing for *PMM2* mutations. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Elevated phenylalanine levels are a hallmark of PKU due to deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Neonatal death/Death in infancy**: Untreated PKU causes severe neurological damage, seizures, and failure to thrive. Without early dietary intervention (e.g., phenylalanine-restricted diet), progressive toxicity can lead to fatal complications.  
3. **Abnormality of prenatal development**: Likely reflects **maternal PKU syndrome**, where high maternal phenylalanine levels during pregnancy disrupt fetal development (e.g., congenital heart defects, microcephaly). While the infant’s own PKU does not cause prenatal abnormalities, maternal PKU explains this symptom.  
4. **Diagnostic confirmation**: PKU is confirmed via newborn screening (elevated phenylalanine, normal tetrahydrobiopterin levels). Untreated cases align with the clinical trajectory of early morbidity/mortality.  

Note: Maternal PKU syndrome and infant PKU are distinct but interrelated; the infant’s symptoms arise from both inherited PAH deficiency and maternal metabolic environment during gestation. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary Hyperparathyroidism is associated with -
Choices:
A. Increased serum PTH and Hypercalcemia
B. Decreased serum PTH and Hypercalcemia
C. Increased serum PTH and Hyporcalcemia
D. Decreased serum PTH and Hyporcalcemia
Answer: [/INST] Increased serum PTH and Hypercalcemia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about revised National Tuberculosis programme (NTP) – a) Active case findingb) DOTS appliedc) Treatment is given only in smear positive casesd) General practitioners are restricted to give the treatmente) It has replaced NTP
Choices:
A. ab
B. ad
C. be
D. ce
Answer: [/INST] be </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cystinuria is associated with excretion of which amino acid in urine
Choices:
A. Cystine, lysine, Tyrosine and alanine
B. Cystine, lysine, ornithine and alanine
C. Cystine, ornithine, lysine and arginine
D. Cystine, ornithine, leucine and arginine
Answer: [/INST] Cystine, ornithine, lysine and arginine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles is infective for:
Choices:
A. One day before and 4 days after rash
B. Four days before and five days after rash
C. Entire incubation period
D. Only during scabs falling
Answer: [/INST] Four days before and five days after rash </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Leprosy, most common renal lesion seen is -
Choices:
A. MGN
B. MPGN
C. Focal glomerulosclerosis
D. Diffuse glomerulosclerosis
Answer: [/INST] MGN </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is seen in which of the following infections-
Choices:
A. Chicken pox
B. Mumps
C. Diarrhoea
D. Measles
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Congenital Rubella syndrome is
Choices:
A. It will become a chronic infection
B. Virus can be isolated only upto 6months after bih
C. Triad of CRS are cataract, cardiac defects, cerebral palsy
D. Infection is most serious after five months of pregnancy
Answer: [/INST] It will become a chronic infection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal saccadic eye movements', 'Lethargy', 'Spasticity', 'Death in infancy', 'Bradycardia', 'Hyperammonemia', 'Vomiting', 'Apnea', 'Drowsiness', 'Sleep disturbance', 'Hyperglutaminemia', 'Oroticaciduria', 'Low plasma citrulline', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Carbamoyl-phosphate synthetase 1 deficiency/Carbamoyl phosphate synthetase I deficiency, hyperammonemia due to  
Reasoning:  
1. **Hyperammonemia** and **hyperglutaminemia** are hallmark features of urea cycle disorders (UCDs), indicating impaired ammonia detoxification.  
2. **Low plasma citrulline** localizes the defect to the first two steps of the urea cycle (CPS1 or OTC deficiency), as citrulline is synthesized downstream.  
3. **Neonatal death** and **lethargy/drowsiness** align with severe, early-onset UCDs like CPS1 deficiency, which often presents catastrophically in infancy.  
4. **Vomiting**, **apnea**, and **spasticity** reflect acute neurological toxicity from hyperammonemia.  
5. **Oroticaciduria** is atypical for CPS1 deficiency (classically seen in OTC deficiency) but may occur due to secondary pyrimidine pathway dysregulation or overlapping metabolic stress in severe hyperammonemia.  
6. **Abnormal saccadic eye movements** and **sleep disturbances** suggest chronic CNS injury from ammonia accumulation.  
7. **Bradycardia** and **death in infancy** underscore the systemic metabolic crisis typical of untreated CPS1 deficiency.  
8. While **oroticaciduria** raises consideration of OTC deficiency, the absence of elevated citrulline and the constellation of neonatal lethality strongly favor CPS1 deficiency as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['High palate', 'Long philtrum', 'Low-set ears', 'Congenital hypothyroidism', 'Hirsutism', 'Death in infancy', 'Polyhydramnios', 'Dysphagia', 'Poor suck', 'Limb hypertonia', 'Central apnea', 'Short nose', 'Bilateral single transverse palmar creases', 'Bilateral microphthalmos', 'Feeding difficulties in infancy', 'Axial hypotonia', 'Intracranial cystic lesion', 'Feeding difficulties', 'Fetal distress', 'Abnormality of fundus pigmentation', 'Abnormality of movement', 'Postaxial polydactyly']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: PLAA-associated neurodevelopmental disorder/Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies  
Reasoning:  
1. **Neurodevelopmental and Brain Anomalies**: Symptoms like *intracranial cystic lesions* and *central apnea* indicate structural brain abnormalities and brainstem dysfunction, aligning with the disease’s hallmark brain anomalies.  
2. **Axial Hypotonia and Limb Hypertonia**: The combination of *axial hypotonia* (trunk weakness) and *limb hypertonia* reflects progressive spasticity, a core feature of PLAA-associated disorder.  
3. **Feeding and Swallowing Issues**: *Dysphagia*, *poor suck*, and *feeding difficulties in infancy* correlate with neurological impairment and are consistent with early-onset neurodevelopmental deficits.  
4. **Congenital Dysmorphisms**: Features like *high palate*, *long philtrum*, *bilateral microphthalmos*, and *postaxial polydactyly* suggest multisystem involvement, often seen in genetic neurodevelopmental syndromes.  
5. **Perinatal Complications**: *Polyhydramnios* (due to impaired fetal swallowing) and *fetal distress* are linked to in utero neurological dysfunction, supporting a congenital etiology.  
6. **Severe Prognosis**: *Death in infancy* and *central apnea* underscore the disorder’s severity, typical of PLAA mutations causing progressive neurological decline.  
7. **Overlap with Known Features**: While *congenital hypothyroidism* and *hirsutism* are less typical, they may represent phenotypic variability or secondary endocrine dysregulation in severe multisystem disorders. Genetic testing for PLAA mutations would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Patients with 'Hemophilia A' have bleeding disorder because of -
Choices:
A. Lack of platelet aggregation
B. Lack of reaction accelerator during activation of factor X in coagulation cascade
C. Neutralization of antithrombin III
D. Release of Thromboxane A2
Answer: [/INST] Lack of reaction accelerator during activation of factor X in coagulation cascade </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Disease(s) transmitted by Aedes aegypti include – a) Yellow feverb) Denguec) Chikungunya feverd) West Nile fever e) Rift valley fever
Choices:
A. bcde
B. abcd
C. acde
D. abce
Answer: [/INST] abce </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Vascular involvement and thrombosis is seen in -a) Coccidioidomycosisb) Aspergillosisc) Mucormycosisd) Histoplasmosis
Choices:
A. a
B. bc
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine is prepared from:-
Choices:
A. Street viral strain
B. Fixed viral strain
C. Wild viral strain
D. Any of the above
Answer: [/INST] Fixed viral strain </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common presentation of Renal Tuberculosis is:
Choices:
A. Renal colic
B. Sterile Pyuria
C. Intractable urgency
D. Painful micturition
Answer: [/INST] Sterile Pyuria </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya has spread widely from Asia and Africa into the Caribbean in recent years. This has been mainly facilitated by:? 
Choices:
A. Mutation in the virus allowing replication in the mosquito Aedes albopictus
B. Air Travel
C. Climate change
D. Poor mosquito control and the absence of DTT
Answer: [/INST] Mutation in the virus allowing replication in the mosquito Aedes albopictus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Confirmatory test for the diagnosis ofAmyloidosis is?
Choices:
A. Diagnostic peritoneal lavage
B. Tongue biopsy
C. Rectal biopsy
D. Whole body CT scan
Answer: [/INST] Rectal biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The immunoglobulin least commonly involved in Multiple Myeloma is:
Choices:
A. IgG
B. IgM
C. IgA
D. IgD
Answer: [/INST] IgD </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: CLL is differentiated from Mantle Cell Lymphoma by
Choices:
A. CD 5
B. CD 17
C. CD22
D. CD 23
Answer: [/INST] CD 23 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acute Infective Endocarditis with abscess formation is most common associated with -
Choices:
A. Listeria
B. Staphylococcus
C. Streptococcus
D. Enterococcus
Answer: [/INST] Staphylococcus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of the genitourinary system', 'Abnormality of the nervous system', 'Growth delay', 'Pancytopenia', 'Immunodeficiency', 'Bone marrow hypocellularity', 'Short telomere length']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Ataxia-pancytopenia syndrome (APS):  
- **Pancytopenia & bone marrow hypocellularity**: Core features of APS, reflecting bone marrow failure.  
- **Nervous system abnormality**: Likely cerebellar ataxia, a hallmark of APS.  
- **Short telomere length**: APS is linked to germline SAMD9/SAMD9L mutations, which disrupt telomere stability.  
- **Immunodeficiency**: Bone marrow failure predisposes to recurrent infections.  
- **Growth delay & genitourinary anomalies**: Seen in APS due to systemic effects of telomere dysfunction and/or SAMD9L-related developmental defects.  
- **Exclusion of mimics**: Dyskeratosis congenita (similar telomere defects but mucocutaneous triad absent), Fanconi anemia (chromosomal breaks typical, not seen here). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following drugs cannot be used in patient with Multi drug resistant Tuberculosis?
Choices:
A. Ciprofloxacin
B. Tobramycin
C. Clarithromycin
D. Amikacin
Answer: [/INST] Tobramycin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Glioblastoma multiforme may occur in the following except -
Choices:
A. Cerebrum of adult
B. Brain stem of child
C. Spinal cord of adult
D. Adrenal medulla of child
Answer: [/INST] Adrenal medulla of child </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Gingival overgrowth', 'Nystagmus', 'Dystonia', 'Respiratory failure', 'Cerebellar vermis atrophy', 'Poor gross motor coordination', 'Reduced visual acuity', 'Infantile muscular hypotonia', 'Cognitive impairment']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: NKX6-2-related autosomal recessive hypomyelinating leukodystrophy/Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy  
Reasoning:  
1. **Neurological and Motor Symptoms**: The patient exhibits **cerebellar vermis atrophy**, **poor gross motor coordination**, **nystagmus**, and **dystonia**, consistent with cerebellar dysfunction and spastic ataxia, hallmark features of NKX6-2-related disorders.  
2. **Hypomyelination Evidence**: **Cognitive impairment**, **reduced visual acuity** (optic nerve hypomyelination), and **respiratory failure** (brainstem involvement) align with progressive hypomyelinating leukodystrophy.  
3. **Developmental History**: **Infantile muscular hypotonia** often precedes spasticity in early disease stages.  
4. **Uncommon Features**: **Gingival overgrowth** is atypical but may represent a phenotypic variant or secondary effect of chronic neurological dysfunction.  
5. **Genetic Correlation**: NKX6-2 mutations disrupt oligodendrocyte function, causing hypomyelination, cerebellar atrophy, and motor deficits, strongly matching the symptom profile. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Prolactinoma in pregnancy, all are true except -
Choices:
A. Most common pituitary tumor but rarely symptomatic
B. Increase in prolactin levels worse prognosis
C. Macroadenoma > 1 cm is associated with bad prognosis
D. Regular visual checkup
Answer: [/INST] Macroadenoma > 1 cm is associated with bad prognosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Death in childhood', 'Recurrent viral infections', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, leading to toxic phenylalanine accumulation.  
2. **Death in infancy/childhood** aligns with untreated PKU, as elevated phenylalanine causes irreversible neurotoxicity, seizures, and failure to thrive.  
3. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low due to blocked PAH activity). This may suggest a secondary metabolic disturbance, comorbid tyrosinemia, or misdiagnosis of lab values.  
4. **Recurrent viral infections** are not characteristic of PKU and could indicate an unrelated immune disorder or complications from metabolic instability (e.g., malnutrition).  
5. The diagnosis prioritizes hyperphenylalaninemia and early lethality as primary PKU indicators, while acknowledging inconsistencies (hypertyrosinemia, infections) that warrant further investigation for overlapping disorders. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Q fever -
Choices:
A. Rash on palms and soles, headache and fever are common symptoms
B. Transmitted by human body louse
C. Inhaled acrosols spread the infection
D. Mosquito bite prevention is impoant in prevention
Answer: [/INST] Inhaled acrosols spread the infection </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Regarding Listeriosis in pregnancy, which of the following is false?
Choices:
A. Cause 2nd trimester loss
B. Infection on drinking raw milk
C. Symptoms occur after 3 days of exposure
D. Leads to granulomatosisinfantiseptica
Answer: [/INST] Symptoms occur after 3 days of exposure </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Eczematoid dermatitis', 'Skin rash', 'Seizure', 'Lethargy', 'Death in infancy', 'Constipation', 'Respiratory insufficiency', 'Drowsiness', 'Sleep disturbance', 'Ethylmalonic aciduria', 'Cytochrome C oxidase-negative muscle fibers', 'Abnormal circulating glycine concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Mitochondrial complex IV deficiency, nuclear type 1:  
The patient exhibits **ethylmalonic aciduria** and **cytochrome C oxidase (COX)-negative muscle fibers**, which are hallmark biochemical and histopathological findings in mitochondrial complex IV deficiency. This disorder disrupts oxidative phosphorylation, leading to energy depletion in high-demand tissues. **Seizures**, **lethargy**, **drowsiness**, and **respiratory insufficiency** reflect neurological and systemic metabolic dysfunction. **Death in infancy** aligns with severe infantile-onset forms of the disease. **Abnormal circulating glycine concentration** may arise from secondary metabolic disturbances due to impaired mitochondrial function. **Skin rash** and **eczematoid dermatitis** are nonspecific but recurrent in mitochondrial disorders due to oxidative stress and inflammation. **Constipation** and **sleep disturbance** correlate with autonomic nervous system involvement. The collective presentation of multi-organ failure, metabolic acidosis (implied by ethylmalonic aciduria), and COX deficiency confirms the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rabies vaccine Pre exposure prophylaxis schedule is:
Choices:
A. 0,3,7
B. 0,7,28
C. 0,3,7,28
D. 0,3,7,21,28
Answer: [/INST] 0,7,28 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are features of SVC Syndrome except -
Choices:
A. Facial swelling
B. Dilatation and congestion of neck veins
C. Headache
D. Hoarseness of voice
Answer: [/INST] Hoarseness of voice </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True regarding Leprosy
Choices:
A. Any positive smear 1+ is MBL
B. MBL recommended treatment for 12 months duration
C. Grenz zone in Lepromatous spectrum
D. All deformity cases are MBL
Answer: [/INST] MBL recommended treatment for 12 months duration </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cysticercosis present as : a)  Seizuresb)  Neuropathyc)  Encephalitisd)  Muscular hypertrophy
Choices:
A. a
B. bc
C. ac
D. b
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: False about transmission of Rubella ?
Choices:
A. Droplet infection
B. Veical transmission
C. Infection in early pregnancy causes milder disease
D. Fetus affected in late pregnancy may have only deafness
Answer: [/INST] Infection in early pregnancy causes milder disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A 59-year-old male came with Hb 18.0 gm/dl on three occasions. The resident doctor wants to exclude Polycythemia Vera. Which of the following is the most relevant investigation -
Choices:
A. Hematocrit
B. Total leukocyte count
C. Red cell mass
D. Reticulocyte count
Answer: [/INST] Red cell mass </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU;/Phenylketonuria/Phenylketonuria  
Reasoning:  
1. **Hyperphenylalaninemia** is the defining biochemical feature of PKU, caused by mutations in the *PAH* gene, leading to impaired phenylalanine metabolism.  
2. **Abnormality of prenatal development or birth** may occur in maternal PKU syndrome, where elevated phenylalanine levels during pregnancy cause congenital anomalies (e.g., microcephaly, cardiac defects) in the fetus. If the patient is the affected infant, this could reflect intrauterine growth restriction due to metabolic dysregulation.  
3. **Neonatal death/Death in infancy**: Untreated PKU does not typically cause death in the neonatal period, but severe variants (e.g., BH4-deficient PKU) or complications like metabolic crises/sepsis in undiagnosed cases may lead to early mortality.  
4. **Death in early adulthood**: Chronic untreated hyperphenylalaninemia results in irreversible neurological damage, seizures, and systemic complications (e.g., osteoporosis, cardiomyopathy), which may contribute to premature death if dietary management is absent.  

The constellation of symptoms aligns with a severe, untreated PKU phenotype, exacerbated by lack of newborn screening or therapy, progressing from infancy to adulthood with fatal outcomes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Where are the deposits found in IgA Nephropathy-
Choices:
A. Subepithelial
B. Subendocardial
C. Mesangium
D. No deposists
Answer: [/INST] Mesangium </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which parasite causes Cholangiocarcinoma
Choices:
A. Fasciola hepatica
B. Fasciola buski
C. Clonorchis sinensis
D. Paragonimus westermani
Answer: [/INST] Clonorchis sinensis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is used to treat Alkaptonuria?
Choices:
A. Vitamin A
B. Vitamin C
C. Vitamin D
D. Vitamin K
Answer: [/INST] Vitamin C </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin binds to which receptors in intestine-
Choices:
A. Sphingosine through A subunit
B. Sphingosine through B subumit
C. GM1 gangliosides through A subunit
D. GM1 gangliosides through B subunit
Answer: [/INST] GM1 gangliosides through B subunit </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which is the most active single chemotherapeutic agent in the treatment of Leiomyosarcoma -
Choices:
A. Adriamycin
B. Doxorubicin
C. Methotrexate
D. b or a
Answer: [/INST] b or a </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In Rabies, the characterstic pathological manifestation is -
Choices:
A. Ventriculitis
B. Brainstem encephalitis
C. Basal ganglia affection
D. Meningitis
Answer: [/INST] Brainstem encephalitis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Resistance to drugs in Tuberculosis develops by -
Choices:
A. Transduction
B. Conjugution
C. Transformation
D. Mutation
Answer: [/INST] Mutation </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Anthrax bacilli differs from anthracoid bacilli by being -
Choices:
A. Non-capsulated
B. Strict aerobe
C. Non-motile
D. Haemolytic colonies on blood agar
Answer: [/INST] Non-motile </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Congenital Rubella Syndrome has all of the following EXCEPT:
Choices:
A. Sensorineural deafness
B. Cataract
C. Cardiac Defects
D. Hydrocephalus
Answer: [/INST] Hydrocephalus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Polycythemia Vera is characterized by all, EXCEPT:
Choices:
A. Bleeding
B. Increased viscosity of blood
C. Splenomegaly
D. None of the above
Answer: [/INST] Bleeding </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma is associated with -
Choices:
A. Osteosarcoma
B. Hepatocellularca
C. SCC
D. Osteoclastoma,
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Decreased methylmalonyl-CoA mutase activity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Methylmalonic acidemia; MMA; Methylmalonic aciduria  
Reasoning: Metabolic acidosis is a hallmark of methylmalonic acidemia (MMA), an inborn error of metabolism caused by impaired degradation of methylmalonyl-CoA. Death in infancy aligns with severe MMA presentations, where toxic metabolite accumulation leads to rapid clinical deterioration.  

Disease: Vitamin B12-unresponsive methylmalonic acidemia/Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency  
Reasoning: Decreased methylmalonyl-CoA mutase activity directly indicates a defect in the MUT gene encoding this enzyme, which is required for methylmalonyl-CoA isomerization. Vitamin B12-unresponsive MMA is confirmed because mutase deficiency bypasses the B12-dependent pathway (defects in B12 metabolism or transport would retain some residual enzyme activity with B12 supplementation). The triad of symptoms strongly supports this specific genetic subtype. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is used in the treatment of Multiple Sclerosis:
Choices:
A. Interferon Alpha
B. Interferon Beta
C. Infliximab
D. Interferon gamma
Answer: [/INST] Interferon Beta </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is deficiency of which factor:September 2007
Choices:
A. IX
B. XII
C. VIII
D. X
Answer: [/INST] IX </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Nystagmus', 'Pancytopenia', 'Bone marrow hypocellularity']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Ataxia-Pancytopenia Syndrome  
Reasoning: The triad of nystagmus (indicative of cerebellar dysfunction/ataxia), pancytopenia, and bone marrow hypocellularity aligns with Ataxia-Pancytopenia Syndrome (APS). APS is a rare genetic disorder characterized by bone marrow failure (hypocellularity and pancytopenia) and neurological manifestations like ataxia, often accompanied by nystagmus. The absence of typical features of other marrow failure syndromes (e.g., physical anomalies in Fanconi anemia or hypercellular marrow in myelodysplastic syndromes) further supports this diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most Common presentation of Multiple Sclerosis is
Choices:
A. Optic neurosis
B. Intemuclear ophthalmoplegia
C. Transverse myelitis
D. Clinically isolated syndrome
Answer: [/INST] Clinically isolated syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Management of a newborn when Mother has active Tuberculosis & is taking ATT –
Choices:
A. BCG + Rifampicin + INH + Breast Feeding
B. BCG + Isolation of baby
C. BCG + INH for 6 week + Breast Feeding
D. BCG – F 1NH + with hold Breast Feeding
Answer: [/INST] BCG + INH for 6 week + Breast Feeding </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Urticaria', 'Arthritis', 'Fever', 'Abnormal EKG', 'Supraventricular arrhythmia', 'Bilateral sensorineural hearing impairment', 'Elevated circulating C-reactive protein concentration', 'Panic attack', 'Knee pain']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Muckle-Wells syndrome/Muckle-Wells syndrome  
Reasoning: The patient presents with **urticaria**, **arthritis**, **fever**, **bilateral sensorineural hearing impairment**, and **elevated CRP**, which are hallmark features of Muckle-Wells syndrome (MWS). MWS, a cryopyrin-associated periodic syndrome (CAPS), is characterized by recurrent inflammatory episodes, systemic inflammation, and progressive hearing loss. The **supraventricular arrhythmia** and **abnormal EKG** may reflect secondary cardiac inflammation or amyloidosis, a known complication of untreated MWS. **Panic attacks** could arise from chronic stress or autonomic dysfunction linked to systemic inflammation. Other conditions like FCAS (cold-triggered, no hearing loss) or TRAPS (migratory rashes, no deafness) lack key features seen here. CINCA syndrome involves severe neurological involvement (absent in this case). The triad of urticaria, arthritis, and sensorineural deafness strongly supports MWS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A patient with which of the follwing disease is predisposed to develop osteosarcoma -a)  Osteomalaciab)  Osteomyelitisc)  Paget's disease of boned)  Osteopetrosis
Choices:
A. a
B. c
C. bc
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Susceptible cultured cells infected with which of the following viruses would exhibit hemadsorption with the appropriate erythocyte -a) Sindbis virusb) Rabies virusc) Measles virusd) Respiratory syncytial virus
Choices:
A. a
B. c
C. bc
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Aminoaciduria', 'Neonatal death', 'Abnormal circulating glycine concentration', 'Abnormal circulating carnitine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-Methylcrotonyl-CoA carboxylase 1 deficiency  
Reasoning: The symptoms of aminoaciduria, abnormal glycine/carnitine levels, and elevated urinary carboxylic acids stem from impaired leucine metabolism due to MCCC1 gene mutations. This disrupts 3-MCC enzyme activity, causing toxic metabolite accumulation (e.g., 3-hydroxyisovaleric acid). Carnitine depletion occurs as it conjugates with metabolites for excretion, while glycine abnormalities may arise from compensatory detoxification. Severe enzyme deficiency leads to metabolic crises, explaining neonatal/infant mortality.  

Disease: 3-methylcrotonyl-CoA carboxylase deficiency  
Reasoning: This condition, often linked to MCCC2 gene mutations, similarly disrupts the 3-MCC enzyme complex. Leucine catabolism failure results in elevated urinary carboxylic acids (e.g., 3-methylcrotonylglycine). Secondary carnitine deficiency and glycine irregularities align with metabolic compensation mechanisms. Neonatal death or infant mortality reflects acute metabolic decompensation in severe, untreated cases. Both MCCC1 and MCCC2 defects share clinical features but involve distinct genetic subunits of the same enzyme. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera is caused by-
Choices:
A. V.cholerae O1
B. V.cholerae O1 and O139
C. V. cholerae O139
D. NAG vibrios
Answer: [/INST] V.cholerae O1 and O139 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial relapse is seen in -
Choices:
A. P. falciparum and P.vivax
B. P. falcipamm and P. malariae
C. P. ovale and P. malariae
D. ) P. vivax and P. ovale
Answer: [/INST] P. ovale and P. malariae </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The following vaccine, if contaminated can cause Toxic Shock Syndrome (TSS) -
Choices:
A. Measles vaccine
B. DPT
C. Hepatitis B
D. Typhoral
Answer: [/INST] Measles vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: The most common manifestation of moderate /severe Hemophilia A is:
Choices:
A. Recurrent Hemahrosis
B. Recurrent muscle bleeding
C. Recurrent bleeding from gums
D. Recurrent Hematuria
Answer: [/INST] Recurrent Hemahrosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy commonly spreads by -
Choices:
A. Milk
B. Droplet
C. Water
D. Mosquitoes
Answer: [/INST] Droplet </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in infancy', 'Neonatal death', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maple syrup urine disease (MSUD)  
Reasoning: The combination of seizures, neonatal death or death in infancy, and elevated urinary carboxylic acids strongly suggests a severe inborn error of branched-chain amino acid (BCAA) metabolism. MSUD is caused by deficient activity of the branched-chain α-keto acid dehydrogenase complex, leading to accumulation of leucine, isoleucine, valine, and their corresponding α-keto acids (branched-chain carboxylic acids) in bodily fluids. Elevated urinary carboxylic acids reflect this biochemical signature. Neonatal presentation with metabolic decompensation (e.g., seizures, encephalopathy) and rapid progression to lethality without intervention aligns with the classic form of MSUD. Early diagnosis via newborn screening or urinary organic acid analysis is critical, as delayed treatment results in irreversible neurological damage or death. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is true about Diphtheria except-a) Faucial diphtheria is more dangerous than laryngeal diphtheriab) Laryngeal diphtheria mandates tracheotomyc) Child is more toxic with faucial diphtheriad) Myocarditis may be a complicatione) Palatal paralysis is irreversible
Choices:
A. abc
B. bcd
C. abe
D. acd
Answer: [/INST] abe </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: X-rays findings of ""Fibrous Dysplasia"" is:
Choices:
A. Ground glass density
B. Calcifications
C. Coical thickening
D. Bony expansion
Answer: [/INST] Ground glass density </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia** is the hallmark of PKU, caused by deficient phenylalanine hydroxylase (PAH) activity, preventing phenylalanine conversion to tyrosine.  
2. **Hypertyrosinemia** is atypical in classic PKU (where tyrosine is typically low/normal). This may indicate a transient neonatal tyrosinemia, a co-occurring metabolic disorder, or potential misreporting of lab results.  
3. **Abnormality of prenatal development or birth** aligns with maternal PKU syndrome (if the mother had untreated PKU during pregnancy), causing congenital anomalies in the infant.  
4. **Neonatal death/Death in infancy** suggests severe metabolic derangement if untreated. Untreated PKU can lead to progressive neurologic damage, seizures, and fatal complications, though neonatal death is rare unless compounded by other factors (e.g., maternal PKU effects).  
5. PKU is prioritized due to **hyperphenylalaninemia**, the most specific symptom. Conflicting hypertyrosinemia warrants further investigation (e.g., BH4 deficiency or tyrosinemia), but the core presentation fits PKU as the primary diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Boiled cabbage or rancid butter smelling urine is seen in Phenylketonuria
Choices:
A. Tyrosinemia
B. Isovaleric Acidaemia
C. Multiple carboxylase deficiency
D. Phenylketonuria
Answer: [/INST] Tyrosinemia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rhinocerebral Mucormycosis is present with:
Choices:
A. Broad spectrum antibiotic use
B. Pregnancy
C. Diabetic ketoacidosis
D. Renal tubular acidosis
Answer: [/INST] Diabetic ketoacidosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Dermatomyositis is?
Choices:
A. Associated with HLA B27
B. Bimodal age distribution
C. No involvement of joints
D. Myopathy precedes skin lesions in most cases
Answer: [/INST] Bimodal age distribution </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mode of transmission of Q fever is -
Choices:
A. Bite of infected louse
B. Bite of infected tick
C. Inhalation of aerosol
D. Bite of infected mite
Answer: [/INST] Inhalation of aerosol </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Metabolic acidosis', 'Fever', 'Hyperammonemia', 'Vomiting', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Abnormal circulating glycine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Metabolic acidosis and hyperammonemia**: Central features of HMG-CoA lyase deficiency, caused by impaired leucine catabolism and ketogenesis, leading to toxic accumulation of 3-hydroxy-3-methylglutaric acid and secondary urea cycle disruption.  
2. **Dicarboxylic aciduria and 3-methylglutaric aciduria**: Pathognomonic urinary biomarkers due to defective HMG-CoA lyase activity, which prevents cleavage of HMG-CoA into acetoacetate and acetyl-CoA, resulting in excretion of these metabolites.  
3. **Elevated urinary carboxylic acids**: Reflects systemic organic acidemia from blocked ketone body synthesis and mitochondrial energy dysfunction.  
4. **Abnormal circulating glycine**: Secondary glycine elevation occurs as glycine conjugation attempts to detoxify accumulating organic acids (e.g., 3-methylglutaconate).  
5. **Vomiting, fever, and infantile lethality**: Episodic crises triggered by catabolic stress (e.g., fasting, infection), causing acute metabolic decompensation. Untreated, this leads to rapid neurological decline and early mortality.  
6. **Exclusion of mimics**: The specific organic acid profile (3-methylglutaric aciduria) distinguishes it from other organic acidurias (e.g., propionic acidemia), which lack this marker. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Acne', 'Intellectual disability', 'Obesity', 'Hypertyrosinemia', 'Severe short stature', 'Death in childhood', 'Hyperphenylalaninemia', 'Death in adolescence', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: Core diagnostic marker of PKU due to deficient phenylalanine hydroxylase (PAH), blocking phenylalanine conversion to tyrosine.  
2. **Intellectual disability and hyperactivity**: Untreated PKU causes toxic phenylalanine accumulation, impairing neurotransmitter synthesis and brain development.  
3. **Severe short stature and obesity**: Chronic metabolic disruption may alter growth hormone signaling and energy metabolism; obesity can arise from carbohydrate-heavy dietary management.  
4. **Death in childhood/adolescence/early adulthood**: Historically, untreated PKU leads to severe neurological decline, infections, or organ failure. Modern dietary interventions prevent this outcome.  
5. **Hypertyrosinemia discrepancy**: PKU typically causes *low* tyrosine (due to blocked PAH). Hypertyrosinemia suggests a comorbid or misdiagnosed condition (e.g., tyrosinemia type II) or lab error.  
6. **Acne**: Uncommon in PKU but may stem from hormonal imbalances or dietary factors (e.g., synthetic protein supplements).  

Note: Hypertyrosinemia and acne are atypical for PKU and warrant further investigation for overlapping disorders (e.g., BH4 deficiency or tyrosinemia). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pierre-Robin sequence', 'Conductive hearing impairment', 'Strabismus', 'Hypermetropia', 'Atrial septal defect', 'Respiratory distress', 'Scoliosis', 'Feeding difficulties', 'Posterior rib gap']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Pierre-Robin sequence**: A hallmark of CCMS, caused by micrognathia and glossoptosis, leading to airway obstruction and feeding difficulties.  
2. **Posterior rib gaps**: Pathognomonic feature of CCMS, involving costovertebral abnormalities with missing or malformed posterior rib segments.  
3. **Scoliosis**: Associated with vertebral anomalies and rib defects in CCMS.  
4. **Respiratory distress**: Secondary to rib gaps (impaired chest wall mechanics) and micrognathia-related airway obstruction.  
5. **Atrial septal defect**: Reported in some CCMS cases, reflecting broader developmental anomalies.  
6. **Conductive hearing impairment**: Likely due to craniofacial malformations affecting Eustachian tube function.  
7. **Strabismus/Hypermetropia**: May arise from craniofacial dysmorphism or connective tissue involvement, though less specific to CCMS.  
8. **Feeding difficulties**: Direct consequence of micrognathia and glossoptosis in PRS.  
The combination of rib gaps, PRS, and multisystem involvement strongly supports CCMS over other syndromes (e.g., Stickler or Treacher Collins). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Lethargy', 'Generalized hypotonia', 'Growth delay', 'Drowsiness', 'Sleep disturbance', 'Death in childhood', 'Dark urine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine** is the hallmark symptom of Alkaptonuria, caused by the accumulation and oxidation of homogentisic acid (HGA) in urine. This symptom is often noticed in infancy or early childhood.  
2. **Growth delay** and **generalized hypotonia** may occur due to metabolic disruptions from chronic HGA accumulation, though these are less common and not well-documented in typical Alkaptonuria cases.  
3. **Seizures, lethargy, drowsiness, and sleep disturbances** are atypical for Alkaptonuria but could suggest secondary complications (e.g., metabolic acidosis or electrolyte imbalances) or comorbidities.  
4. **Death in childhood** is not characteristic of Alkaptonuria, which typically allows for a normal lifespan with progressive joint/connective tissue issues (e.g., ochronosis, arthritis) manifesting later in life. This may indicate a severe, atypical presentation or misattribution of symptoms.  
5. Despite inconsistencies, **dark urine** remains the critical diagnostic clue, prompting confirmatory testing (e.g., urinary HGA quantification, genetic analysis for *HGD* mutations). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Most common secondary tumor with Retinoblastoma is
Choices:
A. Neuroblastoma
B. Pineoblastoma
C. Osteochondroma
D. Osteosarcoma
Answer: [/INST] Osteosarcoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Cyanosis', 'Edema', 'Neonatal hypotonia', 'Death in infancy', 'Truncus arteriosus', 'Abnormal facial shape', 'Elevated circulating creatinine concentration', 'Pulmonary artery atresia', 'Persistent left superior vena cava', 'Generalized edema', 'Partial anomalous pulmonary venous return', 'Interrupted aortic arch', 'Tricuspid atresia', 'Right aortic arch', 'Tetralogy of Fallot with pulmonary atresia', 'Heart murmur', 'Systolic heart murmur', 'Aortopulmonary collateral arteries']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Structural heart defects and renal anomalies syndrome  
Reasoning:  
1. **Cardiac Anomalies**: Multiple severe congenital heart defects are present, including truncus arteriosus, tetralogy of Fallot with pulmonary atresia, interrupted aortic arch, tricuspid atresia, and aortopulmonary collaterals. These collectively explain symptoms like cyanosis, heart murmurs, and systolic murmurs due to impaired blood flow and mixing of oxygenated/deoxygenated blood.  
2. **Renal Involvement**: Elevated creatinine indicates renal dysfunction, a key feature of the syndrome. Edema (generalized and localized) may result from combined cardiac failure and renal fluid retention.  
3. **Dysmorphic Features**: Microcephaly and abnormal facial shape suggest a developmental/genetic etiology, aligning with syndromic diagnoses that involve multi-organ malformations.  
4. **Early Lethality**: Neonatal hypotonia, critical cardiac defects, and death in infancy reflect the syndrome’s severity, typical of disorders disrupting essential organogenesis.  
5. **Genetic Basis**: The constellation of cardiac, renal, and craniofacial anomalies points to a rare genetic syndrome affecting neural crest-derived structures (heart, great vessels) and renal development, though specific gene mutations (e.g., *NKX2-5*, *NOTCH1*, or chromatin regulators) may require further testing. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are major criteria inthe diagnosis of Acute Rheumatic Fever, except -
Choices:
A. Prolonged PR interval
B. Subcutaneous Nodules
C. Chorea
D. Carditis
Answer: [/INST] Prolonged PR interval </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Diffuse specific lesions on intestinal biopsy are seen in -a) Celiac sprueb) Whipples diseasec) Agammaglobulinemia d) Abetalipoproteinemal
Choices:
A. abc
B. bcd
C. ac
D. bd
Answer: [/INST] bcd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Seizure', 'Ataxia', 'Death in infancy', 'Fever', 'Death in adolescence', 'L-2-hydroxyglutaric aciduria']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: L-2-hydroxyglutaric aciduria  
Reasoning:  
1. **Key Biochemical Marker**: The presence of **L-2-hydroxyglutaric aciduria** (elevated L-2-hydroxyglutaric acid in urine) is pathognomonic for this disorder, confirming the diagnosis.  
2. **Neurological Symptoms**: **Intellectual disability**, **seizures**, and **ataxia** align with the neurotoxic effects of accumulated metabolites damaging the central nervous system.  
3. **Disease Progression**: **Death in infancy/adolescence** reflects the severe, progressive nature of the disease, often due to metabolic crises, neurodegeneration, or complications like status epilepticus.  
4. **Fever**: Likely secondary to intercurrent infections, which can trigger metabolic decompensation and exacerbate neurological symptoms.  
5. **Exclusion of Alternatives**: The specific biochemical signature rules out other organic acidurias (e.g., D-2-hydroxyglutaric aciduria) or leukodystrophies with overlapping symptoms.  

This diagnosis integrates biochemical evidence with clinical progression, consistent with autosomal recessive L-2-hydroxyglutaric aciduria. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All the following are characteristic of Turner Syndrome EXCEPT
Choices:
A. Webbing of Neck
B. Cubitus valgus
C. Umbilical Hernia
D. Coarctation of Aoa
Answer: [/INST] Umbilical Hernia </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Intermittent dysphagia is caused by? 1. Stricture 2. Reflux esophagitis 3. Achalasia cardia 4. Pharyngeal diveiculum 5. Diffuse esophageal spasm
Choices:
A. 1,2 & 3
B. 2,3 & 4
C. 4 & 5
D. 3,4 & 5
Answer: [/INST] 4 & 5 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Feature common to carcinoma pancreas, lungs,stomach is,a) Retinoblastomab) Migratory thrombophlebitisc) Ascitesd) DIC
Choices:
A. acd
B. abd
C. abc
D. ab
Answer: [/INST] abd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera toxin effects are mediated by stimulation of which of the following second messengers -
Choices:
A. cAMP
B. cGMP
C. Ca++ - Calmodulin
D. IP3 / DAG
Answer: [/INST] cAMP </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Dicarboxylic aciduria', '3-Methylglutaric aciduria', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: 3-hydroxy-3-methylglutaric aciduria/3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (HMG-CoA Lyase Deficiency)  
Reasoning:  
1. **Death in infancy**: HMG-CoA lyase deficiency is a severe autosomal recessive metabolic disorder that typically manifests in infancy with life-threatening episodes of hypoglycemia and metabolic acidosis, often leading to early mortality if undiagnosed or untreated.  
2. **Dicarboxylic aciduria**: Impaired fatty acid β-oxidation due to deficient HMG-CoA lyase activity results in incomplete fatty acid breakdown, causing urinary excretion of dicarboxylic acids (e.g., adipic, suberic acids).  
3. **3-Methylglutaric aciduria**: The enzyme deficiency disrupts leucine catabolism, leading to accumulation of 3-hydroxy-3-methylglutaryl-CoA, which is diverted to 3-methylglutaric acid and 3-methylglutaconic acid via alternative pathways.  
4. **Elevated urinary carboxylic acids**: The block in ketogenesis (HMG-CoA lyase converts HMG-CoA to acetoacetate) and leucine degradation causes systemic buildup of multiple carboxylic acids (e.g., 3-hydroxy-3-methylglutaric, 3-methylglutaric, and 3-methylglutaconic acids), which are excreted in urine.  
**Conclusion**: The biochemical profile aligns with HMG-CoA lyase deficiency, where disrupted ketogenesis and leucine metabolism lead to characteristic organic aciduria, hypoglycemia, and metabolic crises in infancy. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Ceificate of vaccination of Yellow Fever is valid for how many years: September 2010
Choices:
A. 1 year
B. 2 years
C. 5 years
D. 10 years
Answer: [/INST] 10 years </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperpigmentation of the skin', 'Thrombocytosis', 'Normocytic anemia', 'Fever', 'Increased susceptibility to fractures', 'Elevated hepatic transaminase', 'Elevated circulating alkaline phosphatase concentration', 'Increased circulating IgA level', 'Myalgia', 'Elevated erythrocyte sedimentation rate', 'Tricuspid regurgitation', 'Concave nasal ridge', 'Elevated circulating C-reactive protein concentration', 'Cough', 'Nodular pattern on pulmonary HRCT', 'Decreased mean corpuscular hemoglobin concentration', 'Abnormal periosteum morphology', 'Ankle pain', 'Elevated gamma-glutamyltransferase level', 'Cytoplasmic antineutrophil antibody positivity', 'Lymphocytosis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Granulomatosis with polyangiitis (GPA)  
**Reasoning**:  
1. **C-ANCA positivity**: Cytoplasmic antineutrophil antibody (c-ANCA), typically targeting PR3, is highly specific for GPa.  
2. **Upper respiratory involvement**: Concave nasal ridge suggests chronic nasal inflammation or cartilage damage, common in GPA due to granulomatous lesions.  
3. **Pulmonary manifestations**: Nodular pattern on HRCT and cough align with necrotizing granulomas in the lungs.  
4. **Systemic inflammation**: Fever, elevated ESR, CRP, and lymphocytosis reflect a systemic inflammatory process.  
5. **Musculoskeletal symptoms**: Myalgia and ankle pain correlate with vasculitis-induced inflammation.  
6. **Hematologic abnormalities**: Thrombocytosis and normocytic anemia are reactive findings in chronic inflammation.  
7. **Additional markers**: Elevated hepatic transaminases and alkaline phosphatase may indicate secondary liver involvement or drug toxicity (e.g., from immunosuppressants).  
8. **Renal implication**: While not explicitly listed, elevated IgA (common in autoimmune dysregulation) and cytoplasmic ANCA often precede glomerulonephritis in GPA.  
9. **Radiologic and pathologic features**: Abnormal periosteum morphology and fractures could stem from chronic inflammation or steroid therapy complications.  

**Conclusion**: The constellation of c-ANCA positivity, sinonasal/pulmonary lesions, systemic inflammation, and multi-organ involvement strongly supports GPA. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Tall stature', 'Myopia', 'Pectus excavatum', 'Thin skin', 'Arachnodactyly', 'Mitral regurgitation', 'Aortic root aneurysm', 'Scoliosis', 'Kyphoscoliosis', 'Decreased body weight', 'Lens luxation']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Marfan syndrome  
Reasoning: The patient exhibits cardinal features of Marfan syndrome, including skeletal manifestations (tall stature, pectus excavatum, arachnodactyly, scoliosis/kyphoscoliosis), ocular involvement (myopia, lens luxation), cardiovascular complications (mitral regurgitation, aortic root aneurysm), and connective tissue abnormalities (thin skin, decreased body weight). Lens luxation and aortic root aneurysm are major diagnostic criteria, while the other findings fulfill systemic involvement.  

Disease: Marfan syndrome type 1  
Reasoning: Marfan syndrome type 1 refers specifically to cases caused by pathogenic variants in the *FBN1* gene, which encodes fibrillin-1. The clinical presentation aligns with *FBN1*-related Marfan syndrome, as lens luxation and aortic root aneurysm are hallmark features of this subtype. Genetic testing for *FBN1* mutations would confirm the molecular basis of the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Leprosy is not targeted for global eradication because
Choices:
A. No effective vaccine
B. Highly infectious but low pathogenicity
C. Only humans are reservoir
D. Long incubation period
Answer: [/INST] Long incubation period </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Keratomalacia is associated with:
Choices:
A. Measles
B. Mumps
C. Rubella
D. All
Answer: [/INST] Measles </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Rx of Phenylketonuria
Choices:
A. Limiting the substrate for deficient enzyme
B. Giving the missing amino acids by diet
C. Gene therapy can be successfully used
D. Child should refrain from milk.
Answer: [/INST] Limiting the substrate for deficient enzyme </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: In a patient suspected to be diagnosed with Rabies, a sample of corneal smear was taken. Which of the following investigations can be done from the specimen?
Choices:
A. RT PCR
B. Immunofluorescence test
C. Negri body visualization
D. Virus isolation
Answer: [/INST] Immunofluorescence test </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: POEMS Syndrome includes all, EXCEPT:
Choices:
A. Polyneuropathy
B. Organomegaly
C. Endocrinopathy
D. Multiple sclerosis
Answer: [/INST] Multiple sclerosis </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Alkaptonuria is caused by defect in which of the following enzymes?
Choices:
A. Enolase
B. Homogentisate oxidase
C. Pyruvate carboxylase
D. None of the above
Answer: [/INST] Homogentisate oxidase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Hyperhidrosis', 'Lethargy', 'Generalized hypotonia', 'Dystonia', 'Death in infancy', 'Fever', 'Vomiting', 'Diarrhea', 'Dyspnea', 'Drowsiness', 'Sleep disturbance', 'Glutaric aciduria', 'Dyskinesia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)  
Reasoning:  
1. **Glutaric aciduria** is a hallmark biochemical feature of GA-I, directly indicating a defect in glutaryl-CoA dehydrogenase, which disrupts lysine and tryptophan metabolism.  
2. **Macrocephaly** often presents in infancy due to abnormal accumulation of neurotoxic metabolites (glutaric acid, 3-hydroxyglutaric acid), causing frontotemporal atrophy.  
3. **Dystonia and dyskinesia** arise from striatal neurodegeneration, typically triggered by acute metabolic crises during infections or fever (aligned with **fever**, **vomiting**, and **diarrhea**).  
4. **Lethargy**, **drowsiness**, and **generalized hypotonia** reflect acute encephalopathic crises caused by metabolic acidosis and energy depletion in the brain.  
5. **Hyperhidrosis** and **sleep disturbance** are linked to autonomic nervous system dysfunction secondary to metabolic stress.  
6. **Dyspnea** may occur during metabolic decompensation due to respiratory compensation for acidosis or muscle weakness.  
7. **Death in infancy** underscores the severity of untreated GA-I, as crises lead to irreversible neurological damage or metabolic collapse.  
The combination of neurodevelopmental, metabolic, and autonomic symptoms, alongside biochemical evidence (glutaric aciduria), confirms GA-I. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which type of Amyloidosis is caused by mutation of the transthyretin protein ?-
Choices:
A. Familial Mediterranean fever
B. Familial amyloidotic polyneuropathy
C. Dialysis associated amyloidosis
D. Prion protein associated amyloidosis
Answer: [/INST] Familial amyloidotic polyneuropathy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperkeratosis', 'Eczematoid dermatitis', 'Skin rash', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Pulmonic stenosis', 'Gastrointestinal hemorrhage', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria; PKU  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Skin rash/Eczematoid dermatitis**: Common in untreated PKU due to phenylalanine accumulation and metabolic byproducts irritating the skin.  
3. **Abnormality of prenatal development or birth/Death in infancy/Neonatal death/Death in childhood**: Severe untreated PKU causes profound neurological damage, leading to developmental failure and early mortality.  
4. **Gastrointestinal inflammation/hemorrhage**: Secondary to metabolic derangements or dietary management complications (e.g., protein-restricted diets).  
5. **Hypertyrosinemia**: Uncommon in classical PKU but may arise from tyrosine supplementation or overlapping metabolic disruptions.  
6. **Pulmonic stenosis**: Likely incidental or unrelated; PKU does not directly cause cardiac defects but may coexist with other congenital anomalies.  

*Note: While some symptoms (e.g., pulmonic stenosis) are atypical for PKU, the diagnosis is strongly supported by hyperphenylalaninemia and dermatological manifestations. Other features may reflect severe untreated disease or comorbidities.* </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Carious teeth', 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: A hallmark of PKU due to deficient phenylalanine hydroxylase, preventing phenylalanine conversion to tyrosine.  
2. **Elevated urinary carboxylic acids**: Phenylalanine accumulates and is metabolized into phenylketones (e.g., phenylpyruvate), excreted in urine.  
3. **Death in infancy/childhood & neonatal death**: Untreated PKU causes severe neurological damage, seizures, and organ failure, leading to early mortality.  
4. **Carious teeth**: Chronic metabolic acidosis (from phenylketone accumulation) and high-carbohydrate/low-protein diets in managed PKU may contribute to dental decay.  
5. **Hypertyrosinemia (apparent conflict)**: PKU typically causes **low** tyrosine levels (blocked conversion). This symptom may indicate a coexisting condition (e.g., transient tyrosinemia in newborns) or misreporting.  
6. **Abnormality of prenatal development**: Likely reflects maternal PKU syndrome (untreated PKU during pregnancy causing fetal defects), suggesting the patient’s condition was inherited from an affected mother.  

While hypertyrosinemia is atypical, the triad of hyperphenylalaninemia, urinary phenylketones, and early mortality strongly supports PKU. Maternal PKU explains prenatal abnormalities and neonatal severity. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Chikungunya is caused by ?
Choices:
A. Mosquito-borne Alphavirus
B. Mosquito-borne Beta virus
C. Mosquito-borne Gamma virus
D. Mosquito-borne Deltavirus
Answer: [/INST] Mosquito-borne Alphavirus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which receptors are blocked in Myasthenia Gravis?
Choices:
A. Ach receptor
B. Ca++ receptors
C. Na+ receptors
D. Opioid receptors
Answer: [/INST] Ach receptor </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cleft palate', 'Pierre-Robin sequence', 'Cleft upper lip', 'Respiratory distress', 'Scoliosis', 'Posterior rib gap', '10 pairs of ribs']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Cerebrocostomandibular syndrome  
Reasoning:  
1. **Cleft palate, Pierre-Robin sequence, and cleft upper lip**: These craniofacial anomalies align with CCMS, which is characterized by mandibular hypoplasia (micrognathia, a key feature of Pierre-Robin sequence) and oral clefts.  
2. **Respiratory distress**: Likely secondary to micrognathia (obstructing the airway) and rib abnormalities impairing lung development/function.  
3. **Scoliosis and posterior rib gaps**: CCMS involves severe rib malformations, including posterior ""rib gaps"" (missing rib segments) and abnormal rib count.  
4. **10 pairs of ribs**: A hallmark of CCMS, as affected individuals often have fewer than the typical 12 pairs, with severe costal defects contributing to thoracic insufficiency.  
5. **Exclusion of alternatives**: While Pierre-Robin sequence and clefts occur in other syndromes (e.g., Stickler or Treacher Collins), the combination with rib gaps and rib count reduction is pathognomonic for CCMS. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Intellectual disability', 'Severe short stature', 'Death in childhood', 'Abnormality of galactoside metabolism']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Classic galactosemia/GALACTOSEMIA  
Reasoning: The patient presents with intellectual disability and severe short stature, which are consistent with the neurological and growth impairments seen in untreated classic galactosemia. Death in childhood aligns with the severe complications of the disease (e.g., liver failure, sepsis) if galactose is not excluded from the diet. The abnormality of galactoside metabolism directly points to the enzymatic defect in galactose-1-phosphate uridylyltransferase (GALT), characteristic of classic galactosemia. Early dietary management is critical to mitigate symptoms, but residual issues may persist despite treatment.  

Disease: Galactosemia; GAL/Galactosemia  
Reasoning: This diagnosis is synonymous with classic galactosemia. The symptoms listed—intellectual disability, severe short stature, childhood mortality, and metabolic abnormalities—are hallmarks of galactosemia caused by GALT deficiency. Accumulation of toxic metabolites (e.g., galactitol) disrupts cellular function, leading to organ damage (liver, brain) and growth failure. The term ""abnormality of galactoside metabolism"" explicitly references the underlying biochemical defect in galactose processing pathways. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Paraneoplastic syndrome not seen in renal cell cancer is?a)  Acanthosis nigricansb) Amyloidosisc)  Polycythemiad)  SLE
Choices:
A. b
B. c
C. ad
D. ab
Answer: [/INST] ad </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: DOC for the treatment of Tularemia is:
Choices:
A. Kanamycin
B. Neomycin
C. Streptomycin
D. Chloramphenicol
Answer: [/INST] Streptomycin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Macrocephaly', 'Abnormality of visual evoked potentials', 'Irritability', 'Seizure', 'Generalized hypotonia', 'Death in infancy', 'Athetosis', 'Glutaric aciduria', 'Neonatal death']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Glutaric acidemia type I (GA-I)/Glutaryl-CoA dehydrogenase deficiency  
Reasoning:  
1. **Glutaric aciduria**: Direct biochemical evidence of the disorder, caused by deficient glutaryl-CoA dehydrogenase activity, leading to accumulation of glutaric acid and 3-hydroxyglutaric acid.  
2. **Macrocephaly**: A hallmark of GA-I, often present at birth due to frontotemporal atrophy or enlarged subarachnoid spaces.  
3. **Neurological symptoms (Seizure, Irritability, Athetosis)**: Result from neurotoxic metabolite accumulation, causing striatal injury (basal ganglia damage) and movement disorders (e.g., dystonia, athetosis).  
4. **Generalized hypotonia**: Early manifestation of metabolic encephalopathy, progressing to spasticity or dystonia after metabolic crises.  
5. **Abnormality of visual evoked potentials**: Reflects metabolic damage to the central nervous system, potentially involving optic pathways or cortical processing.  
6. **Death in infancy/Neonatal death**: Severe untreated GA-I leads to acute metabolic decompensation (often triggered by catabolic stress), resulting in irreversible neurological damage or fatal cerebral edema.  
7. **Consistency with GA-I phenotype**: The combination of macrocephaly, neurodevelopmental regression, movement disorders, and organic aciduria aligns definitively with GA-I pathophysiology. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Confirmatory test for the diagnosis of Amyloidosis-
Choices:
A. Diagnostic peritoneal lavage
B. Tongue biopsy
C. Rectal biopsy
D. Whole body CT scan
Answer: [/INST] Rectal biopsy </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Digoxin toxicity is aggravated by: a) Hypokalemia b) Hyperkalernia c) Hypercalcemia d) Hypermagnesemia e) Hypocalcemia
Choices:
A. ad
B. bc
C. cd
D. ac
Answer: [/INST] ac </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Mucormycosis is caused by:
Choices:
A. Rhizopus arrhizus
B. Rhizopus oryzae
C. Absidia corymbifera
D. All of the above
Answer: [/INST] All of the above </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary Hyperoxaluria occurs in defect in metabolism of
Choices:
A. Cystein
B. Tryptophan
C. Tyrosine
D. Glycine
Answer: [/INST] Glycine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Pierre-Robin sequence', 'High palate', 'Downslanted palpebral fissures', 'Carious teeth', '11 pairs of ribs', 'Specific learning disability', 'Feeding difficulties', 'Hypoplastic L5 vertebral pedicle', 'Posterior rib gap']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Cerebrocostomandibular syndrome: The patient exhibits Pierre-Robin sequence (micrognathia, glossoptosis, and cleft palate/high palate), a hallmark of CCMS. The skeletal anomalies—11 pairs of ribs (rib hypoplasia), posterior rib gaps, and hypoplastic L5 vertebral pedicle—align with costovertebral defects central to this syndrome. Feeding difficulties are secondary to craniofacial and airway challenges from PRS. Downslanted palpebral fissures and specific learning disability suggest broader craniofacial and neurodevelopmental involvement. Carious teeth may reflect oral anatomical challenges or enamel defects. The combined craniofacial, vertebral, and rib anomalies strongly support CCMS, excluding isolated PRS or other rib malformation syndromes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Intellectual disability', 'Seizure', 'Motor delay', 'Muscle weakness', 'Absent speech', 'Tachycardia', 'Torsade de pointes', 'Cardiac arrest', 'Hypoglycemia', 'Increased serum lactate', 'Myoglobinuria', 'Rhabdomyolysis', 'Elevated circulating creatine kinase concentration', 'Generalized muscle weakness', 'Ventricular tachycardia', 'Prolonged QTc interval', 'Cardiorespiratory arrest', 'Lateral ventricle dilatation', 'Acute rhabdomyolysis', 'Arrhythmia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome  
Reasoning:  
1. **Neurological/Developmental Symptoms**: Delayed speech, intellectual disability, motor delay, and absent speech indicate global developmental delay and neurodegeneration, consistent with encephalomyopathic involvement.  
2. **Metabolic Crises**: Hypoglycemia, increased serum lactate, and acute rhabdomyolysis (with myoglobinuria, elevated CK) suggest recurrent metabolic disturbances, a hallmark of the syndrome.  
3. **Muscle Pathology**: Generalized muscle weakness, rhabdomyolysis, and elevated creatine kinase point to myopathic processes and energy metabolism dysfunction.  
4. **Cardiac Arrhythmias**: Torsade de pointes, ventricular tachycardia, prolonged QTc interval, and cardiorespiratory arrest align with life-threatening arrhythmias characteristic of the syndrome.  
5. **Systemic Features**: Hypoglycemia and lactic acidosis further support a mitochondrial or metabolic etiology disrupting energy production.  
6. **Neuroimaging**: Lateral ventricle dilatation may reflect neurodegenerative changes or cerebral atrophy over time.  
7. **Syndrome Alignment**: The combination of recurrent metabolic crises, rhabdomyolysis, severe arrhythmias, and intellectual disability is pathognomonic for this rare disorder, distinguishing it from isolated metabolic or cardiac conditions. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Fungal infection in AIDS -a) Mucormycosisb) Aspergillosisc) Disseminated candidiasisd) Mucocutaneous candidiasis
Choices:
A. ab
B. bc
C. cd
D. ac
Answer: [/INST] cd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following is not true regarding Renal Cell Carcinoma?
Choices:
A. More common in males
B. Has a tendency to invade the renal vessels
C. Usually situated near the poles
D. Hematuria is not a feature
Answer: [/INST] Hematuria is not a feature </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Measles epidemic can be anticipated when propoion of susceptible children in a community reaches -
Choices:
A. 20%
B. 40%
C. 60%
D. 80%
Answer: [/INST] 40% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All are true about Yaws except
Choices:
A. Caused by Treponema pertenue
B. Transmitted non-venerally
C. Later stages involve heart and nerves
D. Secondary Yaws can involve bones
Answer: [/INST] Later stages involve heart and nerves </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following organs may be involved in Leprosy, except:
Choices:
A. Uterus
B. Ovary
C. Testes
D. Eye
Answer: [/INST] Uterus </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Diabetes mellitus', 'Constipation', 'Impaired glucose tolerance']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maturity-onset diabetes of the young, type 1 (MODY1)  
Reasoning:  
1. **Diabetes mellitus and impaired glucose tolerance** align with MODY, a monogenic form of diabetes caused by autosomal dominant mutations (e.g., *HNF4A* in MODY1).  
2. MODY typically presents in non-obese adolescents/young adults with a strong family history of diabetes, distinguishing it from type 1 or type 2 diabetes.  
3. **Constipation** is atypical for MODY but may reflect secondary effects of hyperglycemia (e.g., autonomic neuropathy) or unrelated comorbidities.  
4. MODY1 specifically involves *HNF4A* mutations, which disrupt insulin secretion and may cause subtle extrapancreatic features (e.g., lipid abnormalities, renal Fanconi syndrome), though constipation is not a hallmark.  
5. Definitive diagnosis requires **genetic testing** for *HNF4A* variants. Early identification enables tailored therapy (e.g., sulfonylureas instead of insulin). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: True about Pertussis is/are -a) Incubation period is 7-14 daysb) Main source of infection is chronic carriersc) Can affect any aged) Secondary attack rate in unimmunised persons is 90%e) More common in summers
Choices:
A. abc
B. acd
C. bc
D. bde
Answer: [/INST] acd </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Coma', 'Generalized hypotonia', 'Death in infancy', 'Hyperammonemia', 'Vomiting', 'Increased serum lactate', 'Hepatomegaly', 'Tachypnea', 'Neonatal death', 'Feeding difficulties', 'Functional abnormality of the gastrointestinal tract', 'Metabolic alkalosis']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Argininosuccinic aciduria  
**Reasoning**:  
1. **Hyperammonemia** is a hallmark of urea cycle disorders (UCDs), including argininosuccinic aciduria (ASA), due to impaired ammonia detoxification.  
2. **Vomiting**, **tachypnea**, and **metabolic alkalosis** align with UCDs: vomiting induces alkalosis, while hyperammonemia triggers compensatory tachypnea.  
3. **Seizures** and **coma** result from neurotoxicity caused by elevated ammonia.  
4. **Hepatomegaly** and **increased serum lactate** suggest secondary mitochondrial dysfunction or hepatic stress from metabolic overload.  
5. **Feeding difficulties** and **GI tract abnormalities** are common in neonates with UCDs due to metabolic instability.  
6. **Generalized hypotonia** reflects neurological impairment.  
7. **Neonatal death**/**death in infancy** underscores the severity of untreated ASA, which typically presents catastrophically in the first days of life.  
8. ASA is confirmed by elevated argininosuccinic acid in blood/urine, consistent with argininosuccinate lyase deficiency.  

This constellation of symptoms, metabolic derangements, and clinical course strongly supports ASA as the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malarial pigment is formed by -
Choices:
A. Parasite
B. Bilirubin
C. Hemoglobin
D. Any of the above
Answer: [/INST] Hemoglobin </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Seizure', 'Death in childhood', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Biotinidase deficiency  
Reasoning:  
1. **Elevated urinary carboxylic acids** suggest impaired carboxylase enzyme activity, which requires biotin as a cofactor. Biotinidase deficiency prevents biotin recycling, leading to functional biotin depletion and subsequent carboxylase dysfunction.  
2. **Seizures** occur due to metabolic acidosis and accumulation of toxic metabolites (e.g., lactate, ammonia) affecting the central nervous system.  
3. **Death in childhood** aligns with untreated BTDD progression, as irreversible neurological damage, respiratory failure, or metabolic crises typically occur without biotin supplementation.  
4. The **late-onset multiple carboxylase deficiency** subtype matches the gradual symptom onset (e.g., after the neonatal period) due to partial enzyme activity before biotin stores are depleted.  

This triad of symptoms strongly supports BTDD, confirmed by biochemical testing (low biotinidase activity) and genetic analysis of the *BTD* gene. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Case Fatality Rate (CFR) of Rabies is
Choices:
A. 80%
B. 90%
C. 100%
D. 95%
Answer: [/INST] 100% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Glioma of the optic nerve is associated with -
Choices:
A. Neurofibromatosis type 1
B. Neurofibromatosis type II
C. Both the above
D. None of the above
Answer: [/INST] Neurofibromatosis type 1 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hyperactivity', 'Generalized hypotonia', 'Death in infancy', 'Premature birth', 'Hyperammonemia', 'Neonatal death', 'Death in childhood', 'Decreased plasma free carnitine', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating creatine kinase concentration']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)  
Reasoning:  
1. **Metabolic crisis indicators**: Hyperammonemia and abnormal amino acid concentrations (aspartate family, alanine) suggest a defect in fatty acid oxidation (FAO), leading to energy deficits and secondary metabolic disturbances.  
2. **Carnitine deficiency**: Decreased plasma free carnitine aligns with FAO disorders, as carnitine is required for long-chain fatty acid transport into mitochondria.  
3. **Muscle involvement**: Generalized hypotonia and elevated creatine kinase (muscle breakdown) reflect impaired energy production in muscles, a hallmark of VLCADD.  
4. **Neonatal/Infantile mortality**: Death in infancy/childhood and premature birth correlate with severe VLCADD presentations, including cardiomyopathy, hepatopathy, or hypoketotic hypoglycemia.  
5. **Hyperactivity**: May indicate neurological stress due to energy deprivation or toxic metabolite accumulation (e.g., long-chain acylcarnitines).  
6. **Specific biochemical profile**: VLCADD disrupts very long-chain fatty acid oxidation, distinguishing it from medium/short-chain FAO defects (e.g., MCADD). Confirmatory testing (acylcarnitine profile showing elevated C14:1, genetic analysis) would solidify the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal vertebral morphology', 'Death in childhood', 'Dark urine']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Alkaptonuria  
Reasoning:  
1. **Dark urine**: Alkaptonuria is caused by a deficiency of homogentisate 1,2-dioxygenase, leading to accumulation of homogentisic acid (HGA). HGA oxidizes in urine, causing it to darken upon exposure to air (a hallmark symptom).  
2. **Abnormal vertebral morphology**: Chronic HGA deposition in connective tissues (ochronosis) leads to cartilage degeneration, including intervertebral discs. Spinal deformities (e.g., kyphosis, disc calcification) may manifest early in severe cases.  
3. **Death in childhood**: While Alkaptonuria typically has a chronic course, rare severe forms with systemic ochronosis can cause early complications (e.g., cardiac valve calcification, renal failure) or susceptibility to infections, potentially leading to premature death.  

Note: Childhood mortality is atypical in Alkaptonuria and suggests an unusually aggressive presentation or comorbid conditions. Further genetic testing (HGD gene mutations) and urinary HGA quantification would confirm the diagnosis. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Botulism is most commonly due to
Choices:
A. Egg
B. Milk
C. Meat
D. Pulses
Answer: [/INST] Meat </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Post exposure, Measles vaccine must be given within
Choices:
A. 3-4 days
B. 10-Jul
C. 10-14 days
D. 1-6 months
Answer: [/INST] 3-4 days </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella virus was isolated in-
Choices:
A. 1862
B. 1912
C. 1932
D. 1962
Answer: [/INST] 1962 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hypokalemia is seen with -a) Frusemideb) Cortisolc) Amilorided) Addison's disease
Choices:
A. ac
B. a
C. ad
D. ab
Answer: [/INST] ab </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Neurological complications following Rabies vaccine is common with -
Choices:
A. HDCS Vaccine
B. Chick embryo Vaccine
C. Semple Vaccine
D. Duck Egg Vaccine
Answer: [/INST] Semple Vaccine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Rubella cataract is seen as –
Choices:
A. Posterior polar cataract
B. Nuclear cataract
C. Blue dot cataract in young
D. Cuneiform cataract
Answer: [/INST] Nuclear cataract </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following statements about Churg Strauss Syndrome are true, except:
Choices:
A. Marked Eosinophilia
B. Mononeuritis multiplex is common
C. Renal failure is common
D. Often associated with Allergic Rhinitis
Answer: [/INST] Renal failure is common </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinitis Pigmentosa is associated with all except:
Choices:
A. Usher Syndrome
B. Marfan's Syndrome
C. Kearns- Sayre Syndrome
D. Bassen - Kornzweig Syndrome
Answer: [/INST] Marfan's Syndrome </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene is located on a chromosome -
Choices:
A. 13
B. 6
C. 9
D. 21
Answer: [/INST] 13 </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Abnormal repetitive mannerisms', 'Delayed speech and language development', 'Seizure', 'Hypotonia', 'Delayed CNS myelination', 'EEG abnormality', 'Sleep disturbance', 'Secondary microcephaly', 'Feeding difficulties in infancy']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Rett syndrome, congenital variant  
Reasoning:  
1. **Secondary microcephaly**: A hallmark of Rett syndrome, reflecting postnatal deceleration of head growth due to impaired brain development.  
2. **Delayed speech and language development**: Consistent with neurodevelopmental regression or stagnation, a core feature of Rett syndrome.  
3. **Abnormal repetitive mannerisms**: Stereotypic hand movements (e.g., wringing, tapping) are pathognomonic in Rett syndrome, though they may manifest atypically in the congenital variant.  
4. **Seizures and EEG abnormality**: Epileptic activity and abnormal EEG patterns (e.g., slow background, epileptiform discharges) are common in Rett syndrome due to cortical hyperexcitability.  
5. **Hypotonia and feeding difficulties in infancy**: Early-onset axial hypotonia and oral-motor dysfunction align with congenital variant presentations, distinguishing it from classic Rett syndrome.  
6. **Delayed CNS myelination**: Observed on neuroimaging, reflecting disrupted neuronal maturation linked to *MECP2* mutations (or related genes like *FOXG1* in congenital variants).  
7. **Sleep disturbance**: Autonomic dysfunction in Rett syndrome contributes to disrupted sleep-wake cycles.  
8. **Early-onset symptoms**: Congenital variants lack the typical 6–18-month period of normal development seen in classic Rett syndrome, instead presenting with neonatal/infantile hypotonia and developmental arrest.  
**Exclusion of mimics**: Differentiated from CDKL5 deficiency disorder (earlier seizure onset) and Angelman syndrome (distinct EEG patterns, lack of microcephaly at birth) by the combination of microcephaly, repetitive hand stereotypies, and *MECP2/FOXG1* genetic profile. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Proteinuria', 'Retinopathy', 'Hypertension', 'Acute kidney injury', 'Chronic kidney disease', 'Elevated hemoglobin A1c', 'Death in early adulthood']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Maturity-onset diabetes of the young, type 1 (MODY1/HNF4A)  
Reasoning:  
1. **Elevated hemoglobin A1c**: Indicates chronic hyperglycemia, a hallmark of MODY. MODY1 (HNF4A mutation) disrupts insulin secretion, leading to early-onset diabetes.  
2. **Retinopathy**: A microvascular complication of prolonged diabetes, consistent with poor glycemic control over time.  
3. **Hypertension**: Likely secondary to diabetic nephropathy or chronic kidney disease, exacerbated by diabetes-related vascular damage.  
4. **Proteinuria, Acute kidney injury (AKI), Chronic kidney disease (CKD)**: Diabetic nephropathy from long-standing hyperglycemia explains progressive kidney damage. MODY1 patients with suboptimal glycemic control are at risk for renal complications.  
5. **Death in early adulthood**: Severe renal failure (from CKD/AKI) or cardiovascular complications of uncontrolled diabetes and hypertension could lead to premature mortality.  
6. **MODY1 specificity**: While MODY5 (HNF1B) is classically linked to renal dysplasia, MODY1 can still manifest nephropathy due to diabetic damage. The absence of atypical features (e.g., cysts, genital anomalies) and presence of retinopathy favor MODY1 over other subtypes. Early death underscores aggressive complications from delayed diagnosis or inadequate management. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Aniridia is associated with
Choices:
A. Retinoblastoma
B. Hepatoblastoma
C. Nephrobl astoma
D. Medulloblastoma
Answer: [/INST] Nephrobl astoma </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Malaria -
Choices:
A. Propagative
B. Cyclopropagative
C. Cvclodevelopmental
D. None of the above
Answer: [/INST] Cyclopropagative </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Osteosarcoma can develop in:
Choices:
A. Osteoid osteoma
B. Osteoblastoma
C. Paget's disease
D. All of the above
Answer: [/INST] Paget's disease </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: A couple has 4 children, all unvaccinated for Measles. A child got Measles on 5 August 2015. Two other children developed Measles by 15 August 2015. Secondary attack rate is:
Choices:
A. 0%
B. 33%
C. 66%
D. 75%
Answer: [/INST] 66% </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Retinoblastoma gene regulates-
Choices:
A. Gi - S phase
B. G2 - M phase
C. Go - S1 phase
D. S - G1 phase
Answer: [/INST] Gi - S phase </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Hypertyrosinemia', 'Death in childhood', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning:  
1. **Hyperphenylalaninemia**: PKU is caused by deficient phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This deficiency results in phenylalanine accumulation, directly explaining hyperphenylalaninemia.  
2. **Death in childhood**: Untreated PKU leads to severe neurological damage, seizures, and developmental failure, often causing early mortality without dietary intervention.  
3. **Hypertyrosinemia**: While atypical in classic PKU (as PAH deficiency typically reduces tyrosine synthesis), this could reflect dietary tyrosine supplementation, misreported data, or a concurrent metabolic disturbance (e.g., transient neonatal tyrosinemia). The primary diagnostic markers (hyperphenylalaninemia + clinical severity) strongly prioritize PKU despite this anomaly. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Microcephaly', 'Strabismus', 'Apathy', 'Hyperactivity', 'Intellectual disability', 'Generalized hypotonia', 'Death in infancy', 'Metabolic acidosis', 'Hyperammonemia', 'Vomiting', 'Hyperglycinemia', 'Hyperalaninemia', 'Severe short stature', 'Neonatal death', 'Death in childhood', 'Gastrointestinal inflammation', 'Hyperleucinemia', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Feeding difficulties']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia; PA/Propionic acidemia  
Reasoning:  
1. **Metabolic Disturbances**: Symptoms like **metabolic acidosis**, **hyperammonemia**, **hyperglycinemia**, **hyperalaninemia**, and **hyperleucinemia** strongly suggest a disorder of branched-chain amino acid (BCAA) metabolism. PA disrupts propionyl-CoA carboxylase, impairing catabolism of valine, isoleucine, methionine, and odd-chain fatty acids, leading to toxic metabolite accumulation.  
2. **Neurological and Developmental Features**: **Microcephaly**, **intellectual disability**, **hypotonia**, **apathy**, and **hyperactivity** align with chronic neurotoxicity from elevated propionic acid and ammonia, which damage the central nervous system.  
3. **Life-Threatening Course**: **Death in infancy/childhood/adolescence**, **neonatal death**, and **severe short stature** reflect the rapid progression of untreated PA. Metabolic crises trigger acute decompensation with **vomiting**, **feeding difficulties**, and **gastrointestinal inflammation**, exacerbating catabolism.  
4. **Carnitine Dysregulation**: **Abnormal circulating carnitine** occurs as carnitine conjugates with propionyl-CoA to form propionylcarnitine (C3), a diagnostic biomarker for PA. Secondary carnitine deficiency worsens energy metabolism.  
5. **Biochemical Hallmarks**: Elevated glycine (**hyperglycinemia**) is a key feature of PA due to secondary inhibition of glycine cleavage enzyme by propionyl-CoA. Hyperammonemia arises from urea cycle inhibition by accumulated metabolites.  

The constellation of metabolic derangements, neurodevelopmental deficits, and early mortality strongly supports **propionic acidemia** as the diagnosis. Confirmatory testing would include plasma acylcarnitine profile (elevated C3), urinary organic acids (3-hydroxypropionate, methylcitrate), and genetic analysis of *PCCA* or *PCCB* genes. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Phenylketonuria (PKU)  
Reasoning: The patient exhibits **hyperphenylalaninemia**, a hallmark of PKU caused by deficient phenylalanine hydroxylase (PAH) activity, impairing the conversion of phenylalanine to tyrosine. Untreated PKU results in toxic phenylalanine accumulation, causing neurodevelopmental damage and **death in infancy**. The **hypertyrosinemia** is atypical but may arise secondarily: excessive phenylalanine competitively inhibits tyrosine transport or degradation pathways, leading to its abnormal elevation. This dual metabolic disruption aligns with severe, untreated PKU. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Indicator for outbreak of Plague epidemic is
Choices:
A. Rat burrow index
B. Total flea
C. Specific flea index
D. Cheopis index
Answer: [/INST] Cheopis index </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemolytic uremic syndrome is caused by -a) EIECb) Shigella c) Salmonellad) Cholerae) Klebsiella
Choices:
A. a
B. bc
C. ac
D. ad
Answer: [/INST] bc </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Cryptorchidism', 'Vesicoureteral reflux', 'Tall stature', 'Renal cyst', 'Narrow mouth', 'Broad alveolar ridges', 'Furrowed tongue', 'Microcephaly', 'Macrocephaly', 'Epicanthus', 'Hypertelorism', 'Smooth philtrum', 'Triangular face', 'Micrognathia', ""Widow's peak"", 'Hearing impairment', 'Sensorineural hearing impairment', 'Bulbous nose', 'Choanal atresia', 'Anteverted nares', 'Strabismus', 'Deeply set eye', 'Downslanted palpebral fissures', 'Visual impairment', 'Abnormality iris morphology', 'Abnormal eyebrow morphology', 'Microphthalmia', 'Blepharophimosis', 'Upslanted palpebral fissure', 'Coloboma', 'Hypotelorism', 'Optic atrophy', 'Peters anomaly', 'Atypical behavior', 'Delayed speech and language development', 'Hyperactivity', 'Cafe-au-lait spot', 'Hypertrichosis', 'Syndactyly', 'Hypotonia', 'Global developmental delay', 'Abnormal corpus callosum morphology', 'Spastic tetraparesis', 'Generalized hypotonia', 'Cerebellar vermis hypoplasia', 'Absent speech', 'Hip dysplasia', 'Growth delay', 'Intrauterine growth retardation', 'Macrodontia', 'Ventricular septal defect', 'Patent ductus arteriosus', 'Patent foramen ovale', 'Abnormal cardiac septum morphology', 'Annular pancreas', 'Small nail', 'Abnormal facial shape', 'Frontal bossing', 'Gastroesophageal reflux', 'Pyloric stenosis', 'Ventriculomegaly', 'Delayed gross motor development', 'Duodenal atresia', 'Tetraparesis', 'Focal impaired awareness seizure', 'Hypoplastic nipples', 'Scoliosis', 'Lumbar hyperlordosis', 'Inverted nipples', 'Hyperlordosis', 'CNS hypomyelination', 'Clinodactyly of the 5th finger', 'Short stature', 'Preauricular pit', 'Sacral hypertrichosis', 'Cerebral hypomyelination', 'Attention deficit hyperactivity disorder', 'Abnormal pons morphology', 'Abnormality of the palmar creases', 'Anomalous pulmonary venous return', 'Incisor macrodontia', 'Abnormality of fontanelles', 'Feeding difficulties', 'Delayed myelination', 'Thick vermilion border', 'Abnormal hippocampus morphology', 'Squared superior portion of helix', 'Abnormality of the anterior commissure', 'Narrow palpebral fissure', 'Cerebral visual impairment', 'Small hand', 'Cleft lip']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH)  
Reasoning:  
1. **Neurodevelopmental core features**: The patient exhibits *global developmental delay*, *absent speech*, *delayed speech/language development*, *hyperactivity*, and *ADHD*, aligning with the neurodevelopmental axis of NEDBEH.  
2. **Brain anomalies**: *Abnormal corpus callosum morphology*, *cerebellar vermis hypoplasia*, *CNS/cerebral hypomyelination*, and *abnormal pons/hippocampus morphology* are hallmark brain structural defects in NEDBEH.  
3. **Ocular involvement**: *Coloboma*, *microphthalmia*, *strabismus*, *visual impairment*, *optic atrophy*, and *Peters anomaly* match the ""eye anomalies"" spectrum of the disorder.  
4. **Cardiac defects**: *Ventricular septal defect*, *patent ductus arteriosus*, and *abnormal cardiac septum morphology* fulfill the ""heart anomalies"" criterion.  
5. **Craniofacial/somatic features**: *Microcephaly/macrocephaly*, *triangular face*, *micrognathia*, *cleft lip*, *hypertelorism*, and *epicanthus* are consistent with facial dysmorphisms seen in NEDBEH. Additional features like *syndactyly*, *sacral hypertrichosis*, and *growth delay* support syndromic overlap.  
6. **Systemic/gastrointestinal anomalies**: *Annular pancreas*, *duodenal/pyloric stenosis*, and *hip dysplasia* correlate with reported gastrointestinal/musculoskeletal involvement in NEDBEH.  
7. **Genetic plausibility**: While not specified here, NEDBEH is often linked to *de novo SMARCC2* variants, which disrupt chromatin remodeling—a process critical for neurodevelopment and organogenesis, explaining the multi-system phenotype.  

The convergence of neurodevelopmental delay, brain malformations, ocular/cardiac defects, and variable dysmorphic/systemic features strongly supports this diagnosis over isolated syndromes (e.g., CHARGE, Noonan) due to the absence of pathognomonic features (e.g., choanal atresia in CHARGE is nonspecific here) and the broad phenotypic spectrum of NEDBEH. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: All of the following are features of Achondroplasia except:
Choices:
A. Bullet shaped veebra
B. Trident hand/starfish hand
C. Wimberger ring sign
D. Champagne glass pelvis
Answer: [/INST] Wimberger ring sign </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Spastic paraplegia', 'Spastic gait', 'Difficulty walking']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Autosomal recessive spastic paraplegia type 76 (SPG76)  
Reasoning:  
1. **Symptom alignment**: Spastic paraplegia, spastic gait, and difficulty walking are hallmark features of hereditary spastic paraplegias (HSPs), a group of disorders characterized by progressive lower limb spasticity and weakness.  
2. **Genetic inheritance**: SPG76 is autosomal recessive, requiring biallelic pathogenic variants in the *CAPN1* gene. The absence of dominant family history supports this mode of inheritance.  
3. **Clinical specificity**: SPG76 typically presents with early-onset (childhood to adulthood) progressive spastic paraplegia, consistent with the described symptoms. While classified as a ""pure"" HSP, subtle additional features (e.g., mild neuropathy) may occur but are not required for diagnosis.  
4. **Exclusion of mimics**: The lack of overt cerebellar ataxia, intellectual disability, or peripheral neuropathy in the symptom list helps differentiate SPG76 from other HSP subtypes (e.g., SPG7, SPG11) or complex forms.  
5. **Confirmation pathway**: Definitive diagnosis requires genetic testing for *CAPN1* mutations, alongside neuroimaging (e.g., spinal MRI to rule out structural causes) and exclusion of acquired causes (e.g., vitamin deficiencies, inflammatory myelopathy).  

**Note**: Family segregation analysis and genetic counseling are critical next steps due to the autosomal recessive inheritance pattern. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Delayed speech and language development', 'Eczematoid dermatitis', 'Skin rash', 'Death in infancy', 'Leukopenia', 'Hyperammonemia', 'Hyperglycinemia', 'Hyperglycinuria', 'Elevated circulating alkaline phosphatase concentration', 'Death in childhood', 'Abnormal circulating aspartate family amino acid concentration', 'Abnormal circulating alanine concentration', 'Abnormal circulating carnitine concentration', 'Death in adolescence', 'Abnormal circulating serine concentration', 'Elevated urinary carboxylic acid']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Propionic acidemia  
Reasoning:  
1. **Hyperammonemia & Hyperglycinemia**: Propionic acidemia (PA) disrupts propionyl-CoA metabolism, leading to accumulation of toxic metabolites that inhibit the urea cycle (causing hyperammonemia) and secondary hyperglycinemia due to glycine synthesis interference.  
2. **Elevated Urinary Carboxylic Acids**: Propionyl-CoA carboxylase deficiency results in excretion of methylcitrate, 3-hydroxypropionate, and propionylglycine in urine, consistent with elevated urinary carboxylic acids.  
3. **Leukopenia & Skin Manifestations**: Toxic metabolites suppress bone marrow function (leukopenia) and may trigger eczematoid dermatitis/skin rash via immune dysregulation.  
4. **Abnormal Amino Acid/Carnitine Profiles**: Propionic acid conjugates with carnitine, causing secondary carnitine deficiency. Disrupted amino acid metabolism explains abnormal alanine, serine, and aspartate-family amino acids.  
5. **Hyperglycinuria & Alkaline Phosphatase Elevation**: Glycine overflow (hyperglycinuria) and hepatic stress (elevated alkaline phosphatase) reflect systemic metabolic derangement.  
6. **Neurological & Developmental Delays**: Chronic metabolic acidosis/ammonia toxicity impair neurodevelopment, causing speech delays.  
7. **Early Mortality**: Untreated PA leads to lethal metabolic crises in infancy/childhood; even with treatment, complications (e.g., cardiomyopathy) may cause death in adolescence.  

This constellation of metabolic, hematologic, and neurologic findings is pathognomonic for propionic acidemia. </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cystinuria all of the following amino acids are excreted, except:
Choices:
A. Cystine
B. Ornithine
C. Leucine
D. Arginine
Answer: [/INST] Leucine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cholera presents with symptoms mimicking: TN 10
Choices:
A. Arsenic poisoning
B. Dhatura poisoning
C. Barbiturate poisoning
D. Morphine poisoning
Answer: [/INST] Arsenic poisoning </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Hemophilia B is deficiency of which factor: September 2007
Choices:
A. IX
B. XII
C. VIII
D. X
Answer: [/INST] IX </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> A patient shows the symptoms ['Death in infancy', 'Hyperammonemia', 'Increased total bilirubin', 'Neonatal death', 'Elevated plasma citrulline']. Diagnose the patient with a rare diseases. Let's think step by step. [/INST] Disease: Citrullinemia  
Reasoning: Elevated plasma citrulline directly indicates a urea cycle defect, specifically argininosuccinate synthetase (ASS1) deficiency, which defines citrullinemia. Hyperammonemia arises from impaired ammonia detoxification in the urea cycle. Neonatal death and infant mortality align with the severe, early-onset nature of this disorder. Increased bilirubin suggests secondary liver dysfunction due to metabolic crisis.  

Disease: Citrullinemia type I/Citrullinemia, classic  
Reasoning: The specificity of ""type I"" refers to the classic ASS1-deficient form (OMIM #215700), distinguishing it from type II (adult-onset citrullinemia II, SLC25A13-related). The neonatal presentation with hyperammonemia, citrulline elevation, and rapid progression to death is pathognomonic for type I. Elevated citrulline confirms the enzyme block at the ASS1 step, excluding other urea cycle defects (e.g., ornithine transcarbamylase deficiency). </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Primary Hyperoxaluria occurs due to defect in metabolism of
Choices:
A. Cystein
B. Tryptophan
C. Tyrosine
D. Glycine
Answer: [/INST] Glycine </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Acromegaly is a disorder of:
Choices:
A. Excess growth hormone secretion during adulthood
B. Excess thyroxine secretion
C. Excess ACTH secretion
D. Excess FSH secretion
Answer: [/INST] Excess growth hormone secretion during adulthood </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Major fibril protein in Primary Amyloidosis is -
Choices:
A. AL
B. AA
C. Transthyretin
D. Procalcitonin
Answer: [/INST] AL </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Cerebral Cysticercosis
Choices:
A. Commonly manifests with localizing signs
B. May present with dementia
C. Rarely occurs in children
D. Usually presents with generalized seizures
Answer: [/INST] Commonly manifests with localizing signs </s>"
"[INST] <<SYS>> You are a specialist in the field of rare diseases. <</SYS>> Question: Which of the following represents a ""Web Based Programme for monitoring Tuberculosis?(2018)
Choices:
A. NIKSHAY
B. NISCHAY
C. DOTS
D. RNTCP
Answer: [/INST] NIKSHAY </s>"
